LANCE TO LANCE

#### (19) World Intellectual Property Organization International Bureau



# 

#### (43) International Publication Date 1 August 2002 (01.08.2002)

## **PCT**

## (10) International Publication Number WO 02/059148 A2

C07K 14/195 (51) International Patent Classification7:

(21) International Application Number: PCT/EP02/00546 [AT/AT]; Arnoldgasse 2/7/4/27, A-1210 Vienna (AT). TEMPELMAIER, Brigitte [AT/AT]; Messenhausergasse 10/20, A-1030 Vienna (AT).

(22) International Filing Date: 21 January 2002 (21.01.2002) - (24) Agents: SONN, Helmut et al.; Riemergasse 14, A-1010

Wien (AT).

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

Λ 130/01

26 January 2001 (26.01.2001) AT

(71) Applicant (for all designated States except US): CISTEM BIOTECHNOLOGIES GMBH [AT/AT]; Rennweg 95b, A-1030 Vienna (AT).

(72) Inventors: and

(75) Inventors/Applicants (for US only): MEINKE, Andreas [DE/AT]; Piettegasse 26/1, A-3013 Pressbaum (AT). NAGY, Eszter [HU/AT]; Taborstrasse 9/15, A-1020 Vienna (AT). VON AHSEN, Uwe [DE/AT]; Shmalzhofgasse 22/25 A-1060 Vienna (AT). KLADE, Christoph [AT/AT]; Gröhrmühlgasse 1B, A-2700 Wr. Neustadt (AT). HENICS, Tamas [HU/AT]; Taborstrasse 9/15, A-1020 Vienna (AT). ZAUNER, Wolfgang [AT/AT]; Parkgasse 13/22, A-1030 Vienna (AT). MINH, Duc, Bui [VN/AT]; Rudolf Zeller Gasse 70/6/9, A-1230 Vienna (AT). VYTVYTSKA, Oresta (UA/AT); Leystrasse 110/1/2, A-1200 Vienna (AT). ETZ, Hildegard [AT/AT]; Lortzinggasse 1/21, A-1140 Vienna (AT). DRYLA, Agnieszka [PL/AT]; Pragerstrasse 43-47/2/15, A-1210 Vienna (AT). WEICHHART, Thomas [AT/AT]; Hinterholz 10, A-3071 Böheimkirchen (Al). HAFNER, Martin

- (81) Designated States (national): AE, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC; NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Declaration under Rule 4.17:

of inventorship (Rule 4.17(iv)) for US only

#### Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A METHOD FOR IDENTIFICATION, ISOLATION AND PRODUCTION OF ANTIGENS TO A SPECIFIC **PATHOGEN** 

(57) Abstract: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: - providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, - providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, - screening said at least one expression library with said antibody preparation, identifying antigens which bind in said screening to antibodies in said antibody preparation, - screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, - identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and - optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

WO 02/059148 PCT/EP02/00546

A method for identification, isolation and production of antigens to a specific pathogen

The invention relates to a method for identification, isolation and production of antigens to a specific pathogen as well as new antigens suitable for use in a vaccine for a given type of animal or for humans.

Vaccines can save more lives (and resources) than any other medical intervention. Owing to world-wide vaccination programmes the incidence of many fatal diseases has been decreased drastically. Although this notion is valid for a whole panel of diseases, e.g. diphtheria, pertussis, measles and tetanus, there are no effective vaccines for numerous infectious disease including most viral infections, such as HIV, HCV, CMV and many others. There are also no effective vaccines for other diseases, infectious or noninfectious, claiming the lifes of millions of patients per year including malaria or cancer. In addition, the rapid emergence of antibiotic-resistant bacteria and microorganisms calls for alternative treatments with vaccines being a logical choice. Finally, ! , the great need for vaccines is also illustrated by the fact that infectious diseases, rather than cardiovascular disorders or cancer or injuries remain the largest cause of death and disability in the world.

Several established vaccines consist of live attenuated organisms where the risk of reversion to the virulent wild-type strain exists. In particular in immunocompromised hosts this can be a live threatening scenario. Alternatively, vaccines are administered as a combination of pathogen-derived antigens together with compounds that induce or enhance immune responses against these antigens (these compounds are commonly termed adjuvant), since these subunit vaccines on their own are generally not effective.

Whilst there is no doubt that the above vaccines are valuable medical treatments, there is the disadvantage that, due to their complexity, severe side effects can be evoked, e.g. to antigens that are contained in the vaccine that display cross-reactivity with molecules expressed by cells of vaccinated individuals. In addition, existing requirements from regulatory authorities, e.g.

the World Health Organization (WHO), the Food and Drug Administration (FDA), and their European counterparts, for exact specification of vaccine composition and mechanisms of induction of immunity, are difficult to meet.

Some widely used vaccines are whole cell-vaccines (attenuated bacteria or viruses (e.g. Bacille Calmette-Guerin (BCG) (tuberculosis), Measles, Mumps, Rubella, Oral Polio Vaccine (Sabin), killed bacteria or viruses (e.g. Pertussis, Inactivated polio vaccine (Salk)), subunit-vaccines (e.g. Toxoid (Diphtheria, Tetanus)), Capsular polysaccharide (H. influenzae type B), Yeast recombinant subunit (Hepatitis B surface protein).

A vaccine can contain a whole variety of different antigens. Examples of antigens are whole-killed organisms such as inactivated viruses or bacteria, fungi, protozoa or even cancer cells. Antigens may also consist of subfractions of these organisms/tissues, of proteins, or, in their most simple form, of peptides. Antigens can also be recognized by the immune system in form of glycosylated proteins or peptides and may also be or contain polysaccharides or lipids. Short peptides can be used since for example cytotoxic T-cells (CTL) recognize antigens in form of short usually 8-11 amino acids long peptides in conjunction with major histocompatibility complex (MHC). B-cells can recognize linear epitopes as short as 4-5 amino acids, as well as three dimensional structures (conformational epitopes). In order to obtain sustained, antigen-specific immune responses, adjuvants need to trigger immune cascades that involve all cells of the immune system necessary. Primarily, adjuvants are acting, but are not restricted in their mode of action, on so-called antigen presenting cells (APCs). These cells usually first encounter the antigen(s) followed by presentation of processed or unmodified antigen to immune effector cells. Intermediate cell types may also be involved. Only effector cells with the appropriate specificity are activated in a productive immune response. The adjuvant may also locally retain antigens and co-injected other factors. In addition the adjuvant may act as a chemoattractant for other immune cells or may act locally and/or systemically as a stimulating agent for the immune system.

;;

Antigen presenting cells belong to the innate immune system, which has evolved as a first line host defence that limits infection early after exposure to microorganisms. Cells of the innate immune system recognize patterns or relatively non-specific structures expressed on their targets rather than more sophisticated, specific structures which are recognized by the adaptive immune system. Examples of cells of the innate immune system are macrophages and dendritic cells but also granulocytes (e.g. neutrophiles), natural killer cells and others. By contrast, cells of the adaptive immune system recognize specific, antigenic structures, including peptides, in the case of T-cells and peptides as well as three-dimensional structures in the case of Bcells. The adaptive immune system is much more specific and sophisticated than the innate immune system and improves upon repeated exposure to a given pathogen/antigen. Phylogenetically, the innate immune system is much older and can be found already in very primitive organisms. Nevertheless, the innate immune system is critical during the initial phase of antigenic exposure since, in addition to containing pathogens, cells of the innate immune system, i.e. APCs, prime cells of the adaptive immune system and thus trigger specific immune responses leading to clearance of the intruders. In sum, cells of the innate immune system and in particular APCs play a critical role during the induction phase of immune responses by a) containing infections by means of a primitive pattern recognition system and b) priming cells of the adaptive immune system leading to specific immune responses and memory resulting in clearance of intruding pathogens or of other targets. These mechanisms may also be important to clear or contain tumor cells.

The antigens used for such vaccines have often been selected by chance or by easiness of availability. There is a demand to identify efficient antigens for a given pathogen or - preferably - an almost complete set of all antigens of a given pathogen which are practically (clinically) relevant. Such antigens may be preferred antigen candidates in a vaccine.

It is therefore an object of the present invention to comply with these demands and to provide a method with which such antigens may be provided and with which a practically complete set of an-

.

tigens of e.g. a given pathogen may be identified with a given serum as antibody source. Such a method should also be suitable for rapidly changing pathogens which evolve a fast resistance against common drugs or vaccines. The method should also be applicable to identify and isolate tumor antigens, allergens, auto-immune antigens.

Therefore, the present invention provides a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, especially from a specific pathogen, said antigens being suited for use in a vaccine for a given type of animal or for humans, said method being characterized by the following steps:

- \*providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, \*providing at least one expression library of said specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity,
- \*screening said at least one expression library with said antibody preparation,
- \*identifying antigens which bind in said screening to antibodies in said antibody preparation,
- \*screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,
- \*identifying the hyperimmune serum-reactive antigen portion of said identified antigens which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and
- \*optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

This method is also suitable in general for identifying a practically complete set of hyperimmune serum-reactive antigens of a specific pathogen with given sera as antibody sources, if at

WO 02/059148 PCT/EP02/00546

least three different expression libraries are screened in a pathogen/antigen identification programme using the method according to the present invention. The present invention therefore also relates to a method for identification, isolation and production of a practically complete set of hyperimmune serum-reactive antigens of a specific pathogen, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps:

3

- \*providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen,
- \*providing at least three different expression libraries of said specific pathogen,
- \*screening said at least three different expression libraries with said antibody preparation,
- \*identifying antigens which bind in at least one of said at least three screenings to antibodies in said antibody preparation.
- \*screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen,
- \*identifying the hyperimmune serum-reactive antigen portion of said identified antigens which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera,
- \*repeating said screening and identification steps at least once.
- \*comparing the identified hyperimmune serum-reactive antigens identified in the repeated screening and identification steps with the identified hyperimmune serum-reactive antigens identified in the initial screening and identification steps,
- \*further repeating said screening and identification steps, if at least 5% of the hyperimmune serum-reactive antigens have been identified in the repeated screening and identification steps only, until less than 5 % of the hyperimmune serum-reactive antigens are identified in a further repeating step only to obtain a complete set of hyperimmune serum-reactive antigens of a specific pathogen and
- \*optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by

13

chemical or recombinant methods.

The method according to the present invention mainly consists of three essential parts, namely 1. identifying hyperimmune serum sources containing specific antibodies against a given pathogen, 2. screening of suitable expression libraries with a suitable antibody preparation wherein candidate antigens (or antigenic fragments of such antigens) are selected, and - 3. in a second screening round, wherein the hyperimmune serum-reactive antigens are identified by their ability to bind to a relevant portion of individual antibody preparations from individual sera in order to show that these antigens are practically relevant and not only hyperimmune serum-reactive, but also widely immunogenic (i.e. that a lot of individual sera react with a given antigen). With the present method it is possible to provide a set of antigens of a given pathogen which is practically complete with respect to the chosen pathogen and the chosen serum. Therefore, a bias with respect to "wrong" antigen candidates or an incomplete set of antigens of a given pathogen is excluded by the present method.

Completeness of the antigen set of a given pathogen within the meaning of the present invention is, of course, dependent on the completeness of the expression libraries used in the present method and on the quality and size of serum collections (number of individual plasmas/sera) tested, both with respect to representability of the library and usefulness of the expression system. Therefore, preferred embodiments of the present method are characterized in that at least one of said expression libraries is selected from a ribosomal display library, a bacterial surface library and a proteome.

A serum collection used in the present invention should be tested against a panel of known antigenic compounds of a given pathogen, such as polysaccharide, lipid and proteinaceous components of the cell wall, cell membranes and cytoplasma, as well as secreted products. Preferably, three distinct serum collections are used:

1. With very stable antibody repertoire: normal adults, clinically healthy people, who overcome previous encounters or currently carriers of e.g. a given pathogen without acute disease and symptoms, 2. With antibodies induced acutally by the presence

of the pathogenic organism: patients with acute disease with different manifestations (e.g. S. aureus sepsis or wound infection, etc.), 3. With no specific antibodies at all (as negative controls): 5-8 months old babies who lost the maternally transmitted immunoglobulins 5-6 months after birth. Sera have to react with multiple pathogen-specific antigens in order to consider hyperimmune for a given pathogen (bacteria, fungus, worm or otherwise), and for that relevant in the screening method according to the present invention.

In the antigen identification programme for identifying a complete set of antigens according to the present invention, it is preferred that said at least three different expression libraries are at least a ribosomal display library, a bacterial surface library and a proteome. It has been observed that although all ex-. pression libraries may be complete, using only one or two expression libraries in an antigen identification programme will not lead to a complete set of antigens due to preferential expression properties of each of the different expression libraries. While it is therefore possible to obtain hyperimmune serumreactive antigens by using only one or two different expression libraries, this might in many cases not finally result in the identification of a complete set of hyperimmune serum-reactive antigens. Of course, the term "complete" according to the present invention does not indicate a theoretical maximum but is indeed a practical completeness, i.e. that at least 95% of the practically relevant antigens or antigenic determinants have been identified of a given pathogen. The practical relevance is thereby defined by the occurrence of antibodies against given antigens in the patient population.

According to the present invention also serum pools or plasma fractions or other pooled antibody containing body fluids are "plasma pools".

An expression library as used in the present invention should at least allow expression of all potential antigens, e.g. all surface proteins of a given pathogen. With the expression libraries according to the present invention, at least one set of potential antigens of a given pathogen is provided, this set being prefera-

bly the complete theoretical complement of (poly-)peptides encoded by the pathogen's genome (i.e. genomic libraries as described in Example 2) and expressed either in a recombinant host (see Example 3) or in vitro (see Example 4). This set of potential antigens can also be a protein preparation, in the case of extracellular pathogens preferably a protein preparation containing surface proteins of said pathogen obtained from said pathogen grown under defined physiological conditions (see Example 5). While the genomic approach has the potential to contain the complete set of antigens, the latter one has the advantage to contain the proteins in their naturally state i.e. including for instance post-translational modifications or processed forms of these proteins, not obvious from the DNA sequence. These or any other sets of potential antigens from a pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity are hereafter referred to as "expression library". Expression libraries of very different kinds may be applied in the course of the present invention. Suitable examples are given in e.g. Ausubel et al., 1994. Especially preferred are expression libraries representing a display of the genetic set of a pathogen in recombinant form such as in vitro translation techniques, e.g. ribosomal display, or prokaryotic expression systems, e.g. bacterial surface expression libraries or which resemble specific physiological expression states of a given pathogen in a given physiological state, such as a proteome.

Ribosome display is an established method in recombinant DNA technology, which is applicable for each specific pathogen for the sake of the present invention (Schaffitzel et al, 1999). Bacterial surface display libraries will be represented by a recombinant library of a bacterial host displaying a (total) set of expressed peptide sequences of a given pathogen on e.g. a selected outer membrane protein at the bacterial host membrane (Georgiou et al., 1997). Apart from displaying peptide or protein sequences in an outer membrane protein, other bacterial display techniques, such as bacteriophage display technologies and expression via exported proteins are also preferred as bacterial surface expression library (Forrer et al., 1999; Rodi and Makowski, 1993; Georgiou et al., 1997).

The antigen preparation for the first round of screening in the method according to the present invention may be derived from any source containing antibodies to a given pathogen. Preferably, if a plasma pool is used as a source for the antibody preparation, a human plasma pool is selected which comprises donors which had experienced or are experiencing an infection with the given pathogen. Although such a selection of plasma or plasma pools is in principle standard technology in for example the production of hyperimmunoglobulin preparations, it was surprising that such technologies have these effects as especially shown for the preferred embodiments of the present invention.

Preferably the expression libraries are genomic expression libraries of a given pathogen, or alternatively m-RNA, libraries. It is preferred that these genomic or m-RNA libraries are complete genomic or m-RNA expression libraries which means that they contain at least once all possible proteins, peptides or peptide fragments of the given pathogen are expressable. Preferably the genomic expression libraries exhibit a redundancy of at least 2x, more preferred at least 5x, especially at least 10x.

Preferably, the method according to the present invention comprises screening at least a ribosomal display library, a bacterial surface display library and a proteome with the antibody preparation and identifying antigens which bind in at least two, preferably which bind to all, of said screenings to antibodies in said antibody preparation. Such antigens may then be regarded extremely suited as hyperimmunogenic antigens regardless of their way of expression. Preferably the at least two screenings should at least contain the proteome, since the proteome always represents the antigens as naturally expressed proteins including post-translational modifications, processing, etc. which are not obvious from the DNA sequence.

The method according to the present invention may be applied to any given pathogen. Therefore, preferred pathogens are selected from the group of bacterial, viral, fungal and protozoan pathogens. The method according to the present invention is also applicable to cancer, i.e. for the identification of tumorassociated antigens, and for the identification of allergens or

antigens involved in auto-immune diseases. Of course, especially the recombinant methods are rather simple for pathogens having a small genome or a comparatively small number of expressed proteins (such as bacterial or viral pathogens) and are more complicated for complex (eukaryotic) organisms having large genomes. However, also such large genomic libraries of higher organism pathogens may well be analyzed with the method according to the present invention, at least in a faster and more reliable way than with known methods for identifying suitable antigens.

Preferred pathogens to be analyzed or which antigens are to be extracted, respectively, include human immunedeficiency virus (HIV), hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), Rous sarcoma virus (RSV), Epstein-Barr virus (EBV), influenza virus (IV), rotavirus (RV), Staphylococcus aureus (S.aureus), Staphylococcus epidermidis (S. epidermidis), Chlamydia pneumoniae (C. pneumoniae), Chlamydia trachomatis (C. trachomatis), Mycobacterium tuberculosis (M. tuberculosis), Mycobacterium leprae (M. leprae), Streptococcus pneumoniae (S. pneumoniae), Streptococcus pyogenes (S. pyogenes), Streptococcus agalactiae (S. agalactiae), Enterococcus faecalis (E. faecalis), Bacillus anthracis (B. anthracis), Vibrio cholerae (V. cholerae), Borrelia burgdorferi (B. burgdorferi), Plasmodium sp., fungal diseases such as Pneumocystis carinii, Aspergillus sp., Cryptococcus sp., Candida albicans or parasitic infections such as ascariasis (Ascaris lumbricoides) and taeniasis (Taenia saginata). The method according to the present invention is most applicable for bacteria, worms or candida.

As a model organism for the present application Staphylococcus aureus has been chosen to demonstrate the applicability and efficacy of the method according to the present invention. Especially with respect to the examples it is clear that the invention is easily transferable to all potential pathogens, especially the ones listed above.

It was surprising that the method according to the present invention allows an efficient and fast biological screening of a given pathogen, especially in view of the fact that only a small fraction of a patient's antibody repertoire is directed to a given

pathogen, even in a state where this pathogen is effectively defeated. It has been discovered within the course of the present invention, especially during performance of the S.aureus example that only 1-2% of the antibody repertoire of a patient having high titers against S.aureus are indeed antibodies directed against S.aureus. Moreover, over 70% of this specific 1% portion is directed against non-protein antigens, such as teichoic acid, so that only a total of 0.1% or less of the antibodies are directed to proteinaceous antigens.

One of the advantages of using recombinant expression libraries, especially ribsome display libraries and bacterial surface display libraries, is that the identified hyperimmune serum-reactive antigens may be instantly produced by expression of the coding sequences of the screened and selected clones expressing the hyperimmune serum-reactive antigens without further recombinant DNA technology or cloning steps necessary.

The hyperimmune serum-reactive antigens obtainable by the method according to the present invention may therefore be immediately finished to a pharmaceutical preparation, preferably by addition of a pharmaceutically acceptable carrier and/or excipient, immediately after its production (in the course of the second selection step), e.g. by expression from the expression library platform.

Preferably, the pharmaceutical preparation containing the hyperimmune serum-reactive antigen is a vaccine for preventing or treating an infection with the specific pathogen for which the antigens have been selected.

The pharmaceutical preparation may contain any suitable auxiliary substances, such as buffer substances, stabilisers or further active ingredients, especially ingredients known in connection of vaccine production.

A preferable carrier/or excipient for the hyperimmune serum-reactive antigens according to the present invention is a immunostimulatory compound for further stimulating the immune response to the given hyperimmune serum-reactive antigen. Pref-

erably the immunostimulatory compound in the pharmaceutical preparation according to the present invention is selected from the group of polycationic substances, especially polycationic peptides, immunostimulatory deoxynucleotides, alumn, Freund's complete adjuvans, Freund's incomplete adjuvans, neuroactive compounds, especially human growth hormone, or combinations thereof.

The polycationic compound(s) to be used according to the present invention may be any polycationic compound which shows the characteristic effects according to the WO 97/30721. Preferred polycationic compounds are selected from basic polypeptides, organic polycations, basic polyamino acids or mixtures thereof. These polyamino acids should have a chain length of at least 4 amino acid residues (see: Tuftsin as described in Goldman et al. (1983)). Especially preferred are substances like polylysine, polyarginine and polypeptides containing more than 20%, especially more than 50% of basic amino acids in a range of more than 8, especially more than 20, amino acid residues or mixtures thereof. Other preferred polycations and their pharmaceutical compositons are described in WO 97/30721 (e.g. polyethyleneimine) and WO 99/38528. Preferably these polypeptides contain between 20 and 500 amino acid residues, especially between 30 and 200 residues.

These polycationic compounds may be produced chemically or recombinantly or may be derived from natural sources.

Cationic (poly)peptides may also be anti- microbial with properties as reviewed in Ganz et al, 1999; Hancock, 1999. These (poly)peptides may be of prokaryotic or animal or plant origin or may be produced chemically or recombinantly (Andreu et al., 1998; Ganz et al., 1999; Simmaco et al., 1998). Peptides may also belong to the class of defensins (Ganz, 1999; Ganz et al., 1999). Sequences of such peptides can be, for example, be found in the Antimicrobial Sequences Database under the following internet address:

http://www.bbcm.univ.trieste.it/~tossi/pag2.html

Such host defence peptides or defensives are also a preferred form of the polycationic polymer according to the present inven-

tion. Generally, a compound allowing as an end product activation (or down-regulation) of the adaptive immune system, preferably mediated by APCs (including dendritic cells) is used as polycationic polymer.

Especially preferred for use as polycationic substance in the present invention are cathelicidin derived antimicrobial peptides or derivatives thereof (International patent application PCT/EP01/09529, incorporated herein by reference), especially antimicrobial peptides derived from mammal cathelicidin, preferably from human, bovine or mouse.

Polycationic compounds derived from natural sources include HIV-REV or HIV-TAT (derived cationic peptides, antennapedia peptides, chitosan or other derivatives of chitin) or other peptides derived from these peptides or proteins by biochemical or recombinant production. Other preferred polycationic compounds are cathelin or related or derived substances from cathelin. For example, mouse cathelin is a peptide which has the amino acid sequence NH\_-RLAGLLRKGGEKIGEKLKKIGOKIKNFFQKLVPQPE-COOH. Related or derived cathelin substances contain the whole or parts of the cathelin sequence with at least 15-20 amino acid residues. Derivations may include the substitution or modification of the natural amino acids by amino acids which are not among the 20 standard amino acids. Moreover, further cationic residues may be introduced into such cathelin molecules. These cathelin molecules are preferred to be combined with the antigen. These cathelin molecules surprisingly have turned out to be also effective as an adjuvant for a antigen without the addition of further adjuvants. It is therefore possible to use such cathelin molecules as efficient adjuvants in vaccine formulations with or without further immunactivating substances.

Another preferred polycationic substance to be used according to the present invention is a synthetic peptide containing at least 2 KLK-motifs separated by a linker of 3 to 7 hydrophobic amino acids (International patent application PCT/EP01/12041, incorporated herein by reference).

Immunostimulatory deoxynucleotides are e.g. neutral or artificial

CpG containing DNA, short stretches of DNA derived from non-vertebrates or in form of short oligonucleotides (ODNs) containing non-methylated cytosine-guanine di-nucleotides (CpG) in a certain base context (e.g. Krieg et al., 1995) but also inosine containing ODNs (I-ODNs) as described in WO 01/93905.

Neuroactive compounds, e.g. combined with polycationic substances are described in WO 01/24822.

According to a preferred embodiment the individual antibody preparation for the second round of screening are derived from patients with have suffered from an acute infection with the given pathogen, especially from patients who show an antibody titer to the given pathogen above a certain minimum level, for example an antibody titer being higher than 80 percentile, preferably higher than 90 percentile, especially higher than 95 percentile of the human (patient or carrier) sera tested. Using such high titer individual antibody preparations in the second screening round allows a very selective identification of the hyperimmune serum-reactive antigens to the given pathogen.

It is important that the second screening with the individual antibody preparations (which may also be the selected serum) allows a selective identification of the hyperimmune serum-reactive antigens from all the promising candidates from the first round. Therefore, preferably at least 10 individual antibody preparations (i.e. antibody preparations (e.g. sera) from at least 10 different individuals having suffered from an infection to the chosen pathogen) should be used in identifying these antigens in the second screening round. Of course, it is possible to use also less than 10 individual preparations, however, selectivity of the step may not be optimal with a low number of individual antibody preparations. On the other hand, if a given hyperimmune serum-reactive antigen (or an antigenic fragment thereof) is recognized in at least 10 individual antibody preparations, preferably at least 30, especially at least 50 individual antibody preparations, identification of hyperimmune serum-reactive antigen is also selective enough for a proper identification. Hyperimmune serum-reactivity may of course be tested with as many individual preparations as possible (e.g. with more than 100 or even with

and the second of

では 一般的になる でした

more than 1000).

Therefore, the relevant portion of the hyperimmune serum-reactive antibody preparation according to the method of the present invention should preferably be at least 10, more preferred at least 30, especially at least 50 individual antibody preparations. Alternatively (or in combination) hyperimmune serum-reactive antigen may preferably be also identified with at least 20%, preferably at least 30%, especially at least 40% of all individual antibody preparations used in the second screening round.

According to a preferred embodiment of the present invention, the sera from which the individual antibody preparations for the second round of screening are prepared (or which are used as antibody preparations), are selected by their titer against the specific pathogen (e.g. against a preparation of this pathogen, such as a lysate, cell wall components and recombinant proteins). Preferably, some are selected with a total IgA titer above 4000 U, especially above 6000 U, and/or an IgG titer above 10 000 U, especially above 12 000 U (U = units, calculated from the OD405mm reading at a given dilution) when whole organism (total lysate or whole cells) is used as antigen in ELISA. Individual proteins with Ig titers of above 800-1000 U are specifically preferred for selecting the hyperimmune serum-reactive antigens according to the present invention only for total titer. The statement for individual proteins can be derived from Fig. 9.

According to the demonstration example which is also a preferred embodiment of the present invention the given pathogen is a Staphylococcus pathogen, especially Staphylococcus aureus and Staphylococcus epidermidis. Staphylococci are opportunistic pathogens which can cause illnesses which range from minor infections to life threatening diseases. Of the large number of Staphylococci at least 3 are commonly associated with human disease: S. aureus, S. epidermidis and rarely S. saprophyticus (Crossley and Archer, 1997). S. aureus has been used within the course of the present invention as an illustrative example of the way the present invention functions. Besides that, it is also an important organism with respect to its severe pathogenic impacts on humans. Staphylococcal infections are imposing an increasing

threat in hospitals worldwide. The appearance and disease causing capacity of Staphylococci are related to the wide-spread use of antibiotics which induced and continue to induce multi-drug resistance. For that reason medical treatment against Staphylococcal infections cannot rely only on antibiotics anymore. Therefore, a tactic change in the treatment of these diseases is desperately needed which aims to prevent infections. Inducing high affinity antibodies of the opsonic and neutralizing type by vaccination helps the innate immune system to eliminate bacteria and toxins. This makes the method according to the present invention an optimal tool for the identification of staphylococcal antigenic proteins.

Every human being is colonized with S. epidermidis. The normal habitats of S. epidermidis are the skin and the mucous membrane. The major habitats of the most pathogenic species, S. aureus, are the anterior nares and perineum. Some individuals become permanent S. aureus carriers, often with the same strain. The carrier stage is clinically relevant because carriers undergoing surgery have more infections than noncarriers. Generally, the established flora of the nose prevents acquisition of new strains. However, colonization with other strains may occur when antibiotic treatment is given that leads to elimination of the susceptible carrier strain. Because this situation occurs in the hospitals, patients may become colonized with resistant nosocomial Staphylococci. These bacteria have an innate adaptability which is complemented by the widespread and sometimes inappropriate use of antimicrobial agents. Therefore hospitals provide a fertile environment for drug resistance to develop (close contact among sick patients, extensive use of antimicrobials, nosocomial infections). Both S. aureus and S. epidermidis have become resistant to many commonly used antibiotics, most importantly to methicillin (MRSA) and vancomycin (VISA). Drug resistance is an increasingly important public health concern, and soon many infections caused by staphylococci may be untreatable by antibiotics. In addition to its adverse effect on public health, antimicrobial resistance contributes to higher health care costs, since treating resistant infections often requires the use of more toxic and more expensive drugs, and can result in longer hospital stays for infected patients.

WO 02/059148 PCT/EP02/00546

- 17 -

Moreover, even with the help of effective antibiotics, the most serious staphylococcal infections have 30-50 % mortality.

Staphylococci become potentially pathogenic as soon as the natural balance between microorganisms and the immune system gets disturbed, when natural barriers (skin, mucous membrane) are breached. The coagulase-positive S. aureus is the most pathogenic staphylococcal species, feared by surgeons for a long time. Most frequently it causes surgical wound infections, and induces the formation of abscesses. This local infection might become systemic, causing bacteraemia and sepsis. Especially after viral infections and in elderly, it can cause severe pneumonia. S. aureus is also a frequent cause of infections related to medical devices, such as intravascular and percutan catheters (endocarditis, sepsis, peritonitis), prosthetic devices (septic arthritis, osteomyelitis). S. epidermidis causes diseases mostly related to the presence of foreign body and the use of devices, such as catheter related infections, cerebrospinal fluid shunt infections, peritonitis in dialysed patients (mainly CAPD), endocarditis in individuals with prosthetic valves. This is exemplified in immunocompromised individuals such as oncology patients and premature neonates in whom coagulase-negative staphylococcal infections frequently occur in association with the use of intravascular device. The increase in incidence is related to the increased used of these devices and increasing number of immunocompromised patients.

Much less is known about S. saprophyticus, another coagulasenegative staphylococci, which causes acute urinary tract infection in previously healthy people. With a few exceptions these are women aged 16-25 years.

The pathogenesis of staphylococci is multifactorial. In order to initiate infection the pathogen has to gain access to the cells and tissues of the host, that is adhere. S. aureus expresses—surface proteins that promote attachment to the host proteins such as laminin, fibronectin, elastin, vitronectin, fibrinogen and many other molecules that form part of the extracellular matrix (extracellular matrix binding proteins, ECMBP). S. epider—

midis is equipped with cell surface molecules which promote adherence to foreign material and through that mechanism establish infection in the host. The other powerful weapons staphylococci use are the secreted products, such as enterotoxins, exotoxins, and tissue damaging enzymes. The toxins kill or misguide immune cells which are important in the host defence. The several different types of toxins are responsible for most of the symptoms during infections.

Host defence against S. aureus relies mainly on innate immunological mechanisms. The skin and mucous membranes are formidable barriers against invasion by Staphylococci. However, once the skin or the mucous membranes are breached (wounds, percutan. catheters, etc), the first line of nonadaptive cellular defence begins its co-ordinate action through complement and phagocytes, especially the polymorphonuclear leukocytes (PMNs). These cells can be regarded as the cornerstones in eliminating invading bacteria. As Staphylococci are primarily extracellular pathogens; the major anti-staphylococcal adaptive response comes from the humoral arm of the immune system, and is mediated through three major mechanisms: promotion of opsonization, toxin neutralisation, and inhibition of adherence. It is believed that opsonization is especially important, because of its requirement for an effective phagocytosis. For efficient opsonization the microbial surface has to be coated with antibodies and complement factors for recognition by PMNs through receptors to the Fc fragment of the IgG molecule or to activated C3b. After opsonization, staphylococci are phagocytosed and killed. Moreover, S. aureus can attach to endothelial cells, and be internalised by a phagocytosislike process. Antibodies bound to specific antigens on the cell surface of bacteria serve as ligands for the attachment to PMNs and promote phagocytosis. The very same antibodies bound to the adhesins and other cell surface proteins are expected to neutral- / ize adhesion and prevent colonization.

There is little clinical evidence that cell mediated immunity has a significant contribution in the defence against Staphylococci, yet one has to admit that the question is not adequately addressed. It is known, however, that Staphylococcus aureus utilizes an extensive array of molecular countermeasures to

Mark Transfer

manipulate the defensive microenvironment of the infected host by secreting polypeptides referred to as superantigens, which target the multireceptor communication between T-cells and antigen-presenting cells that is fundamental to initiating pathogen-specific immune clearance. Superantigens play a critical role in toxic shock syndrome and food poisoning, yet their function in routine infections is not well understood. Moreover, one cannot expect a long lasting antibody (memory) response without the involvement of T-cells. It is also known that the majority of the antistaphylococcal antibodies are against T-cell independent antigens (capsular polysacharides, lipoteichoic acid, peptidoglycan) without a memory function. The T-cell dependent proteinaceous antigens can elicit long-term protective antibody responses. These staphylococcal proteins and peptides have not yet been determined.

For all these above mentioned reasons, a tactic change on the war field against staphylococcal infections is badly needed. One way of combating infections is preventing them by active immunisation. Vaccine development against S. aureus has been initiated by several research groups and national institutions worldwide, but there is no effective vaccine approved so far. It has been shown that an antibody deficiency state contributes to staphylococcal persistence, suggesting that anti-staphylococcal antibodies are important in host defence. Antibodies - added as passive immunisation or induced by active vaccination - directed towards surface components could both prevent bacterial adherence, neutralize toxins and promote phagocytosis. A vaccine based on fibronectin binding protein induces protective immunity against mastitis in cattle and suggest that this approach is likely to work in humans (refs). Taking all this together it is suggestive that an effective vaccine should be composed of proteins or polypeptides, which are expressed by all strains and are able to induce high affinity, abundant antibodies against cell surface components of S. aureus. The antibodies should be IgG1 and/or IgG3 for opsonization, and any IgG subtype and IgA for neutralisation of adherence and toxin action. A chemically defined vaccine must be definitely superior compared to a whole cell vaccine (attenuated or killed), since components of S. aureus which paralyze TH cells (superantigens) or inhibit opsonization (protein A)

į.

に展展できる。

can be eliminated, and the individual proteins inducing protective antibodies can be selected. Identification of the relevant antigens help to generate effective passive immunisation (humanised monoclonal antibody therapy), which can replace human immunoglobulin administration with all its dangerous side-effects. Neonatal staphylococcal infections, severe septicemia and other life-threatening acute conditions are the primary target of passive immunisation. An effective vaccine offers great potential for patients facing elective surgery in general, and those receiving endovascular devices, in particular. Moreover, patients suffering from chronic diseases which decrease immune responses or undergoing continuous ambulatory peritoneal dialysis are likely to benefit from such a vaccine.

For the illustrative example concerning Staphylococcus aureus three different approaches have been employed in parallel. All three of these methods are based on the interaction of Staphylococcus proteins or peptides with the antibodies present in human sera with the method according to the present invention. This interaction relies on the recognition of epitopes within the proteins which can be short peptides (linear epitopes) or polypeptide domains (structural epitopes). The antigenic proteins are identified by the different methods using pools of pre-selected sera and - in the second screening round - by individual selected sera.

Following the high throughput screening, the selected antigenic proteins are expressed as recombinant proteins or in vitro translated products (in case it can not be expressed in prokaryotic expression systems), and tested in a series of ELISA and Western blotting assays for the assessment of immunogeneicity with a large human serum collection (> 100 uninfected, > 50 patients sera). The preferred antigens are located on the cell surface or secreted, that is accessible extracellularly. Antibodies against the cell wall proteins (such as the Extracellular matrix binding proteins) are expected to serve double purposes: to inhibit adhesion and promote phagocytosis. The antibodies against the secreted proteins are beneficial in toxin neutralisation. It is also known that bacteria communicate with each other through secreted proteins. Neutralizing antibodies against these proteins

.

will interrupt growth promoting cross-talk between or within staphylococcal species. Bioinformatics (signal sequences, cell wall localisation signals, transmembrane domains) proved to be very useful in assessing cell surface localisation or secretion. The experimental approach includes the isolation of antibodies with the corresponding epitopes and proteins from human serum, and use them as reagents in the following assays: cell surface staining of staphylococci grown under different conditions (FACS, microscopy), determination of neutralizing capacity (toxin, adherence), and promotion of opsonization and phagocytosis (in vitro phagocytosis assay).

The recognition of linear epitopes by antibodies can be based on sequences as short as 4-5 aa. Of course it does not necessarily mean that these short peptides are capable of inducing the given antibody. in vivo. For that reason the defined epitopes, polypeptides and proteins may further be tested in animals (mainly in mice) for their capacity to induce antibodies against the selected proteins in vivo. The antigens with the proven capability to induce antibodies will be tested in animal models for the ability to prevent infections.

The antibodies produced against Staphylococci by the human immune system and present in human sera are indicative of the in vivo expression of the antigenic proteins and their immunogenicity.

Accordingly, novel hyperimmune serum-reactive antigens from Staphylococcus aureus or Staphylococcus epidermidis have been made available by the method according to the present invention. According to another aspect of the present invention the invention relates to a hyperimmune serum-reactive antigen selected from the group consisting of the sequences listed in any one of Tables 2a, 2b, 2c, 2d, 3, 4 and 5, especially selected from the group consisting of Seq.ID No. 56, 57, 59, 60, 67, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 85, 87, 88, 89, 90, 92, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 126, 128, 132, 134, 138, 140, 142, 151, 152, 154, 155 and hyperimmune fragments thereof. Accordingly, the present invention also relates to a hyperimmune serum-reactive antigen obtainable by the method according to the present invention

11年には経済でから出るので、これのはいに指摘で、

F.

. ;

二人的现在分词 经营的

and being selected from the group consisting of the sequences listed in any one of Tables 2a, 2b, 2c, 2d, 3, 4 and 5, especially selected from the group consisting of Seq.ID No. 56, 57, 59, 60, 67, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 85, 87, 88, 89, 90, 92, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 126, 128, 132, 134, 138, 140, 142, 151, 152, 154, 155 and hyperimmune fragments thereof.

Antigens from Staphylococcus aureus and Staphylococcus epidermidis have been\_extracted by the method according to the present invention which may be used in the manufacture of a pharmaceutical preparation, especially for the manufacture of a vaccine against Staphylococcus aureus and Staphylococcus epidermidis infections. Examples of such hyperimmune serum-reactive antigens of Staphylococcus aureus and Staphylococcus epidermidis to be used in a pharmaceutical preparation are selected from the group consisting of the sequences listed in any one of Tables 2a, 2b, 2c, 2d, 3, 4 and 5, especially selected from the group consisting of Seq.ID No. 55, 56, 57, 58, 59, 60, 62, 66, 67, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 87, 88, 89, 90, 92, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 126, 128, 130, 132, 134, 138, 140, 142, 151, 152, 154, 155, 158 and hyperimmune fragments thereof for the manufacture of a pharmaceutical preparation, especially for the manufacture of a vaccine against Staphylococcus aureus and Staphylococcus epidermidis infections.

A hyperimmune fragment is defined as a fragment of the identified antigen which is for itself antigenic or may be made antigenic when provided as a hapten. Therefore, also antigen or antigenic fragments showing one or (for longer fragments) only a few amino acid exchanges are enabled with the present invention, provided that the antigenic capacities of such fragments with amino acid exchanges are not severely deteriorated on the exchange(s). i.e. suited for eliciting an appropriate immune response in a individual vaccinated with this antigen and identified by individual antibody preparations from individual sera.

Preferred examples of such hyperimmune fragments of a hyperimmune serum-reactive antigen are selected from the group consisting of

\$4.00 mm.

Committee Commit

62,

peptides comprising the amino acid sequences of column "predicted immunogenic aa", "Location of identified immunogenic region" and "Serum reactivity with relevant region" of Tables 2a, 2b, 2c and 2d and the amino acid sequences of column "Putative antigenic surface areas of Table 4 and 5, especially peptides comprising amino acid No. aa 12-29, 34-40, 63-71, 101-110, 114-122, 130-138, 140-195, 197-209, 215-229, 239-253, 255-274 and 39-94 of Seq.ID aa 5-39, 111-117, 125-132, 134-141, 167-191, 196-202, 214-232, 236-241, 244-249, 292-297, 319-328, 336-341, 365-380, 385-391, 407-416, 420-429, 435-441, 452-461, 477-488, 491-498, 518-532, 545-556, 569-576, 581-587, 595-602, 604-609, 617-640, 643-651, 702-715, 723-731, 786-793, 805-811, 826-839, 874-889, 37-49; 63-77 and 274-334, of Seq.ID No.56, aa 28-55, 82-100, 105-111, 125-131, 137-143, 1-49, of Seq.ID No. 57. aa 33-43, 45-51, 57-63, 65-72, 80-96, 99-110, 123-129, 161-171, 173-179, 185-191, 193-200, 208-224, 227-246, 252-258, 294-308, 321-329, 344-352, 691-707, 358-411 and 588-606, of Seq.ID No. 58, aa 16-38, 71-77, 87-94, 105-112, 124-144, 158-164, 169-177, 180-186, 194-204, 221-228, 236-245, 250-267, 336-343, 363-378, 385-394, 406-412, 423-440, 443-449, 401-494, of Seq.ID No. 59, aa 18-23, 42-55, 69-77, 85-98, 129-136, 182-188, 214-220, 229-235, 242-248, 251-258, 281-292, 309-316, 333-343, 348-354, 361-367, 393-407, 441-447, 481-488, 493-505, 510-515, 517-527, 530-535, 540-549, 564-583, 593-599, 608-621, 636-645, 656-670, 674-687, 697-708, 726-734, 755-760, 765-772, 785-792, 798-815, 819-824, 826-838, 846-852, 889-904, 907-913, 932-939, 956-964, 982-1000, 1008-1015, 1017-1024, 1028-1034, 1059-1065, 1078-1084, 1122-1129, 1134-1143, 1180-1186, 1188-1194, 1205-1215, 1224-1230, 1276-1283, 1333-1339, 1377-1382, 1415-1421, 1448-1459, 1467-1472, 1537-1545, 1556-1566, 1647-1654, 1666-1675, 1683-1689, 1722-1737, 1740-1754, 1756-1762, 1764-1773, 1775-1783, 1800-1809, 1811-1819, 1839-1851, 1859-1866, 1876-1882, 1930-1939, 1947-1954, 1978-1985, 1999-2007, 2015-2029, 2080-2086, 2094-2100, 2112-2118, 2196-2205, 2232-2243, 198-258, 646-727 and 2104-2206, of Seq.ID No. 60, aa 10-29, 46-56, 63-74, 83-105, 107-114, 138-145, 170-184, 186-193, 216-221, 242-248, 277-289, 303-311, 346-360, 379-389, 422-428, 446-453, 459-469, 479-489, 496-501, 83-156, of Seq. ID No.

aa 14-22, 32-40, 52-58, 61-77, 81-93, 111-117, 124-138, 151-190, 193-214, 224-244, 253-277, 287-295, 307-324, 326-332, 348-355, 357-362, 384-394, 397-434, 437-460, 489-496, 503-510, 516-522, 528-539, 541-547, 552-558, 563-573, 589-595, 602-624, 626-632, 651-667, 673-689, 694-706, 712-739, 756-790, 403-462, of Seq.ID No. 66, aa 49-56, 62-68, 83-89, 92-98, 109-115, 124-131, 142-159, 161-167, 169-175, 177-188, 196-224, 230-243, 246-252, 34-46, of Seq.ID No. 67, aa 11-20, 26-47, 69-75, 84-92, 102-109, 119-136, 139-147, 160-170, 178-185, 190-196, 208-215, 225-233, 245-250, 265-272, 277-.284, 300-306, 346-357, 373-379, 384-390, 429-435, 471-481, 502-507, 536-561, 663-688, 791-816, 905-910, 919-933, 977-985, 1001-1010, 1052-1057, 1070-1077, 1082-1087, 1094-1112, 493-587, 633-715 and 704-760, of Seq.ID No.70, aa 6-20, 53-63, 83-90, 135-146, 195-208, 244-259, 263-314, 319-327, 337-349, 353-362, 365-374, 380-390, 397-405, 407-415, 208-287 and 286-314, of Seq.ID No. 71, aa 10-26, 31-43, 46-58, 61-66, 69-79, 85-92, 100-115, 120-126, 128-135, 149-155, 167-173, 178-187, 189-196, 202-222, 225-231, 233-240, 245-251, 257-263, 271-292, 314-322, 325-334, 339-345, 59-74, of Seq.ID No. 72, aa 4-9, 15-26, 65-76, 108-115, 119-128, 144-153, 38-52 and 66-114, of Seq. ID No. 73, aa 5-22, 42-50, 74-81, 139-145, 167-178, 220-230, 246-253, 255-264, 137-237 and 250-267, of Seq.ID No. 74, aa 10-26, 31-44, 60-66, 99-104, 146-153, 163-169, 197-205, 216-223, 226-238, 241-258, 271-280, 295-315, 346-351, 371-385, 396-407, 440-446, 452-457, 460-466, 492-510, 537-543, 546-551, 565-582, 590-595, 635-650, 672-678, 686-701, 705-712, 714-721, 725-731, 762-768, 800-805, 672-727, of Seq.ID No. 75, aa 5-32, 35-48, 55-76, of Seq.ID No. 76, aa 7-35, 54-59, 247-261, 263-272, 302-320, 330-339, 368-374, 382-.. 411, 126-143 and 168-186, of Seq.ID No. 77, aa 5-24, 88-94, 102-113, 132-143, 163-173, 216-224, 254-269, 273-278, 305-313, 321-327, 334-341, 31-61 and 58-74, of Seq.ID No. 78, aa 16-24, 32-39, 43-49, 64-71, 93-99, 126-141, 144-156, 210-218, 226-233, 265-273, 276-284, 158-220, of Seq.ID No. 79, aa 49-72, 76-83, 95-105, 135-146, 148-164, 183-205, 57-128, of

and the second s

個人の記事 ける

Seq. ID No. 80, aa 6-15, 22-32, 58-73, 82-88, 97-109, 120-131, 134-140, 151-163, 179-185, 219-230, 242-255, 271-277, 288-293, 305-319, 345-356, 368-381, 397-406, 408-420, 427-437, 448-454, 473-482, 498-505, 529-535, 550-563, 573-580, 582-590, 600-605, 618-627, 677-685, 718-725, 729-735, 744-759, 773-784, 789-794, 820-837, 902-908, 916-921, 929-935, 949-955, 1001-1008, 1026-1032, 1074-1083, 1088-1094, 1108-1117, 1137-1142, 1159-1177, 1183-1194, 1214-1220, 1236-1252, 1261-1269, 1289-1294, 1311-1329, 1336-1341, 1406-1413, 1419-1432, 1437-1457, 1464-1503, 1519-1525, 1531-1537, 1539-1557, 1560-1567, 1611-1618, 1620-1629, 1697-1704, 1712-1719, 1726-1736, 1781-1786, 1797-1817, 1848-1854, 1879-1890, 1919-1925, 1946-1953, 1974-1979, 5 to 134, of Seq. ID No. 81, aa 6-33, 40-46, 51-59, 61-77, 84-104, 112-118, 124-187, 194-248, 252-296, 308-325, 327-361, 367-393, 396-437, 452-479, 484-520, 535-545, 558-574, 582-614, 627-633, 656-663, 671-678, 698-704, 713-722, 725-742, 744-755, 770-784, 786-800, 816-822, 827-837, .483-511, of Seq.ID No. 82, aa 4-19, 57-70, 79-88, 126-132, 144-159, 161-167, 180-198, 200-212, 233-240, 248-255, 276-286, 298-304, 309-323, 332-346, 357-366, 374-391, 394-406, 450-456, 466-473, 479-487, 498-505, 507-519, 521-530, 532-540, 555-565, 571-581, 600-611, 619-625, 634-642, 650-656, 658-665, 676-682, 690-699, 724-733, 740-771, 774-784, 791-797, 808-815; 821-828, 832-838, 876-881, 893-906, 922-929, 938-943, 948-953, 969-976, 1002-1008, 1015-1035, 1056-1069, 1105-1116, 1124-1135, 1144-1151, 1173-1181, 1186-1191, 1206-1215, 1225-1230, 1235-1242, 6-66, 65-124 and 590-604, of Seq.ID No. 83, aa 5-32, 66-72, 87-98, 104-112, 116-124, 128-137, 162-168, 174-183, 248-254, 261-266, 289-303, 312-331, 174-249, of Seq.ID No. 84. aa 4-21, 28-40, 45-52, 59-71, 92-107, 123-137, 159-174, 190-202, 220-229, 232-241, 282-296, 302-308, 312-331, 21-118, of Seq.ID No. 85, aa 9-28, 43-48, 56-75, 109-126, 128-141, 143-162, 164-195, 197-216, 234-242, 244-251, 168-181, of Seq. ID No. 87, aa 4-10, 20-42, 50-86, 88-98, 102-171, 176-182, 189-221, 223-244, 246-268, 276-284, 296-329, 112-188, of Seq.ID No. 88, aa 4-9, 13-24, 26-34, 37-43, 45-51, 59-73, 90-96, 99-113, 160-173, 178-184, 218-228, 233-238, 255-262, 45-105, 103-166 and 66-153, of Seq.ID No. 89,

aa 13-27, 42-63, 107-191, 198-215, 218-225, 233-250, 474-367, of Seq.ID No. 90; aa 26-53, 95-123, 164-176, 189-199, 8-48, of Seq.ID No. 92, aa 7-13, 15-23, 26-33, 68-81, 84-90, 106-117, 129-137, 140-159, 165-172, 177-230, 234-240, 258-278, 295-319, 22-56, 23-99, 97-115, 233-250 and 245-265, of Seq.ID No. 94, aa 13-36, 40-49, 111-118, 134-140, 159-164, 173-183, 208-220, 232-241, 245-254, 262-271, 280-286, 295-301, 303-310, 319-324, 332-339, 1-85, 54-121 and 103-185, of Seq.ID No. 95, aa 39-44, 46-80, 92-98, 105-113, 118-123, 133-165, 176-208, 226-238, 240-255, 279-285, 298-330, 338-345, 350-357, 365-372, 397-402, 409-415, 465-473, 488-515, 517-535, 542-550, 554-590, 593-601, 603-620, 627-653, 660-665, 674-687, 698-718, 726-739, 386-402, of Seq.ID No. 96, aa 5-32, 34-49, 1-43, of Seq.ID No. 97, aa 10-27, 37-56, 64-99, 106-119, 121-136, 139-145, 148-178, 190-216, 225-249, 251-276, 292-297, 312-321, 332-399, 403-458, 183-200, of Seq.ID No. 99, aa 5-12, 15-20, 43-49, 94-106, 110-116, 119-128, 153-163, 175-180, 185-191, 198-209, 244-252, 254-264, 266-273, 280-288, 290-297, 63-126, of Seq.ID No. 100, aa 5-44, 47-55, 62-68, 70-78, 93-100, 128-151, 166-171, 176-308, 1-59, of Seq.ID No. 101, aa 18-28, 36-49, 56-62, 67-84, 86-95, 102-153, 180-195, 198-218, 254-280, 284-296, 301-325, 327-348, 353-390, 397-402, 407-414, 431-455, 328-394, of Seq.ID No. 102, aa 7-37, 56-71, 74-150, 155-162, 183-203, 211-222, 224-234, 242-272, 77-128, of Seq.ID No. 103, aa 34-58, 63-69, 74-86, 92-101, 130-138, 142-150, 158-191, 199-207, 210-221, 234-249, 252-271, 5-48, of Seq.ID No. 104, aa 12-36, 43-50, 58-65, 73-78, 80-87, 108-139, 147-153, 159-172, 190-203, 211-216, 224-232, 234-246, 256-261, 273-279, 286-293, 299-306, 340-346, 354-366, 167-181, of Seq.ID No. 106, aa 61-75, 82-87, 97-104, 113-123, 128-133, 203-216, 224-229, 236-246, 251-258, 271-286, 288-294, 301-310, 316-329, 337-346, 348-371, 394-406, 418-435, 440-452 of Seq.ID No. 112, aa 30-37, 44-55, 83-91, 101-118, 121-128, 136-149, 175-183, 185-

193, 206-212, 222-229, 235-242 of Seq.ID No. 114, aa 28-38, 76-91, 102-109, 118-141, 146-153, 155-161, 165-179, 186-202, 215-221, 234-249, 262-269, 276-282, 289-302, 306-314,

PCT/EP02/00546 WO 02/059148 - 27 -

321-326, 338-345, 360-369, 385-391 of Seq.ID No. 116, aa 9-33, 56-62,75-84, 99-105, 122-127, 163-180, 186-192, 206-228, 233-240, 254-262, 275-283, 289-296, 322-330, 348-355, 416-424, 426-438, 441-452, 484-491, 522-528, 541-549, 563-569, 578-584, 624-641, 527-544, of Seq.ID No. 142, aa 37-42, 57-62, 121-135, 139-145, 183-190, 204-212, 220-227, 242-248, 278-288, 295-30, 304-309, 335-341, 396-404, 412-433, 443-449, 497-503, 505-513, 539-545, 552-558, 601-617, 629-649, 702-711, 736-745, 793-804, 814-829, 843-858, 864-885, 889-895, 905-913, 919-929, 937-943, 957-965, 970-986, 990-1030, 1038-1049, 1063-1072, 1080-1091, 1093-1116, 1126-1136, 1145-1157, 1163-1171, 1177-1183, 1189-1196, 1211-1218, 1225-1235, 1242-1256, 1261-1269, 624-684, of Seq.ID No. 151, aa 8-23, 31-38, 42-49, 61-77, 83-90, 99-108, 110-119, 140-147, 149-155, 159-171, 180-185, 189-209, 228-234, 245-262, 264-275, 280-302, 304-330, 343-360, 391-409, 432-437, 454-463, 467-474, 478-485, 515-528, 532-539, 553-567, 569-581, 586-592, 605-612, 627-635, 639-656, 671-682, 700-714, 731-747, 754-770, 775-791, 797-834, 838-848, 872-891, 927-933, 935-942, 948-968, 976-986, 1000-1007, 1029-1037, 630-700, of Seq.ID No. 152, aa 17-25, 27-55, 84-90, 95-101, 115-121, 55-101, of Seq.ID No. 154, aa 13-28, 40-46, 69-75, 86-92, 114-120, 126-137, 155-172, 182-193, 199-206, 213-221, 232-238, 243-253, 270-276, 284-290, 22-100, of Seq. ID No. 155 and aa 7-19, 46-57, 85-91, 110-117, 125-133, 140-149, 156-163, 198-204, 236-251, 269-275, 283-290, 318-323, 347-363, 9-42 and 158-174, of Seq.ID No. 158, aa 7-14, 21-30, 34-50, 52-63, 65-72, 77-84, 109-124, 129-152, 158-163, 175-190, 193-216, 219-234 of Seq.ID.No. 168, aa 5-24, 38-44, 100-106, 118-130, 144-154, 204-210, 218-223, 228-243, 257-264, 266-286, 292-299 of Seq.ID.No. 174, aa 29-44, 74-83, 105-113, 119-125, 130-148, 155-175, 182-190, 198-211, 238-245 of Seq.ID.No. 176, and fragments comprising at least 6, preferably more than 8, especially more than 10 aa of said sequences . All these fragments individually and each independently form a preferred selected aspect of the present invention.

Especially suited helper epitopes may also be derived from these

antigens. Especially preferred helper epitopes are peptides comprising fragments selected from the peptides mentioned in column "Putative antigenic surface areas" in Tables 4 and 5 and from the group of aa 6-40, 583-598, 620-646 and 871-896 of Seq.ID.No.56, aa 24-53 of Seq.ID.No.70, aa 240-260 of Seq.ID.No.74, aa 1660-1682 and 1746-1790 of Seq.ID.No. 81, aa 1-29, 680-709, and 878-902 of Seq.ID.No. 83, aa 96-136 of Seq.ID.No. 89, aa 1-29, 226-269 and 275-326 of Seq.ID.No. 94, aa 23-47 and 107-156 of Seq.ID.No. 114 and aa 24-53 of Seq.ID.No. 142 and fragments thereof being T-cell epitopes.

According to another aspect, the present invention relates to a vaccine comprising such a hyperimmune serum-reactive antigen or a fragment thereof as identified above for Staphylococcus aureus and Staphylococcus epidermidis. Such a vaccine may comprise one or more antigens against S. aureus or S. epidermidis. Optionally, such S. aureus or S. epidermidis antigens may also be combined with antigens against other pathogens in a combination vaccine. Preferably this vaccine further comprises an immunostimulatory substance, preferably selected from the group comprising polycationic polymers, especially polycationic peptides, immunostimulatory deoxynucleotides (ODNs), neuroactive compounds, especially human growth hormone, alumn, Freund's complete or incomplete adjuvans or combinations thereof. Such a vaccine may also comprise the antigen displayed on a surface display protein platform on the surface of a genetically engineered microorganism such as E. coli.

According to another aspect, the present invention relates to specific preparations comprising antibodies raised against at least one of the Staphylococcus aureus and Staphylococcus epidermidis antigens or Staphylococcus aureus and Staphylococcus epidermidis antigen fragments as defined above. These antibodies are preferably monoclonal antibodies.

Methods for producing such antibody preparations, polyclonal or monoclonal, are well available to the man skilled in the art and properly described in the prior art. A preferred method for producing such monoclonal antibody preparation is characterized by the following steps

initiating an immune response in a non human animal by administering a Staphylococcus antigen or a fragment thereof, as defined above, to said animal,

removing the spleen or spleen cells from said animal,
producing hybridoma cells of said spleen or spleen cells,
selecting and cloning hybridoma cells specific for said anti-

gen and
•producing the antibody preparation by cultivation of said

steps.

Preferably, removing of the spleen or spleen cells is connected with killing said animal.

cloned hybridoma cells and optionally further purification

Monoclonal antibodies and fragments thereof can be chimerized or humanized (Graziano et al. 1995) to enable repeated administration. Alternatively human monoclonal antibodies and fragments thereof can be obtained from phage-display libraries (McGuinnes et al., 1996) or from transgenic animals (Brüggemann et al., 1996).

A preferred method for producing polyclonal antibody preparations to said Staphylococcus aureus or Staphylococcus epidermidis antigens identified with the present invention is characterized by the following steps

•initiating an immune response in a non human animal by administering a Staphylococcus antigen or a fragment thereof, as defined above, to said animal,

removing an antibody containing body fluid from said animal,and

producing the antibody preparation by subjecting said antibody containing body fluid to further purification steps.

These monoclonal or polyclonal antibody preparations may be used for the manufacture of a medicament for treating or preventing diseases due to staphylococcal infection. Moreover, they may be used for the diagnostic and imaging purposes.

The method is further described in the following examples and in the figures, but should not be restricted thereto.

1.54 6.

Figure 1 shows the pre-selection of sera based on anti-staphylo-coccal antibody titers measured by ELISA.

Figure 2 shows the size distribution of DNA fragments in the LSA50/6 library in pMAL4.1.

Figure 3 shows the MACS selection with biotinylated human serum. The LSA50/6 library in pMAL9.1 was screened with 10  $\mu$ g biotinylated, human serum in the first (A) and with 1  $\mu$ g in the second selection round (B). P. serum, patient serum; B. serum, infant serum. Number of cells selected after the 2<sup>nd</sup> and 3<sup>rd</sup> elution are shown for each selection round.

Figure 4 shows the serum reactivity with specific clones isolated by bacterial surface display as analyzed by Western blot analysis with patient serum at a dilution of 1:5000.

Figure 5 shows peptide ELISA with serum from patients and healthy individuals with an epitope identified by ribosome display.

Figure 6 shows representative 2D Immunoblot of S. aureus surface proteins detected with human sera. 800 µg protein from S. aureus/COL grown on BHI were resolved by IEF (pI 4-7) and SDS-PAGE (9-16%), and subsequently transferred to PVDF membrane. After blocking, the membrane was incubated with sera IC35 (1:20,000). Binding of serum IgG was visualized by an anti-human IgG/HRPO conjugate and ECL development.

Figure 7 demonstrates a representative 2D gel showing S. aureus surface proteins stained by Coomassie Blue. 1 mg protein from S. aureus/COL were resolved by IEF (pI 4-7) and SDS-PAGE (9-16%). Spots selected for sequencing after serological proteome analysis are marked.

Figures 8Aand 8B show the structure of LPXTG cell wall proteins.

Figure 9 shows the IgG response in uninfected (N, C) and infected (P) patients to LPXTGV, a novel antigen and probable surface adhesin of S. aureus, discovered by both the inventive bacterial

<u>:</u>;

surface-display and proteomics approaches.

Figure 10 shows the surface staining of S. aureus with purified anti-LPXTGV IgGs.

Figure 11 shows a 2D gel where S. aureus surface proteins are stained by Coomassie Blue (left). 1 mg protein from S. aureus/agr grown to early log phase was resolved by IEF (pI 6-11) and SDS-PAGE (9-16%). Spots selected for sequencing after serological proteome analysis are marked. Corresponding 2D-immunoblot (right). 800 µg protein from the same preparation was resolved in parallel by 2DE, and subsequently transferred to PVDF membrane. After blocking, the membrane was incubated with the P-pool (1:10,000). Binding of serum IgG was visualized by an anti-human IgG/HRPO conjugate and ECL development.

#### EXAMPLES

Discovery of novel Staphyloccocus aureus antigens

## Example 1: Preparation of antibodies from human serum

The antibodies produced against staphylococci by the human immune system and present in human sera are indicative of the in vivo expression of the antigenic proteins and their immunogenicity. These molecules are essential for the identification of individual antigens in the approach as the present invention which is based on the interaction of the specific anti-staphylococcal antibodies and the corresponding S. aureus peptides or proteins. To gain access to relevant antibody repertoires, human sera were collected from I. patients with acute S. aureus infections, such as bacteriaemia, sepsis, infections of intravascular and percutan catheters and devices, wound infections, and superficial and deep soft tissue infection. S. aureus was shown to be the causative agent by medical microbiological tests. II. A collection of serum samples from uninfected adults was also included in the present analysis, since staphylococcal infections are common, and antibodies are present as a consequence of natural immunization from

previous encounters with Staphylococci from skin and soft tissue infections (furunculus, wound infection, periodontitits etc.).

The sera were characterized for S. aureus antibodies by a series of ELISA assays. Several styaphylococcal antigens have been used to prove that the titer measured was not a result of the sum of cross-reactive antibodies. For that purpose not only whole cell S. aureus (protein A deficient) extracts (grown under different conditions) or whole bacteria were used in the ELISA assays, but also individual cell wall components, such as lipoteichoic acid and peptidoglycan isolated from S. aureus. More importantly, a recombinant protein collection was established representing known staphylococcal cell surface proteins for the better characterization of the present human sera collections.

Recently it was reported that not only IgG, but also IgA serum antibodies can be recognized by the FcRIII receptors of PMNs and promote opsonization (Phillips-Quagliata et al., 2000; Shibuya et al., 2000). The primary role of IgA antibodies is neutralization, mainly at the mucosal surface. The level of serum IgA reflects the quality, quantity and specificity of the dimeric secretory IgA. For that reason the serum collection was not only analyzed for anti-staphylococcal IgG, but also for IgA levels. In the ELISA assays highly specific secondary reagents were used to detect antibodies from the high affinity types, such as IgG and IgA, and avoided IgM. Production of IgM antibodies occurs during the primary adaptive humoral response, and results in low affinity antibodies, while IgG and IgA antibodies had already undergone affinity maturation, and are more valuable in fighting or preventing disease

#### Experimental procedures

Enzyme linked immune assay (ELISA). ELISA plates were coated with 2-10 µg/ml of the different antigens in coating buffer (sodium carbonate pH 9.2). Serial dilutions of sera (100-100.000) were made in TBS-BSA. Highly specific (cross-adsorbed) HRP (Horse Radish Peroxidase)-labeled anti-human IgG or anti-human IgA secondary antibodies (Southern Biotech) were used according to the manufacturers' recommendations (~ 2.000x). Antigen-antibody complexes were quantified by measuring the conversion of the sub-

· 山田林 · 中国 · 中山

strate (ABTS) to colored product based on OD readings in an automated ELISA reader (Wallace Victor 1420). The titers were compared at given dilution where the dilution response was linear (Table 1). The ~ 100 sera were ranked based on the reactivity against multiple staphylococcal components, and the highest ones (above 90 percentile) were selected for further analysis in antigen identification. Importantly, the anti-staphylococcal antibodies from sera of clinically healthy individuals proved to be very stable, giving the same high ELISA titers against all the staphylococcal antigens measured after 3, 6 and 9 months (data not shown). In contrast, anti-S. aureus antibodies in patients decrease, then disappear after a couple of weeks following the infection (Coloque-Navarro et al, 1998). However, antibodies from patients are very important, since these are direct proof of the in vivo expression of the bacterial antigens tested in or ELISAs or identified as immunogenic during the screens according to the present invention.

This comprehensive approach followed during antibody characterization is unique, and led to unambiguous identification of antistaphylococcal hyperimmune sera.

Purification of antibodies for genomic screening. Five sera from both the patient and the noninfected group were selected based on the overall anti-staphylococcal titers. Antibodies against E. coli proteins were removed by either incubating the heat inactivated sera with whole cell E. coli (DH5a, transformed with pHIE11, grown under the same condition as used for bacterial display) or with E. coli lysate affinity chromatography for ribosome display. Highly enriched preparations of IgG from the pooled, depleted sera were generated by protein G affinity chromatography, according to the manufacturer's instructions (UltraLink Immobilized Protein G, Pierce). IgA antibodies were purified also by affinity chromatography using biotin-labeled anti-human IgA (Southern Biotech) immobilized on Streptavidin-agarose (GIBCO BRL). The efficiency of depletion and purification was checked by SDS-PAGE, Western blotting, ELISA, and protein concentration measurements. For proteomics, the depletion the IgG and IgA preparation was not necessary, since the secondary reagent ensured the specificity.

:

MERCHANICA CANADA CANAD

Example 2: Generation of highly random, frame-selected, small-fragment, genomic DNA libraries of Staphylococcus aureus

## Experimental procedures

Tyreparation of staphylococcal genomic DNA. This method was developed as a modification of two previously published protocols (Sohail, 1998, Betley et al., 1984) and originally specifically adapted for the methicillin resistant Staphylococcus aureus strain COL to obtain genomic DNA in high quality and large scale. 500 ml BHI (Brain Heart Infusion) medium supplemented with 5 μg/ml Tetracycline was inoculated with bacteria from a frozen stab and grown with aeration and shaking for 18 h at 37°. The culture was then harvested in two aliquots of 250 ml each, centrifuged with 1600 x g for 15 min and the supernatant was removed. Bacterial pellets were carefully re-suspended in 26 ml of  $0.1 \, \text{mM}$  Tris-HCl, pH 7.6 and centrifuged again with 1600 x g for 15 min. Pellets were re-suspended in 20 ml of 1 mM Tris-HCl, pH 7.6, 0.1 mM EDTA and transferred into sterile 50 ml polypropylene tubes. 1 ml of 10 mg/ml heat treated RNase A and 200 U of RNase T1 were added to each tube and the solution mixed carefully. 250 µl of Lysostaphin (10 mg/ml stock, freshly prepared in ddH\_O) was then added to the tubes, mixed thoroughly and incubated at 40°C for 10 min in a shaking water bath under continuous agitation. After the addition of 1 ml 10 % SDS, 40 µl of Proteinase K (25 mg/ml stock) and 100  $\mu$ l of Pronase (10 mg/ml), tubes were again inverted several times and incubated at 40°C for 5 min in a shaking water bath. 3.75 ml of 5 M NaCl and 2.5 ml of cetyl trimethyl-ammonium bromide solution (CTAB) (10% w/v, 4% w/v NaCl) were then added and tubes were further incubated at 65°C in a shaking water bath for 10 min. Samples were cooled to room temperature and extracted with PhOH/CHCl,/IAA (25:24:1) and with CHCl,/IAA (24:1). Aqueous phases were carefully collected and transferred to new sterile 50-ml tubes. To each tube 1.5 ml of Strataclean™ Resin was added, mixed gently but thoroughly and incubated for one minute at room temperature. Samples were centrifuged and the upper layers containing the DNA were collected into clean 50ml-tubes. DNA was precipitated at room temperature by adding 0.6 x volume of Isopropanol, spooled from the solution with a sterile Pasteur pipette and transferred into tubes containing 80% ice cold ethanol. DNA was recovered by centrifuging the precipitates with 10-12 000  $\times$  g, then dried on air and dissolved in ddH.O.

Preparation of small genomic DNA fragments. Genomic DNA fragments were mechanically sheared into fragments ranging in size between 150 and 300 bp using a cup-horn sonicator (Bandelin Sonoplus UV 2200 sonicator equipped with a BB5 cup horn, 10 sec. pulses at 100 % power output) or into fragments of size between 50 and 70 bp by mild DNase I treatment (Novagen). It was observed that sonication yielded a much tighter fragment size distribution when breaking the DNA into fragments of the 150-300 bp size range. However, despite extensive exposure of the DNA to ultrasonic wave-induced hydromechanical shearing force, subsequent decrease in fragment size could not be efficiently and reproducibly achieved. Therefore, fragments of 50 to 70 bp in size were obtained by mild DNase I treatment using Novagen's shotgun cleavage kit. A 1:20 dilution of DNase I provided with the kit was prepared and the digestion was performed in the presence of MnCl in a 60 µl volume at 20°C for 5 min to ensure double-stranded cleavage by the enzyme. Reactions were stopped with 2  $\mu$ l of 0.5 M EDTA and the fragmentation efficiency was evaluated on a 2% TAE-agarose gel. This treatment resulted in total fragmentation of genomic DNA into near 50-70 bp fragments. Fragments were then blunt-ended twice using T4 DNA Polymerase in the presence of 100 µM each of dNTPs to ensure efficient flushing of the ends. Fragments were used immediately in ligation reactions or frozen at -20°C for subsequent use.

Description of the vectors. The vector pMAL4.1 was constructed on a pEH1 backbone (Hashemzadeh-Bonehi et al., 1998) with the Kanamycin resistance gene. In addition it harbors a b-lactamase (bla) gene cloned into the multiple cloning site. The bla gene is preceded by the leader peptide sequence of ompA to ensure efficient secretion across the cytoplasmic membrane. A Sma I restriction site serves for library insertion. The Sma I site is flanked by an upstream FseI site and a downstream NotI site which were used for recovery of the selected fragments. The three restriction sites are inserted after the ompA leader sequence in such a way that the bla gene is transcribed in the -1 reading frame result-

4.1.

ing in a stop codon 15 bp after the NotI site. A +1 bp insertion restores the bla ORF so that b-lactamase protein is produced with a consequent gain of Ampicillin resistance.

The vector pMAL4.31 was constructed on a pASK-IBA backbone (Skerra, 1994) with the b-lactamase gene exchanged with the Kanamycin resistance gene. In addition it harbors a b-lactamase (bla) gene cloned into the multiple cloning site. The sequence encoding mature b-lactamase is preceded by the leader peptide sequence of ompA to allow efficient secretion across the cytoplasmic membrane. Furthermore a sequence encoding the first 12 amino acids (spacer sequence) of mature b-lactamase follows the ompA leader peptide sequence to avoid fusion of sequences immediately after the leader peptidase cleavage site, since e.g. clusters of positive charged amino acids in this region would decrease or abolish translocation across the cytoplasmic membrane (Kajava et al., 2000). A Smal restriction site serves for library insertion. The Smal site is flanked by an upstream Fsel site and a downstream NotI site which were used for recovery of the selected fragment. The three restriction sites are inserted after the sequence encoding the 12 amino acid spacer sequence in such a way that the bla gene is transcribed in the -1 reading frame resulting in a stop codon 15 bp after the NotI site. A +1 bp insertion restores the bla ORF so that b-lactamase protein is produced with a consequent gain of Ampicillin resistance.

The vector pMal9.1 was constructed by cloning the lamB gene into the multiple cloning site of pEH1. Subsequently, a sequence was inserted in lamB after amino acid 154, containing the restriction sites FseI, SmaI and NotI. The reading frame for this insertion was chosen in a way that transfer of frame-selected DNA fragments excised by digestion with FseI and NotI from plasmids pMAL4.1 or pMAL4.31 to plasmid pMAL9.1 will yield a continuous reading frame of lamB and the respective insert.

The vector pHIE11 was constructed by cloning the fhuA gene into the multiple cloning site of pEH1. Thereafter, a sequence was inserted in fhuA after amino acid 405, containing the restriction site FseI, XbaI and NotI. The reading frame for this insertion was chosen in a way that transfer of frame-selected DNA fragments excised by digestion with FseI and NotI from plasmids pMAL4.1 or

pMAL4.31 to plasmid pHIE11 will yield a continuous reading frame of fhuA and the respective insert.

Cloning and evaluation of the library for frame selection. Genomic S. aureus DNA fragments were ligated into the SmaI site of either the vector pMAL4.1 or pMAL4.31. Recombinant DNA was electroporated into DH10B electrocompetent E. coli cells (GIBCO BRL) and transformants plated on LB-agar supplemented with Kanamycin (50 µg/ml) and Ampicillin (50 µg/ml). Plates were incubated over night at 37°C and colonies collected for large scale DNA extraction. A representative plate was stored and saved for collecting colonies for colony PCR analysis and large-scale sequencing. A simple colony PCR analysis and large-scale sequencing. A simple colony PCR assay was used to initially determine the rough fragment size distribution as well as insertion efficiency. From sequencing data the precise fragment size was evaluated, junction intactness at the insertion site as well as the frame selection accuracy (3n+1 rule).

Cloning and evaluation of the library for bacterial surface display. Genomic DNA fragments were excised from the pMAL4.1 or pMAL4.31 vector, containing the S. aureus library with the restriction enzymes FseI and NotI. The entire population of fragments was then transferred into plasmids pMAL9.1 (LamB) or pHIE11 (FhuA) which have been digested with FseI and NotI. Using these two restriction enzymes, which recognise an 8 bp GC rich sequence, the reading frame that was selected in the pMAL4.1 or pMAL4.31 vector is maintained in each of the platform vectors. The plasmid library was then transformed into E. coli DH5a cells by electroporation. Cells were plated onto large LB-agar plates supplemented with 50 µg/ml Kanamycin and grown over night at 37°C at a density yielding clearly visible single colonies. Cells were then scraped off the surface of these plates, washed with fresh LB medium and stored in aliquots for library screening at -80°C.

THE PARTY OF

### Results

Libraries for frame selection. Two libraries (LSA50/6 and LSA250/1) were generated in the pMAL4.1 vector with sizes of approximately 50 and 250 bp, respectively. For both libraries a total number of clones after frame selection of 1-2x 10<sup>6</sup> was

received using approximately 1 µg of pMAL4.1 plasmid DNA and 50 ng of fragmented genomic S. aureus DNA. To assess the randomness of the LSA50/6 library, 672 randomly chosen clones were sequenced. The bioinformatic analysis showed that of these clones none was present more than once. Furthermore, it was shown that 90% of the clones fell in the size range of 19 to 70 bp with an average size of 25 bp (Figure 2). All 672 sequences followed the 3n+1 rule, showing that all clones were properly frame selected.

Bacterial surface display libraries. The display of peptides on the surface of E. coli required the transfer of the inserts from the LSA50/6 library from the frame selection vector pMAL4.1 to the display plasmids pMAL9.1 (LamB) or pHIE11 (FhuA). Genomic DNA fragments were excised by FseI and NotI restriction and ligation of 5ng inserts with 0.1µg plasmid DNA resulted in 2-5x 10<sup>6</sup> clones. The clones were scraped off the LB plates and frozen without further amplification.

Example 3: Identification of highly immunogenic peptide sequences from S. aureus using bacterial surface displayed genomic libraries and human serum

#### Experimental procedures

MACS screening. Approximately  $2.5 \times 10^8$  cells from a given library were grown in 5 ml LB-medium supplemented with 50 µg/ml Kanamycin for 2 h at 37°C. Expression was induced by the addition of 1 mM IPTG for 30 min. Cells were washed twice with fresh LB medium and approximately  $2 \times 10^7$  cells re-suspended in 100 µl LB medium and transferred to an Eppendorf tube.

10  $\mu g$  of biotinylated, human serum was added to the cells and the suspension incubated over night at 4°C with gentle shaking. 900  $\mu l$  of LB medium was added, the suspension mixed and subsequently centrifuged for 10 min at 6000 rpm at 4°C. Cells were washed once with 1 ml LB and then re-suspended in 100  $\mu l$  LB medium. 10  $\mu l$  of MACS microbeads coupled to streptavidin (Miltenyi Biotech, Germany) were added and the incubation continued for 20 min at 4°C. Thereafter 900  $\mu l$  of LB medium was added and the MACS microbead cell suspension was loaded onto the equilibrated MS column (Mil-

tenyi Biotech, Germany) which was fixed to the magnet. (The MS columns were equilibrated by washing once with 1 ml 70% EtOH and twice with 2 ml LB medium.)

The column was then washed three times with 3 ml LB medium. The elution was performed by removing the magnet and washing with 2 ml LB medium. After washing the column with 3 ml LB medium, the 2 ml eluate was loaded a second time on the same column and the washing and elution process repeated. The loading, washing and elution process was performed a third time, resulting in a final eluate of 2 ml.

A second round of screening was performed as follows. The cells from the final eluate were collected by centrifugation and resuspended in 1 ml LB medium supplemented with 50 µg/ml Kanamycin. The culture was incubated at 37°C for 90 min and then induced with 1 mM IPTG for 30 min. Cells were subsequently collected, washed once with 1 ml LB medium and suspended in 10 µl LB medium. Since the volume was reduced, 1 µg of human, biotinylated serum was added and the suspension incubated over night at 4°C with gentle shaking. All further steps were exactly the same as in the first selection round. Cells selected after two rounds of selection were plated onto LB-agar plates supplemented with 50 µg/ml Kanamycin and grown over night at 37°C.

Evaluation of selected clones by sequencing and Western blot analysis. Selected clones were grown over night at 37°C in 3 ml LB medium supplemented with 50 µg/ml Kanamycin to prepare plasmid DNA using standard procedures. Sequencing was performed at MWG (Germany) or in a collaboration with TIGR (U.S.A.).

**開発のでなる**:

For Western blot analysis approximately 10 to 20 µg of total cellular protein was separated by 10% SDS-PAGE and blotted onto HybondC membrane (Amersham Pharmacia Biotech, England). The LamB or FhuA fusion proteins were detected using human serum as the primary antibody at a dilution of 1:5000 and anti human IgG antibodies coupled to HRP at a dilution of 1:5000 as secondary antibodies. Detection was performed using the ECL detection kit (Amersham Pharmacia Biotech, England). Alternatively, rabbit antifluA or mouse anti LamB antibodies were used as primary antibodies in combination with the respective secondary antibodies cou-

[ :

pled to HRP for the detection of the fusion proteins.

### Results

The same with the figure

Screening of bacterial surface display libraries by magnetic activated cell sorting (MACS) using biotinylated human serum. The libraries LSA50/6 in pMAL9.1 and LSA250/1 in pHIE11 were screened with a pool of biotinylated, human patient sera (see Example 1) Preparation of antibodies from human serum). The selection procedure was performed as described under Experimental procedures. As a control, pooled human sera from infants that have most likely not been infected with S. aureus was used. Under the described conditions between 10 and 50 fold more cells with the patient compared to the infant serum were routinely selected (Figure 3). To evaluate the performance of the screen, approximately 100 selected clones were picked randomly and subjected to Western blot analysis with the same pooled patient serum. This analysis revealed that 30 to 50% of the selected clones showed reactivity with antibodies present in patient serum whereas the control strain expressing LamB or FhuA without a S. aureus specific insert did not react with the same serum. Colony PCR analysis showed that all selected clones contained an insert in the expected size range.

Subsequent sequencing of a larger number of randomly picked clones (500 to 800 per screen) led to the identification of the gene and the corresponding peptide or protein sequence that was specifically recognized by the human patient serum used for screening. The frequency with which a specific clone is selected reflects at least in part the abundance and/or affinity of the specific antibodies in the serum used for selection and recognizing the epitope presented by this clone. In that regard it is striking that some clones (ORF2264, ORF1951, ORF0222, lipase and IsaA) were picked up to 90 times, indicating their highly immunogenic property. All clones that are presented in Table 2 have been verified by Western blot analysis using whole cellular extracts from single clones to show the indicated reactivity with the pool of human serum used in the screen.

It is further worth noticing that most of the genes identified by the bacterial surface display screen encode proteins that are ei-

PCT/EP02/00546 WO 02/059148 - 41 -

ther attached to the surface of S. aureus and/or are secreted. This is in accordance with the expected role of surface attached or secreted proteins in virulence of S. aureus.

Assessment of reactivity of highly immunogenic peptide sequences with different human sera. 10 to 30 different human patient sera were subsequently used to evaluate the presence of antibodies against the selected immunogenic peptide sequences that have been discovered in the screen according to the present invention. To eliminate possible cross-reactivity with proteins expressed by E. coli, all sera were pre-adsorbed with a total cellular lysate of E. coli DHa cells expressing FhuA protein.

This analysis is summarized in Table 2 and as an example shown in Figure 4 and is indicative of the validity of the present screen. It further shows that already short selected epitopes can give rise to the production of antibodies in a large number of patients (ORF1618, ORF1632, IsaA, Empbp, Protein A). Those peptide sequences that are not recognized by a larger set of patient sera may still be part of an highly immunogenic protein, but the recombinant protein itself may be tested for that purpose for each single case.

Example 4: Identification of highly immunogenic peptide sequences from genomic fragments from S. aureus using ribosome display and human serum

## Experimental procedures

Ribosome display screening: 2.4 ng of the genomic library from S. aureus LSA250/1 in pMAL4.1 (described above) was PCR amplified with oligos ICC277 and ICC202 in order to be used for ribosome Oligos (CGAATAATACGACTCACTATAGGGAGACCACAACGGTTTCCCACTAGTAATAATTTTGTTTAACICC202 TTTAAGAAGGAGATATATCCATGCAGaCCTTGGCCGGCCTCCC) and hybridize 5' (GGCCCACCCGTGAAGGTGAGCCGGCGTAAGATGCTTTTCTGTGACTGG) and 3' of the Fse I-Not I insertion site of plasmid pMAL4.1, respectively. ICC277 introduces a T7 phage RNA polymerase promoter, a palindromic sequence resulting in a stem-loop structure on the RNA level, a ribosome binding site (RBS) and the translation start of gene 10 of the T7 phage including the ATG start codon.

Oligo ICC202 hybridizes at nucleotide position 668 of the &-lactamase open reading frame and also introduces a stem-loop structure at the 3' end of the resulting RNA. PCR was performed with the High fidelity PCR kit (Roche Diagnostic) for 25 cycles at 50°C hybridization temperature and otherwise standard conditions.

The resulting PCR library was used in 5 consecutive rounds of selection and amplification by ribosome display similar as described previously (Hanes et al., 1997) but with modifications as described below.

One round of ribosome display contained the following steps: In vitro transcription of 2 µg PCR product with the RiboMax kit (Promega) resulted in ca. 50 µg A. In vitro translation was performed for 9 minutes at 37°C in 22 µl volume with 4.4 µl Premix Z (250 mM TRIS-acetate pH 7.5, 1.75 mM of each amino acid, 10 mM ATP, 2.5 mM GTP, 5 mM cAMP, 150 mM acetylphosphate, 2.5 mg/ml E. coli tRNA, 0.1 mg/ml folinic acid, 7.5 % PEG 8000, 200 mM potassium glutamate, 13.8 mM Mg(Ac)2, 8 µl S30 extract (x mg/ml) and about 2 µg in vitro transcribed RNA from the pool. S30 extract was prepared as described (Chen et al, 1983). Next, the sample was transferred to an ice-cold tube containing 35.2 µl 10 % milk-WBT (TRIS-acetate pH 7.5, 150 mM NaCl, 50 mM Mg(Ac)2, 0.1 % Tween-20, 10 % milk powder) and 52.8 µl WBTH (as before plus 2.5 mg/ml heparin). Subsequently, immuno precipitation was performed by addition of 10 µg purified IgGs, incubation for 90 minutes on ice, followed by addition of 30 µl MAGmol Protein G beads (Miltenyi Biotec, 90 minutes on ice). The sample was applied to a pre-equilibrated µ column (Miltenyi Biotec) and washed 5 times with ice-cold WBT buffer. Next 20 µl EB20 elution buffer (50 mM TRIS-acetate, 150 mM NaCl, 20 mM EDTA, 50 µg/ml S. cerevisiae RNA) was applied to the column, incubated for 5 minutes at 4°C. Elution was completed by adding  $2 \times 50 \mu l$  EB20. The mRNA from the elution sample was purified with the High pure RNA isolation kit (Roche Diagnostics). Subsequent reverse transcription was performed with Superscript II reverse transcriptase kit (Roche Diagnostics) according to the instruction of the manufacturer with 60. pmol oligo ICC202 for 1 hour at 50°C in 50 µl volume. 5 µl of , this mix was used for the following PCR reaction with primers ICC202 and ICC277 as described above.

Link de de la

Three rounds of ribosome display were performed and the resulting selected PCR pool subsequently cloned into plasmid pHIE11 (described above) by cleavage with restriction endonucleases NotI and FseI.

Evaluation of selected clones by sequencing and peptide-ELISA analysis: Selected clones were grown over night at 37°C in 3 ml LB medium supplemented with 50 µg/ml Kanamycin to prepare plasmid DNA using standard procedures. Sequencing was performed at MWG (Germany) or at the Institute of Genomic Research (TIGR; Rockville, MD, U.S.A.). Peptides corresponding to the inserts were synthesized and coated in 10 mM NaHCO<sub>3</sub> pH 9.3 at a concentration of 10 µg/ml (50 µl) onto 96-well microtiter plates (Nunc). After blocking with 1% BSA in PBS at 37°C, 1:200 and 1:1000 dilutions of the indicated sera were diluted in 1% BSA/PBS and applied to the wells. After washing with PBS/0.1 % Tween-20, biotin-labeled anti-human IgG secondary antibodies (SBA) were added and these were detected by subsequent adding horseradish-peroxidase-coupled streptavidin according to standard procedures.

### Results

The 250-bp genomic library (LSA250/1) as described above was used for screening. Purified IgGs from uninfected adults but with high titer against S. aureus as described above were used for selection of antigenic peptides.

Three rounds of ribosome display selection and amplification were performed according to Experimental procedures; finished by cloning and sequencing the resulting PCR pool.

Sequence analyses of a large number of randomly picked clones (700) led to the identification of the gene and the corresponding peptide or protein sequence that was specifically recognized by the high titer serum used for screening. The frequency with which a specific clone was selected reflects at least in part the abundance and/or affinity of the specific antibodies in the serum used for selection and recognizing the epitope presented by this clone. Remarkably, some clones (ORFs) were picked up to 50 times, indicating their highly immunogenic property. Table 2 shows the ORF name, the Seq.ID No. and the number of times it was identi-

fied by the inventive screen.

For a number of immuno-selected ORFs peptides corresponding to the identified immunogenic region were synthesized and tested in peptide-ELISA for their reactivity towards the sera pool they were identified with and also a number of additional sera from patients who suffered from an infection by S. aureus. The two examples in the graphs in figure 5 show the values of peptides from aureolysin and Pls. They are not only hyperimmune reactive against the high titer sera pool but also towards a number of individual patient's sera. All synthesized peptides corresponding to selected immunogenic regions showed reactivity towards the high titer sera pool and Table 2 summarizes the number of times the peptides were reactive towards individual patients sera, similar as described above.

In addition, it is striking that for those ORFs that were also identified by bacterial surface display described above), very often the actual immunogenic region within the ORF was identical or overlapping with the one identified by ribosome display. This comparison can be seen in Table 2.

Example 5: Identification of highly immunogenic antigens from S. aureus using Serological Proteome Analysis.

## Experimental procedures

Surface protein preparations from S. aureus containing highly immunogenic antigens. S. aureus strains COL (Shafer and Iandolo, 1979) and agr- (Recsei et al., 1986) were stored as glycerol stocks at -80°C or on BHI (DIFCO) plates at 4°C. Single clones were used for inoculation of overnight cultures in either BHI ("standard conditions") or RPMI 1640 (GibcoBRL), last one depleted from iron ("stress conditions") by treating o/n with iminodiacetic acid (Sigma). Fresh medium was inoculated 1:100 the next day and bacteria were grown to O.D. 600 between 0.3 and 0.7. Bacteria were harvested by centrifugation and washed with icecold PBS. Surface proteins were prepared by lysostaphin treatment under isotonic conditions (Lim et al. 1998). Briefly, -3x 10° bacteria (according to O.D. 600 = 1 are about 5x10° bacteria) were re-

COLUMN TO THE TOTAL TO THE SECOND TO THE SEC

suspended in 1 ml digestion buffer containing 35% raffinose (Aldrich Chemical Company), protease inhibitors (Roche) and 5 units lysostaphin (Sigma). After incubation at 37°C for 30 min, protoplasts were carefully sedimented by low-speed centrifugation. This treatment releases surface proteins covalently linked to the pentaglycine bridge of the peptidoglycan cell wall to the supernatant (in Crossley, 1997). Cell surface proteins were either precipitated with methanol/chlorophorm (Wessel, 1984) or concentrated in centrifugal filter-tubes (Millipore). Protein samples were frozen and stored at -80°C or dissolved in sample buffer and used for isoelectric focusing (IEF) immediately (Pasquali et al. 1997).

Serological proteome analysis of surface protein preparations from S. aureus. Samples were obtained from a) S. aureus/agr grown under "stress conditions", b) S. aureus/COL grown under "standard conditions" and c) S. aureus/COL "stress conditions". Loading onto 17 cm-strips containing immobilized pH gradients (pH 4-7, "in-gel-reswelling procedure" done using the BioRad) (Pasquali et al., 1997). The gels for blotting were loaded with 100-800 µg protein, the preparative gels with 400-1,000 µg protein. Isoelectric focusing and SDS-PAGE (9-16% gradient gels) were performed as described (Pasquali et al., 1997). For Western blotting, proteins were transferred onto PVDF-membranes (BioRad) by semi-dry blotting. Transfer-efficiency was checked by amidoblack staining. After blocking (PBS/0.1% Tween 20/10% dry milk, 4°C for 16 h), blots were incubated for two hours with serum (1:2,500-1:100,000 in blocking solution, see Table 3). After washing, specific binding of serum IgG was visualized with a qoat-anti-human-IgG / peroxidase conjugate (1:25,000, Southern secondary antibody and development chemiluminescence substrate (ECL™, Amersham). A representative result is shown in Figure 6. Membranes were stripped by treatment with 2% B-ME/Laemmli buffer for 30 min at 50-65°C, immediately re-probed with a different serum, and developed as described above. This procedure was repeated up to five times. Signals showing up with patient and/or healthy donor control sera but not with the infant pool, were matched to the Coomassie (BioRad) stained preparative gels (example shown in Figure 7). The results of these serological proteome analyses of surface protein preparations from S. aureus are summarized in Table 3.

1. 人名英格兰人姓氏人名

Sequencing of protein spots by peptide-fingerprint MALDI-TOF-MS and tandem MS/MS. Gel pieces were washed alternately three times with 10 ul digestion buffer (10mM NH, HCO, /CAN, 1:1). Afterwards the gel pieces were shrunken with 10 µl ACN and reswollen with 2 μl protease solution (0.05 μg/μl trypsin, Promega, Madison, USA). Digestion was performed for 10-12 h at 37°C. For MALDI-TOF-MS peptides were extracted from the gel pieces with 10 µl digestion buffer. The supernatant was concentrated with ZipTip™ (Millipore, Bedford, USA), the peptides were eluted onto the MALDI target with 0.5 μl extraction buffer (0.1% TFA/CAN, 1:1) and 0.5 μl matrix solution (HCCA in ACN/0.1% TFA, 1:1) was added. MALDI-TOF-MS was done using a REFLEX III (Bruker Daltonik, Bremen, Germany) equipped with a SCOUT384 ion source. The acceleration voltage was set to 25 kV, and the reflection voltage to 28.7 kV. The mass range was set from 700 Da to 4000 Da. Data acquisition was done on a SUN Ultra using XACQ software, version 4.0. Post-analysis data processing was done using XMASS software, version 4.02 (Bruker Daltonik, Bremen, Germany). The results are summarized in tables 3 and 4.

# Example 6: Characterisation of highly immunogenic proteins from S. aureus

The antigens identified by the different screening methods with the IgG and IgA preparations form pre-selected sera are further characterized, by the following ways:

1. The proteins are purified, most preferably as recombinant proteins expressed in E. coli or in a Gram+ expression system or in an in vitro translation system, and evaluated for antigenicity by a series of human sera. The proteins are modified based on bioinformatic analysis: N-terminal sequences representing the signal peptide are removed, C-terminal regions downstream of the cell wall anchor are also removed, and extra amino acids as tags are introduced for the ease of purification (such as Strep-tagII, His-tag, etc.) A large number of sera is then used in ELISA assays to assess the fraction of human sera containing specific antibodies against the given protein (see Fig. 9 as an example). One of the selected antigens is a 895 aa long protein, what was called LPXTGV (see Tables 2 and 4), since it contains the Gram+cell wall anchor sequence LPXTG. This signature has been shown to

**医**2000年 (1000年)

serve as cleavage site for sortase, a trans-peptidase which covalently links LPXTG motif containing proteins to the peptidoglycan cell wall. LPXTGV is also equipped with a typical signal peptide (Fig. 8). ELISA data using this protein as a Strep-tagged recombinant protein demonstrate that this protein is highly immunogenic (high titers relative to other recombinant proteins) in a high percentage of sera (Fig. 9). Importantly, patients with acute S. aureus infection produce significantly more of these anti-LPXTGV antibodies, than healthy normals, suggesting that the protein is expressed during in vivo infection. The overall ELISA titers of the individual antigenic proteins are compared, and the ones inducing the highest antibody levels (highly immunogenic) in most individuals (protein is expressed by most strains in vivo) are favored. Since the antigen specificity and quality (class, subtype, functional, nonfunctional) of the antibodies against S. aureus produced in individual patients can vary depending on the site of infection, accompanying chronic diseases (e.g. diabetes) and chronic conditions (e.g. intravascular device), and the individuals' immune response, special attention was paid to the differences detected among the different patient groups, since medical records belonging to each sera were available. In addition, each patient serum is accompanied by the pathogenic strain isolated from the patient at the time of serum sampling.

- 2. Specific antibodies are purified for functional characterization. The purity and the integrity of the recombinant proteins are checked (e.g. detecting the N-terminal Strep-tag in Western blot analysis in comparison to silver staining in SDS-PAGE). The antigens are immobilized through the tags to create an affinity matrix, and used for the purification of specific antibodies from highly reactive sera. Using as an example strep-tagged LPXTGV as the capture antigen, 20 µg of antibody from 125 mg of IgG were purified. Based on the ELISA data a pure preparation was received, not having e.g. anti-LTA and anti-peptidoglycan (both dominant with unfractionated IgG) activity. The antibodies are then used to test cell surface localization by FACS and fluorescent microscopy (Fig. 10).
- 3. Gene occurrence in clinical isolates
  An ideal vaccine antigen would be an antigen that is present in
  all, or the vast majority of, strains of the target organism to

which the vaccine is directed. In order to establish whether the genes encoding the identified Staphylococcus aureus antigens occur ubiquitously in S. aureus strains, PCR was performed on a series of independent S. aureus isolates with primers specific for the gene of interest. S. aureus isolates were obtained from patients with various S. aureus infections. In addition several nasal isolates from healthy carriers and several lab strains were also collected and analyzed. The strains were typed according to restriction fragment length polymorphism (RFLP) of the spa and coa genes (Goh et al. 1992, Frénay et al., 1994, vanden Bergh et al. 1999). From these results 30 different strains were identified - 24 patient isolates, 3 masal isolates and 3 lab strains. To establish the gene distribution of selected antigens, the genomic DNA of these 30 strains was subjected to PCR with gene specific primers that flank the selected epitope (ORF1361: Seq.ID No. 187 and 188; ORF2268: Seq.ID No. 193 and 194; ORF1951: Seq.ID No. 195 and 196; ORF1632: Seq.ID No. 181 and 182; ORF0766: Seq.ID No. 183 and 184; ORF0576: Seq.ID No. 185 and 186; ORF0222: Seq.ID No. 189 and 190; ORF0360: Seq.ID No. 191 and 192). The PCR products were analyzed by gel electrophoresis to identify a product of the correct predicted size. ORFs 1361, 2268, 1951, 1632, 0766 and 0222 are present in 100% of strains tested and ORF0576 in 97%. However ORF0360 occurred in only 71% of the strains. Thus ORFs 1361, 2268, 1951, 1632, 0766, 0576 and 0222 each have the required ubiquitous presence among S. aureus isolates.

These antigens (or antigenic fragments thereof, especially the fragments identified) are especially preferred for use in a vaccination project against S. aureus.

4. Identification of highly promiscuous HLA-class II helper epitopes within the ORFs of selected antigens

The ORFs corresponding to the antigens identified on the basis of recognition by antibodies in human sera, most likely also contain linear T-cell epitopes. Especially the surprising finding in the course of the invention that even healthy uninfected, non-colonized individuals show extremely high antibody titers (> 100,000 for some antigens, see Example 5) which are stable for >1 year (see Example 1), suggests the existence of T-cell dependent memory most probably mediated by CD4+ helper-T-cells. The molecular

さい は はない はんない はんないい

definition of the corresponding HLA class II helper-epitopes is usefull for the design of synthetic anti-staphylococcal vaccines, which can induce immunological memory. In this scenario the helper-epitopes derived from the staphylococcal antigens provide "cognate help" to the B-cell response against these antigens or fragments thereof. Moreover it is possible to use these helper-epitopes to induce memory to T-independent antigens like for instance carbohydrates (conjugate vaccines). On the other hand, intracellular occurring staphylococci can be eliminated by CD8+cytotoxic T-cells, which recognize HLA class I restricted epitopes.

T-cell epitopes can be predicted by various public domain algorithms: <a href="http://bimas.dcrt.nih.gov/molbio/hla bind/">http://bimas.dcrt.nih.gov/molbio/hla bind/</a> (Parker et al. 1994),

http://134.2.96.221/scripts/MHCServer.dll/home.htm (Rammensee at al. 1999), http://mypage.ihost.com/usinet.hamme76/ (Sturniolo et al. 1999). The latter prediction algorithm offers the possibility to identify promiscuous helper-epitopes, i.e. peptides that bind to several HLA class II molecules. In order to identify highly promiscuous helper-epitopes within staphylococcal antigens the ORFs corresponding to Seq ID 64 (IsaA), Seq ID 114 (POV2), Seq ID 89 (ORF0222), Seq ID 70 (LPXTGIV), Seq ID 56 (LPXTGV), Seq ID 142 (LPXTGVI), Seq ID 81 (ORF3200), Seq ID 74 (ORF1951), Seq ID 94 (Empbp), Seq ID 83 (autolysin) and Seq ID 58 (ORF2498) were analyzed using the TEPITOPE package <a href="http://mypage.ihost.com/usi-">http://mypage.ihost.com/usi-</a> net.hamme76/ (Sturniolo et al. 1999). The analysis was done for 25 prevalent DR-alleles and peptides were selected if they were predicted to be a) strong binders (1% threshold) for at least 10/25 alleles or b) intermediate (3% threshold) binders for at least 17/25 alleles.

The following peptides containing one or several promiscuous helper-epitopes were selected (and are claimed):

Seq ID 56: pos. 6-40, 583-598, 620-646, 871-896
Seq ID 58: no peptide fulfills selection criteria
Seq ID 64: no peptide fulfills selection criteria
Seq ID 70: pos. 24-53
Seq ID 74: pos. 240-260

Seq ID 81: pos. 1660-1682, 1746-1790

Seq ID 83: pos. 1-29, 680-709, 878-902

Seg ID 89: pos. 96-136

Seq ID 94: pos. 1-29, 226-269, 275-326

Seq ID 114: pos. 23-47, 107-156

Seq ID 142: pos. 24-53

The corresponding peptides or fragments thereof (for instance overlapping 15-mers) can be synthesized and tested for their ability to bind to various HLA molecules in vitro. Their immunogenicity can be tested by assessing the peptide (antigen)-driven proliferation (BrdU or 3H-thymidine incorporation) or the secretion of cytokines (ELIspot, intracellular cytokine staining) of T-cells in vitro (Mayer et al. 1996, Schmittel et al. 2000, Sester et al. 2000). In this regard it will be interesting to determine quantitative and qualitative differences in the T-cell response to the staphylococcal antigens or the selected promiscuous peptides or fragments thereof in populations of patients with different staphylococcal infections, or colonization versus healthy individuals neither recently infected nor colonized. Moreover, a correlation between the antibody titers and the quantity and quality of the T-cell response observed in these populations is expected. Alternatively, immunogenicity of the predicted peptides can be tested in HLA-transgenic mice (Sonderstrup et al. 1999):

Similar approaches can be taken for the identification of HLA class I restricted epitopes within staphylococcal antigens.

# Synthetic peptides representing one or more promiscuous T helper epitopes from S.aureus

Partially overlapping peptides spanning the indicated regions of Seq ID 56 (LPXTGV), Seq ID 70 (LPXTGIV), Seq ID 74 (ORF1hom1), Seq ID 81 (EM\_BP), Seq ID 83 (Autolysin), Seq ID 89 (ORF1hom2), Seq ID 94 (EMPBP), Seq ID 114 (POV2) and Seq ID 142 (LPXTGVI) were synthesized. Sequences of the individual peptides are given in Table 5. All peptides were synthesized using Fmoc chemistry, HPLC purified and analyzed by mass spectrometry. Lyophilized peptides were dissolved in DMSO and stored at -20°C at a concentration of 5-10 mM.

Binding of synthetic peptides representing promiscuous T helper

1、日本版の大学の大学に行いて

## epitopes to HLA molecules in vitro

Binding of peptides to HLA molecules on the surface of antigenpresenting cells is a prerequisite for activation of T cells.
Binding was assessed in vitro by two independent biochemical assays using recombinant soluble versions of HLA class II molecules. One assay measures the concentration dependent competitive
replacement of a labeled reference peptide by the test peptides.
The second assay is based on the formation of SDS-stable complexes upon binding of high- and intermediate affinity ligands.
A summary of the results obtained by the two assays is given in
Table 5.

(DRA1\*0101/DRB1\*0101 and Soluble HLA molecules DRA1\*0101/DRB1\*0401) were expressed in SC-2 cells and purified as described in Aichinger et al., 1997. For the competition assay (Hammer et al. 1995) HLA molecules were applied between 50 and 200 ng/well. For DRB1\*0101 biotinilated indicator peptide HA (PKYVKONTLKLAT, Valli et al. 1993) was used at 0.008 µM. For DRB1\*0401 biotinilated indicator peptide UD4 (YPKFVKQNTLKAA, Valli et al. 1993) was used between 0.03 and 0.06 μM. Test peptides were used in serial dilutions from 0.02 nM to 200 µM. Molecules, indicator and test peptides were incubated overnight at 37°C, pH 7. HLA:peptide complexes obtained after incubation with serial dilutions of test and reference peptides (the known highaffinity binders HA and UD4 were used as positive control) were captured in ELISA plates coated with antibody L243, which is known to recognize a conformational epitope formed only by correctly associated heterodimers. Incorporated biotin was measured by standard colorimetric detection using a streptavidin-alkaline phosphatase conjugate (Dako) with NBT/BCIP tablets (Sigma) as substrate and automated OD reading on a Victor reader (Wallac).

# T cell response against promiscuous T helper epitopes assessed by IFNg ELISpot assay

Upon antigenic stimulation T cells start to proliferate and to secrete cytokines such as interferon gamma (IFNg). Human T cells specifically recognizing epitopes within S.aureus antigens were detected by IFNg-ELIspot (Schmittel et al. 2000). PBMCs from healthy individuals with a strong anti-S.aureus IgG response were isolated from 50-100 ml of venous blood by ficoll density gradi-

ent centrifugation and used after freezing and thawing. Cells were seeded at 200,000/well in 96-well plates. Peptides were added as mixtures corresponding to individual antigens, in both cases at 10 µg/ml each. Concanavalin A (Amersham) and PPD (tuberculin purified protein derivate, Statens Serum Institute) served as assay positive controls, assay medium without any peptide as negative control. After overnight incubation in Multi Screen 96well filtration plates (Millipore) coated with the anti-human IFNg monoclonal antibody B140 (Bender Med Systems) the ELIspot was developed using the biotinylated anti-human IFNg monoclonal antibody B308-BT2 (Bender Med Systems), Streptavidin-alkaline phosphatase (DAKO) and BCIP/NBT alkaline phosphatase substrate (SIGMA). Spots were counted using an automatic plate reader (Bioreader 2000, BIO-SYS). Spots counted in wells with cells stimulated with assay medium only (negative control, generally below 10 spots / 100.000 cells) were regarded as background and subtracted from spot numbers counted in wells with peptides.

Table 5: Promiscuous T helper epitopes contained in S.aureus antigens

Amino acio	sequences within S.aureus antigens containing	binding	IFNg
	omiscuous T helper epitopes	1)	ELIspot
inging pr			2)
Seq ID 56	(LPXTGV): pos. 6-40		
p6-28	>PKLRSFYSIRKSTLGVASVIVST//	+	
p24-40	>VIVSTLFLISQHQAQA//		
٠.			44;80;8
	·		;95;112
Seq ID 56	(LPXTGV): pos. 620-646		
p620-646	>FPYIPDKAVYNAIVKVVVANIGYEGQ//	+	
Seq ID 56	(LPXTGV): pos. 871-896		1
p871-896	>QSWWGLYALLGMLALFIPKFRKESK//	<u> </u>	
Seq ID 70	(LPXTGIV): pos. 24-53		
p24-53	>YSIRKFTVGTASILIGSLMYLGTQQEAEA//	nd	34;14;0
•			;57;16
Seq ID 74	(ORF1hom1): pos. 240-260		
p240-260	>MNYGYGPGVVTSRTISASQA//	+	47;50;0
	•		;85;92

: . ::

The State of Williams

The second of th

Seq ID 81 (EM_BP): pos. 1660-1682	1	1
p1660-1682 >NEIVLETIRDINNAHTLQQVEA//	nd	
b1000-1005 MPIAMPILIONINGTITATION		1
•		1
		2;14;5;
·		
77 05 (mc 77) 1746 1790		77;26
Seq ID 81 (EM_BP): pos. 1746-1790	nd	1
p1746-1773 >LHMRHFSNNFGNVIKNAIGVVGISGLLA//	nd	
p1753-1779 >NNFGNVIKNAIGVVGISGLLASFWFFI//	nd.	
p1777-1789 >FFIAKRRKEDEE/	ina —	<del>                                     </del>
Seq ID 83 (Autolysin) pos. 1-29	nd	
p1-29: >MAKKFNYKLPSMVALTLVGSAVTAHQVQA//	1	6;35;7;
•	,	
2 - TD 02 (Nub-legis) mag 979 002		60;49
Seq ID 83 (Autolysin) pos: 878-902	nd	
p878-902: >NGLSMVPWGTKNQVILTGNNIAQG/ Seq ID 89 (ORF1hom2): pos. 96-136		<del> </del>
p96-121 >GESLNIIASRYGVSVDQLMAANNLRG//	_	1
		0;35;0;
p117-136 >NNLRGYLIMPNQTLQIPNG//	l	29;104
Seq ID 94 (EMPBP): pos. 1-29		
p4-29 : >KLLVLTMSTLPATQIMNSNHAKASV//	_	
Seq ID 94 (EMPBP): pos. 226-269		
p226-251 >IKINHFCVVPQINSFKVIPPYGHNS//	_	
p254-270 >MHVPSFQNNTTATHQN//	+	
page 270 - married grants are a constant and a cons		26;28;1
		6;43;97
Seq ID 94 (EMPBP): pos. 275-326		
p275-299 >YDYKYFYSYKVVKGVKKYFSFSQS//	+	l
p284-305 >YKVVKGVKKYFSFSQSNGYKIG//	+	
p306-326 >PSLNIKNVNYQYAVPSYSPT//	+ .	
Seq ID 114 (POV2): pos. 23-47		
p23-47 >AGGIFYNQTNQQLLVLCDGMGGHK//	-	49;20;4
		;77;25
Seq ID 114 (POV2): pos. 107-156		
p107-124 >ALVFEKSVVIANVGDSRA/	_	
p126-146 >RAYVINSRQIEQITSDHSFVN//	nđ	
p142-158 >SFVNHLVL/TGQITPEE//	nd	
Seq ID 142 (LPXTGVI): pos. 1-42		
p6-30 >KEFKSFYSIRKSSLGVASVAISTL//	++	
	nd	1
	nd	
	nd	0;41;20
	nd	
p18-42 >SSLGVASVAISTLLLLMSNGEAQA//	nd	
p18-42 >SSLGVASVAISTLLLLMSNGEAQA// Seq ID 142 (LPXTGVI): pos. 209-244	nd +	
p18-42 >SSLGVASVAISTLLLLMSNGEAQA//  Seq ID 142 (LPXTGVI): pos. 209-244 p209-233 >IKLVSYDTVKDYAYIRFSVSNGTKA//		
p18-42 >SSLGVASVAISTLLLLMSNGEAQA// Seq ID 142 (LPXTGVI): pos. 209-244	+	0;41;20 ;88;109
Seq ID 142 (LPXTGVI): pos. 209-244 p209-233 >IKLVSYDTVKDYAYIRFSVSNGTKA// p218-244 >KDYAYIRFSVSNGTKAVKIVSSTHFNN//	+	

Seq ID 142 (LPXTGVI): pos. 623-647	
p623-647 >MTLPLMALLALSSIVAFVLPRKRKN //	
•	

" binding to soluble DRA1\*0101/DRB1\*0401 molecules was determined using a competition assay (+, ++: binding, -: no competition up to 200 µM test peptide; nd: not done)

7 results from 5 healthy individuals with strong anti-S.aureus IgG response. Data are represented as spots/200.000 cells (background values are subtracted

- 5. Antigens may be injected into mice and the antibodies against these proteins can be measured.
- 6. Protective capacity of the antibodies induced by the antigens through vaccination can be assessed in animal models.

Both 5. and 6. are methods well available to the skilled man in the art.

### Example 7: Applications

- A) An effective vaccine offers great potential for patients facing elective surgery in general, and those receiving endovascular devices, in particular. Patients suffering from chronic diseases with decreased immune responses or undergoing continuous ambulatory peritoneal dialysis are likely to benefit from a vaccine with S. aureus by immunogenic serum-reactive antigens according to the present invention. Identification of the relevant antigens will help to generate effective passive immunization (humanized monoclonal antibody therapy), which can replace human immunoglobulin administration with all its dangerous side-effects. Therefore an effective vaccine offers great potential for patients facing elective surgery in general, and those receiving endovascular devices, in particular.
- S. aureus can cause many different diseases.
- 1. Sepsis, bacteriaemia
- 2. Haemodialysed patients bacteriemia, sepsis
- 3. Peritoneal dialyses patients peritonitis
- 4. Patients with endovascular devices (heart surgery, etc) endocarditis, bacteriemia, sepsis

- Orthopedic patients with prosthetic devices septic arthritis
- 6. Preventive vaccination of general population

B) Passive and active vaccination, both with special attention to T-cells with the latter one: It is an aim to induce a strong T helper response during vaccination to achieve efficient humoral response and also immunological memory. Up till now, there is no direct evidence that T-cells play an important role in clearing S. aureus infections, however, it was not adequately addressed, so far. An effective humoral response against proteinaceous antigens must involve T help, and is essential for developing memory. Naïve CD4+ cells can differentiated into Th1 or Th2 cells. Since, innate immunological responses (cytokines) will influence this decision, the involvement of T-cells might be different during an acute, serious infection relative to immunization of healthy individuals with subunit vaccines, not containing components which impair the immune response during the natural course of the infection. The consequences of inducing Th1 or Th2 responses are profound. Thi cells lead to cell-mediated immunity, whereas Th2 cells provide humoral immunity.

C) Preventive and therapeutic vaccines

Preventive:

active vaccination/passive immunization of

と 私職の 田本の場合 おいしゅうし

people in high risk groups, before

infection

Therapeutic:

passive vaccination of the already sick.

Active vaccination to remove nasal carriage

### Specific example for an application

Elimination of MRSA carriage and prevention of colonization of the medical staff

Carriage rates of S. aureus in the nares of people outside of the hospitals varies from 10 to 40%. Hospital patients and personnel have higher carriage rates. The rates are especially high in patients undergoing hemodialysis and in diabetics, drug addicts and patients with a variety of dermatologic conditions. Patients at highest risk for MRSA infection are those in large tertiary-care hospitals, particularly the elderly and immunocompromised, those

in intensive care units, burn patients, those with surgical wounds, and patients with intravenous catheters.

The ELISA data strongly suggest that there is a pronounced IgA response to S. aureus, which is not obvious or known from the literature. Since the predominant mucosal immune response is the production of IgA with neutralizing activity, it is clear that the staphylococcal epitopes and antigens identified with the highly pure IgA preparations lead to an efficient mucosal vaccine.

•Clear indication: Everybody's threat in the departments where they perform operation (esp. orthopedics, traumatology, gen. surgery)

•Well-defined population for vaccination (doctors and nurses)

•Health care workers identified as intranasal carriers of an epidemic strain of S. aureus are currently treated with mupirocin and rifampicin until they eliminate the bacteria. Sometimes it is not effective, and takes time.

•Available animal model: There are mice models for intranasal carriage.

Table 1: ELISA titers of sera trom non-infected individuals against multiple staphylococcal proteins.

								5	7												
Мар-w			4	3			7								8,9	9			1		2
CIEB			7	1				8,9	5,6	5,6				-,-				**		<u>}</u>	j=1.
Srt.A			3					7			6				8					<u>.</u>	
Fib		3					- 54	5					80								ij
coagul			2									4,5	•								
LP342	\	6													7						
			3			5									9						
enolase LP309				6,7.			5	•	3.4												
EBP			•	7			2	8										3			
sdrC			1			4			3			r	2								
3.ps			11				7	80					5								
FnBPA				2				-					,		5						
D1+D3 FnBPA		4		7					~		6										
CIEA		8	3.												,			11			-2
Đ.									2						2,3			6,7			
LTA		2		******[			9		7	i l				i	S						
вні	lysate	2		******					4,5,6						3					Ü	ij
Sera ID#		7	3	4	5	9	4	8	8	10	11	12	13	14	g 51	16	11	18	19	20	21

\* 11.11 UNIX

1. A HREE SEEDING AND A COLUMN SEED

Sera D#	BHI	LTA.	PG Da	CIEA	D1+D3	D1+D3 FnBPA sdrE		Sd.C	EBP	enolase LP309	ľ	LP342	coagul	eE.	SrtA	CIEB	Map-w
	lysate																
Z																	
ន	4,5,6			2	3	9	2	7	4	6,7	4		6,7		2	2	
24							4		6					·			8,9
25			5	Ĭ													
56	80						•						_	7			
27	11			1227				8	•		4	4,5	4,5		<b>.</b>		
87				1}		·	Š										
29										1							
30																	
31						1							1				
32			4								· ·						. 58
33			80	4	-	4		20	·								
34					7,8			<u>'</u>		2	2	1	6,7	9			
35	4,5,6	8	2,3						5		1*****					3.	4
36		3															
37				7	7,8								3				
38							<u>ښ</u>			3,4							
39																	
40		7	6,7			3						4,5				8,9	

# Table I. ELISA titers of sera from non-infected individuals against multiple staphylococcal proteins.

Anti-staphylococcal antibody levels were measured individually by standard ELISA with total lysate prepared from S. aureus grown in BHI medium (BHI), lipoteichoic acid (LTA), peptidoglycan (PG), 13. recombinant proteins, representing cell surface and secreted proteins, such as clumping factor A and B (ClfA, ClfB), Fibronectinbinding protein (FnBPA), SD-repeat proteins (sdrC, sdrE), MHC Class II analogous protein (map-w), Elastin-binding protein (EBP), enclase (reported to be cell surface located and immunogenic), iron transport lipoproteins (LP309, LP342), sortase (srtA), coagulase (coa), extracellular fibrinogen-binding protein (fib). Two short synthetic peptides representing 2 of the five immunodominant D repeat domains from FnBPA was also included (D1+D3) as antigens. The individual sera were ranked based on the IgG titer, and obtained a score from 1-9. Score 1 labels the highest titer serum and score 8 or 9 labels the sera which were 8th or 9th among all the sera tested for the given antigen. It resulted in the analyses of the top 20 percentile of sera (8-9/40). The five "best sera" meaning the most hyper reactive in terms of anti-staphylococcal antibodies were selected based on the number of scores 1-8. \*\*\*\* means that the antibody reactivity against the particular antigen was exceptionally high (>2x ELISA units relative to the 2<sup>nd</sup> most reactive serum).

# Table 2a: Immunogenic proteins identified by bacterial surface and ribosome display: S. aureus

Bacterial surface display: A, LSA250/1 library in fhuA with patient sera 1 (655); B, LSA50/6 library in lamB with patient sera 1 (484); C, LSA250/1 library in fhuA with IC sera 1 (571); E, LSA50/6 library in lamB with IC sera 2 (454); F, LSA50/6 library in lamB with patient sera P1 (1105); G, LSA50/6 library in lamb with IC sera 1 (471)); H, LSA250/1 library in fhuA with patient sera 1 (IGA, 708). Ribosome display: D, LSA250/1 library with IC sera (1686). \*, identified 18 times of 33 screened; was therefore eliminated from screen C. \*\*, prediction of antigenic sequences longer than 5 amino acids was performed with the programme ANTIGENIC (Kolaskar and Tongaonkar, 1990); #, identical sequence present twice in ORF; ##, clone not in database (not sequence by

TIGR).

S.	Old	Putative function	predicted immunogenic sa**	No. of se-	Location of	Serum reactivity	Seq ID no:
aureus	ORF	(by homology)		lected	identified	with relevant re-	(DNA
antigenic	number			clones per	immuno-	gion (positive/total)	+Prot)
protein				ORF and	genic region		
•				screen			
SaA0003	ORF2963P	repC	5-20, 37-44, 52-59, 87-94, 116-132	C:3	aa 112-189	C:GSBYM94(112-	171, 172
•						189):26/30	
SaA0003	ORF2967P	герС	7-19, 46-57, 85-91, 110-117, 125-	C:18	aa 9-42	C:GSBY153(9-	150, 158
		·	133, 140–149, 156–163, 198–204,		aa 158-174	42):1/1 -	
		,	236-251, 269-275, 283-290, 318-				
			323, 347–363 💠		00.100		
0093	ORF1879	SdrC	23-51, 75-80, 90-99, 101-107, 151-	A:1, D:5,		A:GSBXL70(98-	34, 86
			157, 173-180, 186-205, 215-226,	C:1, F:6,	aa 684-764	182):9/30	
			239-263, 269-274, 284-304, 317-	G:2	ав 836—870	D:n.d.	
			323, 329-336, 340-347, 360-366,			C:GSBYH73(815-	
			372-379, 391-397, 399-406, 413-			870):3/16	
			425, 430-436, 444-455, 499-505,				
		•	520-529, 553-568, 586-592, 600-		4-3		
			617, 631–639, 664–678, 695–701,				
			891-903, 906-912, 926-940	010 53	147 100	O. CCDVID1(142	145 152
0095	ORF1881	SdrE	25-45, 72-77, 147-155, 198-211,	C:12, E:2	aa 147192	,	145, 153
			217-223, 232-238, 246-261, 266-			192):2/14	
			278, 281–294, 299–304, 332–340,			E:GSBZA27(144-	
	'		353-360, 367-380, 384-396, 404-			162):23/41	
			409, 418-429, 434-440, 448-460,				
			465-476, 493-509, 517-523, 531-				
			540, 543–555, 561–566, 576–582,	l			
			584-591, 603-617, 633-643, 647-				
			652, 668-674, 677-683, 696-704,				
Λ.			716-728, 744-752, 755-761, 789-				
			796, 809–815, 826–840, 854–862,		, i		
			887-903, 918-924, 1110-1116,				
0123	ORF1909	unknown	1125-1131, 1145-1159 9-28, 43-48, 56-75, 109-126, 128-	B:3, E:7,	aa 168-181	B:GSBXF80(168-	35, 87
0123	OKLISOS	UIKROWII	141, 143-162, 164-195, 197-216,	G:1	22 100 101	181):5/27	55,07
			234-242, 244-251	]		E:GSBZC17(168-	
			234-242, 244-231			181):25/41	
0160	ORF1941	unknown	4-10, 20-42, 50-86, 88-98, 102-171,	A:I	aa 112-188		36, 88
	Old 1541		176-182, 189-221, 223-244, 246-			188):5/30	
		j	268, 276–284, 29 <del>6</del> –329	l			
0222	ORF1988	homology with	4-9, 13-24, 26-34, 37-43, 45-51,	A:52,	aa 45-105	A:GSBXM63(65-	37, 89
		ORFI	59-73, 90-96, 99-113, 160-173,	C:18*,	aa 103-166	95):1/1	
			178-184, 218-228, 233-238, 255-	H:19	aa 66-153	A:GSBXM82(103-	
	i .		262	l	•	166):14/29	
						A:GSBXK44~	
17	l	1		1		bmd3(65-	
14			•			153):47/51	
0308	ORF2077	Complement, un-	13-27, 42-63, 107-191, 198-215,	A:6, B:2,	complement	A:GSBXK03(bp473	38, 90
		known	218-225, 233-250	C:47,		367):28/69	
		ł	,	E:35		B:GSBXD29(bp465	l
	1	I		1	· ·	-431):10/27	٠.

7

Little Controlle Control

2	Old	Putative function	predicted immunogenic an**	No. of se-	Location of	Serum reactivity	Seq ID no:
aureus	ORF	(by homology)		lected	identified	with relevant re-	(DNA
antigenic	number		•	clones per	immuno-	gion (positive/total)	+Prot)
protein				ORF and	genic region		,
				screen			
0317	ORF2088	preprotein translo-	16-29, 64-77, 87-93, 95-101, 127-	A:I	aa 1-19	A:GSBXP37(1-	39, 91
		case seca subunit	143, 150-161, 204-221, 225-230,			19):6/29	
1			236-249, 263-269, 281-309, 311-		ł :		
			325, 337-343, 411-418, 421-432,			,	
		1	435-448, 461-467, 474-480, 483-	}			
		ĺ	489, 508-516, 542-550, 580-589,				
			602-611, 630-636, 658-672, 688-				
			705, 717-723, 738-746, 775-786,	l			
			800-805, 812-821, 828-834	. * *			
0337	ORF2110	Hypothetical pro-	26-53, 95-123, 164-176, 189-199	D:12	aa 8–48	D:n.d.	40, 92
		tein ·				•	
0358	ORF2132	Clumping factor A	8-35, 41-48, 59-66, 87-93, 139-144,	C:1, D:2,	aa 706-809	D:n.d.	41,93
			156-163, 198-209, 215-229, 236-	E:1			
		i i	244, 24 <del>6-</del> 273, 27 <del>6-</del> 283, 285-326,				
17			328-342, 349-355, 362-370, 372-				
٠.٦			384, 396-402, 405-415, 423-428,			-	
			432-452, 458-465, 471-477, 484-		·		
			494, 502-515, 540-547, 554-559,				
			869-875, 893-898, 907-924				
0360	ORF2135	extracellular	7-13, 15-23, 26-33, 68-81, 84-90,	A:46,	aa 22-56	A:GSBXK24(23-	42, 94
	Empbp	matrix and plasma	106-117, 129-137, 140-159, 165-	B:21,	aa 23-99	55):1/1	
		binding protein	172, 177-230, 234-240, 258-278,	1 ' '	aa 97-115	B:GSBXB43(39-	
			295-319	' '		54):58/71	
1				H: 12	aa 245-265	A:GSBXK02-	•
						bmd1(22-99):59/59	
						B:GSBXD82-	
	'					bdb19(97-115):1/1	
						F:SALAL03(233	
0453	OPENANT		17-25, 27-55, 84-90, 95-101, 115-	C:3	aa 55-101	250):15/41 C:GSBYG07(55~	146, 154
0453	ORF2227	coma operon		ယ	BE 33-101	•	140, 134
0569	ORF1640	protein 2 V8 protease	121 5-32, 66-72, 87-98, 104-112, 116-	A:1, F:1	ва 174-249	101):1/1 A:GSBXSS1(174-	32, 84
1	2,6,0,0	. protosso	124, 128-137, 162-168, 174-183,	,		249):11/30	,
			248-254, 261-266, 289-303, 312-		·	_ :>,	
			331				

2	Old	Putative function	predicted immunogenic aa**	No. of se	Location of	Serom reactivity	Seq ID no:
aureus	ORF	(by homology)		lected	identified	with relevant re-	(DNA
antigenic		(0) 10		ciones per	immnno-	gion (positive/total)	
	Manner			ORF and		g Qy	,
protein			·	screen	Brane segion		
0576	ORF1633	autolysin, adhe-	4-19, 57-70, 79-88, 126-132, 144-	A:21,	za 6-66	A:GSBXN93(6-	31, 83
100,00	Autolysin	sion	159, 161-167, 180-198, 200-212,	B:46,	aa 65-124	66):5/16	
1	recorysta	J	233-240, 248-255, 276-286, 298-			C:GSBYH05(45-	
1			304, 309–323, 332–346, 357–366,	F:85.	aa 590-604	144):7/8	
			374-391, 394-406, 450-456, 466-	H:19		A:GSBXK66-	
}			473, 479-487, 498-505, 507-519,			bmd18(65	
			521-530, 532-540, 555-565, 571-			124):16/30	
			581, 600-611, 619-625, 634-642,			B:GSBXB89(108-	
			650-656, 658-665, 676-682, 690-	;		123):1/1	
			699, 724–733, 740–771, 774–784,			B:GSBXB02(590	
			791-797, 808-815, 821-828, 832-			603):39/71	
			838, 876-881, 893-906, 922-929,			F:SALAM15(579-	
			938-943, 948-953, 969-976, 1002-			592):25/41	
ł l			1008, 1015-1035, 1056-1069, 1105-				
ļ			1116, 1124-1135, 1144-1151, 1173-				
			1181, 1186-1191, 1206-1215, 1225-				
			1230, 1235-1242				
0657	ORF un-	LPXTGVI protein	9-33, 56-62, 75-84, 99-105, 122-	A:2, B:27,	an 527-544	B:GSBXE07-	1, 142
	known	·	127, 163-180, 186-192, 206-228,	F:15		bdb1(527	
			233–240, 254–262, 275–283, 289–			542):11/71	
i			296, 322-330, 348-355, 416-424,	,		F:SALAX70(526-	
			426-438, 441-452, 484-491, 541-			544):11/41	
			549, 563-569, 578-584, 624-641				
0749	ORF1462		8-23, 31-38, 42-49, 61-77, 83-90,	C:2	aa 630-700	C:GSBYK17(630-	144, 152
		phate synthase	99-108, 110-119, 140-147, 149-155,			700):5/9	
			159-171, 180-185, 189-209, 228-				
			234, 245-262, 264-275, 280-302,				
i i	٠		304-330, 343-360, 391-409, 432-				
			437, 454–463, 467–474, 478–485,				
			515-528, 532-539, 553-567, 569-				
			581, 586-592, 605-612, 627-635,				
			639-656, 671-682, 700-714, 731- 747, 754-770, 775-791, 797-834,				
			838-848, 872-891, 927-933, 935-				
İ '			942, 948-968, 976-986, 1000-1007,				
			1029–1037				
944	ORF1414	Yfix		D:4	aa 483-511	D :n.d.	30, 82
		•	112-118, 124-187, 194-248, 252-				
			296, 308-325, 327-361, 367-393,				1
1			396-437, 452-479, 484-520, 535-				
			545, 558-574, 582-614, 627-633,				
· ·			656-663, 671-678, 698-704, 713-	1			
			722, 725-742, 744-755, 770-784,				
			786-800, 816-822, 827-837				
1050	ORF1307	unknown	49-72, 76-83, 95-105, 135-146,	A:1, H:45	aa 57-128	A:GSBXM26(57-	28, 80
		1	148-164, 183-205			128):7/30	1

LEGISTER STORY COLLECTION OF THE STORY

\$ 11 WAS

the second difference of the

<u>.</u>	Old	Putative function	predicted immunogenic as**	No. of se	Location of	Serum reactivity	Seq ID no:
aureus	ORF	(by homology)		lected	identified	with relevant re-	(DNA
antigenic		(b) noncoegy)		clones per	immuno-	gion (positive/total)	
-	Buthber		-	ORF and	genic region		,
protein				screen	Perme serve		
1209	ORF3006	hemN homolog	12-36, 43-50, 58-65, 73-78, 80-87,	B:7, F:8	aa 167-181	B:GSBXB76(167~	54, 106
1207	010 3000	ikalii v ikalikilog	108-139, 147-153, 159-172, 190-			179):25/71	
			203, 211–216, 224–232, 234–246,			F:SALBC54(169-	
			256-261, 273-279, 286-293, 299-			183):18/41	
			306, 340-346, 354-366			,	
1344	ORF0212	NifS protein	8-16, 22-35, 49-58, 70-77, 101-121,	A:11	aa 34-94	A:GSBXK59-	5, 141
		homolog	123-132, 147-161, 163-192, 203-			bmd21(34-94):6/29	
			209, 216-234, 238-249, 268-274,				
			280-293, 298-318, 328-333, 339-			<b>1</b> 1	
			345, 355-361, 372-381				
1356	ORF0197	Hypothetical pro-		D:12	aa 1-49	D:n.d.	4, 57
		tease	137-143				
1361	ORF0190	LPXTGV protein	5-39, 111-117, 125-132, 134-141,		aa 37-49	B:GSBXF81(37-	3, 56
			167-191, 196-202, 214-232, 236-	E:3, F:31	aa 63-77	49):1/1	
			241, 244-249, 292-297, 319-328,		аа 274-334	B:GSBXD45-	
		· .	336-341, 365-380, 385-391, 407-			bdb4(62-77):12/70	
	/		416, 420-429, 435-441, 452-461,			A:GSBXL77(274-	
			477-488, 491-498, 518-532, 545-		•	334):5/30	·
			556, 569-576, 581-587, 595-602,			F:SALAP81(62→	
			604-609, 617-640, 643-651, 702-			77):10/41 1	
			715, 723-731, 786-793, 805-811,				
			826-839, 874-889				
1371	ORF0175	YtpT, conserved	37-42, 57-62, 121-135, 139-145,	C:3, E:2,		C:GSBYG95(624-	143, 151
		hypothetical pro-	183-190, 204-212, 220-227, 242-	G:1	aa 891905	684):7/22	
		tein	248, 278–288, 295–30, 304–309,			E:GSBZB45(891-	
			335-341, 39 <del>6</del> -404, 412-433, 443-		•	905):10/41	
			449, 497–503, 505–513, 539–545,				
			552-558, 601-617, 629-649, 702-				
			711, 736-745, 793-804, 814-829,			·	
			843-858, 864-885, 889-895, 905-				
			913, 919–929, 937–943, 957–965,		•		
			970-986, 990-1030, 1038-1049,				
			1063~1072, 1080-1091, 1093-1116,	i		·	
			1126-1136, 1145-1157, 1163-1171,				
			1177-1183, 1189-1196, 1211-1218,		}	·	1
			1225-1235, 1242-1256, 1261-1269	12.00	30.04	A:GSBXM13(39-	2,55
1491	ORF0053	Cmp binding fac-	12-29, 34-40, 63-71, 101-110, 114-		aa 39-94	`	4,33
		tor I homolog	122, 130-138, 140-195, 197-209,	E:7, F:4		94):10/29	
	<u> </u>		215-229, 239-253, 255-274			F:SALAY30(39-	
1616	ORF1180	leukocidin F ho-	16-24, 32-39, 43-49, 64-71, 93-99,	A:10	aa 158-220	53):4/41 A:GSBXK06(158~	27, 79
1616	OKE 1180	1		17.10		220):8/29	[
	1	molog	126-141, 144-156, 210-218, 226-		1		1
1618	ORF1178	LukM bomolog	233, 265-273, 276-284 5-24, 88-94, 102-113, 132-143,	A:13. B:3	aa 31-61	A:GSBXK60(31-	26, 78
			163-173, 216-224, 254-269, 273-	•	aa 58-74	61):20/29	
		1	278, 305-313, 321-327, 334-341	F:12, G:2,		B:GSBXB48(58-	
	1		, 505 315, 521-321, 354-541	H:10	<b>[</b>	74):49/71	1
	1		ì	ļ <sup>.~.</sup> "	I	F:SALAY41(58~	
			ĺ		1	74):30/41	
	L	<u> </u>	L	<u> </u>	l	1,7,30,71	L

2	Old	Putative function	predicted Immunogenic an**	No. of se-	Location of	Serum reactivity	Seq ID no:
aureus	ORF	(by homology)		lected	identified	with relevant re-	(DNA
antigenic		(4)		clones per	immuno-	gion (positive/total)	+Prot)
	римось	·	٠	ORF and	genic region		
protein			·	screen			'
1632	ORF1163	SdrH homolog	7-35, 54-59, 247-261, 263-272,	B:6, E:11,	aa 105-119	B:GSBXG53(168-	25,77
			302-320, 330-339, 368-374, 382-	F:34	an 126-143	186):39/71	
			411		aa 168-186	F:SALAP07(105-	
						119):11/41	
1763	ORF1024	unknown	5-32, 35-48, 55-76	C:3	complement	C:GSBYI30(98aa):1	24, 76
					bp 237170	/1	
1845	ORF0942	Hyaluronate lyase	10-26, 31-44, 60-66, 99-104, 146-	D:5, F:2	aa208-224	D:n.d.	23, 75
ļ			153, 163–169, 197–205, 216–223,		aa 672-727		
	~~ <sub>17</sub> .		226-238, 241-258, 271-280, 295-		٠.		17 <sub>3</sub> °
			315, 346-351, 371-385, 3 <del>96-</del> 407,	(			
			440-446, 452-457, 460-466, 492-		1		
	•		510, 537–543, 546–551, 565–582,				
			590-595, 635-650, 672-678, 686-				
		Ī	701, 705-712, 714-721, 725-731,				
			762-768, 800-805				
1951	ORF0831	homology with	5-22, 42-50, 74-81, 139-145, 167-	A:223,	aa 137-237	B:GSBXC07(180-	22, 74
1		ORF1	178, 220-230, 246-253, 255-264	B:56,	aa 250-267	190):1/1	
1	•			C:167,		A:GSBXK29(177-	
ł		1	•	E:43,	i	195):15/29	
				F:100,	}	B:GSBXD43(250-	
		}		G:13,		267):10/71	
				H:102	1	F:SALAMI3(178-	
		<u> </u>				191):20/41	21 22
1955	ORF0826	homology with	4-9, 15-26, 65-76, 108-115, 119-	A:1, B:3,		A:GSBXR10(66~	21, 73
		ORFI	128, 144–153	E:1, F:8	aa 66-114	114):5/30	
	1		İ			F:SALAM67(37-	
2021	0000740		10-26, 31-43, 46-58, 61-66, 69-79,	B:2, F:2	aa 59-74	52):16/41 B:GSBXC01(59-	20, 72
2031	ORF0749	unknown	85-92, 100-115, 120-126, 128-135,		14	71):11/26	
	1		149-155, 167-173, 178-187, 189-				Ì
]	ļ	1	196, 202-222, 225-231, 233-240,	1	·	1	1
			245-251, 257-263, 271-292, 314-	l			ĺ
	l	1	1				
2086	ORF0691	IgG binding	322, 325–334, 339–345 6–20, 53–63, 83–90, 135–146, 195–	A:1, B:8,	aa 208-287	A:GSBXS55(208-	19,71
2000	Sbi	protein	208, 244–259, 263–314, 319–327,	E:24, F:9,	aa 261-276	287):38/46	
	"	Picau	337-349, 353-362, 365-374, 380-	G:137	aa 286-314	B:GSBXB34(299-	1
			390, 397-405, 407-415			314)::11/71	
[	ĺ		100,000	1	1	F:SALAX32(261-	ſ
i						276):21/41	

TO SERVED A SERVED SERV

2	Old	Putative function	predicted immunogenic na**	No. of se-	Location of	Serum reactivity	Seq ID no:
aureus	ORF	(by homology)		lected	identified	with relevant re-	(DNA
antigenic		(0, _0,,0,0),		clopes per	immupo-	gion (positive/totai)	•
protein			•		genic region		
protein				screen	B		
2180	ORF0594	LPXTGIV protein	11-20, 26-47, 69-75, 84-92, 102-	A:3, C:3,	aa 493-587	A:GSBXS61(493-	18, 70
		·	109, 119-136, 139-147, 160-170,	E:6, F:2,	aa 633-715	555):1/1	
			178-185, 190-196, 208-215, 225-	Н: 6	aa 704-760°	A:GSBXL64(496-	
<u> </u>			233, 245-250, 265-272, 277-284,		aa 760-832	585):1/1	
1 .			300-306, 346-357, 373-379, 384-		(aa 832	A:GSBXS92(760-	
			390, 429-435, 471-481, 502-507,		887) <sup>#</sup>	841):1/1	
			536-561, 663-688, 791-816, 905-		Ja.,	A:bmd4(704-	
		. "*;	910, 91 <del>9-9</del> 33, 977-985, 1001-1010,			760):16/30"	•
1 1			1052-1057, 1070-1077, 1082-1087,			(A:bmd4(830-	
			1094-1112			885):16/30)*	
1 1			·	السا		F:SALBC43(519-	
1 1						533):4/41	
2184	ORF0590	FnbpB .	5-12, 18-37, 104-124, 139-145,	A:2, C:4,	aa 701-777	A:GSBXM62(702-	17,69
1 1			154-166, 175-181, 185-190, 193-	G:9	aa 783822	777):28/28	
1 1			199, 203-209, 235-244, 268-274,			A:GSBXR22(783-	•
			278-292, 299-307, 309-320, 356-			855):1/1	
			364, 375–384, 390–404, 430–440,				
			450-461, 488-495, 505-511, 527-			0.3	
		-	535, 551-556, 567-573, 587-593,				
]			599-609, 624-631, 651-656, 665-				
			671, 714-726, 754-766, 799-804,				
1 1			818-825, 827-833, 841-847, 855-				
2186	ORF0588	Fnbp	861, 876-893, 895-903, 927-940 8-29, 96-105, 114-121, 123-129,	A:4, C:4,	aa 710-787	C:GSBYN05(710-	16, 68
2100	OKLOSÓB	гиор	141-147, 151-165, 171-183, 198-	D:5, E:2	aa 855-975	787):19/25	10,00
		·	206, 222-232, 253-265, 267-277,	D.J, L.L	aa 916983	D:n.d.	
.			294-300, 302-312, 332-338, 362-			A:GSBXP01(916-	\
1			368, 377-383, 396-402, 410-416,			983):17/30	
]			451-459, 473-489, 497-503, 537-		-	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
			543, 549-559, 581-600, 623-629,				
			643-649, 655-666, 680-687, 694-				
			700, 707-712, 721-727, 770-782,				-
			810-822, 874-881, 883-889, 897-				
]. ]			903, 911-917, 925-931, 933-939,				
			946-963, 965-973, 997-1010				
2224	ORF0551	unknown	49-56, 62-68, 83-89, 92-98, 109-	B:2	aa 34-46	B:GSBXD89(34	15, 67
			115, 124-131, 142-159, 161-167,			46):1/1	
			169-175, 177-188, 196-224, 230-		ļ ·		
			243, 246–252				

2	Old	Putative function	predicted immunogenic aa**	No. of se-	Location of	Serum reactivity	Seq ID no:
aureus	ORF	(by homology)		Jected	ldentißed	with relevant re-	(DNA
antigenic	number			clones per	immuzo-	gion (positive/total)	+Prot)
protein		<b>j</b> .		ORF and	genic region		
				screen			
2254	ORF0519	Conserved hypo-	14-22, 32-40, 52-58, 61-77, 81-93,	D:3	ав 403-462	D.n.d.	14, 66
		thetical protein	111-117, 124-138, 151-190, 193-				
	i		214, 224-244, 253-277, 287-295,	i			Ī
1		i	307-324, 326-332, 348-355, 357-	<b>!</b>			
			362, 384-394, 397-434, 437-460,				
			489-496, 503-510, 516-522, 528-	(	1		
	ł		539, 541-547, 552-558, 563-573,				
			589-595, 602-624, 626-632, 651-				
			667, 673-689, 694-706, 712-739,				•
			756-790			1	
2264	ORF0509	ORFI; homology	5-31, 47-55, 99-104, 133-139, 156-	A:131,	aa 7–87	A:GSBXP22(145-	13, 65
		with putative se-	172, 214–224, 240–247	B:51,	aa 133-242	-	
		creted antigen		C:13,		A:GSBXK05-	
		precursor from S.		E:43,		bmd16(178-	
		epidermldis		F:78, G:2,		218):6/29	
	•			H:17		B:GSBXE24-	
1			·	, i		bdb20(167-178):1/1	
			,			F:SALAQ91(173-	
2268	ORF0503	IsaA, possibly ad-	7-19, 26-45, 60-68, 94-100, 111-	A-7 R-65	aa 67–116	184):15/41 A:GSBXK88(67-	12, 64
	014 0505	hesion/aggrega-	119, 126–137, 143–148, 169–181,	C:3, E:2,	aa 98-184	116):1/1	, 01
1		tion	217-228	F:53		A:GSBXN19(98-	
						184):22/29	
						A:GSBXN32(182-	
1			•			225):34/71	
)						B:GSBXB71(196-	
1			•			209):16/29	
i 1			. ;			F:SALAL22(196-	,
]						210):16/41	
2344	ORF0426	Clumping factor B	4-10, 17-45, 120-127, 135-141,	D:9, E:1,	ва 706-762	D:n.d.	11,63
			168-180, 187-208, 216-224, 244-	F:3, H: 4	aa 810-852	المسيا	
			254, 256-264, 290-312, 322-330,				
			356-366, 374-384, 391-414, 421-			·	
			428, 430-437, 442-449, 455-461,				
l			464-479, 483 <b>-</b> 492, 501-512, 548-				
	ODE:		555, 862-868, 871-876, 891-904	11.55		A CORVOLAÇÃO	
2351	ORF0418	aureolysin	10-29, 46-56, 63-74, 83-105, 107-	A:1, C: 6	aa 83156		10, 62
1	•	•	114, 138–145, 170–184, 186–193,			156):14/29	
	•		216-221, 242-248, 277-289, 303-				
			311, 346-360, 379-389, 422-428,		.		,
			446-453, 459-469, 479-489, 496-		·	ļ	
I		L,L.	501		L		•

2	Old	Putative function	predicted immunogenic sa** .	No. of se-	Location of	Serum reactivity	Seq ID no:
i 1			pressed visiting and it.	lected	identified	with relevant re-	(DNA
aureus	ORF	(ph pomology)		clones per		gion (positive/total)	+Prot)
antigenic	number			ORF and	genic region		
protein					Benie Legion		
	000000	1000	4-29, 92-99, 119-130, 228-236,	screen B:4, F:11	aa 168-184	B:GSBXD01(168~	9, 61
2359	ORF0409	ISSP, immuno-	264-269, 271-280, 311-317, 321-	0.4, 1.11	aa 206–220	184):1/1	,,,,
		genic secreted				B:GSBXD62(205-	
		protein precursor,	331, 341–353, 357–363, 366–372,		201277 307	220):1/1	
		putative	377-384, 390-396, 409-415, 440-			B:GSBXC17(297-	
			448, 458-470, 504-520, 544-563,			309):6/27	
		,	568-581, 584-592, 594-603, 610-			F:SALAL04(205-	
			616			220):9/41	
2378	ORF0398	SmA	18-23, 42-55, 69-77, 85 <sub>5</sub> 98, 129-	C:1, D:7,	aa 198-258		8, 60
۵,۰۰	Old 0370	S.pr.	136, 182-188, 214-220, 229-235,	F:4, H:11	ŧ .	727): 2/9	•
			242-248, 251-258, 281-292, 309-			F:SALA033(846-	
			316; 333-343, 348-354, 361-367,	1	aa 2104-	857):10/41	
			393-407, 441-447, 481-488, 493-		2206	D:n.d.	
			505, 510-515, 517-527, 530-535,	}			
			540-549, 564-583, 593-599, 608-				
			621, 636-645, 656-670, 674-687,	<u> </u>	1		
			697-708, 726-734, 755-760, 765-	· .		,	
			772, 785-792, 798-815, 819-824,	· .			•
(C			826-838, 846-852, 889-904, 907-		1		
		· ·	913, 932-939, 956-964, 982-1000,	]			
<u> </u>			1008-1015, 1017-1024, 1028-1034,	l			
	·		1059-1065, 1078-1084, 1122-1129,				
			1134-1143, 1180-1186, 1188-1194,	Ì	l		
			1205-1215, 1224-1230, 1276-1283,	j			
			1333-1339, 1377-1382, 1415-1421,				
			1448-1459, 1467-1472, 1537-1545,		<u> </u>		
			1556-1566, 1647-1654, 1666-1675,			ļ <u>.</u>	
		Ì	1683-1689, 1722-1737, 1740-1754,		ļ		
			1756-1762, 1764-1773, 1775-1783,				
		1	1800-1809, 1811-1819, 1839-1851,		<b>[</b>		
	1		1859-1866, 1876-1882, 1930-1939,			[	
•	1		1947-1954, 1978-1985, 1999-2007,	ļ			
l		· .	2015-2029, 2080-2086, 2094-2100,		1	1	
			2112-2118, 2196-2205, 2232-2243				
2466	ORF0302	YycH protein	16-38, 71-77, 87-94, 105-112, 124-	D:14	aa 401-494	D:n.d.	7,59
			144, 158-164, 169-177, 180-186,				ŀ
l	ļ.	1	194-204, 221-228, 236-245, 250-	ł			
l			267, 336–343, 363–378, 385–394,	i		1	
		ļ	406-412, 423-440, 443-449		<u> </u>		
2470	ORF0299	Conserved hypo-	4-9, 17-41, 50-56, 63-69, 82-87,	C:3	aa 414-455	C:GSBYH60(414-	169,170
1		thetical protein	108-115, 145-151, 207-214, 244-	1	1	455):28/31	1
1			249, 284-290, 308-316, 323-338,	1			
		1	348-358, 361-378, 410-419, 445-	1.	1		1
1		1	451, 512-522, 527-533, 540-546,	ļ ·			1
l			553-558, 561-575, 601-608, 632-	1	l	ł	1
ļ.	1		644, 656-667, 701-713, 727-733.				· ·
1			766-780	<u> </u>	<u> </u>	<u></u>	L

Transfer of the second

2	Old	Putative function	predicted immunogenic an**	No. of se-	Location of	Serum reactivity	Seq ID no:
aureus	ORF	(by homology)	-	lected	Identified	with relevant re-	(DNA
antigenic	number			clones per	immuno-	gion (positive/total)	+Prot)
protein			•	ORF and	genic region	•	
protein				screen			
2498	ORF0267	Conserved hypo-	33-43, 45-51, 57-63, 65-72, 80-96,	D:12	aa 358-411	D:17/21	6, 58
	0.000	thetical protein	99-110, 123-129, 161-171, 173-179,		aa 588-606		
			185-191, 193-200, 208-224, 227-				
			246, 252-258, 294-308, 321-329,	ĺ			
			344-352, 691-707				
2548	ORF2711	lgG binding	4-16, 24-57, 65-73, 85-91, 95-102,	A:55,	aa 1-48	A:GSBXK68(1-	53, 105
		protein A	125-132, 146-152, 156-163, 184-	B:54,	aa 47-143	73):21/30	
	Ì		190, 204-210, 214-221, 242-252,	C:35,	aa 219-285	A:GSBXK41(47-	
<b>!</b>			262-268, 272-279, 300-311, 320-	F:59,	aa 345-424	135):1/1	
	i		337, 433-440, 472-480, 505-523	G:56,		A:GSBXN38(219-	
			•	H:38		285):19/30	
				ŀ		A:GSBXL11(322	
				1		375):10/30	
						B:GSBXB22(406-	
				ļ		418):37/71	
						F:SALAM17(406-	
						418):29/41	
2577	ORF2683	Hypothetical pro-	4-21, 49-56, 65-74, 95-112, 202-	C:6	aa 99-171	C:GSBYL56(99-	149, 157
		tein	208, 214–235	Cul Ful	6.40	174):1/1	52, 104
2642	ORF2614	unknown	34-58, 63-69, 74-86, 92-101, 130-	CI, EI	aa 5−48	C:bbe3(5 48):25/30 <sup>28</sup>	32, 104
			138, 142-150, 158-191, 199-207,		]		
2664	ORF2593	Conserved hypo-	210-221, 234-249, 252-271 7-37, 56-71, 74-150, 155-162, 183-	D:35	aa 77-128	Dm.d.	51, 103
2004	0.0.255	thetical protein	203, 211–222, 224–234, 242–272				
2670	ORF2588		18-28, 36-49, 56-62, 67-84, 86-95,	D:16	aa 328-394	D:n.d.	50, 102
	1		102-153, 180-195, 198-218, 254-				
]	l '		280, 284-296, 301-325, 327-348,				
	l		353-390, 397-402, 407-414, 431-				
	l .		455				
2680	ORF2577	Coagulase -	4-18, 25-31, 35-40, 53-69, 89-102,	C:26, G:4,		C:GSBYH16(438-	148, 156
1	]		147-154, 159-165, 185-202, 215-	H:8	aa 505-570	516):3/5	
l			223, 284-289, 315-322, 350-363,		aa 569-619	C:GSBYG24(505-	
		į	384-392, 447-453, 473-479, 517-			570):1/7	1
			523, 544-550, 572-577, 598-604,			C:GSBYL82(569-	
			617-623	<u> </u>		619):2/7	40.101
2740	ORF2515	Hypothetical pro-	5-44, 47-55, 62-68, 70-78, 93-100,	D:4	aa 1-59	D:n.d.	49, 101 .
2246	ORF2507	homology with	128-151, 166-171, 176-308 5-12, 15-20, 43-49, 94-106, 110-	A:1, H:13	ga 63-126	A:GSBXO40(66-	48, 100
2746	UKI 2507	ORFI	116, 119–128, 153–163, 175–180,		33 .20	123):8/29	,
1			185-191, 198-209, 244-252, 254-				
			264, 266–273, 280–288, 290–297			1	
2797	ORF2470	unknown	10-27, 37-56, 64-99, 106-119, 121-	B:3, E:2.	2a 183-200	B:GSBXE85(183-	47,99
*'''			136, 139-145, 148-178, 190-216.	F:13, H:3	aa 349~363	200):11/27	
			225-249, 251-276, 292-297, 312-	'		F:SALAQ47(183-	1
	1		321, 332–399, 403–458			200):8/41	
L	<u> </u>	<del></del>					

ببة

Control of the second s

College And September 1 and Andrews College and Colleg

2	Old	Putative function	predicted immunogenic as**	No. of se	Location of	Serum reactivity	Seq ID no:
anrens	ORF	(by homology)		lected	Identified	with relevant re-	(DNA
antigenic	number			clones per	immuno-	gion (positive/total)	+Prot)
protein				ORF and	genie region		
protect				screen			
2798	ORF2469	Lipase (geh)	12-35, 93-99, 166-179, 217-227,	A:41,	aa 48-136	C:GSBYG01(48-	46, 98
			239-248, 269-276, 288-294, 296-	B:42, C:3,	aa 128-172	136):2/6	
			320, 322-327, 334-339, 344-356,	F:35, G:1,	aa 201-258	A:GSBXM31-	
			362-371, 375-384, 404-411, 433-	H:11		bmd12(128-	
			438, 443-448, 455-464, 480-486,			188):11/30	
			497-503, \$16-\$25, \$35-541, \$61-			B:GS8XE16(165-	
			570, 579-585, 603-622, 633-641	}		177):10/30	
						A:GSBXN20(201-	
					A-5.	258):8/30	
						F:SALAW05(165-	
			·			177):13/41	
2815	ORF2451	Conserved hypo-	5-32, 34-49	D:21	82 I-43	D:n.d.	45, 97
		thetical protein			205 100	4 CODYD 11 0/20/	44.04
2914	ORF2351	metC	39-44, 46-80, 92-98, 105-113, 118-		aa 386-402	A:GSBXM18(386-	44, 96
			123, 133-165, 176-208, 226-238,	F:2	1	402):17/29	
}			240-255, 279-285, 298-330, 338-				
			345, 350–357, 365–372, 397–402,				\
-		<b>!</b>	409-415, 465-473, 488-515, 517-	٠.			
	l		535, 542–550, 554–590, 593–601,		1		
			603-620, 627-653, 660-665, 674-				
			687, 698-718, 726-739	C:101.	22 1-85	C:GSBYG32(1-	43, 95
2960	ORF2298	putative Exotoxin	13-36, 40-49, 111-118, 134-140,	E:2, H:58	82 54-121	85)::6/7	
	1		159-164, 173-183, 208-220, 232-	E.Z, 11.30	aa 103-195	C:GSBYG61-	
l	17-79		241, 245-254, 262-271, 280-286,		aa 103-195	bhe2(54-121):26/30	
1			295-301, 303-310, 319-324, 332-	Ì		C:GSBYN80(103-	ŧ
			339	}		195):13/17	1
2963	ORF2295	putative Exotoxin	13-28, 40-46, 69-75, 86-92, 114-	C:3, E:3,	aa 22-100	C:GSBYJ58(22-	147, 155
			120, 126-137, 155-172, 182-193,	G:I		100):9/15	
			199-206, 213-221, 232-238, 243-				
}			253, 270–276, 284–290			_	
3002	ORF1704	homology with	4-21, 28-40, 45-52, 59-71, 92-107,	A:2, C:1,	aa 21-118	A:GSBXL06(21-	33, 85
		ORFI .	123-137, 159-174, 190-202, 220-	H:4		118):50/52	İ
			229, 232-241, 282-296, 302-308,				
	1		312-331	1	1		

2	Old	Putative function	predicted immunogenic sa**	No. of se	Location of	Serum reactivity	Seq ID no:
aureus	ORF	(by homology)		lected	identified	with relevant re-	(DNA
antigenic	pumber	•		clones per	immuno-	gion (positive/total)	+Prot)
protein				ORF and	genie region		
				screen			
3200	ORF1331	putative extracel-	6-15, 22-32, 58-73, 82-88, 97-109,	A:11,	aa 5-134	A:GSBXL07(5-	29, 81
		lular matrix bind-	120-131, 134-140, 151-163, 179-	B:11,		134):6/28	
		ing protein	185, 219-230, 242-255, 271-277,	C:36			
1			288-293, 305-319, 345-356, 368-			-	
1			381, 397-406, 408-420, 427-437,				
			448-454, 473-482, 498-505, 529-				
			535, 550-563, 573-580, 582-590,			•	
		•	600-605, 618-627, 677-685, 718-				
		•	725, 729-735, 744-759, 773-784,	١٠	,	200	
			789-794, 820-837, 902-908, 916-				
			921, 9 <del>29-9</del> 35, 949-955, 1001-1008,				
			1026-1032, 1074-1083, 1088-1094,				
			1108–1117, 1137–1142, 1159–1177,				
,			1183-1194, 1214-1220, 1236-1252,		•		
			1261-1269, 1289-1294, 1311-1329,				
·			1336-1341, 1406-1413, 1419-1432,				
			1437–1457, 1464–1503, 1519–1525,		•		
			1531-1537, 1539-1557, 1560-1567,				
			1611-1618, 1620-1629, 1697-1704,				
			1712-1719, 1726-1736, 1781-1786,				
			1797–1817, 1848–1854, 1879–1890,				
			1919–1925, 1946–1953, 1974–1979				

# Table 2b: Additional immunogenic proteins identified by bacterial surface and ribosome display: S. aureus

Bacterial surface display: A, LSA250/1 library in fhuA with patient sera 1 (655); B, LSA50/6 library in lamB with patient sera 1 (484); C, LSA250/1 library in fhuA with IC sera 1 (571); E, LSA50/6 library in lamB with IC sera 2 (454); F, LSA50/6 library in lamB with patient sera P1 (1105); G, LSA50/6 library in lamb with IC sera 1 (471); H, LSA250/1 library in fhuA with patient sera 1 (IGA, 708). Ribosome display: D, LSA250/1 library with IC sera (1686). \*\*, prediction of antigenic sequences longer than 5 amino acids was performed with the programme ANTIGENIC (Kolaskar and Tongaonkar, 1990). ORF, open reading frame; CRF, reading frame on complementary strand; ARF, alternative reading frame.

THE REPORT OF THE PARTY OF THE

2	Putative function	predicted immunogenic aa**	No. of se-	Location of	Serum reactivity with relevant	Seq ID
aurens	(by homology)		lected	identified	region (positive/total)	no:
antigeni			clones	immuno-		(DNA
c protein			per ORF	genic region		+Prot)
			and			
			sereen			
ARF028	Putative protein	7–14	F:6	aa 25-43	SALAM59(25-43): 1/1	401, 402
CRF014	Putative protein	18-28, 31-37, 40-47, 51-83, 86-126	F:5	aa 81÷90	SALAZ40(81-90): 2/12	403, 404
CRF025 0	Putative protein	4-24, 26-46, 49-86	G:8	aa 60-76	SALAJ87(60-76): n.d.	365, 378
CRF030	Putative protein .	40–46	A:6, B:2,	aa 5-38	A:GSBXK03(7-36):28/69	391, 392
8	6.4		C:47, E:35		B:QSBXD29(10-20):10/27	
CRF033 7	Unknown	4-17	D:3	aa 1-20	D:n.d.	469; 486
CRF049 7	Putative protein	4-28, 31-53, 58-64	B:13, F:5	aa 18-34	GSBXF31(19-34): 1/7	366, 379
CRF053	Unknown	4-20	D: 7	aa 1-11	D:n.d.	470; 487
CRF075 0	Putative protein	4-11, 18-24, 35-40	G:44	aa 25-39	SALAG92(26-39): n.d.	367, 380
CRF114	Unknown	4-57	D:28	aa 16–32	D:n.d.	464; 481
CRF124	Putative protein	4~25, 27 <b>~</b> 56 ·	F:6	aa 36–46	SALAR23(36–46): n.d.	368, 381
CRF125	Putative protein	19-25, 38-47, 55-74, 77-87	G:5	aa 54-67	SALAG65(54-67): n.d.	369, 382
CRF135	Unknown	8-15; 18-24; 27-38	D: 5	aa 5-33	D:n.d.	471; 488
CRF176	Putative protein	4 <del>-9</del> , 23-41, 43-58, 71-85	C:3	aa 1-22	C:GSBYL30(1-22):1/I	407, 408
CRF178	Unknown	8-161	D: 5	aa 76-127	D:n.d.	465; 482
CRF184	Unknown	4-28; 30-36	D: 272	aa 1-17	D:nd.	472; 489
CRF186	Unknown	6-11; 13-34; 36-50	D:8	aa 4–27	D:n.d.	466; 483
CRF192	Putative protein	4 <del>~9</del> , 17–30	F:9	aa 13-22	SALAR41(13-22): n.d.	370, 383
CRF200 4	Putative protein	18-38	F:13	aa 16-32	SALAM75(16-32); n.d.	371, 384
CRF215	Putative protein	4~15, 30-58	F:9	aa 54-66	SALAQ54(54-66):1/12	372, 385
CRF218	Putative protein	4-61, 65-72, 79-95, 97-106	E:13	aa 86-99	GSBZE08(86-99); n.d.	373, 386
CRF220	Unknown	4-13	D: 3	aa 17-39	D:n,d.	473; 490
CRF230	Putative protein	4-9, 22-33, 44-60	C:5	aa 80–116	GSBYL75(80-116); n.d.	374, 387
CRF234	Putative protein	4-23, 30-44, 49-70	F:8	aa 46–55	SALAW31(46-55): n.d.	375, 388
CRF234 9	Putative protein	4-32, 39-46, 62-69, 77-83	B:10, F:4	aa 46-67	GSBXC92(52-67):2/11	376, 389
J	l		L			

S	Putative function	predicted immunogenic aa**	No. of se-	Location of	Serum reactivity with relevant	Seq ID
	(by homology)	bicaicre immo-serve	lected	identified	region (positive/total)	20:
aureus	(by nonsorogy)		clones	immuno-		(DNA
antigeni			per ORF	genic region		+Prot)
c protein			and	Berne Legion		1
·						
			screen D: 3	aa 3-18	D:n.d.	475; 492
CRF235	Unknown	4-18	υ. 3	aa 3 16	D.II.d.	175, 172
6	• • •	4 21	D: 9	aa 7-21	D:n.d.	476; 493
CRF245	Unknown	4–31	D. 7			
2	Datation patric	4-29, 31-41	G:8	aa 2-15	SALAF30(3-15); n.d.	377, 390
	Putative protein	4-29, 31-41	0.0			,
8 CRF255	Unknown	4-35; 37-42	D: 4	as 1-20	D:n.d.	474; 491
2	Ullidiowii	4-33, 37-42				
CRF257	Unknown	5-25; 30-39	D: 11	aa 9-30	D:n.d.	467; 484
8	CIBORWII					
CRF266	Unknown	11-21	D: 17	aa 1-14	D:n.d.	477; 494
4						
CRF272	Putative protein	10-41, 50-57	F:3	aa 40-56	SALAQ25(40-56): 1/1	405, 406
9	•					
CRF286	Unknown	4-43	D: 78	aa 17-40	D;n.d.	478; 495
3/1						
CRF286	Unknown	4-46	D: 78	aa 44-49    .	D:n.d.	479, 496
3/2				·		
CRFA00	Unknown	17-39;52-59	D: 3	aa 38-55	D:n.d.	463; 480
2		<u></u>	<u></u>			160, 405
CRFNI	Unknown	5-20; 37-44; 52-59; 87-94; 116-132	D; 4	aa 94-116	D:n.d. SALAM14(198–209): n.d.	468; 485 397, 398
ORF018	UDP-N-acetyl-	11-18, 43-56, 58-97, 100-118, 120-	B:4, F:29	aa 197-210	SALAM14(198-209). II.u.	391, 390
8	D-mannosamine	148, 152–171, 195–203, 207–214,	1			
1	transferase, puta-	220-227, 233-244				l .
	tive		D: 3	aa 155-175	D; n.d.	297,325
ORF025	Multidrug efflux	4-33, 35-56, 66-99, 109-124, 136-	D. 3	da 155-175	D. I.u.	25,52
4	transporter	144, 151–180, 188–198, 201–236,	ĺ	İ	· .	l
		238-244, 250-260, 266-290, 294-				
		306, 342–377	D: 3	Ba 9 - 44	D; n.d.	298, 326
ORF030	Conserved hypo-	4-23, 25-67, 76-107, 109-148	D. 3	247	D. 11.0.	,
7 OnFore	thetical protein	4-35, 41-47, 55-75, 77-89, 98-113,	D: 5	aa 105-122	D: n.d.	299, 327
ORF045	Conserved hypo-	116-140, 144-179, 194-215, 232-	1			
2	thetical protein		-	Į	·	
1		254, 260-273, 280-288, 290-302,	İ	1	1	1
OPENS	Na+/H+Antiporter	315-323, 330-369, 372-385, 413-432 4-81	D: 66	aa 1-21	D: n.d.	300, 328
	Indi/II Anaponer			1		
6 ORF055	Iron(III)dicitrate	5-23, 50-74, 92-99, 107-122, 126-	D: 10	aa i-18	D: n.d.	301, 329
i .	binding protein	142, 152–159, 172–179, 188–196,				
6	Dilling brotein	211-218, 271-282				
ORF062	Hypothetical	9-44, 63-69, 75-82, 86-106, 108-	D: 313	aa 13 ~ 37	D: n.d.	302, 330
9	Protein	146, 153-161, 166-178, 185-192,				
ľ	'0'	233-239, 258-266, 302-307	'			1
•	1	ws 437, 430-200, 302-301			. <del></del>	

THE STATE OF THE S

Company of the Compan

S	Putative function	predicted immunogenic aa**	No. of se-	Location of	Serum reactivity with relevant	Seq ID
aureus	(by homology)		lected	identified	region (positive/total)	no:
antigeni	(1) 1101110101010		clones	immuno-		(DNA
_			per ORF	genic region		+Prot)
c protein			and			<b>'</b>
		!	screen			
0.00063	CTD binding	10-19, 22-32, 95-105, 112-119, 121-		an 107-119	P:SALAX70(107-119):10/41	393, 395
ORF063	GTP-binding	133, 140-154, 162-174, 186-200,				
7	protein TypA	207-224, 238-247, 254-266, 274-		1		
		280, 288-294, 296-305, 343-351,			:	
				<b>i</b> !		
		358-364, 366-373, 382-393, 403-	1	·		
		413, 415-422, 440-447, 499-507,				
ORF071	Conserved	565-575, 578-588 22-51, 53-71, 80-85, 93-99, 105-	D: 3	aa 487 - 513	D: n.d.	303, 331
3	hypothetical	112, 123-146, 151-157, 165-222,			-	
ď	transmembrane	226-236, 247-270, 290-296, 301-				
	protein, putative	324, 330-348, 362-382, 384-391,	ļ			1
	protein, pulative	396-461, 463-482, 490-515	l ·			
ORF078	Cell division pro-	104-111, 158-171, 186-197, 204-	D: 4	aa 152 - 178	D: n.d.	304, 332
8	tein	209, 230-247, 253-259, 269-277,				
ľ		290-314, 330-340, 347-367, 378-388		·		
ORF079	Conserved	11-40, 56-75, 83-102, 112-117, 129-		na 196-218	D: n.d.	305, 333
7	hypothetical	147, 154-168, 174-191, 196-270,				,
1	protein	280-344, 354-377, 380-429, 431-	1			
1	ľ	450, 458-483, 502-520, 525-532,				
<u> </u>		595-602, 662-669, 675-686, 696-		'		
}		702, 704-711, 720-735, 739-748,	1			
		750756, 770779, 793800, 813				1
		822, 834–862			·	
ORF083	Cell Division Pro-	34-91, 100-119, 126-143, 147-185,	D;5	aa 26 - 56	D; n.d.	306, 334
6	tein	187-197, 319-335, 349-355, 363-				
l	ŀ	395, 397-412, 414-422, 424-440,	1			1
į		458-465, 467-475, 480-505, 507-			•	
1		529, 531-542, 548-553, 577-589,	ł			ŀ
Ī	i	614-632, 640-649, 685-704, 730-	l	1	i	ł
L		741, 744-751, 780-786	ļ	<u> </u>		
ORF131	Amino acid per-	11-21, 25-32, 34-54, 81-88, 93-99,	D: 8	aa127 - 152	D: n.d.	307, 335
8	mease	105-117, 122-145, 148-174, 187-		1		l
1	i	193, 203-218, 226-260, 265-298,			1	l
l		306-318, 325-381, 393-399, 402-	i		İ	
		421, 426-448	<u>                                     </u>		D 000000000000000000000000000000000000	197, 216
ORF132	Pyruvat kinase	4-11,50-67,89-95,103-109,112-	E:6	aa 420-432	E:GSBZE16(420-432):5/41	137, 210
1		135, 139-147, 158-170, 185-204,				
		213-219, 229-242, 248-277, 294-				1
I	ł	300, 316-323, 330-335, 339-379,				
		390-402, 408-422, 431-439, 446-		Ι .		
1		457, 469-474, 484-500, 506-513,	1			1
i	Ī	517-530, 538-546, 548-561	<u></u>	1	<u> </u>	ــــــــــــــــــــــــــــــــــــــ

THE PERSON NAMED IN COLUMN

The second secon

S.	Putative function	predicted immunogenic aa**	No. of se-	Location of	Serum reactivity with relevant	Seq ID
aureus	(by homology)		lected	identified	region (positive/total)	no:
antigeni	(e) nomology)		clones	-ogummi		(DNA
_			per ORF	genic region		+Prot)
e protein			and	Barresegan		, ,
ORF138	LPXTG cell wall	11-31, 86-91, 103-111, 175-182,	screen D: 3	aa 508 - 523	D: n.d.	308, 336
	anchor motif	205-212, 218-226, 242-247, 260-	5.5			
8	ancior mon	269, 279–288, 304–313, 329–334,				1 1
		355-360, 378-387, 390-399, 407-				li
		435, 468-486, 510-516, 535-547,				) ]
		574-581, 604-615, 635-646, 653-				
		659, 689-696, 730-737, 802-812,	1		_	
		879-891, 893-906, 922-931, 954-	·£.			
		964, 997-1009, 1031-1042, 1089-			•	li
		1096, 1107-1120, 1123-1130, 1149-				l i
		1162, 1176-1184, 1192-1207, 1209-			-	] ]
		1215, 1253–1259, 1265–1275, 1282– 1295, 1304–1310, 1345–1361, 1382–				1 1
·		1388, 1394–1400, 1412–1430, 1457–				
		1462, 1489–1507, 1509–1515, 1535–				ľ. ľ
		1540, 1571-1591, 1619-1626, 1635- 1641, 1647-1655, 1695-1701, 1726-				
		1748, 1750-1757, 1767-1783, 1802-				]
ļ		1807, 1809–1822, 1844–1875, 1883–		}		1 1
		1889, 1922-1929, 1931-1936, 1951-				
		1967, 1978–1989, 1999–2008, 2023–				
		2042, 2056-2083, 2101-2136, 2161-				
		2177				
ORF140	3,4-dihydroxy-2-		E:3	aa 121-137	E:GSBZB68(121-137):7/41	198, 217
2	butanone-4-	107-114, 123-139, 144-155, 157-	}			
[	phosphate syn-	164, 191–198, 232–240, 247–272,				
1	thase	284-290, 295-301, 303-309, 311-		1		
		321, 328-341, 367-376				
ORF147	hemolysin II	4-36, 39-47, 57-65, 75-82, 108-114,	F:1	aa 245-256	F:SALAP76(245-256):6/41	199, 218
3	(LukD-Leuktoxin)	119-126, 135-143, 189-195, 234-				
1		244, 250-257, 266-272, 311-316			ì	
ORF152	Iron uptake regu-	13-27, 29-44, 46-66, 68-81, 97-116,	D:3	aa 120- 135	D: n.d.	309, 337
3	lator	138-145				
ORF170	inner membrane	4-23, 57-77, 89-103, 119-125, 132-	F:I	as 104-118	F:SALBC82(104-118):7/41	200, 219
7	protein, 60 kDa	172, 179–197, 210–254, 256–265,	1	}		<b>,</b>
		281-287	<u> </u>	200 200		310, 338
ORF175	amiB	5-10, 16-24, 62-69, 77-96, 100-115,	D: 3	aa 293 - 312	D: n.d.	310, 338
4	1	117-126, 137-156, 165-183, 202-				1
		211, 215-225, 229-241, 250-260,				
		267-273, 290-300, 302-308, 320-	]			
		333, 336–342, 348–356, 375–382,			Į.	
	1	384-389		<u> </u>	<u> </u>	

STATE OF THE STATE

2	Putative function	predicted immunogenic an**	No. of se-	Location of	Serum reactivity with relevant	Seq ID
aureus	(by homology)		lected	identified	region (positive/total)	no:
	(D) Hornorogy)		clones	immuno-		(DNA
antigeni			per ORF	genic region		+Prot)
c protein			and		•	
			screen			
ORF178	Mrp protein	5-29, 46-52, 70-76, 81-87, 155-170,		ва 850-860	F:SALAQ36(850-860):8/41	201, 220
3	(fmtB)	192-197, 206-213, 215-220, 225-				
	(imio)	231, 249-258, 273-279, 281-287,			•	
		300-306, 313-319, 323-332, 335-				
		341, 344-351, 360-382, 407-431,				
		443-448, 459-468, 475-496, 513-		1	•	1 1
		520, 522-537, 543-550, 556-565,				
		567-573, 580-585, 593-615, 619-	-610			i 1
				, i		1 1
		631, 633–642, 670–686, 688–698,		,		}
		759-766, 768-782, 799-808, 842-			•	1 1
		848, 868-877, 879-917, 945-950,				
		979-988, 996-1002, 1025-1036, 1065-1084, 1101-1107, 1113-1119,	1			i ·
ł			l			
1	1	1125-1142, 1163-1169, 1183-1189,	i	1		
l		1213-1219, 1289-1301, 1307-1315,	ĺ			
1		1331-1342, 1369-1378, 1385-1391, 1410-1419, 1421-1427, 1433-1447,	l	<b>i</b>		
1	•	1468-1475, 1487-1494, 1518-1529,	l	<u> </u>		
l	<b>]</b> .	1564-1570, 1592-1609, 1675-1681,				1 1
ł	ì	1686-1693, 1714-1725, 1740-1747,	ł			
1		1767-1774, 1793-1807, 1824-1841,				
ł		1920-1937, 1953-1958, 1972-1978,	l			
		1980-1986, 1997-2011, 2048-2066,	l			
1	1	2161-2166, 2219-2224, 2252-2257,	]			
	<b>)</b> .	2292-2298, 2375-2380, 2394-2399,		]	i	}
1	1	2435-2440, 2449-2468				
ORF184	Map-ND2C	4-27, 42-66, 70-76, 102-107, 113-	E:5	aa 75-90	E:GSBZB15(75-90):6/41	202, 221
8	protein	118, 133–138				
ORF189	ribosomal protein	31-39, 48-54, 61-67, 75-83, 90-98,	F:4	aa 239-257	F:SALAV36(239-257):19/41	203, 222
l <sub>1</sub>	L2 (mB)	103-119, 123-145, 160-167, 169-	[	1		·
		176, 182-193, 195-206, 267-273				
ORF201	Putative drug	5-27, 79-85, 105-110, 138-165, 183-	D:5	aa 205 - 224	D: n.d.	311, 339
1	transporter	202, 204–225, 233–259, 272–292,	1			1
1		298-320, 327-336, 338-345, 363-				
		376, 383-398, 400-422, 425-470,		1		
į		489-495, 506-518, 536-544, 549-		1		
		554, 562-568, 584-598, 603-623	<u> </u>	<b></b>		1004 000
ORF202	lactase permease,	10-33, 38-71, 73-103, 113-125, 132-	E:2	aa 422-436	E:GSBZF58(422-436):6/41	204, 223
7	putative	147, 154-163, 170-216, 222-248,	j			}
	1	250-269, 271-278, 287-335, 337-	1			
	1	355, 360-374, 384-408, 425-442,				
		453-465, 468-476, 478-501, 508-525		1	5 1	312, 340
ORF208	1	8-27, 52-59, 73-80, 90-99, 104-110,	D: 3	aa 126 - 147	iv. n.a.	312,340
7	(putative)	117-124, 131-140, 189-209, 217-	i			1
l		232, 265-279, 287-293, 299-306	<u> </u>	J	<u> </u>	

-	Putative function	predicted immunogenie aa**	No. of se-	Location of	Serum reactivity with relevant	Seq ID
2		blentter impirmogenie au	lected	identified	region (positive/total)	20:
ангенз	(by homology)				region (postavenous)	1 1
antigeni			clones	immuno-		(DNA
e protein			per ORF	genic region	•	+Prot)
	•	•	and			
			screen			
ORF209	preLukS	8-26, 75-82, 118-126, 136-142, 163-	F:2	ва 270-284	F:SALAQ77(270-284):23/41	205, 224
0		177, 182-189, 205-215, 221-236,				
		239–248, 268–274				
ORF209	Hemolysin II	5-22, 30-47, 58-65, 75-81, 87-92,	F:3	aa 238-253	F:SALAQ67(237-252):10/41 .	206, 225
2	(preLUK-F)	99-105, 107-113, 119-126, 189-195,				
		217-223, 234-244, 250-257, 266-272			·	
ORF210	Multidrug	10-28, 30-43, 50-75, 80-113, 116-	D: 9	aa 54 104	D: n.d.	313, 341
7	resistance protein	125, 136-167, 170-191, 197-245,			•	
	(putative)	253-329, 345-367, 375-396				
ORF219	Transcriptional	20-31, 4 <del>6-5</del> 2, 55 <del>-6</del> 9, 74-79, 89 <del>-</del> 97,	D: 3	aa 15 - 35	D: n.d.	314,
2	regulator GntR	108-113, 120-128, 141-171, 188-214				342
	family, putative					
ORF230	Amino acid per-	25-79, 91-103, 105-127, 132-149,	D: 53	aa 363 - 393	D: n.d.	315, 343
5	mease	158-175, 185-221, 231-249, 267-				
	•	293, 307–329, 336–343, 346–359,			·	
		362-405, 415-442, 446-468				
ORF232	Citrate dransporter	10-77, 85-96, 99-109, 111-138, 144-	D: 7	sa 37 – 83	D: n.d. · .	316, 344
4		155, 167–176, 178–205, 225–238,				
		241-247, 258-280, 282-294, 304-			-	ŀ
1.	·	309, 313-327, 333-383, 386-402,				1 1
		405-422, 429-453			`	
ORF242	Anion transporter	7-26, 28-34, 36-53, 55-73, 75-81,	D: 16	aa 275 295	D: n.d.	317, 345
2	family protein	87-100, 108-117, 121-138, 150-160,				
		175-181, 184-195, 202-215, 221-	1			
1		247, 265-271, 274-314, 324-337,				
		341-412, 414-423, 425-440, 447-				
		462, 464-469				
ORF255	SirA	5-22, 54-78, 97-103, 113-123, 130-	D:3	aa 1 – 22	D: nd	318, 346
3		148, 166-171, 173-180, 192-201,	l			
		254-261, 2 <del>66-272,</del> 310-322				
ORF255	omithine cyclode-	20-35, 37-50, 96-102, 109-120, 123-	E:2	an 32-48	E:GSBZB37(32-48):11/41	207, 226
5	aminase	137, 141-150, 165-182, 206-224,		1		
1		237-256, 267-273, 277 <b>-</b> 291, 300-				1
<u> </u>		305, 313–324		٠		
ORF255	Multidrug resis-	11-63, 79-129, 136-191, 209-231,	D: 8	BA 84 - 100	D: n.d.	319, 347
8	tance efflux pro-	237-250, 254-276, 282-306, 311-	l			
	ten, putative	345, 352-373, 376-397		<u> </u>		
ORF261	Сар5М	4-30, 34-40, 79-85, 89-98, 104-118,	D: 13	an 114 - 141	D. n.d.	320, 348
0		124-139, 148-160, 167-178	<u>.</u>			
ORF261	CapSP (UDP-N-	4-9, 17-24, 32-38, 44-54, 68-82,	B:3, F:11	ma 321-341	F:SALAU27(325-337):9/41	208, 227
3	acetylglucosamine	89-95, 101-120, 124-131, 136-142,	1	1		
1	2-epimerase)	145-157, 174-181, 184-191, 196-	1	1		
	.0	204, 215-224, 228-236, 243-250,	ł			
		259-266, 274-281, 293-301, 314-	}			
		319, 325-331, 355-367, 373-378				L

S.	Putative function	predicted immunogenic na**	No. of se-	Location of	Serum reactivity with relevant	Seq ID
aureus	(by homology)	predicted annual grown	lected	identified	region (positive/total)	no:
	(na immoralia)		dones	łmmuno-		(DNA
antigeni			per ORF	genic region		+Prot)
e protein	•		and	Benne region		
					•	
005363	Use otherical area	9-15, 28-36, 44-62, 69-88, 98-104,	screen F:6	aa 694-708	F:SALBD82(1288-1303):9/41	209, 228
ORF262	Hypothetical pro-	111-136, 139-149, 177-186, 195-		aa 790-800	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
8	tein	217, 224-236, 241-257, 260-278,		aa 1288-		
		283-290, 292-373, 395-408, 411-		1305		
		443, 465-472, 475-496, 503-520,		1505		
					•	
		552-559, 569-589, 593-599, 607-				
*		613, 615-636, 648-654, 659-687,			. **,	
		689-696, 721-733, 738-759, 783-				
-		789, 795–801, 811–823, 827–836,		1		
		839-851, 867-875, 877-883, 890-				
		898, 900–908, 912–931, 937–951,		]	•	
	1	961-992, 994-1002, 1005-1011,		1		
1	<b>,</b>	1016-1060, 1062-1074, 1088-1096,				1
		1101–1123, 1137–1153, 1169–1192,				
		1210-1220, 1228-1239, 1242-1251,				1
	• '	1268-1275, 1299-1311, 1322-1330,				ł
		1338-1361, 1378-1384, 1393-1412,			•	ļ
		1419–1425, 1439–1459, 1469–1482,	}	·	÷	1
1		1489–1495, 1502–1519, 1527–1544,	1			ł
	ł	1548–1555, 1600–1607, 1609–1617,		1		1
l		1624-1657, 1667-1691, 1705-1723,	l			1
1		1727-1742, 1749-1770, 1773-1787,	1			Ì
1		1804–1813, 1829–1837, 1846–1852,				
i		1854-1864, 1869-1879, 1881-1896,	!	}		1
ľ	1.	1900-1909, 1922-1927, 1929-1935,	İ	i		ĺ
İ		1942-1962, 1972-2005, 2009-2029,	ļ.		_	l
1		2031–2038, 2055–2076, 2101–2114,	l	1		1
į .	4	2117-2124, 2147-2178, 2188-2202,				1
	ļ	2209-2217, 2224-2230, 2255-2266,		1	•	
Ì		2271–2280, 2282–2302, 2307–2316,	· .			1
<u> </u>		2319-2324, 2379-2387	F.4	ва 106-159	F;SALAW60(106-125):3/41	210, 229
ORF264	PTS system, su-	8-15, 24-30, 49-68, 80-93, 102-107,	r:4	8a 100-139	F;SALAW00(100-123):3/41	12:0,22
. 4	crose specific	126-147, 149-168, 170-180, 185-	l			ł
l	IIBC component	193, 241–305, 307–339, 346–355,	1		ľ	
		358-372, 382-390, 392-415, 418-	i	1		
-		425, 427-433, 435-444, 450-472	D: 5	aa 182 -209	D; n.d.	321, 349
ORF265	l ·	5-61, 72-84, 87-99, 104-109, 124-	J. 3	aa 102 -209	2, 23.	
4	transporter, puta-	145, 158-170, 180-188, 190-216,				
227765	tive	223-264, 270-275, 296-336, 355-372 4-21, 71-79, 99-105, 110-121, 143-		aa 306-323	F:SALBC05(306-323):2/41	211, 230
ORF266	maltose ABC		ľ.,			
2	transporter, puta-	161, 199-205, 219-235, 244-258,	1	·		1
	tive	265-270, 285-291, 300-308, 310-	}			1
1		318, 322-328, 346-351, 355-361,				i
i	I.	409-416	L	1	1	

S.	Putative function	predicted immunogenic sa**	No. of se-	Location of	Serum reactivity with relevant	Seq ID
oureus	(by homelogy)		lected	identified	region (positive/total)	no:
autigeni			clones	immuno-		(DNA
c proteio			per ORF	genic region		+Prot)
			and			
			screen			
ORF271	sorbitol	4-12, 19-40, 61-111, 117-138, 140-	B:2, F:4	ва 244-257	F:SALAX93(249-256):6/41	212, 231
0	dehydrogenase	153, 161-180, 182-207, 226-235,	1			
ľ	,,	237-249, 253-264, 267-274, 277-	1	į		1
		292, 311-323		]		}
ORF274	Hypothetical pro-	4-41, 49-56, 61-67, 75-82, 88-104,	D: 188,	aa 303 - 323	D: n.d.	322, 350
2	tein	114-125, 129-145, 151-165, 171-	H:4			
	4:	178, 187-221, 224-230, 238-250,			·	
		252-275, 277-304, 306-385				
ORF278	brnQ	4-29, 41-63, 74-95, 97-103, 107-	D: 3	ва 26 – 40	D: n.d.	323, 351
0		189, 193-209, 220-248, 260-270,				
	•	273-299, 301-326, 328-355, 366-	Į.			
		397, 399-428				
ORF280	Phage related pro-	10-17, 23-29, 31-37, 54-59, 74-81,	F:3	aa 104-116	F:SALBC34:1/1	213, 232
6	tein	102-115, 127-137, 145-152, 158-				]
		165, 178-186, 188-196, 203-210,			·	
		221-227, 232-237				
ORF290	Conserved hypo-	4-27, 34-43, 62-73, 81-90, 103-116,	D: 24	na 360 - 376	D: n.d.	324, 352
0	thetical protein	125-136, 180-205, 213-218, 227-				l
1		235, 238-243, 251-259, 261-269,				1
		275-280, 284-294, 297-308, 312-				į
		342, 355-380, 394-408, 433-458,	ł	i		1
		470-510, 514-536, 542-567	<u> </u>			
ORF293	conserved .	4-19, 43-54, 56-62, 8 <del>4.9</del> 0, 96-102,	E:6	8a 22~37	E:GSBZA13(22-37):7/41	214, 233
1	hypothetical	127-135, 157-164, 181-187	ł .			
	protein		<u>-</u>		20.122.401.401.401	215 024
ORF295	Exotoxin 2	7-19, 26-39, 44-53, 58-69, 82-88,	F:1	aa 154-168	F:SALBB59(154-168):4/41	215, 234
8		91-107, 129-141, 149-155, 165-178,				
0.0.000	22	188-194	H:5	za 1-70	H:GSBYU66: p.d.	399, 400
	Surface protein,	9-23, 38-43, 55-60, 69-78, 93-101,	n:	Za 1-/U	IN,USB 1 U00: B.G.	223,400
0	putative	103-112, 132-148, 187-193, 201-				1
		208, 216–229, 300–312, 327–352,				
		364-369, 374-383, 390-396, 402-	1		·	1
		410, 419-426, 463-475, 482-491	L	i	<u> </u>	L

Table 2c: Immunogenic proteins identified by bacterial surface and ribosome display: S. epidermidis.

Bacterial surface display: A, LSE150 library in fhuA with patient sera 2 (957); B, LSE70 library in lamB with patient sera 2 (1420); C, LSE70 library in lamB with patient sera 1 (551). Ribosome display: D, LSE150 in pMAL4.31 with P2 (1235). \*\*, prediction of antigenic sequences longer than 5 amino acids was performed with the programme ANTIGENIC (Kolaskar and Tongaonkar,

..:.

1990). ORF, open reading frame; ARF, alternative reading frame; CRF, reading frame on complementary strand. ORF, open reading frame; CRF, reading frame on complementary strand.

.2.	Putative function	predicted immunogenic aa**	No. of	Location of	Serum reactivity with relevant	Seq ID
epidermidi	(by homology)		selected	identified	region (positive/total)	po:
s antigenic			clones	immuno-		(DNA
protein			per ORF	genic region		+Prot)
			baa			
			screen			
ARF0172	cation-transport-	4-34, 37-43	D:6	aa3-32	D: nd	497,
	ing ATPase, E1-					548
	E2 family					
			-		n_1	400
ARF0183	condensing en-	422, 2449	D:4	aa i – 52	D: nd	498,
	zyme, putative,					549
	FabH related					
ARF2455	NADH	4-29	D:3	aa1-22	D: nd	499,
	dehydrogenase,					550
	putative		-			
CRF0001	Unknown	4-14, 16-26	D:3	aa5-21	D: nd	500,
•						551
CRF0002	Unknown	4-13, 15-23, 36-62	D:5	aa21-70	D: ad	501,
						552
<del></del>				4 21	D J	502,
CRF0003	Unknown	4-12, 14-28	D:3	aa 4-31	D; nd	
			<u> </u>	<u> </u>		553
CRF0004	Unknown	5-15, 35-71, 86-94	D:4	aa31-72	D: nd	503,
		,				554
		0.00.00.04	D:3	aa:9-33	D; ad	504,
CRF0005	Unknown '	8-26, 28-34		23.7 33	D. 20	555
			<del> </del>		· · · · · · · · · · · · · · · · · · ·	<del>                                     </del>
CRF0006	Unknown	4-11, 15-28	D:3	Ba10-22	D: nd	505,
•	İ					556
CDEMONA	Ibkaana	4-19, 30-36	D:3	aa 7-44	D: nd	506.
CRF0007	Unknown .				·	557
ļ	<del> </del>	<u> </u>	-	<del>                                     </del>		<del>                                     </del>
CRF0008	Unknown	10-48	D:4	aa:9-44	D: nd	507,
						558
CRF0009	Unknown	41883	D:3	8a5-14	D: nd	508,
					,	559
CRF0192	Putative protein	4-23, 25-68	C:4	aa 15-34	C:GSBBM10(15-34): n.d.	445,
CKTUINZ	auauve process					446

2	Putative function	predicted immunogenie sa**	No. of	Location of	Serum reactivity with relevant	Seq ID
epidermidi			selected	identified	region (positive/total)	no:
			clones	immuno-	rog.o (poditivo total)	(DNA
s antigenic						· ·
protein			per ORF	genic region		+Prot)
		}	and	<b>.</b>		1
			screen			
CRF0275	Putative protein	4-40, 49-65	B:5	aa 35—68	B:SELAK28(35-68): n.d.	447,
		4 12 17 52 52 70 75 B4 B5 100	C:4	aa 75-99	C:GSBBR74(76-99): n.d.	448
CRF0622	Putative protein	4-12, 17-57, 62-70, 75-84, 86-100	L:4	aa 13 <del>-39</del>	C.O3DBR/4(70-99): ILU.	450
CRF0879	Putative protein	4-14, 38-44	A:3, B:10	aa 9~40	B:SELAC39(10-40): n.d.	451,
Cid 0877	i diagro protons	1 1,550 11	,			452
CRF1004	Putative protein	4-40	A:3, B:5	aa 29-65	B:SELA163(35-63): n.d.	453,
	• • • • • • • • • • • • • • • • • • • •	14				454
CRF2248	Putative protein	4-10, 19-40, 53-64, 74-91	C:30	ea 74-111	C:GSBBN64(16-35): n.d.	455,
						456
CRF2307	Putative protein	4-19, 35-41, 80-89	A:19	aa 41-87	A:SEFAL47(41~87):n.d.	457,
						458
CRF2309	Putative protein	15-21	B:6	aa 4-16	B:SELAL02(4-16): n.d.	459,
						460
CRF2409	Putative protein	6–25	B:6	aa 2-24	B:SELAB48(5-24): n.d.	461,
	L					462
ORF0005	hypothetical pro-	13-27, 33-67, 73-99, 114-129, 132-	D:3	8a105-128	D: nd	509,
	tein	158, 167-190, 193-234, 237-267,				560
ŀ		269-299, 316-330, 339-351, 359-	Ì			
		382, 384-423				
ORF0008	Streptococcal he	9-14, 16-24, 26-32, 41-50, 71-79,	B:2	aa 895-926	B:SELAF79(895-926): 7/12	239,
	magglutinin	90-96, 177-184, 232-237, 271-278,				268
		293-301, 322-330, 332-339, 349-1		•		
		354, 375–386, 390–396, 403–409,				
		453-459, 466-472, 478-486, 504-				l
		509, 518–525, 530–541, 54 <del>6</del> –552,	·			
		573-586, 595-600, 603-622, 643-				
		660, 668–673, 675–681, 691–697,				
		699-711, 713-726, 732-749, 753-			•	ŀ
	•	759, 798-807, 814-826, 831-841,				
		846-852, 871-878, 897-904, 921-				<u> </u>
		930, 997-1003, 1026-1031, 1033-			•	
		1039, 1050-1057, 1069-1075, 1097-		• (		
	_	1103, 1105–1111, 1134–1139, 1141–				
		1147, 1168-1175, 1177-1183, 1205-			,	
		1211, 1213-1219, 1231-1237, 1241-				·
		1247, 1267-1273, 1304-1309, 1311-			•	ł
		1317, 1329–1335, 1339–1345, 1347–				}
		1353, 1382-1389, 1401-1407, 1411-				l
		1417, 1447-1453, 1455-1461, 1483-				}
		1489, 1491-1497, 1527-1533, 1545-	V)			
		1551, 1556-1561, 1581-1587, 1591-				1
		1597, 1627-1638, 1661-1667, 1684-				l
		1689, 1691-1697, 1708-1715, 1719-	Į į			
		1725, 1765-1771, 1813-1820, 1823-				l
		1830, 1835–1856	I			l

COMMENSATION OF THE PROPERTY O

galdermidi (vy homology)  settineelilalir protein  ORF0038 extincelilalir chairse procursor (activate procursor)  CRF0038 extincellalir chairse procursor (activate procursor)  CRF0038 extincellalir chairse procursor (activate procursor)  Settineelilalir chairse procursor (activate procursor)  ORF0039 bypothetical (activate procursor)  SP-3184, 458-470, 478-439, 495-200, 243-240, 243-248, 302-2112, 345-340, 362-371, 378-384, 458-470, 478-439, 495-504  ORF0099 bypothetical (activate procursor)  SP-31, 102-109, 119-126, 150-157, 170-179, 185-191, 204-214, 217-223, 237-248, 269-275, 278-316, 320-340, 359-365  ORF0101 bypothetical (activate procursor)  Protein 173, 179-184, 187-198, 217-222, 229-235, 238-246  ORF0121 C4-dicarboxylate (activate procursor)  C4-dicarboxylate (activate procursor)  SSF0121 122, 131-164, 169-193, 204-213, activate procursor)  SSF0123 249, 267-294, 310-329, 336-343, 346-405, 417-468  ORF0143 amino acid permanse (activate procursor)  Messe 157-174, 184-206, 208-219, 231-249, 267-294, 310-159, 150, 153-174, 184-206, 208-219, 231-249, 267-294, 310-159, 150, 153-150, 153-166, 171-176, 198-204, 219-230  ORF0201 putative 157, 170-176, 182-188, 200-217, 233-332, 246-252, 254-259, 254-269, 274-280, 308-314  ORF0201 Robotinase (rbsK) 511, 170-176, 182-188, 200-217, 233-332, 246-252, 254-259, 274-280, 308-314  ORF0201 Robotinase (rbsK) 511, 170-176, 182-188, 200-217, 233-332, 246-252, 254-259, 274-280, 308-314  ORF0201 Robotinase (rbsK) 511, 170-176, 182-188, 200-217, 233-332, 246-252, 254-259, 274-280, 308-314  ORF0201 Robotinase (rbsK) 511, 152-3, 47-55, 82-90, 98-103, 168-114, 126-132, 134-156, 161-168, 191-172, 171-166, 171-176, 198-203, 299-248, 258-264, 275-290  ORF0201 Robotinase (rbsK) 511, 15-23, 47-56, 88-119, 127-146, 149-20  ORF0201 Robotinase (rbsK) 511, 15-23, 47-56, 88-119, 127-146, 149-20  ORF0201 Robotinase (rbsK) 511, 15-23, 47-56, 88-119, 127-146, 149-20  ORF0201 Robotinase (rbsK) 511, 15-23, 47-56, 88-119, 127-146, 149-20  ORF0201 Robotinase (rbsK) 511, 15-23, 47-56, 88-119, 127-	2	Putative function	predicted immunogenic aa**	No. of	Location of	Serum reactivity with relevant	Seq ID
Protein   Prot	i i			selected	identified	region (positive/total)	no:
ORF0036 extracellular 6-25, 29-35, 39-45, 64-71, 82-88, C-6 an 136-165 C-GSBBN08(136-165):1/1 353,359 elastise precursor 96-102, 107-113, 119-131, 170-176, 186-192, 196-202, 215-220, 243-243, 202-212, 245-202, 243-248, 302-312, 245-360, 362-371, 378-384, 458-470, 478-489, 495-504 protein 6-18, 31-37, 42-49, 51-67, 73-85, protein 87-93, 102-109, 119-126, 150-157, 170-179, 185-191, 204-214, 217-223, 237-248, 266-275, 278-316, 320-340, 359-365	s antigenic			clones	immuno-		(DNA
ORF0038 extracellular clastinse precursor clastins precursor clastinse precursor clastins classification clastinse precursor clastins classification classification classification classification classification classification classification classification classification classification classification classification classification classification classification clastins classification classification classification classificatio	protein			per ORF	genic region		+Prot)
ORF0031 elastase precursor elastas el 136–165 CGSBBN08(136–165):1/1 333,3359  ORF0099 bypothetical 6-102, 19-113, 119-114, 19-115, 170-176, 18-167, 73-85, 10-157, 170-179, 185–191, 204–214, 217-223, 237–248, 269–275, 278–316, 320–378, 10-15, 19-15, 1				and			
CRF01099 bypothetical protein 87-93, 102-109, 115-126, 120-127, 12			22 22 22 25 24 21 22 22		20 136-165	C-CCBBN00/136-165)-1/1	153 350
186-192, 196-202, 215-220, 243- 248, 302-312, 345-360, 362-371, 378-384, 458-470, 478-489, 495- 504	ORF0038			C:0	aa 130-103	C.O3BBN00(130-103):171	رددردد
248, 302—312, 345—360, 362—371, 378—384, 458—470, 478—489, 495—504  ORF0099 bypothetical 6—18, 31—37, 42—49, 51—67, 73—85, 170—179, 185—191, 204—214, 217—223, 237—248, 269—275, 278—316, 320—340, 359—365  ORF0101 bypothetical 4—10, 15—27, 67—94, 123—129, 167—222, 229—235, 238—246  ORF0121 C4—dicarboxylate 4—20, 24—62, 73—86, 89—106, 110—122, 131—164, 169—193, 204—213, aerobic, putative 219—236, 252—259, 263—281, 296—306, 318—324, 328—325, 336—397, 410—429  ORF0143 amino acid permease 25—79, 91—103, 105—127, 132—150, 157—174, 184—206, 208—219, 231—249, 267—294, 310—329, 336—343, 346—405, 417—468  ORF0162 Immaurodominant Antigen A 133—150, 158—166, 171—176, 198—214, 194—29  ORF0162 Immaurodominant Antigen A 133—150, 158—166, 171—176, 198—214, 204, 219—230  ORF0201 capa protein, putative 135, 170—176, 182—188, 203—217, 223—232, 246—252, 254—269, 274—280, 308—314  ORF0207 Ribokinase (rbsK) 5—11, 15—23, 47—55, 82—90, 98—103, 108—114, 126—132, 134—156, 161—186, 191—197, 210—224, 228—235, 239—248, 258—264, 275—290  ORF0208 LrgB 7—28, 34—56, 68—119, 127—146, 149— D:4 anal 12—149 D: nd 515,		ensuse precursor					
ORF0099 bypothetical 6-18, 31-37, 42-49, 51-67, 73-85, protein 87-93, 102-109, 119-126, 150-157, 170-179, 185-191, 204-214, 217-223, 237-248, 269-275, 278-316, 320-340, 359-365 D: nd 510, 561  ORF0101 bypothetical 4-10, 15-27, 67-94, 123-129, 167-D: 18 aa26-109 D: nd 511, protein 173, 179-184, 187-198, 217-222, 229-235, 238-246 D: nd 511, 562  ORF0121 C4-dicarboxylate 4-20, 24-62, 73-86, 89-106, 110-122, 131-164, 169-193, 204-213, aerobic, putative 122, 131-164, 169-193, 204-213, 219-236, 252-259, 263-281, 296-306, 318-324, 328-352, 356-397, 410-429  ORF0143 amino acid perpose 25-79, 91-103, 105-127, 132-150, messe 157-174, 184-206, 208-219, 231-249, 267-294, 310-329, 336-343, 346-405, 417-468  ORF0162 Immurodominant 4-27, 35-45, 52-68, 33-89, 113-119, Antigen A 24, 133-150, 158-166, 171-176, 198-26, 198-26, 219-230  ORF0201 capa protein, 10-17, 27-53, 81-86, 98-105, 126-10, putative 135, 170-176, 182-188, 203-217, 223-232, 246-252, 254-269, 274-280, 308-314  ORF0207 Ribokinase (rbsK) 5-11, 15-23, 47-55, 82-90, 98-103, 108-114, 126-132, 134-156, 161-186, 191-197, 210-224, 228-235, 239-248, 258-264, 275-290  ORF0208 LtgB 7-28, 34-56, 68-119, 127-146, 149- D:4 aa112-149 D: nd 515,							
ORF0099 bypothetical collection			378-384, 458-470, 478-489, 495-				i I
Spring   S			504				
170-179, 185-191, 204-214, 217-223, 237-248, 269-275, 278-316, 320-340, 359-365	ORF0099	hypothetical	6-18, 31-37, 42-49, 51-67, 73-85,	D:5	aa218-265	D: nd	510,
223, 237-248, 269-275, 778-316,   320-340, 359-365		protein	87-93, 102-109, 119-126, 150-157,			•	561
223, 237-248, 269-275, 778-316,   320-340, 359-365			170-179: 185-191, 204-214, 217-		•	,	
ORFO101   hypothetical							
ORF0101 hypothetical protein							
ORFO121 C4-dicarboxylate 4-20, 24-62, 73-86, 89-106, 110- transporter, an- 122, 131-164, 169-193, 204-213, aerobic, putative 219-236, 252-259, 263-281, 296- 306, 318-324, 328-352, 356-397, 410-429  ORF0143 amino acid per- 25-79, 91-103, 105-127, 132-150, mease 157-174, 184-206, 208-219, 231- 249, 267-294, 310-329, 336-343, 346-405, 417-468  ORF0162 Immunodominant 4-27, 35-45, 52-68, 83-89, 113-119, Antigen A 133-150, 158-166, 171-176, 198- 204, 219-230  ORF0201 capa protein, 10-17, 27-53, 81-86, 98-105, 126- putative 135, 170-176, 182-188, 203-217, 223-232, 246-252, 254-269, 274- 280, 308-314  ORF0207 Ribokinase (rbsK) 5-11, 15-23, 47-55, 82-90, 98-103, 108-114, 126-132, 134-156, 161- 186, 191-197, 210-224, 228-235, 239-248, 258-264, 275-290  ORF0288 LrgB 7-28, 34-56, 68-119, 127-146, 149- D:4 aa112-149 D: nd 515, 356	<u> </u>					- 11	
ORF0121 C4-dicarboxylate transporter, an 122, 131–164, 169–193, 204–213, aerobic, putative 219–236, 252–259, 263–281, 296–306, 318–324, 328–352, 356–397, 410–429  ORF0143 amino acid per 25–79, 91–103, 105–127, 132–150, mease 157–174, 184–206, 208–219, 231–249, 267–294, 310–329, 336–343, 346–405, 417–468 204, 219–230  ORF0162 Immunodominant 4–27, 35–45, 52–68, 83–89, 113–119, A:11, Antigen A 133–150, 158–166, 171–176, 198–204, 219–230  ORF0201 capa protein, putative 135, 170–176, 182–188, 203–217, 223–232, 246–252, 254–269, 274–280, 308–314  ORF0207 Ribokinase (rbsK) 5–11, 15–23, 47–55, 82–90, 98–103, 108–114, 126–132, 134–156, 161–186, 191–197, 210–224, 228–235, 239–248, 258–264, 275–290  ORF0288 LrgB 7–28, 34–56, 68–119, 127–146, 149– D:4 aa112–149 D: nd 515, 256	ORF0101	hypothetical	4-10, 15-27, 67-94, 123-129, 167-	D:18	aa26-109	D: nd	
ORF0121 C4-dicarboxylate transporter, an aerobic, putative 25-79, 91-103, 105-127, 132-150, 157-174, 184-206, 208-219, 231-249, 267-294, 310-329, 336-343, 346-405, 417-468  ORF0162 Immunodominant Antigen A 133-150, 158-166, 171-176, 198-204, 219-230  ORF0201 capa protein, putative 135, 170-176, 182-188, 203-217, 223-232, 246-252, 254-269, 274-280, 308-314  ORF0207 Ribokinase (rbsK) 5-11, 15-23, 47-55, 82-90, 98-103, 108-114, 126-132, 134-156, 161-186, 191-197, 210-224, 228-235, 239-248, 258-264, 275-290  ORF0288 LrgB 7-28, 34-56, 68-119, 127-146, 149- D:4 aa112-149 D: nd 515, 563		protein	173, 179-184, 187-198, 217-222,				562
ORFO121 C4-dicatostyline 122, 131–164, 169–193, 204–213, aerubic, putative 122, 131–164, 169–193, 204–213, 219–236, 252–259, 263–281, 296–306, 318–324, 328–352, 356–397, 410–429  ORF0143 amino acid per— 25–79, 91–103, 105–127, 132–150, 157–174, 184–206, 208–219, 231–249, 267–294, 310–329, 336–343, 346–405, 417–468  ORF0162 Immunodominant Antigen A 133–150, 158–166, 171–176, 198–204, 219–230  ORF0201 capa protein, 10–17, 27–53, 81–86, 98–105, 126–204, 219–230  ORF0207 Ribokinase (rbsK) 5–11, 15–23, 47–55, 82–90, 98–103, 108–114, 126–132, 134–156, 161–186, 191–197, 210–224, 228–235, 239–248, 258–264, 275–290  ORF0288 LrgB 7–28, 34–56, 68–119, 127–146, 149– D:4 aa112–149 D: nd 515,	· · ·		229-235, 238-246				
DRF0143 amino acid per- 25-79, 91-103, 105-127, 132-150, mease 157-174, 184-206, 208-219, 231- 249, 267-294, 310-329, 336-343, 346-405, 417-468  ORF0162 Immunodominant 4-27, 35-45, 52-68, 83-89, 113-119, A:11, Antigen A 133-150, 158-166, 171-176, 198- 204, 219-230  ORF0201 capa protein, 10-17, 27-53, 81-86, 98-105, 126- putative 135, 170-176, 182-188, 203-217, 223-232, 246-252, 254-269, 274- 280, 308-314  ORF0207 Ribokinase (rbsK) 5-11, 15-23, 47-55, 82-90, 98-103, 108-114, 126-132, 134-156, 161- 186, 191-197, 210-224, 228-235, 239-248, 258-264, 275-290  ORF0288 LrgB 7-28, 34-56, 68-119, 127-146, 149- D:4 aa112-149 D: nd 515,	ORF0121	C4-dicarboxylate	4-20, 24-62, 73-86, 89-106, 110-	D:5	aa323-379	D: md	'
ORF0143 amino acid permease 157–174, 184–206, 208–219, 231–249, 267–294, 310–329, 336–343, 346–405, 417–468   ORF0162 Immunodominant 4–27, 35–45, 52–68, 83–89, 113–119, Aritgen A 133–150, 158–166, 171–176, 198–204, 219–230   ORF0201 capa protein, 10–17, 27–53, 81–86, 98–105, 126–putative 135, 170–176, 182–188, 203–217, 223–232, 246–252, 254–269, 274–280, 308–314   ORF0207 Ribokinase (ibsK) 5–11, 15–23, 47–55, 82–90, 98–103, 108–114, 126–132, 134–156, 161–186, 191–197, 210–224, 228–235, 239–248, 258–264, 275–290   ORF0288 LrgB 7–28, 34–56, 68–119, 127–146, 149– D:4 aa112–149 D: nd 515, 250.		transporter, an-	122, 131-164, 169-193, 204-213,			,	563
ORF0143 amino acid per 25-79, 91-103, 105-127, 132-150, mease 157-174, 184-206, 208-219, 231-249, 267-294, 310-329, 336-343, 346-405, 417-468  ORF0162 Immunodominant 4-27, 35-45, 52-68, 83-89, 113-119, A:11, Antigen A 133-150, 158-166, 171-176, 198-204, 219-230  ORF0201 capa protein, 10-17, 27-53, 81-86, 98-105, 126-putative 135, 170-176, 182-188, 203-217, 223-232, 246-252, 254-269, 274-280, 308-314  ORF0207 Ribokinase (rbsK) 5-11, 15-23, 47-55, 82-90, 98-103, 108-114, 126-132, 134-156, 161-186, 191-197, 210-224, 228-235, 239-248, 258-264, 275-290  ORF0288 LrgB 7-28, 34-56, 68-119, 127-146, 149- D:4 aa112-149 D: nd 515, 364	1	aerobic, putative	219-236, 252-259, 263-281, 296-				
ORF0143 amino acid per- mease  157-174, 184-206, 208-219, 231- 249, 267-294, 310-329, 336-343, 346-405, 417-468  ORF0162 Immunodominant Antigen A  133-150, 158-166, 171-176, 198- 204, 219-230  ORF0201 capa protein, putative  135, 170-176, 182-188, 203-217, 223-232, 246-252, 254-269, 274- 280, 308-314  ORF0207 Ribokinase (rbsK)  ORF0207 Ribokinase (rbsK)  S-11, 15-23, 47-55, 82-90, 98-103, 108-114, 126-132, 134-156, 161- 186, 191-197, 210-224, 228-235, 239-248, 258-264, 275-290  ORF0288 LrgB  7-28, 34-56, 68-119, 127-146, 149- D: nd  513, 564  D: nd  514, 565  B:SELAA19(100-118): 1/1 B:SELAE24(170-190): 11/12 240, B:SELAE24(170-190): 11/12 259  D: nd  514, 565  B:SELAQ30 (20-45): 12/12 241, 270			306, 318-324, 328-352, 356-397,			ļ	
DRF0143   anamo acut per   23-79, 91-103, 103-121, 132-130,   mease   157-174, 184-206, 208-219, 231-   249, 267-294, 310-329, 336-343,   346-405, 417-468   346-405, 417-468   4-27, 35-45, 52-68, 83-89, 113-119,   B:11,   ana 90-227   B:SELAA19(100-118): 1/1   240,   B:SELAE24(170-190): 11/12   269   204, 219-230   C:153   C:153   C:153   D: nd   514,   D: putative   135, 170-176, 182-188, 203-217,   223-232, 246-252, 254-269, 274-   280, 308-314   280, 308-314   D: nd   D: nd   D: nd   D: nd   Construction   108-114, 126-132, 134-156, 161-   186, 191-197, 210-224, 228-235,   239-248, 258-264, 275-290   D: nd   D: nd   S15,   Construction   S15,   Construction   S15,   Construction   S15,   Construction   Construct			410~429				
249, 267-294, 310-329, 336-343, 346-405, 417-468  ORF0162 Immunodominant 4-27, 35-45, 52-68, 83-89, 113-119, A:11, Antigen A 133-150, 158-166, 171-176, 198- 204, 219-230  ORF0201 capa protein, 10-17, 27-53, 81-86, 98-105, 126- putative 135, 170-176, 182-188, 203-217, 223-232, 246-252, 254-269, 274- 280, 308-314  ORF0207 Ribokinase (rbsK) 5-11, 15-23, 47-55, 82-90, 98-103, 108-114, 126-132, 134-156, 161- 186, 191-197, 210-224, 228-235, 239-248, 258-264, 275-290  ORF0288 LrgB 7-28, 34-56, 68-119, 127-146, 149- D: nd 515,	ORF0143	amino acid per	25-79, 91-103, 105-127, 132-150,	D:35	aa247-339	D: nd	513,
ORF0162 Immunodominant 4-27, 35-45, 52-68, 83-89, 113-119, A:11, Antigen A 133-150, 158-166, 171-176, 198- 204, 219-230 C:153  ORF0201 capa protein, putative 135, 170-176, 182-188, 203-217, 223-232, 246-252, 254-269, 274- 280, 308-314  ORF0207 Ribokinase (rbsK) 5-11, 15-23, 47-55, 82-90, 98-103, 108-114, 126-132, 134-156, 161- 186, 191-197, 210-224, 228-235, 239-248, 258-264, 275-290  ORF0288 LrgB 7-28, 34-56, 68-119, 127-146, 149- D:4 aa112-149 D: nd 515,		mease .	157-174, 184-206, 208-219, 231-		Į		564
ORF0162 Immunodominant A-27, 35-45, 52-68, 83-89, 113-119, A:11, Antigen A 133-150, 158-166, 171-176, 198- B:11; C:153  ORF0201 capa protein, putative 135, 170-176, 182-188, 203-217, 223-232, 246-252, 254-269, 274- 280, 308-314  ORF0207 Ribokinase (rbsK) 5-11, 15-23, 47-55, 82-90, 98-103, 108-114, 126-132, 134-156, 161- 186, 191-197, 210-224, 228-235, 239-248, 258-264, 275-290  ORF0288 LrgB 7-28, 34-56, 68-119, 127-146, 149- D:4 aa112-149 D: nd 515, 269  B:SELAA19(100-118): 1/1 240, B:SELAA29(100-118): 1/1 240, B:SELAA29(100-118): 1/1 240, B:SELAA29(100-118): 1/1 240, B:SELAA29(100-118): 1/1 240, B:SELAE24(170-190): 11/12 269  D: nd 514, S65  D: nd 514, S65  D: nd 514, S65  D: nd 514, S65	1		249, 267-294, 310-329, 336-343,				
Antigen A 133–150, 158–166, 171–176, 198– B:11; C:153  ORF0201 capa protein, 10–17, 27–53, 81–86, 98–105, 126– D:9 aal 1–53 D: nd 514, putative 135, 170–176, 182–188, 203–217, 223–232, 246–252, 254–269, 274– 280, 308–314  ORF0207 Ribokinase (rbsK) 5–11, 15–23, 47–55, 82–90, 98–103, 108–114, 126–132, 134–156, 161– 186, 191–197, 210–224, 228–235, 239–248, 258–264, 275–290  ORF0288 LrgB 7–28, 34–56, 68–119, 127–146, 149– D:4 aal 12–149 D: nd 515,	1	·	346-405, 417-468	i i			
ORF0201 capa protein, putative 135, 170–176, 182–188, 203–217, 223–232, 246–252, 254–269, 274–280, 308–314  ORF0207 Ribokinase (rbsK) 5–11, 15–23, 47–55, 82–90, 98–103, 108–114, 126–132, 134–156, 161–186, 191–197, 210–224, 228–235, 239–248, 258–264, 275–290  ORF0288 LrgB 7–28, 34–56, 68–119, 127–146, 149– D:4 aa112–149 D: nd 515,	ORF0162	Immunodominant	4-27, 35-45, 52-68, 83-89, 113-119,	A:11,	aa 90-227	B:SELAA19(100-118): 1/1	
ORF0201 capa protein, 10-17, 27-53, 81-86, 98-105, 126- D:9 aa11-53 D: nd 514, 565 putative 135, 170-176, 182-188, 203-217, 223-232, 246-252, 254-269, 274- 280, 308-314 S-11, 15-23, 47-55, 82-90, 98-103, 108-114, 126-132, 134-156, 161- 186, 191-197, 210-224, 228-235, 239-248, 258-264, 275-290 ORF0288 LrgB 7-28, 34-56, 68-119, 127-146, 149- D: 4 aa112-149 D: nd 515, 665		Antigen A	133-150, 158-166, 171-176, 198-	1		B:SELAE24(170-190): 11/12	269
ORF0201 capa protein, putative 135, 170–176, 182–188, 203–217, 223–232, 246–252, 254–269, 274– 280, 308–314  ORF0207 Ribokinase (rbsK) 5–11, 15–23, 47–55, 82–90, 98–103, 108–114, 126–132, 134–156, 161– 186, 191–197, 210–224, 228–235, 239–248, 258–264, 275–290  ORF0288 LrgB 7–28, 34–56, 68–119, 127–146, 149– D:4 aa112–149 D: nd 515,	<u> </u>		204, 219-230	C:153	<del> </del>	1-1	
223-232, 246-252, 254-269, 274- 280, 308-314  ORF0207 Ribokinase (rbsK) 5-11, 15-23, 47-55, 82-90, 98-103, 108-114, 126-132, 134-156, 161- 186, 191-197, 210-224, 228-235, 239-248, 258-264, 275-290  ORF0288 LrgB 7-28, 34-56, 68-119, 127-146, 149- D:4 aa112-149 D: nd 515,	ORF0201	capa protein,	10-17, 27-53, 81-86, 98-105, 126-	D:9	aal 1-53		
ORF0207 Ribokinase (rbsK) 5-11, 15-23, 47-55, 82-90, 98-103, 108-114, 126-132, 134-156, 161- 186, 191-197, 210-224, 228-235, 239-248, 258-264, 275-290  ORF0288 LrgB 7-28, 34-56, 68-119, 127-146, 149- D:4 aa112-149 D: nd 515,		putative	135, 170-176, 182-188, 203-217,		]	<u>)                                    </u>	565
ORF0207 Ribokinase (rbsK) 5-11, 15-23, 47-55, 82-90, 98-103, B:10 aa 20-45 B:SELAQ30 (20-45): 12/12 241, 108-114, 126-132, 134-156, 161-186, 191-197, 210-224, 228-235, 239-248, 258-264, 275-290  ORF0288 LrgB 7-28, 34-56, 68-119, 127-146, 149- D:4 aa112-149 D: nd 515,			223-232, 246-252, 254-269, 274-			1	
ORF0288 LrgB 7-28, 34-56, 68-119, 127-146, 149- D:4 aal 12-149 D: nd 515,							<u> </u>
186, 191-197, 210-224, 228-235, 239-248, 258-264, 275-290  ORF0288 LrgB 7-28, 34-56, 68-119, 127-146, 149- D:4 aal 12-149 D: nd 515,	ORF0207	Ribokinase (rbsK)	1	B:10	aa 20-45	B:SELAQ30 (20-45): 12/12	1 1
239-248, 258-264, 275-290  ORF0288 LrgB 7-28, 34-56, 68-119, 127-146, 149- D:4 aa112-149 D: nd 515,							2,0
ORF0288 LrgB 7-28, 34-56, 68-119, 127-146, 149- D:4 aa112-149 D: nd 515,	1						
	ORF0288	LrgB		D:4	aa112-149	D: nd	515,
		-	180, 182-189, 193-200, 211-230		1		566

2	Putative function	predicted immunogenic aa**	No. of	Location of	Serum reactivity with relevant	Seq ID
epidermidi	(by homology)		selected	identified	region (positive/total)	no:
s antigenic			clones	lmmuno-		(DNA
protein			per ORF	genic region		+Prot).
<b>,</b>		·	and			
			sereen			
ORF0304	Herpęsvirus	8-16, 30-36, 83-106, 116-122, 135-	D:8	aa69-117	D: nd	516,
	saimiri ORF73		·			567
	Saimin OKF /3	143, 152–165, 177–188, 216 <del>–</del> 225				,
	homolog, putative		ļ			ļ
ORF0340	nitrate transporter	7-21, 24-93, 101-124, 126-139,	D:5	aa238-309	D: nd	517,
		141-156, 163-179, 187-199, 202-		,		595
		242, 244-261, 267-308, 313-322,				
		340~353, 355–376				
ORF0346	hypothetical pro-	8-27, 65-73, 87-93, 95-105	D:8	aa 1-29	D: pd	518,
OKC0340		0-21, W-13, 01-33, 93-103	J			
	tein		2.6	- (2.96	CCCPPI 20//2 00.1/3	568 354,
ORF0355	conserved	5-30, 37-43, 57-66, 85-94, 103-111,	C:5	aa 63-86 -	C:GSBBL39(63-86):1/1	360
	hypothetical protein	118-125			•	,
		4 44 01 50 50 146 151 132 135	D.f	61-01	D: pd	519.
ORF0356	conserved hypo-	4-14, 21-53, 60-146, 161-173, 175-	כט	aa51-91	D: BG	
	thetical protein	182, 190-198, 200-211				569
ORF0406	hypothetical pro-	12-32, 35-63, 68-102, 106-137,	D:19	aa1-48,	D: ad	520,
	tein	139-145, 154-168, 173-185, 203-		aa69-102		570
		222, 230-259, 357-364, 366-374				
ORF0425	amino acid per-	40-58, 75-86, 93-110, 117-144,	D:3	aa401-440	D: nd	521,
	mease	150-173, 199-219, 229-260, 264-				571
		300, 317–323, 329–356, 360–374,				
		377-390, 392-398, 408-424, 427-	·			
		452	<b>l</b> •			
ORF0442	SceB precursor	7-22, 42-48, 55-66, 83-90, 109-118,	C-38	aa 60-102	C:QSBBM60(65-84):1/1	355,
O/Gross2	Seen precursor	136-141		2.00 102	C.Gobbinoo(co bvj.i/1	361
ORF0448	SsaA precursor	6-25, 39-47, 120-125, 127-135,	C:170	aa 15-208	C:GSBBN58(81-105):1/1	356, -
		140-148, 157-168, 200-208, 210-	•		C:GSBBL13(167-184):1/1	362
		220, 236-243, 245-254			C:GSBBL25(22-45):1/1	
ORF0503	Ribosomal protein	31-39, 48-54, 61-67, 75-83, 90-98,	A:1, B:3	aa 212-273	B:SELAA47(238-259):12/12	242,
	1.2	103-115, 123-145, 160-167, 169-	Ì			271
ORF0551	Conserved hypo-	176, 182-193, 195-206, 267-273 5-25, 29-36, 45-53, 62-67, 73-82,	A:16, B:9	aa 162-213	B:SELAL12(164-197); 8/12	243,
וננטשטו	thetical protein	84-91, 99-105, 121-142, 161-177,	,	102 213	D.O.L. 101 1713. 0/16	272
	linetions process	187-193, 203-224, 242-251, 266-				
l		271, 278-285			_	
ORF0556	hypothetical pro-	4-24, 30-41, 43-68, 82-90, 107-114,	D:3	aa 1-26	D: nd	522,
						596
	tein	123-143, 155-168	<u></u>	I		296

2.	Putative function	predicted lmmunogenic an**	No. of	Location of	Serum reactivity with relevant	Seq ID
epidermidi	(by homology)	-	selected	identified	region (positive/total)	no:
s antigenic	(0)		ciones	immuno-		(DNA
protein			per ORF	genic region		+Prot)
protein			and			
,			screen	• /		
ORF0623	Fumble, putative	10-17, 32-38, 55-72, 77-84, 88-96,	A:10,	8a 95-150	B:SELAB86(95-128): 3/12	244,
		126-134, 152-160, 176-185, 190-	B:12; C:1			273
		203, 208-214, 217-225, 233-252,	1			
		257–262				
ORF0740	Hypothetical pro-	18-24, 47-61, 69-83, 90-96, 125-	B:3	aa 1093—	B:SELAB23(1097-1114): 7/12	245,
	tein	132, 140-163, 171-188, 222-249,	1 .	1114		274
1		281-296, 305-315, 322-330, 335-	•		'z;	
		351, 354-368, 390-397, 411-422,	ļ		,	
		424-431, 451-469, 479-485, 501-	1			
		507, 517-524, 539-550, 560-568,			·	l i
		588-599, 619-627, 662-673, 678-	1			
		689, 735-742, 744-749, 780-786,		Į		
		797-814, 821-827, 839-847, 857-		Ì		
į		863, 866-876, 902-911, 919-924,		Ì	•	
		967-982, 1005-1015, 1020-1026,				1.
		1062-1070, 1078-1090, 1125-1131,				1
1		1145-1150, 1164-1182, 1208-1213,	1	1		
1	<b>,</b>	1215-1234, 1239-1251, 1256-1270,	1			
		1298-1303, 1316-1325, 1339-1349,				
		1362-1369, 1373-1384, 1418-1427,	Į			i
ļ	ļ	1440-1448, 1468-1475, 1523-1532,	1			1
		1536-1542, 1566-1573, 1575-1593,	<u> </u>			]
Ì		1603-1619, 1626-1636, 1657-1667,	l	1 .		1
	İ	1679-1687, 1692-1703, 1711-1718,		j		]
Í		1740-1746, 1749-1757, 1760-1769,	l	1		1
		1815-1849, 1884-1890, 1905-1914,		ļ		1
		1919–1925, 1937–1947, 1955–1963,	i			
İ	i	1970-1978, 2003-2032, 2075-2089,		ļ ·		į
1		2117-2124, 2133-2140, 2146-2151,		j		
		2161-2167, 2173-2179, 2184-2196, 2204-2220, 2244-2254, 2259-2264,			ļ	
1		2285-2296, 2300-2318, 2328-2334,	}			
		2347-2354, 2381-2388, 2396-2408,	1	ļ		
	1	2419-2446, 2481-2486, 2493-2500,		1		
		2506-2516, 2533-2540, 2555-2567,	1			
1		2576-2592, 2599-2606, 2615-2639,	}	]		
		2647-2655				
ORF0757	hypothetical	13-20, 22-28, 33-40, 60-76, 79-86,	C:6	aa 260-284	C:GSBBN01(260-284):1/I	357,
	protein	90-102, 112-122, 129-147, 157-170				363
		178-185, 188-193, 200-205, 218-	1			
	ł	228, 234-240, 243-250, 265-273,				
	1	285-291, 310-316, 330-348, 361-				1
		380, 399-405, 427-446, 453-464		1	<u> </u>	

2	Putative function	predicted immunogenic aa**	No. of	Location of	Serum resettivity with relevant	Con TD
		predicted imminiogenic as	1	1		Seq ID
epidermidi	1	•	selected	Identified	region (positive/total)	no:
s antigenic			clones	immuno-		(DNA
protein	l ·		per ORF	genic region	•	+Prot)
	•		and			
			screen			ļ
ORF0912	DNA mismatch	9-16, 28-39, 47-56, 69-76, 104-121,	A:25	aa 242-304	SEFAT31(242-290); n.d.	441,
	repair protein	124-130, 137-144, 185-195, 199-				442
		214, 238–243, 293–307, 317–337,				l
•		351-370, 385-390, 411-428, 472-	}			1
		488, 498-516, 518-525, 528-535,	l			l
		538-545, 553-559, 563-568, 579-	ŀ			l
		588, 592-607, 615-622, 632-638,			21	ĺ
		641-648, 658-674, 676-705, 709-	i			
		720, 727–739, 742–750, 753–760,	l			
		768-773, 783-788, 811-819, 827-	]	ļ		ł
		838				
ORF0923	GTP-binding	4-10, 18-27, 42-55, 64-72, 77-92,	B:13	aa 144-163	B:SELAD55(151-163): 8/12	246,
	protein	114-126, 132-157, 186-196, 206-				275
		217, 236–243, 257–280, 287–300,	]	]		·
		306-312, 321-328, 338-351, 360-		<u> </u>	ī	
		367, 371-382, 385-399				
ORF0979	Conserved hypo-	4-28, 44-51, 53-84, 88-107, 113-	Ą:9, B:18	aa 12-51	B:SELAH01(26-49):5/12	247,
	thetical protein	192	<u> </u>		*	276
ORF0982	sodium/alanine	13-21, 24-50, 73-84, 91-118, 126-	D:3	aa277-305	D: nd	523, ·
	symporter (alsT)	133, 142–149, 156–175, 189–249,				572
	o, inponter (alb.)					٠
		251-273, 294-332, 339-347, 358-	l			l
		381, 393-413, 425-448, 458-463				
ORF1230	Simal nentidase I	6-33, 44-59, 61-69, 74-82, 92-98,	D:14	aa 1-53	D: nd	524,
010 1250	Signal peptionse i		J		D. 50	
	•	133-146, 163-175				573
ORF1232	Exonuclease		B:6	aa 188-219	B:SELAA13(188-216): n.d.	443,
·	RexA	136-142, 144-165, 176-190, 196-				444
		202, 211-222, 231-238, 245-251,				
		268-274, 280-286, 305-316, 334-	l			
		356, 368-376, 395-402, 410-417,	•			
		426-440, 443-449, 474-486, 499-	i			
		508, 510-525, 540-549, 568-576,		ł		
	•	608-617, 624-639, 646-661, 672-			•	
	,	678, 688-703, 706-717, 727-734,				
		743–755, 767–773, 783–797, 806–				
		814, 830-839, 853-859, 863-871,				
		877-895, 89 <del>9-9</del> 18, 935 <del>-94</del> 8, 976-			•	
		990, 998-1007, 1020-1030, 1050-	· ·			
	}	1062, 1070-1077, 1111-1125, 1137-	l .			
		1149, 1153-1160, 1195-1211				
ORF1284	permease PerM,	10-60, 72-96, 103-109, 127-133,	D:27	na\$5-106	D: nd	525,
	putative	146-177, 182-189, 196-271, 277-				574
		289, 301-319, 323-344, 347-354				
			L			

						, ,
.2.	Putative function	predicted immunogenic an**	No. of	Location of	Serum reactivity with relevant	Seq ID
<i>epidermidi</i>	(by homology)		selected	identified	region (positive/total)	no:
s autigenic			clones	immuno-		(DNA
protein			per ORF	genic region		+Prot)
			and			
			screen			
ORF1319	2-oxoglutarate	9-31, 36-45, 59-67, 71-81, 86-94,	B:5; C:1	8a 400-413	B:SELAF54(404-413): 11/12	248,
	decarboxylase	96-107, 111-122, 127-140, 153-168,				277
İ	(menD)	180-211, 218-224, 226-251, 256-			•	
		270, 272-289, 299-305, 310-323,	l			
		334-341, 345-353, 358-364, 369-	i			
		379, 384-390, 396-410, 417-423,	l			]
		429-442, 454-464, 470-477, 497-				ļ
	71	505, 540-554				;
ORF1326	autolysin AtlE	6-25, 40-46, 75-81, 150-155, 200-	B:7; C:5	aa 1282-	B:SELAD20(1282-1298): 10/12	249,
	(lytD)	205, 237-243, 288-295, 297-306,		1298		278
		308-320, 341-347, 356-363, 384-	1			
		391, 417-429, 440-452, 465-473,	l		-	
		481-514, 540-546, 554-560, 565-	j			
		577, 585-590, 602-609, 611-617,	1			}
		625-634, 636-643, 661-668, 676-				
		684, 718-724, 734-742, 747-754,	1			[
		766-773, 775-781, 785-798, 800-				
		807, 825–832, 840–857, 859–879,	1			
	ľ	886-892, 917-923, 950-956, 972-	l		• ,	
		978, 987-1002, 1028-1035, 1049-	l	1		
		1065, 1071-1099, 1111-1124, 1150-				
		1172, 1185-1190, 1196-1207, 1234-				
		1241, 1261-1271, 1276-1281, 1311-				
		1320, 1325-1332				
ORF1333	quinol oxidase	4-27, 33-55, 66-88	D:4	aa 3-93	D: nd	526,
	polypeptide iv (ec.					575
			ļ			
	1.9.3) (quinol	•			•	
•	oxidase aa3-600,					
	subunit qoxd)					
ORF1356	hypothetical pro-	9-36, 44-67, 74-97, 99-149, 161-	D:32	na54-95	D: nd	527,
\	tein	   181, 189–198, 211–224, 245–253,		].		597
		267-273, 285-290, 303-324, 342-				
		394, 396–427			•	
ORF1373	dihydrolipoamide	33-39, 42-78, 103-109, 126-136,	A:3, B:1	aa 124-188	A:SEFAP57(124-188): 2/12	250,
CICLING		184-191, 225-232, 258-279, 287-	, 5	ma 12.7 100	7.000, 100, 2014	279
	acetyltransferase	294, 306–315, 329–334, 362–379,				
	٠.	381-404, 425-430	1			
		1301 101, 123 130	<del>                                     </del>			<u> </u>
ORF1381	hypothetical pro-	21-45, 62-67, 74-106, 108-142,	D:5	aa7-44	D: nd	528,
	tein .	154-160, 230-236, 245-251, 298-				576
· _ ·		305	L	l		<b></b>

2	Potative function	predicted immunogenic sa**	No. of	Location of	Serum reactivity with relevant	Seq ID
epidermidi	[	<b>F. C</b>	selected	identified	region (positive/total)	no:
s antigenic	1		clones	lmmuno-		(DNA
protein			per ORF	genic region		+Prot)
			and			
			screen			
ORF1420	Muts2 protein,	8-32, 34-41, 46-55, 70-76, 81-89,	B:7	aa 581-608	B:SELAM40(581604): 9/12	251,
	putative .	97-115, 140-148, 153-159, 165-171,	d			280
		175-188, 207-239, 256-276, 280- 289, 297-319, 321-335, 341-347,	•			
		352-360, 364-371, 384-411, 420-	]			
		440, 449-460, 495-502, 505-516,		<u> </u>		
		560-566, 573-588, 598-605, 607-	ľ			
	-1,	614, 616-624, 674-694, 702-717				
ORF1443	cell division	61-66, 111-117, 148-155, 173-182,	D:4	an175-229	D: nd	529,
	protein (divIB)	194-224, 263-293, 297-303, 313-				577
		321, 334-343, 345-356, 375-381,				
		384-395, 408-429, 448-454				
ORFI500		100-107, 154-167, 182-193, 200-	A:2, B:3	aa 77-182	B:SELAP37(139-162): 9/12	252,
	tein FtsY	206, 223–231, 233–243, 249–257,			•	281
]		265-273, 298-310, 326-336, 343- 362, 370-384				
ORF1665	amino acid ABC	4-25, 44-55, 66-76, 82-90, 93-99,	D:5	aa 1-52	D: nd	530,
	transporter,	104-109, 176-209, 227-242, 276-				578
1 1					$r_{i}$	,,,
	permease protein	283, 287–328, 331–345, 347–376,			o <sub>d</sub> .	
		400-407, 409-416, 418-438, 441-			177	
		474				
ORF1707	putative host cell	12-31, 40-69, 129-137, 140-151,	D:4	aa 20-76	D: nd	531,
	surface-exposed	163-171, 195-202, 213-218				598
	lipoprotein	•				
ORF1786	D-3-	4-10, 16-32, 45-55, 66-78, 87-95,	D:5	aa400~442	D: nd	532,
1	phosphoglycerate	103-115, 118-124, 135-150, 154-			·	579
	dehydrogenase,	161, 166-174, 182-193, 197-207,			·	
	putative	225-231, 252-261, 266-304, 310-			•	
1		315, 339 <del>-</del> 347, 351-359, 387∸402,				
		411-423, 429-436, 439-450, 454-				
		464, 498-505, 508-515				
ORF1849	yhjN protein	8-51, 53-69, 73-79, 85-132, 139-	D:5	an254-301	D; nd	533,
·		146, 148-167, 179-205, 212-224,				580
		231-257, 264-293, 298-304, 309-			· ·	
	•	317, 322-351			<u></u> /	

The second of th

2	Putative function	predicted immunogenic as**	No. of	Location of	Serum reactivity with relevant	Seq ID
epidermidi	(by homology)	predicted industries	selected	identified	region (positive/total)	not
s antigenic	(by montology)		ciones	immuno-		(DNA
protein			per ORF	genic region		+Prot)
protein	•		and			·
			screen			
0051033		6-19, 26-39, 41-51, 59-67, 72-85,	D:7	aa367-409	D: nd	534,
ORF1877	protein-export		D.,	Jan. 405	J. 13	581
	membrane protein	91-98, 104-111, 120-126, 147-153,				201
	SecD(secD-I)	158-164, 171-178, 199-209, 211-			•	
		218, 233-249, 251-257, 269-329,				
		362-368, 370-385, 392-420, 424-				
		432, 454-489, 506-523, 534-539,				
		550-556, 563-573, 576-596, 603-				
		642, 644-651, 655-666, 685-704,				1
		706-733, 747-753				
			- ·	121 107	D -4	535,
ORF1912	unknown con-	23-35, 37-70, 75-84, 90-112, 129-	D:4	aa131-187	D: nd	1
	served protein	135, 137-151, 155-180, 183-209,				582
	(conserved)	211-217, 219-225, 230-248, 250-			,,	
	<b>[</b>	269, 274-284, 289-320, 325-353,		·		
		357-371, 374-380, 384-399, 401-				ľ
		411,				
ORF2015	Trehalose 6	8-17, 30-54, 82-89, 94-103, 157-	A:3, B:8	aa 465-498	B:SELAH62(465-498): 5/12	253,
	phosphate	166, 178-183, 196-204, 212-219,				282
	hydrolase	222-227, 282-289, 297-307, 345-	l			
	,	364, 380–393, 399–405, 434–439,				·
	ł	443-449, 453-475, 486-492, 498-				
		507, 512-535, 538-548		050 007	D 077 A 1100000 0700 2/12	254,
ORF2018	Glucose 6	4-16, 21-27, 39-51, 60-69, 76-83,	B:17	aa 250-287	B:SELA119(250-279): 3/12	283
	phosphate 1-DH	97-118, 126-132, 159-167, 171-177,				203
		192-204, 226-240, 247-259, 281-	<u> </u>			
•	\	286, 294–305, 314–320, 330–338,		İ		ĺ
		353-361, 367-372, 382-392, 401-	•	]		
		413, 427-434, 441-447, 457-463				536
ORF2040	LysM domain	51-56, 98-108, 128-135, 138-144,	D:23	aa259-331	D: nd	536,
	protein protein	152-158, 177-192, 217-222, 232-	l		17	583
-		251, 283-305, 406-431, 433-439	<u> </u>		( )	
ORF2098	PilB related	13-18, 36-43, 45-50, 73-79, 95-100,	A:60	aa 1-57	A:SEFAQ50(15-57): 5/12	255,
	protein	111-126, 133-139		ļ		284
ORF2139	sodium:sulfate	7-12, 22-97, 105-112, 121-128,	D:41	aa42-118	D: nd	537,
	symporter family	130-146, 152-164, 169-189, 192-	•		i, '	584
	protein, putative	203, 211-230, 238-246, 260-281,				
		304-309, 313-325, 327-357, 367-				
		386, 398-444, 447-476, 491-512	<b>[</b>	l		}
	I	300, 370-444, 447-470, 471-312	<u> </u>	<u> </u>	<u> </u>	ــــــــــــــــــــــــــــــــــــــ

2	Putative function	predicted immunogenic aa**	No. of	Location of	Serum reactivity with relevant	Seq ID
epidermidi	(by bomology)		selected	identified	region (positive/total)	RO:
s antigenic			ciones	immuno-		(DNA
protein		·· ·	per ORF	genic region		+Prot)
			and			
			screen			-
ORF2172	SceB precursor	4-23, 28-34, 38-43, 45-51, 63-71,	A:438,	aa 6-215	B:SELAH53(188-209): 3/12	256,
	(lytE)	85-96, 98-112, 118-126, 167-174,	B:40, D:4			285
		179-185, 219-228, 234-239, 256- 263	ł			
				1/2 22		620
ORF2200	zinc ABC	4-31, 33-40, 48-64, 66-82, 92-114,	D:19	aa162-225	D: nd	538,
	transporter,	118-133, 137-159, 173-246, 248-				585
•	permease protein,	266		·		
	putative					
ORF2248	membrane protein,	4-11, 17-34, 72-78, 127-137, 178-	D:17	aa1-59,	D: nd	539,
	MmpL family.	227, 229-255, 262-334, 352-380,		aa159-225,		586
	putative	397-405, 413-419, 447-454, 462-		aa634-674		
	Palzirve	467, 478–490, 503–509, 517–558,				
		560-568, 571-576, 582-609, 623-				
·		629, 631-654, 659-710, 741-746,			·	
		762-767, 771-777, 788-793, 85 <del>6-</del>				
·		867 .				
ORF2260	Unknown con-	5-10, 18-29, 31-37, 66-178, 196-	B:4	aa 123-142	B:SELAG77(123-142): 12/12	257,
	served protein in	204, 206-213				286
ORF2282	others conserved hypo-	16-22, 41-50, 52-64, 66-74, 89-95,	A:4	aa 51-97	A:SEFAR88(51-97): 3/12	258,
010 2202	thetical protein	107-114, 123-130, 135-159, 167-	1		,	287
	_	181, 193-199, 223-231, 249-264,				
		279-289				ļ
ORF2376	DivIC homolog,	27-56, 102-107, 111-116	D:7	aa15-58	D; nd	540,
	putative					587
ORF2439	membrane bound	4-9, 11-26, 36-56, 59-73, 83-100,	A:459,	aa 10-217	B:SELAC31(75-129): 12/12	259,
	lytic mur <del>c</del> in	116-130, 148-163, 179-193, 264-	B:2, D:53			288
	transglycosidase	270, 277-287, 311-321				
	D, putative		<b> </b> -			<del> </del>
ORF2493	conserved hypo-	4-29, 37-77, 80-119	D:6	aa <del>69</del> 113	D: nđ	541,
	thetical protein					588
ORF2535	ATP-binding	5-28, 71-81, 101-107, 128-135,	D:8	aa 1~65	D: nd	542,
	cassette	146-52, 178-188, 209-214, 224-233,				589
	transporter-like	279-294, 300-306, 318-325, 342-	ļ			
	protein, putative	347, 351-357	<u></u>	1		

· Bulletting the comme

2	Putative function	predicted immunogenie sa**	No. of	Location of	Serum resetivity with relevant	Seq ID
epidermidi	(by homology)	predated name of	selected	identified	region (positive/total)	no:
s antigenic	(by noniology)		ctones	immuno-		(DNA
_			per ORF	genic region		+Prot)
protein			and	genne regard		11111
			screen			
ORF2627	cation-	8-31, 34-80, 125-132, 143-153,	D:3	an61−105	D; ad	543,
	transporting	159-165, 176-189, 193-198, 200-				590
	ATPase, EI-E2	206, 215-242, 244-262, 264-273,				
	family, putative	281-289, 292-304, 318-325, 327-	l	}		
	,,,=	338, 347-371, 404-416, 422-429,				
				1.	•	
		432-450, 480-488, 503-508, 517-	1			
		525, 539–544, 551–562, 574–587 <b>,</b>			·	
		600-631, 645-670				
ORF2635	Hypothetical	4-10, 17-24, 26-42, 61-71, 90-96,	A:2, B:2	aa 139—169	B:SELAB63(138-163): 7/12	260,
	p <del>ro</del> tein	102-111, 117-125, 158-164, 173-				289
		182, 193–201, 241–255, 268–283,		i .		•
		289-298, 305-319, 340-353, 360-	1	İ		
		376, 384-390, 394-406			D. 077 4 700 (00 61) 6/10	261
ORF2669	Hypothetical	4-21, 35-42, 85-90, 99-105, 120-	A:14, B:8	aa 22-81	B:SELAE27(22-51): 5/12	261,
	protein	125, 148-155, 175-185, 190-196,				290
		205-210, 217-225		aa 23-68	B:SELAD21(36-61): 5/12	262,
ORF2671	Hypothetical pro-	4-23, 43-49, 73-84, 93-98, 107-113,		aa 25-08	D:SELAUZI(30-01): 3/12	291
	tein	156-163, 179-190, 197-204, 208-	B:14			
ORF2673	Hypothetical	218, 225-231, 248-255 4-20, 65-71, 99-105, 148-155, 171-	A:16, B:3	aa 23-68	B:SELAE25(23-54): 2/12	263,
UKT 2013	protein	182, 190-196, 204-210, 221-228,	1			292
	process	240-246	1		·	
ORF2694	Hypothetical	4-26, 93-98, 121-132, 156-163,	A:19,	aa 25-82	B:SELAB26(27-60): 5/12	264,
	protein	179-192, 198-204, 212-220, 225-	B:30			293
		238		ļ		
ORF2695	Hypothetical	4-26, 43-50, 93-98, 107-113, 156-	A:7	aa 22-78	A:SEFAH77(22-66): 6/12	265,
	protein	163, 179-190, 198-204, 212-218,				294
		225-231, 247-254				
ORF2719	two-component	5-52, 60-71, 75-84, 91-109, 127-	B:4	aa 123-132	B:SELAA62(123-132): 6/12	266,
	sensor histidine	135, 141–156, 163–177, 185–193,	l		į	295
	kinase, putative	201-214, 222-243, 256-262, 270-				
		279, 287-293, 298-303, 321-328,	1	1	1	
		334-384, 390-404, 411-418, 427-		1		
ŀ		435, 438-448, 453-479, 481-498,	1	1		1
		503509	L _			
ORF2728	Accumulation-	4-13, 36-44, 76-86, 122-141, 164-	A:265,	aa 803-	B:SELAA10(850-878): 11/12	267,
	associated protein	172, 204-214, 235-242, 250-269,	B:448;	1001	·	296
		291-299, 331-337, 362-369, 377-	C:4, D:9			
l.		396, 419-427, 459-469, 505-524,				1
ľ		547-555, 587-597, 618-625, 633-	1	1		
	1	652, 675-683, 715-727, 740-753,				
	1	761-780, 803-811, 842-853, 962-	1			
		968, 1006-1020	1 _	1		<u> </u>

2	Putative function	predicted immunogeale sa**	No. of	Location of	Serum reactivity with relevant	Seq ID
epidermidi	(by homology)		selected	identified	region (positive/total)	no:
s antigenic			clones	immuno-		(DNA
protein			per ORF	genie region	•	+Prot)
			· and		•	Ĭ
			screen			<u> </u>
ORF2740	lipase precursor	4-21, 190-200, 218-228, 233-241,	C3	as 110-177	C:GSBBL80(110-177):1/1	358,
	\*\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	243-261, 276-297, 303-312, 316-	1			364
		325, 346–352, 381–387, 436–442,	}		-	Ì.
	52	457~462, 495~505, 518~532, 543~	}			
		557, 574-593	ļ		<u> </u>	
ORF2764	oligopeptide ABC	14-36, 62-131, 137-147, 149-162,	D:4	aa 6-41: 1	D: nd	544,
	transporter, per-	164-174, 181-207, 212-222, 248-				591
	mease protein,	268, 279-285	l			
	putative					<u> </u>
ORF2767	unknown con-	7-20, 22-35, 40-50, 52-61, 63-92,	D:4	aa276~316	D: nd ,	545,
	served protein in	94-101, 103-126, 129-155, 161-178,				592
	others	192-198, 200-208, 210-229, 232-	l	· I	•	
		241, 246-273, 279-332, 338-359,				
		369-383	l		•	
ORF2809	sodium:sulfate	4-29, 37-53, 56-82, 87-100, 108-	D:9	za266317,	D: nd	546,
	symporter family	117, 121–138, 150–160, 175–180,	}	aa357-401		593
	protein	189-195, 202-214, 220-247, 269-				
		315, 324-337, 341-355, 361-412,				
		414-423, 425~440, 447-467				
ORF2851	putative trans-	7-13, 20-32, 37-90, 93-103, 107-	D:11	ma137-185	D: nd	547,
	membrane efflux	126, 129–155, 159–173, 178–189,				594
	protein	195-221, 234-247, 249-255, 268-	1		,	
		303, 308-379		1		[

## Table 2d: Immunogenic proteins identified by bacterial surface and ribosome display: S. aureus (new annotation)

Bacterial surface display: A, LSA250/1 library in fhuA with patient sera 1 (655); B, LSA50/6 library in lamB with patient sera 1 (484); C, LSA250/1 library in fhuA with IC sera 1 (571); E, LSA50/6 library in lamB with IC sera 2 (454); F, LSA50/6 library in lamB with patient sera P1 (1105); G, LSA50/6 library in lamb with IC sera 1 (471). Ribosome display: D, LSA250/1 library with IC sera (1686). \*\*, prediction of antigenic sequences longer than 5 amino acids was performed with the programme ANTIGENIC (Kolaskar and Tongaonkar, 1990); #, identical sequence present twice in ORF.

2	Old	Putative	predicted immunogenic an**	No. of se-	Location of	Serum reactivity with rele-	Seq
aureusan	ORF	function		lected	identified	vant region (positive/total)	ID no:
tigenic	number	(by homology)		clones per	immuno-		(DNA
protein	40.200	(e) Lumbregy,		ORF and	genic re-		+Prot)
protein				screen	glon		
SaA0003	ORF2967	repC	7-19, 46-57, 85-91, 110-117, 125-	B:3, C:14;	- 4	C:GSBYI53(9-42):1/1	394,
	&		133, 140-149, 156-163, 198-204,	F:29	aa 156-241	C:GSBYG39(156-241):1/1	396
	ORF2963		236-251, 269-275, 283-290, 318-		aa 300-314	C:GSBYM94(343-420):26/30	
			323, 347–363		aa 343-420		
ORF0123	ORF1909	unknown	4-10, 25-30, 38-57, 91-108, 110-	B:3, E:7,	aa 145-163	B:GSBXF80(150-163):5/27	409,
	— 18 aa at		123, 125-144, 146-177, 179-198,	G:1		E:GSBZC17(150-163):25/41	410
	N-		216–224, 226–233				
	terminus		·				
ORF0160	ORF1941	unknown	4-26, 34-70, 72-82, 86-155, 160-	A:l	aa 96—1 <i>7</i> 2	A:GSBXO07(96-172):5/30	411,
	-16 aa at		166, 173-205, 207-228, 230-252,				412
	N-	ŧ	260-268 , 280-313	i			
	terminus						
ORF0657	ORF wn-	LPXTGVI	9-33, 56-62, 75-84, 99-105, 122-	1 ' '	aa 526-544	B:GSBXE07-bdb1(527-	413,
	known	protein	127, 163-180, 186-192, 206-228,	F:15	Ì	542):11/71	414
			233-240, 254-262, 275-283, 289-	l	1	F:SALAX70(526-544):11/41	
			296, 322-330, 348-355, 416-424,				1
			426-438, 441-452, 484-491, 541-	ł	ŀ		
			549, 563-569, 578-584, 624-641				
ORF1050	ORF1307	unknown	45-68, 72-79, 91-101, 131-142,	A:1, H:45	aa 53-124	A:GSBXM26(53-124):7/30	415,
	–4 aa at		144-160, 179-201				416
	N-termi-	ŀ					
	nus						417
<b>-</b> 1-	1	NifS protein	13-26, 40-49, 61-68, 92-112, 114-	A:11	aa 24-84	A:GSBXK59-bmd21(24-	417,
	-10 aa at	homolog	123, 138–152, 154–183, 194–200,			84):6/29	418
	N-		207-225, 229-240, 259-265, 271-				
	terminus		284, 289-309, 319-324, 330-336,	l			
/			346-352, 363-372		٠.		

2	Old	Putative	predicted immunogenic as**	No. of se-	Location.of	Serum resctivity with rele-	Seq
aureusan	ORF	function		lected	identified	vant region (positive/total)	ID no:
tigenic	number	(by homology)	•	clones per	immuno-		(DNA
protein				ORF and	genic re-		+Prot)
				screen	gion		
ORF1632	ORF1163	SdrH homolog	4-31, 50-55, 243-257, 259-268,	B:6, E:11,		B:GSBXG53(164-182):39/71	419,
	-4 aa at		298-316, 326-335, 364-370, 378-	F:34	aa 115-139	F:SALAP07(101-115):11/41	420
1 1	N-		407	I	aa 158–186		
	terminus						
ORF2180	ORF0594	LPXTGIV	9-17, 24-45, 67-73, 82-90, 100-107,	A:3, C:3,	aa 491-587	A:GSBXS61(491-555):1/I	421,
1	– 2 aa at	protain	117-134, 137-145, 158-168, 176-	E:6, F:2,	aa 633-715	A:GSBXL64(494-585):1/1	422
1 . [	N-		183, 188-194, 206-213, 223-231,	H:6	aa 702-	A:GSBXS92(758-841):1/1	
	terminus		243-248, 263-270, 275-282, 298-		757*	A:bmd4(702-757):16/30°	
		ž.	304, 344-355, 371-377, 382-388,		aa 758-830	(A:bmd4(830-885):16/30)°	77.
			427—433, 4 <del>69</del> —479, 500—505, 534—		(aa 830-	F:SALBC43(519-533):4/41	
:			559, 597607, 662687, 790815,		885)°		
			918 <del>-94</del> 3, 1032-1037, 1046-1060,		,		
			1104–1112, 1128–1137, 1179–1184,				
			11971204, 12091214, 12211239				
ORF2184	ORF0590	FnbpB .	10-29, 9 <del>6-</del> 116, 131-137, 146-158,	A:2, C:4,		A:GSBXM62(694-769):28/28	423,
	- 8 aa at		167–173, 1 <i>77</i> –182, 185–191, 195–	G:9	aa 774-847	A:GSBXR22(774-847):1/1	424
1 1	N-termi-		201, 227–236, 260–266, 270–284,				
	nus		291-299, 301-312, 348-356, 367-				
] [			376, 382–396, 422–432, 442–453,				
			480-487, 497-503, 519-527, 543-				
			548, 559–565, 579–585, 591–601,				
			616-623, 643-648, 657-663, 706-				
			718, 746–758, 791–796, 810–817,				
			819-825, 833-839, 847-853, 868-		•		
ORF2470	OB 50300		885, 887-895, 919-932 4-27, 36-42, 49-55, 68-73, 94-101,	C:3	02.400-441	C:GSBYH60(400-441):28/31	425,
	- 14 na at	,	131-137, 193-200, 230-235, 270-	ω	22 400 441	C.USD 11100(400-443).28/31	426
1 1	N-	protein	276, 294–302, 309–324, 334–344,		,		720
1 1	terminus	piotein	347-364, 396-405, 431-437, 498-				
	ucriminus						
			508, 513-519, 526-532, 539-544, 547-561, 587-594, 618-630, 642-				
			653, 687-699, 713-719, 752-766				
ORF2498	ORF0267		8-19, 21-44, 63-76, 86-92, 281-286,	D:12, F:6	aa 358-411	D:17/21	427,
1	ORF app.	pothetical	303-322, 327-338, 344-354, 364-		aa 588-606	F:SALAT38(895-909):8/41	428
1 1	580 aa	protein	373, 379-394, 405-412, 453-460,		aa 895-909		
1 1	longer at	•	501-506, 512-518, 526-542, 560-				
1 1	N termi-		570, 577-583, 585-604, 622-630,				
1 1	nus; plus		645-673, 677-691, 702-715, 727-				
1 1	other		741, 748-753, 770-785, 789-796,				
1 1	changes		851-858, 863-869, 876-881, 898-				
.[ ]	J		913, 917 <del>-9</del> 24, 979 <del>-9</del> 86, 991- <del>99</del> 7,			·	
			1004-1009, 1026-1041, 1045-1052,				
			1107-1114, 1119-1125, 1132-1137,				
			1154-1169, 1173-1192, 1198-1204,		.		
			1240-1254, 1267-1274, 1290-1298,				
			1612-1627				

2	Old	Putative	predicted immunogenic as**	No. of se-	Location of	Serum reactivity with rele-	Seq
aureusan	ORF	function		leeted	identified	vant region (positive/total)	ID no:
tigenic	number	(by homology)		ciones per	·immuno		(DNA
protein			:	ORF and	genic re-		+Prot)
			£	screen	gion	!	
ORF2548	ORF2711	IgG binding	4-37, 44-53, 65-71, 75-82, 105-112,	A:55,	aa 1-123	A:GSBXK68(1-73):21/30	429,
1	-12 aa at	protein A	126-132, 136-143, 164-170, 184-	B:54,	aa 207-273	A:GSBXK41(35-123):1/I	430
	N-		190, 194-201, 222-232, 242-248,	C:35,	aa 310-410	A:GSBXN38(207-273):19/30	
	terminus		252-259, 280-291, 300-317, 413-	F:59,		A:GSBXL11(310-363):10/30	
			420, 452-460, 485-503	G:56,	i	B:GSBXB22(394-406):37/71	
-				H:38		F:SALAM17(394-406):29/41	
ORF2746	ORF2507	homology with	4-9, 12-17, 40-46, 91-103, 106-113,	A:1, H:13	aa 63-126	A:GSBXO40(66-123):8/29	431,
	- 3 aa at	ORFI	116-125, 150-160, 172-177, 182-	i	ŀ		432
	N-	, ६५	188; 195-206, 241-261, 263-270,	l			' es.
	terminus		277-285, 287-294				<u> </u>
ORF2797	ORF2470	unknown	13-32, 40-75, 82-95, 97-112, 115-	B:3, E:2,	aa 159-176	B:GSBXE85(159-176):11/27	433,
	-24 an at		121, 124-154, 166-192, 201-225,	F:13, H:3	aa 325-339	F:SALAQ47(159-176):8/41	434
	N-termi	ŀ	227-252, 268-273, 288-297, 308-				
	nus		375, 379-434				
ORF2960	ORF2298	putative	8-31, 35-44, 106-113, 129-135,	C:101,	aa 1-80	C:GSBYG32(1-80)::6/7	435,
	- 5 aa at	Exotoxin	154-159, 168-178, 203-215, 227-	E:2, H:58	RA 48-121	C:GSBYG61-bhe2(48-	436
	N-		236, 240-249, 257-266, 275-281,		aa 98-190	116):26/30	
	terminus		290-296, 298-305, 314-319, 327-			C:GSBYN80(98-190):13/17	
			334				/00
ORF2963		putative	8-23, 35-41, 64-70, 81-87, 109-115,		aa 17–95	C:GSBYJ58(17-95):9/15	437,
	−5 aa at	Exotoxin	121-132, 150-167, 177-188, 194-	G:1			438
	N-		201, 208–216, 227–233, 238–248,				
	terminus	·	265-271, 279-285		L		

2	Old	Putative	predicted immunogenic na**	No. of se-	Location of	Serum reactivity with rele-	Seq
	ORF	function	Promotor management	lected	identified	vant region (positive/total)	ID no:
oureusan				clones per		rant refront (hostprestern)	(DNA
tigenic	number	(by homology)		ORF and			+Prot)
protein	1				genic re		TEIOU
0777000	OPELSS		922 45-52 02-103 154-150 162-	sereen A:11,	gion aa 8543—	A:GSBXL07(8543-8601):6/28	430
ORF3200	1	putative	8-32, 45-52, 92-103, 154-159, 162-		8601	1.03BALO/(0343-0001).W20	440
	+8506 aa		168, 207–214, 232–248, 274–280,	B:11, C:36,	aa 8461-		***
	at N-	_	297-303, 343-349, 362-375, 425-		8475		
	terminus	protein	442, 477–487, 493–498, 505–512,	H:32	04/3		
			522-533, 543-550, 558-564, 568-				
	ļ		574, 580-600, 618-630, 647-652,				
i i			658-672, 692-705, 711-727, 765-				
1			771, 788-798, 812-836, 847-858,				
			870-898, 903-910, 1005-1015,				
			1018-1025, 1028-1036, 1058-1069,				
		i .	1075-1080, 1095-1109, 1111-1117,				
			1119-1133, 1166-1172, 1183-1194,				
		j	1200-1205, 1215-1222, 1248-1254,			•	
			1274-1280, 1307-1317, 1334-1340,			• •	
			1381-1391, 1414-1420, 1429-1439,		1		
ŀ			1445-1467, 1478-1495, 1499-1505,				
		!	1519-1528, 1538-1550, 1557-1562, 1572-1583, 1593-1599, 1654-1662,			•	
	l	1	1668-1692, 1701-1707, 1718-1724,				4
	l		1738-1746, 1757-1783, 1786-1793,				
	1		1806-1812, 1815-1829, 1838-1848,				
	1		1853-1860, 1875-1881, 1887-1893,				
	1		1899-1908, 1933-1940, 1952-1961,				
			1964-1970, 1977-1983, 1990-1996,				
1	l	l i	2011-2018, 2025-2038, 2086-2101,				
	l		2103-2117, 2177-2191, 2195-2213,			•	
			2220-2225, 4*2237-2249, 2273-				
	Ì		2279, 2298-2305, 2319-2327, 2349-				
	l		2354, 2375-2381, 2391-2398, 2426-				
1	1		2433, 2436-2444, 2449-2454, 2463-			•	
i i		Į .	2469, 2493-2499, 2574-2589, 2593-		•		
	l		2599, 2605-2611, 2615-2624, 2670-				
	i		2684, 2687-2698, 2720-2727, 2734-				
1	l.	ŀ	2754, 2762-2774, 2846-2866, 2903-				
			2923, 2950-2956, 2985-2998, 3011-				
			3031, 3057-3064, 2*3102-3117,				
l .		1	3137-3143, 3186-3195, 3211-3219,	1	·		1
1	ŀ		3255-3270, 3290-3300, 3327-3334,				
			3337-3343, 3390-3396, 3412-3419,			1	
			3439-3446, 3465-3470, 3492-3500,				1
	}		3504-3510, 3565-3573, 3642-3650,				ļ
	1		3691 <b>-</b> 3698, 3766-3775, 3777-3788,	1			1
		[	3822-3828, 3837-3847, 3859-3864,				1
1	·	[	3868-3879, 3895-3902, 3943-3951,	1	•		
I			3963-3971, 3991-3997, 4018-4030,	1			
			4054-4060, 4074-4099, 4123-4129,	1			Ì
1	<b>l</b> .		4147-4153, 4195-4201, 4250-4255,		I	•	
I	1	I .	4262-4267, 4270-4277, 4303-4310,	ı	j	1	I

A STEER A PERSONAL DESIGNATION OF STATE OF THE

4321-4330, 4343-4352, 4396-4408, 4446-4451, 4471-4481, 4503-4509, 4516-4534, 4596-4604, 4638-4658, 4698-4710, 4719-4732, 4776-4783, 4825-4833, 4851-4862, 4882-4888, 4894-4909, 4937-4942, 5047-5054, 5094-5100, 5102-5112, 5120-5125, 5146-5153, 5155-5164, 5203-5214, 5226-5236, 5278-5284, 5315-5321, 5328-5342, 5348-5359, 5410-5420, 5454-5466, 5481-5489, 5522-5538, 5597-5602, 5607-5614, 0"5623-5629, 5650-5665, 5707<del>,</del>5719, 5734-5742, 5772-5778, 5785-5790, 5833-5845, 5857-5863, 5899-5904, 5908-5921, 5959-5971, 5981-5989, 6010-6017, 6034-6043, 6058-6064, 6112-6120, 6154-6169, 6210-6217, 6231-6240, 6261-6268, 6288-6294, 6318-6324, 6340-6349, 6358-6369, 6402-6407, 6433-6438, 6483-6493, 6513-6519, 6527~6546, 6561–6574, 6599– 6608, 6610-6616, 6662-6673, 6696-6705, 6729-6743, 6769-6775, 6792-6801, 6819-6828, 6840-6846, 6860-6870, 6915-6928, 6966-6972, 7021-7028, 7032-7047, 7096-7101, 7109-7117, 7138-7149, 7157-7162, 7201-7206, 7238-7253, 7283-7294, 7296-7302, 7344-7365, 7367-7376, 7389-7404, 7413-7433, 7475-7482, 7493-7500, 7535-7549, 7596-7608, 7646-7651, 7661-7678, 7722-7731, 7741-7754, 7764-7769, 7776-7782, 7791-7806, 7825-7837, 7862-7875, 7891-7897, 7922-7931, 7974-7981, 7999-8005, 8039-8045, 8049-8065, 8070-8075, 8099-8112, 8119-8125, 8151-8158, 8169-8181, 8226-8232, 8258-8264, 8291-8299, 8301-8310, 8325-8335, 8375-8389, 8394-8400, 8405-8412, 8421-8436, 8478-8485, 8512-8521, 8528-8538, 8564-8579, 8587-8594, 8603-8615, 8626-8637, 8640-8646, 8657-8672, 8684-8691, 8725-8736, 8748-8761, 8777-8783, 8794-8799, 8810-8825, 8851-8862, 8874-8887, 8903-8912, 8914-8926, 8933-8943, 8954-8960, 8979-8988, 9004-9011, 9035-9041, 9056-9069, 9077-9086, 9088-9096, 9106-9111, 9124-9133, 9183-9191, 9224-9231, 9235-9241, 9250-9265, 9279-9290, 9295-

:

2.0

:

:

. [3

5	
	9300, 9326-9343, 9408-9414, 9422-
	9427, 9435-9441, 9455-9461, 9507-
	9517, 9532-9538, 9580-9589, 9594-
	9600, 9614-9623, 9643-9648, 9665-
1 1	9683, 9688-9700, 9720-9726, 9742-
	9758, 9767-9775, 9795-9800, 9817-
	9835, 9842-9847, 9912-9919, 9925-
	9938, 9943-9963, 9970-10009,
	10025-10031, 10037-10043, 10045-
	10063, 10066-10073, 10117-10124,
	10126-10136, 10203-10210, 10218-
	10225, 10232-10242, 10287-10292,
	10303-10323, 10352-10360, 10385-
	10396, 10425-10431, 10452-10459,
	10480-10485

\*\*\*

Table 3. Serological proteome analysis of S. aureus surface proteins using human sera

a) S. aureus/agr "stress conditions"

Spot ID/sera	1:20,000	IC35, N26, C4 1:50,000 each	Infant pool C2,5,6,10,12 1:10,000	N22 1:10.000 IC40 1:50,000
РСК2	+	+		+
PCK4	+	+++	_	+++
PCK5	_	(+)	- '**	+
PCK6	+	+		+

Spot ID/sera	IC35, 40 1:50,000 N22 1:10,000	P-pool (P6,18,25,28,29) 1:50,000 each	Infant pool C2,5,6,10,12 1:10,000	
PAC1	++	11	_	
PAC2	++	+++		
PAC3	_	+	_	
PAC5	_	++	<u> </u>	

Spot ID/sera	P-pool (P6,18,25,28,29) 1:50,000 each	Infant 14 1:10,000	IC pool / IgG (N26, IC34,35) 1:30,000 each	IC pool/IgA (N26, IC34,35) 1:30,000 each
PAC11	++	_	++	++
PAC12	++	_	++ '	++
PAC13	_	_	_	++ .
PAC14	_	-	+	+
PAC15	_	_	+++	+++
PAC16	+	-	+	+
PAC17	+	-	+	+
PAC18	++		_	
PAC19	_	_	++	++
PAC20	++	_	_	_
POV31	+++	_	_	-
POV32	+	-	-	
POV33	+			
POV34	+	-		-
POV35	+	-	_	
P OV36	+	-		-
P OV37	++	<u> </u>	<u> </u>	<u> </u>

0.000 x 2000

P OV38	++	<u> </u>			
P OV39	+++		-		
P OV40	+++	_	-	-  -  -  -  -  -  -  -  -  -  -  -  -	

b) S. aureus/COL "standard conditions"

Spot ID/sera	IC pool (N26,IC34,35) 1:30,000 each	IC35 1:20,000	P18 1:10,000	P25 1:10,000	P1 1:5,000	P29 1:2,500	Infant 18 1:10,000
POV2	111	+++	+++	+++	+++	<u> </u>	
POV3.1	+++	+++	+++	+++	+++		_
POV3.2	+++	+++	+++	+++	+++ '	-	
POV4	+	+++	-	_		<u> </u>	
POV7		-	111		<u>-</u>	<u> </u>	_
POV10	_	++	(+)	(+)	<u> </u>	(+)	
POV12	_		_	-	_	+++	<u> </u>
POV13	++	+++	+++	+++	++	++	_
POV14	++ .	+++	+++	++	++	++	
POV15	+	+	-	+	(+)		

c) S. aureus/COL "stress conditions"

Spot ID/sera	P-pool (P6,18,25,28,29) 1:50,000 each	1:20,000 each	P18 1:10,000	P29 1:10,000	Infant 14 1:10,000
POV16		+++			<u></u>
POV17	_	+++	(+)		
POV18	+	_	++		-
POV19	(+)	_	+++	_	-
POV21	<b>_</b>		+		
POV23	-	+	<u> </u>		<u>-</u>
POV24	-	+	<u> </u>		-
POV25	+		-	_	_

1 --- 1

Table 4. S. aureus antigens identified by MALDI-TOF-MS sequencing (ORFs in bold were also identified by bacterial surface display)

Prediction of antigenic regions in selected antigens identified by serological proteome analysis using human sera

spot ID	S. aureus pro- tein	Putative function (by homology)	Seq ID no: (DNA, Prot)	Putative local- ization
` <u>.</u>	(ORF no. / ab- brev.)	·		÷
PCK2	ORF0599	Glycinamide-ribosyl synthase	107, 108	cytoplasmic
PCK5	ORF0484 yitU	conserved hypoth. protein (yitU)	109, 110	cytoplasmic
PCK6	ORF2309	membrane-associated malate-quinone oxidase	111, 112	peripheral mem- brane
POV2	ORF0766 aux1	protein phosphatase contributing to me- thicilin resistance	113, 114	trans-membrane
POV4, 17 PAC14, 19	ORF0078 EF- Tu	C-terminal part of 44 kDa protein similar to elongation factor Tu	115, 116	cytoplasmic/ se- creted
POV5 <sup>1)</sup>	ORF0782	3-ketoacyl-acyl carrier protein reduc- tase (fabG)	117, 118	cytoplasmic
POV7	ORF0317 SecA	protein transport across the membrane SecA	39, 91	cytoplasmic
POV10	ORF1252 yrzC	hypothetical BACSU 11.9 kd protein (upf0074 (rff2) family)	119, 120	cytoplasmic
POV12	ORF0621 pdhB	dihydrolipoamide acetyltransferase (pdhB)	121, 122	cytoplasmic
POV14	ORF0072 rpoB	DNA-directed RNA polymerase B	125, 126	cytoplasmic
POV15	ORF0077 EF-	85 kD vitronectin binding protein	127, 128	cytoplasmic
POV18	not found YLY1	general stress protein YLY1	129, 130	cytoplasmic
POV30 "	ORF0069 RL7	ribosomal protein L7	131, 132	cytoplasmic
POV21	ORF0103 yckG	probable hexulose-6-phosphate syn- thase (yckG)	133, 134	cytoplasmic
,POV24	ORF0419 yurX	conserved hypothetical protein (yurX)	137, 138	cytoplasmic

;. ;:

spot ID	S, aureus pro- tein (ORF no. / ab- brev.)	Putative function (by homology)	Seq ID no: (DNA, Prot)	Putative local- ization
POV25	ORF2441 gidA	glucose inhibited division protein a (gidA)	139, 140	cytoplasmic
PAC1	ORF1490 prsA	protein export protein prsa precursor (prsA)	173, 174	periplasmic
PAC2	ORF1931 ModA	periplasmic molybdate binding protein (ModA)	175, 176	surface
PAC3	ORF2053	heavy metal dependent transcriptional activator, putative regulator of multidrug resistance efflux pump pmrA	177, 178	cytoplasmic
PAC5	ORF2233 ydaP	pyruvate oxidase (ydaP)	179, 180	cytoplasmic .
PAC11	ORF1361	LPXTGV, extracellularmatrix-bdg.	3, 56	surface
PAC12	ORF1244 alaS	alanyi-tRNA synthetase	159, 160	cytoplasmic
PAC13	ORF0835	RNA processing enzyme/ATP-bdg.	161, 162	cytoplasmic
PAC15	ORF1124 bfmBB	lipoarnid acyttransferase component of branched-chain alpha-keto acid dehy- drogenase complex	163, 164	cytoplasmic
PAC16	ORF0340 GAPDH	głyce raldehydes-3-phosphate dehydrogenase	165, 166	cytoplasmic
PAC17	not found Contig83	5'-methylthloadenosine nucleosidase / S-adenosylhomo-cysteine nucleosidase		cytoplasmic
PAC20	ORF2711	75% identity to ORF2715 similar to hypothetical proteins	167, 168	unknown
POV31	ORF0659	29 kDa surface protein	238, 238	surface
POV32	ORF0659	29 kDa surface protein	236, 238	surface
POV33	ORF0659	29 kDa surface protein	236, 238	surface
POV34	ORF0659	29 kDa surface protein	236, 238	surface
POV35	ORF0659	29 kDa surface protein	236, 238	surface
P OV36	ORF00661	LPXTG-motif cell wall anchor domain protein	235, 237	surface
P OV37	ORF0659	29 kDa surface protein	236, 238	surface

Butto Legge Colonia

THE CONTRACTOR OF THE PROPERTY

spot ID	S. aureus pro-	Putative function (by homology)	Seq ID no: (DNA, Prot)	Putative local- ization
	(ORF no. / ab-			
	brev.)			
P OV38	ORF0659	29 kDa surface protein	236, 238	surface
P OV39	ORF0657	LPXTG-anchored surface protein	1, 142	surface
P OV40	not identified	·		

[]

		171		
Seq ID no: (Protein)	spot iD	S. aureus ORF no. / abbrev.	Putative local— ization	Putative antigenic surface areas (Antigenic package)
112	PCK6	ORF2309 mqo	peripheral membrane	61-75, 82-87, 97-104, 113-123, 128-133, 203-216, 224-229, 236-246, 251-258, 271-286, 288-294, 301-310, 316-329, 337-346, 348-371, 394-406, 418-435, 440-452
114	POV2	ORF766 aux1	trans-mem- brane	30–37, 44–55, 83–91, 101–118, 121–128, 136–149, 175–183, 185–193, 206–212, 222–229, 235–242
116	POV4	ORF078 EF-Tu	cytoplasmic/ secreted	28–38, 76–91, 102–109, 118–141, 146–153, 155–161, 165–179, 186–202, 215–221, 234–249, 262–269, 276–282, 289–302, 306–314, 321–326, 338–345, 360–369, 385–391
176	PAC2	ORF1931 ModA	periplasmic	29–44, 74–83, 105–113, 119–125, 130–148, 155–175, 182–190, 198–211, 238–245
174	PAC1	ORF1490 ·	periplasmic	5-24, 38-44, 100-106, 118-130, 144-154, 204-210, 218-223, 228-243, 257-264, 266- 286, 292-299
168	PAC20	ORF2711	unknown	7-14, 21-30, 34-50, 52-63, 65-72, 77-84, 109-124, 129-152, 158-163, 175-190, 193-216, 219-234

spot ID	GI no. or TIGR no.	S. aureus pro- tein (ORF no. / ab- brev.)		Seq ID no: (DNA, Prot)
PCK2	TIGR1280	ORF0599	Glycinamide-ribosyl synthase	107, 108

一般的学生にあるとは、 いいいいには異ない。

	•		<u>.</u>	
PCK4	7672993	ORF2268 IsaA	possibly adhesion/aggregation	12, 64
PCK5	TIGR6209	ORF0484 yitU	conserved hypoth. protein (yitU)	109, 110
PCK6	TIGR6182	ORF2309	membrane-associated malate-quinone oxidase	111, 112
POV2	6434044	ORF0766 aux1	protein phosphatase contributing to methi- cilin resistance	113, 114
POV3.1	7672993	ORF2268 IsaA	possibly adhesion/aggregation	12, 64
POV3.2	7672993	ORF2268 IsaA	possibly adhesion/aggregation	12, 64
POV4	TIGR8079	1	C-terminal part of 44 kDa protein similar to elongation factor Tu	115, 116
POV5 <sup>1)</sup>	TIGR8091		3-ketoacyl-acyl carrier protein reductase (fabG)	117, 118
POV7	2500720	ORF0317 SecA	protein transport across the membrane SecA	39, 91
POV10	TIGR8097	ORF1252 yrzC	hypothetical BACSU 11.9 kd protein (upf0074 (rff2) family)	119, 120
POV12	2499415	ORF0621 pdhB	dihydrolipoamide acetyltransferase (pdhB)	121, 122
POV13	7470965	ORF0094 SdrD	fibrinogen-bdg. (LPXTG) protein homolog (SdrD)	123, 124
POV14	1350849	ORF0072 rpoB	DNA-directed RNA polymerase β	125, 126
POV15	6920067	ORF0077 EF-G	85 kD vitronectin binding protein	127, 128
POV17	TIGR8079	ORF0078	C-terminal part of 44 kDa protein similar to elongation factor Tu	115, 116
POV18	3025223	not found	general stress protein YLY1	129, 130
POV30 "	350771	ORF0069 RL7	ribosomal protein L7	131, 132
POV21		ORF0103	probable hexulose-6-phosphate synthase (yckG)	133, 134
POV23		ORF0182	lipoprotein (S.epidermis)	135, 136

<sup>&</sup>quot;identified from a total lysate from S. aureus 8325-4 spa- grown under standard conditions. Seroreactivity with 1/1 patient and 2/4 normal sera but not with infant serum (C5).

1000 TESTER TO

## References

Aichinger G., Karlsson L., Jackson M.R., Vestberg M., Vaughau J.H., Teyton L., Lechler R.I. and Peterson P A. Major Histocompatibility Complex classII-dependent unfolding, transport and degradation of endogenous proteins. J. Biol. Chem., v.272, 1997, pp. 29127-29136

Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A. and Struhl, K. Eds. (1994). Current protocols in molecular biology. John Wiley & Sons, Inc.

Betley, M.J., Lofdahl, S., Kreiswirth, B.N., Bergdoll, M.S. and Novick, R.P. (1984). Staphylococcal enterotoxin A gene is associated with a variable genetic element. Proc. Natl. Acad. Sci. U.S.A. 81:5179-5183.

Bruggemann M, Neuberger MS (1996) Immunol. Today 17:391-397

Burnie, J.P., Matthews, R.C., Carter, T., Beaulieu, E., Donohoe, M., Chapman, C., Williamson, P. and Hodgetts, S.J. (2000). Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect. Immun. 68:3200-3209.

Chen, H.Z. and Zubay, G. (1983). Methods Enzymol. 101:674-690.

Coloque-Navarro, P., Söderquist, B., Holmberg, H., Blomqvist, L., Olcen, P., and Möllby, R. (1998) Antibody response in Staphylococcus aureus septicaemia - a prospective study. J. Med. Microbiol. 47, 217-25.

Crossley, K.B. and Archer G.L., eds. (1997). The Staphylococci in Human Disease. Churchill Livingston Inc.

Flock, J.-I. (1999). Extracellular-matrix-binding proteins as targets for the prevention of Staphylococcus aureus infections. Molecular Medicine Today 5:532-537.

Forrer, P., Jung, S. and Plückthun, A. (1999). Beyond binding: using phage display to select for structure, folding and enzymatic activity in proteins. Curr. Opin. Struct. Biol. 9:514-520.

Foster, T.J. and Hook, M. (1998). Surface protein adhesins of Staphylococcus aureus. Trends Microbiol. 6:484-488.

Frénay, H. M. B., Theelen, J. P. G., Schouls, L. M., Vanden-broucke-Grauls, C. M. J. E., Vernoef, J., van Leeuwen, W. J., and Mooi, F. R. (1994). Discrimination of epidemic and nonepidemic methicillin-resistant Staphylococcus aureus on the basis of protein A gene polymorphism. J. Clin. Microbiol. 32:846-847.

Georgiou, G., Stathopoulos, C., Daugherty, P.S., Nayak, A.R., Iverson, B.L. and Curtiss III, R. (1997). Display of heterologous proteins on the surface of microorganisms: From the screening of combinatorial libraries to live recombinant vaccines. Nature Biotechnology 15:29-34.

Goh, S.-H., Byrne, S. K., Zhang, J. L., and Chow, A. W. (1992). Molecular typing of Staphylococcus aureus on the basis of coagulase gene polymorphisms. J. Clin. Microbiol. 30:1642-1645.

Graziano et al. (1995) J. Immunol. 155:4996-5002

Hammer et al. J. Exp. Med (1995) 181: 1847-1855

Hanes, J. and Plückthun, A. (1997). In vitro selection and evolution of functional proteins by using ribosome display. PNAS 94:4937-4942.

Hashemzadeh-Bonehi, L., Mehraein-Ghomi, F., Mitsopoulos, C., Jacob, J.P., Hennessey, E.S. and Broome-Smith, J.K. (1998). Importance of using lac rather than are promoter vectors for modulating the levels of toxic gene products in Escherichia coli. Mol. Microbiol. 30:676-678.

Hryniewicz, W. (1999). Epidemiology of MRSA. Infection 27:S13-16.

Immler, D., Gremm, D., Kirsch, D., Spengler, B., Presek, P.,
Meyer, H.E. (1998). Electrophoresis 19:1015-1023.

Kajava, A.V., Zolov, S.N., Kalinin, A.E. and Nesmeyanova, M.A. (2000). The net charge of the first 18 residues of the mature sequence affects protein translocation across the cytoplasmic membrane of Gram-negative bacteria. J. Bacteriol. 182:2163-2169.

Kluytmans, J., van Belkum, A. and Verbrugh, H. (1997). Nasal car-

riage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol. Rev. 10:505-520.

Kolaskar, A.S. and Tongaonkar, P.C. (1990). A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 276:172-174.

Lim, Y., Shin, S.H., Jang, I.Y., Rhee, J.H. and Kim, I.S. (1998). Human transferring-binding protein of Staphylococcus aureus is immunogenic in vivo and has an epitope in common with human transferring receptor. FEMS Microbiol. Letters 166:225-230.

Lorenz, U., Ohlsen, K., Karch, H., Hecker, M., Thiede, A. and Hacker, J. (2000). Human antibody response during sepsis against targets expressed by methicillin resistant Staphylococcus aureus. PEMS Immunol. Med. Microbiol. 29:145-153.

Mamo, W., Jonsson, P. and Muller, H.P. (1995). Opsonization of Staphylococcus aureus with a fibronectin-binding protein antiserum induces protection in mice. Microb. Pathog. 19:49-55

McGuiness BT et al. (1996) Nature Biotech. 14:1149

Modun, B., Evans, R.W., Joannou, C.L. and Williams, P. (1998). Receptor-mediated recognition and uptake of iron from human transferring by Staphylococcus aureus and Staphylococcus epidermidis. Infect. Immun. 66:3591-3596.

Nilsson, I., Patti, J.M., Bremell, T., Höök, M. and Tarkowski, A. (1998). Vaccination with a Recombinant Fragment of Collagen Adhesin provides Protection against Staphylococcus aureus-mediated Septic Death. J. Clin. Invest. 101:2640-2649.

Parker, K. C., M. A. Bednarek, and J. E. Coligan (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152:163.

Pasquali, C., Fialka, I. & Huber, L.A. (1997). Electrophoresis. 18:2573-2581.

Phillips-Quagliata, J.M., Patel, S., Han, J.K., Arakelov, S., Rao, T.D., Shulman, M.J., Fazel, S., Corley, R.B., Everett, M., Klein, M.H., Underdown, B.J. and Corthesy, B. (2000). The IgA/IgM

. }-

1:-

receptor expressed on a murine B cell lymphoma is poly-Ig receptor. J. Immunol. 165:2544-2555

Rammensee, Hans-Georg, Jutta Bachmann, Niels Nikolaus Emmerich, Oskar Alexander Bachor, Stefan Stevanovic (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50: 213-219

Recsei P., Kreiswirth, B., O'Reilly, M., Schlievert, P., Gruss, A. and Novick, R.P. (1986). Regulation of exoprotein gene expression in Staphylococcus aureus by agr. Mol. Gen. Genet. 202:58-61.

Rodi, D.J. and Makowski, L. (1999). Phage-display technology—finding a needle in a vast molecular haystack. Curr. Opin. Biotechnol. 10:87-93.

Schaffitzel et al., Ribosome display: an in vitro method for selection and evolution of antibodies from libraries; Journal of Immunological Methods 231, 119-135 (1999).

Sanchez-Campillo, M., Bini, L., Comanducci, M., Raggiaschi, R., Marzocchi, B., Pallini, V. and Ratti, G. (1999). Electrophoresis 20:2269-2279.

Schmittel A, Keilholz U, Thiel E, Scheibenbogen C. (2000) Quantification of tumor-specific T lymphocytes with the ELISPOT assay. J Immunother 23(3):289-95

Sester M, Sester U, Kohler H, Schneider T, Deml L, Wagner R, Mueller-Lantzsch N, Pees HW, Meyerhans A. (2000) Rapid whole blood analysis of virus-specific CD4 and CD8 T cell responses in persistent HIV infection. AIDS 14(17):2653-60.

Shafer, W.M. and Iandolo, J.J. (1979). Genetics of staphylococcal enterotoxin B in methicillin-resistant isolates of Staphylococcus aureus. Infect. Immun. 25:902-911.

Shibuya, A., Sakamoto, N., Shimizu, Y., Shibuya, K., Osawa, M., Hiroyama, T., Eyre, H.J., Sutherland, G.R., Endo, Y., Fujita, T., Miyabayashi, T., Sakano, S., Tsuji, T., Nakayama, E., Phillips, J.H., Lanier, L.L. and Nakauchi, H. (2000). Fc<sub>a</sub>/<sub>g</sub> receptor mediates endocytosis of IgM-coated microbes. Nature Immunology 1:441-446.)

Skerra, A. (1994). Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in Escherichia coli. Gene 151:131-135.

Sohail, M. (1998). A simple and rapid method for preparing genomic DNA from Gram-positive bacteria. Mol. Biotech. 10:191-193.

Sonderstrup G, Cope AP, Patel S, Congia M, Hain N, Hall FC, Parry SL, Fugger LH, Michie S, McDevitt HO (1999) HLA class II transgenic mice: models of the human CD4+ T-cell immune response. Immunol Rev 172:335-43

Sturniolo, T. et al., E Bono, J Ding, L Raddrizzani, O. Tuereci, U Sahin, M Braxenthaler, F Gallazzi, MP Protti, F Sinigaglia, and J Hammer (1999) Generation of tissue-specific and promiscuous HLA ligand databases using DNA chips and virtual HLA class II matrices. Nature Biotechnology 17: 555-562.

Valli et al. J. Clin. Invest. (1993) 91: 616-62

VandenBergh M. F. Q., Yzerman E. P. F., van Belkum, A., Boelens, H. A. M., Sijmons, M., and Verbrugh, H. A. (1999). Follow-up of Staphylococcus aureus nasal carriage after 8 years: redining the persistent carrier state. J. Clin. Microbiol. 37:3133-3140..

Wessel, D. and Fluegge, U.I. (1984). Anal. Biochem. 138:141-143.

## Claims

- 1. Method for identification, isolation and production of hyperimmune serum-reactive antigens from a pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, characterized by the following steps:
  - \*providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,
  - \*providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity
  - \*screening said at least one expression library with said antibody preparation,
  - identifying antigens which bind in said screening to antibodies in said antibody preparation,
  - \*screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,
  - \*identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and
  - •optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.
- 2. Method for identification, isolation and production of a practically complete set of hyperimmune serum-reactive antigens of a specific pathogen, said antigens being suited for use in a vaccine for a given type of animal or for humans, characterized by the following steps:
  - \*providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen,
  - •providing at least three different expression libraries of said specific pathogen,

Higher of the second

- \*screening said at least three different expression libraries with said antibody preparation,
- \*identifying antigens which bind in at least one of said at least three screenings to antibodies in said antibody preparation,
- \*screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen,
- \*identifying the hyperimmune serum-reactive antigen portion of said identified antigens which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera,
- \*repeating said screening and identification steps at least once,
- \*comparing the hyperimmune serum-reactive antigens identified in the repeated screening and identification steps with the hyperimmune serum-reactive antigens identified in the initial screening and identification steps,
- •further repeating said screening and identification steps, if at least 5% of the hyperimmune serum-reactive antigens have been identified in the repeated screening and identification steps only, until less than 5 % of the hyperimmune serum-reactive antigens are identified in a further repeating step only to obtain a complete set of hyperimmune serum-reactive antigens of a specific pathogen and
- •optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.
- 3. Method according to claim 1 or 2 characterized in that at least one of said expression libraries is selected from a ribosomal display library, a bacterial surface library and a proteome.
- 4. Method according to claim 2 characterized in that said at least three different expression libraries are at least a ribosomal display library, a bacterial surface library and a proteome.
- Method according to any one of claims 1 to 4, characterized

高級のは特別にあっ

in that said plasma pool is a human plasma pool taken from individuals having experienced or are experiencing an infection with said pathogen.

- 6. Method according to any one of claims 1 to 5, characterized in that said expression libraries are genomic expression libraries of said pathogen.
- 7. Method according to any one of claims 1 to 6, characterized in that said expression libraries are complete genomic expression libraries, preferably with a redundancy of at least 2x, more preferred at least 5x, especially at least 10x.
- 8. Method according to any one of claims 1 to 7, characterized in that it comprises the steps of screening at least a ribosomal display library, a bacterial surface display library and a proteome with said antibody preparation and identifying antigens which bind in at least two, preferably which bind to all, of said screenings to antibodies in said antibody preparation.
- 9. Method according to any one of claims 1 to 8, characterized in that said pathogen is selected from the group of bacterial, viral, fungal and protozoan pathogens.
- 10. Method according to any one of claims 1 to 9, characterized in that said pathogen is selected from the group of human immunedeficiency virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, Rous sarcoma virus, Epstein-Barr virus, influenza virus, rotavirus, Staphylococcus aureus, Staphylococcus epidermidis, Chlamydia pneumoniae, Chlamydia trachomatis, Mycobacterium tuberculosis, Mycobacterium leprae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Enterococcus faecalis, Bacillus anthracis, Vibrio cholerae, Borrelia burgdorferi, Plasmodium sp., Aspergillus sp. or Candida albicans.
- 11. Method according to any one of claims 1 to 10, characterized in that at least one of said expression libraries is a ribosomal display library or a bacterial surface display library and said hyperimmune serum-reactive antigens are produced by expression of the coding sequences of said hyperimmune serum-reactive antigens

contained in said library.

- 12. Method according to any one of claims 1 to 11, characterized in that said produced hyperimmune serum-reactive antigens are finished to a pharmaceutical preparation, optionally by addition of a pharmaceutically acceptable carrier and/or excipient.
- 13. Method according to claim 12, characterized in that said pharmaceutical preparation is a vaccine.
- 14. Method according to claim 12 or 13, characterized in that said pharmaceutically acceptable carrier and/or excipient is an immunostimulatory compound.
- 15. Method according to claim 14, characterized in that said immunostimulatory compound is selected from the group of polycationic substances, especially polycationic peptides, immunostimulatory deoxynucleotides, alumn, Freund's complete adjuvans, Freund's incomplete adjuvans, neuroactive compounds, especially human growth hormone, or combinations thereof.
- 16. Method according to any one of claims 1 to 15, characterized in that said individual antibody preparations are derived from patients with acute infection with said pathogen, especially from patients with an antibody titer to said pathogen being higher than 80%, preferably higher than 90%, especially higher than 95% of human patient or carrier sera tested.
- 17. Method according to any one of claims 1 to 16, characterized in that at least 10, preferably at least 30, especially at least 50, individual antibody preparations are used in identifying said hyperimmune serum-reactive antigens.
- 18. Method according to any one of said claims 1 to 17, characterized in that said relevant portion of said individual antibody preparations from said individual sera are at least 10, preferably at least 30, especially at least 50 individual antibody preparations, and/or at least 20 %, preferably at least 30 %, especially at least 40 %, of all individual antibody preparations used in said screening.

er vala i i i 😘 alama 🔒 i i

. . .

(のないないないない) へいいし

- 19. Method according to any one of claims 1 to 18, characterized in that said individual sera are selected by having an IgA titer against a lysate, cell wall components or recombinant proteins of said pathogen being above 4000 U, especially above 6000 U, and/or by having an IgG titer being above 10000 U, preferably above 12000 U.
- 20. Method according to any one of claims 1 to 19, characterized in that said pathogen is a Staphylococcus pathogen, especially Staphylococcus aureus. and/or Staphylococcus epidermidis.
- 21. A hyperimmune serum-reactive antigen selected from the group consisting of the sequences listed in any one of Tables 2a, 2b, 2c, 2d, 3, 4 and 5, especially selected from the group consisting of Seq.ID No. 56, 57, 59, 60, 67, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 85, 87, 88, 89, 90, 92, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 126, 128, 130, 132, 134, 138, 140, 142, 151, 152, 154, 155 and hyperimmune fragments thereof.
- 22. A hyperimmune serum-reactive antigen obtainable by a method according to any one of claims 1 to 20 and being selected from the group consisting of the sequences listed in any one of Tables 2a, 2b, 2c, 2d, 3, 4 and 5, especially selected from the group consisting of Seq.ID No. 56, 57, 59, 60, 67, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 85, 87, 88, 89, 90, 92, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 126, 128, 130, 132, 134, 138, 140, 142, 151, 152, 154, 155 and hyperimmune fragments thereof.
- 23. Use of a hyperimmune serum-reactive antigen selected from the group consisting of the sequences listed in any one of Tables 2a, 2b, 2c, 2d, 3, 4 and 5, especially selected from the group consisting of Seq.ID No. 55, 56, 57, 58, 59, 60, 62, 66, 67, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 87, 88, 89, 90, 92, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 126, 128, 130, 132, 134, 138, 140, 142, 151, 152, 154, 155, 158 and hyperimmune fragments thereof for the manufacture of a pharmaceutical preparation, es-

どうので

and Straight of the state of the straight of the state of

pecially for the manufacture of a vaccine against staphylococcal infections or colonization in particular against Staphylococcus aureus or Staphylococcus epidermidis.

24. Hyperimmune fragment of a hyperimmune serum-reactive antigen selected from the group consisting of peptides comprising the amino acid sequences of column "predicted immunogenic aa", "Location of identified immunogenic region" and "Serum reactivity with relevant region of Tables 2a, 2b, 2c and 2d and the amino acid sequences of column "Putative antigenic surface areas" of Table 4 and 5, especially peptides comprising amino acid No. aa 12-29, 34-40, 63-71, 101-110, 114-122, 130-138, 140-195, 197-209, 215-229, 239-253, 255-274 and 39-94 of Seq.ID No. 55, aa 5-39, 111-117, 125-132, 134-141, 167-191, 196-202, 214-232, 236-241, 244-249, 292-297, 319-328, 336-341, 365-380, 385-391, 407-416, 420-429, 435-441, 452-461, 477-488, 491-498, 518-532, 545-556, 569-576, 581-587, 595-602, 604-609, 617-640, 643-651, 702-715, 723-731, 786-793, 805-811, 826-839, 874-889, 37-49, 63-77 and 274-334, of Seq.ID No.56, aa 28-55, 82-100, 105-111, 125-131, 137-143, 1-49, of Seq.ID No. 57, aa 33-43, 45-51, 57-63, 65-72, 80-96, 99-110, 123-129, 161-171, 173-179, 185-191, 193-200, 208-224, 227-246, 252-258, 294-308, 321-329, 344-352, 691-707, 358-411 and 588-606, of Seq.ID No. 58, aa 16-38, 71-77, 87-94, 105-112, 124-144, 158-164, 169-177, 180-186, 194-204, 221-228, 236-245, 250-267, 336-343, 363-378, 385-394, 406-412, 423-440, 443-449, 401-494, of Seq.ID No. 59, aa 18-23, 42-55, 69-77, 85-98, 129-136, 182-188, 214-220, 229-235, 242-248, 251-258, 281-292, 309-316, 333-343, 348-354, 361-367, 393-407, 441-447, 481-488, 493-505, 510-515, 517-527, 530-535, 540-549, 564-583, 593-599, 608-621, 636-645, 656-670, 674-687, 697-708, 726-734, 755-760, 765-772, 785-792, 798-815, 819-824, 826-838, 846-852, 889-904, 907-913, 932-939, 956-964, 982-1000, 1008-1015, 1017-1024, 1028-1034, 1059-1065, 1078-1084, 1122-1129, 1134-1143, 1180-1186, 1188-1194, 1205-1215, 1224-1230, 1276-1283, 1333-1339, 1377-1382, 1415-1421, 1448-1459, 1467-1472, 1537-1545, 1556-1566, 1647-1654, 1666-1675, 1683-1689, 1722-1737, 1740-1754, 1756-1762, 1764-1773, 1775-1783, 1800-1809, 1811-1819, 1839-1851, 1859-1866, 1876-1882, 1930-1939, 1947-1954, 1978-1985, 1999-2007, 2015-2029, 2080-2086, 2094-2100, 2112-2118, 2196-2205,

and the second

2232-2243, 198-258, 646-727 and 2104-2206, of Seq.ID No. 60, aa 10-29, 46-56, 63-74, 83-105, 107-114, 138-145, 170-184, 186-193, 216-221, 242-248, 277-289, 303-311, 346-360, 379-389, 422-428, 446-453, 459-469, 479-489, 496-501, 83-156, of Seq.ID No. 62,

aa 14-22, 32-40, 52-58, 61-77, 81-93, 111-117, 124-138, 151-190, 193-214, 224-244, 253-277, 287-295, 307-324, 326-332, 348-355, 357-362, 384-394, 397-434, 437-460, 489-496, 503-510, 516-522, 528-539, 541-547, 552-558, 563-573, 589-595, 602-624, 626-632,

651-667, 673-689, 694-706, 712-739, 756-790, 403-462, of Seq.ID No. 66,

aa 49-56, 62-68, 83-89, 92-98, 109-115, 124-131, 142-159, 161-167, 169-175, 177-188, 196-224, 230-243, 246-252, 34-46, of Seq.ID No. 67,

aa 11-20, 26-47, 69-75, 84-92, 102-109, 119-136, 139-147, 160170, 178-185, 190-196, 208-215, 225-233, 245-250, 265-272, 277284, 300-306, 346-357, 373-379, 384-390, 429-435, 471-481, 502507, 536-561, 663-688, 791-816, 905-910, 919-933, 977-985, 1001-

1010, 1052-1057, 1070-1077, 1082-1087, 1094-1112, 493-587, 633-715 and 704-760, of Seq.ID No.70,

aa.6-20, 53-63, 83-90, 135-146, 195-208, 244-259, 263-314, 319-

aa.6-20, 53-63, 83-90, 135-146, 195-206, 244-259, 263-314, 315-327, 337-349, 353-362, 365-374, 380-390, 397-405, 407-415, 208-287 and 286-314, of Seq.ID No. 71,

aa 10-26, 31-43, 46-58, 61-66, 69-79, 85-92, 100-115, 120-126, 128-135, 149-155, 167-173, 178-187, 189-196, 202-222, 225-231, 233-240, 245-251, 257-263, 271-292, 314-322, 325-334, 339-345, 59-74, of Seq.ID No. 72,

aa 4-9, 15-26, 65-76, 108-115, 119-128, 144-153, 38-52 and 66-114, of Seq.ID No. 73,

aa 5-22, 42-50, 74-81, 139-145, 167-178, 220-230, 246-253, 255-264, 137-237 and 250-267, of Seq.ID No. 74,

aa 10-26, 31-44, 60-66, 99-104, 146-153, 163-169, 197-205, 216-

223, 226-238, 241-258, 271-280, 295-315, 346-351, 371-385, 396-

407, 440-446, 452-457, 460-466, 492-510, 537-543, 546-551, 565-

582, 590-595, 635-650, 672-678, 686-701, 705-712, 714-721, 725-

731, 762-768, 800-805, 672-727, of Seq.ID No. 75,

And the second s

aa 5-32, 35-48, 55-76, of Seq.ID No. 76,

aa 7-35, 54-59, 247-261, 263-272, 302-320, 330-339, 368-374, 382-411, 126-143 and 168-186, of Seq.ID No. 77,

aa 5-24, 88-94, 102-113, 132-143, 163-173, 216-224, 254-269, 273-

278, 305-313, 321-327, 334-341, 31-61 and 58-74, of Seq.ID No. .78, aa 16-24, 32-39, 43-49, 64-71, 93-99, 126-141, 144-156, 210-218, 226-233, 265-273, 276-284, 158-220, of Seq.ID No. 79, aa 49-72, 76-83, 95-105, 135-146, 148-164, 183-205, 57-128, of Seq.ID No. 80, aa 6-15, 22-32, 58-73, 82-88, 97-109, 120-131, 134-140, 151-163, 179-185, 219-230, 242-255, 271-277, 288-293, 305-319, 345-356, 368-381, 397-406, 408-420, 427-437, 448-454, 473-482, 498-505, 529-535, 550-563, 573-580, 582-590, 600-605, 618-627, 677-685, 718-725, 729-735, 744-759, 773-784, 789-794, 820-837, 902-908, 916-921, 929-935, 949-955, 1001-1008, 1026-1032, 1074-1083, 1088-1094, 1108-1117, 1137-1142, 1159-1177, 1183-1194, 1214-1220, 1236-1252, 1261-1269, 1289-1294, 1311-1329, 1336-1341, 1406-1413, 1419-1432, 1437-1457, 1464-1503, 1519-1525, 1531-1537, 1539-1557, 1560-1567, 1611-1618, 1620-1629, 1697-1704, 1712-1719, 1726-1736, 1781-1786, 1797-1817, 1848-1854, 1879-1890, 1919-1925, 1946-1953, 1974-1979, 5 to 134, of Seq.ID No. 81, aa 6-33, 40-46, 51-59, 61-77, 84-104, 112-118, 124-187, 194-248, 252-296, 308-325, 327-361, 367-393, 396-437, 452-479, 484-520, 535-545, 558-574, 582-614, 627-633, 656-663, 671-678, 698-704, 713-722, 725-742, 744-755, 770-784, 786-800, 816-822, 827-837, 483-511, of Seq.ID No. 82, aa 4-19, 57-70, 79-88, 126-132, 144-159, 161-167, 180-198, 200-212, 233-240, 248-255, 276-286, 298-304, 309-323, 332-346, 357-366, 374-391, 394-406, 450-456, 466-473, 479-487, 498-505, 507-519, 521-530, 532-540, 555-565, 571-581, 600-611, 619-625, 634-642, 650-656, 658-665, 676-682, 690-699, 724-733, 740-771, 774-784, 791-797, 808-815, 821-828, 832-838, 876-881, 893-906, 922-929, 938-943, 948-953, 969-976, 1002-1008, 1015-1035, 1056-1069, 1105-1116, 1124-1135, 1144-1151, 1173-1181, 1186-1191, 1206-1215, 1225-1230, 1235-1242, 6-66, 65-124 and 590-604, of Seq.ID No. 83, aa 5-32, 66-72, 87-98, 104-112, 116-124, 128-137, 162-168, 174-183, 248-254, 261-266, 289-303, 312-331, 174-249, of Seq.ID No. 84. aa 4-21, 28-40, 45-52, 59-71, 92-107, 123-137, 159-174, 190-202, 220-229, 232-241, 282-296, 302-308, 312-331, 21-118, of Seq.ID aa 9-28, 43-48, 56-75, 109-126, 128-141, 143-162, 164-195, 197-216, 234-242, 244-251, 168-181, of Seq.ID No. 87,

我一只不 1

Transfer Transfer Ti

aa 4-10, 20-42, 50-86, 88-98, 102-171, 176-182, 189-221, 223-244, 246-268, 276-284, 296-329, 112-188, of Seq.ID No. 88, aa 4-9, 13-24, 26-34, 37-43, 45-51, 59-73, 90-96, 99-113, 160-173, 178-184, 218-228, 233-238, 255-262, 45-105, 103-166 and 66-153, of Seq.ID No. 89, aa 13-27, 42-63, 107-191, 198-215, 218-225, 233-250, 474-367, of Seq.ID No. 90, aa 26-53, 95-123, 164-176, 189-199, 8-48, of Seq.ID No. 92, aa 7-13, 15-23, 26-33, 68-81, 84-90, 106-117, 129-137, 140-159, 165-172, 177-230, 234-240, 258-278, 295-319, 22-56, 23-99, 97-115, 233-250 and 245-265, of Seq.ID No. 94, aa 13-36, 40-49, 111-118, 134-140, 159-164, 173-183, 208-220, 232-241, 245-254, 262-271, 280-286, 295-301, 303-310, 319-324, 332-339, 1-85, 54-121 and 103-185, of Seq.ID No. 95, aa 39-44, 46-80, 92-98, 105-113, 118-123, 133-165, 176-208, 226-238, 240-255, 279-285, 298-330, 338-345, 350-357, 365-372, 397-402, 409-415, 465-473, 488-515, 517-535, 542-550, 554-590, 593-601, 603-620, 627-653, 660-665, 674-687, 698-718, 726-739, 386-402, of Seq.ID No. 96, aa 5-32, 34-49, 1-43, of Seq.ID No. 97, aa 10-27, 37-56, 64-99, 106-119, 121-136, 139-145, 148-178, 190-216, 225-249, 251-276, 292-297, 312-321, 332-399, 403-458, 183-200, of Seq.ID No. 99, aa 5-12, 15-20, 43-49, 94-106, 110-116, 119-128, 153-163, 175-180, 185-191, 198-209, 244-252, 254-264, 266-273, 280-288, 290-297, 63-126, of Seq.ID No. 100, aa 5-44, 47-55, 62-68, 70-78, 93-100, 128-151, 166-171, 176-308, 1-59, of Seq.ID No. 101, aa 18-28, 36-49, 56-62, 67-84, 86-95, 102-153, 180-195, 198-218, 254-280, 284-296, 301-325, 327-348, 353-390, 397-402, 407-414, 431-455, 328-394, of Seq.ID No. 102, aa 7-37, 56-71, 74-150, 155-162, 183-203, 211-222, 224-234, 242-272, 77-128, of Seq.ID No. 103, aa 34-58, 63-69, 74-86, 92-101, 130-138, 142-150, 158-191, 199-207, 210-221, 234-249, 252-271, 5-48, of Seq.ID No. 104, aa 12-36, 43-50, 58-65, 73-78, 80-87, 108-139, 147-153, 159-172, 190-203, 211-216, 224-232, 234-246, 256-261, 273-279, 286-293, 299-306, 340-346, 354-366, 167-181, of Seq.ID No. 106, aa 61-75, 82-87, 97-104, 113-123, 128-133, 203-216, 224-229, 236-246, 251-258, 271-286, 288-294, 301-310, 316-329, 337-346,

:. ?: ₹.

1. (2.14)

A COMPANY OF THE PROPERTY OF T

348-371, 394-406, 418-435, 440-452 of Seq.ID No. 112, aa 30-37, 44-55, 83-91, 101-118, 121-128, 136-149, 175-183, 185-193, 206-212, 222-229, 235-242 of Seq.ID No. 114, aa 28-38, 76-91, 102-109, 118-141, 146-153, 155-161, 165-179, 186-202, 215-221, 234-249, 262-269, 276-282, 289-302, 306-314, -1321-326, 338-345, 360-369, 385-391 of Seq.ID No. 116, aa 9-33, 56-62,75-84, 99-105, 122-127, 163-180, 186-192, 206-228, 233-240, 254-262, 275-283, 289-296, 322-330, 348-355, 416-424, 426-438, 441-452, 484-491, 522-528, 541-549, 563-569, 578-584, 624-641, 527-544, of Seq.ID No. 142, aa 37-42, 57-62, 121-135, 139-145, 183-190, 204-212, 220-227, 242-248, 278-288, 295-30, 304-309, 335-341, 396-404, 412-433, 443-449, 497-503, 505-513, 539-545, 552-558, 601-617, 629-649, 702-711, 736-745, 793-804, 814-829, 843-858, 864-885, 889-895, 905-913, 919-929, 937-943, 957-965, 970-986, 990-1030, 1038-1049, 1063-1072, 1080-1091, 1093-1116, 1126-1136, 1145-1157, 1163-1171, 1177-1183, 1189-1196, 1211-1218, 1225-1235, 1242-1256, 1261-1269, 624-684, of Seq. ID No. 151, aa 8-23, 31-38, 42-49, 61-77, 83-90, 99-108, 110-119, 140-147, 149-155, 159-171, 180-185, 189-209, 228-234, 245-262, 264-275, 280-302, 304-330, 343-360, 391-409, 432-437, 454-463, 467-474, 478-485, 515-528, 532-539, 553-567, 569-581, 586-592, 605-612, 627-635, 639-656, 671-682, 700-714, 731-747, 754-770, 775-791, 797-834, 838-848, 872-891, 927-933, 935-942, 948-968, 976-986, 1000-1007, 1029-1037, 630-700, of Seq.ID No. 152, aa 17-25, 27-55, 84-90, 95-101, 115-121, 55-101, of Seq.ID No. 154, aa 13-28, 40-46, 69-75, 86-92, 114-120, 126-137, 155-172, 182-193, 199-206, 213-221, 232-238, 243-253, 270-276, 284-290, 22-100, of Seq.ID No. 155 and aa 7-19, 46-57, 85-91, 110-117, 125-133, 140-149, 156-163, 198-204, 236-251, 269-275, 283-290, 318-323, 347-363, 9-42 and 158-174, of Seq.ID No. 158, 1 aa 7-14, 21-30, 34-50, 52-63, 65-72, 77-84, 109-124, 129-152, 158-163, 175-190, 193-216, 219-234 of Seq.ID.No. 168, aa 5-24, 38-44, 100-106, 118-130, 144-154, 204-210, 218-223, 228-243, 257-264, 266-286, 292-299 of Seq.ID.No. 174, aa 29-44, 74-83, 105-113, 119-125, 130-148, 155-175, 182-190, 198-211, 238-245 of Seq.ID.No. 176, and fragments as depicted in Tables 2 and 4 and fragments comprising at least 6, preferably

more than 8, especially more than 10 aa of said sequences.


- 25. Helper epitopes of an antigen or a fragment, as defined in anyone of claims 21 to 24, especially peptides comprising fragments selected from the peptides mentioned in column "Putative antigenic surface areas" in Table 4 and 5 and from the group aa 6-40, 583-598, 620-646 and 871-896 of Seq.ID.No.56, aa 24-53 of Seq.ID.No.70, aa 240-260 of Seq.ID.No.74, aa 1660-1682 and 1746-1790 of Seq.ID.No. 81, aa 1-29, 680-709, and 878-902 of Seq.ID.No. 83, aa 96-136 of Seq.ID.No. 89, aa 1-29, 226-269 and 275-326 of Seq.ID.No. 94, aa 23-47 and 107-156 of Seq.ID.No. 114 and aa 24-53 of Seq.ID.No. 142 and fragments thereof being T-cell epitopes.
- 26. Vaccine comprising a hyperimmune serum-reactive antigen or a fragment thereof, as defined in any one of claims 21 to 25.
- 27. Vaccine according to claim 25, characterized in that it further comprises an immunostimulatory substance, preferably selected from the group comprising polycationic polymers, especially polycationic peptides, immunostimulatory deoxynucleotides (ODNs), neuroactive compounds, especially human growth hormone, alumn, Freund's complete or incomplete adjuvans or combinations thereof.
- 28. Preparation comprising antibodies against at least one antigen or a fragment thereof, as defined in any one of claims 21 to 25.
- 29. Preparation according to claim 27, characterized in that said antibodies are monoclonal antibodies.
- 30. Method for producing a preparation according to claim 28, characterized by the following steps:
  - •initiating an immune response in a non human animal by administering an antigen or a fragment thereof, as defined in any one of the claims 21 to 25, to said animal,
  - ·removing the spleen or spleen cells from said animal,
  - •producing hybridoma cells of said spleen or spleen cells,
  - ·selecting and cloning hybridoma cells specific for said anti-

gen and

producing the antibody preparation by cultivation of said cloned hybridoma cells and optionally further purification steps.

- 31. Method according to claim 29, characterized in that said removing the spleen or spleen cells is connected with killing said animal.
- 32. Method for producing a preparation according to claim 27, characterized by the following steps:
  - •initiating an immune response in a non human animal by administering an antigen or a fragment thereof, as defined in any one of the claims 21 to 25, to said animal,
  - removing an antibody containing body fluid from said animal,and
  - producing the antibody preparation by subjecting said antibody containing body fluid to further purification steps.
- 33. Use of a preparation according to claim 27 or 28 for the manufacture of a medicament for treating or preventing staphylococcal infections or colonization in particular against Staphylococcus aureus or Staphylococcus epidermidis.
- 34. A screening method assessing the consequences of functional inhibition of at least one antigen or a fragment thereof, as defined in any one of claims 21 to 25.

IgA vs. IgG titer against total S. aureus lysate



**IgA** titer 10.000X





Figure 2






Figure 3






Figure 4

Little Ber Libert Ber Charles and Charles and Libert Ber Charles



Figure






Figure 7

EXTRACELLUIARDONAIN TOTAL





Figure 8.

Constitutive Cell Wall Proteins of S. aureus with LPXTG motif

_	Known proteins	Predicted	Electricity of the control of the control of the control of the controls
		Mw/pI	
1	Mrp protein	255/4.6	azioooxilaahitawevorterahiahoonaseedahixe
2	Pls (MRSA)	167/4.1	NKELPOTIENDADNOTURPOSLIPALIGODELVORRRRRNROWERK
5	SdrD (SD-repeat)	133/4.1	AKOÁLPÉTGÁBYSGSPÁGTTEGGSTERÁTGSTALLFGRRKKONK
4	Cha	126/5.6	Transpirition of the second se
2	SdrE	117/4.1	AKOTIPERGSENNIGSINNATIFICEDFALCESLLLINGFREKDINK
Ġ	FnBPA	104/4.5	KSELLERINGERERINGENTEGGIEST LEGENTURKKKRIKK
-	SdrC	94/4.1	AKADIBBIĞSEMINBINGILLEĞELERİLĞELLERIRKKONK
8	Fhare	96/4.5	KSEPERTGEERIMMENTERSTEET WITHERMEN
6	ClfA (clumping factor 89/3.4	89/3.4	Keplédégedeántslíngilmsiúsfilerkkkennokk
ង	10 ClfB (clumping factor 88/3.7	88/3.7	TO A LIBERTON SENTENCE STATE OF THE STATE OF
H	11 Spa (Protein A)	48/5.2	ACAMPERICE ENTRY FOLTON COLLAND IN ACAMPER I.

Figure 8B

The state of the s



Surface staining of S. aureus (strain 8325-4 spa-) with purified anti-LPXTGV IgGs

["]




Figure 10

Control of the Contro

CONTRACTOR OF STREET, ST. C. C. C.

## SEQUENCE LISTING

Intercell Biomedizinische Forschungs- und Entwicklungs AG Cistem Biotechnologies GmbH

R 39035

Priority: Austrian Patent Application No. A 130/2001 of 26.01.2001

Seq. ID Nos. 1-598

Organisms: S.aureus; S.epidermidis

cctagcaaaccaacaccaccacctgttgaaaaagaatcacaaaacaagacagccaaaa gatgacaataaacaattaccaagtgttgaaaaagaaaatgacgcatctagtgagtaaaggcgtaaacgcttgctacaagaccaactagaggtagtacaact ccaactaaggtagtatctacgactcaaaatgttgcaaaaccaacaactggtcatcaaaa ccaacaaaaggatgttgttcaaacttcagcaggttctagcgaagcaaaagatagtgtccca ttacaaaaagcaacattaaacacaaaatgatgtgaagcacactcaaagccaaaacaataaa aatacacaagaaaataaagcaaaatcattaccacaaactggtgaagaatcaaataaaa atgacattaccattaatggcattattagctttaagtagcatcgttgcattcgtattacct agaaaacgtaaaaactaa cttgaaaatcgtagattctacaatcctgaatcactcgat

i:

ij

Ì,

- 7

i.

gatttettaga 5 ttgatgattaate

Ask.

6.

7.

Land the factor of the American

atgagtaaaagacagaaagcatttcatgacagcttagcaaacgaaaaacaagagtaaga ctttataaatctggaaaaaattgggtaaaatccggaattaaagaaatagaaatgttcaaa attatggggctaccatttattagtcatagtttagtgagtcaagataatcaaagcattagt ttacaacaagtacaatttggaacattcgaatatacagagtctgctgttacacaagtgaga tacgttgatgtaacaacaggtaaagatattattccaccaaaaacatattcaggaaatgt ggaagtacacaacatctcaaagtggtcaacaagtaagtcgactcacaaagtgcac acgagtacatcaggatcgattgtggtatctacatcagctagtacctcgaaatcggcaagt gtaagcctatctggatcgtggagtgcatctaagtcattaagcacatctgaaatcggcaagt gtatcaagctcaacaagcacaagtttagtgaattcacaaagtgtatcatcaagcatgteg gattcagctagtaaatcaacatcattaagcgattctatttcaaactctagcagtactgaa aaatccgaaagtctatcaacaagtacatctgattcattggtacatcaacaacatcactcagt anatccganagtctatcancangtacatctgattcattggucatcancacatcactcag gactcattnagtatgagtacatcaggangttgtctnagtcacangctnatcancgagt atatcangggtcgtctagtacatcagcatcattangtgacagtacatcgantgcanttagt acatcancatcattgagcagtcagctagcactcggactctatcagtatttnaattagt atagcanatctcanagtgcgtcnacangcanatcagnatcanangtacatcantatca ttangtacangtgattcanantcgatgagtacatcagnatcattgagcgattcgacgagc ttaagtacaagtgattcaaaatcgatgagtacatcagaatcattgagcgattcgacgagc acaagtggttctgtttctggatcactaagcatagcagcatcacaaagtgctcaacaagt acatcagactcgatgagtacttcagagatagtaagtagtactctatcagtacaagtgggtca ttatctgcatcagacagtacaatcaatgtccgtaagtagttcaatgagcacgtctcagtca gtagtacatcagaatcatcaagtgattcacaaagtacatctgattctgatagtaagtca ttatcacaaagtactagtcaatcaggttcaacaagtacatcaactgcaagtgcttca gtacgtacttcggaatcacaaagtacgtctggttcaatgagtgcaagtcaatccgattca atgagcatatcaacgtcgtttagtgattcaacgagtgatagcaaatcagcatcaactgca tcaagtgaatcaatatcacaaagtgcttctacgagcacatctggttcggtaagtactcaactgca cagtcaacaagtcaaagtgaatccacatcgacatcaacgtcactaagcgattcaacaagt atatctaaaagtacgagtcaatcaggttcggtaagcacatcagcgtcattaagtggttca gagagtgaatctgattcacaaagtattcaacaagtgcaagtgagtcaacatcagaaagt gcgtcaacatcactcagtgactcaacaagtacaagtaatccgattgcaccatcatcagaatacgtca acatcgctcagtaactcagcaagcgcaagtgaatccgatttgtcgtcaacatcattaagt gattcaacatctgcgtcaatgcaaagcagtgaatccgattcacaaagcacatcagcatca ttaagtgattcgctaagtacatcaacttcaaacgcatgtcgaccattgcaagttatct acatcggtaagtacatcagagtctggctcaacatcagaaagtacaagtgaatccgattca acatcaacatcattaagcgattcacaaagcacatcaagaagtacaagtgcatcaggatca gcaagtacatcaacatcaacaagtgactctcgtagtacatcagcttcaactagtacttcg atgcgtacaagtactagtgattcacaaagtatgtcgctttcgacaagtacatcaacaagt atggtacaagtactagtgattcacaaagtatgtcgctttcgacaagtacatcaacaagt atgagtgattcaacgtcattatctgatagtgttagtgattcaacatcagactcaacaagt gcgagtacatctggttcgatgagtgtgtctatatcgttaagtgattcgacaagtacatca acatcggctagtgaagtaatgagcgcaagcatatctgattcacaaagtatgtcagaatct gtaaatgattcagaaagtgtaagtgaatctaattctgaagtgactctaaatcgatgagt ggctcaacaagtgtcagtgattctggctcattaagtgctcatcaagtagacaatca gaaagtgtaagcgagtcaagttcattagggtgtcacaaatcgatgagcgattcagtaagc acaagcgattcgtcatcattaagtgtatcgacgtcactaagaagttcagaaagcgtaga 

AND MALE ST

25,525

.

1990年の日本日本の

Children Charles

9.

10.

tiganamangantigatiatigicgantangcagnatangtaticgattagagtittagagtaggagtittagagagtittaggagagtittagga				t
acagtaggitaccacatcaglacigataggiggaacuticite te gyamad habepeagt caagcacaaget tecapaacaatcagan ya tacaaccacaatcaga tecapacagatcagaatc	1			1
casgcarasgcttcagaacaatcgaatcgaatcgaatcgaatcgaat	11.	ttgaaaaaagaattgattattgttgatgataagaagaattaagaataagaattaa		1
casgcarasgcttcagaacaatcgaatcgaatcgaatcgaatcgaat	- 1	acagtaggtaccacatcagtaatagtaggggcaactatactatcagggaataatagtagagg		1
geagattecgaaaaaacaaattgategacaatgacaatgatagacaacaaaacaa	1			1
acatetgatattagtgeaaacacatanagegeaaagetetaaacaagtaaacacata tetaacacaagegeaattecatataaaacaagaagattecaaatgeagaacaacaa cagacggeaattaaaaatteaataaaacaacgaabgatgetaaatgeaaatgeteetaa gaagettaaaaatteaaataaacaacgaabgatgetaaatgeaatageacaaa gaagettaaaattegaaacaattagattecacaataagatacgatteca aatgegecaagaacatgaaacaagtgttagaacaagagetgtacgtaagtaagtacgatte getgaacggdataaatgetgatgatgaagtgataaagagattacgaagagagagagag				1
tctacacaacgagcaataccactacaacgagcaatyttoaagatcaatgattccaagacgagcaattctcaagaatacgagcaatyttoaagattacaacgagcaatgagcaaattctcaagagcaacaatgagtagagcaattctcaagagcaattctcaagagcaattctcaagagcaattctcaagagcaattctcaagagcaattctcaagagcaattcaagattcaagattcaagagcagagcagttagagagag	1			1
ccgacgacattcaagatactaagacatcycatgatatuccaatagacatactagacatactagacatactagacatactagacatactagacatactagacatactagacatactagacatactagacaaatagacagac	Į.			1
gaagcaaattctcaagtagtaataaataagtttactaagtcaattcaagtttacaagtgagtttaaaattgagtttacaagtgtttagaattgagttaaattgagtttacaagtgttaggtagttaagtgagttaagtgagttaggtaggtaggtaattgaggttaggtaggtaggtaggtaggtaggttaggttaggtaggtaggtaggttaggtaggtaggttaggtaggtaggtaggtaggtaggtaggtaggttagggtaggtagggtagggtagggtagggtagggtagggggg	1			ı
agigagettaaanatteteaaseatagettaaneensgetgiaegigaegigaegigaegigaegigaegigaegig	1	ccgacggcactaaaaatcaagcaacagcagcagcagaacagcagacaacaaac		1
agigagettaaanatteteaaseatagettaaneensgetgiaegigaegigaegigaegigaegigaegigaegig	1	gaagcaaatteteaagtagataataaacaacgaacgaacgatataaagaaaga		1
astgcqcaaggactagtaaaccaagtyttagagttcaagastgagtagtagtagtaggggggggggg	ľ			1
gctgaaccggtagtaatgctggtgtgtgaagtgtabaset aanabtggtabaccabtt gcaagtaatttaagtgaagaagatbcatttgaccababtagatggtabaccabtt atggcggcaattttaagtgaagaagatbcatttgaccababtaggatttattctaagaagat ttaccagatagtttaactgatgaagagatgaagatggattttattctaabtcaaatagatt ccaattgcagatttaatgatgaagatgagatg	- 1			ı
grangt satttcangttagnanga tangttynant-neggign tattttacagnanga atggggraattt tacagnanga ttacagnanga teatttangtynanga typertatattenattenatatagnatg ttacagnanga ttacagnanga teattanga transpirent tacagnanga transpirent tatttacagnanga transpirent tutacagnanga transpirent tutacagnanga transpirent tutacagnanga transpirent tutacagnanga transpirent tutacagnanga transpirent tutacagnanga transpirent tutacagnanga transpirent tutacagnanga transpirent tutacagnanga transpirent tutacagnanga transpirent tutacagnanga transpirent tutacagnanga transpirent transp	1			
ttaccagnitatitaticagrantygiantygiantatygyantetingtethantenatagaty crantugcagacatunangungungungungungungungungungungungungun				1
ttaccagatajttaactggatajggatgggatgttachetaagtatagtatta ccaattgagacattaagatgagatg	1	geangtantiticage tagantanage tanggar tattitacage aag		ı
ceasttgcagacattanaagtacgaatgggatttgtgtaataanaagaanatattaattgataggacgtatacatttfgtctttacagaattattgtaanataanagaanatattgggacaattttcattactttfgttttacagaccgagcgaaggaattttggtaaggacattttgtttattataatttggtttaggacaattttgtttaggtattaggttaggacaattttgtttaggtttggcaatttggtttaggacattttgtttaggttaggacaattttggtttaggacattttggttaggacaattttggtttaggacattttggttaggacaattttggttaggacaattttggttaggacaattttggttaggacaattttggttaggacaattttggttaggacaattttggttaggacaattttggtgtggtaggatacaatcaggacgaggactttaggaagga	1	atggcggcaaattttacagtgacagataaagtgaaattatatggaaatagaatacgatg		1
ceasttgcagacattanaagtacgaatgggatttgtgtaataanaagaanatattaattgataggacgtatacatttfgtctttacagaattattgtaanataanagaanatattgggacaattttcattactttfgttttacagaccgagcgaaggaattttggtaaggacattttgtttattataatttggtttaggacaattttgtttaggtattaggttaggacaattttgtttaggtttggcaatttggtttaggacattttgtttaggttaggacaattttggtttaggacattttggttaggacaattttggtttaggacattttggttaggacaattttggttaggacaattttggttaggacaattttggttaggacaattttggttaggacaattttggttaggacaattttggttaggacaattttggtgtggtaggatacaatcaggacgaggactttaggaagga		ttaccagatagtttaactggtaacggagacgcggattatccaactca		-
ttgactaagacytatacattcytettuaugacyaaaaggacactaaytagacattataggacattatatatatatatatag gagacattttcattacttattatatagaccyaacaaaggacacattatyttaacctaagtat gatgcyaatattaattatattyggatyaaacaaatygyaacatttettetaaattattyd tegcaaattycagyaatagatacagatyaaacaaatygyaaatttettetaaacatattyg ttagcaattycagyaataggatacagyayaacagacaaattttyttaaaccaagcaa gagttttaggataacagyayaacaaatgagactacaaggataaaattgagaaagaaggacaa gagtttaaaaaataggatacaaggaccaaatgagactaaacagaaggacatttt aggagtaaggatgatacagagatacaaatgagactaaacaggaagaacaa aattataaaaatagaattattaggaaatgaccaaatgagactaaaatagagatacaagaactta aattataaaaatattaggaaaatyttgtacgtaatattaggagatacaaatgagactacaagtagaagacaaaacaagaagactacagaaccaa aattataaaaatagaaatttgtacgttatgattaggaggactacagaacaagaacaagaaccaa aattatagaaagaacaagatacagaacaaggaccaggaacaagaacaaggaccaa gataacagaaaccaagatcagaacaagtcagaaccagaaaccagaaccagaaccaag gaaccagaaccaagaacaagatcagaatcagatagagatgatgagattcagaatcagaatcaga gaacagaactaagatacagattcagaatgagattcggattcagaatcagaatcagaatcaga gaacagaactaagattcagaataggattcggattcagaatcagaatcagaatcagaatcaga gactcagaatcagaatagaat	1			1
gaccaatttcattattattatatagatcggatgaatgtttatatata				-1
gatggaatataattagtgaaattgaaattgagaatttetteteaaatttgg tegcaatttgggaattggtaaactaaatggcgaacatttetteteaattattgg tagatacagcttcaggtcaaacacatacaagcaaatattgtgtaaccatagcaa gagtttaggtaataggtggtgtatabaggaataccaagataanatcgaagaagt agcggtaaagtagtacacagataacaaatgaccaaattttgaagtgaatgatactt aaattatcagatagtacatataagaacaaatgaccaaatgagataacacaga caatttaaanatagtagtattatagtagaacacaaatgagcttaacaatgagataaatttt aaaactcaggatattaatagtagaatgcacaaatgagattacaataaggataaaatttt aaaactcaggatattagaaaatgttagtattagtggtggaagtgctgatggtgaggagatttta gaacagaactcagaattagtagtagtaggattaggaatgaggaacaaggaacaag gaacagaaacaaagcagatcagaacaagtcagaacaagaacagaaccag gaacagaaca				
tcgccaattgcaggtactgaaccaactacaagcaaccagtattttataacctaagcaagc				-
glagatacagcttcaggtcaaaacactacagatacagtacagatctsgaatttugaatacagtcagatttagtaatactt cagatttagtaatactt gagttaattaaaaggcacacaagatctagaatttugagtgaatagtacatt agcagtaaagtaagtactattagaagtcacaaagtctagaatttutugagtgaatagtacatt agcagtaaagtacattaacattaaagaacaacattagaagtcaaaatttaacattagaagtcaaatttaaagaacatattaaagaacaaagtagtaattagaagggcattaagaacaagtagtagtattattaaaaaacatattaaaagaacaaagtagtagtattagaagggcattaagaacaaggaagtattta aaaaccaagttaattacaagaaagtacaggaattatta aaaaccaagttaatacaagtagtagtgtgaattattaaagaacaagggcattaagaaggaattatta ggtagtagaattatta ggtagtagaatcaagattagaattacaaggaagtacaagaacaaggcaggtcagaacaagtcaggaaccaagtcagaaccaagtcagaaccaagtcagaaccaagaccaggaacaaggaacaaggaacaaggaacaaggaacaaggaacaaggaacaaggaacaaggaatcagaatcagaattagga	i	gatgegatatatagatagacagatagacagacatttcttctcaaattattggt		-
cgagttttaggtaatacgttgggtgtatattaasggcattagatagatagtagtagtagtagtagtagtagtagtag	.	tegecantigenggantigatantentingggggganacantattattaaccetaaccan		1
agcggtaaagtagttactagatacaaaagtctaaccttaaccttaaagaagtaccpaa caatttaaaaatagtagtactatagagatccaaatgtagtagtatacagag caatttaaaaatagtagtattagagaagggattaaccgaatgtagtagtagtataaaattggtgat attactaaaaacatagtgattagtatagagaagggattacagaatagtagtactta aaaactagggttattcaagaaaagtgtgatccttgtaacaaataggaactacagtattta ggttggaatatagaaagtgtgtactgtagaaggaattaggaattacaggactacag gtaaatccgaaagaccaactcagggccgcggttgaaccagaaccagaaccgaaccag gaaccagaacaaccaagtcaggatcagaaccaagtccggaaccagaaccaggaccag gaccagaatcagaattagaattagaattaggattaggattaggattaggattaggattagagttagagttag gattcagaatagattagaattaggattaggattaggattagagttagagttagagttag gattcagaatagattagaattaggattaggattaggattaggattagagttagagttagagttag gattcagaatagattaggatta	1	gtagatacagctccaggtcaaadcacatacaagcamtacagctcagatcagangaagt		-
agcggtaaagtagttactagatacaaaagtctaaccttaaccttaaagaagtaccpaa caatttaaaaatagtagtactatagagatccaaatgtagtagtatacagag caatttaaaaatagtagtattagagaagggattaaccgaatgtagtagtagtataaaattggtgat attactaaaaacatagtgattagtatagagaagggattacagaatagtagtactta aaaactagggttattcaagaaaagtgtgatccttgtaacaaataggaactacagtattta ggttggaatatagaaagtgtgtactgtagaaggaattaggaattacaggactacag gtaaatccgaaagaccaactcagggccgcggttgaaccagaaccagaaccgaaccag gaaccagaacaaccaagtcaggatcagaaccaagtccggaaccagaaccaggaccag gaccagaatcagaattagaattagaattaggattaggattaggattaggattaggattagagttagagttag gattcagaatagattagaattaggattaggattaggattagagttagagttagagttag gattcagaatagattagaattaggattaggattaggattaggattagagttagagttagagttag gattcagaatagattaggatta	i i	cgagttttaggtaatacgtgggtgtatattaaaggctattatgataatattgatacatg		- [
caattaaaatagattattatagagatcaaatattattataaattgggattaaatatattaaattgggattataaatatatatagagattagaaccaaattaaggatattaaattatatagagattagatataaggattataaattaaggattatt	i i			ı
attactasaacatatytattatytatatytatacytacaatacaa			-3,	1
attactasaacatatgiagtattagiagaaggiattagigtatatattagaagactacagtatttte ggttygaatastgagaatgitgtacgittagagtgiggaaggigtattatte ggttygaatastgagaatgitgtacgittagagtgiggaagacaagiccagacca gtaaatccgaaagaccaactccaggaccaggiccagaaccagaccaa gaaccagaaccaagccagatccagaaccagaaccagaaccaagcca gaaccagaaccaagccagatccagaatgactagaccagaaccaagcca gaccaggatcagaatcagattaggattaggattagaacaggattcagattcagattcag gattaggatagcagattcagattcagattaggattcagaattcagattcagattcagattcag gattaggattagcagattcagattaggattaggattcagattcagattcagattcag gactaggattagacagtatagattaggattaggattcagattcagattcagacag gactagacta	ľ			П
asaactcaggitattcagaaatgitgatctgatgggggggggg	1			- 1
gttsgaatastagaatgttgucgttgugtgtguccagaaccaagaccaaccaaagaccaaccaaagaccaaccaaagaccaaccaaagaccaaccaaagaccaaccaaagaccaaccaaagaccaaccaaagaccaaccaaagaccaaccaagaccaagaccaaccaagaccaagaccaagaccaaccaagaccaagaccaaccaagaccaaccaagaccaaccaagaccaagaccaaccaagaccaaccaagaccaaccaagaccaaccaagaccaaccaagaccaaccaagaccaaccaagaccaagaccaacaa	)	attactadatatatagagaratataatcctataacaaatagagactacagtattttc		í
gtaaatccgaaagaccaagtccagatccagaccagatccagaaccagatccagaccagaaccagaccagatcagatccagatccagatcagatccagatccagatcagatcagatccagatagat		aaaactcaggttactcaagaaatgttategtgaagtgatgatgatgattcagca		1
gaaccagatccagatccagatccagatccagatcagatc	l l	ggttggaataatgagaatgttgtacgttatggtgytgyaagaggtgaagagg		1
gaaccagatccagatccagatccagatccagatcagatc		gtaaatccgaaagacccaactccagggccgccggttgacccagaaccagaaccag		1
gaccggatccggattcagattgatcagattcagattgatcagattcagattgatcagattcagattgatcagattcagattgatt	i			ł
gataggactagaatcagatcagatcagatcagatcagat	1			- 1
gactcagaatcagattcaattcattc	1			- 1
gattcagattcagattcagattcagattcagattcagattcagattcagattcagattcagattcagatgagacagac	1			- [
gacagcgactcagatcagatcagatacagatactagatactagatatyagattagatagatagatagatagatagataga	l	l		- 1
gactcagacaga		gattcagatagcgattcagattcagattcagattagatcagattcagacagt		
gattcagactagattcagattcagattcagattcagactcagactcagactagacgagattagattcagattcagactagactagattcagattcagattcagactagacgagattagattcagactagacgagattcagactagagattcagactagagattcagactagagattcagattcagattcagattcagacaga	1	gacagcgactcagaatcagatagcgactcagatagcgattcagatagcgattca		- 1
gactagactcagattcagattcagattcagatgagattcagatcagactcagatcagatcagatcagatcagatcagattcattc	Į.	gacteggacteagacagtgatteagacteagacagtgatacagacteagacteagactea		
gactagactcagattcagattcagattcagatgagattcagatcagactcagatcagatcagatcagatcagatcagattcattc	ī	gatteagacagegaeteagatteagacagegaeteagacteagatagacagegaeteagacaga		- 1
gattcagattaggattaggattaggattaggattaggattagattagattagattatag gattcagattaggattaggattaggattaggattaggattagattagattag gattagattaggattaggattaggattaggattaggattaggattagattag gattagattaggattaggattagtagtaggattaggattaggattag gattaggattaggattaggattaggattaggattaggattaggattag gattaggattaggattaggataggataggattaggattaggattag gattagatggattaggataggataggatgattaggattaggattag aggataacacaaatatggaacagatggtgtttacaagaaaggagataag agcgaaaacacaaatgaacattatttggtgcaatggtgettacaagaaggagataag agcgaaaacacaaataggaacattagtggtgattaggattataggattacta ttgtttagaaaacgaagataataagaaaggag attaggataaaaggataataggagattaggaggattaggattaggat gattagagataaacaaggatagtgtgagattaggtgataaggatgtgatag gattagaggataacaaggatgatgtgagataaacgttgatggggattagga gattagaggataaaagaagttgatagatgataaattagatggtgataaaggattaggg tcatggagataataacaaggattaaatgatgataaatagatggttaatagg gactacaattattaaacaaggattaaatgataatacatac	1			- 1
gatteggatteggatteggatteggatteggatteggatteggatteggatteggatteggateggateggateggateggatteaecacacaaataggatgatgatgattetaaaggataaacacacaaaactgatgetttaccagaaacaggagataaaggagataaaggagaaacacaaatgaaggattattgggattattaggattaataatttggtattaggataaaggattatt	i			- 1
gattagattcatagatgatagatcattcat				ı
gacteggataggateggatteggataggacteggatetagatetagatetagatetagateggataggateggateggatteggataggaggateggattegataggaggategate	Į.			- 1
gacteggataggacteggatteggateggateggatetagatetagateggatatacacacacaaatatgaacagaaaggacateaatetaaaaggtagatatacacacacaaatatgaacagaaagcacateaatetaaaaggtagatetaaaacacacaaaactgatgetttaccagaaacaggagataaagaggaaacacaaatgcaagtetatttggtgcaatgatggattattaggateatactatttttgttggaaatgatggattattaggateatacatttttttgtgaaaaaaggagatatatggattaetaaggacacacttagtttgagaaggacaacaaggacaaggacaacaaggacaactaggttgacaaggacaactaggttgacaaggacaactaggttgacaaaggacaactaggttgactacaggacacactaggttgactacaggacacactaggttgactacaggacacactaggttgactacaggacacactaggttgacaactacactaggacacacac	1			- 1
agagttacaccacaatatagaaaaaatgagagtstattacaagaaaacagagagataag cattctaataaggtacaaaaacaacaaaaatgatgattattacaagaaacagagagataag agcgaaaacacaaatgcaactttatttgytycaatgatgycattataggatcattacta ttgtttagaaaacgcaagcaagatcataaagaaaaagag  12. atgaaaaaggcaaattatgycatcatcattagcagtygcattaggtgaacaggttacagca gcaggtacaggacatcaagcacacgctyctyaagtaaacgttgatcaagcacacttagtt gacttagcgcataatcaccaagatcaattaaatgcagtccaattaaaatggtycatat gactcactttytaaaagatggttccaattaaattcacttcaaatggtycatat gactcactttytaaaagatggttcaaatgtaaatcagttagagttgcag tcatggagctatgaagcagctaatggtcaaactgctggtttctcaaacgttgcaggtyca gactacactacttcatacaaccaaggttcaaatgtacaatcagtaagctacaat tcaggtactcaagttagagctgtttcagctccaacttaccatacatcaagcacttca actactcaagttcagtgagattaagcaatggtaatactgaggtgctacaggttcatca gcagctcaaatcatggctcaacgtactgytgtttcagagttcatcaggttctacag gcagctcaaatcatggctcaacgtactgtyttacaactcaagtgcttcaaggttattc gcagctcaaatcatggtcaggaaacaacactgttgaccaacaacacacac	i i			ı
cattctaataaggtatcaaaacaaaacatgatgttattattaggatcattaata aggaaaacacaaatgaaacttaattgytgcaatgatggcattaataaggatataata ttgtttagaaaacgcaagatcataaaggaaaaaagg  atgaaaaaggaaattatggcatcatcattaggagtggcattaggtgaacaggttaggca gcaggtacaggacatcaagcacagctgctgaagtaaacgttgatcaagcacacttagtt gacttagcgcataaacacaaggtctgaaaatgatcaataaaggatggcatat gactcactttgtaaaagatggtttccaatataacttcaaatggtactacatgg tcatggagctatgaagcagatcaaactgatggtttctcaaacgttgcaggtgca gactcactacttcatacaaccaaggttcaaatgtacaatcagtaggtactacaatgcacaa tcaagtaactcaaacgttgaagctgtttcagctcaacttacataca	1	gaeteggatagegateggateagagagagagagategaategaagtgaagtaaac		- 1
agcgaaaacgcaagcaagtcttatttgycgcatgaaggcattattaggcattattaggagtctattagaaaacgcaagcaa		agagttacaccaccaataatgaatagatagataatttaccacaaacagagataag		- 1
12. atgaaaaagcaattatgcatcataaggaaaaaggg atgaaaaaggcaacttatgcattaaggaataaggggattaaggaaaaaggtgataaggaaattatggcatcaagcaacacttagtt gacttagggacatcaagaacaatcaattaaatta		cattctaataaggtatcaaaacacacacacactgatgatgattacta		- 1
12. atgaaaaagcaattatgcatcataaggaaaaaggg atgaaaaaggcaacttatgcattaaggaataaggggattaaggaaaaaggtgataaggaaattatggcatcaagcaacacttagtt gacttagggacatcaagaacaatcaattaaatta	1	l accommence and to the control of t		ı
atgaaaagacaattatggcatcatcattaggcagtggcattaggtgtaataggttacaggttaggagtacaggacagaca		tratttagaaacgcaagcaagatcataaagaaaaagcg		-1
geagtacaggacatcaagcacagctgctgagtaagtaacttgtgttgatcattgacttaggactaattaggactaattaggactaattaggactaattaggactaattaggactaattaggactaattaggactaattaggactaattaggactaattaggactattagagacgtttcaattagactcaattagacgttgaaggtgactaattgactacttgaaggactattgaggactaattggactaattgagactaattgagactaattgagactaattgagactaattgagactaattgagactaattagacaattcaagtagtactaattcaattcaatcaa		T		ŀ
gacttagegeataateacaagateattaaatteatteatteaattaggtagtaggeatateattaggageatateacatttytaaaagatggtteaaattaaatteatteaatteaa	12.			- 1
gacatccacttytaaaagatggtttccaatataatttcaattgattcaaaggtgcaaggtgcaagagatgagatatgagagcaatggttcaaaatgtacaatcaaagatgcaagatgaagatgattcaaatgtacaatcaaatgtacaattaaatcaagattgaaggtgcaagattcaaatgtaactcaaacgttgaaggtgtcaaagtcaagttcaaggtactaaatgtaacaatcaagtagtacaagttcaaagtacaaggtactaaggtaatactgggtgctactggttcatcaggtcaacatcaggtccaaatcaatggcaatcaaggtactggtgtttcaaggtgctcaacatcaggtggttcaacaggtcaggtcaacaaggtcaggtcaacaaagcagtggttcaacaggtcaggttcaacaagtcaaggtcaatacaaggtcaggttcaacaaggtcaatggtcaaagaaaacacatggtggtcaacaaagcagcaggtttaaaggcataaaagcaacaaggtttaggtggttggggtcaacaaaacaatggttaaaggttaaaggttaaggtggttggggtcaacaaagcacaaatggatattaggcaaagagaatgattaagacaagagaatttaggagaatttaaagataataaagttaaaagaacaacaaggaaatgataacaattgatgacaaggaaatgatgaaacaagaacaacaacaacaacaacaacaacaacaacaa		gcaggtacaggacattagcacacgcacttagatgcacactcaatcaa		- 1
teatggagetatgaageagetatggteaaactgetggttattettaaatgtetgagetaggetggagetggagetggagettetteaatgteaaatgteaaatgtaagetagagetteaatgteaaatgtaaateageaetteaatgteaaatgtaaateageaetteaaatgteaatgteaatgtaatacageaetteaactgeageteteaageteaatggtattaageaatggtaatacageageteteageteaatggteataageagetgetaatggetgetaataggeteaatggetgetaatggetgetaatggetgetaatggetgetggetg		gacttagcgcatantcaccaagattaactataggcataggactacatag		- 1
gactacactacttcatacaccaaggttcaaatgtacactactactactactactactactactactactacta		gacatccactttgtaaaagatggtttcaatattattattataaaagatgataca		- 1
gactacactacttcatacaccaaggttcaaatgtacactactactactactactactactactactactacta		teatggagetatgaageagetaatggteaaactgetggtygtetetaaactgeageageageag		- 1
tcaagtaactcaaacgttgaagctgtttcagttctaatttactactacsgttcactagttcatca actacttcaagttcagtgaagttagtgaatagtaatactgcaggtgctaatggttcatca gcagctcaaatcatggctcaacgtactggtgtttcagcttctacatgggctgcatcatc gctcgtgaatcaatggtcaagtaatgcttacaaccatcaggtgcttcaggtttattc caacctatgcaggttggggtcaacaaacactgttgaccaacaaatcaacgcagctgtt aaagcatacaaagcacaaggtttaggtgcttggggattc  13. ttgggaggatatttaattatgaaaaaaatgttacagctacaatcacaaggagactt gcacctatcgcatttgcaggacatgatgcacaagcgcagaacaaaataacaatggatat aattctaatgacgctcaatcatacagctataccattgatgacaaggtaattat cattcacttggacaggaaattggaatccaagtcaattaacaattgatgacacaactactac tacaacaactacaatactataagttataacaatgcatcttacaataactactacac tacaacaactacaatactataagtatataacaatgcatcttacaataactataattact ggtggttcaggtgcaagttatagcacaacaagtaaatagttcatggacaacagagagcacactacaca gcgccatctcaaatggtcgttcaatttctaatggttatgcatcaggaggaaattggttcaaca tggggtaacgcaagtaattggctaacgcagctgcaccatctggctaacaaggaacaa tggggtaacgcaagtaattggctacacacaagcacacaatacaggcaacaat acaccaaaagtggctaccacttgcaacacacaagcacattacggtcatcatggt	•			- 1
actacttcaagttcagtgagattaagcaatggtaatattgtagtgtgtatattg gcagctcaaatcatggctcagtgtgttttcagcttctacatgggctgcaatcatc gctcgtgaatcaaatggtcaagtaatgcttacaaccattcaggtgcttcaggtttattc caaactatgccaggttggggtccaacaacactgttgaccaacaaatcaacgcagctgtt aaagcatacaaagcacaaggtttaggtgctttggggattc  13.				ı
gcagctcaaatcatggctcaagtaatggtgtttagatgtgttttatataggttgtttatte gctcgtgaatcaaatggtcaagtaaatgcttaaacccatcaggtgtgtttatte caaactatgacaggttggggtcaacaaaacctgttgaccaacaaatcaacgcagctgtt aaagcatacaaagcacaaggtttaggtgcttggggatte  13. ttgggaggatattaattatgaaaaaaatcgttacagctacaatcgctacaggagactt gccactatcgcatttgcaggacatgatgcacaagccgcagaacaaaataacaatggatat aattctaatgacgctcaatcatacagctatacgtatacaattgatgcacaaggtaattat cattacacttggacaggaaattggaatccaagtcaattaaccaagcaaacaacaatactac tacaacaactacaatcatataggtataacaatgcaatcatacaactactactacaaccaac				- 1
gctcgtgaatcaaatggtcaagtaaatgcttacaactatagtgtteaggactatteaggtctatescaactatgccaggttggggtcaacaaaaacactgttgaccaacaaatcaacgcagctgtt aaagcatacaaagcacaaggtttaggtgcttggggattc  13. ttgggaggatatttaattatgaaaaaaatcgttacaagcgcagaacaaaataacaatggatat acattcaatgcatttgcaggacatgatgcacaagcgcagaacaaaataacaattgatat aattctaatgacgctcaatcatacagctatacgattaacaattgatgcacaaggtaattat cattacacttggacaggaaattggaatccaagtcaattaacgcaaaacaacaacaactacac tacaacaatacaat				- 1
caaactatgcaggttggggtcaacaacaactgttgatcaataattaacgtgggttcaaaagcacaaggtttaggtgttggggattc  13. ttgggaggatatttaattatgaaaaaaatcgttacagctacaatcgctacagcaggactt gcactatcgcatttgcaggacatgatgcacaagccgcagaacaaaataacaatggatat aattctaatgacgtcaatcatacagctatacgtatacaattgatgcacaaggtaattat cattacacttggacaggaaattgggatcaattatacgcaacaacaacacacac				- 1
13. ttgggaggatattaattatgaaaaaaatcyttacagctacaatcgctacagcaggactt gccactatcgcatttgcaggacatgatgcacaagccgcagaacaaaataacaatggatat aattctaatgacgctcaatcatacagctatacgtatacaattgatgaccaaggtaattat cattacacttggacaggaaattggaatccaagtcaattaacgacaaaacaacaatactac tacaacaactacaatcatatagttataacaatgcaatcatacaatacatac	i	gtttgtgaattaatagstatgaacaacaacaacaacaacacaac		- 1
13. ttgggaggatatttaattatgaaaaaatcgttacagctaatatgctacagaggactt gccactatcgcatttgcaggacatgatgcacagccgcagaacaaataacaattgatat aattctaatgacgctcaatcatacagctatacgtatacaattgatgcacaaggtaattat cattacacttggacaggaaattggaatccaagtcaattaacgcaaaacaacacatactac tacaacaactacaatactataagttataacaatgcatcttacaataactactataatcat tcatatcaatacaatacatatacaaacaa		Caaactatgccaggtcggggtctaattagttg		- 1
gccactatogcattigcaggacatgatgcacaagccytagacaaaataatatagatataa aattetaatgacgctcaatcatacagtataacgtatacaattgatgcacaaggtaattat cattacacttggacaggaaattggaatccaagtcaattaacgcaaaaacacacatactac tacaacaactacaatacttatagttataacaatgcacttacaataacaaataactattatact tcatatcaatacaatactatacaaacaa		aaagcacaaaggcttaggtgctcggggutte		ヿ
gccactatogcattigcaggacatgatgcacaagccytagacaaaataatatagatataa aattetaatgacgctcaatcatacagtataacgtatacaattgatgcacaaggtaattat cattacacttggacaggaaattggaatccaagtcaattaacgcaaaaacacacatactac tacaacaactacaatacttatagttataacaatgcacttacaataacaaataactattatact tcatatcaatacaatactatacaaacaa	13.	ttoggaggatatttaattatgaaaaaaatcgttacagctacaatcgctacagcaggactt		- 1
aattetaatgaegeteaateatacagetataegtataactgatgtataagstataegeteetee cattacacttggacaagsaaattggaatceaagteaattaacgateattacactataetactaetacaactaactaetacaactaact		I was a bar bar a bar bar a carract ratification and a carract additional and a carract bar a carract according to the ca		i
cattacacttggacaggaattggaatcaagttaattaatgtaatactattatte tacaacaactacaataattatagttataacaatgactcttacaataactactataatcat tcatatcaatacaataactataacaacaataagtcaaacaagtaactactaataatt gggggttcaggtgcaagttatagcacaacaagtaataagttcatggactaacaactgca ggggctactctcaaatggtcgttcaatttctaatggttatgcatcaggaagtaacttatat acttcaggacaatgtacttattatgtatttgatcgtgttggtaggaaaattggttcaaca tggggtaacgcaagtaattgggctaacgcagtgtggttatacagtgaacaat acaccaaaagttggtgctatcattgaaacaacacaaggctattacggtcatgttgcttac acaccaaaagttggtgctatcattgcaaacaacacaaggctattacggtcatgttgcttac				ı
tacaacaactacaatacttatagttataacaatagtacttataaacaataactattatacttatacttatacttatactattat	'			- 1
tcatatcaatacaataactatacaacaatagtcaacagtaataatattactattagggggttcaggtgeagttatagcacacagtaataatgtcaacactgca ggtggttcaggtgeagttatagcacaacaagtaatgatcatcagggagtaacttatat gcgccatcttcaaatggtcgttcaatttctaatggttatgcatcagggaggtaacttatat acttcaggacaatgtacttattatgtatttgatcgtgttggtgggaaaaattgggttcaaca tggggtaacgcaagtaattgggctaccgcagctgcatcatctggctatacagtgaacaat acaccaaaagttggtgctatcatgcaacacacacaaggctattacggtcatgttgcttac acaccaaaagttggtgctatcatgcaacacacaaggctattacaggtcatgattacggt		Carractery and application of the control of the carracter and the		ŀ
ggtggttcaggtgcaagttatagcacaacaagtaataatgttcatgtgattatctcatgtg gcgccatcttcaaatggtcgttcaatttctaatggtgttatgcatcaggaagtaacttatat acttcaggacaatgtacttattatgtatttgatcgtgttggtgggaaaattggttcaaca tggggtaacgcaagtaattgggctaacgcagctgcatcatctggctatacagtgaacaat acaccaaaagttggtgctatcatgcaaacaacacaaggctattacggtcatgttgcttac		Lacadeac Lacadeactideagteatheacharteachartactateacharteach		J
ggtggttcaggtgcaagttatagcacaacaagtaataatgttcatgtgattatctcatgtg gcgccatcttcaaatggtcgttcaatttctaatggtgttatgcatcaggaagtaacttatat acttcaggacaatgtacttattatgtatttgatcgtgttggtgggaaaattggttcaaca tggggtaacgcaagtaattgggctaacgcagctgcatcatctggctatacagtgaacaat acaccaaaagttggtgctatcatgcaaacaacacaaggctattacggtcatgttgcttac		ECAERICAAEACAACAACAACAACAACAACAACAACAACAACAACA		ļ
gegecatetteaaatggtegtteaattettattggtetteggggaaattggtteaaea actteaggacaatgtaettattatgtatttgateggtgttggtgggaaaattggtteaaea tggggtaaegeaagtaattgggetaaegeagetgeateatetggetataeagtgaaeaat tggggtateggtggtgetateatggaaaeaeaeaaaggetattaeggteatgttgettae acaccaaaagttggtgetateatgaaaeaeattattteaggaatgaaetatgagaatggt				
acttcaggacaatgtacttattatgtatttgatcgggtgygygygaaanttygttaata tggggtaacgcaagtaattgggctaacgcagctgcatcatctggctatacagtgaacaat acaccaaaagttggtgctatcatgcaaacacacaaggctattacggtcatgttgcttac acaccaaaagttggtgctatcatgcaacacatttcaggatagaatgactatgacatggt				
tggggtaacgcaagtaattgggctatcatgcgatcatttggtaatagtgutatataa acaccaaaagttggtgctatcatgcaaacaacggctattataggctatgttgcttac				
acaccasaagttggtgctatcatgcasaccasagctattatggttatgttgttat				- 1
				1
gctggtgtgttacgtctcgtacaatttcagcaaaccaagcaggttcatataatttcatt				
gctggtgtgtcacgtcccgcacaaaaaaaaaaaaaaaaa		gregated and the control of the co		
		Arradiadegaceaceaceaceaceaceaceaceaceaceaceaceacea		

1.44

14.

15.

S í

Secretarion of the con-

.

÷

ļ.

一般に さいざい

18.

19.

1.00 to 1.00 t

第十六日本語によることに 1000年

20.	atggccgtattttcaaaagagaaaaagagagagatgtatcgttgtgatagaaacatttaaa gcgtttgtaattgataaagatgagagtggtaaagtgacaccaactttcaaacaatttatcg cctactgatttacctaaaggagatgtgctgatagattaaagtacattactctgtataaattat aagatgctttacctaaaggagatgtgctgattacagtacattactctgattcca agaatgctttagcgactcaagaccataatgcagtcgtaaaatcgtatcctatgattcca ggaatagatttagcggaacaattgttgaatccgaagcaccaggctttgaaaaaggagaa caagtaattgtaacgagttgacctaggtgtcagccattatggcggttttagtgaatat ggcgtgtaaaatcagaatggattatcaagcttcctgatactttaacattagaaggaatca atgatatatggcacagctggttatactgcggtttagcaattgaaagattgagagatca atgatatatggcacagctggttatactgcggtttagcaattgaaagatgtgtgtg	
21.	atgaaaaattagtaacagcaactacgttaacagcaggaatcggcacagcattagtaggt caagcatatcatgcagatgctgcaaaattatacaaattacaacaactataactacaac acaactacaacgactacacgacaactacgacaactacatcatcaattcacattct ggtaacttalacactgcaggacaatgtacttggtatgtatatgataaagttggcggagaa atcggttctacttggggaaatgctaataattgggctgctgcacaaggggctggattc acagtaaatcatacaccttctaaaggcgctatcctacaatcttctgaaggaccatttggt cacgttgcatagtggaaatgtaaacagtgatggttcagttacaatttcagaaatgaat tatagtggcgacctttctcagaagttctagaactatttctgcaagtgaaggaag	
22.	atgaagaaatcgctacagctactatcgcaactgcaggattcgctacatcgcaattgca tcaggahatcaagctcatgcttctgagcaagataactacggttataatccaaacgacca catcatatagctatacttacactattgatgcacaaggtaactaccattacacatggaaa ggtaactggcatccaagtcaattaaaccaagattaatggctactacagctattactactac aatggttacaataactataacaattacaacaacggttataagctacaataactacaagcgt tacaacaactactcaaataataatcaatcatacaacaaca	
23.	acytcaatgacatatagaatanaganatgycaaaattatccaccattacgttataatg gctgytytgattactttyaatgytygattcaagagtytyaattacaaccattygct gtygtytaatgaatyttcaaacgcagattatagagaagagtygac gtaactatgyttatgataagtatgagaataatccagatatgaagaagagttygat gctaccagaganagagggagagaattactcaaggaatyagaaactagaggagaa gctaccagaganagaggggagagaattactcaaggaaatgaaagtgyaggaaa tactytygtcaggaggggaacccttgaaactaatcttctctatatgactcytacctat cytaatattyaganaatcycagaagcgatggggagatctaanaccactttaataactgac gaanataagaagaangtgaaagatcaagtyggaatttactaanaccactttaaatactgac gaanataagaagaangtgaaagattaagtyggaattttactaaaacactgycaagaat accacttaanttygtgggattatgaaattygaaactctaatacttaacaatcacctt atattgctgaatgatcaattttcaantgaggaaaaaaatcactgccatataaa acttccgcccagatagtgacaantattacatttetgtggaaaagtgaacttyctaaa gycggaaatcagtgagaaaattatatttttagaaggaagagaagtgaacttyctaaa gycggaaatctagtagaaaaatgatatttttaaagatgaatttactacaaacgtaacttyctaaa gycggaaatcagtgaaaaagattaagattttataaagattcactcac	
24.	tccggcgtgcactttgaattaactaaa gtgaatgatttgaagcaatttctatatattgcgttagtatgtggtgtatagcaggtctt ggtgctttcttacatataccgcagtatccgagcatgacaattccacgtatagtagctatt ttaggaattatcagtgctatgttgacttttaaagacaagcaaatcagcgcctcattaaag tttagcgcattgttaattaatgtgctgccattatgcggtacctttgtagcttcaaat	

•

. :

.....

25.	gtgtctcgtgaaatgtcatatcattggtttaagaaaatgttactttcaacaagtattta atttaagtagtagtttagggcttgcaacgcacacgttgaagcaaaggataactta aatgggaaaaaccaactactaatttgaatcataatataacttcaccatcagtaaataag gaaatgaataataatgagactggacacctcacgaatcaaatcaaacgggtaatgaaga acaggttcgaataatgtgtgtaatcaaaccagattcgaataaccaagatccaaac cacaaacccaagtacagattcaaaccagaccaaaataaccaagccagatcaaa cctaaaccagatccagataaccgaaccaaaaccggatccaaaaccagatccagat ccaaagccaaatccggatcaaaaccagatccagataaaccagatccagatca aaccagaccag
26.	atgaaaantaaaaaacgtgttttaatagcgtcatcattatcatgtgcaattttattgtta tcagcagcaacgactcaagcaaattcagctcataaaagactctcaagaccaaaataagaaa gaacatgttgataagtctcaacaaaaagacaaacgtaatgttactaataaagataaaaat tcaacagcaccggatgatattgggaaaaacggtaaaatcacaaaacgaactgaaacagta tatgatgagaaacaaatatactccaaaatttacaattcgacttatcgatgatccaact tatgacaagaatgtattacttgttaaaaaacaaggctcaattcatcaaatttaaagtt gaatttcaaagaagaaaaaatcgtaaaactgaaatattacaattgcactattcaaatttaaagtt gaatttcaagtaaaaagaaaacgtaaaactgaaatattagaccaattgccgaaaaataa atttcaaatgcaaaaagtagacagtacatttatatagaccaattgccgaaaaataa atttcaactgcaaaaagtagacagtacattttcatatagccagtggtaaattcgatca caaaatatggacgaacttcatcaaaatagctactccaaaacggtggtaaatcag caaaattatgacacaattgccagcggtaaaaataactggcagtgcagtgtaaattctg tatgcgaatgacttgaagtaggtggaagtgaaaaacagaatgttgctcaaaaata tatgcaaaatactgaagaattgctactgtagaaaaccctgaactaagctttgctccaaaata agatacccagcattagtaagaagtggcttaaaccagaaattttaacttatttactaat gaaaagcaaatagaaaaacgcaattggaagaggaatacaacagaaattttaacttatttaatcaa agaaaccagaatagaaaaacgcaattgaagaagtgaaaaacagaaattttaactaatttta
27.	atgtatacacgtacagctacaacaagtgatagtcaaaaaaatattactcaagcttacaa tttaatttcttaactgaacctaattatgataaagaaacagtatttatt
28.	gtgytgaaatttatgaattatccaaatggtaaaccatatcgtaaaaatagtgctatagac ggagggaaaaagaccgctgcctttagtaatattgagtatggtgacgtggtattgtcactt gaaaaagatatcgaacattcaaatacgttttatctaaaagcgacattgcagttattcac aaaaagctacgcagtacaaatagttaatgtcaactatcctaagcggagtaaagctgtg attaacgaagcttatttcgtacaccttcaacaactgattacaacggcgtttatcaaggt tattaattgatttgat

.

100 M

29.

cycaagcaagaayutattaytayaattaaagacttttcaaatgaaaaataaatagcact cgaaatagtgaaattggcacagctgatgaaaaacaagcagcaatgaatcaaattaacgaa attgtgcttgaaacaattagagatattaataatgcgcatacattacagcaagttgaggct 

remarkani siledi.

PRINCIPLE OF THE PRINCI

aaagaagatgaagaagatgttactgttgaagaaaaagattcgctaaataatggcgagtca ctcgataaagttaaacatacgccgttcttcttaccaaaacgtcgtcgtcgaagaagatgaa gaagatgtggaagttacaaatgaaaacacagatgaaaaagtgttgaaagattaacgaacat tcaccactcttattcgcaaaacgacgcaaggataaaagaggaagatgttgaaacaacact agtattgaatctaaaagatgaggacgttcctttattattggctaaaaagaaaatcaaaaa gataaccaatccaaagacaaaaagtcagcatcaaaaaatacttctaaaaaggtagcagct aaaaagaagaaaaagacaaaaactaagaaaaa

. 14

The second secon

Handle of the

Ŕ,

.:.

THE STATE OF THE STATE OF

31.

32.

	gtgcaaaaaaagtaattgcagctattattgggacaagcgcgattagcgctgttgcgggaactcaagcaaatagcggcgattacaactcacacagtaaaaacgggtgaatcagtgtgggaaattcaagcaaattgcaactcacacagtaaaaacgggtgaatcagtgtgggaaattcaattaaagtattggatttcgattgctaaattaaagtactataatagcaatttaactcaattcaatctaatttcacaagcaggactcaactaact	·
34.	atgaataataaaaagcaagcaacaaatagaaaaggcatgataccaaatcgattaaacaa ttttcgattaagaagtattctgtaggtactgcttcaattttagtagggacaacattgatt ttttgggttaagtggtcatgaagctaagcggcgagaacatacgaatggagaattaaatcaa tcaaaaaagtaacgacagcccaagtgagaataaaacaactaaaaagttgatagtcgt caactaaaagacaattagcaaactgcaactgcagatcagcctaaagtgacaatgagtgat agtgcaacagttaaagaaactagtagtaacatgcaatcaccacaaaacgctacagctaat caatctactacaaaaactgcaatgtaacaacaaatgaataatcacactacaataag aatgaaactgataaaagtaatttaaacagcaaagatgttcaactacacctaaaaca acgactattaaaccaagaactttaaatcgcatggcagtgaatactgttgcagctcacaaa caaggaacaaatgttaatgataaagtaattttcaatattgcaattggatataa ggacatgttaatcagactactggtaaaactgaattttcaatattgcaattggatgttta aattaaaagcaaattaccaagtagttattgtgataaactgaattttaaaggacggcgatacatttacttt aaattaaaagcaaatttccgtccaggatcagtagttaccttcacaaactcaaaatta taaattggccaaagtaatttccgtccaggatcagtagttaccttcacaaactcaaaattta tataatgcccaaggtaatattattgcaaaaggtatttatagatag	64
	acatatacttttacgaactactagtagatcaatatacaatataaatagatgatagagattataaaatggaagta attgcatttgcgaaaacgtaaaaatgcaacaactgataaaacagcttataaaatggaagta actttaggtaatgatacatatagcgaagaaatcattgtcgattatggtaataaaatggac caacagcttatttaagtacaaaataatatacaaatgaagatttatcgcgtaattgac gcatatgtaaatcaacctaaaaatacatatactaaacaacgttgttactaatttaac ggatataaatttaatccaaatgcaaaaacttcaaaactttaaagatgttactgatcaaatc caatttgtggatagtttcaaccctgatacttcaaaacttaaagatgttactgatcaattc gatgttatttatagtaatgataataaaaacagctacagtcgatttaatgaaaggccaaaca agcagcaataaacaatacatcattcaacaagttgcttatccagataatgccaacaga aatggaaaaattgattatactttagacactgacaaaactaaataagttgctaaatagt tattcaaatgtgaatggctcatcaactgctaatggcgaccaaaagaaataaat	
	gatgaaaatggtaaatatcagttcactggtttaagcatgyaacttaagtgtagat tcaacaccagceggttatcacaccgacaactgcaaatgtaggtacaacatgacattagatag tctgatggactaactacaacaggtgtcattaaagacgctgacaacatgacattagatagt ggattctacaaaacaccaaaatetagtttaggtgattatgtttggtacgacagtaataaa gatggtaaacaagattcgactgaaaaaggaattaaagtgttatatttgcaaaac gaaaaaggcgaagtaattggtacaactgaaacagatgaaaatggtaaataccgctttga aatttagatagtggtaaatacaaagttatctttgaaaacctgctggcttaactcaaaca ggacaaatacaactgaagatgataaaagatgccgatggtggcgaagttggtgtaacaata acggatcatgatgattcacacttgataatggcgattacgagaagaaaacatcagatag gactcagattctgacagcgattcagactcagatgcgattcagattcagatagcgactca gatcagactcagacagcgattcagactcggatagcgactcagatcagatagcgactcagactcagacagcgactcagactcagactcagacagcgattcagacagcgactcaga	
-	gacagtgattcagattcagattcagattgattcagattcagattcagattcagattcagat gacagcgattcagatcaga	
35.	atggacatasattcagaagaatacaaacaagaggtacttatcaaagacgttgtcatgct gctgctcgcatactattagaatctggtgcagaaggtacgcgtgtagaagataccatgaca cgtattgcaasaaaacttggttacagtgaaagatacagcttgttacaaacactgtcatc cagtttacgttacattcggaatcgtttcctagaatatttagaattacctccgagataca aacttaataaaaatttctcaagctaataaaattttcgcgtcaaattacaaccatgaaat tctttagccgaagcaaaaacgcaacttgaaaaaatatatgttgctaagcgtgacagcagt cttccctttaaaggttttgctgcagcaatgattgcaatgagttcttatatatttacaagg ggtagattgattgatgtttaactgcgatattagcagtagttcaggatacctagtcat gaagatttagatgctaagttacacgacaagttatccaacaggtgacttgcaactagt attgggattacgcagttattggacatacacttattccaacaggtgacttggcaactat atcattggggcagtcatgcctattgtcctggtgtttaatacaacaggtaatcaggattactggtatttagtggacacatgttagtgtgtccaacaggatactagagattatttagttggtgacacatgttgatgtccaacacgaatcaattagaagcattaggttactgg tttggcatcggtgctggcgttggtagcgatttaattta	

	gtgattgctataatgaatgtaattatcgatgaaagaaaggaatgctatgacatttaat aaagtattattgagctggatagtcatattgattataacaactagcatatatctatttgg cagttggcgatatcaatgatgtatttaaccagtcattttaactattgttgagttagattaccag agattattagaagcattgttgacaggtatgatattaactgttgcaggccttatattcaa acagttttaaataatgcattggcagatagcttacattaggttggcaagcggcgctaca tttggttcaggattagcattatttttaggtttaacaacgtatatggattccgtattttca ataacatttagtttgataacattaataagtgtattagtcaattaggtcggtattgagccaa ggctatccagttagaatcttaatattaagtggtttaatgatggtggttattcaattac cttctatattttttgatttattaaaacctgtattaatataatagcagtattcgagtcattatctg tttggtggttttggtgatgcagaatactcaaatgtatcataatatagcaatcaat	
37.	ttgaaaaaattagcatttgcaataacagcaacatctggtgcagctgcatttttaacgcat catgatgcacaagcttctacacaacatacagtacaatctggtgaatcattatggagtatt gctcaaaaatacaacacttcagtagagagtattaaacaaaataaccaattaggagtat ttggtattccctggtcaagttatctcagtaggtggaagtgatgcacaaaatacgtcaaac acttctccacaagctggtcagcatcatctcatactgtacaagctggtgaatcattaaaat actattgctagcagatatggtgtttcagttgatcaattactgtacagcaataacttacgt ggtatttaatatgcctaaccaaacattacaaattcctaatggtggatcaggtggtaca acaccaacagctaccacaggtagcaatggcaatgcatcatcttttaatcaccaaaattta tacactgctggtcaatgtacatggtagcaatgcatcactctttaatcaccaaaattta acactgctggtcaatgtacatggtacgtagcatgcatgca	~ <b>3</b> .
38.	atgccagattcaatcacaattatagatgaaaacaaagtgattgat	
39.	atgggattttatcaaaaattcttgatggcaataataaagaaattaaacgtaaattctgctgataaagtttaagtgataatcgctttagagaaaaaacggcaattttaactgatgaaagaaa	

40.	gtgagggagagtatgtcgaatcaaaattacgactacaataaaaatgaagatggaagtaag aagaaaatgagtacaacagcgaaagtagttagcattgcgacggtattgctattactcgga ggattagtatttgcaatttttgcatagatcattggaatgaagtaaagctaaagaacgtatg ggattagtatttgcaatttttgcaatagatcattggaataaagctaaaagaagag atgaacgaaagcaggaacaaaaagagagagaatgagatgagattagattagacgaaaccaa atatcagcaattgccacagcagaatcaatatcaatatgtgccacctcagcaacaagcacct acaaagcaacgtcctgctaaagaagagaatgatgataaagcatcaaaggatgaaa gataaggatgacaaagcatctcaagataaatcagatgataatcagaagaaaactgatgat aataacaaccagctcagcctaaaccaacagcgcaacaaccaac	
41.	atgaatatgaagaaaaagaaaacacgcaattcggaanaaatcgattggcgtgcttca gtgcttgtaggtacgttaatcggttttggactactcagcagtaaagaagcagatgcaagt gaaaatagtgttecgcaatctgatagcgcaagcagaagcanaagtaagtagtagt gaaaatagtgttecgcaatctgatagcgcacaaacgtgagtgatactaaaaccgtca agcgttagtgctgcacctaaaacagacgaccaaacgtgagtga	
	anagaattaaacttaaatggtgtaatcgatagtgatggtaattagtgtgattattaggggagatagagtatggtaattgggtaatgggtaatgggatggatggaatgggatggaatgggatggaatgggatggaatgggatggaatgggatggaatgggatggaatgggatggaatgaattagtaatggaatttaataa	
42.	atgaattcaaatcacgctaaagcatcagtgacagagagtgttgacaaaaaatttgtagtt ccagaatcaggaattaataaaattatccagctacgatgactagaattaagaattcgccaaaa gtaaattgtagtaatttaactgacaataaaaactttgtagttctcgaagataaattgaat aagattgcagattcatcggcagctagtaaaattgtagataaaaactttgtcgtaccagaa tcaaagttaggaacattgtgccagagtacaaagaaatcaataaatcgcgtgaaatgtagca acaaacaatccagcttcacaacaagttgataagcattttgttgtcaaaggcccagaagta aatagatttattacgcaaaaccaagttgataagcattttgttgtgctaaaggcccagaagta aatagatttattacagacaaagataaaccaacacttcattactacgcaaacccactac aagaaagttattacttcatacaaatcaacaactgtacataaacgcaactaca gattcattaataaaacactttattgttaaaccatgaatcgcctagaatacacactca tctcaatctttaattacaagcatcattttgcagttcctggatatcacggcataaaatt gttacaccagggaatgctagcatcaattttgcagttcctggatgcacgacaaataaat	

43.	ttggagcatacaattatgaaaatgagaacaattgctaaaaccagtttagcactagggctt ttaacaacaggcgcaattacagtaacgacgcaatcggtcaaagcagaaaaaatacaatca actaaagttgacaagtaccaacgcttaaagcagagagcagacgagagaga
44.	atgacaacattaaaactaaacttaggtcaaagaagattctaaggaagattagaatagaatagaatagaaatagaaatagaaatagaatatagatatactactaaaagaaatttattataaaaagaagattaacattacattagatagcatccagttggtgatttctctttatatgacatatattagatacgtcattatattacataca
45.	caagaa atgagcgacacatataaaagctacctagtagcagtactatgcttcacagtcttagcaatt gtacttatgccgtttctatacttcactacagcatggtcaattgcgggattcgcaagtatc gcacattcatattttataaagaatacttttatgaagaa

46.	tcagttaagaggacaagaagaaagaaagtatagtattagaaagtattcaataggcgtggtg tcagtgttagcggctacaatgtttgttgtgtcatcacatgaagcacaagcctcggaaaaaa acatcaactaatgcagcggcacaaaaagaanacactaaatcaacgggagaacaagggaat gcgataacgtcacatcaaatgcagtcaggaaagcaattagcatatgcataaagagaat ggataaagtgaacagtgacagaaggtaaagatacgctcaatcatcaagtaaagcaatca ggtaaaagtggaacagtgacagaaggtaaagatacgctcaatcatcgaagcatcaatca	
47.	atgattratctattaaggggaagatgatcataaagttttgtgtattatataaaaagggggttgttttaatgaatraattattatatgatcatatcaatgacaagaggggtggtttt tttgtctatagtttaatggaggatactatgttttttttatccttttacgattaatggtaac aacactatttcgtcgatcatgttcatctagccattcgctcaatcataggtccacttatg ccctatgttgcactgattatgattttaattggtacaggttaccaatagtggagaggtact tttatgacttcaatcacaaacttggtcattacatta	
48.	atggttattatgaagaaaacaattttactgacgatgacaactcttactttattattagtatg tcgcctaactcggctcaagcatatacgaatgatagcaaaacattagaagaagaaaagaaa gcacacccaaacgacagttcaaagtgatatgaagacacggcggtatacttatacatat gacaaaacaacacgccaacaacaacaatcatcaaaacaagtacaatcat caacacgcaaatcaacggatcttaacaacaacaatcatcttcattaagtggtcag tatacgcacattaatgacgeaattgattcacaacacacgcctcaaacgacaatcat cctttgacaccagcaataccgaatgtcgaagacaatgagattaaattaacgcttt tcaaaagataacaaaggggttattacaggcatcyattagacgaattgattagacgaatta ccaatcgccgaatttaatgacgaaagccaatcagtcgcaagatgaattagacgattagat caaatcgccgaatttaatgacaaagccaagacgctgacggtaaacctttagactaggt aacggtaaaatcattgatcagcctcttatcacaagtaagaacaacttatatactgctgga caatgtacatggtatgtctttgataaacgtgccaaagatagacacacgattagaccattt tggggaatgctaaaaactgggcaggccaagcttcaagcaatggtccaagtagacaac gtgaaaaagttaatattgatgagaagatatctaagcaatggtcaatgatggtgaa taatcgtttcatcaagaagatgagatatctaagaattattaatta	
49.	ttggaggtatcgtcaatgaagccttatatacaacttgttgtgttcaagcaatggttacaa tacatcttgctcgtaaccaaccattgtcatcgcactcgtacttattggtatcggttaccgt gtagcacatgacaaccattgtcatcgcactcgtacttattggtatcggttaccgt gtagcacatgacaacttcaaaataccgattaccattcaagatttagaccaaaccactgca tcaaaatcattcgtcaataaaattaaacaatctgactatgtaactattaaaaagtcgat gasgatgaaagctatattgaagatgatgttactaaaaaggaagctatttaagtatgcaa attcctaaaggtttctctccaaaaattaaaagagaaccgtttaaaaagaaacggtaacagtta tatggtagagatgactttataggtggtattgctgtagaaattgttagtagttcattatat gagcagcaaattcctaacattatttatgaacaccttgaggatatgaaacagcatcaatcc atcgatgctatcaacaagtcctatcataaacatcacctgaatctaaaaatacaaatttgtg tcgcttactaaacaagccctatcataaacatacacctgaatctaaaaattcggggtattta tttgttagcgctgttcaagtagtacttcattatagttaaaccaacaagcacaac cgattatcacaaatacattaagccgtttcaaaccaacaaaca	

50.	atgattgaggtgacagagatgaacttttttgatatccataagattccgaacaaaggcatt ccattatcggtacaacgtaaattatggcttagaaacttcatgcaagctttcttcgtagtg tcctttgtttatatggctagtatttaattcgaaacatttatgaggggacaaaccgttt ttaaaagaggaaattggattatctacattagaacttggttatatcggattagcattagt atcacgtacggtttaggaaaanacattacttggatattttgtcgatggacgacaacaaaa cgtattatctcgttcttacttatctatcttggattatatggttatattagggattagcacaaaa cgtattatctggttcgtaatgggattattaattggattatttggcggacgacacaaaa cgtattatctggttcgtaatgggattattaaattgtactttggggacttaacggggtg ttcaattaggttggtggacctgcaagttattcaacgatttcaagatggggcccaagaacg aaacgtggccgatacttagggattctgaaatatatcatcacataatacggtggggccatagaacg ggtggtgttgcactttggggtgctaatgtattctcatggaaatgttataaggatgttc attttcccatcggtgattgcattacttattggtctgcaagaaattttaaagagatggcggtcgaaaa gaaacattggattctaaggtagtgatgacggaaattttaacattattatcgggaaaa gaaaatattgattctcaaggtatgacgaaatgggaaattttaaaaatatacctggga aatcctgttatatggatggaacggtttcaaacggatttacaacttagtaaaggcgatga gttaatacgatattctactttgaaattggtgcattagttttgaaattgtacacgtaacggt attaggacttattaaaaggtcgtcggaattgagcatttagcaagtttattatggggctac gttaatacgatattctactttgaaattgtgcatagattgtacgtatggttatgtttatagat tacatttggtgtcttattctacacaaatgctacaagtgtactagggttaacatttcattg tttgcattaggtgcgttaatctttggtcgcaattattaattggtgtatacttact	
51.	atgacaaagaagaaaacatattaaaagcaatcggtatttacagttttatagcgatgatg tttgtcatcatttatatccactactgtggacatttggcattttcccttaatccaggtacg aacttgtattgta	
52.	gtgatgganaatagtacgacggaggggtaatgaaggacgatgatgtatgatgaaatg actgtggaagagggtttaattacgatgaataaagaagatcacgtagtaccgttagcagtt cgaaaggcaatacacaattgacaaaatgataattaaaaaatg ggtggacgattgatttatatcggtgcaggtacaagtggaaggttgggtgtcttagatgca gcggggtgtgtacctacattcaatactgaccctcatgaaattataggtattattgcgtgt ggacaactgctatgacgatggatgtgaaaggtgcggaaggtcacaaaaaattaatgggaa gaagattgaaaaatatagatttaacatcaaaagatgtcgttataggaattgccgcgat ggcaaaacgccatatgttataggcggttaacattttcacaaaagatgcgttataggaattgccgcgat ggcaaaacgccatatgttataggcggttatacatttgcaacaatcggtgctacaaca gtatcattcattcatgcaatgaacatgcagttaaaagtagtcgttaaagtagcagaa gttaaagttggtccagaagtattaactgttcaacacgtttaaagtctggtacagcacaa aagttaattttaaatatgttaacacatcacaatggttggt	
53	ttgcaatacataattcgttatattagatgactttacaatacatgaggggtattaat ttgaaaaagaaaaacatttattcaattcgtaaactaggtgtaggatttgcatctgtaact ttagaaaaggaaaaacatttattcaattcgtaaaactaggtgtaggatttgcatctgtaact ttaggtacattacttatatctggtggggtaacacctgctgcaaatgctgcgaaacacgat gaggtcaacaaatgcttttatcaaagatgatctaaatagcctaacttaaatgcttaaa cgcaatggttttatccaaagccttaaagatgatccaagccaaagtgctaacgttttaggt gaggtcaaaaacttaatgacttcaagatccaagccaag	

54.	ttggataaaaagtctgagaagcggggcattaaaatgacggtacaaagtgcatatatacat attccattttgtgtaagaatatgtacatattgtgatttcaataaaattttatacagaat caacctgtagatgagtacttagatgagcgtaatatagtgagattcaaaaaatattttatacagaat atctaaagacaatgtagtgagtggggacaccaacggccctttctattaataagg aactttaaagcaatacgtgatacgtttacaatcacaggcggtatacatttgaa gcaaatcttaaagcgagttaactaaagaggaagtcaactattagagaaatatggagtaaaa aggattcaatggggttcaaacattcaagcggggttattgtctgttttaggtagaacg cacaatactgaagatatttaacattcaggcgggttaatgcagttaaatca cacaatactgaagatatttaacattcaggggttaaatgcagaagtattaaatca cacaatactgaagatatttaattta
55.	MRNIENIANGOSVOHPPIVHKATOGVTAQGKDYWTLHLQDKSGEIEAKPWTATKNDMATI KPEEIVHVKGDIINYRGNKQMKVNQIRLATTEDQLKYPOPVDQAPISPABIQBEISHYLL DIENANLORITRHLLKKYOBRPYTYPAASSHEHNFASGLSYHVLTMLRLAKSICDIYPLL NKSLLYSGIILHDIGKVRRLSGPVATSYTVEGNILGHISIASDEVVPARELNIEGEBIM LIRHMILSHHGKUBYGSPKLPYLKEAHILCYIDNIDARMNMFEKAYKKTDKGQFTDKIFG LENRRFYMPESLD
	MNKHHPKLRSPYSIRKSTLGVASVIVSTLPLITSQHQAQAAENTNTSDKISENQNNNATT TOPEDDTNOTOPATOPANTARNYPAADESLKDAIKDPALENKEHDIGPEQVHPQLLDKN METQYYHPFSIKDPADVYYTKKRAEVKILDINTASTMKPEVYENDKLLVKLVSYSPYPE DHAYTRPVSDGTQELKIVSSTQIDDGEBTNYDYTKLVPAKPIYNDPSLVKSDTNDAVVT KDQSSSVASNQTNYINTSRQNTSTINNANNQPQATTRHSQPAQPKSSTNADQASSQPAHET NSNGNIDMETNESSNQSDVNQQYPADBSLQDAIKNPAIIDKEHTADNMRPIDFQMXNDK GERQPYHYASTVEPATVIFTKTGPIIELGLKTASTWKKPEVYBGDKLLYELVSYDSDKD YAYIRPPVSNGTRRVKIVSSIEYGBNIHEDYDYTLMVPAQPITNNPDDYVDEETYNLQKL LAPYHKAKTLERQVYELEKLQBKIPEYKABYKKKLDQTRVELADQVKSAVTEFENVTPT NDQLTDLQBAHPVVPESERNSBSYMDGFVEHPPYTATINGGKYVVMKTKDDSYNKDLIVE GKRVITVSKDPKNNSRTLIPPYIPDKAVYNAIVKVVVANIGFEGQYHVKINDQINTKDD DTSQNNTSEPLNVQTGQBGKVADTDVAENSSTATNPKDASDKADVIEPESDVVKDADNNI DKDVQHDVDHLSDMSDNNHFDKYDLKEMDTQIAKDTCKNDADNSVGMSSNVDTDKDS NKNKDKVIQLMHIADKNHTGEAKAKLDUVKQNYNNTDKVDADNSVGMSSNVDTDKDS NKNKDKVIQLHHADKNHTGEAKAKLDUVKQNYNNTDKVDKTTEHLPBJIHKTVDKTV KTKERGATPSKENKLSQSKMLPKTGETTSSQSWWGLYALLGNLAFIPKFRKESK
57 <u>.</u>	Msdfnhtdhsttnhsqtpryrrpkfpwfktvivaliagiigallvlgigkvlnstilnkd Gstvqttnnkggnqldgqskkfgtvhemiksvaptivgvinmqkassvddllkyksskps Eagvysgviyqinnnsayivtnnhvidganeirvqllmkkqvkaklvgkdavtdiavlki Entkgikalqfansskvqtgdsvfamgnplglqfansvtsglisasertidaettggntk Vsvlqtdaainpgnsggalvdingnlvqinsmkiaatqvegigfaipsnavkvtieqlvk Hgkidrpsigiglinlkdipeeereqlhtdredgiyvakadsdidlkkgdiiteidgkki Kddvdlrsylyenkkpgesvtvtvirdgktkevkvklkqqkeqpkrqsrserqspgqdr dffr
58.	VNQQQEKTTITPTTINPLIGEKVGEGEPTTEVTKEPVDE I TOFGGESVPQGHKDEFDPNIL PIDGTEEVPGKPGIKNPETGEVVTPPVDIVTKIEPKAGE PEVTKEEI PFEKKREPNPDLK GEEKKVQGEGYGEKTTITPTTINPLIGEKVGEGEPTTEVTKEPVDEI TOFGGESVPQGH KDEPDPNLPIDGTEEVPGK PGIKNPETGEVVTPPUDUTKHGPKAGE PEVTKEEI PYETK RVLDPTMEPGS PDIKVAGKGENGEKTTTTPTTINPLITGEKVGEGEPTTEVTKEP IDEI VNY APEI I PHGTREEI DPNLPEGETKVI PGKDCLKDPETGEI I EEPQDEVI I HGAKDDSDADS DSDADSDSDADSDSDADSDSDSDSDSDSDSDS
59.	MKSLKTVICKNIKKHIKSVILALLVLMSVVLTYMVMNFSPDIANVDMTDSKKSETKPLTT PMTAKIDITTIPPQIIHSKNDHPEGTIATVSNVNKLIKPLKNKEVKSVBHYRENHAMIP DLNSDFILFDFTYDLPLSTYLGQVINMARKVPAHFNFNRLVIDHDADDNIVLYAISKORH DYVKLITTTKNDHPLDALAAVKDMQPYTDIITTKDDTIDRTTHVFAPSKPEKLKTYKNVF NTISVSKMMAILPDDSTIVASSKSGUTTYNNNTGVANKYHYKNLSEDEASSSKM EBTIPGTPDFINGHGGPLNEDFRLFSTNNQSGBLTYQRFLNGYPTRKEGSNQIQVTWGB KGVFDYRRSLLRTDVLUNSEDNKSLPKLBSVRSLANNSDINFEKVTNIAIGYEMQDNSD HNHIBVQINSELVPRWYVKYDGEMYVYNDGRLB

60.	MSKRQKAFHDSLANEKTRVRLYKSGKNWKSGIKEIEMFKINGLPFISHSLVSQDNQSIS KMMTGGLKTTAVIGGAFTVNNIHDQQAFASDAPLTSELNTQSETVGNONSTTIEASTS TADSTSYTKNSSSVOTSNDTVSSEKSEKVISTINSTNOQEKLETSTESETSKNTTSSS DTKSVASTSSTEQPINTSTNQSTASNNTSQSTFPSSWLNKTSTTSTAPVKLRTFSRL AMSTFASAATTAVTANTITVNKDLKQWTTSGNATVDQSTGIVVILTQDAYSQKGAITL GTRIDENKSFHFSGKVNLGNKYBGHENGGDGGFAFSPQVLGSTGLNGAANGIGGLSNAF GFRIDENKSFHFSGKVNLGNKYBGHENGGDGGFAFSPQVLGSTGLNGAANGIGGLSNAF GFRIDENKSFHFSGKVNLGNKYBGHENGGDGGFAFSPQVLGSTGLNGAANGIGGLSNAF GFRIDENKSFHFSGKVNLGNKYBGHENGGDGFAFSPQVLGSTGLNGAANGIGGLSNAF GFRIDENKSFHSGKVNLGNKYBGHENGGDGFAFSPQVLGSTGLNGAANGIGGLSNAF GFRIDTHTPTQPFDINNGDFKWHTWKYAGQTYTTNSSTADNAAKLN VQFTNMTFQDFDINNGDFKWHTWKYAGQTYTTNISDTAKSGTTNFSLSHTASTGATN VQFTNMTPQDFDINNGDFKWHTWKYAGQTYTTVISGTATTYSSSTADNAAKLN VQFTNMTTQDFDINNGDFKWHTWKYAGQTYTTVISGTATTYSSSTADNAAKLN VQFTNMTTQDFDINNGDFKWHTWKYAGQTYTTVISGTATTYSSTADNAAKLN VQFTNMTTQDFDINNGDFKWHTWKYAGQTYTTVISGTATTYSSTADNAAKLN VQFTNMTTQDFDINNGDFKWHTWKYAGQTYTTVISGTATTYSSTADNAAKLN VQFTNMTTQDFDINNGDFKWHTWKYAGQTYTTVISGTATTYSSTADNAAKLN VQFTNMTTQDFDINNGDFKWHTWKYAGQTYTTVISGTATTYSSTATTATTYTTY TSVDSSYASTYNDTNKTVKWHTANGQSVYYTTDUKAPTYVGNQTI EVGKTMIPTVLTTT TSVDSSYASTYNDTNKTVKWHTANGQSVYYTTDUKAPTYVGNQTI EVGKTMIPTVLTTT TSVDSSYASTYNDTNKTVKWHTANGQSVYYTTDUKAPTYVGNQTI EVGKTMIPTVLTTT TSVDSSYASTYNDTNKTVKWHTANGQSVYYTTTUKAPTYVGNQTI EVGKTMIPTVLTTT TSVDSSYASTSISLISGSTKYSISLSDKASKTISTSTSISDSLSTSTNTTTITVV DITAPTVTPI EDGSSEVYSPISIKLADDNSAKRILSGSTGGTQQSVSTSKADSQSAB TSTSGSIVVSTSASTEKSE SUSLEDSBARKSLSTSESSTSSTSISLNSGSSTSSTSTSTSTSTSTSTSTSTSTSTSSS DSASKSTSLSDSISNASTSKSSSSLSTSTSDLKTSTSSSSSSSSSSSSSSSSSTSSSSSSSSSS	
61.	MPRIKILTYLLSTTLVLPTLVSPTAYADTPOKDTTAKTTSHDSKKSNDDSTSKUTTSKOI DKADKNYTSNQDNIDKKFKTIDDSTSSNNIIDTYTKNIPOTNINDLITYNKYDDNYSLT TILQNLFYLNSDISDYDQPRWEKSTYDSNKNSDNSIKNDTUTQSSKQDKADWQKAPKSN NTRSTSNKQPNSPKPTQPYNQSKSQPASIDKANQRSSSKDNQSHSDSALDSILDQYSSDA KKTQKDVASQSKKUKNBKSNTKPPQLPTOBLKHKSKPAQSPNIULTWNQWDTRATSLPPTD PSISNNDDSGQPNVVDSKDTRQPVKSIAKDAHRIGQDNDIYASVMIAQAILESDSGRSAL AKSPNHNLFGIKGAPEGNSVPPHTLRADGAQLYSINAGPRKYPSTKESLKDYSDLIKNGI DGNRTIYKPTWKSEXDSYKDATSHLSKTYATDPNYAKKLNSIIKHYQLTQPDDERMPDLD KYERSIRDYDDSSDEPKPPREVSDSHPYFHGQCTWVVYNRHKQFGTSISGDLGDAHNNIN RAQYRDYQVSHTPKRHAAVVPEAGQFGADQHYGHVAPVEKVNSDGSIVISESNVKGLGII SHRTINAAAAKELSYITGK	
62.	MRKFSRYAFTSMAAL/ILLSTLSPAALAIDSKNKPANSDIKFEVTQKSDAVKALKRLPKSB NVKNIYQDYAVTDVKTDEKGPTHYTLQPSVDGVHAPDKEVRVHADKSGKUVLINGDTDAK KVKPTNKVTLSKDDADKAFKAVKIDENKAENLKDEVIKENKVELDGDSNKYVTNVELLT VTPBISHWKVKIDAQTGEILEKMHAKEAAFTGKGKGVLGDTKDININSIDGGFSLEDLT HQGKLSAFSFNDQTGQATLITNEDENPVKDEQRAGVDANYYAKQTYDYYKDTFGRESYDN QGSPIVSLTHVNNYGGONKRNAAMIGDKHIYGDGDGKTFTSLSGANDVVAHELTHGVTQ STANLBYKDQSGALMESPSDVFGYPVDDEDFLMGEDVYTPGKEGDALRSNSNPEQFGQPA HMKDYVFTEKDNGGVHTNSGIPNKAAYNVIQAIGKSKSEQIYYRALTEYLTSNSNFKDCK DALYQAAKDLYDEQTAEQVYEANNEVGVE	
63.	MKKRIDYLSNKQNXYSIRRITVGTTSVIVGATILFGIGNHQAQASEQSNDTTOSSKNNAS ADSKNNANIETPQIANTIANDISDISARTMSANVDSTTKPMSTQTENTTTEPASTNETPQ PTAIKNQATAAKAQDQTVPQBANSQUNIKTTNDANSIATNSELRNSQTLDLPQSSPQTIS NAQGTSKPSVRTRAVRSLAVAEPVVNAADAKGTNVNDKVTASNFKLEKTITPDPNQSGNTP MAANFIVTDKVKSGDYFTAKLPDSLTGKSEVDYSNSNRTMFIADIKSTNGDVVAKATYDI LTKTYTFVFTDYVNNKENINGQPSLPLFTDRAKAPKSGTYDANINIADEMPNNKTYNYS SPIAGIDKEPGANISSQIIGVDTASGQNTYKQTVFVNPKQRVLGYTWVYIKGYQDKIEES SGKVSATDTKLRIFERVNDTSKLLSDSYYADPNDSNLEKVTDQFKNRIYYEHPNVASIKFGD ITKTYVVLVSGHYDNTGKNLKTQVIQENVDFVTROVSIFGKNNENVVRYGGGSADGDSA VNPKDPTPGPPVDPEPSPDPEPPPPPEPSPDPEPPSPDPDPDSDSDSDSGSDSDSGS DSDSSDSDSDSDSDSDSDSDSDS	
64.	MKRTINASSLAVALGVTGYAAGTGHQAHAAEVAVDQAHLVDI,AHNHQDQLAVAPIKDGAY DIHFVKDGFQYNFTSNGTTM9MSYBAANGQTAGFSNVAGADYTTSYNQGSNVQSVSYNAQ SSNSNVBAVSAPTYNNYSTSTTSSSVRI,SNGMYAGATGSSAAQIMAQRTGVSASTWAAII ARESNGQVNAYNPSGASGLPQTMPGNGPTNTVDQQINAAVKAYKAQGLGANGP	
65.	MGGYLIMRKIVTATIATAGLATIAPAGHDAQAAEQNNAGYNSNDAQSYSYTYTIDAQGNY HYTWTCHWNPSQLTQNNTYYYNNYMTYSYNNASYNNYYNHSTQYNNYTNNSQTATNNYYT GGSGASYSTTSNNVHVTTAAPSSMGRSISMYASGSNLYTSGQCTYYVPDRVGGKIGST WGNGSNWANAAASSGYTVNNTPKUGAIMQTTQGYYGHVAYVEGVNSNGSVRVSEMNYGHG AGVVTSRTISANQAGSYNPIH	

66.	MANTEKTTLDITGHTCAACSNRIEKKLNKLDDVNAQVNLTTEKATVEYNPDQHDVQEFIN TIQHLGYGVAVETVELDITGHTCAACSSRIEKVLNKMDGYQNATVNLTTEQAKVDYYPEB TIQHLGYGVAVETVELDITGHTCAACSSRIEKVLNKMDGYQNATVNLTTEQAKVDYYPEB TDADKLVTRIQKLGYDASIKDNNKDQTSEKAEALQHKLIKLIISAVLSLPLLMIMFVHLP NDHIPALFTNEWPGPILATFVQFIIGWDYYVGAYKNLRNGGANDVLVAVGTSAAYFYSI YEMVRWLNGSTTQPHLYFETSAVLITLILPGKYLEARARSGYTNALGELLSLQAKERIL KDGNEVMIPLNEVHVGDTLLVKPGBKIFVDGKIIKGMTAJDESHLJESSIPVERNVDDTV KGSTMYKNGTITHTATKVGGGTALANIIKVVEBAQSSKAPIQRLADIISGYPVPIVVGIA LLTFIVWITLVTPGTFEPALVASISVLVIACPCALGLATFFSIMVGTGRAAKNGILFKGG EFVERTHQIDTIVLDKTGTITNGREVVTDYHGDNQTLQLLATAEKDSEMPLAERALVMYAK ERQLILIETTTYKAVFGHGIERTIDHHHILVGNRKIMADRDISSPKHISDDLTHYERDGK TAMLIAVNYSLTGIIAVADTVKDHAKDAIKQLHDMGIEVAMLTGDNKMTAQAIAKQUID TVIADILPEKRAQIAKLQQOGKKVANVGGGVADAPALVKADIGIAIGTGTEVALEAADI TLLGGDUMLIFKAIVASKATIRNIRGNLFWAPGYNIAGIPIAALGLLAFWVAGAAMALSS VSVVTNALRLKKMRLEPRKDA	
67.	MEDSIARTIDYAVENNMSFADIMVKEEMELSGKSRDEVRAQMKQNLDVMRDAVIKGTTGD GVESVTGYTGHDAAKLRDYNETHHALSGYEMIDAVKGAIATNEVNAAMGIICATFTAGSS GTIPGALPKLEKTHDLTEEQMIDPLFTSALFGRVVANNASVAGATGGCQABVGSGASAMAA AANVAIFGGSPEASGHAMALAISNLLGLVCDPVAGLVEIPCVMRNAIGSGNALISADLAL AGIESRIPVDEVIEAMDKVGRNLPASLRETGLGGLAGTPTGEAIKRKIFGTAEDMVKNN	
68. ****	HONNLAYGIRKHKLGAASVFLGTMIVVGMGQDKEAAASEQXTTTVEENGNSATDNKFSET QTTATNVNHIEBTQSYNATVTEQPSNATQVTTEEAPRAVQAPQTAQPANIETVKEEVVKB PAKPQVKETTQSQDNSGDQRQVQDLTPKKATQNVATGVVBVQPBTASESKPRVTRSADV AEAKEASNAKVETGTDVTSKVTVEIGSIEGHRNTNKVEPHAGQRAVLKVKLKFENGLHG DYFDFTISNNVMTHGVSTARKVPEIKNGSVVMATGEVLEGGKIRYTFTNDIEDKVDVVTAE LEINLFIDPRTVQTINGNQTITSTIANEEQTSKELDVKYKDGIGNYTANLAGSIETFNKANN RFSHVAFIKPNGKTTSTVTVTGTLAKGSNQNKROPKVRIFEYLGRNEDLAKSVVANTTDT SKFKEVTSNMSGNIALQRNGSYSLNIENLDKTYVAVHYGEKILATDEVDFRTQNKGPPO LYKYYTORGYTLTWONGLVLYSNKANGKNOPILQRNKFEYKEDTIKETLTKGQVDKHLV TTVEEBTDSSTLDIDYHTAIDGGGGVVDGYIETIEETDSSALDIDYHTAVDSEAGHVGGY TESSEBSRPIDPERSTHENSKHHADVVSYREDNDRGGQVTEESTKJEVFDESTKGIVTG AVSDHTTVEDTKEYTTESNLIELVDKLFBEHGQAQGPVEEITBNNHHISHSGLGTENGHG NYDVIEBIERSHVDIKSELGYFBGGONSGNQSPEEDTEBKYFPQGGTVIDIDPDSVPQ HGGNKGNGSPEEDTERDKFKYEHGGKIIDIDFDSVPHHHGFNKTEILEEDTNKDKPSY OFGGHNSVDFEEDTERVSCHREGONTEDKTPPTVPTPFBVPSSPETPTPPTEV PSSPETPTPPTPEVPSEPETPTPPTPEVPARPCREVPPAKEERKYSKVEGKVVTPVI EINEKVKAVAPTKKPQSKKSELFFTGGEESTNKGMLFGGLFSILGLALLRNKKNHKA	·*.
69.	IHIRENIIVKSNLRYGIRKHKLGAASVPLGTMIVVGMGQEIRAAASBQNMTTVERSGSSA TESKASETQIFITINNVNIIDETGYS SARTSTEDPSGSTQVTTEEAPKTVQAPRVETSRYDLP SEKVADEKTTGTQVDLAQPSNVSEIKPRMKRSTDVTAVAEKEVVEETKATGITDVINKVEV EDGSBIVGHKQDTNVVNPHNABRVTLKYKMKFGBGIKAGDYFDFTLSDNVETHGISTLAK VPEIKSTDGQVMATGEIIGERKVRYTFKEYVQEKKDLTABLSLIN.PIDPTTVTOKGNONV EVKLGETTVSKIENIQYLGGVRDNWGVTANGRIDTLAKVDGKPSHFAYNKPNNQSLSSVT VTGQVTKGNKPGVNNPTVKVYKHIGSDDLAESVYAKLDDVSKFBDVTDIMSLDFDTNGGY SIMPNNLDQSKNYVIKYBGYYDSNASNLEPQTHLEGYTHYYTYSNLTMKNGVAPYSNNAQ GDGKDKLKEPIIENSFPIELBEKKSEPPVEKHELTGTIERSNDSKPIDFRHTTAVBGAECH ABGTIETEEDSINVDFEPSTHENSKHHADWEYEEDINPGCGQVTVESNLVBFDRDSTKG IVTGAVSDHFTIEDTRHYTTESNLIBLYDELFEHGQAQGPIERITERNHISHSCLGTE NGHGNYGVIEEIRSNSHVDIKSELGYEGGGDSGNQSFERDTEDERFKPGGGNIVDIDPD SVPOIHOGNNGNGSFERDTEKDKPKYEGGGNIDDIDFDSVPHIHGFNKHTEIIEDTNND KPNYGFGGHNSVDFERDTLPQVSGHNEGQOTIEDDTSVPHIHGFNKHTEIIEDTNND KPNYGFGGHNSVDFERDTLPQVSGHNEGQOTIEDDTSVPHIHGFNKHTEIIEDTNND FFKKAGSGKKSELPFFEDGEESTNNGMLFEGGLPSILGLALLRNNKNNHRA	
70.	MQMRDKKGPUNKRUDPLSKRLANY SIRKPTVGTASILIGSLMYLGTQQBARAAENNIENP TTLKDNYQSKEVKIEEVTNKDTAPQGVEAKSEVISNKDTIEHEPSVKAEDISKKEDTPKE VADVABVQPKSSVTHNAETPKVKKARSVDEGSFDITRDSKNVVESTPITIQSKEHPBGYG SVDIQKKPPDLGVSEVTRFNVGNESNGLIGALQLKNKIDFSKDFNFKVRVANNHGSNTYG ADGWGFLPSKGNAESYLFNGGILGDKGLUNSGGFKIDTGYIVTSSDKTEKQAGQGYRGY GAPVKNDSSGNSQBVGENIDKSKTNFLNYADNSTNTSDGKFHGQRLNDVILTYVASTGM RAEVAGKTWHISTTDLGISKNQAYNFLITSSQNMGINGSINNGMRTDLKGSEFTFTPB APKTITELEKKVEELPPKKERKFMPDLAPGTEKVTREGQKGEKTITTPTLKNPLTGVIIS KGBPREEITKDPINELTBYGPBTIAPGHRDEPDFKLPTGEKEEVPGKPGIKNPETGDVVR PFVDSVTKYGPVKGDSIVEKEELPFKKERKFNPDLAPGTEKVTREGQKGEKTITTPTLKNP PLTGGIISKGBSKREEITKDP INELTBYGPFTTTPGHRDEPDFLPTGEKEEVPGREGIKN PETGDVVRPPVDSVTKYGPVKGDSIVEKEEIPFFKERKFNPDLAPGTEKVTREGGKGEKT TTTPTLKNPLTGRIISKGESKEEITKDP INELTBYGPETTTPGHRDEPDFLPTGEKEEVPGREGKT PGKPGIKNPETGDVVRPPVDSVTKYGPVKGDSIVEKEEIPFKERKFNPDLAPGTEKVTREGGKGEKT PGKPGIKNPETGDVVRPPVDSVTKYGPVKGDSIVEKEEIPFETTTPGHRDEPDFLPTGEKEEV PGKPGIKNPETGDVRPPVDSVTKYGPVKGDSIVEKEEIPFETTTPGHRDEPDFLPTGEKEEV PGKPGIKNPETGDVRPPVDSVTKYGPVKGDSIVEKEEIPFEKERKFNPDLAPGTEKVTR GGGKGEKTITTPTLKNPLTGEIISKGESKEEITKDPVNELTEFGGEKLPQGHKDIPDFNL PTDOTBKVPGKPGIKNPDTGKVIEPEVDYKHGFKTOPFFTKTVBIPFFFTKRPMPKLQ PGEERVKQEGQPGSRTITTPITVNPLTGEKVGEGQPTEEITKQPVDKIVEFGGEKFRDPK GPENPEKPSTHIPSGVINPDINGVIERPEUSKDRAKFRPVHSMKRDKNDKVKKSKIAKESVANQEK KRAELPFTGLESTOKGLIPSSIIGTAGIAHLLARRKN	•
71.	MKNKYISKLLUGAATITLATMISNGBAKASENTOQTSTKHOTTONNYVTDQQKAPYQULH LKGTTEEQRNOYIKTLREHPERAORVFSBSLKOSKNPDRRVAQONAPYNULKNDRLITEQE KNNYIAQIKENPDRSQQVWVBSVQSSKAKERQNIENADKAIKOPQDINKAPHDHKSAAYBAN SKLPKDLRDKNNRPVERVSIEKAIVRHDERVKSANDAISKLEKDSIENRLAQREVNKA PMDVKEHLOKQLDALVAQKDAEKKVAPKVBAPQIQSPQIEKPKVBSPRVEVPQIQSPRVE VPQSKLLGYYQSLKDSPNYGYKYLTDTYKSYKEKYDTAKYYYNTYYKYKGAIDQTVLTVL GSGSKSYIQPLKVDDKNGYLAKSYAQVRNYVTESINTGKVLYTPYQNPTLVKTAIKAQET ASSIKNTLSNLLSPWK	
72.	MAVPSKEKKRGCIVVIETPKAFVIDKDESGKVTPTYKOLSPTDLPKGDVLIKVHYSGINY KDALATOPHNAVVKSYPHIPGIDLAGTIVESEAPGPEKGEQVIVTSYDLGVSHYGGFSEY ARVKSBNIIKLPDTJTLEESEMIYGTAGYTAGLAIERLERVCHMIEDGPULVRGASGGVGT LAVLMINELGYKVIASTGKQDVSDQLLELGAKEVIDRLPVEDPHKKPLASSTWQACVDPV GGEGINYVTKRLNHSGSIAVIGMTAGNTYTNSVPPHILGGVNILGJDSVFTAHKLRQRVW RRLAKDLMPENLHRIKGVITFDELPEQLAKVIKHENKGRIVIDFGVDK	
73.	MKKLVTATTLTAGIGTALVOQAYHADAAENYTNYNYNYTTOTTTTTTTTTTTTSSISHS GNLYTAGQCTMYVYDKVGGEIGSTMCNANNMAAAQGAGFTVNHTPSKGAILQSSEGPFG HVAYVESVNSDGSVTISEMNYSGGPFSVSSRTISASEAGNYNYIHI	

74.	MKKIATATIATAGPATIAIASGNQAHASEQUNYGYNPHDPTSYSYTYTIDAQGNYHYTWK GWHPSQLWQDNGYYSYYYYNGYNNYNNYNGYSYNNYGRYNNYGRYNNYNSYNNYNNYNSYN TNSYRTGGLGASYSTSSNNQVTTTMAPSSNGRSISSGYTSGRNLYYTSGQCTYYVFDRVG GKIGSTWGRASNWANAARAGYTVNNYPKAGAIMQTTQGAYGHVAYVBSVNSNGSVRVSE MNYGYGPGVVTSRTISASQAAGYNPIH
75.	MSMYTRIKWOKLSTITLLMAGVITLNGGEPRSVDKHQIAVADTNVQTPDYEKLRNYMLD VNYGYDKYDENNPDMKKKYDATEKEATNLLKEMKTESGRKYLWSGAETLETNISSHMYTRTY RNIEKIAEAMRNFKTTLNYDENKKKVKDALEWLHKNAYGKEPDKKVKKLSENFTKYTGKN THLNNMDYBIGTPKSLTWYLILLNDQPSNEEKKKFTAPIKTPAPDSDKILSSVGKABLAR GGNLVDISKVKLLECIIEDKOMMKKSIDSPNKVFTXVQDSATGKERNGFYKDGSYIDHQ DVPYTGAYGVYLLEGISQMMPHIKETPFNDKTQNDTTLKSWIDDGFMFLIYKGEMHDLSR GRAIGRENETSHSASATVMKSLLRLSDAMDDSTKAKYKKIVKSSVESDSSYKQNDVLNSY SDIDKMKSLWTDNSISKNGLTQQLKIYNDEDRVTYHNKDLDPAFGLSKTSKNVARVESIN GENLKGWHTGAGMSYLIYNSDVKHYHDNFWTADMKRLSGTTTLDNEILKDTDDKKSSKTF VGGTKVDDQHASIGMDFENQDKTLTAKKSYFILNDKIVFLGTGTKSTDSKNPVTTIENR KANGYTLYTDDKQTTNSDNQENNSVFLESTDFKKNIGYHFLNRFKITVKRESHTGKWKEI NKSQKDTQKTBYYEVTQKHSNSDNIKYGYVLYPGLSKDVFKTKCDEVTVVKQEDDFHVVK DNBSVMAGVMYSNSTQTFDINNYKVEVKAKGMFILKKRDLNTYECSFYNPESTNSASDIE SKISHTGYSITNKNTSTSNESGVHFELTK
76.	Indlroflytalvcgviaglgaplhipqypsmtiprivailgiisamltykdrqisaslk Psallinvlplcgtfvasn
77.	VSREMSYHHERKHILISTSILILSSSSLGLATHTVEAKDNLINGEKPTTNLINHNITSPSVIS EMININETGTPHESNOTGNESTGSNSRDANPDSRIVKPDSRIVIPSTDSKFDFRINGRIPSPN PKPDPENPER-KPDFRCPDPDKPKPPPPPPRFKPPDRPKPPPPPPPPPRFPPPPRFKPPPDKP KPNPPPKPPDRIKAPENPSEDPDOPEDSNHSGGSKNGSTNIPNAEDGSNQGQWQFNGNQGN KPNPPPKPDFINFAPENPSEDPDOPEDSNHSGGSKNGSTNIPNAEDGSNQGQWQFNGNQGN SONPTGNDFVSQRPLALANGAYKVNPYILINQINKLGRDYGBVTDEDIYMIIRKQNFSGNA YLINGLQQQSMYFRFQYFNPLKSERYYRNLDEQVLALITGBIGSMFDLKKPEDKPDSKQRS PEPHEKDDFTVVRKQBUNKKSASTAYSKSWLAIVCSMMVVFSIMLFLFVKRNKKNRKES QRR
78.	MKNKKRVLIASSLSCAILLLSAATTQANSAHKDSQDQNKKEHVDKSQQKDKRNVTNKDKN STAPDDIGRNGKITKRTETVYDEKTNILQNLQFDFIDDPTYDKNVLLVKKQGSIHSALKF STAPDDIGRNGKITKRTETVYDEKTNILQNLQFDFIDDPTYDKNVLLVKKQGSIHSALKF ESHKEKKNSWMLKYPSEYHVDFQVKRNRKTEILDQLPKNKISTAKVDSTFSYSSGSKFDS TKGIGRTSSNSYSKTISYNQQNYDFIASCKNNNWHVHWSVIANDLKYGGEVKNRNDELLF YRNTRIATVENPELSFASKYRYPALVRSGFNPEFLTYLSNEKSNEKTQFEVTYTRNQDIL KNRPGIHYAPPILEKNKDGQRLIVTYEVDWKNKTVKVVDKYSDDNKPYKEG
79.	MYTRTATTSDSQKNITQSLQFNFLTEPNYDKETVFIKAKGTIGSGLRILDPNGYWNSTLR WPGSYSVSIQNVDDNNNTNVTDFAPKNQDESREVKYTYGYKTGGDFSINRGGLTGNITKE SNYSETISVQPSYKTLLDQSTSKKGVGWKVEAHLINNMGHDHTRQLTNDSDNRTKSEIP SLTRNGNLMAKDNFYTPKDKNPVTVSEGFNPEFLAVMSHDKKDKGKSQFVVHYKRSNDEFK IDWNRHGFWGYWSGENHVDKKEEKLSALYEVDWKTHNVKFVKVLNDNEKK
80.	VVKFMYPNGKPYRKNSA1DGGKKTAAPSNIEYGGRGMSLEKDIEHSNYFYLKSDLAVIH KRPTPVQIVNYNYPKRSKAVINEAYFRYPSTTDYNGVYQGYYLDPEAKETKNKTSFPLAN HDHQVEHMKNAYQQKGIVPLMIRFKTLDEVYLLPYSKPEVFWKRYKDNIKKSITVDEIR KNGYHLPYQYQPRLDYLKAVDKLILDBSEDRV
81 -	VMTTKRALHGUVKLQNDKDHAKQTVSQLAHLNNAQKHEUTLIDSETTETAVKQDLTERQ ALDQLMDALQQSIADKDATRASSAYVNAEPNIKKQSYDEAVQNAESIIAGINNPTINKGNV SSATQAVISSKNALDGVERLAGDKQTAGRSINHIDQLTPRQQQALENQINNATTRGBVAQ KLTEAQALINQAMEALRNSIQDQQQTEAGSKFINEDRPQRDAYQAAVQNARDLINQTINNPT LDKAQVEQLTQAVNQAKDNLHGDQKLADDKQHAVTBLINQLISCLANPTROBPT LDKAQVEQLTQAVNQAKDNLHGDQXLADDKQHAVTBLINQLISCLANPGROALESQINNAT RGEVAQKLAERAKALDQAMQALRNSIQDQQTESGSKFINEDKPQKDAYQAAVQNAKDLIN QTCNPTLDKSQVEQLTQAVTTAKDNLHGDQKLARDQQQAVTTVNALPRLINHAQQQALTDA INAAPTRTEVAQHVQTATELDHAMETLKRKVDQVINTVAQPNYTEASTDKKEAVDQALQA AESITDPTNGSNANKDAVDQVLTKLQEKENELIGNERVARAKTQAKQTIDQLTHINADQI ATAKQNITQATKLQPIAELVDQATQLNQSMDQLQAVWBHANVEQVTVDYTQADSBKQNAY KQALADARNVLKQNANKQQVDQALQNILNAKQALNGDERVALAKTNGSHDIDQLARALNNA QDQFFKGRIDQSNDLNQIQQIVDERKALNRAMDQLSQBITDNEGRTKGSTNYVNADTQVK QVVBFTVDKAXQALDESTGQNITAKQVI KINDAVTAAKKALNGBERLINNKABALQKLDQ LVTHLNNAQRQLAIQQINNAETINKASRAINRATRLDKNAKKALNGBERLINNKABALQKUJQ UVTHLNNAQRQLAIQQINNAETINKASRAINRATRLDKNAKALNGBERLINNKABALQKUJC QUVBTVDKAXQALDESTGGNITAKQVI KINDAVTAAKKALNGBERLINNKABALQKUJC QUVBTVDKAXQALDRSTGGNITAKQVI KINDAVTAAKKALNGBERLINNKABALQKUJC QUVBTVDKAXQALDRSTGGNITAKQVI KINDAVTAAKKALNGBERLINNKABALQKUJC QUVBTVDKAXQALDRSTGGNITAKQVI KINDAVTAAKKALNGBERLINNKABALQKUJC QUVBTVOKADDNAKTHYDDAKRLANTLLNSDRYNVNDIDLAQNALNGQUILANAKUK ANAFVNSLINGINQQQQLALKARINDAVYDVDTD'UNNQ IDLAQMALNGQUILANAKUK ANAFVNSLINGINQQQQLAKAKANNANDVDKQVQALIDEIDAMBTILKHLYNBI PNA BOTVNYQNADDNAKTHYDDAKRLANTLLNSDRYNVNDINGALQAVDALINILAGDQRLQD AKDKALQSINQALANKLKUE REASNATQDDKLIAKNAKBRLANGI INNINGATSNQAVSQV QTAGNIRILGUPANLKEE REASNATQDDKLIAKNAKBRLANGI INNINGATSNQAVSQV QTAGNIRIAGUPANLKEE REASNATQDDKLIAKNAKBRLANGI INNINGATSNQAVSQV QTAGNIRALEQVIRABTYKABIDANQALQDIKDUVAREDAKQALLKURINQIL QQCHNGINNAMTKEHIBQAKAQLAQALQDIKDUVAREDAKQALDIKUNDAPOVIBVENI LDKRQALDDEDQONPHITOKEKQALKDRINQILQGENDINNALTTERE IQAKAQLAQA LQDIKDLVKAKEDAKNAIKDALARARDQINSNPDLITPERQAKARLKELDBAKRALONUSN AQTIDQILNGLINILGUDDIRTHVWBVUBQPAVHEIPEATPEQILVNGELIVHRDDITTEQ QQCHSINILGUDDIRTHYMBVUBQPAVHEIPEATPEQILVNGELIVHRDDITTEQ QQCHSICINAGESIDHITGSVILTEDINNAHTIQQUBAKU

Committee of the Commit

45.40 1.28/01.1

82.	MNGEVRNKIPSILKITFATALPIPVAITLYRELSGINFKDTLVEFSKINRMSLVLLPIGG GASLVILSMYDVILSRALKMDISLGKVLRVSYIINALMAIVGFGGFIGAGVRAMVYKNYT HDRKKLVHFISLILISMLTGLSLLSLLIVFHVFDASLILDKITWYMRVLYVVSFFIPLPI IYSMVRPPOKNNRFVGLYCTLVSCUEMLAAAVVLYFCGVIVDAHVSFMSPIAIFIIAALS IVSMVRPPOKNNRFVGLYCTLVSCUEMLAAAVVLYFCGVIVDAHVSFMSPIAIFIIAALS ILVSPIPGGGAPDLVVLLGPKTLGVPERKVLLMLLYRFAYYFVYVIIALILSSFRFGT SARKYIEGSKYFIPARDVYFFLMSVYBOIIAKIPSLSLAILVPFPSMIFFVNNLTIVVDA LUDGMILTYYILLAHTSACLLLLINVVGIYRGSRRAIIFAMISILLITVATFPTYASYI LUTWLAIIFYVLLIVAFRRARRLRFPUMENIVAMLLFSLFILVVNNIFIAGTLYALDIYT IEMHTSVLRYYFMLTILIIAIIGMIAWLFDVQFSKVRISSKIBCEBIINVYGGNYLSH LIYSGKQFFTMENITAFLMYRYKASSLVVLGDPLGBENATDELLEAPYNYAEYLGYDVI PYQVTQHMPLYHNFGNQFFKLGEBAIIDLTQFSTSGKKRRGFRATLNKFDELNISFEII PFOVTQHMPLYHNFGNQFFKLGEBAIIDLTQFSTSGKKRRGFRATLNKFDELNISFEII EPPFSTEFINELQHVSDLWLDNRQEMPSVGEPNEEYLSKAPIGWMRNENEVIAFCLM PTYPNDAISVDLIRWLPELDLPLMGCLYLIMLLWSKECGYTKFNGMATLSNVGQLHYSY LERELAGRVPEHFNGLYRPGGLRRYKSKYNPNWEPRFLVYRRONSLÆSLSKVKRVIRKK
83.	MVALTLUGSAVTAHQVQAAETTQDQTTRIKNVLDSIKVKATTEQAKAEVKNPTQAISGIV YQDPAIVQPKTANIKTGNAQVSQKVDTAQVIGOTRANGSATTINTOPVAKSTSTTAPKTN YQDPAIVQPKTANIKTGNAQVSQKVDTAQVIGOTRANGSATTINTOPVAKSTSTTAPKTN TNYTINGYSLVDDEDDINSENQINPELIKSAAKPAALETQYKTAAPKAATTSAPKAKTEAT PKVTTYSASAQPRSVAATPKTSLPKYKPQVINSSINDYIRKINLKAPKIEDYTSYPYKYA YRMSVGRPEGIVVHDTANDRSTINGEISYMKINYQARAYVHAPVDGORIIETTAPTTYLSNG VGAVGNPEPINVELIVHTHDYASPARSMINYADYAATQLQYYGLKPDSABYDGNGTVWTHY AVSKYLGGTDHADPHGYLRSHNYSYDQLYDLINKKYLLKMEKVAPWSTQSTTTPTPPSKP TTPSKPSTGKLTVAANNGVAQIKPTNSGLYTTYVDRYGKATHEVQKTPAVSKTATLGNGK PYLVQDYNSGNKFGWLEGDVVYNTAKSPUNVNOSYSIKPGYRLYTYPWGTSKQVAGSVS GGONQTFKASKQQQIDKSIYLYGSVOKSKGNVSKAYLVDTARPTPFPFPKPSTPTNINKL TVSSLNGVAQINAKNNGLPTTVYDKTGKPTRAVTKASLGGNKPYLVKDYNSPT LIGWKQGDVIYNNAKSPVNWQTTYVKPGFKLVSVFMGTYKQEAGAVSGTGNQTFKATK QQQIDKSIYLFGTVNGKKGNVSKAYLAVPAAPKKAVAQPKTAVKAYTVTKPGTTOTVSKI AGVKPNYGIRASVYEKTAKNGAKYADRTFYVTHERAHGNETYVLLNYTSHNIPLSMPNV KDLNVQHLGKEVKTTOKYTVNKSNNGLSMVPMGTRNQVILAGENIAQGTFNATKQVSVGK DVYLYGTINNRTGWVNAKDLTAPTAVRPTSAAKUNYTYVIKGENYYVYTPNSOTAKY SLARPNSQPFAVVKEQVINGGTWYYGKLSNCKLAWIKSTDLAKELIKYNQTGMALNQVAQ IQAGLQVKPQVQRVPGKWTGANFNDVKHAMDTKRLAQDPALKYQFIRLOQPNISINKIN QFILKGKGVLENQGAAPNKAAQMYGINEVYLISHALLEFGNSTGOLAKGADVVNNKVVTNS NTKYHNVPGIRAYDNDPLREGIKYAKQAGMDTVSKAIVGGAKPIGNSYVKAGQNTLYKMR MYSHHOPTHQVATDVUMANINAKIIKGYYDKIGSUGKFPDOYNSSKOOTPKLOKGGNLKP
84.	LEGREHANVILPNNDRHQITDYTNGHYAPYTYIQUEAFIGIF IASSAVAGADILINIAN VDATHGDHALKAPPSAINQDNYPNGGFTARQITKYSDEGDLALVKFSPNSQHKHIGEVV KPATMSNNADTQVNQNITVTGYPGDRFVATMWESKGKITYLKGEAMQYDLSTTGGNSGSP VFNEKNEVIGHWXGVPNEFNGAVFINENVRNFLKQNIEDIHFATMTNLITQIILITLTI LITLTTDNNDITTITTLITGHIJOTMAIXIIOFIOMOLN
85.	MOKKVIAAIIGTSAISAVAATQANAATTHTVKPGESVWAISNKYGISIAKLKSLANLITSN LIPPNQVLKVSGSSNSTSNSSRPSTNSGGSSYTTVQACBSLSLIASKYGTTYQNIMRLNG LINPPTYPGOKLKVSGTASSSRAASNSSRPSTNSGGGSYTTVQAGDSLSLLASKYGTTYQ KIMSLNGLANPPTYPGOKLKVJGNASTNSGSATTTNRGKNTPVFSHONLYTWGOCTYHVP NRRARIGKGISTYWHNANNDUNAAAADGYTIDARPTVGSIAQTDVGYYGHVMPVERVRND GSILVSENNYSAAPGILTYRTVPAYQVNYRYIH
	MNNKKTATNIKGMI PHILLIKP SIRKY SYGTASILVGTTLIFGISGHBAKAABHTNGBINQ KNBETTAPS EBRKTTKKVDRQLKUNYQTATADQPKVTMSDSATVKETSSNNGSPINATAN QSTFKTSAVTTNDKSSTTYSNETDKSALIQARDVSTFPKTTTKPRFLNRMAVNTVAAPQ QGTMNDKVHFSNIDI AI DRGHVNQTTGKTEPMATSSDVLKLKANYTIDDSVKEGDIFFIF KYGQYFRPGSVKLIPSQYDALVHAQGNI IAKGIYDSTINTTYTFFTNYVDQYTNVRGSPEQ VAFARKNATTDKTAYKMEVTLGNDTY SEBI IVDYGNKRAQPLI SSTNYINNEDLSRMMT AYVMQPKNTYTKQTFVTHICTYKFNPNAKNFKI YEVTDQMQFVDSFTPDTSKLKDVFDQF DVI YSNDKKTATVDLMGQTSSNKQYI IQQVAYPDNSSTDNGKI DYTLDTDKTKYSWSNS YSNVNGSSTANGDQKKYNLGDYVWEDTNKDGKQDANEKGIKGYVILKDSSNGKELDRTT DBNGKYQFTGLSNGTYSVEPSTP PAGYTPTTANVGTDDAVDSDGJITTGVIKDANNTLDS GPYKTPKYSLGDYVWYDSNKDGKQDSTEKGIKGVKVTLQNEKGBVIGTTETDENGKYRFD NLDSGKYKVTYFEPPAGLTQTTTTEDDKDADGGEVDVTITDHDDFTLDNGTYBEFTSDS DSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSD
87.	MDINSBEYKQEVLIRDVYMLAARILLESGAEGTRVEDTMTRIAKKLGYSESNSFYTNTVI  QPTLHSESFPRIFRITSRDTNLIKISQANKISRQITYNNEISLAEAKTQLEKIYVAKRDSS LPFKGFAAAMIAMSFLYLGGRLIDVLTAILAGSLGYLVTEILDRKLHAQPIPEFJGSLV IGIIAVIGHTLIPTGDLATIIIAAVMPIVPGVLITNAIQDLFGGHMLMFTTKSLEALVTA FGIGAGVGSVLILV
88	VIAIMNVIIDERKENAMTFNKVILSWIVILIITTSIYIFNOLEDINDVPNQSIIJNVILP RILEALIYOMILTVAGILIPQITUNNALADSFTLGIASGATFGSGLALFIGLTTIMIPVPS ITPSLITLITVLVITSVISQGYPVRILIISGIMIGALPNSLLYFLILLKPRKLNTIANYL FGGFGDABYSNVSIIAITFIIALFGIPIILNQLKLLQLGELKSQSLGLNVQLITYIALCI ASMITAINVAYVGTIGFIGAVIPQLIRKWQNKQSLGRQLALNIVTGGQIMVMADPIGSHI ISPNOLPASIIAILIGIPULFVMLISOSERIH
89.	MKKLAPATTATSGAAAFLTHHDAQASTQHTVOSGESLMSIAQKYNTSVESIKQNYQLDNN LVPPGQVISVGGSDAQNTSNTSPQAGSASSHTVQAGESLNIIASKYGSVDQUMAANNIR GYLIMPNQTIQIPNGGSGGTPPTATTGSNGNASSFRHQNLYTAGQCTWYVFDRRAQAGSP ISTYMSDAXYWAGNAANDGYQVNNYIPSVGSIMQSTPGPYGHVAYVERVNGDGSILISEMN VTYGPVNNNYBTI DASFUSSYAPIK
90.	MPDSTTIIDENKVIDVVLIAGRILLESGAETYRVEDTMNRIAHSYGLHYYYSFVSSTAII PSLNDRTSTRLIRVQERTTDLEKIALTNSLSRKISMEELFIDEAKSEFHLQHASLQYSF LTNFFAAAIACGFFLFMFGGVASDCWIAVIAGGSAPLFFSFVQRYIQIKFFSEFVAAAVV ISIAATFTKLGIATNQDIITIASVMPLVFGILITNAIRDLLAGELLAGMSRGVEAALTAF AIGAGVAIVULII

THE RESERVANCE OF THE STREET

91.	MGFLSKILDGNNKBIKQIGKLADKVIALEEKTAILTDBEIRNKTKQFQTELADIDNVKKQ NDYLDRILPEAYALVRGSSKRVPNPTFYKVQIMGGIAIHKGDIAEMRNEGKTLTATHFT YLNALAGRGVHVITVNEYLSSVQSEEMAELWHFLGIVGIALNSKTITEEKREKYAQDITY STINNELGFDYLRDNHVNYSEDRWRPLHFAIIDEVDSILIDEARTFLIISGBEEKSTSLY TQANVFARMIKQDEDYKYDEKTKAVHLTEQGADKARMFKVENLYDVQNVOVISHINTAL RAHVFLQRDDYMYWDGSVLIVOPTGRTHFGGRFSEGLAQAIEAKBGVQIQNESKTMAS ITFQNYFRMYNKLAGMTGTAKTESEEFRNIYNMTVTQIPTNKFVQRNDKSDLIYISQKGK FDAVVEDVVEKKAGQFVLLGTVAVETSEYISNLLKIRGIRHDVLNAKHEREAEIVAGA GOKGAVTIATNMAGRGTDIKLGEVBELGGLAVIGTERHESGRIDDQLRGRSGRQGDKGD GRAYTIATNMAGRGTDIKLGEVBELGGLAVIGTERHESGRIDDQLRGRSGRQGDKGD SRFYLSLQDBLMIRFGSERLQNMSRLGLDDSTPIESKMVSRAVESAQKRVEGNNFDARK RILEYDSVLRKQREIIYNERNSIIDEEDSSQVVDAHLRSTLQRSLNYIMTANDEPEVQP FIDYINDIFLQBEGITEDDIKGKDAEDIF BVVWAKIEBAYQSQKDILEEQMNEPERMILL RSIDSHWTDHIDTMDQLRGGIHLRSYAQQNFLRDYQNEGHELPDIMQNIEEDTCKFILK SVVQVEDNIEREKTTEFGEAKHVSAEDGKEKVKPKPIVKGDQVGRNDDCPCGSGKKFKNC
92.	MRESMSNONYDYNKNEDGSKKKMSTTAKVVSIATVLLLLGGLVPAIPAYVDHSNKAKERM LNEDKQEQKERRQKENAEKERKKKQQEEKEQNELDSQANQYQQLPQONQYOYVPPQQQAP TKQRPAKEENDDKASKDESKMUDKASQDKSDINQKKTDDNKQPAQPKPQPQQPTPKPNN NQQNNQSNQQAKPQAPQQNSQSTTNKONNANDK
93.	MMKKKEKHAIRKESIGVASVLUOTLIGFGLLSSKEADASENSVTGSDSASNESKSNDSS SVSAAPKTDDTINVSDTKTSSNTRNGETSVAQDPAQQETTQSSSTRATTEETFVTGEATTT TTNQAMFPATTQSSDNTARELVKNTSNETTSIDTINVSSVRSPQNSTNAENVSTTQDTST EATPSNNESAPQSTDASNKUVNQAVNTSAFRIKRAFSLAAVAADAPAAGTDITTQLTINVT VGIDSGTTVYPHQAGYVKLNYGFSVPNSAVKGDTPKITVPKELMIKQVTSTAKVPPIHAG DQVLARGVIDSDGNVIYTFTDYVNTKDBUKATLIMPAYIDPENVKRTGNVTLATGIGSTT ANKTVLVDYEKYGRFYNLSIKGTIDQIDKTNNYTYRQTIYVRSGENVIAFVLITGRIKFNT DSNALIDQONTSILVYKVDNAADLISESYFVNEPRIFEDVINSVNITTPPNPQYKVEPNTPD DQITTPYTVVVNGHIDPNSKGDLALRSTLYGYNSNITWRSMSNDNSVAFNRGSGGGID KPVVPDQPDEFGILEPIPEDSDSDGSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDS
94.	MNSNHAKASVTESVDKKYVVPESGINKI I PAYDEPKNSPKVNVSNL/TDNKNFVASEDKLN KI ADSSAASKLYDKNFVVPESKLENI VPEYKE I KIRKINVASTRINPASOQVDKHFVAKGPEV NRF I TONKVNHHFI I TOOTHYKKVVT SYKSTHVIKHVNHAKDSINKHFI VKRSESFRYTHP SQSLI I KHHFAVPGYHAHKFVTPGHASI KINHFCUVPQINSFKVI PPYGINSHRMHVPSF QMNTTATHQNAKVNKAYDYKYFYSYKVUKGVKKYPSPSQSNGYKI GKPSLNI KNUNYQYA VPSYSPTHYVPEFKGSLPAPRV
95.	Lehtinkmrtiaktslalgiltigaityttosvkaekiostkydkvptikäerlaminit Agansattoaantroertpklekapintneektsaskiekisopkoeboktlinisatpapk Oeosottesttpkrevitypsymtyopkostkodtposptikoaotdipkykbolrayy TKPSPEPEKOPOPMLRPHTVRPMAVIPRRPIVKIALVGKDEKKYKDGPVDNIDVFIVLE DRKYOLKKYSVGGITKTNSKKVNHKVELSITKKUNGGHISRDVSENMITKERISKLDF KURKOLIEKINLYGGRGSOFIVTKMKNGGKYTPELHKKLQEHRMAGTNIDNIEVNIK
96.	MTTIKTSNLGPPRLGRKREMKKAIESYMAKKI SKEPLLOTLIDLHERNLLLQKYPHLOSI PYGDFSLYDHILDTSLIPNI PERPGGRTIDDDLLPDIARGNKDKVASALIKMFNTNYHY IVPEMDNUBFRUSRRWLLDRIKYAQSIANNAHPVIVGPITFVKLSKGGHQPPERKVKTLL PLYKEVPESLIDAGARYIQVDEPILVTDDSESYENITHEAYDYPEKAGVAKKLVIQTYPE RAHLKFLSSLPYGGIGLDPVHDRIMGYNLKQIEAGGPDZSKTLVAGILDGRNWASDIEAKK VLIDKLLAHTNELVIQPSSSLLHVPVSLDDETLDTSVGGGLSPATEKLDELDALRRLFNQ NDSVKYDKLKARYERFQNGSFKNLDYDFESVRTSRQSPFAQRIEQQQKRLNLPDLPTTTI GSPPQSRVRYKYRADMKNRHITDRAYETFLKNELARNIKLQEDIGLDVLVHGEFENDAV BFFGEKLOGFLVTKFGNVQSYGSRAVKPPIIYGDVMYAPLTVDETVYAQSLTDKFVKGM LTGPVTILMSFERDULPRKVUQDQIALATHEEVLALERAGIKVIQVDEPALREGLPLRS EYHQVIKDAVLSPKLATSSVRDETQIHTHMCYSQFCQIIHAHDLDADVISIETSRSHG DLIKDFEDINYDLGIGLGVYDIHSFRIPTKEBITTAINRSLQQIDRSLFWVNPDCGLKTR KREUKVDALTVLVNAVKARUGE
97.	MSDTYKSYLVAVLCPPVLAIVLMPPLYFTTAWSIAGPASIATPIPYKBYFYEE
98.	MLRGQEERKYSIRKYSIGVVSULAAIMPVVSSHBAQASEKTSINAAAGKETLINGPGEGGN ATTSHGMQSGKQLDDRHKENGKSGTVTEGKOTLQBSKHQSTQNSKTIRTONLNOVKQDSE ROGSKQSHQNAATNIPTERQNDQVQNTHHAERNGSQSITISQSNDUKSQPSIPAQKVIPNH DKAAPTESTPPENDRTAPKSTKAODATTDRHPNQQOTHQPAHQIIDAKQDDTVRQSBQKP QVGDLSKHIDGQNSPEKPTDKNTIBKQLIKDALQAPKTRSTTNAAADAKVRPLKANOVQ PLINKYPVVFVHGFLGLVGDNAPALYFNYWGCNKPKVIEELRKQGYNVHQASVSAPGSNYD RAVELYYYIKGGRVDYGAAHAAKYGHERYGKTYKGIMPNWBFGKKVHLVGHSMGGQTIRL MEEPIRNONKEBIAYHKAHGGEISPLFTGGHNNWASITTLAFTHNGSQAADKGPWTEAV RKIMFALNRFMGNKYSNIDLGLTQWGPKQLPNESYIDVIKRVSKSKIWTSDDNAAYDLTL DGSAKLANNFISNIPNITYTTTGVSHTGFLGYENPDLGTFFILMATTSRIIGHDAREEWR KNDGVVPVISSLHPSNOPFVNVFNDEPATRRGIWQVKFIIQGWP KNDGVVPVISSLHPSNOPFVNVFNDEPATRRGIWQVKFIIQGWP
99.	MINLIKGMHHTVLCIHLNKGVALMNOYHSNAQOPSANRFFVYSLVGILCFFIFFINGN NYIFVDHVHLAIRSIIGPLMPYVALIMILIGTALPLVRTFHTSITINLVITLFKVAQAMI GIMYVFXIGPSILFKANYGPFLFEKLMMPLSILIPVGAIALSLLVGYGLLEPVGVYMEPI MRPIFKTGKSAVDAVASFVGSYSLGLLITNRVYKQGMYNKREATIIATGFSTVSATFMI IVARTLGLMPHMILYFMITLVITFVVTAITAMLPPISNESTHEYNGQEGEQEVAIFGSRL KTAYAEANKQNALTPSLVKNVMDNIRGGLENTVGILPSILSIGFLGLTVANYTPFIDMLG YIFYFFIXIFPIADQALLAKASAISIVEMPLPSLLVTKAAMSTKFVVGVVSVSAIIFFSA EVPCILATEKKI PWKKLIIMPLRVALSLLITTFVALLIFG
100.	Mvinertilltyttltpsmspnsaqaytndsktleearkahpnaqpkvnkdtgaytyty Dknytpnnhhqngsrthinhohangrdlnnqyhsslscqythindatdshtpppytspsn Pltpaipnvednddelnnapskohkglitgidldelydelqiaefndkaktadgkplalg Ngkiidqplitsknnlytagqctwyydkrakdghtistpwgdaknwagqassngpkvdr Hptrgsilqtvngppghvayvekvnidgsilisemwigeyivssrtisasevssynyih

101.	MEVSSMRPYIQLVVPKQMLQYILLVTTIVIALVLIGIGYRVAHDNPKIPITIQDLDQTTA SKSFVNRIKQSDYVTIKKVDEDESYIEDDVFKXEAILSAQIPKGFSQRLKENRLKETIQL YGRUDPIGGIAVEIVSSSLYEQQIPNIIYEHLEDHKQHQSIDAINKSYHKHTPESKIKPV SLTKQAQHSISISLIFAVILFVSAVQVVLHYRLNQQAALQRLSQYHLSRPKLYSTYVMTH TILLLIVLLAVSLYLSQPLSLIFYLKSLILILIYBIGIVPILFHIQYISHRLFMTFIYAL AMGIVYLIIFM
102.	Mievtemppdihkipnkgiplsvorklalrnemoafpvvffyvmamylirnnfkaapp keeiglstielgyiglafsityglgktilgyfvdgrntrrispllisattvlimgfy lsyfsgymglivlaglagyfosvgrasystisraaprtkrgrylgfwytshniggaia ggvalwganvpphgnvighpifpsvialligiatlfigrddpeelgwnrabeiweepvdk enidsggwtxweipkkytignpuwilcvsnpvyytyrigiddwaplvysbilhpskoda wytipyfeigalvasliwgyvsdllkgrraivaigcmfnitfvvlfytnatsvmmynisl falgalifgpglligysltgfypkalsvangwtgspaylfgdbmakvglaaiadptrng
103.	MTKKKNILKATGIYSPIAMMPVIILYPILWTFGISLNPGTNLYGAKMIPDNATFKNYAFL LPDDSSQYLTWYKNTLIVASANALFSVIFVTUTAYAFSRYRFVCRKYGLITFLILQMFPV LHAMVATYILLMTIGLIDSLFGLTLVYIGGSIFMNAFLVKGYFDTIPKELDESAKIDGAG HMRIPLQIMLPLAKPILAVVALFNFMGFFMDFTLPKILLRSPEKFTLAVGLFNFINDKYA NNFTVFAAGATMIAVPIAIVFLFLQRYLVSGLTTGATKG
104.	MMENSTTEARNEATMHLDEMTVEEALITMNKEDQQVPLAVRKAIPQLTKVIKKTIAQYKK GGRLIYIGAGTSGRLGVLDAAECVPTPNTDPHEIIGIIAGGOHAMTMAVEGAEDHKKLLA EDLKNIDLTSKUVVIGIAASGKTPYVIGGLTPANTIGATTVSISCNEHAVISEIAQYPVE VKVGPEVLTGSTRIK SGTAQKILINMISTITMVGVEKYYDNIMIDVKATNQKLIDRSVRI IQEICAITYDEAMALYQVSEHDVKVATVMGMCOISKEBATRRLLNNGDIVKRAIRDRQP
105.	LQYIIRYIMMTLQIHTGGINLKKKNI YSIRKLGUGIASUTLGITLLI SGGUTPAANAAQHD BAQQNAFYQUMMPHLNADQRNGFI QSLKDDPSQSANVLGBAQKLNDSQAPKADAQQRNIP NKDQQSAFYBILMMMINBAQRNGFI QSLKDDPSQSSINVLGBAKKLNBSQAPKADNNFNK EQQNAFYEILMMMINBEQRNGFI QSLKDDPSQSANLLSBAKKLNBSQAPKADNKFNKEQQ QNAFYBILMLPNLNBEQRNGFI QSLKDDPSQSANLLABAKKLNDAQAPKADNKFNKEQQN AFYBILMLPNLNBEQRNGFI QSLKDDPSVSKEILABAKKLNDAQAPKEDNNKPGKEQNN KPGKEDNNKPGKEDINKPGKEDGIN FGKEDNKKFGKEDGNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDGNKPGK EDGNKPGKEDGNGVHVVHGDIVADI JAKANGTITADKIADNKALDKNNLI PQGBLVVDKK OPANHADANKAQALPETGEERIPFI GITTVFGGLSLALAGRALLAGRREL
106.	MDKKSEKRGIKMTVQSAYIHIPFCVRICTYCDFRKYPIQNQPVDBYLDALITEMSTAXYK ILKTMYVGGGTPTALSINQLERLLKAIRDTFTITGEYTFEANFDELTKEKVQLLEKYGVK RISMGVQTPKPELLSVLGRTHNTEDIYTSVLARKAGIKSISLDLMYHLPKQTIEDFPQS LDLALDMDIQHISSYGLILEPKTQFYNMYRKGLIKLPNEDLGADMYQLLMSKIEQSPFHQ YEISNFALDGHESEHNRUYMFNEEYYGPGAGASGYVDGVRYTNINPVNHYIKAINKESKA ILVSNKPSLTERMKEEMFLGIRLNEGVSSSRPKKKFDQSIESVPGQTINNLKEKKELIVEK NDVIALTKRGKVIGNEVFRAFLIND
107.	atgaatgtattagtaattggtggtggtggacgagacatgcacttgcatataaacttaat caatcgaatctagttaaacaagtgttgtcatttgcattcaggtaatgaggcaatgacactata gctgaagtcacactgaaatttcagaacctgatatcaagcgtaatagagtcatagatttgcaa cgcaaaatgttgattgggtgttcagaatgtcagaacagccgctaattgatggatagca gacatttacgagcgaatggttcaaagtgttgtggtcaaataggatagagccgaatgtgatagga gacatttacgagcgaatggttcaaagtgtttgagaggatgatagaggaggtaattaggatagca gaggctcaaaattatttgctaaaaagataatggaaaaataatatatccaactgctgat tataaagaagttgagcgaaaaaaggatgctttaacatattgaaaactgtgaattgcc gtgttgtcaagaaagatggttagctgctgggaaagggttattattgcagatactatt gaagcagccagaagtgctattgagattattgtatggtgatgaagaaggagtactgttgta tttgaaacgtttttagaaggtgaagagttctccyctaattgacatttgttaatggtgatta gcagtacctttcgactgtattgcacaagatcataaacgcgcatttgatcatgaagga ccaaatactggtggtatggggggttattgcacaaccattgaacaattagaagagtgttta aaacttacaaatgaaacaattgcacaaccattgcaaaggcaatgcttaatgaagttat caattcttcggtgtattatacattggtgctattttaactaaagatggccaaggaagt gaatttaatgccgtttttggtgatcctgaagcaagtaatattaaagtcgcaaggaaa gagcataagtacattattgattagttagaaggaaacgaatctgaatcaaatggaaa aggcataaagtaagggcttgattaatgaagaaaaggacatactgaatcaaatgaaaa agggcataaaagtaagtggctttgattaaatgaaaaagtactcagaggaaagtgacaagggaaacatttattacttagtgaaaaa aggcataaaagtaagtggctttgattaaatgaaaacatatttgcacacggaaaaagggcaataccttgatcaaggaag caaggtgatacctttgttactcaggtggtagagtatacacaattaaaa attactacagcaagagagacgcaacacaaaaaagtaacaaaaaaaa
108.	MNVLVIGAGGREIALAYKLINGSNLVKGVPVIPGIKAMPPIARVHTKISEPDHQALLDPAK RQNUMVVIGBEQFLIDGLADILRANGFKVFGPHKQAAQIEGSKLPAKKIMEKYNIPTAD YKEVERKKDALTYIERCELPVVKKDGLAAGKGVIIADTIRAARSAIEIMYGDEEEGTVV FBTPLEGKEFSLMTFVNGDLAVPFDCIAQDHKRAFDHDEGPMTGGMGAYCFVPHIEDDVL KLIMETIAQPIAKAMLAPEGYQFPGVLYIGAILHTKDGPKVIEFNARFGDPRAQVLLSRMES DLMQHIIDLDEGKRTEPKWKNESIVGVMLASKGYPDAYEKGHKVSGDLAENTYPVSGLKK QGDTPVTSGGRVILAIGKGDNVQDAQRDAYKKVSQIQSDHLFYRHDIANKALQLK
109.	atgcaaccacatttaatatgtctagacttagacggacattattaaacgataacaaagaa atttcatcatatactaaacaagtattanatgaattacaacaacgtggacaccaanttatg attgcgactggcagaccttatcgtgcaagtcaatgtattatcatgaattaaatttaacg acaccaattgttaattttaatggggcttacgtacatcacctaaagataaaaacttcaaa acttgccatgaaattttaagtttaggcatcgcacaaaacattattcaaggattacaaaa tatcaagtatcgaatattatagcagaagtgaaagattatgttttcattaacaatcatgat ccaagattattgaaggtttttcaatgggtaatccaagaattcaaactggtaatttactt gtccacttgaaagaatcccctacctcaattttaattgaagcgtagagaagtaaaatacct gaatcaaaaatatgcttactcatttttatgccgatcatattgagcatcgacgctgggc gcaccattccctgtcattgaaattgtaaaacttggtatataaagcaagaggcattgag caagttagacaattttataaaattgacgaataatattattgagcatcggtgatgaataatattattgagaattgagacattgagacattgagacaataccaggtgttgctatggagaataatagagattgcaagagattaaagagattgcaagagaagaagaagagaagagaagaaaga
110.	MOPHLICLDLDGTLLNDRREISSYTKQVLNELQQRGHQIMIATGRPYRASQMYYHELNLT TPIVNFNGAYVHHPKDKNFKTCHEILDLGIAQNIIQGLQQYQVSNIIABVKDYVFINNHD PRLPEGFSMGNPRIQTGRILLVHLKESPTSILIEAEBSKIPEIKNMLTHFYADHIEHRAGG APFPVIBIVKLGINKARGIEQVRQFLNIDRNNIIAFGDEDNDIEMIEYARHGVAMENGLQ ELKDVANNITFNNNEDGIGYYLNDFFNLNIRYYC

Carried Street

The state of the state of

111.	gtgaaaccaatggctaagtctaatagtaaagacatcgttttaattggagccggtgtactt agcacaacatttggttcaatgttaaaagaaattgagccagactggaatatccacgtttac gaacgcttggatcgtcctgcaatcgaaagttcaaacgaagaatatatgcaggtacagggt catgcagcattatgtgagttgaactacacagtttacaacgatggattcaatcc gaaaagcgagtagcatcgaagagagtttgagatttcaaacattgtggttcatta gtgaaaagcggtagcatcgagaacccaagagaatttatcaaacaattctggggtcactta gtgaaaagcggtagcatcgagaacccaagagaatttatcaaacaattaccaccaatcagt tagttagaggtaaaaacaatgttaaattcttaaaagatcgtagaagcagtgaagaagct ttcctatgttcgataatatcgaatatactgaagacatcgaagtaatgaaaaattggac ttccttagttcgataatatcgaagatataccatgaagtattacagcgaagtaaaattgac gaagtacagatgtaaaattcggtgaattaaccatgaagttgttagagcaattaaaat ggtcaatggaagttactgttaaaaatcgcataacagtgagaaattcaaacaagtact gactacgtattcatcggtgctggcggtggagcaattcatttatacaaaaacaggtatc cctgaaggaagattactgtaaaaatcgccaaagttattaggtacaatcttagctgtacaaca ccacaagttattgaacaacagatgccaaagttataggtcaattctagctgtacacac ccacagttattgaacaacacgatgccaaagtttatggtaaagaacattatttt ggaccatttgctaatgttggactaaattcttgaaaattggtctaacttaatttatt ggaccatttgctaatgttggacctaaattcttgaaaaagggtgttaacttaattattt ggaccatttacacaacaca
112.	MKPMAKSNSKDIVLIQAGVLSTTPGSHLAKH REDWNIHVYRRLDRRAIESSNERNNAGTG HAALCELNYTVLOPOGSIDIEKAKVINERPEISKOFNGELVKSGSIENPREPINPLPHIS YVRGKNNVKPLKORYEAMKAPPMFDNIKYTEDIEVMKWIFLMKGREENPGIHAASKID EGTDVNFGELTRKMAKSIEAHPNATVOPNHEVVDPEOLSNGOWEVTVKNRLIGEKPKOVT DVVPIGAGGGAIPLLOKTGIPESKHLGGPPISCOPLACTNPOVIBOHDAKVYGKEPPGTP PMTVPHLOTRVIDGORTLLFGPPANVGFKPLKNGSNLDLFKSVKTVNITTLLAAAVKNLP LIKYSPDOVIMTREGCMNHLRTPYPEARNEDWOLYTAGKRVQVIRDTPEHGKGFIOFGTE VVNSOHTVLALLGESPGASTSVSVALEVLERNPPEYKTEWAPKIKKMIPSYGRSLIEDE KLMRKIRKOTSKOLKLGYYEN
113.	atgctagaggcacaattttttactgatactggacaacatagagataagaatgaagatgcg ggtggtatttttataatcaaactaatcaacaacttttagttctgtgtgatggtatggt ggcgataatttttataatcaaactaatcaacaacttttagttctgtgtgatagtatggtt ggccataaagcaggagagsttgcaagtaaatttgttacagatgagttgaaatcccgtttt gaagcggaaaatcttatagaacaacatcaagctgaaaattggttgcgtaataatataaag gatataaattttcagttattacctatgcacaagataaatgcagaatataaaggtatgggt acaacatgtgtttgtgcacttgtttttgaaaaatcagttgtgatagcaaattgcggtgat tctagagcctatgttattaatagtcgacaaattgaacaaattactagtgatacactattt gttaatcatcttgttttacgggtcaaaattacgccggaagaagaatttacacacac
114.	matdtghrdkndaggyntnvcdgmgghkagvaskvtdksranhanwrnnkdnyhyanayk gmgttcvcavksvvanvgdsrayvnsrtsdhsvnhvtgtathrntkvmgtdkrvsdkrny dynsdgtdyvkdnkrvkgtdhgdmadnhskdnvtaagdkv
115.	atggcaaagaaaattcgatcgttctaaagaacatgccaatatcggtactactggtcac gttgaccatggtanaacaacattaacagcagcaatcgctactgtattagcaaaaaatggt gactcagttgcacaatcatatgacatgattgacaacgtccagaagaaaaaagacgtggt atcacaatcaattcacattgagtaccaaacgtagcaaacgtcactacgctcacgtt gactgccaggacacgctgactacgttaaaacatgacaaacgtcactacgctcacgtt gactgcccaggacacgctgactacgttaaaaacatgacaaacgtcactacgctcacgtt gactgcccaggacacgctgactacgttactggtagcaatgccaatgccaataggac ggcggtatcttagtagtatctgctgctgacggtccaatgccaataactgtgaacacatt ctttatcacgtaacgtggtyaccagcattagtagtatcttaaaaagattgacatg gttyacgatgaagaagaattattagaaattagtagaagttgtgaagattagaa ggcgatgctcaatacgaagaaaaaatcttagaattaatggaagctgtagaacgattacaatt ccaactccaggacgtgatcttgacaaacattcatgatgccagttgaagagtgagatacttacat ccaactccagaacgtgatcttgacaaacattcatgatgccagttgaagagagtgtgtga gaagagttgaaatcatcggtttacatgacacattaaaacaactgtaacaggttgaa atgtccgtaaaatatagactacgctgaagacgtggacaacattggtgcagtatatacg ggtgtgctcgtgaagacgtacaacgtggtcaagtattacaaagaaggtggacgtcac accactactcgaatcaaagagagtaccacactaaaacactgatcaaagaggtggacgtcac actccattcttccaaactacgcacacactaaatctcaaaagaaggtggacgtcac actccattcttccaaactacgcactgaaacgtgataacgtggtgaaacattggt ggaggtactggtacaggcgtcgattgaaagaggtggaaacaggtggaaacaggggaggacgaacagaggtggacacaacgtgaaacggtggaaacacaggaggagagacacaacgagaggtagaacaacacacaaaagaatacacagaaagtacacacac
116.	MAKEKFDRSKEHANIGTIGHUDHGKTFLITAALATVIJAKNODSVAQSYDMIDNAPEEKERG ITIMTSHISYQTDKRHYAHVDCPGHADYVKNMITGAAQMDGGILVVSAADGPHQTREHI LLSRNUGVPALVVFLNKUDMVDDEELLELVEMEVRULLSEYDPPGDDVPVLAGSALKALE GDAQYEEKILELMEAVDTYIPPERDSDKPFMMPVEDVFSITGRGTVATGRVERGQIKVG EEVEIIGLHDTSKTTVTGVEMFRKLLDYAEJACDNIGALLRGVARERIQRGVLJAAPGSIT PHTEFKAEVYVLSKDEGGRHYPFSMYRPGPYFRTTDVTGVVHLPEGTEMVMPGDNVEMT VELLAPIAIDBOTRFSIREGGRTVGSGVVTEITE

117.	atgactaagagtgctttagtaacaggtgcatcaagaggaattggacgtagtattgcgtta caattagcagaaggatataatgttagcagtaaactatgcaggcag
118.	MTKSALUTGASRGIGRSIALQLAEEGYNVAVNYAGSKEKAEAVVEEIKAKGVESPALQAN VADADEVKAMIKEVVSQFGSLDVLVNNAGITRDNLLARMKEQENDDVIDTNLKGVFNCIQ KATPOMLRQRSGAIINLSSVVGAVENPGQANYVATKAGVIGLTKSAARELASRGITVNAV APGFIVSDMTDALSDELKEQMLTQIPLARPGQDTDIANTVAPLASDKAKYITGQTIHVNG GMYM
119.	atgaaaatttctactaaagggagatatggacttacattgatgatttctcttgctaaaaaa gaggggcaaggatgtatatcattaaagtcaattgctgaagaaaataatttgagtgattta tattagaacagcttgtaggtcctttaagaaattgaggggttaattcgagtggt gctaaaggtggataccaattaaggagtgcagcggaagaaatctcagcaggggatattata agactgttagaaggtccaattacatttgttgaaagtattgaatcagaaccactggcaa aaacaactatggattcgcatgagagatgcagtgaagaatgtttagataatacaacattg aaatatttagcggaatatgtagatacaagtgaagatgtatagatactatgtttatatt
120.	Mikistegrygijtimielakkhgegetsiksiaqteellebhyleqlvsplenaglvksir Gayggyvlgsepdaitagdiirvlegpisllecwkhrslpsvssgpasghl
121.	gtggcatttgaatttagattaccogatatcggggaaggtatccacgaaggtgaaattgta aaatggtttgttaaagctggagatactattgaagaagaagttttagctgaggtacaa aacgataaatcagtagtagaaatccatcaccagtatctggtactgtagaagaagttatg gtagaagaaggtacagtagctgtagttggtgacgttattgttaaaatcggatgcactgat gcagaagatatgcaatttaaaggtcatgatgatgatgatcatcatactactaaagaagaacctgcg aaagaggaagcgccagcaagagcacctgtagctactcaaactgaagaagatggaaa aacagaactgttaaagcaatgccttcagtacgtaaatacgcacgtgaaaaaggtgttaac attaaagcagttctggatctggtaaattggcgtattacaaaagaagatggatg
122.	Mapepripdigegihegeivkwyvkagdtieeddvlaevondksvveipspvsgtveevm veedtvavvgdvtvkidapdaedmopkghddssskeepakeeapaeoapvatoteevde nrtvkampsvrkvareegvnikavsgegkortkeedvdavlingappasnesaasatse evaetpaapaavtleegppettekipamrraiakamvnskhtaphvtladeldvoalwoh rkkprelaaeogtklitlyyvvkalvsalkkypalntseneergeivhkhywnigiaadt drgilvpvvkhadrksipoisdenekarapakanbenkgatctisnicsagocapt pvinhpsvailgigrioorpivkdgeivaapvlalslspdhrqtdgatgonamnhikril

775,4

٠,

持续的效

123.

: .

7,567.75

Salam Charles and all the salar back

i.

125.

700 mg 120 mg

. 126.	MAGQUVQYGRHRIRRNYARISEVLEI.PNLIEIQTKSYEMPLREGLIEMPROLSPIEDFTG NLSLEPVDYRLGEPKYDLEESKNRDATYARPLRVEVRILIKETGEVREQEVFMGDFPLMT DTGTFVINGAERVIVSQLVSPSSVYPNEKIRKERNYARITIKETGEVREQEVFMGDFPLMT DTGTFVINGAERVIVSQLVSPSSVYPNEKIRKIKNGRENYADATIIPRRGMLEYETDARDVV YVRIDRTRKIPLIVLLRALGPSSDQEIVDLLGDMSFLRWTLEEDGTENFEQALLEIYERL RPGEPPTVENASSLLYSRFFDFRYDLASVGRYKTNKILHLKHRLFNQKLABPIVNTETG EIVVEGGYLDRRKIDBIMDVLESKNNSEVFELHGSVIDEPVEIQSIKVYVPNDDEGRTT TVIGNAPPDSEVKCITPADIIASMSYPYNLLSGIGYTDDIDHLGRRRIRSVGELLQNOFR RFGSMERVURENSIQDTESITPQQLINIRPVIASIKEPFGSSOLSQFMDQANPLAELT HKRRLSBALGPGGI/TRERAQMEVRDVHYSHYGRMCFIETPEGFNIGLINSLSSYARVNEFG FIETPYRKVDLDTHAITDQIDYLTADEEDSYVVAQANSKLDENGRFMDDEVVCRFRGNNT VMAKEMDYMDVSFKQVVSAATACIPPLENDDSNRALMGANMORQAVPLMNFEAPFYGTG MEHVAARDSGAAITAKHRGRVEIVESNEILVRRLVEENGVEHEGELDRYPLAKFKSNSG TCYNQRPIVAVCDVVZYNEILADGPSMELGEMALGRNVVUGFTMOGSTNYEDAVINSEBAL VKDDVYTSIHIESYESRRQRDTKLGFEEITRDIFMVSESALKNLDDRGIVYIDAWBDWDD ULVGKVTPKGVTELTAEERLLHAIFGEKARKVRDTSLRVPHGAGGIVLDVKVFNREEGDD TLSPGNNOLVRVVIVQKRKIHVCDMNGGRHGNKGVISKIVPEEDMPYLPDGRPIDIMLNP LGYPSRMIGGVULEHLGMAARNIGIHVASFVFDGANDDLVWSTIERAGMARDGRVTVLYD GRTGEPPDNRISVSVMYMLKLAHNVDDKLHARSTGPYSLVTOGPLGGRAQFGGGRFGEME WWALEAYGAAYTLQEILTYKSDDTVGRVKTYEAIVKGENISRSY
	atgettagggeategeeatatetategtatttatteagtaatataaactggaaggagaas aaatacatggetagagaatttteattagaaaaaaategtaatateggtatecae atgatgtggtaaacaeggaggggetteacaaatggactggatggaggaagac casaattggtgaaaacaeggaggggetteacaaatggactggatggaggaagacaagac
128.	MAREPSLEKTRNIGIMAHIDAGKTTTTERILYYTGRIHKIGETHEGASOMMEGEODRG ITITSAATTAAMEGHRVNIIDTFCHVDPTVBVERSIRVLIGAGVAVVILDAGSVEPQTETVW RQATTYGVPRIVFVNKMDKIGAMEPSYSVSTLHIRLQANAAPIQIPIGABDRPEAIIDLUB MKCPKYTNDLGTEIRBIBIPBOHLDRAEEARASLIRAVABTSDEIMEKYLGDEBISVSEL KEAIRQATTHVEFYPVLCCTAFKNKGVQLMLDAVIDYLPSPLDVKPIIGHRASNPEBEVI AKADDSAEPAALAFKNMTDPYVGRITFPFRVYSTMTSGSYVKNSTKGRRERVGRLLQMHA NSRQBIDTVYSGDIAAAVGLKDTOFGDTLCGKKNDIILESMBFPEVIHLSVEPKSKADQ DKHTQALVKLQEEDPTPHAHTDEETGQVIIGGMSBLHLDIILVDRMKKEPNVECHVGAPHV SYRETFKSSAQVQGKPSRQSGGRQYGDVHIEFTENETGAGFEPENAIVGGVVPREYIPS VERGLKDAMENGVLAGYPLIDVKAKLYDGSYHDVDSSBMAFKIAASLALKEAAKKCDFVI LEPHMKVTIEMPERYMGDIMGWTSRGRVDGMBPRGNAQVVNAYVPLSEMFGYATSLRS NTQGRGTYTHYFDHYAEVPKSIAEDIIKKNKGB
129.	atgactaaaaagtagcaattattctagcaaacgaatttgaagatatagaatattcaagc cctaaagaggcattagagaatgcaggctttaatactgtagtgattggagatactgcaaat agtgaagttgttggtaaacacggtgaaaaagttactgtcgattgaggcattgcagaagct aaaccagaagattatgatgcattattaattcctggaggattttcaccagatcatttacgt ggagatacagaaggtcgatatggcacatttgctaaatactttactaaaaatgatgtacca acatttgcatttgtcatgggcacaaaatactaatagatacagacgatttaaaaggtcgt acgttaacagcagtattaataatgacgcaaagattatacagacgatttaaaaggtcgt gatgagtcagtagttgtagacaacaatattgtaacaagtcgagtaccagacgatttagat gattttaatcgagaaatcgttaaacaatttacaa
130.	mtkkvalilanepedibyssprealenasprtvvigdtansevvkhobkvtvdvgiaea kpedydallipggpspehlhrgdtbsrystfakytptravvpptalchgpqilidtddlkgr titavlwrdlsnasahvvdbsvvvdnnivtsrypdblddfnreivkqlq
131.	atggctaatcatgaacaatcattgaagcgattaaagaaatgtcagtattagaattaaac gacttagtaaaagcaattgaagaagaatttggtgtaactgcagctgctccagtagcagta gcaggtgcagctggtggcgctgacgctgcagcagaaaaactgaatttgacgttgagtta acttcagctggttcatctaaaatcaaagttgttaaagctgttaaagaagcaactggttta ggattaaaagatgctaaagaattagtagacggagctcctaaagtaatcaagaagcttta cctaaagaagasgctgaaaaacttaaagaacaattagaagagttggagctactgtagaa ttaaaa
132.	Manheqiièaikemsvlelndlvkaieeefgvtaaapvavagaaggadaaaektefdvel Tsagsskikvvkavkeatglglkdakelvdgapkvikealpkeeaeklkeqleevgatve Lk

133.	gtggaaltacaattagcaattgatttattaaacaaagaagacgcggctgagttagcaaat aaagtaaaagattatgttagatatcgtagaaatcggtacgccaatcatttacaacgaaggt ttaccagcagttaaacatatggcagacaacattagtaatgtaaaagtattagcagacattg aaaattatggatgcagctgattatgaagttagccaagcaattaaatttggcgcggatgta attacaatactaggtgttgcagaagatgcatcaattaaagcagctattgaagaaagctcat aaaaataataaacaattactagttgatatgattgctgttcaagatttagaaaaacgtgca aaagaactagatgaaatgggtgtgtattatattgcagtacacactggttatgatttacaa gcagaagggcaatcaccattagaaagtttaagaacgttaaatctgttattaaaaattct aaagttgcagtagcaggtggaattaaaccagatacaattaaagatattgtcgctgaaagt cctgatcttgttattgttggtggggaatcgcaaatgcagatgaagatgcagatgcagatgcagatgcagatgcagtgaaatcgcagtaaa
134.	MELQLAIDILANKEDAAELANKVKDYVDIVEIGTPIIYNPGLPAVKHMADNISNVKVLADM KIMDAADYEVSQAIKFGADVITILGVAEDASIKAAIERAHQNNKQLLVDMTAVQDLEKRA KELDEMGADYIAVHTGYDLQAEGSELESLETVKSVIKNSKVAVAGGIKPDTIKDIVAES PDLVIVGGGIANADDPYRAAKQCRAAIEGK
135.	atgaaaaaattagtacctttattattagccttattacttctagttgctgcatgtggtact ggtggtaaacaaagcagtgataagtcaaatggcaaattcaaagtagtaaacgacgaattca attttatatgatatg
136.	MKKUPILLALLLIVAACGTOGKOSDKSNGKLKVVTTNSILYIMAKNYGGDXVDIHSIV PYGQDPHBYEVKPRDIKKITDADVILYNGLDLETGNGWFEKALEQAGKSLKDKKVIAVSK DYKPIYLNGREGHENDKODPHAWISLINGITVAKTIQOTIIDADKHKADYEKQCHKYIAQ LEKLINDSKDKPNDIPKEQRAMITSBOAPKYFSKQYGITPGYIWEINTEKQCTPBQNRQA IEPVKKHKLKHLLVBTSVDKKAMESLSEBTKKDIFGEVYTDSIGKEGTKGDSYYKMKSN IETVHGSMK
137.	atgacaactgatattttgaacatttctgaagaacaacttgttgattattctaaagccac aatgaaccttcttggatgacagaattacgtaaaaaagctttgaaattacagaaacttta gaaatgcaaaacctgataaaacaaattaagaaaatgggattttgattctttaaacaa cacgatgtaaaaggtgatttattaaaaaacttatacagaaacttta gaaatgcaaaacctgataaaaacaaattaagaaatgggattttgatccagtaagagaa attattgacgtagataatgcatctaaaaacttagtaattcaacataacaattagcgtac cacacagttgatgataatgcatcgaaagatggcgttatcgttgaaggttagcagtagagaga cacacagttgatgataatgcatcgaaagatggcgttatcgttgaaggttagcagtagacgct cttatgaaccatagtgattagtacaaaagtactttatgaaagatgcagtaacagtagat gaacatcgtatcacagcgctacacacggcattagttataggaggagtattgttatgtt cctaaaaatgtagttgtagaacatccagtacaatacgttgtgttgcacgacgacgaaaat gcaagcttttataaccatgttatcatcgttgaagaaagcgccgaagtcacatagtt gaaaattactatcaaatgcatcggtgaaggaaatcaattaaattattttgaagg attgctggtgcaaattcaaataggctcggtgacaattaatgggacata ggttaatcattagacgtggtattactgaagcggatgcctaattaggaaaaggcc tcaacaagttcacttaaatcggtgtttaggtacagcggaacaaaattattttggtgatcg tcaacaagttcacttaaatcagtagttgtaggtaacagcggaacaaaaaattaatt
138.	MTTDILNISEBOLVDYSRAHNEPSMITELARKALKLTETLEMPKEDKTELARKMOPDSFKQ HDVKGDVYGLSQLPBSVRRIIDVDHSKRLVIQHNYTIAYTQVDDNASKDGVIVEGLADA LMNHSDLVQKYPMKDAVTVDBHRITALHTALVNGGVPVYVPKNVVEHPUQVVVHDDEN ASPYNHVIIVTEBSABVTYVBNYLSNASGEENQLNIISEVIAGANSNITYGSVDYMKGF TGHIIRRGITEADASINNALGLAMEGSOIIDMTMLFGDRSTSSLKSVVVGTGEQKINLT SKIVQYGKETDGYILKHGVMKEHASSVFNGIGYIKHGGTKSIANQESRVLMLSEHARGDA NPILLIDEDDVQAGHAASVGRVDPDQLYYLMSRGISQREABRLVIHGFLDPVVRELPIED VKROLBEVIERKYSK

139.	gtggttcangantatgatgtantcgttataggtgcgggacatgcaggtgtagangcaggt ttagcatctgcangacgtggtgctanaacattantgctancantantttagatantatt gcatttatgccatgtancccatctgtaggtggaccagctanaggtatcgttgttcgtgan attgatgctttaggtggacanatggcananacantcgatanaacacacattcanatgaga atgttanatacaggtanaggacctgctgtanagagcactangagcgcangcagatanagta atgttanatacaggtanaggacctgctgtanagagcactangagagtatatgcan
	cttatcaacaagaatgaacggytgattgaagagagaagataagagtgatgaggacaattattgggtatgagaggaacttattatagaagataatgaagtgataaggtgaccaatttttacgtgtgaaggtaaagagtaattattacaacgggaacatttttacgtgtgaagtacagagtaattattacaacgggaacatttttacgtgtgaaatcattttaggtgataagaggaccaaatcaccaattaccatcaatca
	aaagatggtattttagctatcgatttattacgagatcttgaaagaactaattatttat
140	MVQEYDVIVIGAGHAGVERGLASARGARTIAHITINLINIAPMPCNPSVGSPAKGIVAR IDALGCCMAKTIDRTHIQMRMIANTGKGPAVRALRAQADKVLYQQDEMKRVIEDDESILHIMQ GMVDELI IEDNEWKGVRTNIGTEYLSKAVIITTGTFLRGEIILGNMXYSSGPNHQLPSIT LSDRIABELSPDIVRFKTGTPPRVNSKTIDYSKTBIQPGDDVGRAPSFETTSYILDQLPCW LTYTNABTHKVIDDNLHLSAMYSGMIKGYGPRYCPSIEDKFVRFNDRPRHGLFLEPEGRN TNEWYVQGLSTSLPEHVQRQMLETIPGLEKADMRAGYAIHYDAIVPTQLMPTLETKMIK NLYTAGQINGTSGYEEAAGGCIMAGINAAGKVLMTGEKILSRSDAYIGVLIDDLVTKGTN EPYRLLTSRAFYRLLIRHDNADLRUTUNGYBLGHISERYARFNERKQQIDABEIKRLSDI RIKNEHTQAIIEQHGGSRLKDGILAIDLLRRPEMTYDIILELLEEHQLMADVEEQVBI QTKYEGYINKSLQQUEKVKRMEKKRIPEDLDYSKIDSLATEAREKLSEVKPLNIAQASRI SGUNPADISILLIYLDGGKLORVSD
141.	IMINEREVPILIYLDNAAXTRAPEEVLDTYLKVNQSMYYNPNSPHRAGLQANQLLQQAKT QINAMINSKINYDVVPTSGATESNNIALKGIAYRKPDTAKBIITSVIEHPSVLEVVRYLB AHBGFKVKYVDVKKDGSINLEHPKELMSEKVGLUTCHVYNNVTGQIQPIPQMAKVIKNYP KAHPHVDAVQAFGKISMDLINNIDSISLSGHKPNGLKGQGVLLVNHIQNVEPTVHGGGQBY GVRSGTVNLENDLIAMVKAMKIANENPEALNAPYTELANDURQFIANKYHGVYINSSTSGSP FVLNISPPGVKGEVLVNAFSKYDIMISTFACSSKRNKLNEVLAAMGLSDKSIEGSIRLS FGATTTKEDIARFKKIFIIIYEEIKKLLK
142.	MNKOOKEFKSFYSIRKSSLGVASVAISTLLLLMSNGEAQAAAEETGGINTEAQPKTEAVA SPITTSEKAPETKPVANAVSVSNKEVEAPTSETKRAKEVKKVKAPKETKEVKPAAKATNN TYPILNGELREAIKNPAIKUKDHSAPNSRIDFEMKKUGTQQFYHVASSVKAPAKVIFTD SKPEIELGLQSQPWRKFEVYSGUKKLPIKLUSYDTVKDYAYIRFSVSNGTKAVKIVSST HFNNKKEKYDYTLMEFAQPIYNSAUKFKTEEDYKAEKLLAPYKKAKTLERQVYELNKIQD KLPEKLKAFYKKKLEDITKKALDEQVKSAITEPQNVQPINEKHTDLQDTKYVVYESVENNE SMEDFFVKHPIKTGHLNGKKYMVMETINDDYWKDFNVEGQRVRTISKDAKNTKTIIFPY VBGKTLYDAIVKVHVYTIDYDCQYHRLVINKEAFTKANTDKSJKKEQQDDSAKKEATPAT PSKPLTSPUKKESQKQDSQKDDNKQLPSVEKENDASSESGKGVTLATKPTKGEVESSSTT PTKVVSTTQNVAKPITGSSKTTKDVVQTSAGSSEAKDSAPLQKANIKHTNDGHTQSQNNK

i Tirez

W. C. STORY

143.

150

atgagetggtttgataaattatteggegaagataatgatteaaatgatgaettgatteat tttgcacattaccatgtacgtaatataacagcatttaacaaaaaagcaccatatgatgaa
agaattgcaaaaaattgtcattgtaattgatgagttggctgatttaatgatgatgctcag
caagaagttgaacagtctattgctagaattgctcaaaaagcgagagcatgtggtattcat
atgttagtagctacgcaaagaccatctytcaatgtaattacaggtttaattaaagccaac
ataccaacaagaattgcattattggtatcatcaagtgtagattcaggaacgatattagac
agtggtgggcagaacgcttgttaggatatggcgatatgtatatcttggtagcggtatg
aataaaccgattagagttcaaggtacattttttctgatgacgaaattgatgttgttg
gatttatcaaacaacaagaaaccggactatctatttgaagaaaaagaattgttgaaa
aaaacacaaaccaatcacaagatgaattatttgatgatgtttgtgcatttatgttaa
gaaggacatatttcaacatcattaatccaaagacatttccaaattggctataataggca
gcaagaattatcgatcaattagagcaactcggttatgttcggttaaatggtcaaaa
ccaagggatgtttatgttacggaagcagatttaaataaaagaa
ccaagggatgtttatgttacggaagcagatttaaaaaaaga

THE PROPERTY OF THE PARTY OF

我就接近你的 人名英格兰

145. 146. aaacctttaaaa 147. aatagtgaacaaattaaaaacatcgaagtgaatttgaaa

Lineary Brille on a

148.	atgaaaaagcaaataatttcgctaggcgcattagcagttgcatctagcttatttacatgg gataacaaagcagatgcgatagtaacaaaggattatagtgggaaatcacaagttaatgct gggagtaaaaatgggacattaatagatagcagatatttaaattcagctctatattatttg gaagactatataatttatgctataggattaactaataatatgaatatggagataatatt tataaagaagctaaagataggttgttggaaaaggtattaagggaagatcaatatcttttg gagagaaagaaatctcaatatgaagattataaacaatggtatgcaaattaaaaaagaa aatcctcgtacagatttaaaaatggctaattttcataaatattaatttagaagaacttcg	
	atgaaggaatacaatgaattacaggatgcattadagagagcattagatgatcagagagagagagagagagagag	
	tggaaaaagaaagttgaagaactcaaagagaactgaaactgaagactaaaactaagttgataaccaacaagggttaaa gaagagaaga	
	actcaaggagaatcaagtgatattgaagttaaacttcaagcaactgaatatactagaagtttctcaatatggtagatttcaatatggtagatttcaatatggtagatttcaatatggtattcaatatggtagaactatggtacaggattcaagatggaacatttggaatatgaagcgagaacaagattcaataagagattcaataaagtgaaacatggaaacaagagaagcaaggaagcaaggaacaagaagacaagatataacatgcaaacgagacaagtatcatacggagctcgtccgacaaaacaagccaagcaag	
	acacaaaacaagccaagccaaacaaatgcatacaacgtaacaacatgcaaacggtcaa gtgtcatacggagctcgcccgacatacaagaagccaagtaaaacaatgcatacaatgta acaacacatgcagatggtactgcgacatatgggcctagagtaacaaaa	_
149.	atgaaaaattagcaacagtaggttetttaattgtaacaagcaetttagtatteteaagt atgeetttteaaaatgegeatgeegaeacaactteaatgaatgtgtegaataaacaaagc caaaatgtacaaaateategteettatggeggagtagtaecacaaggaatgaegcaagca	
	tataatatgaaattgatgatgcgacgcaaaatattgctgataaattatgtgtgataatt acaactaatgtaggggtatttaaaccacatgctgttagagatatgaatggcatgcgcta cctttaacaaaggatggcaattttatacaacgaatgtagatgcaaatggtgttaatcat ggtggtagtgaaatggtgcaaataaaaccaacggccatatgagt cagaacacacacatggaaccaacaatgcaacaatgcaacaaggccatatgcaatcatcaaac cagaacacacatggaaccaacaatgcaacaatgcaacaaggtcatatgcaatcatcaaac	
	aacaaaaagttttaccagctgctggtgaaagtatgacatcaagtattcttactgcaagt attgccgcactactattagtatctgggttattcttagcatttagacgacgttcaacaaat	
150.	gtgcttaggagtgatttttatatgtcttattccattgttagagtttcaaaagttaaatct ggaacaaatacaacgggcatacaaaaacatgttcaaagagaaaataataattatgaaaat gaagatatagaccatagtaaaacttacttaaattatgatttggtaaatgctaataaacag aattttaataacttgattgatgaaaaaatcgaacagaattatacaggcaaaagaaaaatt agaacagacgggattaaacacattgatggtttaattacatcagacaatgattctttgat	
	lantcanacyccagaagatacaaagcagttttttgaatatgctanagagtttttagaacad gaatacggtaaagataatttattatatgcaacagttcacatggacgaanaaacaccacat atgcattatggcgttgttccaataactgatgatggtcgtttaagtgctaaagaagttgta ggtaataanaaagctttaacagcgtttcaagatagatttaatgagcatgttaaacaacga ggraataataagacgtaggcaatcaagacaactacaaatgctaaacaatgagcaata	
	agtcagtatanacananacagantatcatnagcangantatganacgtgagagcanana acagaccatatanagcanangancgatanattantganagagtaccananattgttanat acgcttananagcetatnantgttccgtatgagcanganactgananagtaggtggttta tttngcanagnantacanganactgganatgttgtantangccananagatttcantgan tttnaganacagatanangctgctcangatatttcggangattacgngtatatanangcct	
	ggtagagccttagatgataaagataaggaaatacgagagaaagatgattattaaataaa	
151.	MSWPDKLPGEDNDSNDDLIHRKKKRRØSONIDNDHDSLLPONDDIYSBPRGKPRPPMSV AYENENVBOSADYI SDEKEQYHRUYRQSHDSRSQKRHRRRRNQYTEBONYSBORGNSKI SQOSLKYKDHSHYHTINKPGTYVSAINGI EKETHKPKTHKNYSNYINHRAKDSTPDYHRES PKTSEVPSAI PGTMKPKKLENGRI PVSKPSKRVESDKOKYDKYVAKTOTSQNKQLEQEKQ NDSVVKQGTASKSSDENVSSTYKSMPNYSKVDNYIKLENIYASQIVBEI REREKKULOK RRFKKALQOKREEHKNEEQDAI QRAIDEMYAKQABRYVGDSSLNDDSDLTDNSTDASQLH	
	TNGI EMBTYSNDENKQASI QNEDTNDTHVDESPYNYEEVSLAQVSTTKQLSIDBSVTVSNV TSQHQSALQHNVEVNDKDELKNQSRLIADSEEDGATMKEBYSGSQI DDABFYELMDTBVD EDTTSNIEDNYNNKASISHIVDAFKTQBYAVTESQVNNIDKTVDNEIELAPRHKKDDQTNL SVNSLKTNDVNDRNVVEGSMNEI EKNNAEITENVQNBAABSBQNVESKTI ENVNPKKQT SVNSLKTNDVNDRNVVEDSSMNEI EKNNAEITENVQNBAABSBQNVESKTI ENVNPKKQT SVN SOM EVEN DENN HADDBYRD VENNADDBYR SVNAUPEL KVDVSKOAVSEMPASOKTPSSR	
	SDSQESNYNAYKTNINTSINVENNOLIGHAETENDYQNAQQYSEQKPSVDSTQYELFESS QDDNQLENEQUDQSTSSSVSEVSDITESSEETTHPINTSGQQDADDQQKDLQSSFSNKNE DTANENRPRINQQDVATNQAVQTSKPHIRKGPNIKLPSVSLLEEPQVIESDEDWITDKKK ELDDALFYFNUPAEVQDVTEGPSVTRFELSVEKGVKVSRITALQDDIKMALAAKDIRIERA ANDOREDWITHUNDSTANDSTAND SGILFGSPENNAESKILTVAMKYRINNEPLLEMIAKTPH	
	ALIAGATGSCKSVCINSILISLLYKNIPEELRLLLIDPKMVELAPYNGLPHLVAPVITDV KAATQSLKWAVEEMERRYKLFAHYHURNITAFNKKAPYDERMPKIVIVIDELABLIMAP GEVEGSIARIAQKARACGIHGUVATQRSSVNITGLIKANIPTRIAFMVSSSVDSRTILD SGGAERLLGYGDMLYLGSGMNKPIRVQGTFVSDDBIDDVVDFIKQQRBPDYLFEEKELLK KTQTQSQDELFDDVCAFMVNEGHISTSLIQRHFQIGYNRAARIIDQLEQLGYVSSANGSK PRDVYVYEADLINKE	

	· · · · · · · · · · · · · · · · · · ·
152.	MPKRNDIKTILVIGSGPIIIGQAAEFDYAGTQACLALKREGYRVILVNSNPATIMTDKEI ADKUYIEPLITHDPIARIIRKEQPDALLPPIGGOTGLMMAIQHESSVLQDRNVQLLGTEL TSIQQAEDREMFRTLANDIANU-VPESDIUMVVEQAFKFRQOGYPLIVRPAFTMGGTGGG ICHNDERLHBIVSNGLHYSPATQCLLEKSIAGFKBIEYEVMEDKNDNAIVUCNMENIDPV GIHTGDSIVVAPSQTISDUBYQMLRDUSLKVIRALGIEGGCNVQLALDPHSFDYYIIEVN PRVSRSSALASKATQYPIAKLAKLAVGLITLDEMLNPITGTSYAAFEPTLDYVISKIPRP PPDKFEKGERELGTQMKATGEVMAIGRTYEESILKAIRSLEYGVHHLGLENGESFDLDVI KERISHQDDERLPPIGBAIRGGTILEBINNNTIDYFPHKFQNIIDLENGESFDLDVI KERISHQDDERLPPIGBAIRGGTILEBINNNTIDYFYHKFQNIIDLENGLKEHQGDLE YLKYAKDYGFSDKTIAHFPNNTIEEBYYQLEMWANDIKPYXMVDTCAAEFESSTPYYYGTY ETENESIVTDKEKILVLGSGPIRIGGGVEPDYATVHAUWAIQKAGYBAITVNNNPETVST DFSISDKLYFEPLTEEDWANIINLEKPKGVVVQFGGGTAINLADKLAKHGVKILGTSLEN LNRAEDREMFERLLRINVPQPQGKTATSPEEALANABEIGYPVVVRPSVVLGGRAMEIV DNDKELENYMTQAVKASPEHPULVDRYLTGKEIBVDAICDGGTVIIFGHHIBRAGVHS GDSIAVYPPQTLTEDBLATLEDYTIKLAKGLNIGFULHDGFVIAHDGVVLLBYBFSSKT VPFLSKITDIPMAQLAMRAIIGEKLTDMGYQEGVQPYAEGVFVKAPVFSPNKLKNVDITL GPPMKSTGEVMGKDTTLEKALFKGLTGSGVEVKDHGFVLNTVSDKDKEEVVKLAGRLNEV GYKILATSGTANKLAEYDIPAEVVGKIGGSGDLLTRIQNGDVQIVINTWTKGKEVERDGF QIKRTTVENGIPCLTSLDTANALTNVIESNTFTNRQM
153.	MINRONKKAITKKCMISNRLAKFSIRKYTVGTASILVGTTLIFGLGNORAKAAEMTSTEN AKQDATTSDNKEVVGETENNSTTENNSTNPIKKETNTDSQPEAKKESTSSTQKQQNNV TATTETR PQNI KEKENKPSTDKTATROTSVILBEKKARNINNDVITKPSTSEPSTSEIQ TKPTTPQESTNIENSQPQPTPSKVUNQVTDATNFEPUNVSKELKENPEKLKELVRNDS NTDHSTKPVATAPTSVAPKRVNAKHFRAVAQPAAVASNNVNDLIKVTKQTIKVGDGKDNV AAAHDGKDIBVOTEPTIDNKVKKGDTMTINVDRNVIPSDLITDKNDPLDITDPSGEVTAKG TFDKATKQITYTFTDVVDKYEDIKSRLTLVSYIDKKTVPNETSLNLTFATAGKETSQNVT VDYQDPMVHGDSNIQSIPTKLDEDKQTIEQQIYVNFLKKSATNTKVDIASGVDDYGNIK LGRGSTIIDQNTEIKVYKNNSDQQLPQSNRIYDFSQYRUVTSQFDNKKSPSNNVATLDPG DINSAYIIKVVSKYTPTSDGELDIAQGTSKRETKYGYYNYAGYSNFIVTSNDTGGGDGT VKPEEKLYKIGDYWEDDVKNGSVQGTDSKREKPHANNVLYDLTYFDGTTKSVRTDANGHYEP GGLKDGETYTVKFETPTGYLPTKVNTTDGEKDSNGSSVTVKINGKDDMSLDTGFYKEPK YNLGDYWWEDTNKDGQDDANREGIKDVKVTLKDSTGKVIGTTTTDASGKYKFTDLDNGNY TVEFETPAGYTFTVKNFTADDRSNSLITTTGVIKDADNHTLDRGFYTTFYKSLEDYVWYD SNKDGKQDSTEKGIKDVTVILQNEKGEVIGTTKTDENGKYRPINLDSGKYKVIFKRAGL TQTVVTNTTEDDKADAGGEVDVTITDHDFFLINGFYFELDTSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDS
154.	MTHLLETFEMSIDHQEDGLVVISMPVTDKVKQPFGYLHGGASTALGETACSLGSANLIDT TKPIPLGLEMNANHIHSAKDGRVTATABIIHRGRSTHVWDIKIKNDREQLITVMRGTVAI KPLK
155.	MEHTTMKITTIAKTSLALGILITGVITTTTQAANATTPSSTKVEAPQSTPSTKIEAPQS KPRATTPPSTKVEAPQQTANATTPPSTKVTTPPSTNTPQFMQSTKSUTPQSPTTKQVPTE INPKPROLRAYYTKPSLEFKNEIGIILKRWTTIRFMNVPDVFIYRTALVGKDDKKYGEG VHRNVDVFVVLEENNYMLEKYSVGGITKSNSKKVDHKAGVRITKEDNKGTISHDVSEFKI TKEQISLKELDFKLRKQLIEKNNLYGNVGSGKIVIKMKNGGKYTPELHKKLQENRMADVI NSKQIKNIEVNLK
156.	MKKQII SICALAVASSI.FTWINKADA.IVTKDYSCKSQUNAGSKNGTI.IDSRYLNSALIYYL BDYII YALGILTHKYBYGDNI YKEAKDRILEKVI.REDQYILIERKKSQYBDYKQWYANYKKE NPRTDLKMANPHKYNI.BELSHKEYNBI.QDALKRALDDPHREVKDI.KDKNSDLKTFNAABE DKATKEVYDLVSBI.DTI.VVSYYGDKDYGEHAKELFAKLDI.ILGIDTNPHKI.TNERI.KKEM IDDLINSI I.DDPHBETKQNRPRSSITKNPHTHNYKTNSDNKPHPDKI.VBETKKXVERADDS WKKKTVKKYGETETKSPVVKEKKVEEPQAPKVINQQBVKTTAGKABERTYDPVAQPLVKI PQGTITGEIVKGFEYPHTHENKTVQGETVQGFDFLIMEQSGPSLSNNYINPLITNPILEGIL BGSSKLBI.KPQGTESTI.KGTQGESDI.EVRPQATETTASAQVGPRQFNKTPKVKYKYD AGTGIREYNDGTFGYBARPRPNKPSETNAYNVTTHANGQVSYGARPTYKKPSETNAYNVT THANGQVSYGARPTQNKPSKTNAYNVTTHANGQVSYGARPTQNKPSKTNAYNVTTHANGQ VSYGARPTYKKPSKTNAYNVTTHANGTPFORKP
157.	MKKLATVGSLIVTSTLVPSSMPFQNAHADITSMNVSNKQSQNVQNHRPYGGVVPQGMTQA QYTELBKALPQLSAGSNMQDYNMKLYDATQNIADRYNVIITTNVGVFKPHAVRDMCHAL PLIKDGNPYQTNVDANGVNHGGSEMVQNKTGHMSQQGHNQNFHMQQPHMQQGHQSSN HQMMSPKANMHSSNHQMNQSNKKVLPAAGESMTSSILYASIAALLLVSGLFLAPRRRSTNK
158.	VLRSDPYMSYSTVRVSKVKSGTMTTGIQKHVQRENNYENEDIDHSETYLNYDLVWANKQ NFNNLIDEKIEGNYTGKRKIRTDAIHHIDGLITSDMDFFDNOTPEDTKQFFFYAKEFLEQ EYGKDNILLYATVHMDEKTPHEMFYGVPITDDGRLSAKEVVGNKKALTAFQDRFNBHVKQR GYDLERGOSRQVTNAKHEQISQYKQKTEYHKQBYERESQKTDHIKQRNDKLMQEYQKSLN TLKKPINVFYEQETEKVGGLFSKBIQETGNVVISQKDFNEFQKQIKAAQDISEDYBYIKS GRALDKDKEIREKDDLLNKAVERIENADDNFNQLYENAKPLKENIBIALKLLKILLKILLKEL ERVLGRYYFAERVNKLTEDBENA

Gaaatateleabateattaagettattabagattaeattababateta
MMKKLKASEIROKYLDFYVEKGHMVEPSAPLVPIDDTILININGVATILKYYDGRETPK
KPRIVANSOKAIRTADIENVGFTARHHTPFEMIGHPSIGDYFKOBAIEPAWBFLFISDKAMG
HEPDKLYVTIHPEDMEAYNIWHKDIGLEESRIIRIEGHPWOLGEGPSGPHTEIFYDRGHA
YGODDPAKEMYFGGENERYLEVWNLVPSERHHKUHSTTPLPNKNIDTGMGLERMASVSQ
NYRTNTETDLFMPIHMSIEKVGSGQYLVNNEQDVAFKVIADHLRTIAPAISDGALPANBG
RGYVLRRILRRAVRFSGTIGINEPFMYKLVDIVADIMEPYYPAVKEKADFIKRVIKSEB
RPHETLEDGLAILNELIKKAKATHBINGEDAPKLYDTYGPFIELTBEIAVOGALKVDMT
TYESEMQQGRORAROARONSGSMGVGSEVLKNITSASTFVGYDTATAGTTLTHLIYNGEB
VSQVEAGETVYFMLTETPFYAISGGVADTGIVYNDNFEIAVSEVTKAPNGGRIHRGVV
SHFGPMTNDBIDQVERLVNEEIWKGIDVNIQEMDIASAKEMGAMALFGEKYGDVRVVNM
APFSIELCGGIHVRNTSBIGLFKKVSESGTGAGVRRIBALTGKAAPLYLEDIGEKFYTMK
SQLKVKSDDQVVDKLTQLQDESKALLKQLEQRDKRITSLKMGNIEDQVEEIRGYKVLVTE
VDYPNAKAIRSTWDDFKSKLQDTIILASSVDDRVSMVATVPKSLTMNVKAGDLIKQMAP
IVVGKGGGRPDMAQGGCTQPENISKSLSFIKDYIKNI

160.

161.

. . . . . . . . . X

	MNSEFIYGRVTNLGGKILSLIKKKNKDIRIIPLGGVGBIAKNMYIVEVDDEMFMLDAGLM
162.	
	Language movement to committe the committee of the control of the
1	
1	
{	
ì .	LAABAGVAPEKIFLVEKGDVINYNGKUMILNEKVNSGNILIDGIGICDVGNIVLRDRHLL
1	LAAKAGVAFEATEUVEAGIJVINTROAATII AEDGIFIAVVTLDPKNRRIAAGPEIQSRGFVYVRESEDLLREAEEKVREIVEAGLQEKRI
i .	ABIGIPIAVVTLDPRNACIAAGIST SQUARE EWSBIKQNMRDQISKLLFESTKRRPMIIPVISBI
	EWSELKQNARDQUISKDDEESTROOMETTY
163.	atggaaataacaatgcctaagttaggtgagagtgttcatgaaggcaccattgaacaatgg ttagtttctgttggtgatcatattgatgaatatgaaccattatgtgaagttattacagaa
1	tragttetgttggtgacatattgatgaatatgaattatatgagaagatttagagaaatttagttgaa aaagtgacagctgaagtcccttccacgatatcaggaacaattacagaaattttagttgaa
i	aaagtgacagctgaagtcccctccacgatattaggaacaattagaaactgctgatgaaaaag gcggggcagacagtagctattgatacaattatctgtaaaattgaaactgctgatgaaaaag
1	gcggggcagacagcagcagctactactactactactagaaatactactactacaaaaatgaaatgaaaacaactgaagagatacaagcaaaagtggatgagcatactcagaaaactaact
1	acasatgasactactgasgacatasgcastctactgctsasacasaatcasaccacgtast
	aaaaaagctagtgtaacagtggaacagatacttactgtcaatagacatgacattgattatca aatggtcgcttttcacctgttgtatttaaactcgcttcagagcatgacattgattatca
1	aatggtcgcttttacttgttgtatttaaatttgtttagagtagtatataatgtcagttatt caagttgtaggtagtggatttgaaggtcgtgtaactaagaaggatataatgtcagttatt
	gaaaatggtggtaccacagctcaatctgacaaacaagttcaaacaaa
1	ltoppotescaltcatctasaascataataasaacaacacacacacac
1	ggtgtgcgtaaagcaattgcgcaaaatatggttaatagtgtaacagagattccacatgca
l .	hamakankankankankankankankankankankankankan
	-correspondence to the contract of the contrac
	l managementtennammentaterettettaattagtagttggcaaggaaatyaaattyt
	i trocatecamenattantatticanticinticinatonananalinaticaturytuccu
1	mtmattagccatgcagacgaaaagtcaatcaaaggtatagctagagaaattaatdcttd
1	
1	
	canacaggtaaatttatgaatcatattaaacagcgtatcgaacagtatactttagaaaat
	acaantatatat
164.	MPTOWONI CRESHECT TROWN VSVCOHI DRYEPICEVITOKVTABVPSTISCTITEILVB
104.	I ACOURT TOWE TOWE TO THE TORK THE PERSON TO A KYDERTOK STRAGASAT VEGI STRAGAGI VEGI S
-	I NYCED COMPRESA GRADITED SCRINGSCHEGRUTKKDIMSVI KNGGTTAQSDKQVQTKSTSV
l .	I procence consistency to include the Constant of the Constant
1 .	L CHANGE CONTROL OF THE WAY AND ALKAYPI INSCRICT WHICH KOINI SIAVADENALIVY
	VIKWADERSTRGTAREINTLATKARNKOLTAEDMOGGTFTVNRIGIFGSVSSEGILNHPQ
	AAILOVESIVKKPVVINDMIAIRNMVNLCISIDHRILDGLQYGKPMNHIKQRIEQYTLEN
	TNIY
165.	
166.	
167.	atggaggacaacatgatttatgcaggtattttagcaggaggtattggttcgagaatgggg
107.	l apontoccattaccaaaacaatttttagatattgataataataaaccgattttaatccataca
	attracaeqtreattttagtgagtgagtttattagggattattatcgcagccagc
1	l togatttcocatacacaggatattttaaaaaaatataacattacagatcaacqtqtcaaa
1	mtanttmcanntmntacmmatcmaantmaaacaattatdaacattatcqaccatattcqc
	aargraaatggaattaataatgatgatgtgatgtaactcatgatgccgtaagaccattt
1	transferancetattattaangagaacattgaagtagcagcaaaatatggtgcagtagat
i	l acagteattgaageaattgatacgattgtaatgtetaaagataaacagaacatacacagt
	l atcontotagggaatgaaatgtatcaaggccaaacaccacaatcatttaatattaaatta
i	ttacaagatagttatcgcgccttaagtagtgaacaaaaagaaatcttatcagatgcatgt
i	aaaatcattgtcgaatctggacatgcagttaaattggtacgtggagaactatacaacatt
1	aaagtgacaacacgtatgatttaaaagtagcaaatgccattattcaaggtgatattgcc
	gatgat
168.	MEDNMIYAGILAGGIGSRMGNVPLPKQPLDIDNKPILIHTIEKPILVSEPNEIIIATPAQ
	WISHTODILKKYNITDQRVKVVAGGTDRNETIMNIIDHIRNVAGINNDDVIVTHDAVRPP
]	I TOOD TYKENTEWAAKYGAVIYEVTRATIYETVMSKDKONIHSI PVRNEMYOGVI PQSYNLAL
1	LQDSYRALSSBQKBILSDACKIIVBSGHAVKLVRGKLYNIKVTTPYDLKVANAIIQGDIA
1	DD

"K

LEEMING CONTRACTOR

	atgataatattggtgtatgacagttaatggagggaacgaattgaaagctttattatt aanacagtgtatggcccgttttgctttttatttttagtgtaatgggatattatggcaagcc gcggctgagcagcatcacccaatgaaagcacatgcagtaacaacgatagacaaagcaca gcggctgagcacatcaccccaccaaggaaggcgctcatcattctggcaaagaagg gcaaccacgtatcagcatcagcgcagggaacacggtgatgacaacagcaagtaaca gcaaccacctactaacagcaccacttacagtagtttcaacaaaagtaacagtcacaccacctacacagcacacgtcacaccaccacacaca	
170.	MIIYWCMTUNGCNEMKALLIKTSWIJULIFSUNGIMQVSNAABQHTPMKAHAVTTIDKAT TDKQQVPFTKRAHHSGKEAATNVSASAQGTADDTNEKVTSNAPSNKPSTVUSTKUNETR DVDTQQASTQKPHTTATPKLSNAKTASLSPRMFANNAPQTTTHKILHTNDIHGRLAEEKG RVIGMAKIKTVKEQEKPDLMLDAGDAPQGLPLSNOSKGEDMAKMAVGVDAMAVGNHEF DPGYDQLKKLECHLDFMLSTNVYKDGKRAFKPSTIVFKNGITKYGIIGVTTPETKTKTRP EGIKGVEPRDPLQSVTARMMRIYKDVDTPVVISHLGIDPSTQBTWRGDYLVKQLSONPQL KKRITVIDGHSTTVLQNGQIYNNDALAQTGTALANIGKITFNYRNEVSNIKPSLINVKD VENVTPNKALASQINOADQTTRAQTASVIIPNNTIDERGERDUKTRETNIKINAIADAME AYGVKNPSKKTDPAVTNGGGIRASIAKGKVTRYDLISVLPPGMTLAQIDVKGSUWMTAPE HSLGAPTTQKDGKTVLTANGGLLHISDSIRVYYDINKPSGKRINAIQILNKETGKPENID LKRVYHVTMNDFTASGGDYSMFGSPREEGISLDQVLASYLKTANLAKYDTTEPQRMLLG KPAVSEQPAKGQQGSKGSKSGKDTQPIGDDKVMDPAKKPAPGKVVLLIAHRGTVSSOTES SGRTIEGATVSSKSGKQLARMSVPKGSAHEKQLPKTGTNQSSSPEAMPVLLAGIGLLATV	
. 171.	atgcaagagtaccaaaaatcgttaaatacgcttaaaaagcctataaatgttccgtatgag caagaaactgaaaaagtaggtggttaattattagcaaagaaatacaagaaactgaaatgtt gtaataagccaaaaagattcaatgaatttcagaaacagaataaaagctgctcaagatatt tcggaagattacgagttatataaagtctggtagagccttagatgataaagataaaggaaata cgagagaaagatgatttattaaataaagcagttgagcgtattgaaacgcagaacgataat tttaaccaactttacgaaaatgcaaagccacttaagaagaatatagaaataggttaaag cttttaaaaattctactaaaaagattagaacgagtttaggaagaatatagaataggttaaag actttaaagttaactagaagatgaaccaaaactaaatggtttagcaggaaacttagat aaaaaaatgaatccagaatataattcagaacaggaacatgaacaagaacaacaaaagaat caaaaacgagatagaggtatgcactta	
172.	MQBYQKSLNTLKKPINUPYEQBTEKUGGLFSKEIQBTGNVVISQKDFNBFQKQIKAAQDI SEDYBYIK SGRALDDKDKEIRKKDDLLNKAVERIENADDNRNQLYENAKFLKENIBIALK LLKILLKKLERVLGRWTFABRVNKLTEDEPKLNGLAGNLDKKMNPBLYSEQEQQQEQQKN OKRDRGMHL	
173.	atgaagatgataaacaaattaatcgttccggtaacagctagttgctttattataggcgct tgtggcgctagtgccacagactctaaagaaaatcacttaatttcttctaaagctggagac gtaacagttgcagatacaatgaaaaaaatcggtaaagatcaaattgcaaattgcatcattt actgaaatgttaaataaaaatttagcagataaagaag attgacgaacaaattgaaaaaatgcaataacagcggtaaagataaatttgaaaag attgacgaacaaattgaaaaaatgcaaaagcggtaaagaaatttaaagaaga gccttcaacagcaaggtttaacagccgataaatataaagaaaatttacgtactgctgct tatcataaagaattactatcagataaaaattaaaatctctgattctgaaattaaagaagac agcaagaaagcttcaacaattttaattaaagataaatctaagaaaaagaagattcaaagaaggc ttagatgataaagaagcgaaacaaaaagctgaagaaattcaaaaagaagttcaaaagaaggc ccaagtaaatttggtgaaatcgctaaaaaagaacaatggataaaggtcacaaaa gatggcgaattaggtatgttcttaaagagacaaactgataaagatttgaaaaaagaagcacta tttaaagcttaaagatgtgaagtatcagaggttgttaaaatcaaggtttggatatcatatt attaaagctgataaaccaacagactttaacagtgaaaaacaaagactgataaagaaaatta gtcgatcagaaagtacaaaaaaaaccaaagtgataatgatgcatacaaagactatta aaagaatacgatgttgactttaaagatgtgatattaaatcagttgtcyaagataaaatc ttaaaccctgaaaagttacaaaaaaatcaaagtggatataaagatgataaaaa	
174.	MKMINKLIVPVTASALLIGACGASATDSKENTLISSKAGDVTVADTMKKIGKDQIANASF TEMLNKILADKYKNKVNDKKIDEQIEKMOKOYGGKDKFEKALOQOGIFÄDKYKENLRTAA YHKELLSDKIKISDSBIKEDSKKASHILIKVKSKKSDKEGLDKEAKQKAEEIQKEVSKD PSKFGEIAKKESMOTGSAKKDGELGYVLKGGTDKDFEKALPKLKDGEVSEVVKSSFGYHI IKADKPTDFNSEKQSLKEKLVDQKVQKNPKLLTDAYKDLLKEYDVDFKDRDIKSVVEDKI LNPEKLKQGGAQGGGSGMSQ	·

175. atypettitagitattagitagitagittagittagittagitt			
gatagitamittagicamaspartiguaityamittagityamitt	175.	gtaaccaagaaattagcttcagaatttaaaaaagagcataaaaugctgatattaauttaaacttaagagagcattaagaaaaaaatgctgatattaaattaactaaaaaaaa	
NYGSSALRROIESGAPUPPRSANTEUPUNALDKARAMIPTYTAARSIVLIGUALDSSALRS SYKDIAMBRIKALBSVAYVPAKSTAVQUIRARSI, PERUSSKERT LAUGUSSALRS LEGYHTAA.  177. tiggetalaanataanattaaaattaaaagattattattyeringskertaaattaagattattattye titagattattattaaaattattaagattattaattaagattatt		gatagtamattagcamangagtggatggaattcttamamtcagatamagctamagamaca	$\left  \right $
ttacattattacgatgaaatugaaaatugaagatttatagtucagatagtittataaatuttugi gittataaangaaagagtttagaaaaatugagatttataatugagatttagataaatugatttugaaaagatttugaaaaagatttugaaaaagatttugaaaaagatttugaaaagatttugaaaagatagat	176.	NYGGSGALRKQIESGAPUDVFMSANTKDVDALKDKAKAHDYTKYAKNSLVLIGDKDSNYT SVKDLKDNDKLALGEVKTVPAGKYAKQYLDNNNLPKEVESKIVYAKDVKQVLNYVEKGNA KQGFVYKTDLYKQNKKIDTVKVIKEVELKKPITYEAGATSDSKLAKEWMEPLKSDKAKEI LKEYHFAA	
tctgtatigtgsattattanaggsactctctatatagtacacgoattttaaacaacga ctacagtacaacaattgataaagaagacacttaaaattgacaacaattgatacaa tcatttattagacgtaaagacgacttacaatcgcaggatatcagaacaatta tcattattagacgtaaagacgacttacaatcgcaggatatcagacattaa tcttaattgacgtaaagacgactttacaatcgcaggattatttagaagacatta tcttaattgacgtattgaagacgactttataatttattgagaacatta tgctgattgctaaaacatatgaagatgataactatacgctggattttaatttattattatta tgctgattgctaaaacatatgaagatgataactatttttaatttattatta gataatcaaaatttagacgatagacgatttatatttttagagacaatta gataatcaaaatttagacgatagagacgatttatatttttagagacaattg aataagagcgacaatttt  178. ANTTINSDI BINDVINKTINYDDIGLIVPUNDKNINKVYKQQDLKKLQKILIIKSFDF FDTAKIKQYISTDRNIGHAVGFIRKDDIGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGA		ttacattattacgatgaaataggattattagtteeagataaaatgataaaaattatuge gettataaacagcaagacttagaaaaattacaaaagattttaatactcaagtetttigat ttbratategetaaaataaaacaatacatttegtatgataatgacaattgegaaagtta	
178	eTires.	tctgtafgtgaatttaftaaaggactctctctaatagataccagcattttaaacaagaca ctacagtcacaatatgataaagaagcatctataaaatatggtcatacgaaagcatatcaa tcattattagacgtaaagacagcttacaatcgaaggatatcagacataaattgacaact atcttcaataaatttaatcatatgtctttgagtcattatccaatccaagattgtagtgat ctcgtatttgagtggaaggcatttatgaacactatcgctgattttgatgatgaaacatta tgctgtattgctaaaacattatagaagatgataacgctttcaaagattactttaattcatat gataatcaaaatttagcatcatacatttcagaagctgttaattattttttgagcatgtg	
atgycamantaaagcaatgyagcattagttaagcatgyggtatagty cagtygtagtygagtyagtagtyagttagttaagtacagty agagatcaatttaaattttatcatgtacgtcatgyagagttaggtatgagtyggttta agagatcaattttaattttataatgytaagtacgyttagtagtagtyggcctygttta attcatttattaaatgytatgtatgatgyacgttaggtagtagtagtagtatagta	178.	MAYTYTLKOIIBITGVTKRTLHYYDEIGLLVPDKNDKNYRVYKQQDLEKLQKILLLKSFD FDIAKIKQYISYDNBQLAKLLSEQISKLDKKISDLQLIRSVCEFIKGLSLIDTSILAKT LQSQYDKEASIKYGHTKAYQSFIRRKDSLQSQDIRHKITTPRKFMENSLSHYPIQDCSD LVFEWKAFMNTIADFDDETLCCIAKTYEDDTRFKDYFNSYDNQNLASYISBAVNYFLSNV	
GTTKLTGKIGVALSIGGEGLIHLLNGMYDAKHENNYOLILGGGTMSTALGTKAPGETNLQ KLCEDVAVYNKQIEKGDNVPELVNEAI TRAYPDKGVAVVICPNDLITERIKEDTYNKFUPT SRPTVVSPKYKDIKKAVKLINKSKKPVMLIGVGAKHAKDELREPIEMAKIPVIHSLPAKT ILPDDHFYSIGNLGKIGTKTSYQTMGEADLLIMVGTNYPYUDYLPKKRIKAJQIDTNEKN IGHRPNINVGITUGDSK IAHGUTENIKVVAERPFINKTIERKAVMENNEGOENGKNNNSKPL RPERLHASINKFIKDDAVISADVGTATVMSTRYLNIGVNEKPISWLGTMGCGLPGATA SKIAYPNRQAIAIAGGGAPQNVMQDPATAVQYDLPVIVVLNNKQLAFKYEDQAAGELE YAVDFSDHDHAKPARAAGGKGYTIKSASEVDALVERALAGUVPTIVDVYVDPNAAPLPGK IVNEEALGYGKWAFRSITEDKHLDLDQIPPISVAAKKFL  181. gtagtagtttagggcttgcaacgcac  182. caccatcataggacttgcaacgac  183. ctgatactggacaacaatagaga  184. aagtaacgttatctttcgatggt  185. atttctggcactcaagtatacaattggt  186. tggcttaggtgttggtaggc  187. ataatgcaactacaactcagcc  188. ttgatgttgatgttattttgattagat  189. ctacaataactacagcgttaca  190. gtgaatgaagttatacaagag  191. cacgctaaagcatcagtgacaga		atggcamanatamangcamatgangcattagttmangcattmacagcatgggatatagat cacttgtatggtattccanggagactcantcgacgatgatggttagttacgtacagtg angagatcamtttmacatgtmanatcggtcatgangagagagcangcttagcggctgt ggttacacamanttmactggtmanantcggtgggattmacgtacggggcctggttt attcattmatmantggtmatgatgatggcamattggmangcattcagtggccctggttta attcattmatmantggtmatgatgatgccamantggmangcatccagamacaattmatata tctggmacamacgamatagtacagcacttggmacgamagcattccamgamacamattmacaa amattmatgtmangcagcgtttmatmatcaccamattgmamangggmacamattgtt gmantcgttmacgamgcamtcgtmacgcatatgmaccamamaggggtmacamttgtt tgcctmacgmactmattcgtmanamattmangatacmamaggggttmactmatt tagamacamacagtmatacacamamatmanagatmanaccamatagragatmac tcmagaccamacagtmatacacamamatamangacatcmamamaggggttmanactmatt amtmamagatmamanagcctgtcatgttmattggtgtmacamamagcggttmanactmatt amtmamagatmamamaggctmanattcctgtcattcattmaccagcamamagag ctmagtagamattmattgmamattcctggtmacttmagtmamatcggtmacamamaca tcttatcmamamaggaggamattattmattmatggttggtmacamamataccama tcttatcmamamaggaggagatttmattmattmaggtggtmacamamataccama tcttatcmamatagamagamaggatttttgggmamatagtmamattggttgcat cagtmacagamatttmatmangagaggmacamamatatcamatt gtggatmacttccatamamatggatggmacamamatattcttmamamacamt acgtmanacggttttgggamamatggatggmacamamamatatmatagtmamaccattm cgtccagmacggtttgggamataggatggmacamamatatmamagatgmaggagagagagagagagattca gcagatgtmaggtacamacagtttggtcamactcgatacttmaccttggtgmamacama cgtmacagattcatattcamataggatacamattggttgggctttccamattggt tcmamatagcamagatttggttmaggtmacamagagagggggggggg	
182. caccatcatagaacatacaattgctagc  183. ctgatactggacaacatagaga  184. aagtaacgttatetttcgaattggt  185. atttctggcactcaagtatatcaagac  186. tggcttaggtgttggtgtgggc  187. ataatgcaactacaactcagcc  188. ttgatcgttgatgttattttgattagat  189. ctacaataactacagccgttaca  190. gtgaatgaagttatacaagcggt	190.	GYTKLITGKIGVALSĪGGFGLIHLLNGMYDAKHUNVPQLILSGQTNSTALGTTĀRPĢSTNLQ KLCEDVAVYNHQIEKGDNVPEIVNEAIRTAYPQRGVAVVICPRDLITEKLEDTINKPVDT SRPIVVSFRYKDIKKAVKLINKSKKPVHLIGVGAKHARDELREFIEHAKIFVIHSLPAKT ILPDDHPYSIGNLGKIGTKTSYQTMQEADLLINVGTNYPYVDYLPKKNIKALQIIDTNPRN IGHRPNINVGIVGDSKIALHQIPENTKIVHZERPFINKTIRRAKVHKOMEQDKNNNSKPL RPERLMASINKPIKDDAVISADVGFATVMSTRYLMLGVNNKPISSSHLGTMGCGLPGAIA SKILYPRNQAIAIAGDGAFQMVMQPDLPTVVTVINKQLAFIKYBQQAAGELE YAVDFSDMDHAKFARAGGKGYTIKSASEVDATVERALAQDVPTIVDVVVDNNAPLPGK	
183. ctgatactggacaacatagaga 184. aagtaacgttatctttcgaatggt 185. atttctggcactcaagtatacaagac 186. tggcttaggtgttgggtaggc 187. ataatgcaactacaactcagcc 188. ttgatcgttgatgtattttgattagat 189. ctacaataactacagccgttaca 190. gtgaatgaagttataaccagcag 191. cacgctaaagcatcaggaga			4
184. aagtaacgttatetttegaatggt 185. atttetggcacteaagtatateaagac 186. tggcttaggtgtggtgtagge 187. ataatgcaactacaacteagce 188. ttgategttgatgtattttgattagat 189. ctacaatactacagcegttaca 190. gtgaatgaagttatacagcggt			$\dashv$
185. atttctggcactcaagtatatcaagac 186. tggcttaggtgtggtgtaggc 187. ataatgcaactacaactcagcc 188. ttgatcgttgatgtattttgattagat 189. ctacaataactacagccgttaca 190. gtgaatgaagttataaccagcag 191. cacgctaaagcatcagtgacaga			
187. ataatgcaactacaactcagcc 188. ttgatcgttgatgtattttgattagat 189. ctacaataactacagccgttaca 190. gtgaatgaagttataaccagcag 191. cacgctaaagcatcagtgacaga	185.	atttctggcactcaagtatatcaagac	4
188. ttgatcgttgatgtattttgattagat 189. ctacastaactacagccgttaca 190. gtgaatgaagttataaccagcag 191. cacgctaaagcatcagtgacaga			$\dashv$
189. ctacaataactacagccgttaca 190. gtgaatgaagttataaccagcag 191. cacgctaaagcatcagtgacaga			+
190. gtgaatgaagttataaccagcag 191. cacgctaaagcatcagtgacaga			J
191. cacgctaaagcatcagtgacaga			1
192.   agcattttgatgtgttgttgttgtt		cacgctaaagcatcagtgacaga	4
	192.	agcattttgatgtgttgttgtgtt	٢

.. ....

and the second of

The contract of the contract o

	was been congress tanks	
193.	gaatccccaagcacctaaac gtaaacgttgatcaagcacact	
194.	tttgcaataacagcaacatctggtgcag	
195.		
196.	gaaacttctgaagctggaattgtacgg atgagaaaaactaaaattgtatgtacaattggaccagcttcagaatcagaagaaatgatt	
197.	[	
	l annoncentaragettestararatteetaaadtadetaaadtagacagacc	
		•
	l about two of the agent of the contract of th	
,	atttacttgatgatggcttaattgaattacaagttaaagatattgacatgctaaaaaa gaagttaaatgtgatattttaaactctggtgagcttaaaaacaaaaaaggttaactta	
	gaagttaaatgtgatattttaaatttggtgagtttaaattaataggagatatcgtttc cctggcgtaagagtaagtttacctggtattacagaaaaagatgctgaagatatccgtttc	
	l meentt naamapapatottoartroartoonoonadeeeedeedeedeedeedeedeedee	
	FEDERAL PROPERTY AND A THE PROPERTY AND ARREST ARREST AND ARREST AND ARREST AND ARREST AND ARREST ARREST AND ARREST AND ARREST AND ARREST AND ARREST ARRE	
	l annonnesser and the tratestattoromanal totto and totto tot	
	l artacratartarcetamentationneticanticalcumnanducucuduluucuudaaa	
	gatttaatcagacaatgtaacaaattaggtaaaccagttattacagctacacaaatgtta	
-	gattttattgcaacgtaacccacgtgctacacgtgcagaagetagtgacgttgccaacgca atctatgatggtacagatgcagtaatgttatctggtgaaactgctgctggtttattacct	
	cances of the transport of the transpo	
	aammadtrattatcamatcatactaattaattaattaaattaattaat	
194		
	paragreesecorescotectatetecasatategtecaeatteaatteaattattattattattattattattatta	
	actorsecto	
	aaaaaaggacgtaagagtacagatgcattgttaaacaatgcagttgcaacagctgttgaa	
	actggtagagtatctaatggtgatttaatcattattactgctggtgtaccaactggtgaa actggtagagtatctaatgatgaaaatccacctagttggtgacgaaattgctaatggtcaa	
	l matattagaegtggatggatggttggtagtagtaggtaggt	
	l gaaggtaaagatttatctgacaaagttatcgttactaactcaatcgatgaaacgtttyta	
	ccttatotagaaaaagctttaggcttaattacagaagaaaatggtattacaccaagc	
•	i gcaattottootttagaaaaaggtattccaacagttgtaggtgtagaaaaagctgttaaa	
	acataagcaataacatgttagttacgattgatgctgctcaaggtaaaatctttgaagga	
	tatgcaaacgtacta	
198.	atgcaattcgataatattgacagtgctttaatggctttaanaaatggagaaccaattatt	
	gtagtagatgatgagaatcgtgaaaatgaaggtgatttagtagcggttactgaatggatg aacgataataccattaattttatggcgaaagaagcaaggggattaatatgcgcaccagtg	
	totaaagatattgcacaacgtttggatttggtacaaatggttgatgataactccgacatc	
	tttggraggaatttacagtgagtattgatcatgtagatacaacaacaggaattagtgct	
	tatgaacgtacattgactgccaaaagctcattgatcctagtagtgaagctaaagatttt	
	l aatomtootootoottatttooattagtagcacaagataaaggcgtattagctagaaat	
	! ggarararagagggggtgttatttagttaatttagttatttgtgtgtgtgtgtgtgtgtgtt	
	atttgtgagattatgaatgatgacggcacgatggcgaaaggacaagatttacaaaagttt	
	aaagaaaacatcaattaaagatgattacgattgatgatttaattgaatatcgtaaaaaa ttagaaccagaaattgaatttaaggcaaaagtgaaaatgcctacagatttcggaacattt	
	gatatgtatggttttaaagcgacatacacagatgaagagatagttgtactgacaaaaggt	
	gcasttcgacascatgaaaatgtacgcttacattctgcgtgccttacaggcgatattttc	
	catagtcaacgttgtgattgtggtgctcaacttgaatcgtctatgaagtatatcaatgaa	
•	catggtggcatgattatttatctacctcaagaaggtcgtggcataggattgttaaacaaa	
	ttacgcgcatatgaattaattgagcaaggatatgatacagtaactgcaaatttagcatta ggttttgatgaagatttgcgagattatcatattgctgcacagattttaaaatattttaac	
	atcgaacatatcaatttattaagtaataatccaagtaaatttgagggattaaaacaatat	
	ggcattgatattgcagaaagaattgaagttatcgtaccagaaacggtacataatcatgat	
•	tatatggaaacgaaaaaataaaaatgggtcatttaata	
199.	atgaaaatgaaaaattagtcaaatcatcagttgcttcatcaattgcactgcttttgcta	
	tcgaatacagttgatgcagctcaacatatcacacctgtaagcgagaaaaaagtagacgac	
	aanatcactttatacaaacaacagcaacatctgataatgataaattgaatatttctcaa	-
	attttaacgtttaatttcattaaggataaaagttatgacaaagatacgttagtacttaag	
	gcagccggaaacattaattcaggttataaaaagcctaatccaaaagattacaattactca	
	cagtittatiggggcggtaagtataatgtitcggtiagticagaatcaaatgatgcigta aatgtigtigactatgcacctaaaaatcaaaatgaagaaticcaagticaacaaacatta	
	l gottattettatogeogagatattaatatatetaatggettateaggtggattaaatgga	
	treeastrattttramaarominaattatmaacaagaaagttacagaactacqattgat	
	acapaggaatestasatesattmctouddtdttdsQQCCCacaaattatQaataat	
	anttonnaccatatontagagatagttatgacccaacatatggtaatgaactgtttta	
	amount amacaaant ant to aaa too too too too aaaa t t t c t g c caaca c c c c c c c c c c c c c c c	
	ttattggcgcgtggtaactttaacccagaatttataagcgtactttctcataaacaaaat gatacaaaaaaatctaaaatcaaagtaacttaccaaagagaaatggatagata	
	caatggaatcgactacactgggttggtaataactacaaaaatacagtaaagttt	
	acatctacttatgaagttgactggcaaaaccatactgttaaattaatcggtacggattct	
	aaagaaactaatcctggagta	
200.	Argagagagagggtagtagtattatttttaggtattatggtctttttggctggttgt	
	Gactartcraacctgaaaaacqtagtgggtttttctacaatacattcgtagatccaatg	
	laaaardraffugaffugffuggaaffacttattaaacgacaattatggtttagctatt	
	Attatecttotattootaattegtattattitattaceatteatgttgteaaactataaa	
	Aatagtcatatgatgcgtcaaaaaatgaaagttgcaaagccagaagttgaaaaaattcaa Gaaaaagtgaaacgtgcgcgtacacaagaagaaaaaatggctgcaaaccaagaattaatg	
	Gaadaagtgaaacgtgcgcgcacacaagaagaahaantggctgcaaaccaagaaccaatg Caagtatataaaaagtatgacatgaacccgattaagagtatgttgggttgtttaccaatg	
	Ctaatccaattaccaatcatcatgggattatactttgtacttaaagaccaacttgtagat	
	Gqtttqtttaaatatccacacttcttatggttcgatttaggacgtcctgatatttggact	
	Ggtttgtttaaatatccacacttcttatggttcgatttaggacgtcctgatatttggatt Acaattattgccggtgttttatactttatccaagcatatgtatcaagtaaaacgatgcca	
	Acaattattgccggtgttttatactttatccaagcatatgtatcaagtaaaacgatgcca Gacgaacaacgtcaaatgggttacatgatgatggtcatttcaccaattatgattatctgg	
	Acaattattgccggtgttttatactttatccaagcatatgtatcaagtaaaacgatgcca Gacgaacaacgtcaaatgggttacatgatgatggtcatttcaccaattatgattatctgg Attcattaagatcagcattagctttgtttgttactggtcattcagtcag	
	Acaattattgccggtgttttatactttatccaagcatatgtatcaagtaaaacgatgcca Gacgaacaacgtcaaatgggttacatgatgatggtcatttcaccaattatgattatctgg	

atgaatttattcagacaacaaaaatttagtatcagaaaatttaatgtcggtattttttca gctttaattgccactgttactttatatctactaacccgacaacagcgtctgcagcagag caaaatcagcctgcacaaaatcaaccagcacaaccagctgatgccaatacacagcctaac cangctcangnancaycuntryatgganatautygcucancantganyaanangcang gctanacaacangttcanactganananacaacagctgatgccgaatagatgcagcacat acanatgcggangttgangcggctanananagcagcanttgctananatgangcganttcag ccagcancancactanagatantgcyanangangcanttgctacagnangcgantgancgt anaacagcantcgctcanacgcangacattartgctganganattgcagcggctantgcg gacgtagatantgctgtgacacangcanantagcancattgangctgctantagtcanan gatgtagaccaagcgaanacgacaggtgaanatagtattgatcaagtaacaccaacagtt aataanaagcaactgcacgtantgaaatcacagcaattttaaataacaaattgcaagag attcaagctacgccagatgcaacagatgaagaaaaacaagcagctgatgctgaagcaaat attaanaagctactgcagtantgaattaagtaattatataattaattataagtaattataagtaattaaaatta etteatgeanateetgttangaanaceageagtanananagantagateetgeaget gatangaanacacanatagaacanacacacaatgeateacanacangaaattaatgatgea anacangaagttgatactgaattanateangegananacanatgtegateanaca antgaatatgttgataatgeagttanangaaggananagetananttaatgeagttananac tttagtgagtacananagatgetttagetananttgangatgeatatantgetanangta acgangeggatanactetanageategaetteangtganattgetgangegaacanana ettgetgaattannacanactgeggateanantgtanteangetactettanagatga atgangtteanatteatantgeagtatattagtagtaattacacanteeanget ananagnateagetacaneagatttatatgettatgeagateagaagananatatt teagetgacactantgeanacacangatganangeanagaatanatagtgeggettgaegat anatracacangettananceagaattatatatgetgtggataatgggaegttgaeta gcattaacacaaggtaaagcagcaattgatgctattcaagtagatgctactgttaaacct aaagcgaaccaagctattgaagttaaagcagaagatacgaaagaatctattgatcaaagt

: --

PROPERTY OF STREET

202.	atgaaactaaaatcatttgttactgccactttagcattgggattattatcaacggtcgga gctgcattaccgagtcacgaagcatctgcagatagtaataacggctataaagaaatgact gtggatggttatcacactgttccttacacaatttcagtagtatggtattacttcacttacat cgaacttactttatcttcccagaaaataaaaatgttctttatcaagaaattgacagtaaa gtaaaaaatgaattagcttctcaacgtggtgttacaacagaaaaaattaataatgcccaa acagcaacttatacgcttactttgaatgatggtaataaaaaagtagtgaatctaaagaaa aatgacgacgctaaaaattcaattgatccaagtacaatcaaacagatacaaattgatgat aaa
203.	atggctattaaaagtataagccaataacaaatggtcgtcgtaatatgacttcgttagat ttcgcagaaatcacqctaaaactgaaaagtcattattaaaaccgctaccgaaaaa gcgggacqtaacaaccaaggtaaattgactgtaagaaccatggtggtgggacacaaaacgt caataccgtgttatcgatttcaaacgtaacaaagtggtatcaatgcaaaagttgattct attcaatatgatccaaaccgctcagcaaacatcgcttagtgtgtgatgaagtggtaa aaacgatatatcattgctcctaaaggattagaagtaggtcaaatcgttgaaagtggtac gaagctgacatcaaagttggtaacgcattaccattacaaaacattccagttggtagcagtagtacaacacacgagctaaacactggaagtgacaatcaaagttggtaaagtagaagtggacaaacatccagtagtagtacaacaacatcgagcttaaacctggtaaaggtgacaaatcgctgttagaagtggca agtgctcaagtacttggtaaagaaggtaaatacgtattaatcagattaagatctggtgaa gttcgtatgatcttatctacttgccgtgctacaatcggtcaagttggtaacctacaacac gaattagttaacgttggtaaagccggacgttcacaatcggtgaaggtatccgtccaacagtt cgtggttctgtaatgaaccctaacgatcacccacacggtggtggtgaaggtcgtgctcct atcggtagaccatctccaatgtcaccatggggaaacctacgcttggtaagaaactcgt cgtggtaaaaaatcatcagacaacttatcgttcgtgggagaaaaaa
204	atgttagtaatacgtttaacccattgtataatttattattacgtctttaattgcagca ataccgattgtactgttttactatgtttaactgttttaaaatgaaaggatattatgca gctattacaacactgttgtaacattactaattgcaataccatttttcaaattgccagtt ggtatcgcttctggtgcagtagcgaaggtttcttccaaggtatcatccgattgccat atcgttatgatggcagtattgttatacaaaattactgttgaatctggacaattgttaaca atcaagatagtattacaaatattcacaagaccaacgtattcaagttttacttattgga tttgcattcaacgatttttagaaggtgagcaggatttggtgtaccaattgcaatttgt gcacttttattaacaaattaggatttaatccattaaaaagctggagtttatgttagtc gcaaatgcagcgtctggtgcttttggtgcgattggtatcctgtaggtgttgttagtc gcaaatgcagcgtctggtgcttttggtgcgattggtatcccaattgcaatttgt gcaatctacctgagagtgttccattatagtgtttctcaatcagcaacttaacactg gcaatcaaaattccattactacttacttatttatttattgaggt gttaaagaaacattaccagcaattttagtagtttcaatcacttaacacttactcaagga ttataactgtattcagtggacctgaattagcagatattatcaccgttattaacacttactcaagga ttataactgtattccagtagaactgaattagagatattatcaccgttattaacaatg ttagcattagcagtatttctaaaaaattcaaccaaaacacattatccgtgttaataaa gatgaagaaattgaacctgcaaaagcacattctgcaaaagcagatattacatgctgtaaaaa gatgaagaatagccttaacaattagtattgaggtgcgccattctttaaaaactta tcttaccaaatggtgctttatcatcattagtattgaagtggcgccattctttaaaaactta tcttaccaaatggtgctttatcatcattagtatttaaattcaacttacctggaacaac gctatttattaacagtcattattatacaatttaaatttaattggacaaacaggtaca gctatttattaacagtattctaaaatttaaagagttgggttaacatttgt ttcatctagcaatttctaaaaccaactattagtggtttaagtgagcaatggtcaa ggtattgctaaagcaggtaattctcccagttcattattggtttaggtggcacaattggtcaa ggtattgctaaagcaggtaattgctcccaattattgtgtttaagtgagcaacaggtcat gtgtcacacaaatttggaacaagtggtcacacactcattatttgcaccaattcaagcttct gtgcaccacacaattggaaccaacaccactcattatttgcaccaattcaagcttct gtgcaccacacaattggaaccaacaccactcattatttgcaccaattcaagcttct gtgcaccacacaattggaaccaacaaccactcattatttgcaccaattcaagcttct gtgcaccacacaactaggatcaacaccactcattatttgcaccaattcaagcttct gtgcaccacacaacttggaaccaacaccactcattattattgcaccaattcaaacaa gttggtaaggaacagaaca
205.	atgcttaaaaataaaatataactacaactttatctgtgagcttacttgcccctcttgcc aatccgttattagaaaatgctaaagctgctaacgatactgaagacatcggtaaaggcagc gatatagaaattatcaaaaggacagaaggtaaaaaagtaataaatggggcgtgactcaa aatattcaatttgattttgtaaaggataaaaaatataacaaagatgctttgatattaaag atgcaaggattcattagctctagaacaacatattacaactatacaaaaaactaatcatgtt aaagctatgcgatggcattccaatataatat
206.	atgaaaatgaataaattagtcaaatcatccgttgctacatctatggcattattatactt tctggtactgctaatgctgaaggtaaaataaaccagtcagcgtaaaaaaagtcgatgac aaagttactttatacaaacaacaagccacagcagcttctgataaatttaaaatttcacag attttaacatttaattcatcaaagataaaagttatgataaagatactttagtacataa gctactgggaatattaactcaggctttgtgaaacctaatcctaatgactatgactttca aaattatattggggagctaaatacaatgtatctataagctcacaatctaatgattcagta aacqtcgttggttatggcacaaaaaatcaaaatgaagagtttcaagttcaaaatacttta ggctatacatttggtggtgacataatagatctctaatggttactggtggacttaatgga aatacagctttttctgaaacaattaattatctaaagagaagttcaagacaacattaagt cgcaacacaaattataaaaatgttggctggggagttgaagcacataaaatcattaagt cgcaacacaaattatggaaggatagcttcacccaacatatggtaaatcattctata ggttgggaacttatggaaggatagctccaccaacatatggtaaatcatctcttat gctggcagacaaagcagtgcatacgctggccaaaacttcataggcaacacaaatgcca ttatatctagaagtaacttcaatccagaattttaagcgcactacacaagac ggcgctaaaaaaatctaaaattacagtaacttatacacgtagaattgcattcacacagacag

THE COUNTY

207. i	atgaatagagagatgttgtatttaaatagatcagatattgaacaagcgggaggtaatcat tcacaagtttatgtggacgcattaacagaagcattaacagcccatgcgcacaatgattt gtacaaccgcttaagccgtattaagacaggatcctgaaaaatgacacatcgcagatcga attattgcaatgccaagtcatatcggtggtgaacacgcaatttcaggtattaagtggata ggtagtaagcacaatccatcgaaacgtaatatggaggtgcaagtggcgtcattatt ttgaatgatccagaaacgaattatccaattgcagttatggaggtaagtggcgtcattatt ttgaatgatccagaaacgaattaccaattgcagtatgaagcaagtthaatagtagt atgcgtactgcagcagtttcagtgatgcagcaagcaatttggcaagtagattaaa gacttaacaatcattggatgggctaatcggaggacaagcaattcaaagtatgttagag caattcgatcatattgaacggtgtttgtttacgatcaatactcaaagtatgtacacgc tttgttgatagatggcaacaacagcgtccggaaattaatt
	cgagaaaagaaactattaaccaattggtgttagaaggtgaatttagtaagaagtett catgctgaactaggacaacttgtggcaggtgacataccaggacgtgaagacgatgatgatga atcatattacttaatccgatgggtatggctatcgaagatatttcaagtgcttattttatt tatcaacaggcacaacaacaaatattgggacaacattgaacctatat
208.	atgaaaaaattatggttattttcggtacgagacccgaagcaataaaatggcaccatta gtaaaagaaattgatcataatgggaacttggagacccgaagcaataaaaatggcaccatta gtaaaagaaattgatcataatgggaacttggaggaccattgtgattcatgatttaaat agagatatgttagatatgtggttaagtatatttgagattcaaggtgatcatgatttaaat attatgcaggatcaacaacaggacttacgggcgaatgcacttgctaaacttgat agcatcattaatgaggaacaccggatatgattttagtacatggtgatactacaacgact tttgtaggaagtttggcagcatttatcatcaaattccggtgacatgtaggaagctgga cttcgaacacatcagaaatactcaccatttcctgaagaggttaaatcgagtcatggaagt aatattgctgaattgaat

程程度,18 F. 68

1

209.

و الموادر

LINE HARDEN

(1994)

210.	atgaccaagaacaacacttgcagaacgaattattgctgcagtaggtggtatggatatatat	
211.	atyttaaaattttaaaatytatcacyttagccytyytaatyttattaatcytaatyca tytygcctaatcyttogaagaagaagattygataaaycattyaataaagataattctaaa gacaagcctaaccaacttacyatytyytygatyycgacaagcaaatygcytttataaa aaaattacyyatcaatatactaaaaaatyycatcaaagtaaatygcytttataa taaaatyatcaactaagaaaatttcyctagacyctctycaggaaaagytccagatac tttttcttagcacatyataatactgaaaytycctatctacaagyctagtygctagctygtgaatc anattacaaaagatgagttyaaagyttcaataagcaagcattaaagcgatyaattat gacaataagcaactagcattyccagctacyttgaaacaaccactttttaataaa aaattagtgaaaaatgcaccycaaacyttagaagaagttgaagctaatycccaaacta actyatagtaaaaagaaacaatacygtatyttattyaagctaatyctyccaaacta actyatagtaaaaagaaacaatacygtatyttatttyaatyctaaaaatttctattttaat tatccyttttattcygcaatyatyatattatttcaagaaaaatygcaytyaaatatyat attatcagctaygactaaattcaaaacatycytcaagaatyctyaacyattacaaaa tygtacyacaaagygtatcttcctaaggcagcaacacatyatytatyattyttttt taaagaagagaaagtagacaatttytcactygaccytygaacattaatyatagaaa acyttygtaaagatttaggagtacattactyaacytygaaaattaatyaatagaaa ccattclaggtytacytygttygtatttatctgaatatagtaacaaatatacagatgaaa agcaagcagtcatgctgaacygtygtaaatcatcaattcaaacaattaacaaattaaagatygaaa acyaaattaatygacytyttyaagytyaaatcatcaattcaaacaattaaaaaatttaaagattygaa agcaagcagtcatgctgaaacgatyctaaatattacaaaaatatacagatygaaa ccyaaggcaaatyataacagatttatttcaaatygaaagaatcctaaacaagcyttagaa agcaagcagtcatatyctgaaccygtyaaatcatctaatccaaattaacaaaacgcyttagaa agcaagcagcagtaatttatttcaaatygaaagaatcctaaacaaacgcyttagaa aaggagaagaagaatgaatattaattaaaaatatacaaaaaagcyttagaa aaggagagaaagagaatgatattaattaaaaatatacaaaaacgcyttagaa aaggagagaaagagaaagaatattaattaaaaatatccaaaaaaaa	
212.	gtgaaagcattgaaattatatggcgtggaagatttacggtatgaggataatgaaaagcca gtcattgaaagtgcgaatgacgttattattaaagtacgagcactggcatatgtgttca gacacgtcacgatacaaaaaaatggggccatacattaaaggtatgccattggtgttca ttttcaggtgagtagatgccattggaagtgatgttacgcattgtgcattgaa ttttcaggtgtagaagtaccttgtattcaatgcggtattatgttatggggcgacaaa gtgacaggttgcaaaagttattcqtcattggctcatatgaactgggatcgttcgcgggaatat gcacgatgtgaaaaagttattcqtcattggctcatatgaacctggatcgttcgcgggaatat gtcaaattgccagcgcaaaatgtttaaaggttccagacaatgttgattacattgaagca gcaatggttgagccatcagcgttgtgcgcatgaggttttataaatcgaatatacacct ggtatgaccgttgagcaatggggttggcagtataggttttataaatcgaatatacacct ggtatgactgttgcagtaatggggttggcagtataggtttgttagctattcaatggca cgaatatttggtgctgcacatcaaccatcatcatcaaagaagacgcataaactagatat gcaacatcattggggccacatcaaacaatcaattcaaatgaaatccttgagaaattc atcgaaaatcattacgccaatcaaacagtcattcaaagagagaaaatcttgagaatc acgattggtcaaatattgagctacctaaaaaaggtggcgaggtggtattactcggaata ccatatgatgatattgagattgatcgcgttcattttgaaaaaattctgcgtaaagagtg acagtatgtggccttgggaactgtttgccagtaatttccggaaaagaggggcga accttacattatatgaagacgaaagatattaatgtaaagcctattatttctcattttta ccgttagaaaaaggccgggacaatttgataaaattagttaacaagaagaagaatttgat aaagtcatgtttacgattat	
213.	atgcaagcattacaancatttaattttaagagctaccagtaagaacagtagaaattgaa aacgaaccttattttgtaggaaaagatattgctgagattttaggatatgcaagatcagac aatgcattagaaatcatgttgatagcgaggcaagctgacgcaccaatttagtgcatca ggtcaaaacagaaatatgatcattatcaacgaatcaggattatacagtctaatcttcgat gcttctaaacaagcaaaaacgaaaaatcaggatacaggatattcaaacgatgg gtaacatcagatgtcctaccagctattgcaaacacggttgtaattacgcaacaagcaatgta attgaacaaacattaaaagatccagactacatcattacegtgttgactggatataagaaa gaaaaagagcaaaacttactttacaacaagaaatcgggagactaaaaccaaagcaac tatgtagatgaaatcttaaaagtcaactggcacattagccacaactcaaatcgcggcagac tacggtatatcagcacaaaagttaaacagacactagcacaagctagactacaacgaaa gtaaataaaacagtgggtgctttactcagaacacatggcaagagttacacaagaacaa atagcaattgtacgctctgacggtagagaagatttacacagaatcgac caaaaaggcagattgaaaatcatgaaatcatgactgaatcggttatgaagacagattta gggggaggg	
214.	atgaaattaaaatcattagcagtgttatcaatgtcagcggtggtgcttactgcatgtggc aatgatactccaaaagatgaaacaaaatcaacaaggtcaaatactaatcaagacactaat acaacaaagatgttattgctttaaaagatgttaaaacaagcccagaagatgctgtgaaa aaagctgaagaaacttacaaaggccaaaagttgaaaggaatttcatttgaaaattctaat ggtgaatgggcttataaaagtgacgcaacaaaaatctggtgaagagtcagaagttctgtt gctgataaaaataaaaagtgattaacaaaaagactgaaaaagaagatacaatggatgaa aatgataactttaaatatagcgatgctatagattacaaaaaagccattaaagaagacaa aaagaatttgatggtgatattaaagaatggtcacttgaaaagatggcaaacttgtt tacaatatcgattgaaaaaaggtaataaaaaaaagaagattactgttgatgcaaacttgtt tacaatatcgatttgaaaaaaggtaataaaaaaaaagaagattactgttgatgcaaactggt ggtaaagtattaaagagggagcaagatcac	

TH.

215.	atgaaaatgaaaatattgcaaaaataagtttgttattaggaatattagcaacaggtgta aacactacaacggaaaaacggtcatgccgaaaagaaacctattgtaataagtgaaaat agcaaaaaattaaaagcttattataatcaaactaggattgaatattgaatataaaaatggaagtg tatatcagtttcattcaaccaagtattaaatttatgaatatcatagaggtgtaattctgtt aataatattgctttaattggcaaaagataagcaacattatcaataggggtaattcatagtaat cttaatattttacgttaattggggataaggattgaagggtgtacatcggtaat cttaatatttttacgttaattggggataaggattggaaggtcatactcattggg ggtatcacgagtgcaaacgataaagctgtcgacctaatagcagaagcaagagttattaaa gaagatcatactggtgaatagattattagactttttcccatttaaaatagataaagaagcg atgtcattgaaagagattgattttaaattaagaaaataccttattgataattatggct tacggtgaaatggatacaggaaaaattacagtcaaaaaagaaatactatggaaagcag tttgaattggataaagattacaagaagaccgtatgtccgatgttatcaatgtcacagat attgatagaataaaaagttacaagaaccgtatgtccgatgttatcaatgtcacagat attgatagaattgaaatcaaagttataaaagca
216.	mrktkivctigpaseseemieklinagmmvarlnfshgsheehkgridtirkvakrldki vailldtkgpeirthnmkdgiielergnevivsmmevagtpekfsvtyenlindvydsy illddglielqvkdidhakkevkcdilnsgelknkkgwlppyrvslpyitekdaedirf gikenvdfiaasfvrrpsdvleireileeqkanisvfpkienqegidniaeilevsdglm vargdmgveippekvpmwqkdlirqcnklgkpvitatcmldsmqrnpratraeasdvana iydgtdavmlsgetaaglypeeawktmrniavsaeaagdykkllsdrtklvetslvnaig isvahtalnlnvkaivaatesgstartiskyrphsdiiavtpseetarqcsivwgvqpvv kkgrkstdallmmavatavetgrvsngdliiitagvptgetgttmmmkihlvgdaiangq gigrgsvygttlvaetvkdlegkdlsdkvivtnsidetfvpyvekalgliteengitsps aivglekglptvvgvekavknisnmmlvtidaaggkifegyanvl
217.	mqfdnidsalmalkngepii.vvddenrenegdlvavtewmndntinfmakearqlicapv skdiagrldlvgmvddnsdifgtqftvsidhvdtttgisayertltakklidpsseakdf nrpghlfplvaqdkgvlarnghteaavdlakltgalpagviceimnddgtmakgydlqkf kekhqlkmitiddlieyrkklepeiefkakvkmptdfgtfdmygfkatytdeeivvltkg airqhenvrlhsacltgdifhsqrcdcgaqlessmkyinehggmiiylpqegrgigllak lrayelieqgydtvtanlalgfdedlrdyhiaaqilkyfniehinllsnnpskfeglkqy gidiaerievivpetvhnhdymetkkikmghli
218.	mkmkklvksavassialllsntvdaaqhitpvsekkvddkitlykttatsdndklnisq iltfnfikdksydkdtlvlkaagninsgyktpmpkdynysqfywggkynvsvssesmdav nvdyapkuquesfquqqtlgysyggdinisnglsgglngsksfsetinykqesyrttid rktnhksigwgveahkimmngwgpygrdsydptygnelflggrqsssnagqnflpthqmp llargnfnpefisvlshkqndtkkskikvtyqremdrytnqwnrlhwvgnnyknqmtvtf tstyevdwqnhtvkligtdsketnpgv
219.	mkkkallplflgimvflagcdyskpekrsgffyntfvdpmknvldwlgnnllndnyglai iilvlviriillpfmlsnyknshmurghmkvakpevekiqekvkrartqeekmaanqelm qvykkydmnpiksmlgclpmliqlpiimglyfvlkdqlvdglfkyphflwfdlgrpdiwi tiiagvlyfiqayvssktmpdeqrqmgymmnvispimiiwislssasalglywsvsaafl vvqthfaniyyekvakkevqpfieayerehnggsnkkgkntqvvskkkkk
220	milfrqqkfsirkfnvgifsaliatvtfistnpttasaaeqnqpaqnaqpaqaadntqpn anaqaaqmtaqpaapangqaavqpanqqaqpaqqaaqpaqqadpnnaaq aqpmqatpanqaqqmaqtpnnmatpanqtqpanapaaaqpaapvaanaqtqdpnasn tyegsinttltfddpaistdenrqdptvtvtdkvnyyslinnykigfvnselxrsdmfdk mpqnyqakqmaalgrvnandstdpmfngisktvnvkpdseliinfttmqtnskqgat nlvikdakkntelatvnvaktgtahlfkvptdadrldlqfipdntavadasrittnkdgy kyysfidnylfsgshlywkndlapkatnnkeytintsignmgnfgsalkadqfkyevt lpqytyvnnsltttfpngmedstvlknmtvnydqnankvtftsqyvttarythtkevlf pdkslklsykvnvanldtbmidfheltlyxtasdvvinnaqpevtltarythtkevlf pdkslklsykvnvanldtbmidfheltlyxtasdvvinnaqpevtltadyfsvevemmk dalqqynsqvdnshyttasiaeynklkqadtilnedanhvktanrasqadidglvtkl qaalidngaalaeldtkaqekvtaaqqskkvtqdevaalvtkinndknnalaeinkqtta qyvtekdngiavleqdvltptvkpqakqdiiqavttrkqqikksnsslqdekdvandki qkietkalkdidaattnaqveaiktkaindinqttpattakaaaleefdevvqaqidqap lnpdttneevaeaierinaakvsgvkaieatttaqdlervkneeiskienitdstytkmd aynevkqaatarkaqnatvsnatneevaeadaavdaaqkqglhdiqvvkskqevadtksk vidkinalqtgkvkpaadtevenayntrkqeignsnastteekqaayteldtkkqart nldaantnsdvttakdnsiaainqvqaattkksdakaeiaqkaserktaieammdsttee qqaakdkydqavtanadidnaaanndvdnakttneatiaaitpdanvkpaakqaiadhv qaqetaidgnngstteekaaakqqvqtekttadaaidaahtnaeveaakkaalakleaiq patttkdnakeaiatkanerktaiaqtqdltaeeiaanadvdnavtqansnieaansqn ydqakttgensidqvytvnkkatarneitailnnklqqtqtpdatdeekqaadaean tengkangaisaattnaqvdeakmaeaainavtpkvvkkqaakdeidqlqatqtnvinn dqatteekeaaiqqlatarvtdakhatarneitailnnklqqtqtpdatdeekqaadaean tengkangaisaattnaqvdeakmaeaainavtpkvvkkqaakdeidqlqatqtnvinn dqatteekeaaiqqlatarvtdakhanitaatddaydqakdaghnsigstgpatavksna kndvdqavttqqaidnttgatteeknaaaklvlkakekayqdllnaqvkqagttqqq ieneqsiddvntakdnalqaidpiqastdvktnaraelltemgnkiteilnnmetrneek gndigyrraayeeglnninaatttgdvttakdtavqkvqqlhanpvkpagkkeldqaaa dktqiqtpnasqqeindakqevdtelnqakktnvdqsthadatvqbkqalkqalqqqq nvqtalesinngvdngdvddaltgykasidaiqdatvkpkaqq nvqtalesinngvdngdvddaltgakgitdattaevekakaqgleafdniqdstokyki eeletaldqieagvnvnadatteekeaftnledilskatedisdqttnaeiatvknal eqlkaqrippevknaleeirevvnkqieilknadadasakeiartdlgryfdrfadkld ktqnareppernaaeteentyptomaattakte
221.	mklksfvtatlalgilstvgaalpsheasadsnngykemtvdgyhtvpytisvdgitalh rtyfifpenknvlygeidskvknelasgrgvttekinnagtatytltlndgnkkvvnlkk nddaknsidpstikgigivvk
222.	maikkykpitngrrnmtsldfaeitkttpeksllkplpkkagrnnqgkltvrhhggghkr qyrvidfkrnkdginakvdsiqydpnrsanialvvyadgekryiiapkglavgqivesga eadikvgnalplgnipvgtvvhnielkpgkggqiarsagasaqvlgkegkyvlirlrsge vrmilstcratigqvgnlqhelvnvgkagrsrwkgirptvrgsvmnpndhphgggegrap igrpspmspwgkptlgkktrrgkkssdklivrgrkkk

223.	mlvntfnpfdnillssliaaipivlflicitvfkmkgiyaaittlvvtiliaipffklpv giasgavvegffcgiipigyivmmavllykitvesgqfltiqdsitnisqdqriqvllig fafnaflegaagfgvpiaicallltqlgfnplkaamiclvanaasgafgaigipvgvvet lklpgdvsvlgvsqsatltlaiinfiipfllifiidgfrgvketlpailvvsitytltqq lltvfsgpeladiipplltmlalavfskfqpkhiyrvnkdeeiepakahsakavlhaws pfivltvivmiwsapffknlflpngalsslvfkfnlpgtisevthkplvltlnligqtgt ailltiiitilmskkvnfkdagrlfgvtfkelwlpvlticfilaiskittygglsaamgq giakagnvfpvlspilgwigvfmtgsvvmnnslfapiqasvaqqigtsgsllvsantvng vaaklispqmiaiataavkqvgkesellkmtlkysvcllificiwtfilsll
224.	mlknkilttlavallaplampllenakaandtedigkgsdieiikrtedktsnkwgvtq niqfdfvkdkkynkdalilkmggfissrttyynykktnhvkamrwpfqyniglktndkyv slinylpknkiestnvsqilgyniggnfqsapslggngsfnysksisytqmyvseveqq naksvlwgvkansfatesggksafdsdifvgykphskdprdyfvpdselpplvqsgfnps fiatvshekgssdtsefeitygrnmdvthaikrsthygnsyldghrvhnafvnrnytvky evnwktheikvkggn
225.	mkmmklvkssvatsmalllisgtanaegkitpvsvkkvddkvtlykttatadsdkfkisq iltfnfikdksydkdtlvlkatgminsgfvkpmpndydfsklywgakynvsissgendsv nvvdyapkmqneefqvgntlgytfggdisisnglsgglngntafsetinykqesyrttls rntnyknvgwgveahkimngwgpygrdsfhptygnelflagrqssayagqnfiaqhqmp llsrsnfnpeflsvlshrqdgakkskitvtyqremdlyqirwngfywaganyknfktrtf kstyeidwenhkvklldtketennk
226.	mnremlylnrsdieqaggnhsqvyvdaltealtahahndfvqplkpylrqdpenghiadr ilampshiggehäisgikvigskhdnpskrnmerasgviilndpetnypiavmeasliss mrtaavsviaakhlakkgfkdltiigcgligdkqlgmleqfdhlarvfvydqfseacar fvdrwqqqrpainfiatenakeavsngevvitctvtdqpyieydwlqkgafisnisimdv hkevfikadkvvvddwsqcnrekktinqlvlegkfskealhaelgqlvtgdipgreddde iillnpmgmaledissayflyqqaqqqnigttlnly
227.	mkkimvifgtrpeaikmaplvkeidhngnfeanivitaghrdmldsvlsifdiqadhdln imqdqtlagltamalakldsiineeqpdmilvhgdttttfvgslaafyhqipvghveag irthqkyspfpeelnrwwsniaelnfaptviaaknilfenkdkerifitgmtvidalst tvqndfvstiinkhkgkkvvlltahrrenigepmhqifkavrdladeykdvvfiypmhrn pkvraiaekylsgrnriellepldaiefhnftnqsylvltdsggiqeeaptfgkpvlvlr nhterpegveaqtsrvigtdydnivrnvkqlieddeayqrmsqannpygdgqasrricea ieyyfglrtdkpdefvplrhk
228.	mimgnlrfqqeyfrjydnntestthrnaywwkladnweathmwyalstivqqhasirhff duttddnltmllheflpfieikyopssanydleaffkqelstyhfndsplfkvklfqfa dasyilldfhvsifddsqldiflddlcnayrgntvinntrqhahinrnddkdnqdashia ldsmyfrlennsdlhidsyfpikhpfeqalyqtyliddmtsidmsalavsvylanhimsq qhdvtlgihypshlpndlhgniyltltidakdvcqffttdfinkcvlqmmsqlqcakssl sletifhcyhhmmsccndviedvhqihdahtsladieifphqhgfkiiynsaaydllsie tlsdlvrniylqiteengmkrttvdelnlmterdiqlyddinlslpeiddaqtvvtlfeq qweatpnhvavqfdgvfitytlnarandlahrlrnqygvepndrvaviaeksiemliam igvlkaggayvpidpnypsdrqeyilkdvtbyvityqalyengkqnihidlnkiawlm idnlskcntledhayviytsgttgnpkgtliphrgivrlvhqnhyvplneettillsgti afdastfelygallnggklivakkeqllnplaveqllnendvntmwltsslfnqiaseri evlvslkylijggevlnakwdllnqkphhpqtingyyptenttftttyniphkvpnrip igkpilgthvyimggerrcgvgipgelctsgfglaagylnqpeltadkfikdsninqlmy rsgdivrllpdgnidylyrkdkqvkirgfrielsevehalerigqinkavivqnhdqdq yivayyeamhtlshnkiksqlrmtlpeymipvnfmhleqipitingkldkkalpimdyvd tdayvapstdtehllcqffadithvnqvylhdmffelgghslkatlvvnrieastgkrlq igdllqkptvfelaqaiakvqeqnyevipetivkddyvlssaqkrmyllwksnhkdtvyn vpflwrlsselnvaqlqavqrliarhelrtrqyivvddevrqrlvadvavdfeevnthf tdeqeimrqfvapfnlekpsqirvyirsplhaylfidthriindgmsniqlmmdlnaly qhklllplklqyddysewmshrdmtkhrqywlsqfkdevpllslptdyvpnikttngam msftmqmrqllqkyvekhqidmffsuvvyirsplaylfidthriindgmsniqlmmhlyte qmlgmfantlvyrgqppddmwtqflqevkemsleayehqeypfeclvndldqshdasrn plfdvmlvlqmetnahfghsklthiqpksvtakfdlsfiieedrddytinieyntdly hsetvrhmgnqcmimidyilkhqdtlqicdipngteellnwvnthvndrmlnvpgnksii syfnevvsrqgnhvalvmmdltmtyetlrryvdaiamllsfiyergngtvalftersfem iamlatvkyasyipididfpmkrqgailedakvatwsyveiettlpviqlenakgf veskenegyddlbgnqlentamldnemyalytsgttympkyvairqrnllnlvhawstel qlgmevflqdaivfdasvmeiyccllophtlvpdfreervnpeqlqqlinkhrvtvas iplqmcsvmedfyieklitggststasfvkylekhcgtyfnaygpsectvitsywshhog dlipetipigkplsniqvyimsgllcgjmpsglclagdslagyinrpelmadwqnn pfgkgklyhsgdlarytsdgyeieflgriddqvkwngyrieldelenailairgisdcvvt vshfdthdlinayyvegeqvegdlkylndqlpkymlpktithddemytthdaynlyrisetv elmlsnievivgdfecmddvvlpemdtiihagartdhfgdddefekvnvggtvdvirla qqhharliyvstisvgtyfddtdotfseadvtggnlktitgyskriysftys
229.	mtkeqqlaeriiaavggmdnidsvmncmtrvrikvldenkvddqelrhidgvmgvihder iqvvvgpgtvnkvanhmaelsgvklgdpiphhhndsekmdyksyaadkakankehkakq kngklnkvlksianifiplipafigagliggiaavlsnlmvagyisgawitqlitvfnvi kdgmlaylaiftginaakefgatpglggviggttlltgiagknilmnvftgeplqpgqgg iigvifavwilsivekrlhkivpnaidiivtptiallivglltififmplagfvsdslvs vvngiisiggvfsgfiigasflplwmlglhhiftpinieminqsgatyllpiaamagagq vgaalalwvrckrnttlrntlkgalpvgflgigepliygvtlplgrpfltacigggigga vgaigighigakaigpsgvsllplisdnmylgylagllaayaggfvctylfgttkamrqtd llgd

230.	mskilkcitlavvmllivtacgpnrskedidkalnkdnskdkpnqltmvvdgdkqmafyk kitdqytkktgikvklvnigqndqlenisldapagkgpdifflandntgsaylqglaaei klskdelkgfnkqalkamnydnkqlalpaivettalfynkklvknapqtleeveanaakl tdskkkgymlfdaknfyfnypfifgnddyifkkngseydihqlglnskhvvknaerlqk wydkgylpkaathdvmiglfkegkvgqfvtgpmineyqetfgkdlgvttlptdggkpmk pflgvrgwylseyskhkywakdlmlyitskdtlqkytdemseitgrvdvkssnphlkvfe kqarhaepmpnipemrqvwepmgnasifisngkmpkqaldeatnditgnikilhpsqndk kgd
231.	vkalklygvedlryednekpviesandviikvratglcgsdtsrykkmgpyikgmpfghe fsgvvdaigsdvthvnvgdkvtgcpaipcyqceyclkgeyarceklfvlgsyepgsfaey vklpagnvlkvpdnvdyieaamvepsavvahgfyksniqpgmtvavmgcgsigllaiqwa rifgaahiiaiddahkldiatslgahqtinskeenlekfienhyanqidlaiessgakv tigqiltlpkkggevvllgipyddieidrvhfekilrneltvcgswnclssnfpgkewta tlhymktkdinvkpiishflplekgpetfdklvnkkerfdkvmftiy
232.	mqalqtfnfkelpvrtveienepyfvgkdiaeilgyarsdnairnhvdsedklthqfsas gqnrmaiiinesglyslifdaskqsknekiretarkfkrwttsdvlpairkhgiyatdnv ieqtlkdpdyiitvlteykkekeqnlllqqeigelkpkadyvdeilkstgtlatqiaad ygisaqklnkllhearlqrkvnkqwvlysehmgksytesdtiaivrsdgredtvlqtrwt qkgrlkiheimtefgyeanlgga
233.	mkikslavismsavvitacgndtpkdetkstesntnqdtnttkdvialkdvktspedavk- kaeetykggkikgisfensngewaykvtqqksgeesevivadknkkvinkktekedtmme ndnfkysdaidykkaikeggkefdgdikewslekddgklvynidikkgnkkqevtvdakn gkvikseqdh
234.	mkmkniakislllgilatgvntttekpvhaekkpivisenskklkayyngpsieyknvtg yisfiqpsikfmniidgmsvnnialigkdkqhyhtgvhrnlnifyvnedkrfegakysig gitsandkavdliaearvikedhtgeydydffpfkidkeamslkeidfklrkylidnygl ygemstgkitvkkkyygkytfeldkklqedrmsdvinvtdidrieikvika
235.	Ttgaaaaatattttaaaagtttttaatacaacgattttagcgttaattatcatcatcgcg Acattcagtaattctgcaaatgccgcagatagcggtactttgaattatgaggtttacaaa Tacaataacaatggacacgtcaattgctaatgactattttaataaaccggcaaagtacatt Aagaaaatggtaaattgttagttcaaataactgtcaaccacagtcattggattactgga Atgagtatcgaaggacataaagaaaatattattagtaaaacactgccaaagatgaacgc Acttctgaatttgaagtaagtaagttgaacggtaaaatagatggaaaaattgacgttat Atcgatgaanaagtaaatggaaagccattcaaatatgacatcattacaacattacatat Aaatttaatggaccaactgatgtagcaggtgctaatgcaccaggtaaagatgataaaaaat Tctgcttcaggtagtgacaaaggacttgatgaagacacacggtaaaagatgataaaaat Agttcgaataaagaagaagaagacaaagcacacaaacaaatgctggtacacctgcatatat Tatacaataccagttgcatccttagcattattaatcgcaatcacttgtttgt
236.	atgacaaaacattatttaaacagtaagtatcaatcagaacaacgttcatcagctatgaaa aagattacaatgggtacagcatctatcattttaggttcccttgtatacattaggcgcagac agccaacaagtcaatgcggcaacagaagctacgaacgcacctaataatcadagcgcaccaa gtttctcaagcaacatcacaaccaattaatttccaagtgcaaaaagatggctcttcagag aagtcacacatggatgactatatgcaacacctggtaaaagaagtagcactataataataa tattatttccaaaccgtgttaaacaactgtgtaacgaatacaaaattttacaat gcaaacaatcaagaattagcaacaactgttgttaacgatataaaaaagcggatacataga acaatcaatgttgcagttgaacctggaatataagaagttaataaaaaagcggatacatagc gtgcacaaattaattacaatcataggatatactacgcatttggaattgaaaaacaagcagct cctacattagctgacgcagcaaaaccaaacagttgaaacagttgaaacagtgaaaacaagcacaact ccaacctaaacaccactactgagcaaactaaacagttcaaccaaagttgaaaaagtact gacacaacaaaagaatcaaactaaaacacagttcaacctaaagttgaaaagtact gccaagaacaaaataaagttcaaaccaaac
237.	Lknilkvfnttilaliiiiatfsnsanaadsgtlnyevykyntndtsiandyfnkpakyi Kkngklyvqitvnhshwitgmsieghkeniiskntakdertsefevsklngkidgkidvy Idekvngkpfkydhhynitykfngptdvaganapgkddknsasgsdkgsdgtttgqsesn ssnkdvenpqtnagtpayiytipvaslalliaitlfvrkkskgnve
238.	mtkhylnskyqseqrssamkkitmgtasiilgslvyigadsqqvnaateatnapmnqstq vsqatsqpinfqvqkdgssekshmddymqhpgkvikqmnkyyfqtvlnnasfwkeykfyn annqelattvvndnkkadtrtinvavepgykslttkvhivvpqinynhrytthlefekai ptladaakpnnvkpvqpkpaqpktpteqtkpvqpkvekvkptvtttskvednhatkvvst dttkdqtktqtahtvktaqtaqeqmkvqtpvkdvataksesmqavsdnksqqtnkvtkh netpkqaskakelpktgltsvdnfistvafatlallgslslllfkrkesk

:

÷.

ggaancanagtantauguttuus gaancanagtantangcigatanteetcanacaacciggattiacticatcanant cgittacangatanagtcgitanacaaccgactanaggagangatggagtigtangcanc ggittiatagtagcagtagcantagtatiggcinicticggittiggcannanantcinga

	•
240.	atgaaaaaaaaagttatcgcttctacattagcagtatctttaggaattgcaggttacggt
	ttatcaggacatgaagcacacgcttcagaaactacaaacgttgataaagcacacttagta
1	gatttagcacaacataatcctgaagaattaaatgctaaaccagttcaagctggtgcttac
	gatattcatttcgtagacaatggataccaatacaacttcacttcaaatggttctgaatgg
1	tcatggagctacgctgtagctggttcagatgctgattacacagaatcatcatcaaaccaa
1	gaagtaagtgcaaatacacaatctagtaacacaaatgtacaagctgtttcagctccaact
	tetteagaaagtegtagetacageacateaactactteatacteageaceaagecataac
1	tacagctctcacagtagttcagtaagattatcaaatggtaatactgctggttctgtaggt
	teatatgetgetgetcaaatggetgeacgtactggtgtatetgettcaacatgggaacae
	atcattgctagagaatcaaatggtcaattacatgcacgtaatgcttcaggtgctgctgga
1	ttattccaaactatgccaggttggggttcaactggttcagtaaatgatcaaatcaatgcc
	gcttataaagcatataaagcacaaggtttatctgcttggggtatgt
241.	atgaataaaataaagtgattgtaattggatcaacaaatgtagataaatttcttaatgtt
1	aaaaggtttccaaaacccggtgagacattacatattaatcaagctcaaaaggagtttggt
1	gggggcaagggagccaatcaagccatagcagctagtagattagcagcagatacaacattt
ł	atcagtaaagttggtaaagatggcaatgccaacttatattggaagatttcaanaaagca
<b>[</b>	ggtattcatacacaatatattttaacttcagaaagtgaagaaactgggcaagcatttatc
	actgttgatgaagcaggacaaaatacgattcttgtttacggtggtgcgaatatgacatta
· ·	agtgcaactgatgttgagatgagtgtggatgcgtttattggtgcagactttgttgtagcg
ł	cagcttgaagttccatttgaggcgatagaacaagcatttaaaattgctcgtaaacaaaat
	atcactactgtattaaatcctgcaccggcaattgaattg
1	actgatatattatteeaaatgaaacggaagtatattattataggtatatetgcagta
	ttaattactttaggggagcaaggcacgtattgtgcatatcaagaacaatacaaaatgatt
1	Cctgcgtgtaatgtaaaagcaatagatacgacagcagcaggagatacatttataggtgct
i	tttttaagtgagttaaataaagatttgagcaatttagaatcggctattcgacttgcaaat
1	caagcgtcgtctctaacggtacaacgaaaaggagcacaagcttctataccaacacgtaaa
1	gaagtagaggcagaatataat
242	
242.	atggctcttaaaaaatataagccaattacaaatggtcgtcgtcgtaatatgactactttagat
	ttcgctgaaatcacaaaacaacacctgaaaagtcattattacaaccgctaccgaaaaga
1 .	gcgggacgcaataaccaaggtaaattgactgttcgccatcatggtggtggacacaaacgt caataccgtgttatcgattttaaacgtaacaaagatggaatcattgctaaagttgattca
1	attcaatatgatccaaaccgttcagcaaacattgcattg
1	aaaagatatatcatcgcacctaaaggattacaagtaggtcaaactgtcgaaaagtggtgct
1	gaggcagatatcaaagttggtaatgctttaccattacaaaatattccagttgggacagta
	attcataacatcgagttaaaacctggtaaaggtggacaacttgctcgttctgctggtgct
1	agctctcaagtattaggtaaagaaggtaaatatgtattaatcagattaagatctggtgaa
1	gtacgtatgattttatctacatgtcgtgcaacaattggtcaagttggcaacttacaacat
1	gaattagtaaatgttggtaaagcaggacgctctagatggaaaggcgttcgcccaactgta
1	egtggttetgtaatgaaceetaatgateaceeacacggtggtggtgaaggtegtgctcca
1	atcggtagaccatctccaatgtcaccatggggtaaacctacgcttggtaagaaaactcgt
1	cgtggtaaaaaatcttctgacaaacttatcgttcgtggacgtaagaaaaaa
243.	atgaagtcaaaattcacaattctattattacaatcttttctacaaca
	gttattattataacaaaactcaatcccaatcatacatttcgactcactattctaataat
	aaaataaaaacaacagcaacactttttttacatggttatggtggtagcgaacgctcagaa
1	acqtttatggtcaaacaagcgttaaataaaaatgtaaccaatgaggtgataaccgctaga
1	gtgagtagtgaaggaaaagtatattttgataaaaaattaagtgaagatgcagcaaaccct
1	attgtcaaagtagaatttaaagataataaaaatggaaattttaaagaaaatgcttattgg
[	attaaagaagttctatcacaactaaaaagtcaatttggaattcaacaatttaattttgta
Ī	ggacattcaatggggaacatgtcatttgctttttacatgaaaaattatggggacgatcga
1	catttgccacaacttaaaaaggaagttaatatagcgggagtttataaacgggattttgaat
1	atgaatgagaacgtgaatgaaattatcgttgataaacaggggaaaccaagtagaatgaat
1	geegeatateggcaattgttatcactgcataagatttattgtggtaaggaaatagaagtt
1	ttaaatatctacggagatttagaagatggctcacattcagatggacgtgtgtcaaatagc
1	tetteteaategetteaatatttaetaagaggtageactaagtettateaagaaatgaaa
	tttaaaggtgcaaaggcacaacatagtcaattacatgagaataaagatgttgcaaatgaa
ļ	atcatacaattcttatgggaaact
244.	atgaagattggaattgatgccggagggactttaattaaaattgtacaagagcatgacaat
1	cgtagatattacagaactgaattaacaactaatatccaaaaagtcatagattggcttaac
	aatgaagaaatcgaaacattaaagcttacaggtggaaatgctggagtaatagcagatcaa
1	attcatcattccctgaaatatttgragagttcgatgcatcatcaaaggtttagaaatt
1	ttattggatgaacaaggtcatcaaattgaacattacatt
	acttctttccactatttgatggaaaagaccagcaacgtgttggaggtgtaggtaccgga
l .	ggcgggatgatacaaggtttaggctatttattgtccaatataacagattataaaagaatta
I	acgaatttagctcaaaatggagatcgtgatgccattgatttaaaagtaaaacatatttat
1	aaagatactgaaccaccaattcctggagatttaacagcagcaaattttggaaatgtatta
,	catčacttagataatcagtttacatcagctaacaacttgcctctgcaattggcgtcgtt ggtgaagttataacaactatggctattacattagcacgtgaatataagactaagcacgtt
i	gtatatatoggttcatcattataacaatcaattactacgtgaagttgttgaaaattac
	actgttctaagaggatttaaaccgtactatattgagaatggtgctttttcaggogcttta
	actylicianyayattiaadeglaciatattyayaacygigeteeteenygigitte

•

上版を取けるのでは

-

245.

gatattetaaacagcagcttttgctgatggagttatcacagatgttgaaaaacgtttgatt tctgaaactcttgctcaacttgaaaaaggaaatagagaattcgaagataaaattaactta gctttaaaccaccttacatcactgaggaagatactattgagttaaataattctatcgtt aatacatacaacacaacattaactgcttattctaaaacaattcaagaagctctaaataca
ttatcacaaatcatctcttctgatgtagcaagtaaaaaagttgaagaattcaatggtgta
ataactacaatttcttcagacgttgatacaatcaagaaacaaagagatggtgcagtaatc
acttattattatatagcggtgtacctacattatctaacgatccagctaaaagttggacgac
aatgatttaaaagacttacatattaaagatatgtagtactacaatatgcattatgat
ataactttactaataattagtgattattcttggaaaccacttactggttatg
gttagctcattgaaacaagcaaaaaatgcacaagacacagcggacaataaacgtagagt
tttgtaactcaacctattcctccttatgatcaaggagatatgtggactcaaggttcacaa
ggagatatttatgtctgtggaacttcgagagctactggctcattcgtaggtgcattagg
gttaaagcgagcaaatacactgacgatacagtagctaaacaggcagcaaaagatttaga
gattataaagtcaaaatgactaaagacttcaagatttgtaactgggtgtatctacttt
aaaactgaagattaaaagattaaaagattgaagttgaaactaga 

and the second of the second

.

٠,

. . . . . . . . . . . . .

. 246.	atgtataacytgacacagcatgcgacttataaaacaaaaataaacgagaaactgctgta ttaatcggtgtacatgctcaaacggatcgtcaatttaattttgaatctactatggaagaa ctcgatgctttatcacaaacttgccaacttaatgttaaaggacaaatcactcaaaataga gagcaatttgaccataaatattatgttggaaaaaggaaaaatcgatgaagaactcaaaatagt gagcaatttgaccataaatattatgttggaaaaaggaaaaatcgatgaaataaaatcttc aaaacgttaaatgataatttgggcattaaaaatcatcgatgaaataaacggcacagtc aatttggcgttgcagcgagaagtagagagggaaagctacaagtagaacttgcacaattttagag atatttgttaccaagactacatggtcatggtaaaagctacaagtagaacttgcacactc gattatttgttaccaagactacatggtcatggtaaaggacgtcgcatattggaaca cgtatgaatgagattaaacatcaatgtcatggtaaaggactacggaaagatagaagacacggaaaataaacgtgaaacaaaatcaagtttttcaaaacggtcgtggatcatcgggaaagataaga aatacgtgaacaaaaatcaagtttttcacaaatgagacgactatgaaaaaaaa	
<sub>ज्यस</sub> ् 247.	atgatgatcatcgtcatgttaatcttgagttatctgattggtgcattcccaagcgggtta attattggtaaattattttttaaaaaagatataaagcaaatacggtagtggaaatactgg gcaactaacagttttcgtgttcttggagagcagctgggatttatagttacgttttagat attttcaagggatttattacagtcttttttccactatggttcccagttcatgcggatgg gttataagcaccttctttacaaatggtttaatagtaggattgttgcaatactgggtcac gtgtatccaatatatctgaaaattaatggcggaaaagcagtagctaccagtgcaggagt gtattagggtgtcaatcctattttacttcttatcttggcaattatcttttttagtgtgtat gtattaggtgtcaatcctattttacttcttatcttggcaattatctttttttgtgtattgg tcaatcatcattcatgattatattttacttgctgttagcggaattgtttcaatcatatta ataatcgaccaaaatctaatatgttagattttaaatgtggggaattgtttcaatcatatta ataattcgaccaaaatctaatatagttagaatttttaaaggagaagaacctaaaattaaa ttggatg	794, f -
248.	atgatgaatcatagtgaagtttaactgaacagtattttcatttgcttcagagctttat gcttatggtgtaagagaagtagtattagtccaggttcaacgttcaacaccattagcactt gcttttggtgttaagagaagtagtattagtccaggttcaacgttcaacaccattagcactt gtttttgcttttaggtcttattaaaggtagcgaaattcacctgatgagcgaagttgtgtcgca ttttttgcttttaggtcttattaaaggtagcgaaaaacctgtagcaattctttgtacatc ggaacagcgctggaactacacacccgcatagactgaagtcgaaattgcttgc	

.

.

THE PARTY IN

17.00

249.

atggcgaaaaaattcaattacaaattaccgtctatggttgctttaacgttatttggcaca acygcyddaaaaccaaaccaaaaccacaaacacacagaatcagctatttggcaca gcttttactgcacatcaagcaaatgctgctgtacaaccacagaatcagtctaatcataaa aatgtattagatgatcaaactgcctcaaacaagcagaaaaagctaaaagcgaagttaca 

250.

1337

S

No. of Contract of

700

251. caggcggttttaagcaattacgaacaagtttatattattcatggtaaaggtacgggggca cttcaaaaaggtgttcaacaacatttgaaaaaacataaaagcgttagacaatttagggga ggtatgcctagtgaaggtggatttggtgtcactgtggcagaactcaag 252. teegttgaatetgaagaaggtaae atgaaaagaaattggtggaaagaagcagttgcatatcaagtatatccacgaagttttaat 253.

254.	ttgagtcatagaaagctatttccttctatattccatttatatcaacaagacaatttagat gaacatattgctattattggtataggacgtcgcgattataataacgaacaatttcggac caagttaaagcgtcaattcaaacttatgttaagatacagatagaattgatgagttatg acgcatgtttttatcataaactgacgtgagtgataaagaaag	
255.	atgattaaaaaaacaaagaagaactgaatgacatggagtatctagtcactcaagaaaat ggtactgaacctccgtttcaaaacgagtattggaatcactttgaaaaaggaatttacgtt gataaattgtccggcaaaccattatttacttcagaggataaatttgaatcaattgcggt tggccaagtttctccaaagcattaaatgatgatgaaatcgtagaacttgttgataaatca tttggtatgattagaactgaagttcgatcagaaaaaggcaaatagtcacttggggcatgtt tttaatgacggacctaaagaaaaaggtggtttaagatactgtatataactctgctgcggatt cagttataccttatgataaactagaagagttaggatatggagatttaattaa	
256.	ttgaaaaagttagcctttgcaattacagccgcttcaggcgcagcagcagcagtactatacaat catgatgctgaagcttctacacaacataaggttcaatctggagaatcctatt gcacaacaatacatacttcagtagaaagcattaagcagaataatactttagcaacaat atggtattcccaggacaagttattaatgtaggtggaagtgcttcacaaaatactgtca aacacttcttcaagttcagcatcttcacatactgtagtaggaggtgaatacttaaacatc atagctaataaatatggtgtttcagttgatgcattaatgcaagcaa	
257.	atggcacgtattgctacaaaattgggctatcctgaaagcaatagtttcgtgactaatact gtaattgaattg	
258.	atgacagaatttgactatccactagagagggtcgttggaaacatttcggttctgttgac cctgtcaaaggtacgaaaccaactactaaaaatgaaatg	
259.	gtgcaaaaaaatatattactgccattattggaacaactgcccttagcgcattggcatca actcatgcacaagctgcaacaagcgcatacagtaaaaagtggagaatctgtattggtcaatt tctcacaaatatggattagtattgctaaattaaaattaggagaaatctgtattggtcaatt tctcacaaatatgggattagtattgctaaaattagagtcatcttcaagagcaacgtcaaca aatagtgcacagtttatacagttaaaggtggagattcatcttctaatggtcaaaca aatagtggcacagttatacagtaaaggtggagattcatcttctattgctgcaaaa tacggtacaacttatcaaaaaattcatgcaacttaatggttaaataactatcttatttc cctggacaaaagttgaaagtttctggtaaagcgagttccagtcgtgcaaaagctagt gggtctagtggtgtattgcaaacatatactgttaagtatggagactcactatctgcaatt gctagtaaatatgggacaacgtatcaaaaaattatgcaattaaatggattaactaatttc tttatctatcctggacagaagttaaaaagtcctggaggtagttcagtagtcactattctct tattatctatcctggacagaagttaaaaagtcctggaggtagttctagttagt	

260.	gtgaccaaaaaagcttttatttcttattctagaacaagtgatgaacatttaaatagagtt gtgagaataggagaaagtttgaagttgatcatggaattgatgttattttagatgtatgg gattgcctgaggaggatgacttgaattttttatatggagtctatggttattttagatgg gattgcctgaggaggatgacttgaattttttatatggagtctatggttattgaaggaag
261.	acacaagaaatacctactatttttaatttattgataaagaagaaattggcagctat atgcactatctaaagaaagtaactatatacataagtttattagtgagtg
262.	gtgaaacattcgaaaaagttacttttatgcatcagtttttattaataacgtttttatt ggtggatgtggatttatgaataaagacgatggtaaagaaag
. 263 .	atgcgttatctcaagaaagtaacgatatacataagtttattaattttggtaagtggttgt ggaaacggtaaagaaacggaaatcaaacaaactttaataatatgtagacatgtatccg actaaaatctagaagacttttatgataaagaaggctatcgaagaggtttgataaa aaggataaagggacatggatagttggatctaccatgacaattgaaccaaaaggcaagtac atggaatctagaggtatgtttctataattaatcgcaatactagaacaactaaaggcaagtac atggaggagaacacagatgacagtaaaggtagactaaaagatgatgaaaaggaga tatctgtaaaaatggaacacaataaaattattccaacgaagccaatactaatgaaaaa ctaaaaaagagaatagaaaacttcaaattttttgtacaatatggagattttaaaaactta aaggattataaagatggtgacattcaatacaatctaatgtacctagttattctgcaaaa tatcaatgagtaataatgaacattaatgtaaaacaattactaatgtacctagttattctgcaaaa tatcaatgagtaataatgacaattattgtaaaaagaggaatgtatgatattccc accaaccaagcccctaaattattgttaaaagagagatgggacttaaaaggctcatctata ggttccaaaagtttagaatttactttatagaaaaagaagagaatatcttttttca gatggtgtacaatttactcctagcgaggatggaca
264.	atganacattcaagcanaatantagtatttgtaagtttcttaattttaacgatttttatt ggaggatgtggttttatanatanaggaagatagcanagaagctganatcanacanacttt antannacgttaagtatgtatccaactananatctagaagacttttatgatanagagggc tatcgtgatgangagtttgacadagatgacanagggatgattattatattctanaatg attgttganccganaggganggatggangcanaggggatggttttacgtatanataga antacganacagctannaggtaactttattatanacaganatanacaganatatanasagga atacctgatgttannagacanananatatccagtananantgagaacttcanattattcca acanacanattannagatanananatatcanatnananaganattgagaacttcanattttttgta cantatggnanttttannacattanananaggatatanagacggaggatatctacantcct antggcangttactcagcgcantatcanttgaacattatatatattattananaca ctagganattgatattccacagaatcangctcctanattattattganaggtaca ggagatttnnaggatcctctgtaggttatanacatttgattatctttttgtagaagtaca annaggananaggatctctgtaggttatanacatttgattanactttttttgtagaant annagganattttattttattgacagtatanacatttanaccgagtaggggaat
265.	atgcgttatctcaagaaagtaactatatacataagtttattaattttaacgattttatt ggaggatgtggttttataaataaagagatagcaaagaaacggaaatcaaacaaa

and the second of the second o

· . ..

Compared to the control of the contr

.

13

主義的

16 THE

266.

267..

268.	mtkkekdykksleqqktrvkiyksgkswvkasineiellktmglpflskneiqenvtekt kghklksaakttalvggaftfnmlnnhqafaasetpitseissnsetvangnsttikms qketvnstslesnhsnstnkgmssevtntagsekagisqgssetsngsskintyastdh vesttinndtaqdqnkssnvtskstqsntsseknissnltqsietkatdslatsear tstnqisnltststsngssptsfanlrtferftvlntmaaptttstttssltsnsvvvn kdnfnehmmlsgsatydpktgiatltpdaysqkgaislntrldsnrefrfigkvnlgnry egyspdgvaggdgigfafspgplgqigkegaavgigglnnafgkldtyhmtstprsdak akadprnvgggafgafvstdrngmatteestaaklnvqptdnsfqdfvidyngdtkvmt vtyagqtftrnltdwiknsggttfslsmtastggaknlqvqfgtfeytesavakvryvd antgkdiippktiagevdgtvnidkqlnnfknlgysyvgtdalkapnytetegtptlklt nssqtviykfkdvggqisvdsqtrevgktinpitittdnskdvlttvtglpsglsfd qtnntligtpsevgttvtvnttdatgnvtskqftitqdtispvvnvtpsqasevftpi npititatdnsgkvvthtvtglpqglkfdastnsivgtptqigtntitiestdasgnktt tkinyevtrnsaasdstsisvnsvstsisnstslsdsvkasqslstksstskslsgslsa stsnsnikasesastskklsesastsmsdssikasesastskklsesaststsdsastgsesast kasesastskklsesastsmsdsvsikasesastsklsesaststsdsastgsesast skslseststsdsaststsesdstsestslsdstssslsestststststst skslsestststsdsaststsesdstsestslsdsststststst sdsaststsesdsastslgssstsvsdsnsastslreststslsdststst sdsaststsesdsastslgssstsvsdssaststsesaststslsdsststst sdsaststsesdsastslgssstsvsdsnsastslseststslsdststs stslsestststsdsastsmsvsdsnsasislseststslsdsnststslsest stslseststsvessststklsesaststsvsdsnsastslseststslsgstst stsesaststsvessststklsesaststsvsdsnsastslseststslsgstst stsesaststsvsdsnsastslseststslsdststssastsesdsnststses slstsvsdstststsdsaststsvsdsnsastslseststsdsastssses slstsvsdstattsdsaststsvsdsnsastslseststsdsaststse slstsststsdsastststsdsaststsesaststsvsdsnststslse stslsdstststsdsastststsesaststsvsdsnststslse stslsdstststsdsastststsesaststsvsedsnststslse slstsstststsdsastststsesaststsvsesdsestmmvsdsn stslsdstststsdasstststsesaststsvsesdsestmmvsdsn stslsdstststsdasstststsesaststsvsesdsestmmvsdsn stslsdststsvadgridelsedtivtqsntmmlnktgkdydlqeqryvtdsedn etgmqanhhmnldllhpmrlqdkvvkmptkgedgvvsngfivavalvlaifglakkr
269.	mktviastlavslgiagyglsgheahasettnvdkahlvdlaqhnpeelnakovqagay dihfvdngyqmftsngsewswayavagsdadytesssnqevsantqsssntnvqavsapt ssesrsyststtsysapshnysshsssvrlsngntsgavgsyasaaqmaartgvsastweh iiaresngqlharnasgaaglfqtmpgwystgsvndqinaaykaykaqglsawgm
270.	mmknkvivigstnydkflnykrfpkpgetlhinqaqkefgggkganqaiaasrlaadttfiskvgkdgnanfiledfkkagihtqvlltseseetgqafitvdeagqntilvyggammtl satdvemsydafigadfvvaqlevpfeaieqafklarkqnittvlnpapaielpksllel tdiiipneteaelltgisinnesdmketatyfldlgisavlitlgeqgtycayqeqykmi pacnykaidttaagdtfigaflselnkdlsnlesairlanqassltvqrkgaqasiptrk eyeaeyn
271.	malkkykpitngrrnmttldfaeitkttpeksllqplpkragrnnqgkltvrhhggghkr qyrvidfkrnkdgiiakvdsiqydpnrsaniallvyadgekryiiapkglqvgqtvesga eadikvgnalplqnipvgtvihnielkpgkggqlarsagassqvlgkegkyvlirlrsge vrmilstcratigqvgnlqhelvnvgkagrsrwkgvrptvrgsvmnpndhphgggegrap igrospmspwqkptlgkktrgkkssdklivrgrkkk
272.	mkskftillftifsttvlvlvijynktgsgsyisthysnnkikttatlflhgyggserse tfmvkgalnknvtnevitarvssegkvyfdkklsedaanpivkvefkdnkngnfkenayw ikevlsqlksgfgiqqfnfvghsmgnmsfafymknygddrhlpqlkkevniagvyngiln mmenvneiivdkggkpsrmnaayrqllslhkiycgkeievlniyydledgshsdgrvsns sanslovllrgafksvgemkfkgakadpsglhenkdvaneiiqflwet
273.	mkigidaggtlikivqehdnrryyrtelttniqkvidwlnneeietlkltggnagviadq ihhspeifvefdasskgleilldeqghqiehyifanygtgtsfhyfdgkdqqrvggygtg ggmiqglgyllsnitdykeltnlaqngdrdaidlkvkhiykdteppipgdltaanfgmvl hhldnqftsanklasaigvvgevittmaitlareyktkhvvyigssfnnnqllrevveny tylrgfkpyyiengafsgalgalyl

274.	mtlnnhfaytfeerptpklwlckpdgtrieriadfsklggtfkftnvntlhfdlplqvfs edtkqiernkvvdlvknkylidyryngyrdifviddikksandsditlnldsraselnk kaaneiellgstipgmmkilsvyaplwklphvdgkiidvkreltgsnttvnalidnics lfdavalynninrtisfyhkdnvgtnrglrvrensylksfedqfvskdivtrlypfggs ltiqsvmpagssyledfsyfmspfkrdmrnvlqhsdymsdelchalldydefyaskkd agelskqysailkehsqedfrlnqlsatlqrlnervelvkpkseyidlgtkvknfkitvp kssyylimirndgsftrikfnnkqydipsgewlyiklktgkfndatkfekqleypleils ananlrvytrssegdyeedtktieekynlekykilvkdgekvvasierrlkafedqka svirsmaknflseklynerelyvfesvvteenhtdagelyddavkqmkeqkkinrtitv dlvnfigsldhkddwklnvgdkinthtkkayltemqldfqtnqvktisdifd ykdldtiteklaqttstssqudfhkqqireqtgritdmtrliegewdankkrvmagnet vdigshgvkviskenpnefvimvggviamtrdngetfkfgjtpeginaemligkmivget ltfenesgtvkfdkglyvnsknfhlvsndgeedyfdklkremsenakqtdrmleeykk evsqtiseatdvrnivdnaadilqaafadgvitdvekrlisetlaqlekenrefedkinl alnhpyiteedtielnnsiveyssmyetlvisinesvsdkmitpqeseeinqminfree ikdiislveeliertknaqlqatleeakdyttrvrddikdelkdlmsfkslnstveesl qdnifdaeleaiktvvlvtkseyqditnryssmsantdlkseskldltksyktldtsfn dfvkyidemtmdriadetekvnykkkydtlqmlsdymkkydncileiskkysndaadkv lgdftaiatelqndfqdvkdnwaefkqttlesfkdgivteaekarlrvqldmldresmdi eeryksllangvtntdiknrltssrspylsvhaslrkvieqtiadgkvdesektlannsl ntynttlaysktiqealntlsqlissdvaskkveefngvtttissdvdtikkqfdgavi tyyysgvplsmdpakswttndlkdlhkdwyldtksgysytftksgyswkpltdqvi vsaskytddtvakqaakdledykvmktdfkdlndngvstfktevvkdfkgjvteaektr lrvqldildresqdieerynsifnsgvadtqvktsisnarstymsltklnrtiqtvied gkvtpekttanqtltaynnaltsyssaiqealnsmskviaqkeatsgvnqfneviknin nnitdigkqvdgaietfyysgvptlnipasywttaskreahlgdlyldtatyayrflk kgttsptyywspisdqiidalnraktaqdtadgkrrfvntpyppydtgdmwtqgasgd ilvcktpkaggiysisdwvkaskytddtwansavqqlneykrnnidiadlrktedfe ktvvmafddrvisisesssikgqlallnhekdrltrqveniirnsnlvgaektklstays nnitklsdlstlinsaivdmkivdaeskvtskfelykasvneytiafdhalnsiireia ssqakdrldewkrtefstdsdgiiervagakfdskvdtwntvmpaiqqvsnitygsen llnsesrsdganttthsfiryyltrpletgktyllasvalttdergsqqisynysppn aretvnikdgitytftaqtestqfliykdvagasdvdnvtiekailvegnkvtgwspa peetssalrdyntrisseetfieknkekisqialksdvdsalkvtytquysesply nniktledgasksynynthep	
	lynkrylkiqmsassrgksklyiifktktgdttlhqeivssssmvypditidlqaklgyp pnnlpdffelqagiaygennsidgffrirrmamtdtpnaev	
275.	mynvtqhatyktknkretavligvhaqtdrqfnfestmeeldalsqtcqlnvkgqitqnr eqfdhkyyvgkgkideiksfiefhdidvvvtndelttaqsktlndnlgikiidrtqlile ifalrarsregklqvelaqldyllprlbghgkslsrlgggigtrgpgetklemdrrhirt rmeikhqlktvvdhreryrnkreqnqvfqialvgytnagksswfnvlaneetyeknilf atldpktrqiqvnegfnllisdtvgfiqklpttlvaafkstleeakgadvlmhvvdashs eyrtqidtvnqiindldmdhipqvvifnkkdlcneqmdvpvsksahvfvssrdendkqkv knlviqeiknslspyeeivdsadadrlyflkqhtlvtelifdetqasyrikgfkkl	
276.	mmiivmlilsyligafpsgliigklffkkdirqygsgntgatnsfrvlgrpagfivtfld ifkgfitvffplwfpvhadgvistfftnglivglfailghvypiylkfnggkavatsagv vlgvnpillilaiiffsvlkifkyvslssiiaaiscvigsiiihdyillavsgivsiil lirhksnivrifkgeepklkwm	
277.	mmnhsealteqvfsfaselyaygvrevvispgsrstplalvfeahmiktwihndersaa ffalglikgsekpvailctsgtaaanytpalaesqisrlplvvltsdrphelrsvgapqa inqvmmfsnyvnfqfdlpladgsehtidtinyqmqiasqylygphrgpihfnlpfreplt pdldrvdlltsvtktlphyqksiavddikdilqekngliivgdmqhqavdqlltystiyd lpiladplsqlrkekhpnvittydllyraglnlevdyvirvgkpviskklnqvlkktday qiivqnndqidvfptpphisyeisandffrslmeeplverkwlqqwqsleqqarieisd ylkhatdeaayvgsliqkltkedtlfvgnsmpirdvdnllfdseasvyanrgsmgidgvv stalgmaahknvtlligdlsfyhdmagllmaklnelhinivlvnnngggifsylpqkrsa tkyferlfgtptglnfeytallydftfkrfdnltdfkyaelskmgshmyevitnrdenlh qhqnlyqklseivnvtl	
278.	makkinyklpsmvaltligtaftahqanaaeqpqqqsnhknvlddqtalkqaekaksevt qsttnvsgtqtyqdptqvqpkqdtqsttydasldemstyneissnqkqqslstddanqnq tnsvtknqgeetndltqedktstdtnqlgetgsvakenekdlgananneqqdkkmtasqp senqaietqtasndnesqqksqqvtseqnetatpkvsntnasgynfdyddedddsstdhl epislnnvnatskqttsykykepaqrvttntvkketasnqatidtkqttpfsataqprtv ysvssqtsslpkytpkvnssinnyirkknmkaprieedytsyfpkygynngvgpegiv vhdtandnstidgeiaimkrnytnafvhafvdgnriietaptdylswgagpygnqrfinv eivhthdydsfarsmmyadyaatqlqyynlkpdsaendgrgtvwthnaisnflgytdha dphqylrshmyspaelydliyekyliktkqvapwgttstkpsqpskpaggtmkltvsan rqvaqikptnnglyttvydskghktdqvqktlsvtktatlgnnkfylvedynsgkkygwv kqgdvyntakapvkvnqtynvkagstlytvpwgtpkqvaskvsgtgnqtfkatkqqqid katylygtvngksgwiskyylttaskpsnptkpstnnqltvtnnsgvaqinaknsglytt vydtkgkttnqiqrtlsvtkaatlgdkkfylvgdyntgtnygwwkqdeviyntakspvki nqtynvkpgvklhtvpwgtynqvagtvsqkydqtfkatkqdqidkatylygtvngksgwi skyyltapskvqalstqstpapkqvkpstqtvnqiaqvkannsgirasvydktaksgtky anrtflinkqrtqmntyvllqdgtsntplgwvnindvttqnlgkqtqsigkysvkptnn glysiawgtknqdllapntlanqafnaskavyvgkdlylygtvnnrtgwiakdlignst daqstpynytfvinnsksyfymdptkanryslkpyyeqtftvikqkningvkwyygqlld gkyvwikstdlvkekikyaytgmtlnnainiqsrlkykpqvnneplkwsnanysqiknam dtkrlandsslkyqfirldqpqylsaqalnkllkgkgulenqgaafsqaarkyglneiyl ishalvetgngtsqlakggdvskgkfttktghkyhnvfgigafdnnalvdgikyaknagw tsvskaiiggakfignsyvkaggntlykmrwnpanpgthqyatdinwanvnaqvlkqfyd kigevgkyfeiptyk	

10 Tolther 2000

HAMP CONTRACTOR

279.	vafefrlpdigegihegeivkwfikagdtieeddvlaevqndksvveipspvsgtveevl vdegtvavvgdvivkidapdaeemqfkghgddedskkeekeqespvqeeasstqsqekte vdesktvkampsvrkyarengvnikavngsgkngritkedidaylnggsseegsntsaas estssdvvnasatqalpegdfpettekipamrkaiakamvnskhtaphvtlmdeidvqel wdhrkkfkeiaaeqgtkltflpyvvkalvsalkkypalntsfneeagevvhkhywnigia adtdkgllvpvvkhadrksifeisdeinelavkardgkltseemkgatctisnigsaggq wftpvinhpevailgigriaqkpivkdgeivaapvlalslsfdhrqidgatgqnamnhik rllnnpelllmeg
280.	mmetdeisqiynkhrlpsisglakvsplvhrasiggvlnvaelnrikrlvqvqnqfktfy ngmleedeevkypilhdkmmhlpiltdlfkeinetcdahdlfdhasytlgairskisrtn qrirqnidrivknqgnqkklsdaivtvrndrnvtpvkaeyrqdfngivhdqsasgqtlyi epnsvvemmnqisrlrndeavererilteltgfvsaeadalliaesvmqqidfliakary artikgtkptfkedrtiylpnafhplldkdtvvantiefiddvetvitigpntggktvtl ktlglilvmaqsglliptldgsqlsifenvycdigdeqsiegslstfsshmknivellqd adqmslilfdelgagtdpsegaalamsildyvrrlgslvmatthypelksysynregvmn asvefdvetlsptykllmgvpgrsnafdisklglslniinkaktmigtdeqeinamies leqnskrvdqqrieldrlvreaqqthdalskqyqdyqnyetslmdeakekanqrvksatk eadeilkelrnlrdhkgaevkehelidkkqlddqyevksikqhydkkydtihtgdevk vlsygdkgevlelvgdeeavvqmgilmklpiedlektkkkkekptkmvtrqnrqtikte ldlrgyryeealneldqyldqavlsnyeqvyiihgkgtgalqkgvqqhlkkhksvrqfrg gmpsegafnytwaelk
281,5.	msffkrlkdkfsskneddigkdldesvdsnvnsdsdsmdpndsdeqvkpkkkpkklsead fdedglisiedfeeieaqkigakfkagleksrqnfqeqlnnliaryrkvdedffealeem litadvgfntvmkltdelrteaqrxniqetedlrevivekiveiyhqeddhseamnledg rlnvilmvgvngvgktttigklayryqqegkkvmlaagdtfragaiqqlnvwgervgvav vsqnegsdpaavvydainaaknkdvdilicdtagrlqnksnlmqeldkmkrvinraipda pheallcldattgqnalsqarsfkevtnvsgivltkldgtakggivlairnelhipvkyv dlgekmddlgpfspesyyvylfadmiegnedipeeisrnssvaseegn
282.	mkrnwkeavayqvyprsfndsngdgigdlpgliekldylenlgidviwlspmypspndd ngydisdykgimsefgtmmdfdgllssihqrgmklildlvvnhtsdehpwfieskssktn akrdwyiwadpkpdgsepnnwesifngstwefdestkqyyfhlfskkgpdlnwenpdvrq avfemmnwwfekgidgfrvdaithikknfeagdlpvpdgkkfapafdvdmnqpgiqewlq emkdkslsrydimtvgeangvtpndaeewvgeengkfnmifgfehlglwstgdtkfdvks ykqvlnrwqkqlenvgwnalfienhdgprrvstwyddknywyesatshatayfdqgtpf iyqqeigmtnypfesiesfndvavkteyqivkkeggdvnqlldkykmenrdnartpmqw mnsinagfttgkpwfhvnpnyteinvkqqlndkfsilsyykaliqlkksdliytygkfnm vdaenkqvfaytrtfknntvlivanltnevselnlpfeldissvdiklhnyhlndinldh ikpyesfvvei
283.	lshrklfpsifhlyqqdnldehiaiigigrrdynneqfrdqvkasiqtyvkdtdridefm thvfyhktdvsdkesyqsllqfserldsefalggnrlfylamapqffgvisdylkssglt qttgfkrlviehpfgsdlksaeslnnqirrsfkeeeiyridhylgkdmvqnievlrfana mfeplwnnkyisniqvtssevlgvedrggyyessgalkdmvqnlmalgmvallameaplsl nsediraekvkvlkslrqlkpeevkhnfvrqqvdgmidgkqvksyreedrvakdsvtpt fvsgkltidnfrvagvpfyirtgkrmksktiqvvvefkevpmnlyyetdnlldsnllvin iqpnegislhlnakkniqgidtepvqlsyamsaqdmmtvdayenllfdclkgdatnfth beelkstwkfvdalqdovtmvcofpnyeagtngplesdlllsrdgnhwddih
284.	mikknkeelndmeylvtqengteppfqneywnhfekgiyvdklsgkplftsedkfesncg wpsfskalnddeivelvdksfgmirtevrsekanshlghvfndgpkekgglrycinsaai qfipydkleelgygdlikhfkk
285.	lkklafaitaasgaaavlshhdaeastqhkuqsgeslwtiaqqyntsvesikqnnnlsnn mvfpgqvinvggsasqntssntssssasshtvvageslniiankygvsvdalmqanhlng ylimpnqiltipnggsgsgsggtatqtsgnytspsfnhqnlytegqctwyvfdkrsqagk pistywsdakywasnaandgyqvdntpsvgaimqstpgpyghvayveringdgsilisem nyangpynmmyrtipasevssyafih
286.	mariatklgypesnsfvtntviefvlhmeayprlyriktrdtnlikisqaneisrqitng tmtleeakyqleeiyvakrdsslpfkqiaaaiiatsflylqggrlvdiitavlagtigyl vveildrklhaqfipefigslvigiisvighafvpsgdlatiiiaavmpivpgvlitnai qdlfgghmlmfttkslealvtafgjgagvssiliiv
287.	mtefdlstregrwkhfgsvdpvkgtkpttknemtdlqsthknflfeieevgiknltypvl idqyqtaglfsfstslnknekginmsrilesvekhydngtelefntlhqllrtlqdkmmq naagvdvsgkwffdryspvthikavghadvtyglaienhtvtrkeltiqakvttlcpcsk eiseysahngrgivtvkayldknndviddyknkildameanassilypilkrpdekrvte ravenprfyedlirliaadlyefdwiegfdiecrneesihqhdafarlkyrk
288.	vqkkyitaiigttalsalasthaqaatthtvksgesvwsishkygisiaklkslngltsn lifpnqvlkvegsssratstnsgtvytvkagdslssiaakygttyqkimqlnglnnylif pgqklkvsgkatsssrakasgssgrtatytvkygdslsalaskygttyqkimqlngltnf fiypgqklkvpggssssssnntrmggyysptfnhqnlytwgqctwhvfnrraeigkgi stywmannwdnasaadgytidyrptvgsiaqtdagyyghvafvervnsdgsilvsemw saapgmmtyrtipayqvrnykfih
289.	vtkkafisysrtsdehlnrvrigeslrydhgidvildvwdctegddlaffmesmyndet idfvillsdfqyfnrandreggvgkestiitsqiydkqkdskfipvfldildmgkpslpt fcntrfaidmtdieldiekieeiarkihdkplfekprlgkvpdynqmqnelkkaikkltl sksynetrnfeealdiiyktleniensveeyakddmtlkevfdtwkefityalnudmfy freliiehynrclklteeefenpmtrifnyfsfilivseslssganefikdilnakfhfs rreanyyilslypqvlskkysyntnvkkmlaemyfegkelkkvqdadvilyteslmkkdi hsvyetwhgyllysrwpmleqqtinilinkfrskkyldqfdflfgssqrevfenydkiks treiptifnfidkeeigsv
290.	mhylkkvtiyisllilvsgcgdsketeikqnfnkmlnvyptknledfydkegyrdeefdk ddkgtwiirsemtkqpkgkimtskgmvlhmmrntrsttgyyvirkisednkseiddeekk ypikmvnnkiiptqkindnklkneienfkffvqygsfknsddykegdieynpnapnysaq yhlsnddynikqlrkrydiktkktprllmrgagdpkgssvgyknleftfvknneeniyft dsinfnpskgksl
291.	vkhskkillcisflitffiggcgfmkddgketeikanfnkmlnvyptknlenfydkeg yrdeefdkddkgtwivhskmviepkgkmesrgmvlfinrntrtskgyfivneiekdrkg rpinnkkkypvkmknnkiiptkpisndklkkeienfkffvqygnfkdiknykdgdisynp nvpsysakyqlsnneynvqqlrkrydiptkkvpklllkgdgdlkgssvgsknleftfien keeniyftdsvlfspsednes

292.	mrylkkvtiyisllilvsgcgngketeikqnfnkmldmyptknledfydkegyrdeefdk kdkgtwivgstmtiepkgkymesrgmflyinrntrttkgyyyvrkttddskgrlkddekr ypvkmehnkiiptkpipndkikkeienfkffvqygdfkmlkdykdgdisynpnvpsysak yqlsmndywkqlrkrydiptnqapklllkgdgdlkgssigsksleftfienkeeniffs dgvqftpsedses
293.	mkhsskiivfvefliltifiggcgfinkedskeaeikqnfnktlsmyptknledfydkeg yrdeefdkddkgtwiinskmivepkgeemeargmvlrinrntrtakgnfiikritennkg ipdvkdkkypvkmehnkiiptkqikdkklkkeienfkffvqygnfknlkdykdgeisymp nvpsysaqyqlnnydnnvkqirkrydiptnqapklllkgtgdlkgssvgykhleftfven kkeniyftdsinfnpsrgn
294.	mrylkkvtiyislliltifiggcgfinkedsketeikqnfnkmlnvyptkmledfydkeg frdeefdkgdkgtwiirsemtkqpkgkimtsrgmulyinrntrtakgyflideikddnsg rpienekkypvkmmhmkifptkpisddklkkeienfkffvqygdfknlkdykdgeisynp nvpsysaqyqlnnndnnvkqlrkrydiptnqapklllkgdgdlkgssvgsknleftfven keenifftdavqftpseddes
295.	mktykpyrhqlrrslfastifpvfmwniiglisfyaiyiwvehrtihqhtyqtqtelqri dkhfhtfvtqqqkqwrhvdlshptditkmkrqllkqvhqqpailyydlkgssqsftnnye qldttkmyliskyridfkddtyilkiymsstpllknikknsgqsalivdsydtvlytndd rfsigqkyqppqfgfmmeslklnshhahliiykdihetiedgiallvvmgvvlillvifg yisadrmakrqsedieaivrkiddakmrhlgsyeplkkhseleeinnyiydlfesneqli qsieqterrlrdiqlkeierqfqphfifntmqtiqyliplspkvaqtviqqlsqmlrysl rtashtvklaeelsyiqqyvaiqnirfddmiqlyldapedydytigkmmlqplvenaik hgrqseplkitirirltkrklhilvhdngigmspshlervrqslhhdvfdtthlglnhlh nraiiqyqtyarlhifsrshqgtlmcyqiplv
296.	vddvtkygpvdgdpitsteeipfdktrefdpnlapgtekvvqkgepgtktittpttknpl tgekvgegeptekitkqpvdeivhygeeiktghkdefdpnapksgtttqpkpgvknpd tgevvtppvddvtkygpvdgdpitsteeipfdktrefdpnlapgtekvvqkgepgtktit tpttlmpltgekvgegeptekitkqpvdeivhyggeeikpghkdefdpnapkgsqedvpg kpgvknpdtgevvtppvddvtkygpvdgdxitsteeipfdktrefdpnlapgtekvvqkg epgtktittpttkmpltgekvgegeptekitkqpvdeiteyggeeikpghkdefdpnapk gsqedvpgkpgvknpdtgevvtppvddvtkygpvdgdpitsteeipfdktrefdpnlapg tekvvqkgepgtktittpttknpltgekvgegeptekitkqpvdeivhyggeeiktghkd efdpnapkgsqtttopgkpgvknpdtgevvtppvddvtkygpvdgdpitsteeipfdkkre fdpnlapgtekvvqkgepgtktittpttknpltgekvgegeptekitkqpvdeivhygge eikpghkdefdpnapkgsqedvpgkpgvknpdtgevvtppvddvtkygpvdgsitstee ipfdkkrefdpnlapgtekvvqkgepgtktittpttknpltgekvgegeptekitkqpvdeivhygge eivpghkdefdpnapkgsqedvpgkpgvknpdtgevvtppvddvtkygpvdgsitstee ipfdkkrefdpnlapgtekvvqkgepgtktittpttknpltgekvgegeptekitkqpvdg dsitsteeipfdkkrefdpnlapgtekvvqkgepgtktittpttknpltgekvgegkste kvtkqpvdeiveygptkaepgkpaepgkpaepgkpaepgtpaepgkpaepgtpaepgkpa epgkpaepgkpaepgtpaepgtpaepgtpaepgtpaepgkpaepgtpaepgkpa esgkpvepgtpaegsapeqpnrsmbstdhknqlpdtgenrqanegtlygsllaivyslfi
297.	atgaataaacagatttttgtcitatattttaatattttcttgattttttagtatcggt ttagtaataacagatttttgtcitatattttaatattttcttgatttttttaggtatcggt ttagtaatacagtcttgcctgtttatttaaaagatttgggattaactggtagtgatta ggattactagttgctgcttttgcgttatctcaaatgattatatcgccgtttggtggtacg ctagctgacaaattagggaagaaattaattattgtaaggattaatttttcggtg tcagaatttatgtttgcagttggccacaatttttcggtattgatgttatcgagggtgatt ggtggtatggatggtatggt
298.	atgetattttatttatttacaateagetttatateaacagtactttetetate atgetattttattatttatttacaateagetttatateaacagtacttttetetate atttteaatgeacecaaacgectettagtageatgtggatttgtgggttgcattggggt acgatttaceaattaacggtagatttagagtttggaaaagttggcggtteatttttggga agettaattttaggettaatgagteatactatgagtegcagatataaacgaceggtaatt atatteatagtgccaggeattataceattagtacetggtggtgcagettateaagegact egttttttagtateaaatgattatacaatgtgetgtaaatacattttagaagetateaacetg attteaggtggattgettteggtatattagttetgaaateattttagaagetaeacac egtateaacaactgtatggtaaaateaaaggtagagaatataaaaaaatettacaaca aataatagagtt

•

299.	atgataaatgcagtagtaatagcagtaattttaatgattatgctatgtttatgtcgatta aacgtagttataagcttattatatatgtggcgctagtggtggcttaatttcaggcatgagc attgaaaaagttataaatgtatttgggaaaaatatagtcgatggtgctgagtttcacgagcatta agctatgcttattaggtggatttgcagcattaatttcatacagtggtatcacagactat ttagtaggaaaaattataaatgcaattcacgctgaaaatagtcgatggtcaaagagttaaa gtcaaagtgacaataatcattgcattatagctatgagtatcatgagtcaaaaacttaaatt cctgtacatattgcattcattccaattgtcatcccaccattgttaagtctgtttatgttcacgat ttaaaaatagatagacgtttaatcggttgattatcggttttggtttatgttcccgtat gtgttattaccatatggattcggttcaatttccaattttccagcaaattattcaaagtggctttgca aaggcaaatcacccaattgagtttaatatgttttggaaagcaatgcttattccttcaatg gggstaattggttacttatatggtttatatgttattcgttacacagtggctttgca aaggcaaattgtggcttacttatatggttatatggtatatcgagaatagaa acacgtaaaatttcagataggtacaatgttacagagttaatccaatgatttt ggtgcactggcagggtactcgtattctttattcacgacttatatcctaatagt ggtgcaagtttgttggatgtataaaattatggcttatattggtgtagttatttaaca gcaaatggatttgttggstgtaataaaattatggcttatattggtgtagttattttaaca gcaaatggatttgctggtgtaatgaatgctactggtgatatagatgaatagtaaaact ttaacaagtattactggtgataataaattattggatatatacatgatgtatgt
300.	atgaatcataatgttattatcgttattgcattaatcatagttgtcatttctatgttagct atgctcattcgcgttgtgctaggcccatcacttgccgatcgtgttgtcgcattagatgcg attggtcttcaattaatggcagttatagcattattcagtattttattaaatattaaatac atgattgtcgttattatgatgattggtatattagcttttttaggtactgcagtattctct aaatttatggacaaaggtaaggt
301.	gtgaataggantatcgttaaactagttgttcatgctaattttagttgtagcagtagcg ggttgtggtcaaaangatactgaagagaaaactgaaatgacgacaataaaagatgaatta ggaactgaaaanaattaagaaaaactctaaacgtgttgttgtattagaatatagttttgct gattatttagcagcattagatatgaaacctgttggtattgcagatgatggcagcataaa aatataacaaagtcagtaagagatagattgggcagtattggcagcactaaa aatataacaaagtcagtaaggataagattgggcaatatggacgatgttagc caaccgaatatggaagtgataagataa
302.	atgactggagaacaatttactcaaattaaacgtccagtaagta
303.	gtggaanatacaattaatgaaagtgaanagannanangatttaaattanaaatgccaggt gcatttatgattttattcattttaacggttgttgcagttatagcaacatgggttattcct gctggtgcatattctaaactttcttaacgaaccttcatcccaagnactaaagatagttacc cctcatnaccaagtganaaaggttccgggtacgcaacaggaactagacaanatgggggtt aaaattaagattgaacaatttaaatcaggtgcaattaataagacggtattccggat acttatgaaagattanagcaacatccagctggaccagaacaaataacaagtagcatggt gaaggtacgatagaaggcggtgcattaattcattcttgtactaggggacattatt ggcgtagttcaagcagtggttcttttgahtcgggattgtatcattgtactagggggacattatt ggcgtagttcaagcagtggttcttttgahtcgggattgtacattattggcgggaca aangggcatgaatttatgctanttgtgtttgtatcaatactaatgattatcgggggaca tattgtgtattgaagaagaagactgtagacatttatccgattttagtccctatatttata gcgtlaggatacgattctatcgttctcggttgtattccgattttagtccctatatttata gcgtlaggatacyattctatcgttctcggttgtaattgccattttgtccggt agtacattttcaactattaacccgttctcggttgtaattgccgttggcaca acttttacggatggcttgtattggagaaaaggtgttgtattaaaggtgctgtgcatattct tatgaagacaagaagctttggaagaaaaggtgttgtattaaagagtgctgtattttt tatgaagacaagadgcttttgaacaccaatggtctgtattaaagagtgctatattct tatgaagacaagadgcttttgaacaccaatggtctgtattaaaagagtaccaatagtgcc cattttactttgcgtaagaagataaccttacattatttgtaccaattaccaattac tttacaattataataatgtttattgctggagatcccaatttccaattatg gtatggagtattaaccataggtggtgttcccagttagattcttaata tttacaattataataatgtttattgctggagacaagatgattgat

11、11年第二五十二年

ALC: COMPANY

er e san e

.

PART TAKE

305.

Man Div Carting his

306.

307.

٠.

308.

gancanantattgcantagcacaagttgannagagttaattaaagctanacaaatt

警問終發 医人名克拉尔克克 英文 医萎缩的

:

į.·

1. 食水化 · 1. 以题

.

7.4

•

.

.

 $\mathbb{E}_{\mathcal{L}_{\mathrm{opt}}} = \mathbb{E}_{\mathcal{L}_{\mathrm{opt}}} = \mathbb{E}_{\mathcal{L}_{\mathrm{opt}}} = \mathbb{E}_{\mathcal{L}_{\mathrm{opt}}} = \mathbb{E}_{\mathcal{L}_{\mathrm{opt}}}$ 

• . •

1	1		
309.	atgagtgttgaaatagaatcaattgaacatgaactagaagaatcaattgcatcattgcga		
	caagcaggcgtaagaattacacctcaaagacaagcaatattacgttatttaatttcttca catactcatccaacagctgatgaaatttatcaagcactttcacctgattttccaaatata		
	agtgttgcgacaatatataataacttaagagtgtttaaagatattggaattgtaaaagaa		
	ttaacatatggagactcatcaagtcgattcgactttaatacacataatcattatcatatt		
İ	atatgtgaacaatgtggtaagattgttgattttcaatatccacagttaaatgaaattgaa		
ŀ	agattagctcagcatatgactgactttgacgtaacacatcatcgaatggaaatttatgga		
310.	gtttgtaaagaatgccaagataaa		
310.	atgagtgaaaaacaacaaattctcgattatatagaaacaaataaat		
1	actttaatagatcgtttgaaagagcatgattttgaaattgaaaccgagattgctgggcat		•
i	gcaactgggtttatagcgacatatgattcaggacttgacgggccagctataggtttttta		
1	gcagaatacgatgctttgccaggattgggtcatgcttgtggtcataatatcattggaact		
	gcaagtgttcttggtgcaattggtttgaagcaagtgattgaccaaattggtggtaaagta gtcgttcttggatgtccagctgaagaaggtggggaaaatggtagcgctaaagcttcttat		
1	gtcaaggctggtgtgattgatcaaatagacattgccttaatgattcatccgggaaatgaa		
1	acttataaaacgattgatactttggcagtggatgttttagatgttaaattttacggaaaa		
ŀ	agtgctcatgcctctgaaaatgcagatgaagcgttaaatgcattagacgctatgattagt		
1	tattttaatggtgtagcacaactacgacaacatattaaaaaagatcaacgtgtgcatggt gtgattttagatggcgggaaagcagctaatattattccagactatacacatgctcgtttt		
1	tatactagagcaatgacgcgtaaagaattggatatattaacagaaaaagtaaatcaaatc		
	gcacgtggagctgcgatacagactggttgtgattatgaatttggtcgaattcaaaacggt		
177	gtgaatgaattcattaaaacgccgaaattagatgatttattt	7.4	
	gttggtgaagcagttattgatgatgattttggttatggctctacggatacagggaacgta		
1	agtcatgttgtgccaacaatacatcctcatattaaaataggatcacgtaatttagtagga catacgcatagatttagagaagcggctgcgagtgtacatggtgatgaagcattaatta		
1	ggcgctaaaataatggcgttgatggggttagagttaattacaaatcaagacgtttatcaa		
	gacattattgaagagcatgcgcatttgaaagggaatgggaag		
311.	atgactacgaccttcattattagctacattattttagcgctcattattgttggggttatc		
	aatttattttaataagatcaagaaaaaaaggcaaacgccaacaaaaggaacaacaattt		
	acgacacgtcaatcaatcaatctaatctaaatttaaagctagtgatttagacaaaacaactgat caatcgacacaacgtatgacgcatgaagagttgcgtgttgacaatcaagatgatcatagc	•	
j	caagttagtctaaatggttacacaaaggggtctgagaaagatcaagaagcattcactaat		
	aataaggatgaggaagcagttgctgctaaaaatcctgaatcagaagaatataaagtgaat		
1	gaaaaaataaaaaaagaacataaaaaactttatttttggtgaaggtgtttcacgcggtaaa		
	atattagcggcattattattcggtatgtttattgcgattttaaaccaaacattattaaat gttgctttaccaaaaattaataatacggaatttaatattctgcgtcaacagggcaatggttg		
	atgacgggattcatgttagtaaacggtattttaataccaattacggcgtatctatttaat		
1	aaatattcatatcgaaaattatttttagttgcgttagtactctttacaattggttcatta		
i	atctgtgcgatttcaatgaatttcccaatcatgatggttggacgtgtattacaagccatt ggtgcaggtgtactaatgccattaggttcaattgttattactacaatttatccacctgaa		
1	aaacgtggtgctgccatgggtacaatgggtatcgcaatgattttagcacctgcaattggt	•	
ì	ccaacattatcaggttatattgtacaaaattaccattggaatgtgatgttttacggtatg		
1	ttcattatcgggattatcgctattttaattggttttgtatggtttaagttatatcaatat		•
	acaacaaaccctmaagctgatatcccaggtatcattttttagtacgattggtttttggtgct ttgttatatggtttctcagaagctggcaacaaaggttggggttcagtagagatagaaaca		
i	atgtttgcgattgytattatctttattattctattcgttattagagaattaagaatgaaa		
	teaceaatgttgaatttagaagtattgaaatteecaacatttacattaacaacaattatt		
	aatatggttgtaatgttaagtttatatggtggtatgatttatta		
	atgggtetactaggaccatttgcaggtaaattgttagatactattggtttaaaaccatta		
į.	gctatctttggtattgctgtaatgacttatgcaacatgggaattaactaaattaaatatg		
1	gatacaccatatatgacaatcatgggtatctatgtacttcgttcatttggtatggcattt		
1	ataatgatgccaatggtaactgcagctattaatgcgttaccgggacgacttgcctctcat		•
l .	ggtaatgetttettaaataegatgegteaattageaggetetataggtaeageaatetta gttaetgtaatgaeaacaeaaactaeaacaettateagettttggggaagagttagat		
	asaacgaatcctgttgtacaagatcatatgcgtgaattagcatcacaatatggcggacaa		
	gaaggcgcaatgaaagtgttactacaatttgtaaataaactagcaacggttgaaggtatt		
i	aatgatgcatttatagttgcaacgatatttagcatcatcgccttaattttatgtttattt		
Į.	ttacaaagtaataaaaaagcaaaagctacagctcaaaagttagatgcagataatagtatc aatcatgaa		
312	atgattaaaaataaaatattaacagcaactttagcagttgytttaatagcccctttagcc		
	aatccatttatagaaatttctaaagcagaaaataagatagaagatatcggccaaggtgca		
1	gasatcatcasaagaacacaagacattactagcaaacgattagctataactcaaaacatt		
	caatttgattttgtaaaagataaaaaatataacaangatgccctagttgttaagatgcaa ggcttcattagctctagaacaacatattcagacttaaaaaaatatccatatattaaaaga		
J	atgatatggccatttcaatataatatcagtttgaaaacgaaagactctaatgttgattta		
1	attaattatcttcctaaaaataaaattgattcagcagatgttagtcagaaattaggctat		
I	aatatcggcggaaacttccaatcagcgccatcaatcggaggcagtggctcattcaactac		
1	tctaaaacaattagttataatcaaaaaaactatgttactgaagtagaaagtcagaactct aaaggtgttaaatggggagtgaaagcaaattcattcgttacaccgaatggtcaagtatct		
	gcatatgatcaatacttatttgcacaagacccaactggtccagcaggagactatttc		
	greccagataateaaetaeeteettaatteaaagtggetttaateeateatttattaea		
	acattgtcacacgaaagaggtaaaaggtgataaaagcgagtttgaaatcacttacggcaga		
	aacatggatgctacatatgcttacgtgacaagacatcgtttagccgttgatagaaaacat gatgcttttaaaaaaccgaaacgttacagttaaatatgaagtgaactggaaacacatgaa		
	gtaaaaattaaaagcatcacacctaag		
	The state of the s		

313.	atgcaatcaacgaaaaccaaaacgaagcattttcattttattgctaattacgttaggc gtcatgaccgcttttggcccactaactatagatatgtacgtac	
314.	atgatgtatggatatccagagaaatggttggaaggtatgacaactggagaaggtatcgcg 'gcagaattacgcttaggcattgtgaatggtcacatagctgaaggtacgttactcatgan aatcaaatggcaaagcaatttaatgtgagtcgttcgccaattcgagatgcatttaaatta ttgcaacaaaatcaactcatccaattagaaagaatgggtgcacatgtgttgccgtttggg gaacaagaaagaaagaaatgtattgcgatttgcgatgttagagtcatttgcattttca agagttaaaaatcaagagcgactacctatcgtaaaagaaatgaagaaacaacttgaaattt catgaaagtggcagtaaaatttgaggatgcagaatcatttacaagagcatgactttgaattt catgaaacattaatcaaagcatctaatcatcatattttaaactcattttgagtcattta aaaccagtaatgatggcactcgttttaacatccatagtgacacacgtatgcaacagaacccg caagattttgaacgcatacatcataatcatcaagtgtttattgatgcagtggaacaatac gacagtcaaattttgaaagaagcgtttcatttaaattcgacgatgtagaaagatatt gaaggattttgaaagaagcgtttcatttaaattcgacgatgtagaaagatatt gaaggattttgatgaat	***
315.	atgggaagttttttcaataaatagcacgaaaagaggatcoggctatctaccaaataa gatggtcatttaaagcgtacacttcgggtgggtgatttcttagctttaggaaca attggtatcgacatctatctttacgctacctggcattgttgctgcagaacatgcaggacca gccgttgcgttatcattcttaccgctgctattgttgctggtttagttgcatttacttat gcagaaatggctgccgctatgccatttgcaggttcagctattcttgggtaatgttaatta tttggtgaattttttggatgggttcagggtctattagctgaatatttatcgcc gtagcctttgttgcatcaggattctcagcgaatttaccgggatttggaaaccaattggc atcgaattacctgcagcattattcaaatccatttggtaacaatggggtttatcgatatt attgctgctatcgtattttattacaatccatttggtaacaaatggggttttatcgatatt attgctgctatcggtattttattataaaccgcattattaccacgtggtattgccgaagca gctcgtatggaaaatattttagttatttaaaagattagctattatttat	
316.	atgaatagtgataatatgtggttaacagtaatggggctcattattattatttcaattgta ggtttactcattgccaaaaagataaatccagttgtaggtattgacaatcataccttgctta ggggcaatgatgtttattagtgtagacagatttgttgtgtgtttttttaggtataagggtta gatcaagtcatcaacgttgttattatgttgtagatttttttt	

SHOP CONTRACTOR OF CONTRACTOR

	317.	atggaaaacacggttaaatatggtaagtttatactccctatcgttgtaggtctcctatt tgggcacttacaccttttaaaccggatgctgtggatccaacaggatggtatatgttcga atattcgtcgcgacaatcattgcttgtattacacaaccgatgccaattggtcgct ggtttggtaataatagcttggtaattgctcgttggcattgtgacattgaaaacggctgtcgct ggttttggtaataatagcatttggttaattgcattgtgacattttaatttggtaaaaa acattaggattagcatattcatcgtcggtgtagattttaattctagcgctgtcgacacca agtaataccgacggtctggtgaatcatgttcccaattactaatcattctgacacca agtattcaaggtattaacattcatcgtcggtgtagatttaattctagcgctgtcacca agtattcaaggtaattaatactgcggtagatcagttccaattatcaaatcactttctgaatca tttggttcgaaaccgaaagacggatcagcaccaaaatgggtgcatttcttgtttcaca gaattccaaggtaatttaatt	
	318.	atgaataaagtaattaaaatgcttgttgttacgcttgctt	
1		atcacttgaacttagtegcagatataaatcttcattaaaacttattgattaatt gaaagttaatattgaacacactaatcaataaatcttcattaaaacttattgacgatttatat gaaaagttaatattgaaaacaatcaaaa	
	319.	atgattaatcagtctatatggcgcagtaactttcgcatttatggctcagtcag	
	320.	atgaagcgattattcgatgtagtgagttcaatatatggtttagtagttttagtccgatt ctgttaattacagcattcataattaaaatggaatcacctggaccagccattttcaaacaa aaaagaccgacgattaataatgaattgtttaatatttataagtttagatcaatgaaaata gacacacctaatgttgcaactgatttaatggattcaacatcgtatataacaaagacaggg aaggtcattcgtaagacctctattgatgaattgcacaattattgaatgttttaaaagga gaaatgtcaattgtaggtcctagaccagcgctttataatcaatagaattaatcgaaaaa cgtacaaaagcgaacgtgcatacgattagaccaggtgtgacaggactagctcaagtgatg ggyagagatgatatcactgatgatcaaaaagtagcgtatgatcattattacttaacacat caatctatgatgcttgatatgtatatcatatataaaacaattaaaaatatcgttacttca gaaggtgtgcatcac	

•		1.0
321.	atggcacaacttaattcaaagatagcttccttaaaattattcgcaagttacgccatagca acttatattttagttatattacacgagtgcattaaatctttttaatattgcgcatagcagattacgtcgtataacttttaatttattt	·
322.	atgaaaacaatacattgtttcgcatctaccactctttttattgaaaaagtggtatttg attatctatttactatttatattagcgcactccttattcattacagacaatccaaccat ggaacagaagafggacatcattttaatatagggtgtggtagataaaagatcaatccaagtgaa acgaaattaatcttaaactctattggtaaagggagtaacctaggaaaacaggcaat aaagcatatgatgataaggcaagcacatactttgttaaaaaaacataaacttcaaggctat tttgttttgattaaaggtatgaccaaggcatttataaacaaggcgaactaccaattca gtatatacatatgatcaacaatccatgaaaagtgggtgctttcagcattcagcattct gtttaccaacgtcttatgcgatcaatgggtggcatcttagctttcaaggattacc gtttaccaacgtcttatgcgatcaatgggtggcatcttagcttttcaagacttagcacc gttcaggtgcatttaactaggatcaatgttatgactgatttgctgattacaggattaaac cgttcaggtgcatttaactaggaccgattcatttatacgatacgggcagttattatgca attacaggatttttaacaacggtattcattttatacgatacgtttgaa atcaaggatttttaacaacggtattcattttatacgatactttatttcaaagagcgt ttattaatcattcgtacgtagaaagcgcgattgaaaatgtttcattttctaaagagcgt ttattagaattggattgg	
323.	ttgaaaaacaagttattatttogggcctcatgttattttcactatttttggagccgga aatttaatattcccgccatgcttggccatacagcgggtcaaaattatggattggtatg ctaggctttgcccttacaggcatattactcccctttattactgttattgtttt tatgatgaaggtgttgaaagtgtagcaatcgtatacatccatggttcgggtttatttt gctgtcgtgatttacatgtcatcggaagcatttacggtattccagtgctgcaaatgtc gcgtacgaaattggtaagacacattttacctgtgcataaccaatggactttaattata ttcgcagcaaattggtacaagacacattttacctgtgcataaccaatggactttaattata ttcgcagcaaattgtttttgccatcgtttactggattagtttaaatccatcgaaaatcgtt gataatttaggtaaattattaacaccgttattacatggactatatactgaaaatcgtt gataatttaagaaattattaacaccgttattacaaggactaaatataacacat ccttccatttcaggaagtttggaaggctattaagtttacaaggataaatatataacacat ttttccgtagcaattgtcaatggcaatagtgcacctaaggacacagagcgcatgaaaatt ttaaaaatagtctgcttttcaggtcttattgcagccatattacttggaatgattactt gcacttgcatacgttggggcatcaacagctccaggaaactttaaagatggtacagaata ttgacgtacaactcattacggttattggtcgttcgttcggtaacctgtattggaatgacg gttatccttgcatgcctaacaacatgtataggactgtcaatgcttgcgccacattact aagaaacacgtacctaagttttctataaaatattgccactatttttctctatacataggg ttcttatttacaacacttggtttagaaatgatttaaaaattgctgccccattattgac ttaatatacccgtgtcgattcgactgcaactgcattattacttgctaacact ttcagattcagttggggcctatcgaactgtatatattgctaacact ttcagattcagttggggcctatcgaactgtatatattgctaacact ttcagattcagttggggcctatcgaactgtattatacatttgctaacactgttatcac caacacaaaatagttcaacttattacacggtgttattatttgaaactttatacggt ttctatacaacatagatttacacttattacacggtgttattatttgaaactttatcggt ttctaacacactagatttacacctgccgcaccactactactcttgctataccact tcagatacagatacgatttacacctgcctttattacatttcctctacacttactaccac tccagaaaccagaaccagatcgcttgtactcataccatttttacaactttaccaccact tccagattcagtttagaactcgctccgaacactgttattacatttcactttccacttaccaccact tccagattcagattcagctggctgccaacactgccctttactcataccacttactcactc	
324.	gtgaaacattatttgactaaatttgtagcaatgctaataactgctgtattggtgtagc tttgggttactgaaagtcaggcagcagaacaacaagtattagtgatgtatatagtgg ataacggatgcgaaatctgcactttctaataattcgatatcgatgaatga	

1.00 CONT. 1.00 CONT. CO

THE PROPERTY OF THE PARTY OF TH

	•
325.	mnkqifvlyfnifliflgiglvipvlpvylkdlgltgsdlgllvaafalsqmiispfggt ladklgkkliiciglilfsvsefmfavghmfsvlmlsrviggmsagmvmmgvtgliadis pshqkaknfgymsaiinsgfilgpgiggfmaevshrmpfyfagalgilafimsivlihdp kksttsgfqklepqlltkinwkvfitpviltlvlsfglsafetlyslytadkvnyspkdi siaitgggifgalfqiyffdkfmkyfseltfiawsllysvvvlillvfandywsimlisf vvfigfdmirpaitnyfsniagerqgfagglnstftsmgnfigpliagalfdvhieapiy maigvslagvvivliekqhraklkeqnm
326.	mlfylfhftisfistvlfsiifnapkrllvacgfvgalawtiyqltvdlefgkvgasflg slilglmshtmsrrykrpviifivpgiiplvpggaayqatrflvsndytsavntflevtl iggalafgilvseilyylytrikqlygklkgktykksynmnnrv
327.	minavviavilmimlelerlnvvislfisalvgglisgmsiekvinvfgknivdgaeval syallggfaalisysgitdylvgkiinaihaensrwsrvkvkvtiiiallamsimsqnli pvhiafipivippllslfndikidrrligliigfglefpyvllpygfgqifqdiqsgfa kanhpiefnmiwkamlipsmsyivplliglyvyrkpreyetrkisdsdnvtelkpyiliv tivailatflvqtftdsmifgalagylvffisraynwyeldakfvegikimayigvvilt angfagvmnatgdidelvktltsitgdnklfsiimmyviglivtlgigssfatipiissl fipfgasigldtmalialigtasalgdsgspasdstlgptaglnvdgqhdhirdtevpnf lfyniplmifgtiaamvl
328.	mnhnvijvialiivvismlamlirvvlgpsladrvvaldaiglqlmavialfsillniky mivvimmigilaflgtavfskfmdkgkviehdqnhtd
329.	mnrnivklvvfmlilvvavagcgqkdteektemttikdelgtekikknpkrvvvleysfa dylaaldmbpvgiaddgstknitksvrdkigayesygsrpqpnmevisklkpdliiadvs rhkkikselskiaptimlvsgtgdynanieafktvakavgkekegekrlekhdkilaeir kkieqstlksafafgisragmfinnedtfmgqflikmgiqpevtkdktthvgerkggpyi ylnmeelaninpkvmilatdgktdknrtkfidpavwkslkavkdnkvydvdrnkwlksrg iiasesmaedlekiaekak
330.	mtgeqftqikrpvsrltekvlgwlcwvmllvltvitmfialvsfsmntsianlentlmm afiqqllagngynttqfviwlqngiwaiivyfivcllisflalismnirilsgflflisa ivtiplvllivtliipilffiiammlfirkdkvemvapqyyeeyngpiydyrepvyerpq pkddyydvpkyekeldksntvydqeqerdkydqfpkraveseynhderteeepsvlsrqa kykqsteelgieddgyyaepevdpkelkaqqkrekaeikakkkekrkaynqrmkerrkn qpsavsqrrmmfeerrqiynndiseernssevkdkkeqe
331.	mentinesekkkrfklkmpgafmilfiltvvaviatwvipagaysklsyepssqelkivn phnqvkkvpgtqqeldkmgvkikieqfksgainkpvsipntyerlkqhpagpeqitssmv egtieavdimvfilvlggligvvqasgsfesgllaltkktkghefmlivfvsilmiiggt legieeavafypilvpifialgydsivsvgaiflassvgstfstinpfssviasnaagt tftdglywrigacivgaifvisylywyckkikndpkasysyedkdafeqqwsvlkdddsa hftlrkkiiltlfvlpfpimwgvmtqgwwfpvmassfliftiilmfiagtgksglgekg tvdafvngasslvgvsliiglarginlvlnegmisdtilhfssslvqhmsgplflivllf iffelgfivpsssglavlsmpifapladtvgiprfvivttyqfgqyamlflaptglvmat lqmlnmryshwfrfwppvafvlifgggylitqvliys
332.	nsffkrlkdkfatnkeneevkslteegggdkledthsegstqdandlaenaevkkcprkl seadfdddgllsiedfeeleagkmgakfkagleksrqmfqeqlmnliaryrkvdedffea leemlitadvgfntvmtlteelrmeagrrniqdtedlrevivekiveiyhqeddnseamn ledgrlnvilmvgvngvyktttigklayrykmsgkkvmlaagdtfragaldqlkvwgerv gvdvisqsegsdpaavmydainaaknkgvdilicdtagrlqnktnlmqelekvkrvinra vpdapheallcldattgqnalsqarnfkevtnvtgivltkldgtakggivlairnelhip vkyvglgeqlddlqpfmpesyvyglfadmieqneeittvendgivteekdmhgsk
333.	mlkkwlnsnvkqffvitfisviltlilfsthiydyivngtvfsgagdgfrqmmpfqmyly ehlrsfsslydasfglggdmkglsyyyslsplmwlnflfikigetvgifnpttihfwpt nqlimamiraiitfvvtfylfkilhfkrsammiatilygmstvviyfnftwsfygmllyl lplsilgleryfqqrkigifivaialtlfsnfyfsyyqailigcyylyrliftykydivs rtqklicvisatvlsvlssvfglftgisaflendrkmpnydipfltpldyhyfffsdgf yitisiltivallsfklyrfyfyrlfaivtwilfigslsqyfdsafngfsfperrwvyll alsssalcglfiqhlstlmmkyylirtipvciiailyvllsptbplalivgiillivlav ilkfslwrykkltvailvlivmiqqivildnnknmaikpyqqslstlkqhdyhsnyvnqdl ikkinqmatgsfnridymsdyalnspfiyhyngislyssifngdilkyydktlqinmpld kmstyrllgnrqmllslwnvndrirvnhddnlpygfkiksehkmkvrwinskntihyps ahitnkvfsnkelkspldkeqamlqgivsnnikdvnthfkanknllsdstiklnsaawqs ptkhllqvkqnnggltvqlpksvsnqfkdlyfemdlellspdkahdvkvneytqernklt ykyrrvvtpvtirikapdrirlslpkgkyrvnlkgiygedyttlkdasnsleavkvsktk hgytitknknssgyivlptaynqgmkatsgdqslkveqvngvmtgikapknitkiqlsyt ppyyyllititifglicsiiftrwarqk
334.	mrqlaqakkkstakkkttskkrtnsrkkmdnpiryviailvvvlmvlgvfqlgligrli dsffnylfgysryltyilvllatgfityskripktrrtagsivlqiallfvsqlvfhfns gikaerepvlsyvqsydnshfpnfgggylgfyllelsvplislfgvciitilllcssvi lltnhqhrevakvalenikmvfgsfnekmsernqekqlkreekarlkeeqkarqneqpqi kdvsdftevpqerdiplyghtenesksqsqpsrkkrvfdaenssnnivnhhqadqqqlt eqthnsvesentieeagevtnvsyvvppltllnqpakqkatskaevqrkqqvlentlkdf gvnakvtqikigpavtqyeiqpaqgykvskivnlhndialalaakdvrieapipgrsavg ievpnekislvslkevldekfpsmklevglgrdisgdpityplnemphllvagstgsgk svcingiitsillnakphevklmlidpkmvelnvyngiphllipvvtnphkaaqalekiv aemerrydlfqhsstrnikgynelirkqnqeldekqpelpyivvivdeladlmmvagkev enaiqritqmaraagihlivatqpsvdvitgiiknnipsriafavssqtdsrtiigtgg aekllgkgdmlyvgngdssqtriqgaflsdqevqdvvnyvveqqqanyvkemepdapvdk semksedalydeaylfvveqqkastsllqrqfrigynrasrlmddlernqvigpqkgskp rqvlidlindev
335.	maeklgrelsnrhiqliaiggaigtglflgagqtialtgpsilltyiiigfmlfmfmrgl geiiiqmtefksfadvtntyigpfagfvtgwtywfcylitgmaevtavakyvsfwfpeip nwisalfcvlllmsfnllsarlfgelefwfsiikiatiiglivvgfvmilfafktqfgha sftnlyehgifakgagffmsfqmalfsfvgiemigvtagetkdpvktipkainsvpiri lifyvgalavimsiipwqqvdpdnspfvklfaligipfaaglinfvvltaaasscnsgif snsrmlfglssqqqappnfsktnkygvphvaifassalllvaallnyifpdatkvftyvt tistvlflvvwgliiiayinysrknpdlhknatykllggkymgylifvffifvfgllfin vdtraalyfipiwfillafmylrykriaaksnk

336.	mnllkmkysirkykvgifstligtvlllsnpngaqalttdnnvqsdtnqatpvnsqdkd vannrglansaqntpnqsattnqatnqalvnhnngsivnqatptsvqsstpsaqnnnhtd gnttatetvsnanndvvsmntalnvptktnengsgphtlkeiqedvrhssnkpelval aepasnrpkkrerraapadpnatpadpaaaavgnggepvaitapytpttdpnannagqna pnevlsfddngirpstnrsvptvnvvnnlpgftlinggkvgvfshamvtsmfdsgdnkn yqaqgnvialgrihgtdtndhgdfngiekaltvnpnselifefntmttkngqgatnviik nadthdtiaektveggptlrlfkvpdnvrnlkiqfvpkndaitdarglyqlkdgykyysf vdsiglhggshvfverrtmdptatnnkeftvtslknngngsaldtndfvyqvqlpegv eyvnnslkdfpsnnsgvdvndmvtydaanrviikstgggtansparlmpdkildlry klrvmvyptprtvffnetltyktytqdfinsaaeshtvstnpytidiimkdalqaevdr riqqadytfasldifnglkrraqtiidenrmvplnkrvsqayidsltnmqhtlirsvd aenavnkvdqmedlvnqmdeltdeekqaaiqvieehkneiignigdqttddgvtrikdq giqtlsgdtabyvkpnakkairdkatkqreinatpdvtedeiqdalnqlatdetdaid nvtnattnadvetaknngintigavvpqvthkkaardainqatatkrqqinsmreatqee knaalneltqatnhaleqinqattnadvdnakgdglnainpiapvtvvkqaardavshda qqhiaeinanpdatqeerqaaidkvnaavtaantnilnantnadveqvktnaiqqiqait patkvktdaknaidksaetqhntifnnndatleeqqaaqqlldqavatakqninaadtnq evaqakdgdtqnivviqpatqydtdtrnvvndkareaitninattgatreekqeainrvn tlknraltdigvtsttamvnsirddavnqigavqphvtkkqtatgvlndlatakkqeinq ntnatteekqvalnqvdqelatainninqadtnaevdqaqlgtkainaiqmivkkpaa laqinqhynaklaeinatpdatndeknaaintlnqdrqqaiesikqantnaevdqaatva emidavqvdvvkkqaardkitaevakrieavkqtpnatdeekqaavnqinqlkdqainq inqndtqdvtttnaavnaidmvaevvvikpaiaidekakekqqidnsldstdeke evasqalakekekalaaidqaqtnsqvnqaatngvsaikiiqpetkvkpaarekindainq elrakinqdvattnaavnativkippeaqqaikasaenqvesikdtphatvdeldeanqlisd tlxqqqeientnqdavtttnaavnaidmvaevvikpkaiaditnurrtraqvddttsqaldsialvtpdhvrvetngiatlkgvqphivikpeaqqaikasaenqvesikdtphatvdeldeanqlisd tlxqqqeientnqdavtttntaqavnativnqtikaieqilpkvrrrraaldsieennhalqainq niiskikpatvkatalqqiqniatnkinlikanneatdeeqniaiaqvekelikakqvidasinaq niiskikpatvkatalqqiqniatnkinlikanneatdeeqniaiaqvekelikakqvidasinaq niiskikpatvkatalqqiqniatnkinlikanneatdeeqniaiqdyhkkqaektinddlar vtalvqnyrkvsnrnkadalkaitalklqmdeelktartnadvdavlkrfnvalsdieavitekenslltdinkqdielakekvekqbelqpapkvctpikkeethesrkvekelpntgeegmd	
337.	lplkefalitgaallarrrtknekes msveiesieheleesiaslrqagvritpqrqailrylisshthptadeiyqalspdfpmi svatiymnlrvfkdigivkeltygdsssrfdfnthnhyhiiceqcgkivdfqypqlneie	
338.	rladmudfdvthhrmeiygvekecqdk  msekqqildyietnkysyleishriherpelgneeifasrtlidrlkehdfeieteiagh atgfiatydsgldgpaigflaeydalpglghacghniigtasvlgaiglkqvidqiggkv vvlgcpaeeggengsakasyvkagvidqidialmihpgnetyktidtlavdvldvkfygk sahasenadealnaldamisyfngvaqlrqhikkdqrvhgvildgkaaniipdytharf ytramtrkeldiltekvnqiargaaiqtgcdyefgriqngvnefiktpklddlfakyaee vgeavidddfgygstdtgnyshvyptihphikigsrnlvghthrfreaaasvhgdealik gakimalmglelitnqdvyqdiieehahlkgngk	
339.	mtttfiisyiilaliivgvinlflirsrkkgkrqqkeqqfttrqsnqskfkasdldkttd qstqrmtheelrvdnqddhsqvslngytkgsekdqeaftrnkdeeavaaknpeseeykvn ekikkehknfiigegvsrykilaallfgmfiailnqtllnvalpkintefnisastgqwl mtgfmlvngilipitaylfnkysyrklflvalvlftigslicaismmfpimmvgrvlqai gagvlmplgsiviitiyppekrgaamgtmgiamilapaigptlsgyivqnybmvmfygm fiigiiailigfvwfklyqyttnpkadlpgiifstigfgallygfseagnkgwgsveiet mfaigiifiilfvirelrmkspmlnlevlkfptftlttiinmvvmlslyggmillpjylq nlrgfsaldsqllllpgslimpllgpfagklldtigfkplaifgiavntyatweltklnm dtpymtimgiyvlrsfgmafimmpmvtaainalpgrlashgnaflntmrqlagsigtail vtvmttqttqhlsafgeeldktnpvvqdhmrelssqyggqegamkvllqfvnklatvegi ndafivatifsiiaillclflqsnkkakataqkldadnsinhe	
340.	miknkiltatlavgliaplanpfielskaenkiedigggaeiikrtqditskrlaitqni qfdfvkdkkynkdalvvkmqgfissrttysdlkkypylkrmivpfqynislktkdsnvdl inylpkhkidsadvsqklgyniggnfqsapsiggsgsfnysktisynqknyvtevesqns kgvkwgvkansfvtpngqvsaydqylfaqdptgpaardyfvpdnqlppliqsgfnpafit tlehergkgdksefeitygramdatyayvtrhrlavdrkhdafknrnvtvkyevnwkthe vklksitpk	
341.	mqstktktkfsflllitlgvmtafgpltidmyvpslpkvqgdfgsttseiqltlsftmi glalgqfifgplsdafgrkriavsiliifilvsglsmfvdqlplfllrfiqgltgggvi viakasagdkfsgmalakflaslmvvmgiitilaplagglalsvatwrsiftiltivali iligvasqlpktskdelkqvnfssvikdfgsllkkpafiipmllqgltyvmlfsyssasp fitqklynmtpqqfslmfavngvgliivsqvvallveklhrhilliitiiqvvgvalii ltlfhlplwvlliafflnvcpvtsigplgfmameertggsgnassllglfqfilggav aplvglkgefntspymiifitaillvslqiiyfkmikkqhva	
342.	mmygypekwlegmttgegiaaelrlgivnghiaegtlltenqmakqfnvsrspirdafkl lqqnqliqlermgahvlpfgeqekkemydlrlmlesfafsrvknqerlpivkemkkqlem mkvavkfedaesftkhdfefhetlikasnhqylnsfwshlkpvmmalvltsmrqrmqqnp qdferihnnhqvfidaveqydsqilkeafhlnfddvgkdiegfwln	
343.	mgsffnkiarkedpaiyqmkdghlkrtlrvrdflalgvgtivstsiftlgdivaaahagp avalsflaaivaglvaftyaemaaampfagsayswvnvlfgeffgwvagwallaeyfia vafvasgfsanlrglvkpigielpaalsmpfgtnggfidiiaaivilltalllsrgmsea armenilvilkvlaiilfvivgltainvsnyvpfipehkvtatgdfggwgilyagvsmif layigfdsiaansaealdpqktmprgilgslsvaivlfiavalvlvgmfhysqvannaep vgwalrqsghgvvaaivqaisvigmftaligmmlagsrllysfgrdgllpswlshlndkh lpnralviltiigvllgsmfpfaflaqlisagtlvafmfvslamyrlrkregkdlpipaf klplypvlpaitfvlvllvfwglgfeaklytliwfivgiilylsyglrhskkndvaeyhp pk	

\*\*\*\*.

The Server weeks

344.	mnsdnmwltvmgliiiisivglliakkinpvvgmtiipclgamilgysvtdlvgffakgl dqvinvvimfifaiiffgimndsglftplvkrlilmtrgnvvivcamtaligtiaqldga gavtfllsipallplykalnmmkyllilllalsaaimnmvpwggpmarvaavlkaksvne lwyglipiqiigfilvmlfavylgfkeqkrikkaiernelpqtqdidvhklvevyerdqd vrfpvkgrartkswikwvntaltlavilsaliniappefafmtgvslalvinfksvdeqm erlrahapnalmmaaviiaagmflgvlnetgmlkaiatnlikvipaevgpylhiivgllg vyldlltstdayyfavlpiveqtaqqfgvpsvstaysmvigniigtfvspfspalwlaig laeanmgtyikyaffwiwgfaivmlviamlmgivti
345.	mentvkyrkfilpivvglliwaltpfkpdavdptawymfaifvatiiacitqpmpigavs iigftimvlvgivdmktavagfgmnsiwliamaffisrgfvktglgrrialhfvklfgkk tlglaysivgvdlilapatpsntaraggimfpilkslsesfgskpkdgsarkmgaflvft efggmlitaamfiltamagnplagmlasstanvhltwmnwflaalvpglvslivvpfilyk iypptvketpnakswaenelatmgkialaekfmfgifvvaltlwivgsfihidatltafi alallltgvltwqdilnetgawmtlwwfsvlvlmadqlnklgfipwlsksiatslggls wpivlvlilffyfshylfasstahlsamyaallgvalaagapplfsalmlgffgmllas tthyssgpapilfssgyvtqkrwwtmmlilgfvyfiiwiglgslwmkvigif
346.	mnkvikmlvvtlafllvlagcsgnsnkqssdnkdkettsikhamgtteikgkpkrvvtly qgatdvavslgvkpvgaveswtqkpkfeyikndlkdtkivgqepapmleeisklkpdliv askvrnekvydqlskiaptvstdtvfkfkdttklmgkalgkekeaedllkkyddkvaafq kdakakykdawplkasvvnfradhtriyaggyageilndlgfkrnkdlqkqvdngkdiiq ttskesiplmmadhifvvksdpnakdaalykktesewtsskewknldavknnqvsddlde itwnlaggyksslkliddlyeklniekqsk
347.	minqsiwrsnfrilwlsqfiaiagltvlvpllplymaslqnlsvveiqlwsglaiaapav ttmiaspiwgklgdkisrkwmvlrallglavclfimalcttplqfvlvrllqglfggvvd assafaseespaedrgkvlgrlgsvsagslvgpliggytasilgfsallmslavitfiv cifgalklietthmpksqtpninkgirrsfqcllctqqtcrfiivgvlanfamygmltal splassvnhtaiddrsvigflgsafwtasilsaplwgrfndksyvksvyifatiacgcsa ilqglatnieflmaarilqgltysaligswmfvvvnachqqlkgfvyttnsmlvvgqli gslsgaaitsyttpattfivmgvvfavsslflicstitnqindhtlmklwelkqksak
348.	mkrlfdvvssiyglvvlspillitallikmespgpaifkqkrptinnelfniykfrsmki dtpnvatdlmdstsyitktgkvirktsidelpqllnvlkgemsivgprpalynqyeliek rtkanvhtirpgvtglaqvmgrdditddqkvaydhyylthqsmmldmyiiyktiknivts egvhh
349.	maqlnskiaslklfasyaiatyilviltsalnlfkgyvadtfyiaetllivltiiliili tteqtwkhhdlwrrivevllllmtltgnvftllmfvsirryqrtsqihsyngwesfirkt trhriaiigllilvymltlsivsqftfdttlatknqfnallhgpslaypfgtddfgrdlf trvvvgtkltfsisiisvviavifgvllgtiagyfnhidnlimrildvvfaipslllava iiasfgasipnliialsignipsfartmrasvleikrmeyvdaaritgentwniiwryil pnaiapmivrfslnigvvvlttsslsflglgvapdvaewgnilrtgsnylethsnlaivp qvcimfvvlafnfigdavrdaldprih
∙350.	mktihlfriyhsfllkwyliiyllfilaallitlttiqhvteddnhfnigvvdkdqsse tklilnsigkgsnlgknvsikayddkqahtllkkhklqgyfvfdkgmtkafykqgelpis vytydqqsmksvvlsqltdsvyqrlmrsmgilafqdlapkashadsinvmtdllitgln rsgafnlepihlydtgsyyaitgflttvfifalslftvlkmnqdtvlkarlkmfhfsker lliirtlltwfytmlwsivgvvwivfsipmifelynwptlaihlsyyvtflilwllliel lttgllnsiskvilaivilvlsgltiptiflqhiangvfniqpfavvtnqlleiilnnyi lelhpsfylsfialliinlavlwryrq
351.	mkkqviisglmlfslffgagnlifppmlghtagqnmwigmlgfaltgillpfitvivvaf ydegvesvgnrihpwfgfifavviymsigafygipraanvayeigtrhilpvimqwtlii faaiffalvywislnpskivdnlgklltpllllmvallsiavifnpesalsapkdkylth pfisgslegyftmdlvaalafsvvivngykfkgltdrmkilkyvcfsgliaaillgmlyf alayvgastapgnfkdgtdiltynslrlfgsfgmlvfgmtvilacittciglunacatft kkhvpkfsykifalifsiigflfttlglemilkiavplltliypvsialvlisfanmfst frfswayrlatvitliisilqilnsfnllhgvilksfmmlpladidlawlvpfmlfaiig fiidvfirrpkqatt
352.	mkhyltkfvamlitaamvcsfgllksqaaeqqsisdvysvitdaksalsnnsisndhkqk aieqvvsavkklslednsesnavksdvrkledakandngkdtleqltksliayeeklask dagskikllqqqvdakdamtkahikdnkaeleslnnslnqiwtsnetvirmydanqygq ievallqlriaihkspldtakvshawttfksnidhvdkksntsandqyhvsqlndaleka ikaiddnqlsdadaalthfietspyvegqiqtkdgalytkiedkipyyqsvldehnkahv kdglvdlnnqikevvghsysfvdmiifireglevlliwmlttutrnvkdkkgtasvig gaiaglvlsiilaitfvetlgnsgilresmeaglgivavilmfivgvwmhkrsnakrwnd miknmyanaisngnlvllatiglisvlregvevlifymgmigelatkdfiigialaivil iifallfriivklipifyifrvlsififimgfkmlgvsiqklqllgamprhviegfptin wlgfypsyepliaqgayimvvailifkfkk

THE PROPERTY OF THE

353.	atgaagaatttttotaaattogaattacaagtattgoogaataactgtgooagtoot ttagtaatacygaggttgaagotaaggataaagtatcagcaactcaaaacatogatgo aaagtaaccaagaattacaagatataaaggattacagcattgaaaagattaccaagaattgoaaaa ataaanaagcattacaaagattataaggtagcaactacagtatgaaccagaacaaaggattt acgattacacattgcaaccgaagtgggcaacacgtatgaaccagaacaaaggattt acgattacacattgcaaccgaagtgggcaacacgtatgaaccagacaaagagtaaaa gttcatcgaataaggaggtaaggta
354.	atgictaaacatagtgictagtiagtiattatgittittaataactitattgicctattitt caatatcaagctictgicacatgigactitagaaaaatcaacacacaacagcaaggggit attaaagacaaaccagaagcaatcaagttagagtitaatgaacctgigaacaccaaatac tcgagtgigaccttattigatgataaaggiaaaaagattaaagacctiaaaaccaataaca actggatggictcagacagtigtattitcatcigagcaaattgitaatggicacgaatact attgaatggiatacggiatctgiggatggacatgaagtigaagagtigaacttgaattitca gtigaagaaagtigagictaaagatg
355.	atgaaaaaaatcaaaacaatctcgacattggtagctggacttggtatagcatttctaggt cacacaacaca
356.	atgaaaaaatcgctacagctacaattgcaactgcaggaatcgctactttcgcatttgca caccatgacgcacaagcagcagcaaatgcagaatgagtggtacaatccaaacgacccttat tcatatagctacacttacacaatcgatgctgaaggtaactacactacacttggaaaggt aactggagtccagatcgtgtaaatacttcatataactataattataataattacaactacaac tactatggttacaataactatagcaactaccaataactacaattacaacaac aactatcaatca
357.	ttggaagataaaaagctccagtaaatgaagatttttaattacatcaaaaactatgcc gatgtaagaacatacctcttcaagacgtaagatggcctcgttgtttcacacttctaaa actgcaattgatgatgtctcacaagaaaaactaaatacttggttacgaaaacctgataag ttttacgtgaatattatcgagctttcgaaagacttatattacaagtctggtgaatatcgt ggctacttaattacttattgatatggctcgtttcattattacaagtctggtgaatatcgt agcttacttaattacttattgatatggctcgtttcattattgatgattgat

÷.,

stoppsglocjataccanicaciaciacystictacyangacjaccanacanacystachang grotytysanasystachangacystictacyanguscystopacanguscystagacs grotytysanasystachanguscystictacyanguscystopacan strypacacanagagatacatactacttitacttacquaettynaccangusgystyspaca grotytysacacanagagatacatactacanagagatacanacystacanacystacanagagatacanacystacanagatacanaguscystagacanacystacanagagatacanacystacanacystacanacystacanagagatacanacystac			
ctaggitttcicastgggettcaaacsgcaacctaatgaatctatgctgaatatgcaa aacgutaggaatagttaguagattgggaactgaagttagagttaaacguttaaccaa actyctgaagcagaatgttaguagattgaagtcaattgaatctaatcgtctaataca actyctgaagcagaaagttaaaccaattgaccacattgaatctaattagtctaataa actyctgaagcagaagttaaaccaattgaatctagaatctaaatagattgaagaattaa aagaagtaagtagtagtaactaaccagaattgaaagagtatattgaaagagtatta aagaagtaaatgatggaatacttagaattagtgygttagaaggagagtgaagaagagt agaataaatgatgggaatacttagaattagtgaaagaggtatttgaaaagagtagtgaagaa	358.	gctgctgaaatgacacaatcatcatcagattctaacgaacagtcacaacaaaca	
minfekfaltsiaaltvasplvntevdakdhvsatquidakvtqesqatnalkelpksen   ikhykykytdtekdhigfthytiqkvgmtyadpakevvhithkegkvvlvngddakk   vuptnkvaiskesatdkafealkidrqkaknlksdviktnkveidgeknyvynieiitt   spkishwikidaetgqvdklnnikeaattgtgkylgddkqlninsggytlqdtq   qgtlsaynydantgqsylnqdkdhnivddegragvdanyyaketydykntfgresydng   gspisialahunngagpalmasydytliddedtingedvytpyngdalrsmssperfsgpsh   midfyrtpaggalarssstyfgyfiddedtingedvytpyngdalrsmssperfsgpsh   midfyrtpaggalarsssydyfyfiddedtingedvytpyngdalrsmsperfsgpsh   midfyrtpaggalarssydhavyy   midfyrtpaggalarssperfsgpsh   midfyrtpaggalarssydhavyy   midfyrtpaggalarssydhavyy   midfyrtpaggalarssydhavyy   midfyrtpaggalarssydhavyy   midfyrtpaggalarssydhavyy   midfyrtpaggalarssydhavyy   midfyrtpaggalarssydhavyy   midfyrtpaggalarssydhavyy   midfyrtpaggalarssydhavyy   midfyrtpaggalarssydhavyy   midfyrtpaggalarssydhavyy   midfyrtpaggalarssydhavyy   midfyrtpaggalarssydhavyy   midfyrtpaggalarssydhavyyaynyngynynynynynynynynynynynynynynynyn	5.0	attaagatacaattaatagaattggaaaaattggtggaactaaagcgctcgatttagaa ctaggtttttctcaatggggcttcaaacagcaacctaatgaatcatatgctgaatatgca aaacgtatagcgaatagtaaagtttgggagactgaagatcaggctgtaaatgattaaca actgctggagcagaaaagttaaaccaaatgacgacattgaatcctaatatcgtctataca tcatatacaggtgctgcaacacatactggaccattaggcaatgaagtgccgaatattaga caattcccactattcgatttaacaagtcgtgtgataggtggagatgataataaaatgtc agagtaaatgatggcatagtacctgtgtcttctcactacaccaagtgatgaagcattt aagaaggtaggtatgatgaacctagcaactgacaagygtatctggcaagtgagaccgtt caatatgattgggatcatctagattagtcggcttagatactactgatatataagcgaact ggagaagaattaggtcaattctatatgagtagataaaaaaatattgaaagtcgaagag	· • • • • • • • • • • • • • • • • • • •
ikkhykdykvitdekdhafiflyliqhkyghtyapåkevkyhtnkejkvylnejditk vgpinkvaisjeseatdhafeaiklärqkakalnikavitkintykeidgehkhyvynieiitt spisishunvkidaetgqvdkinaikeaattgtgkyljdikqininsveggytiqditq gtlesyndantgqaylundkdnivddegragvdanyaketydykhitgresydnq gspisishunniggdanmaaayddkaniyadggrtftalsgandvvaheltbyvtqq tanlyyrseggalnesfsdyfyiddedfingedvytpyggdalrsmaperfggsh mndfvytnsdnggvdnusgjnakayntlrsigkyrseqiyyraltvyltansdfqdaka siqqafdlydgdiqqyggasdavyy  360. mshhatlvimfiltilpifqyasahatlekstpqqqyvikdlybeaiklefnepvntky ssvtifddkykikdlytitpwaqtvvfsseqivngtntieshtvsadghevydtfefs vgkvrlkm  361. mkkiktistlvagligiaflghthadaaemnqqqstynysttevsfsnsgnlytsqct vyvydktggkigstwgnanswataagaagftvmntpeegalmgasegafghvafvesvnn dgsitvsemnydgpfalstrtisaseassynyihin  362. mkkiataistaglatfafahhdagaeqmdgynpdysysytytidaegnyhytukg nepdrvntgynyminynynyynynynynynynynynynynynynynyny	350		
sevilfddkgkikidlkpittyseqtvyfsseqivngtntieshtvsadghevgdtfefs ygkvylkm  361. mkklktistlvaglijaflghthadaaemnqqqstynysttevsfansgmlytsgqct wyvydktggkigstwgnanswataaqaaftvmlpeegaimqssegafghvafvesvnn dgsitvsemnydgpfalstrtisaseassynyihln  362. mkklatatiatajatfafahhdaqaaeqndgynpndysysytytidaegnyhytwkg mspdrvntsynynnynynyynynsynnynsynnymnynmytemtqsqrttuptgglg asystsssnvhvtttsapssnyslsmaraaagnlytsgqctyyfdruggkigstwgna nnwanaaarsgytvmnyshygynysynnynsynnymnynmytemtqsqrttuptgglg asystsssnvhvtttsapssnyslsmaraaagnlytsgqctyyfdruggkigstwgna nnwanaaarsgytvmspakyalldtsgqaydhwayvegvnsngsjirvsemnyjhgagvv tsrtisaaqaasynyth  363. ledkkapwedfinylknydvrniplsrrkmaslfhtsktaiddvsqeklntwlrkpdk fyvnielskdlyyksgeyrsllnyfidmarfyyvidplfsadskmskekvkkdlskisl qlnkmlkhelakiyktcvlediffgyeledkdnyfnlkldpkycklygisdgmytyafn lsyfdgmldllktfpeefgraylersidkqadlmwfipldftksvvfkineddptlippfs tnfepldlahdyktlkagakinnymllhqkymhdnankdyadnfaisaeamdyfsel vnenlpdeigsivspmevnpikldrddktdkvleatrdvynasgvsfifnndknstggl tysvkdelfvinfyrqerelnrkirygnivaknqwrisllnvtymsedtyleqltksg tfgfevrgriaalhgldyhtlagslelannildldtnliplassbtgglntaveqtkgki edsgprytkatklafsdgqanrdssnsetkelegddtne  364. vgvvsiitgltifvsgchaqaaemtgasdanegsgqteqvelkedtthlsyelnqeet adsgktagenqdgnvykksmqiqdstytsplndkytsmegakhntymsradtyp kgqnddkkqqfkhohspdebpgntpmnhdgdsdkkdhpadtdssskytghkag qsiedrdtvkgpsskvhkimiktdktvktunkkqtsltsprvvsksqtkhingltaqa qykngyvvvfngfvgyadafsmynwggtkynvkqeltklgyrvheanvgafssny dravelyyikggrvdysgaahaakyghkrygrtyegimpdwepskthluphsmagtglir lmehflyngageidgytygedafsmynwggtkynvkqeltklgyrvheanvgafssny dravelyyikggrvdysgaahaakyghkrygrtyegimpdwepskthluphspandklyskf ikdinrigkiggtkaldlelgfsqwfkqtpnesywsyarlanskwetedqavndlt tagaaklngmtlinmivytsytgaathtyglapevpnirqfplfdlsvriggddmhv rvndgivyvssslpsdeafkvymmlatdkgldwyrpvydwhhldlydlttdykrt geelgfymsminnalkveeldglitrk  365. tcaataaggtgtttetaaagatttttetcacataaa tccgttaatttggacattttaaaaatttggtgtaattaacaatga tttagtgaatttteaaaagtttgacataacaggactaataaacagttggtaataaa tctggtcaattteaaagattttettaaaagatggacttaaaacagttggtataaaaattggtaacaagacattg tgtaagaacatttttettaa		ikkhykdykutátekánkafthytlapkyantyapåkavkvhtnikegkuvlungátdakk puptnikvaiskesatdkafeaikiárqkalmiksäviktnikveidgeknikyvynieiiitt spkishwnykldaetgquydklimikeaattatakyylgatkqininsvsagytladlta qqtlsaynydantgqaylmqdkdinfyddagragvdanyyaketydyykntigresydn aspiisiahvnniqaqdnrmnaavigdkmiyddagtrittalsgandvaaheithydra tanlvyrsagsalnesisdvigyfiddedilmgedvytpgvagdalrsmsnperiagpsh mndfyytnsdnggyhtnsgipnkaayntirsigkarseqiyyraltvyltsnsdfadaka siqaafdlyadgiaqqvagawdsvyv	
wyvydktogkigstwgnanswataaqaagftrmmtpeegaimgssegafghvafvesvun dgsitvsemydgplaistrtisaseassynihin  362. mkkiataiatagiafafahhdaqaaequndgynpndpysysytytidaegmyhytukg mwspdrvntsynymynnynynynynsynnynsynnynsyntysmtgqrttoptgig asystsssnvhvttsaspssnyslanarasagilytsgqctyyfdrygskigstwgna nnwanaaarsytvmnspakgailqtsggaydhvayvegvnsngsirvsemmydhgagvv tsrtiasagaasynyhh  363. ledkkapvnedflnyiknyadvrniplsrrkmaslfhtsktaiddvsqeklntwlrkpdk fyvniielskilyyksgeyrsllnyfidmarfyyvidplfssdskmskekykkdiskisl qlnkmnlkhelakiyktcvlediffgyeiedkdnyfmlkldpkycklygisdgmytyafn lsyfdmidliktfpeefgraylarsidkyadlmrfjdftfksvvfkinedgltilpffs tmfeplidlndykklkagakinnymllhgkpmhdnankdyqadnfaisaeandyfsel vnenlpdeigsivsmevnpikldrddktdvleatrdvynnasyvssifinndknstggl tysvrkdelfvinfyrqverwlnrkirygmivaknqvrisllnvtgmsedtyleqltksg tfgfsvorgriaalhldybtlsgalelanniidldthlplasshtgglntaveqtkgki edsggrptketkdlsdsgganrdssnsetksleggdtnne  364. vyvvsiitgltifvsgdhaqaaemtgsssdsnegsqcteqvehkedtthlsyelnqeget asgsktsgengsdgnvqkkmmiqdstsdtsplnddytsmeqagskdnhvtpnsrydtyp kggnqddkgkqffkdnchsgtehqpntcpnandqdssdkkqhpsdqtdssskgtcpkga qstedrdtvkqpsskyhkigntktktvktnqktgltsprvvkskqtkhinqltaqa qyknqypvvfvhgfvglvgedafsmypnywgtkynvkgeltklgyvrbeanvyafssny dravlyyyikgrvdygahaaksyhkrygttyglmpdeppkkhlnythamggqtir lmehflrngnqeeidyrrqygtvsdlfkgqdmwstittlgtphngtpaadklgstkf ikdinrigkiggtkaldlelfgfaqwfkqpnegsysyakrinskwetedqwndlt tagaeklngmtlnpnivytsytgaathtgplgnevpnirqfplfdltsrviggddnhv rvndglvpvssslhysdeafkwymmlatdkglwqvrypqydwdhldlwyldttbgt gelggfymsninmmlkweeldgitrk  365. tcataaggttettaaaagatttteccatcaagtattagaaccaattagaatttggtcaat ccgttaatttggcacaacacaa	300.	ssytlfddkgkkikdlkpittgwsqtvvfsseqivngtntiewhtvsadghevgdtfefs	
mwspdrvntsynymynynynynysnynnys	361.	wyvydktggkigstwgnanswataaqaagftvnntpeegaimqssegafghvafvesvnn	
fyvniielskilyyksgeyrslinyfidmarfyyvidplfssakmskekvkldiskisl qlnkmmlkhelskiyktevlediffgygeiedkdnyfmlkldpkyclvgisdgmytyafn lsyfdgmldlktfpeefgraylersidkqadlnwfipdftksvvfkineddptilppfs tmfeplidlndykklkhagakinnymllhqkvpmhdmankdyqadnfaisaeamdyfsel wnenlpdeigsivspmevnpikldrddktdvleatrdvynnagvasfifmdknattggl tysvrkdelfvinfyrqverwlnrkirygnivaknqwrisllnvtgmsedtyleqltksg tfgfsvrgriaalhpldybtlsgalelenmildldfulplasshtgglntaveqtkgki edsggrptketkdlsdsgqanrdssmsetksleggdtnne  364. vyvsitgltifvsgdhaqaaemtgsssdsnegsqteqvehkedtthlsyelnqeget asgsktsgengsdgmvqkksmitgdstgtsplndqkgtsmegagkkhhvtpnsrqdtyp kgqnqddkgkqqfkdnchsqtehpptqmndqdssdkkqhpsdqtqdsskytgpkgs qsiedrdttvkqpsskvhkigntktdktvktnqkkqtsltsprvvkkqtkhinqltaga qyknqypvfvhgfyglvgedafsmypnywggtkynvkqeltklgyrvbeanvgafssny dravelyyyikggrvdygahaakyghkrygrtyggimpdwepgkkihlvghsmggdtir lmehflrngndeeidygrqygtsdalfkggdmusvtittlgtphngtpaadklgstkf ikdtinrigkiggtkaldlelgfsqwgfkqqpnesyaeyakrianskvwetedqavndlt tagaeklnqmttlnpnivytsytgaathtgplgnepynirqfplfdltsrviggddmhv rvndgiypvsslhpsdeafkkvgmmlatdkglwqvrpvqvdwhldvgldttdykrt geelggfymsminnmlkveeldgitrk  365. tcaataagstgtttctaaagaatttttctcattcgattatgcataaaaaccagtttgtgtcaat tccqttcattttgcgaccattttattggaacttgtttgaaagcttggtataga gtttcaggatactggtcatttagacattagatttggaatctttgaaagcttggtataga gtttcaggatactttggtcatttagacataag tccgttcattttgaacgataaaatggactcacacgtctttgaagcttgtataga gtttaggatactttggtcattacacataa  366. ctgttgaccatttgatctttgacctaagtcaattgatacttgccagtattaatt gttatgtgcaatttcaattggtcgttaattcaattagatttgagacttgtattcaattgtttaa  367. gatgacactttagtctttaataacatggtgttatactttaaaaatgattcttaaaacagtgtatttca aacttggcataa  368. tacacaaccactatgtttaccattttcttaccatcaagtgttatcatatcaccagt tcgtagatattaaa  368. tacacaaccactatgtttaccatttttttaaaaaatgatttttaaaaaatgttttaagaacaatccttgaccacattc tagcagataaaaaatgttttaaaaaatgtttttaagagttatcaaaacaaatg cctgtagaaatttttttttt	362.	nwspdrvntsynynnynyygynnysnynnynnynnynntagtrttqptgglg asystsssnyhvtttsapssngvalsnarsasgnlytsgqctyyvfdrvggkigstwgna nnwanaaarsgytvnnspakgailqtsggayghvayvegvnsngsirvsemnyghgagvv tsrtisasgaasynyih	
asgsktsgengsdgnvgkksmqiqqdstqtsplndqkqtsmkqdhybgdqdssskytgpkqs kgnqddkgkqqfkdnqhsqtelqpntpgmndqdssdkkqhpsdqtdssskytgpkqs qsiedrdktvkqpsskvhkigntktdktvktnqkkqtsltsprvvkskqtkhinqltaga qyknqypvrfvhgfvglvgahaakyphrygrtysgimpdwspgkkihlvghsmgqqtir lmehflrngnqeeidyqrqygtvsdlfkggqdmwstlttlgtphngtpaadklgstkf ikdtinrigkiggtkaldlelgfsqwgfkqpnesyaeyakrianskvwetedqavndlt tagaeklnqmttlnpnivytsytgaathtpplgnevpnlrqfplfdltsrvligddnknv rvndgivpvssslhpsdeafkkvgmmlatdkgiwqvrpvqydwdhldlvgldttdykrt geelgqfymsminnmlkveeldgitrk  365. tcaataaggtgctttctaaagaatttttctccccatgtccaatctataaataa	363.	fyvniielskallyyksgeyrsllnyfidmarfyyvidplfssdskmskekvkkdlskisl qlnkmlkhelakiyktcvlediffgyeieddxdnyfmikldpkycklygisdgmytyafn lsyfdgnldllktfpeefgraylersidkqadlnwfipdftksvvfkineddptllppfs tmfeplldlndykllklagakinnymllhqkvpmhdnankdyqadnfaisaeamdyfsel vnenlpdeigsivspmevnpikldrddktdkvleatrdvynasgvssfifnndkstggl tysvrkdelfvinfyrqverwlnrkirygnivaknqwrisllnvtgmsedtyleqltksg tfgfsvrgriaalhgldyhtlsqslelennildldtnliplasshtgglntaveqtkgki edsgyrptketkdlsdsgqanrdssmsetksleggdtnne	
gttaaaaattgcgacacaacaattctcattcgattatgcataaaaccagtttgtgtcaat tccattattgctgcatcaatgattggaaatcctgtttgcccttcgcaccatgcattaaaa tccgcttcattttgcgaccatttatctgtcgatattaggtttgaaagcttggtatgag gtttcaggatactgtgtcattaacacataa  366. ctgttgcaccatttggtccttttgcacctaggtcaattgatacttgcccagttgccatat caggaattaacattggtccttttgcacctaagtcattgggcctttatccattaatt gtttatgtgcaatttcaaatgttccataccacgataccagaaccaatccatacacga ttcgatctgcagtattttcat  367. gatgcacctttaggtctaatacctggtgttacttttaaaaatgatgtacctaacttttca gtcaacatacgactttcaagaggtgaacaaacaacgccatctaaaccagctgcatttgc aacttggcataa  368. tacatcaaaccactatgttacccattttctaccatcaagtgttactatatcaccggt tgtgcaggtaaatattgtgataaaaatgttttaaaagttttttcgcataaacaaatg cctgtaqaatctttttcttagcacacagtccttgtttctcagcaatt	364.	asqsktsqenqsdgnvqkksmqiqqdstqtsplndqkqtsmeqqskdnhvtpnsrqdtyp gqnqddkgkqqfkdnqhsqtehqpntqnqnndqdssdkkqhpsdqtqdssskgtqpkqs qsiedrdktvkqpsskvhkigntktdktvktnqkkqtsltsprvvkskqtkhinqltaqa qyknqypvvfvhgfvglvgedafsmypnywggtkynvkqeltklgyrvheanvgafssny dravelyyyikggrvdygaahakyqhkrygrtyegimpdwepgkkihlvghsmgqqti lmehflrngnqeeidqyqqyggtvsdlfkggtqmwstittlgtphngtpaadklgstkf ikdtinrigkiggtkaldlelgfsqwgfkqqpnesyaeyakrianskvwetedqavndlt tagaeklnqmttlmpnivytsytgaathtgplgnevpnirqfplfdltsrviggddmhnv rvndgivpvssslhpsdeafkkvgmmlatdkgiwqvrpvqydwdhldlvgldttdykrt geelgqfymsminnmlkveeldgitrk	
caggaattaacattggtacgaaaaatggactcacacgtcttgggcctttatccattaatt gtttatgtgcaatttcaatgtttccataccaccgataccagaaccaatccatcaccga ttcgactgcagtatttcat  367. gatgcacctttaggtctaatacctggtgttacttttaaaaaatgatgtacctaacttttca gtcaacatacgactttcaagagtgaacaaacaacgccatctaaaccagctgcatttgct aacttggcataa  368. tacatcaaccactatgtttacccattttcttaaccatcaagtgttatcatacaccggt tgtgcaggtaaatattgtgataaaaatgttttaaagtttttttcgccgataaaacaatg cctgtaqaatctttttcttagcagtcaacaagtccttgttcttcagcagcact	365.	gttamaaattgcgacacaaccattctcattcgattatgcataaaaccagtttgtgtcaat tccattattgctgcatcaatgattggaaatcctgtttgcccttcgcaccatgcattaaaa tccgcttcattttgcgaccattttatctgtcgatatttaggtttgaaagcttggtatgag gtttcaggatactgtgtcattaacacataa	
367. gatgcacctttaggtctaatacctggtgttacttttaaaaatgatgtacctaacttttca gtcaacatacgactttcaagaggtgaacaacaacgccatctaaaccagctgcatttgct aacttggcataa  368. tacatcaaaccactatgtttacccattttcttaccatcaagtgttatcatatcaccggt tgtgcaggtaaatattgtgataaaaatgttttaaagtttttttcgccgataaaacaaatg cctgtaqaatcttttttcttagcagtaacaagtccttgttcttcagcaatcgacgact	366.	caggaattaacattggtacgaaaatggactcacacgtcttgggcctttatccattaatt gtttatgtgcaatttcaaatgtttccataccaccgataccagaaccaatccatacaccga ttcgatctgcagtattttcat	•
368. tacatcaasccactatgtttacccattttcttaccatcaagtgttatcatatcaccggt tgtgcaggtaaatattgtgataaaaatgttttaaagtttttttt	367.	gatgcacctttaggtctaatacctggtgttacttttaaaaaatgatgtacctaacttttca gtcaacatacgactttcaagaggtgaacaaacaacgccatctaaaccagctgcatttgct	
	368.	tacatcaaaccactatgtttacccattttcttaccatcaagtgttatcatatcacccggt tgtgcaggtaaatattgataaaaatgttttaaagtttttttcgccgataaaacaaatg cctgtaqaatctttttcttagcagtaacaagtccttgttcttcagcaatcgacgcact	

Control of the Contro

369.	cgtttcgcatcttcatcatattctaataatggccaatctgtcacccataagaagtttaat tttgtttcatcgattaaacctaattctttagctaatttgacacgtaatgcacctaaactt
•	tgtgcaacgacatttggtttgtctgcaacaaacattactaagtcaccagcttcagcacca
	gttaatgtaagtaargtttcaacattttctgtttcaaaagaaacgtccaattggacctgtc
	aaaccatcttccacaactttaacccacgctaatcctttagcacca
370.	cgtcaacgtcctgtccatgtgtttccaaaaaataataatcacatgggcaatataatcat
	caatatcaacatcactacgtaacgctagcaaatgctttt
371.	atgaatgaagcatctaatttaatcttaaccatgccaaatgaatccaaagccgcaactaaa atagcaaagattaagccgccaatcactggtgctggtatacaaatacgttttaaaaaatta
	acg
372.	attetateageegeattatecacaceggeattattaaacaacacategattettecaaac
	tgttcctttatgtcagacacaaagtctaccacttgttgttcgcttgcattatccacatta
	tacgccttcgcattgtcaccattacttttaattttatcgacagtctccgataccgcttca gctatgtctaccgccaatacatacgcaccttat
373.	ectggcgctattgtttcaggtccgtattctgttaattcattaatcggatcttttgtaatc
	tcttcttttggttcacctttactaataattactccagttaatggattttttagtgttggt
Į	gtegttattgtetteteacetttttgteettetettgttactttttetgteetggtget
1	anatocggattanatttacgttctttttttttttttttttttttt
Ì	tctgttattgtttttggcgcttctggtgtaaaagtaaactctgaacctttcaagtcagtt ctcatccagccatttgcatttatccct
374.	ttactaacatttattgctgttaaacctacgatgacaaataaaataatagctaatactttt
	anastactaaaatattttccatacgagctgcttccgacataccacgtgatagtaataat
	geagttaataaaataacgatageageaataatatcgataaaaccgccatttgtaccaaat
Į	ggatttgataatgctgcaggtaattcgatgccaattggtttcacaagtccgcgtaaattc
	gctgagaatcctgatgcaacaaaggctacggcgataaaatattcagctaatagagcccaa ccggcaacccatccaaaaaattcaccaaataatacattgacccaagaa
375.	gatgtgttgaaactgagttcaattaaattatatgtttttattatacactttttgacatat
	tttttaaatttaagaatgcgaagatttttaacatttctgatgctagctttcttt
}	ttteaaatgettaataaateaaageeaggtegeetttageeaatgetteeateate
376.	ataccaatccgaaccgacttgttgatatatttttgcaa
3/6.	tctatcattgtaaatactgtatctaagtgcataaaagttcgactagttggaatttcaatt gctactacttttttaaacgtcgcctgcggattttcaaaaatacgtcgcgctaacttttca
i	atagettgtgcagatgtacgttetgnaacgcetatagccaaagacatetttagataanaca
1	agttcategcegccttcaatattgaatgggcaatctcgatctaaccagattggaatattc
	gcatctttaaatctagga
377.	gaagtettggccattcccttgagtamacatgaagccccagccatctgctcctgttgtatt
	accitggtigttgtttgctactggaacagtaattgtaaagtctttattaaaatctatttt atcattatattctaa
378.	sircflknfsphygsinkslyknedttilirlcikpycynsiiaasmignpycpshhalk
	sasfcdhficrylglkawyevsgycvint
379.	llhhlvllhlsqlilaqlpyqeltlvrkmdshvlglyplivyvqfqmfpyhryqnqsihr   fdlqyfh
380.	daplglipgvtfkndvpnfsvnirlsrgeqttpskpaafanla
381.	yikplclpiflpssviispgcagkycdknvlkffspikqmpvésfflavtspcssairrt
	slfsmspignitfescc
382.	rfasssysmgqsvthkkfnfvssikpnslanltrnapklcattfglsatnitkspasap vnvsnvstfsvskkrpigpvkpssttlthanplap
383.	rgrpvhvfpkmnphggynhgyghhyvtlanaf
384.	mmeasnliltmpneskaatkiakikppitgagiqirfkklt .
385.	ilsaalstpallnntsilpncsfmsdtksttccslalstlyafalsplllilstvsdtas
	amstantyapy
386.	pgaivsgpysvnsligsfvissfgsplliitpvngffsvgvvivfspfcpslvtfsvpga   ksglnlrsflngisstffsnsvivfgasgvkvnsepfksvligpfafip
387.	11tfievkptmtnkiiantfkitkifsiraasdiprdsnnavnkitiaaiisikppfvpn
L 30	gfdnaagnsmpigftsprkfaenpdatkataikysanragpathpknspnntltge
388.	dvlklssiklyvfiihfltyflnlrmrrfltflmlafffifgmlnkikarspfsgcfhhi
	ipirtdlliyilq
389.	siivntvskcikvrlvgisiattflnvacgfskirranfsiacadvrsetplaktsldkt
390.	sssppsilngqsrsnqigifaslnlg
390.	evlaiplskheapaicsccitlvvvcywnsnckvfikiyfiiif cgttgcacaaagctgaatgttaaaaatgcggatccgccagcaatgactgdaatccaacaa
391.	tetgatgegacaccaccaaccaacataaatgeggaccaccatgeaatggcagetgcaacaa
L	aaattcgttaaaaaagaatattgtaatgatgcatgctgtaaa
392.	rctklnvknadppamtaiggsdatppninrkkphamaaakkfykkeycndacck

12.30 · 12.50

STATE SECTIONS OF SECTION SECT

399.	atgatgaaaatttaagttacgtaaaatgaaagtcggtttagtatctgttgcaattaca atgttatatattatgacaancggacaagcagaagcatctgaaaatcaaaacgctttaatc tctaatataaatgtagaaacatcaggaaaaacagaatatgtaaatcaagcgtttaatc tctaatataaatgtagaacatcaggaaaaacagaatttaccaagtcgttcagct caaattaatactaatgaaacatcaaaagtacggctaattttgtcaaattgaatgatat aaaccaggtgatacttctatacaaggaaacacttaccaaatcaatttatcatattaact attgataaaaagatgtgagctcagttgaagatttgcaaaattgtatatattgtctgat aaagatgggaattttaagtatgacttaaatggtcgcaaaattgtcataatcaagaaatt gaagtgtcttcatcagatccctatttaggtgacgatgaagaagatgagaagaa actcaactgaagaagttggtgctgaggaagaagtacagaagctaaagctacaatataca acacgcgatatgaaaaggttgtgtgagagaagatacagaagctaaagctacaatataca acacgcgatatgaaaaggtgatactatatctgaaggttcaggtattattaacatttgga catcaccaagttttatcgaacctattactgaaggttcaggtattattaacatttggagcatacc tctgtaaaaggtaaagttgctctatctattaataataaattattatactttgagacaaa gctaatggtggtccaaataaagaagaagaggaaactggatcagaagaatctggatcaga gctatggacgaaaatgagagatcttaatttaacatttgcacctgatgacgaagatctggattaag ttaagaaaaaaggagatcttaaacttaacatttgcacctgatgacgaagatttgaagaact aaattgaccatactaaagagaagctaaagagtattgaaaggatttaaagagaaact aaatatgaccatactaaagtaagaacataatcacgaaaaggtattaaagagaatta catgaagatgaatttacggaagcttatatcatacagaaaaggtattaaaggagattta catgaagatgactaaagtaattacaggaaaacataaaggtaatcttgaa gacctgaactaggtgaaggtcaagaattccctgattgcaagtgatgaggaacctaaacctaa tcacgtagtgagaccataaactacggattagatcacataaacctaa acactgcatatcataaatacaggaaaagaacggatttggggtttgggtttgagaacctaaaacca acacctgcataccatctctgaagaaaaagaaagaaagatttgcggaatttccctggtttaaccatggtgattaaccagaatta acactgcatatcataaattacatggtgaaaaacacaaaaaccaaaaccacaacccaaacccaacaccaaaa
400.	gaaaaa msenfklrkmkvglvsvaitmlyimtnggaeasemmalisninvdnqekqnnvnqavqp qmntnetskvpanfvklndikpgdtsiqgttlpnqfilltidkkdvssvedsdssfvmsd kdgnfkydlngrkivhnqeievsssdpylgddeedeeveetsteevgaeeesteakatyt tpryekayeipkeqlkekdghhqvfiepitegsgiikghtsvkgkvalsinnkfinfetn
	anggphkeeaksgsegiwmpiddkgyfnidfxtkriddlefkmdelsifrapideear kslifktkvtsledidkaetkydhtkvekvkykdykedlhvdeiygslyhtekgkgild kegtkvikgktkfanavvkvdselgegqefpdlqvdxkgefsfdvdhagfrlqngetlnf tvvdpitgellegnfvsknidlyespeekadrefdermentpayhklhgdkivgydtngf nitwfynlgekkverkapklek
401.	gtctatatgctatcaagtaccaggtttattgttaggtggtacaacaattgtaataagtcc actaatatcattaatgazagatcaagtggatcaattaaaagcgatgggaattcaagctgc ttttttaaa
402.	vymlsstrfivrwynncnkstniinerssgsiksdgnsscffk
403.	tttaaatataaaaaaacagaaaaatacctagtattatgatgcaacaaataaaattacct atactatattcatatttaacgataaataaatgggaataccttettaacataaca
404.	fkykknrkipsimmqqikitilysyltinkwayllnitpnktvlpatgqkelilavftmf kvsksfsliltyffgisqliigkksanhvltksiikysslyliilylgfllifsvsqsnv stsfqlyly
405.	ggaatgaaaatgatttcgatttccgatgaaatcaattgtttaatttgttgcaattgtgta gggttatgttcttttatttcttctgctaagtatattttttggatttccatttcttctaac actgtagctaagacatcaataaagcgtggtaagtttttagttacagctaggtcgatacga cga
406.	gmkmisisdeincliccncvglcsfissakyifwisissntvaktsikrgkflvtarsirr
407.	tttgaagctacaaaggtaccgcataatggcagcacattaatta
408.	featkvphngstlinnalnfnealiclslkvnialiipkiatirgivmlgycgickkapr paitphtnaiyrncfksftpklllhyyt
409.	atgettgetgetegeataetattagaatetggtgeagaaggtaegegttagaaggataec atgacaegtattgeaanaaaacttggttaeagtgaangtaacagetttgttacaaacaet geatecagtttaegttaeatteggaategtteetagaattattagaattaecteega gataeanaettaataaanatteetaageetaataaaatteegegteaaattaeaaacaat gaaatteetttagaegagaanaanaegeaaettgaanaaatatatgttgetaagegtgae ageagtetteeetttaaaggttttgetgeageatgattgeaatgatgetagegtgae caaggtggtagattgattgatgttttaactgegatattageaggtagteetaggataecta gteaetgagattttagategtaagttaeaeggatgttateeeagaatteattggtea ttagttattgggattategeegttattggacacaettateeaaacaggatgaettggea actattateattgeggeagteatgeetattgtteetggtgtataataacaaacgcaata caagatttatttggtggacacatgttgatgtteacaagaaatcattagagcattggtt actgegtttggeaacaggaacaatgttgatgtteacaagaaatcattagaagcattggtt actgegtttggeaacggteggettggtagagataatttaatt
410.	mlaarillesgaegtrvedtmtriakklyysesnsfvtntviqftlhsesfprifritsr dtnlikisqankisrqitnneislaeaktqlekiyvakrdsslpfkyfaaamiamsflyl qygrlidvltailagslgylvteildrklhaqfipefigslvigiiavightliptydla tiiiaavmpivpgylitnaiqdlfgyhmlmfttkslealvtafylgagygsvlilv

The state of the s

411.	atgacatttaataagtattattgagctggatagtcatattgattataacaactagcata tatctattttggcagttgggcgatatcaatgatgtatttaaccagtctatttaatcaat gtagattaccagaattagtagcattgttgataggatgtatttaactgttgcaggc ctatatttcaacagttttaaataatgcattggcagatagctttacaataggattggca agcggcgctacatttggttcaggattagcattatttttaggtttaacaacgttatggatt cctgtattttcaataacatttagtttgataacattaatactgtattagtcattacgtcg gtattgagccaaggctatccagttagaatcttaatattaagtggtttaacaacgttatggtgcg ttatcaattcacttctatattttttgattttattaaacactgaatagtattaaatagtgg gcaattatcagttggtggtttggtggaataccagaagtataatagac accattatctgttggtgtttggtgagaatactcaaatgtactataatagca atcacatttatcattgcattg
412.	mtfnkvllswivillittsiylfwqlgdindvfnqsflinvrlprllealltgmiltvag lifqtvlnnaladsftlglasgatfgsglaffglttwipvfsitfslitlitvlvits vlsqvypvrililsglmigalfnsllyflillkprklntianylfggfgdaeysnvsiia itfiialfgifiilnqlkllqlgelksqslglnvqlitvialciasmitainvayvgiig figmvlpqlirkwqwkqslgrqlalnivtggqimvmadfigshilspvqipasiiialig ipvlfymlisqskrlh
413.	atgaacaacagcaaaaagaatttaaatcatttattatagaaagtcatcactaggc gttgcatctgtagcaattagtacactttattattattgtcaaatggcgaagcaacaagca gcagctgaagaaacaggtggtacaaatacagaagcacaaccaaaaactgaagcagttgca agtccaacaacaacatctgaaaaagctccagaaactaaaccaaaaactgaagcagttgca agtccaacaacaacatctgaaaaagctccagaaactaaaccagtagctaatgcttcca gtatctaataaagaagttgaggccccacttctgaaaacaagagctaaaggctaaagaagttaaa gaagttaaagccactaaggaaacaaaagaagttaaaccagcagcaaaagccactaacaat acatatcctattttgaatcaggaacttagagaagttattttgaaatgaaaagaaag
414.	Agaaacglaaaac  MNKQKEFKSFYSIRKSSLGVASVAISTLLLIMSMCEAQAAAEETGGTNTEAQFKTEAVA SPTTTSEKAPETKPVANAVSVSNKEVEAPTSETKEAKEVKEVKAPKETKEVKPAAKATNN TYPILNQELREAIKNPAIKDKDHSAPNSRPIDFEMKKKDGTQQFYHYASSVKPARVIFTD SKPEIBLGLQSGGFWKKFEVYEGDKKLPIKLUSYDTVKDVAYIRSVSSATKAVKIVSST HTMNKEEKYDYTIMEFAQPIYNSADKFKTEEDYKAEKLAPYKKAKTLERQVYELNKIQD KLPEKLKABYKKLEDTKKALDEQVKSAITEFQNVQPTNEKMTULQDTXYVVYESVENNE SMODTFVKHPIKTGMLMCKKYMVMETTNDDDYKKDMVEGGRVRISKDARNYTFTIIFPY VEGKTLYDAIVKVHVKTIDYDGQYHVRIVDKEAFTKANTDKSNKKEQQDNSAKKEATPAT PSKPTPSFVEKESQKQDSQKDDNKQLFSVEKENDASSESGKUKTPATKFTKGEVESSSTT PTKVVSTTQNVARFTTASSKTYKDVVQTSAGSSEAKDSAPIQKANKKYNDGHYQSQNNK MTQENKAKSLPQTGESNKDMTLPLMALLALSSIVAFVLPRKKN
415.	atgaattatccaaatggtaaaccatatcgtaaaaatagtgctatagacggagggaaaaag accgctgcctttagtaatatggtatgg
416.	mnypngkpyrknsaidggkktaafsnieyggrgmslekdiehsntfylksdiavihkkpt pvqivnvnypkrskavineayfrtpsttdyngvyqgyyidfeaketknktsfplnnihdh qvehmknayqqkgivflmirfktldevyllpyskfevfwkrykdnikxsitvdeirkngy hipyqygprldylkavdkliildesedrv

	- Alban an abat to an battar
417.	ttgatatatctagataatggggcaacgacgaagcatttgaagaagtgttagatactat ttaanagtaaatcaatcaatgtattataatccgaatagtccgcataaagctggtttgcag gcaaatcaattactacaacangcaaaaaccaaattaatgaatgattgattactaaaaaca aatatgatgttgtattcactagtggtgcaactgaatccaattaatcttgctttaaaaggt attgcctatcgtaaatttgatacagcgaaggaaataattacatcgtgttagagcatccg tccgtattagaaggttgtaagatatttggaagcacagaaggatttaaagttaaatatgtt gatgtaaagaaaga
418.	liyldnaattkafeevldtylkvnqsmyynnsphkaglqanqllqqaktqinaminskt nydvvftsgatesnnlalkglayrkfdtakeiitsvlehpsvlevvryleahegfkvkyv dvkkdgsinlehfkelmsdkyglvtcmyvnvtgqiqpipqmakviknypkahfhvdavq afgkismdlnnidsislsghkfnglkgqgvllvnhiqnveptvhggqqeygvrsgtvnlp ndiamvkamkianenfealnafvtelnndvrqflnkyhgvylnsstsgspfvlnisfpgv kgevlvnafskydimisttsacsskrnklnevlaamglsdksiegsirlsfgatttkedi arfkeifiijeeikellk
419.	atgtcatatcattggtttaagaaaatgttactttcaacaagtattttaatttaagtagt agtagtttagggcttgcaacacgattgaagcaaggataacttaaatggagaaaaa ccaactactaatttgaatcataatataacttcacactagtaaatagtgaaatgaataat aatgagactgggacacctcacgaatcaaatca
420.	msyhwfkkmllstsililsssslglathtveakdnlngekpttnlnhnitspsvnsemm netgtphesnqtgnegtgsnsrdanpdsnnvkpdsnnunpstdskpdpmnunpspnpkpd pdnpkpkpdpkdpkpnpdpkpdpdnpkpnpdpkpdpdkpkpnpdpkpdpdkpkpnp npkpdpnkpnpnpspdpdqpgdsnhsggsknggtwnpnasdgsnqggwgngnqgnsqnp tgndfvsqrflalangaykynpyilnqinklgkdygevtdediyniirkqnfsgnaylng lqqqsnyfrfqyfnplkseryyrnldeqvlalitgeigsmpdlkbpedkpdskqrsfeph ekddftvvkkqednkksastayskswlaivcsmmyvtsimlflfvkrnkknknesqrr

٠.

CARD MELLON

w . . . . . . . .

0.77

ALTERNATION OF THE

tttaatccaaaattacaacctggtgaagagcgagtgaaacaagaggacaaccaggaagt aagacaatcacaacaccaatacacagtgaacccattaacaggtgaaaaagttggcgagggt caaccaacagaagagatcacaaaaccaccagtagataagattgtagagttgggagag aaaccaanagatccaanaggacctgaaaacccaggataagccgagcagaccaactcatcca agtggcccagtaaatcctaacaatccaggattatcgaagagcagagcaaaaccaaatggc ccagttcattcaatggataaaaatggataaaagttaaaaaatctaaaatggcaaaaccaaatgg gtagctaatcaagaggaaaaaacgagcagaattaccaaaaacaggtttagaaagcacgcaa aaaggtttgatctttagtagtataattggaattgctggattaatgttattggctcgtaga

422

aaaggtttgatctttagtagtataattggaattgctggattaatgttattggctcgtaga
aggaagaat
mrdkkgpvnkrvdfisnklnkysirkftvgtasiligslmylgtqqeaeaaennienptt
lkdnvqskevkieevtnkdtapqgveaksevtsnkdtiehepsvkaediskkedtpkeva
dvaevqpkssvthnaetpkvrkarsvdegsfditrdshuvvestpitiqskehfegygsv
digkbptdlgvsevtrfnvgnesngligalqlknkidfskdfnfkvrvannhqsnttgad
gwgflfskgnaeeyltnggligdkglvnsggfkldtgylytssmdktekqagqgyrgyga
fvkndssgnsqmvgenidksktnflnyadnstntsdgkfhgqrlndviltyvastgkmra
eyagktwetsitdlglsknqaynflitssqrwglnqginangwmrtdlkgseftftpeap
ktitelekkveeipfkkerkfnpdlapgtekvtregdkgektittptlkmpltgviiskg
epkeeitkdplnelteygpetiapphrdefdpklptgekeevpgkpgikmptegdvvrpp
vdsvtkygpvkgdsivekeeipfekerkfnpdlapgtekvtregdkgektittptlkmpl
tgviiskgepkeeitkdpinelteygpetitpghrdefdpklptgekeevpgkpgikmptegdvyrp
tgdvrtppvdsvtkygpvkgdsivekeelpfkkerkfnpdlapgtekvtregdkgektit
tptlknpltgeiiskgeskeeitkdpinelteygpetitpghrdefdpklptgekeevpg
kpgiknpetgdvvrppvdsvtkygpvkydsivekeeipfkkerkfnpdlapgtekvtregdkgektit
gekeevpgkpgimpetgdvvrppvdsvtkygpvkgdsivekeeipfekerkfnpdlapg
tekvtregdkgektittptlkmpltgeiiskgeskeeitkdpvneltefggekipqghkd
ifdpnlptdqtekvpgkpgiknpdtgkvieepvddvikhgpktgtpetktveipfetkre
fnpklqpgeervkqeqqpgsktittpitvnpltgekveegqpteeitkqpvdsivekge
kpkdpkgpenpekpsrpthpsgpvnpnnpglskdrakpngpvhsmdkndkvkkskiakes
vanqekkraelpktglestqkglifssiigiaglmlarrrkn

423.

424.

gattatttagcattttagcgttattacgcagaaataaaagaatcacaaagca
vksnlrygirkhklgaasvflgtmivvgmgqekeaaaseqnnttveesgesateskaset
qttmnvntidetgsysatsteqpsgtqvtteeapktvvqpkvatsrvdlpsekvadke
ttgtqvdlaqpenvseikprmkrstdvtavaekevveetkatgtdvtnkveveegseivg
hkqdtmvvnphnaervtlkykwkfgegikagdyfdftlsdnvethglstlrkvpeikstl
gqvmatgeiigerkvrytfkeyvqekkdltaelshlfidpttvtqkpmqnvevklgett
vskifniqylggvrdnwgvtangridtlnkvdgkfshfaymkpnnqelssvtvtgqvtkg
nkpgvnnptvkvykhigsddlaesvyaklddvskfedvtdnnsldfdtnggyslnfnnld
gsknyvikyegyydsnasnlefqthlfgynyyytsnltwhgvafysmaagdgkdklk
epiiehstpielefkseppvekheltgtieesadskpidfeyhtavegaeghaegtiete
edsihvdfeesthenskhhadvveyedtnpgggqvttesnlvefdedstkgivtgave
httiedtkeyttesnlielvdelpeehgaqgpieeitennhhishsglgtenghgnygv
ieeieenshvdikselgyegggmsgmasfeedteedkpkycggmivdidfdsvpqing
nngngsfeedtekdkpkyeggmiididfdsvphingfinkhteiieedtnkdkpwyfgg
hnsvdfeedtlpqvsghmegqtieedttppivpptpptpevpsepetppptpevpsep
etptpptpevptepgkpippakeepkkpskpveggkvvtpvleinekvkavvptkkaqsk
kselpetggeestnngmlfgglfsijglallrrnkknhka

Ź

**MEC 150 MI** 

425. ggtttaatcgcgactgtacgacgtagaaaagctagc
mkalliktswivllfsvmglwqvsnaaeqhtpmkahavttidkattdkqqvpptkeaah
hsgkeaatnvsasaqgtaddtnskvtsmapsnkpstvvstkvnetrdvdtqqastqkpth
hsgkeaatnvsasaqgtaddtnskvtsmapsnkpstvvstkvnetrdvdtqqastqkpth
hatfilsnaktaelsprmfainapqttthkilhtndihgrlaeekgrvigmaklktvkeq
ekpdlmldagdafqglplsnqskgeemakamnavydamavgnhefdfgydqlkklegml
dfpmlstnvykdykrafhpstivtkngirygiigvttpetktktrpegikgvefrdplqs
vtaemmriykdvdtfvvishlgidpstqetwrgdylvkqlsqppqlkkritvidghshtv
lqngqiynndalaqtgtalanigkltfnyrngevsnikpslinvkdvenvtpnkalaeqi
nqadqtfraqtaeviipnntidfkgerddvrtretnlgmaladameayydvnfskktdfa
vtngggirasiakgkvtrydlisvlpfgntiaqidvkgsdvwtafehslgapttqkdgkt
vltanggllhisdsirvyydinlpsgkrinaiqilnketgkfenidlkryhvtmdfta
sggdgysmfggpreegjsldqvlasylktanlakydttepqmmllgkpavseqpakgqqg
skgsksgkdtqpigddkvmdpakkpapgkvvlllahrgtvssgtegsgrtiegatvssks
gkqlarmsvpkgsahekqlpktgtnqssspeamfvllagigliatvrrkas ggtttaatcgcgactgtacgacgtagaaaagctagc 426.

お押むり 多数を放送して

-

428.	mmknskkldflpnklnkysirrftvgtasilvgatlifgvandqaeaaemmttqkqdds sdaskvkgnvqtiegsansnesdipeqvdvtkdteqasteekantteqasteekadbt eqatteeapkaegtdkveteeapkaeetdkatteeapkaeetdkatt eeapaaeetskaateeapkaeetskaateeapkaeetdkatteeapkeetdkveteeap kaeetskaateeapkaeetnkveteeapaaeetnkateetpavedtnaksnanagpset ertqvvdtvakdlykksevteaekaeiekvlpkdisnlsneeiktialsevlketanken aqpratfrsvssnarttnvnysatalraaaqdtvtkkgtgnftahgdiihktykeefpne gtltafntnfnptgtkgaleyndkidfnkdftitvpvannngmttgadgwgfmftqgn gddlnggiirdkgmanasgfkidtaynnvngkvdkldadktnnlsqigaakvgygtfv kngadgvtnqvgqmalntkdkpvnkiiyadntthldgqfhgqrlndvvlnydaatstit atyagktwkattddigidksqkynflitsshmqnrysngimrtnlegvtittpqadlidd vevtkqpiphktirefdptlepgspdvivqkgedgektttptkvdpdtgdvvergeptt evtkmpvdeivhftpeevpaghkdefdpnlpidgteevpgkpgiknpetgevvtppvddv tkhgpkagepevtkeeipfekkrefnpdlkpgeekvtqegqtgektttpttinpltgek vygegsttevtkepvdeitqfggeevpqghkdefdpnlpidgteevpgkpgiknpetgev vtppvddvtkhgpkagepevtkeeipfekkrefnpdlkpgeekvtqegqtgekttttt impltgekvygegpettevtkepvdeitqfggeevpghkdefdpnlpidgteevpgkpgi knpetgevvtppvddvtkhgpkagepevtkeeipfekkrefnpdlkpgeekvtqegqtgek tttttttinpltgekvgegepttevtkepvdeitqfggeevpqghkdefdpnlpidgte evpgkpgiknpetgevvtppvddvtkhgpkagepevtkeeipfekkrefnpdlkpgeekvtqegqtge kttttpttinpltgekvgegepttevtkepvdeitqfggeevpqghkdefdpnlpidgte evpgkpgiknpetgevvtppvddvtkhgpkagepevtkeeipfekkrefnpdlkpgeekytqegdtge kttttpttinpltgekvgegepttevtkepvdeitqfgeevpqghkdefdpnlpidgte evpgkpgiknpetgevvtppvddvtkhgpkagepevtkeeipyetkrvldptmeppspdk vaqkgengektttpttinpltgekvgegeptevtkepideivnyapaijphgtreeid pnlpegetkvipgkdglkdpetgelieepqedevilpakddsdadsdsdadsdsdadsd dsdsdadsdsdsdsdsdsd	
429.	ttgaaaagaaaaacatttattcaattcgtaaactaggtgtaggtattgcatctgtaact ttaggtacattacttattattgtggggtaaacactgctgcaaatgctggcaaacgat gaagctcaacaaaatgctttttatcaagtcttaaatatgccaaatgctggcaacacgat gaagctcaacaaatgctttttatcaagtcttaaatgtgatcaa cgcaatggttttatccaaagccttaaagtgtcaaagtgatgctaacgttttaggt gaagctcaanaacttaatgactctcaagctccaaaagtgatgctaacgttttaggt gaagctcaacaaagcgcettctatgaaatcttgaacatgccaaagcaagagcg caacgtaacggcttcattcaaagatcttaaagacgaaccaagccaaagcactaacgaagcg caacgtaacggcttcattcaaagatcttaaagacgaaccaagccaaagcactaacaacttcaacaa ggacaacaanatgctttctatgaaatcttgaatatgcctaacttaaacgaagaacaacgc aatggttcatccaaagcttaaaagatgcaagccaaagcgataacaattcaacaaa gctaaaaagttaaatgaatctcaagcaccgaaagcggataacaattcaacaagaacaa caaaatgctttctatgaaatcttacactaacttaacgaagaacaacacgcaatggt ttcatccaaagcctaaaagatgaaccaagaccaaaggctaaccttttagacagagctaaa agctaaatgatgctcaagcaccaaaagccaagagctaaccttttaagcagaagctaaa agctaatgatgctcaagcaccaaaagctgacaacgacttaacctttatcacaaagcttaacct caaagccttaaaagatgaacaccaacacacacacacacac	
430.	lkkiniysirkligvglasvtlgtllisggvtpaanaaqhdeaqqnafyqvlnmpnlnadq rngfiqslkddpsqsanvlgeaqklindsqapkadaqqnnfnkdqqsafyeilnmpnlnea qrngfiqslkddpsqstnvlgeakklnesqapkadnnfnkeqqnafyeilnmpnlneeqr ngfiqslkddpsqsanllseakklnesqapkadnkfnkeqqnafyeilhlpnlneeqrng fiqslkddpsqsanllaeakklndaqapkadnkfnkeqqnafyeilhlpnlteeqrngfi qslkddpsqsanllaeakklndaqapkednkfnkeqqnafyeilhlpnlteeqrngfi qslkddpsyskeilaeakklndaqapkeednnkpgkednnkpgkednnkpgkednnkpgke edgnkpgkednkpgkedgnkpgkedgnkpgkedgngyhvvkpg dtvndlakangttadkiaadnkladknmikpgqelvvdkkqpanhadankaqalpetgee npfigttvfgglslalgaallagrrrel	
431.	atgaagaaaacaattttactgacgatgacaactcttactttattta	
432.	mkktilltmttltlfsmspnsagaytndsktleeakkahpnagfkvnkdtgaytytydkn ntpmnhqmqsrtndnhqhanqrdlnnnqyhsslsgqythindaidshtppqtspsnplt paipnvednddelnnafskdnkglitgidldelydelqiaefndkaktadgkplalgngk iidqplitsknnlytagqctwyvfdkrakdghtistfwgdakmwagqassngfkvdrhpt rgsilqtvngpfghvayvekvnidgsilisemmwigeylvssrtisasevssynyih	

CAMPA MISSISSION CONTRACTOR

"我我要你一起我!

Consideration of the Constitution of the Const

433.	atgaatcaatatcattctaatgcacaacaacCaagtgcatgcgtttttttgtctatagt ttagtgggcatactatgtttctttattccttttacgattaatggtacaacacacttttc gtcgatcatgttcattacattgttccaatcaatggtggagtcacttatgccctatgttgca ctgatcatgttcattacattgttcacaatcagtggagacgtacttttagacttca atcacaaacttggtcattacatta
434.	mnqyhsnaqqpsawrffuyslygileffipftingmitifvdhyhlairsiigplmpyva limiligtalpivrrtfmtsitnlvitlfkvagamigimyvfkigpilfkanygpflfe klmmplsilipvgaialsllvgygllefvgvymepimrpifktpgksavdavasfvgsys lgllitnrvykqgmynkreatiiatgfstvsatfmiivaktlglmphwnlyfwitlvitf vvtaitawlppisnesteyyngegeqevaiegsrlktayaeamkamaltpslvknwwdn lkdglemtvgilpsilsigflglivanytpfidwlgyifypfiyifpiadqallakasai sivemflpsllvtkamstkfvvgvvsvsaiiffsalvpcilatsikipvwkliiiwflr valsllitjavallifg
435.	atgaaaatgagaacaattgctaaaaccagtttagcactagggcttttaacaacaggcgca attacagtaacqacgcaatcggtcaaagcagaaaaaatacaatcaactaaagttgacaaa gtaccaacgcttaaagcagagcgattagcaatgataaacataacagcaggtgcaaattca gcgacaacacaagcagctaacacaagaaagaacgcacgcctaaactcgaaaaggcacca aatactaattgagaaaaaccctagcttcaaaatagaaaaaattacacaacctaaacaa gaagagcagaaaacgcttaatatatcagcagacgcctaaacacgacacacac
436.	mkmrtiaktslaigilttgaitvttgavkaekigstkväkvptlkaerlaminitagans attgaantrqertpklekapntneektsaskiekisqpkqeeqktlnisatpapkqeeqsq tttesttpktkvttppstntpqpmgstksdtpqsptikqaqtdmtpkyedlrayytkpsf efekqfgfmlkpwttvrfmnvipnrfiykialvgkdekkykdgpydnidvfivlednkyq lkkysvggitktnskkvnhkvelsitkkdnqqmisrdvseymitkeeislkeldfklrkq liekhnlyqmmgsgtivikmknggkytfelhkklqehrmagtnidnievnik
437.	atgaasataacaacgattgctasaacaagtttagcactaggccttttaacaacaggtgta atcacaacgacaagcagcaagcagcaacacgcgacacaccatcttccactaasgtggaagca ccacaatcaacacgcctcaactasaatagaagcaccgcaatcaaaaccaasgcgaca acaccgccttcaactaasgtagaagcaccgcaacaaacagcaaatgcgacacacaccgcct tcaactaasgtgacaacacaccccacaacaaacagcaaatgcgacacacac
438.	mkittiaktslaiglittgvittttqaanattpsstkveapqstppstkieapqskpnat tppstkveapqtanattppstkvttppstntpqpmqstksdtpqspttkqvpteinpkf kdlrayyttpslefkmeigiilkkwttirfmuvpdyfijkialvgkddkkygegvhrnv dvfvvleennynlekysvggitksnskkvdhkagvritkednkgtishdvsefkitkeqi slkeldfklrkqliekmlygnvgsgkivikmknggkytfelhkklqenrmadvinseqi knievnlk

and the second of the second of

439.

gtgaattatcgtgataaaattcaaaagtttagtattcgtaaatatacagttggtacattt
tcaactgtcattgcgacattggtatttttaggattcaatacatcacaagcacatgctgct
gaaacaaatcaaccagcaagcgtggttaaaccgaaaccaaggtaataatgaacagact
gagaatcgagaatctcaagtacaaaattctcaaaattcacaaaatggtaaatcattatct
gctactcatgaaaatgagcaaccaaatattagtcaagctaatttagtagatcaaaaagta
gcgcaatcatctactaatgatgaacaaccagcatctcaaaatgtaaatacaaagaa
gattcggcaacggctggacaacaacaaccagcaataatgaacaaagtaagataaacaaaac
gaaagtcaattgctagtaaaaaaaggaaacgacaatgtaagatcaatgaa
gaagcaaatgtagtaacagattcagtacagatcaattagtagatacagacaa
aatgaattacaagcgttttttgatgcaattatacqattatccgtttattcaccatcaa aatgaattacaagcgttttttgatgcaaattatcatgattatcgctttattgaccgtgaa aatgcagattctggcacatttaactatgtaaaaggcatttttgataagattaatacgtta aatgcagattetycacattaactatytamagytattetyatamagattaatattytte ttaggcagtaatgattecaattaaacaatmagagacttgcaacttgcatacaaagaattgaa caagetgttgetttaattegtacaatgcetcaacgtemacagaetagcegacgtemaca agaattecaacgegtteggttgagtcaagagetgtgaggcectagatcagtateagattacagactat camaatgcamattcaatgattatgttgaamatgctmatgatggttegggctatcetgtt ggtacatatatcaatgcttetagtamagggggcccatataatttaccaactacaccatgg aatacattgaaggeetetgaeteaaaggaaattgetettatgaeagegaaacaaactgga qaegggtaecaatgggttattaagtttaataaaggaeatgeteeacateaaaatatgate gacgatactcaaaatattgctgaaaaaccattttcaaaacaagctgggcatccagtttc tatgtatatgcaggtaaccaagggaatgcttccgtgaatttaggtggtacgctaacatct attcaaccattacgtattaatttaacaagtaatgagaattttacagataaagattggcaa attacaggtattccgcgtacattacacattgaaaactcgacaaatagacctaataatgc aggaaacgcaatattgaacttgttggtaacttattaccaggggattactttggaacgata cgttttggacgtaagaacaattattcgaaattcgtgttaaaccacatacaccacaat acaacgacagctgagcaattaagaggtacagcattacaaaaagtgcctgttaatattt agaatacgttggatccatcggcattgtttatttagttgcaccaacaaatcaacaca aatggtggtagtgaggcagatcaaataccatctggttatacgatacttgcgactggtaca gaaccggcagctaatggtgctggcgcatttacaatgaccacgttgtaaaaggtaattct gaaccggcagctaatggtgctggcgcatttacaattgaccacgttgtaaaaggtaattct acacataatgcaagtgatgcagttataaagcacagttatacttaacgccatatggtcca aaacaatatgttgaacatttaatacaaaatacaagaaatactactgacgctattaaccat taatttgtaccaagtgacttagtgaatccaacaatttcagtaggtaattacactaatcat caagtgttctcaggtgaaacatttacaaatactattacagcgaatgataactttggtgtg tttactgaaacagtaccaaatagaagttatgcaagagcaagtgcgaatgaaatcactagt aaaacagttagtaatgtcagtcgtactggaaataatgccaatgtcacagtaactgttact gtaagtggacaagcgccaaataaagataatacacgtattggtgaagatataactgtaact gcacatatcttaattgatggcgaaacaacgccgattacgaaaacagcaacatataaagt gcacatatettäättgatggcgaaacaacgccgattacgaaacagcaacatatataaagg gtaaggaactgtaccgaaacatptetttgaaacagaggtgttttatacccaggtgtt tcagatatgtatgatgcgaaacatatgttaagccagtaaataattettggtcgacaaat gcgcaacatatgaatttccaatttgttggaacatatggtcctaacaaagatgttgtaggc atatctactcgtcttattagaggtgacatatgataatagacaacagaagattaactatt ttatctaaagttaaacctgacccacctagaattgacgaaactctgtgacatataaaagca

ř

Ġ

ggtettacaaaccaagaaattaaagttaataacgtattaaataactcgtcagtaaaatta tttaaagcagataatacaccattaaatgtcacaaatattactcatggtagcggttttagt aaattagcacaatctaaaacagatyctycaagagcaattyatycattaccacatttaat aatgcacaaaagcagatyttaaatctaaaattaatgctycatcaaatattyctygcyta aatactyttaaacaacaagytacaayatttaaatacagcyatgggtaacttycaagytyca atcaatgatyaacaaacgacycttaatagtcaaaaatttaaagatycgacacctagtaag aaaacagcatacacaaatycyytacaagctgcgaaagatatttaaataaatcaaatggt caaaataaaacgaaagatcaagttactgaagcygtgaatcaagtyaattctyctaaaata aacttagatygtacgcytttattagaacggaagcaacacagcaaaacagcagttaat aatatyacgcatttaacaactycacaaaaaacggaatttaacaaaccaaattaatagtygt actactyttcyctygtyttcaaacgyttcaatcaaatyccaatacattagatcaagccatg aatacgttaagacaaagtattyccaacaaagatygaactaaagcaaytyaagattacgta gatgctaataatgataaycaaacagcatataacaacgcagtagctyctyctyaaacgat

Landerson and the control of the con

١

2000年1日1日

i

ľ

おおお

18.

\* 74.

Albert Chile

į:

794

caattgaaacaagtattgcgaataaagcacaaattaaaggtagcgagaactatcacga gctgatactgacaagcaaacagcatatgataatgcagtaacaaaagcagaagaattgtta aaacaaacaaatcaaacaatggatccaaatacaattcaacaagcattaactaaagtg aatgacacaaatcagcacttaacggtaatcaaaaattagctgatgccaaacaagatgct aagacaacacttggtacactagatcatttaaatgatgctcaaaaacaagcgctaacaac caagttgaacaagcaccagatattgcaacagttaataatgttaagcaaaatgctcaaaaa ctgaataatgctatgcagatcaagctaagaaagatgcttaactaatgcagttcaaaa agcattaactttactgatgcagatcaagctaagaaagatgcttaactaatgcggttca gatccacaacaagtggctcaagcgttacaacaagtgaatcaagctaagggtgatttaaac ggtaaccataacttacaagttgctaaagacaatgcaaatacagccattgatcagttacca aacttaaatcaaccacaaaaaaacagcattaaaagaccaagtgtcgcatgcagaacttgtt anacaasaacaacaagcatataacaagcagctaaccaagcgcaacaaatggc caagacaaacaacaggatataacaatgcggctaaccaagcgcaacaaatggc ataccaacacctgtattgacgcctgatacagtaacacaagcagtgacaacatatgaatcaa gcgaaagatgcattaacggtgatgaaaaattagcacaagcgaaacaagaagctttagc aatcttgatacgttaacgcgattaaatcaacacacgtgatgcattacgtaaccaaaatg aatcaagcacaagcgttagctacagttgaacaaactaaacaaaatgcacaaaatgtgaat aatcaagcacaagcgttagctacagttgaacaaactaaacaaaatgcacaaaatggaaa caagcaatgagtaacttgaaacaaggtatttgcaacaaaagtactgcacaaaatggaag aactatcatgatgctgatgccgataagcaaacagcatatacaaatgcagtgtctcaagcg gaaggtattatcaatcaactgacaaatccaacgcttaacccagatgaaataacacgtgca ttaactcaagtgactgatgctaaaaatggtctaaacggtgaagctaaattgcaactgga aagcaaaatgctaaagatgccgtaagtggggtgaggcatttaaacggtgccaactgaa gcattaaaaggtcaaatcgatcaatcgctgaaattgctcaagtgaaccaagttaaacaa acagcaacgagctaagatcaagcaatggatcaattatcacaaggcattaatagcaacaagtaataaacaa caggcagtagcanaagctgaagcattattgantaaacaaagtggtactaatgaagtacaa gcacaagttgaaagcatcactaatgaagtgaacgcagcgaaacaagcattaaatggtaat gacaatttggcanatgcaaaacaacaagcanaaacaattggcgaacttaacacactta gacaattiggisaatgicaaataataagtaaataataatgiggisaattiaatatta aatgatgicacaaaaaataattattigaaagtcaaattacacaagggicactigttacagat gtcactacgattaatcaaaaggacaataggitagatcatgcgatggaattattaagaaat agtgttgcggataatcaaacgacattagcgtctgaagattatcatgagcaactgcgaa agacaaaaatgactataaccaagctgtaacagctgctaataatatcattatatcaaactaca tcgcctacgatgaatccagatgatgttaatggtgcaacgacacaagtgaataatatagaaa atgattaacaacaactggtcaaaatgcgaaccaaacagaagtagaacaagctattact aaagttcaaacaacacttcaagcgttaaatggagaccataatttacaagttgctaaaaca aatgcgacgcaagcaattgatgctttaacaagcttaaatgatcctcaaaaaacagcatta aatgcgacgcaagcaattgatgctttaacaagcttaatgatcctcaaaaacagcatta aaagaccaagttacagctgcaactttagtaactgcagttcatcaaattgacaaaatgcg aatacgcttaaccaagcaatgcatggtttaagacagagcattcaagataacgcagcaact aaagcaaatagcaaatatatcaacgaagatcaaccagagcaacaaaactatgatcaagc tttcaagcagcgacaatgttatcaatgaacaactgtcaacattagataatatgcgatt aatcaagcagcgacaactgtgaatacaacgaaagcagcattacatggtgatgtgaagtta caaaaacgataaagatcatgctaagcaacagttagtcaattagcaacatgtagaagatgagttaagcaa gatttgactgaagcacaagcattagaacatatggaagacagcagttaagcaa gatttgactgaagcacaagcattagaacatatggatgcaattacaacaagtattgct gactangatgcaaqqcattagattaqttatggatgcattataangatgtatgatgaa gacnangatgcaacacgtgcgagcagtgcatatgtcaatgcagaaccgaatnananaccaa tcctatgatgaagcagttcanantgctgagtctatcattgcaggattnanataccaact atcaatnanggtatgtatcangtgcgactcangcagtaatatcatctananatgcatta gatggtgttgaacgaatagctcangatnangcanactgctganaattctctananatgattta gatcaattancaccagctcancancangcgctaganaatcanattantaatgcancaact caaactaacaatccaacgcttgataaagcacaagttgaacaattgacacaagctgttaac caagctaaagataacctacacggtgatcaaaaacttgcagacgataaacaacatgcggtt gattaatgaatgaagtattaagtattagtattaagattaagaattagaattagaattagaattagaattagaattagaattagaattagaattagaattagaattagaatagaattagaatagaattagaatagaattagaatagaattagaatagaattagaatagaatgaatagaatgaatagaatagaatagaattagaatagaattagaatagaattagaatagaattagaatagaattagaatagaattagatagaatagaatagaatagaatagaatagaatagaatgaatagaatgaatagaatgaatagaatgaatagaatgaatagaatgaatagaatgaatagaatgaatagaatgaataaatgaatgaatgaatgaatgaatgaatgaatgaatgaatgaatgaatgaatgaatgaatgaatgaatgaatgaatagaat ttaaatcaaatccaacaaattgtagatgaggctaaggcacttaatcgtgcaatggatcaa ttgtcacaagaaatcactgacaatgaaggaaggcacgaaaggtagcacgaactatgtcaat gcagatacacaagtcaaacaagtatatgatgaaacggttgataaagcgaaacaagcactt

The transfer of the second section is the second

SERVE ELECTRON

::

ALC: CALC.

Ş

gataaatcgactggtcaaaacttaactgcaaaacaagttatcaaattaaatgatgcagtc gaaattaccaaaagcaaaaattgatgccaataaagacgttgataagcaagttcaagcattaataagaa attgacgaaattgatcgaaattccaaatctaacgataaggaaaacaagcattaaagaa gaaattgacaagccaaagcacaacttgcgcaagcattaacaagacatcaaagatttaaga gaaagctaaagagagagaacaagatgttgataacaagttcaagttcaagattgacgaa atcgatcaaaatccaaaatctaacagatgtgataacaagtcaagtcaagatcgataa caagcaaaagaacgtttaagcgcaacattaacaaggcatgacaaagaagcaattgaa gaagatgggaaaaatgatattgataaacgttgaagacattaattgacgaaagaagcaattgaa gaagatgggaaaaatgatattgataaacgttgaaagacttaattgacgaaaccgatcaa aaaaaganaaatcaaaaagataaccaatccaaagacaaaaagtcagcatcaaaaaatact tctaaaaaggtagcagctaaaaaagaagaaaaagctaagaaaaataaaaaaataa

and the second second second

440.

vnyrdkiqkfsirkytvgtfstviatlvflgfntsqahaaetnqpasvvkqkqqsnneqt enresqvqnsqnsqngqslsatheneqpnisqanlvdqkvaqssttndeqpasqnvntkk dsataattqpdkeqskhkqnesqsankngndnrahvenheanvvtasdssdngnvqhdr nelqaffdanyhdyrfidrenadsgtfnyvkgifdkintllgsndpinnkdlqlaykele dataattopokegakungnesgaankundnat aanvenneanvitassasinjuhgnelafifdanyhdyriidrenadsytinyvkgifdkintligandpinnkalqlaykale
qavalirtmpunqtarranriqtravearaaepravadyunanasyyvenandgagypy
gtyinasskyapynlpttpwntlkasdakeialmtakqtgdgyqwikinkyhaphunmi
fwfalpadqypygrtdfvtvnsdgtnydwabyagagankpluqmweygundphrahdfki
rnragqyiydwptvhiyaledlaraadyfaeagatpatkafgrunfeyingdpaeagay
pkvytfigqgdasytisfktqgptvnklyyaaggraleynqlfmyaqlyvestqdhqqrl
nglrqvunrtyrigttkrvevsqgnvqtkvleatnlniddfvddplsyvktpsnkvlgf
yannantnafrpggaqqlneyqlsqlftdqklqeaartrmpirlmigfdypdaygnaeti
vpwnltvlpeiqhnikffunddtqniaekfskagahpwfyvyagnqanasvnlggavts
iqplrinltsmenftdkdwqitgiprtlhlenstnrpnnarernielvgnllpgdyfgti
rfgrkeqlfeirvkphtptitttaeqlrqtalqkvpvnisgiplopsalvylvaptnqtt
nggseadqipsgytllatgtpdgyhmtitirpqdyvvfippykqiravyynkvasnm
snavtilpddiptimpvginakyyrgdevnftmgvsdrhsgiknttittlpmgwtsnl
pivlgntekvvvnptavsndekgsitafmnknqnirgylastdpvtvdnngmvtlhyr
dgssttldatnwtyepvvkpeyqtvnaaktatvtiakgasfsigdikqyftlsngqplg
rvyrtstydlttdelskvkqafinanrdvitlaegdisvtntpnganvstitvninkgrl
tksfasnlammflrwvnfpqdytvtwtnakianrptdgglswsddhksljyrydatgq
tqttnittdltmlkattvpglrmnitgneksqaeaggrpfrttgysganattdgqrqfti
ngqviqyldiinpsngygqpvtnsntranhsnstvvnvnepaangagafcidhvvksn sgit finitsedrijstagevsgmastqlyhi tatnayhkdsedyisiki dikopegdg
ryytstydltdeiskvagafinanrivit il aegdi vututpuganvsit tvinikgri
tksfasnlammfirwnfpqdytvtwtnaki anrytdgglswaddhksliyrydaligt
qittedil tunikattryglrmitgysekagaaggrpnfirttgysganattdggrgfti
ngqviqvldi inpsagyggpytnantranhanstvvnvepaangagaftidhvvknns
thnasdavykaglyl typykgyvehlindptgmtdatiniyfopsdlwytsiavymytni
qyfsgetfinitandnfgvgsvtypntsqitgtvdnnhqhvsatapnvtsatnktinli
atdtsgmtattsfnvtvhglrdkyrvytsetaanpvrianismatvsqadqttiinslt
fietvpnrsyarasansitsktvsavsrtgmanvtvtvtydgttstvtypvkhvipei
tehspagydgdfpangssaadyfklamgdiadatitvvsgqankdatrigeditvt
ahilidgettpitktatykvvrtykhvfetargvlypgvsdmydakqyvknnsvstn
admmfqfydtypynkdvystrlirvydmrteditilskvhqdprppridansvvyka
gltngeikvnnvlnnssvklfkadntplnvtnithgsffssvvtvsdalpnggikakssi
smmvtyttydehgqvvtvtrnesvdsndsvtvtvtplqattegavflkgdgfdfghv
erfiqnpphgatvawhdspdtvkntvqnthktavvtlpnggtrnverpvkvypymaka
gltngeikvnnvlnnssvklfkadntplnvtnithgsffssvvtvsdalpnggikakssi
smmvtyttydehgqvvtvtrnesvdsndsvtvtvtplqattegavflkgdgfdfghv
erfiqnpphgatvawhdspdtvkntvqnthktavvtlpnggtrnverpvkvypymaka
gltngengrunthsgmttyaddivlkrympvtsfftvtspwvksabstyvyst
ttgndanssamhpnvakvvnakydvlynghlfatelpakvvknapydvlynlvdtypgi
saatrypvtvnvyqfefpqttytttvggllasgtagsyahmantglptdgftykmrd
ttgndanssamhpnvakvvnakydvlynghlfatelpakvvknapydvlynlvdtypgi
saatrypvtvnvyqfefpqtsytttvgglaggstynvystyperfinithyppydaggstytvetaag
sitiapgangrunthsgmtynakydvystypsystypetaggstylnvdtypgi
sitiapgangrunthsgmtynakydvystypsystypetaggstylnvdtypgi
sitiapgangrunthsgmtynayhdystypsyst tigatnyegyntykakaqqldgamgqletsirdkdttlqsqnyqdaddakrtaysqavna aatilnktaggmtpkadveramqavtqantalngiqmldrakqaantaitnasdlntkqk ealkaqvtsagrvsaangvehtatelntamtalkraiadkaetkasgnyvnadankrqay

; ;;

-

ある世界では

dekytaaenivsgtptptltpadytnaatqytnaktqlngnhnlevakqnantaidglts dekvtaaenivsgtptptltpadvtnaatqvtnaktqlngnhnlevakqnantaidglts
lngpqkaklkeqvgqattlpnvqtvrdnaqtlntamkglrdsianeatikagqnytdasq
nkqtdynsavtaakaiigqttspsmnaqeinqakdqvtakqqalngqenlrtaqtnakqh
lnglsdltdaqkdavkrqiegathvnevtqaqnnadalntamtnlkngiqdqntikqgvu
ftdadeakrnaytnavtqaeqilnkaqgpntskdgvetalenvqraknelngnqnvanak
ttaknalnnltsinnaqkealksqiegattvagvnqvsttaselntamsnlqngindeaa
tkaaqkytdadrekqtayndavtaaktlldktagsndnkaaveqalqrvntaktalngde
rlneakntakqqvatmshltdaqkanltaqiesgttvagvqqiqanagtldqamqdlrqs
iaskdatkssedyqdanadlqnayndavtnaegiisatnnpemmpdtingkasqvnsaks
alngdeklaaakqtaksdigrltdlnnaqrtaanaevdqapnlaavtaaknkatslntas
mlkhalaekdntkrsvnytdaddgokqasqdtavtgaeaitnangsnanetovalalm tgynalkqnadalnnamgtlkqqiqansqvpqsvdftqadqdkqqaynnaanqaqqiang
iptpvltpdtvtqavttmqakdalngdeklaqakqealanldtlrdluqpqrdalrnqi
nqaqalatveqtkqnaqnvntamshlkqqiankdtvkasenyhdadakqtaytravsqa
eqiinqttnptlnpdeitraltqvtdaknglngeaklatekqnakdavsgmthlndaqkq
alkqqidqspeiatvnqvkqtatsldqanqdlsqaindkaqtladgnylnadpdkqnayk
qavakaeallnkqstnevqaqvesitnevnaakqalngndhlanakqaakqqlanlthl
ndaqkqsfesqitqaplvtdvttlnqkaqtldhamellrnsvadnqttlasedyhdataq
rqndynqavtaanniinqttsptmpddvngattqunntkvaldqdenlaakqqannrl
dqidhlnmaqkqqlqsqitqsadiavnqhkqtaeslntamgnlinaiadhqaveqrynf
inadtdkqtayntavneaaminkqtgqnanqteveqaitkvqttlqalngdhnqvakt
natqaidaltslndpqktalkdqvtaatlvtavhqieqnantlnqamhglrqsiqdnaat
kanskyinedqpeqmydqavqaamilneqtatldmalnqattvnttkaalhgdvkl
ndkdhakqtvsqlahlnnaqkhmedtlidsettrtavkqdlteaqaldqlmdalqqsia
ddvarlaqdkqtapqsinhldqltpaqqqalenqinnattrgevaqklteaqalnqamea
lrnsiqdqqteagskfinedkpqkdayqaavqnakdlinqtnptldkaqveqltqavn
qakknlhgdqkladdkqhavtdlnqlnglmnpqralesqinnastrgevaqklaeakal
damqalrnsiqdqqtesgskfinedkpqkdayqaavqnakdlinqtnptldkaqveqltqavn
qakdnlhgdqkladdkqhavtdlnqlnglmnpqralesqinnastrgevaqklaeakal
damqalrnsiqdqqtesgskfinedkpqkdayqaavqnakdlinqtnptldksqveq
ltqavttakdnlhgdqklardqqqavtenthakqnpyteastdkkeavdqalqaaesitdptngsnan
kdavdqvltklqekenelngnervaeaktqakqtidqlthlnadqiatakqmidqatklq
piaelvdqatqlnqsmdqlqqavnehanveqtvdytqadsdkqnaykqaladaenvlkq
piaelvdqatqlnqsmdqlqqavnehanveqtvdytqadsdkqnaykqaladaenvlkq
nakqqvdqalqninnakqdqqtesgskfinedkperlystastnyinaddnlkanydai
anaaheldkvqqnaiakaeaeqlkqniidagnalngdqrlqakdknapkqaldqathlq
qdlahkainnadtvsdvtdivnnqidlndametlkhlvdneipnaeqtvnyqnaddnak
tnfddakrlantllnsdntnvndingaiqavndaihnlngdqrlqdakdkniqsinqali
qqdlahkainnadtvsdvtdivnnqidlndametlkhlvdneipnaeqtvnyqnaddnak
tnfddakrlantllnsdntnvndingaiqavndaihnlngdqrlqdakdkniqsinnamtke
eieqakaqlaqalqdikdlvkakedakqdvdqyqalideidqnpnltdkekqalkdrinqilqqphdinnaltkeqilahinlidqlsa
evidtpstatisdsltakvevtlldgskvivnvpvkvvekelsvvkqaiesienaeqqhen
eipkakidankdvdqqqalideilartqllqdedikhlykakedakdinpnltdkeqaiqalqqqtesiennsyllaqdesiennspdlteqakaqlaqalqdikdlvkakedakdiqhlnnspdynsvelaqqqqe

aag

mffddakeasrvleitltrdakkenpipmcgvpyhsadnyietlinkgykvaiceqmed
pkqtkgmvrrevvriitpgtvmdqngmdekknnyilsfieneefglcycdvstgelkvth
fkdtatllneittinpnelvikqalseelkrqinmitetitvredisdedydmnqlthql
mhdttqllldyihhtqkrdlshieevieyaavdymkmdyyakrnleltesirlkskkgtl
lwlmdetktpmgarrlkqwidrplinkqqindrlniveefmdrfierdtlrnhlnqydi
erlvgrvsygnvnardliqlkhsiseiphikallnelgaqtttqfkeleplddllqilee
slveeppisikdgglfkmgfnaqldeyleaskngktwlaelqakerertgikslkisfnk
vfgyfieitranlnnfqpeafgynrkqtlsmaerfitdelkekedilgaekaveleye
lfvklrehiktyterlqkqakiiseldclqsfaeiaqkynyvkptfsddkvlhlensrhp
vvervmdyndyvpndchlddetfiylitgpnmsgkstymrqvaiisimaqmgayvpcdsa
tlpiffqiftrigaaddlvsgkstfmvenleaqkaltyatensliifdeigrgtstydgl
alaqamieyvaqtshaktlfsthyheltsldmlkclknvhvaaneyqgeliflhkvkdg
avddsyqiqvakladlpnevidraqvilnafeqkpsyqlshentdnqqtvpsyndfgrte
eeqsviethtsnhnyeqatfdlfdgynqqsevecqirelnlsmmtplealiklnelgsqlk

442.

· .

443.	atgattccaactaaacctcatgatgtgatttggacagatgcacaatggcaaagtatttat gcgaaaggacaggac
	gttgagcgtattatacaacgtatactaagagatgatgtagatgtagatcggttactagtt gtaacatttacgaatttaagcgcacgtgagatgaagcatcgagttgataaacgtatacaa
	gaagcatctttaaggatcctaacaatgaacatttaaagaatcagcgaatcaaaattcat
•	Caageacagatttetactttacacagtttetgtttgaaattgattcagcagcattatgat
	gtattagatatcgatcctcattttagaaccagtagtgaagcggaaaatattattatta
	gaacaaactattgatgatgttttagaacaacactatgataaattagatcctcactttata gaattaaccgaacaactatcatcagataggaatgatgatcaatttagaagtattattaag
	cagttatatttttcagtattgctaatcctcaaccatttgaatggctcaatcaa
	caaccatacaaagaagaaaataaacagcaacaattaatgcagcttatcaatgatttagca
	atgatititatgaaagcaggatatgaggaattacaaaaaagttatgacttattctcaatg atggaaagtgttgataagcagcttgaagttattgaaaccgaacgcatgttattactaaa
	gctattgaaggtaaagtattaaatacagatgttatcacgcaacatgaatttatgagtcgt
	tttccggcaataaatagcaagataaaagaagcaaatgaaggcatggaagatgctttaaat
	gaagcaaaacaacattatgataaatataaatctttagttatgaaagtaaagaatgattat
	ttttctaganatgcagaagatttgcaaagagatatgcaacactcgcactcgagtggct tatttagctcaaatagttcaagatgtgattcaatcatttggtgttcaaaaacgaagtcgt
	aatattttggatttttcagattatgaacattttgcattacgcattcttactaacgaagat
	ggctcaccttcgcgtatcgctgaaacgtatcgtgaacattttaaagaaatcctagttgat
	gagtatcaagatactaatagagtgcaagaaaaatattatcttgtattaaaactggtgaa
	gaacacgatggtaacttgttcatggttggggatgtgaagcagtctatttataaatttaga caagctgatcctagtttatttattgaaaaatataatcgcttttctagtagtggaaatgaa
	agtggcttgcgcattgacttatcgcaaaactttcgttcgagacaggaagtgttatctaca
	accaattacttgttcaaacatatgatggatgaacaagtaggagaaatttcatatgatgat
	gcagegcaattgtattttggtgeaccatatgaegaagttteacateetgtteaattaega gcaettgttgaggeaagtteagaaaàtagtgaettaaetggaagtgaacaagaagegaat
	tacattgttgaacaagttaaagatattattaatcatcaaaacgtatacgatatgaaaaca
	ggtcaatacagaaaagcaacatataaagatatcgtaattttagagcgaagttttggtcaa
	gcgcgtaatcttcaacaagcttttaaaaataatgatatccctttcacgtaaatagtaag
	gaagggtattttgagcaaactgaagtacgtcttgtgctttcatttttaagaacaatagat aatccacttcaagacatttatttagtgggattgatgcgttctgtaatatatcaatttact
	gaagaagaattagctgaaataagagttgtaagccctcatgatgattacttttatcaatct
	ataaaaattatatgattgatgaaaaagctgattctagattggttgacaagttaaatcgt
	tttattcaggatatacaaaaatatcaaaattatagtcaaagtcaaccggtttaccaatta attgataaattttataatgatcattttgtaattcagtactttagcggtcttattggaggt
	anaggtagaagagcaaatctgtattggyctatttaataaagctgttgaatttaaaagtca
	agtttcagaggtttattccaatttattcgttttattgatgagcttattgatcgtaaaaaa
	gattttggtgaagaaaatgtcgtaggtcctaacgataatgtggttagaatgatgacgatt
	cacagtagtaaaggattageatttccatttgtaatttactcaggattatctaaaaaattc aacaaaggtgacctgaatgcaccagttattctaaatcaacaatatggtttaggtatggat
	tattttgatgtmaataaagatatggetttteetteaettgeetetgtggeatatagagea
	atamatgammagamettatatcagamgagatgcgtttaatctatgttgcgttgacacga
	gcaaaagagcaacttattttagttggaagagtcaaagatgaaaagtcgttaattaa
	ccatttgttctaatttatggtgttttggctaagcatcaatcgccttcattgccaaatgat
	canagatttgaaagagatattgatcaattaaattctgaagtgaagccacgtgtatcaata
	gtgattgatcattatgaggatgtttcaactgaagaagtagtcaatgataatgaaataaga acaatcgaagaattaaaggccataaatactggtaatgaagatgtgaaaattaaaattcat
	caacagctttcttatgactatccttttaaagttaacacgatgaaaccatctaaacagtcg
	gtatcagagttaaacgtcaattagaaactgaagaaagtaatacaaattatgatagagta
	egtcaatalegtattggtgttgcateatatgaaagaeceaagtttettaeeeaaacaaaa aaaagaaaageaaatgaaatagggaetttaatgeataeagteatgeaacaettaeetttt
	agagaacaacgtttaacaaaagacgaattatttcaatatatcgatcg
	caacttattgatgaagatgcaaaagaggatattagaatagatgagattatgcatttcatt
	gatggccctctctatatggaaatagctcaagctgacaatgtttatactgaattacctttt gtggtaaatcaaattaaagttgatggacttacaagtgaagatgaagatgtatccattatt
	caaggtatgattgattaatatatgaaagtgacggacaattttactttgttgattacaaa
	acagatgcttttaatagaagaaaaggtatgaggaggaatgagggaatcagctcaaa
	gaaaaatatcagatacaaatgacgtattatcgaaatactttagaaaccatacttaaacga cccgtaaagggttacttatattttttcaaatttggtacattagaaatagatgat
444.	miptkphdviwtdaqwqsiyakqqdilvaaaagsgktavlveriiqrilrddvdvdrllv
271.	vtftmlsaremkhrvdkriqeasfkdpanehlknqrikihqaqistlhsfclkliqqhyd
	vldidphfrtsseaenillleqtiddvleqhydkldphfielteqlssdrnddqfrsik
	qlyffsianpqpfewlnqlaqpykeenkqqqlmqlindlamifmkagyeelqksydlfsm mesvdkqlevietermfitkaiegkvlntdvitqhefmsrfpainskikeanegmedaln
	eakqhydkykslvmkvkndyfsrnaedlqrdmqqlaprvaylaqivqdviqsfgvqkrsr
	nildfsdychfalriltnedgspsriaetyrchfkeilvdeygdtnrvqckilsciktge
	ehdgnlfmvgdvkqsiykfrqadpslfiekynrfsssgnesglridlsgnfrsrqevlst
	tnyltkhmmdeqvgelsyddaaqlyigapydevsmpvqlralveassensdltgseqean viveqvkdiinhqnvydmktgqyrkatykdivilersfgqarnlqqafkmndipfhvnsk
	egyfegtevrlylsflrtidnplgdiylvglmrsviygfteeelaeirvvsphddyfygs
	iknymidekadsrlvdklnrflqdiqkymysqsqpvyqlidkfyndhfviqyfsgligg kgrranlyglfnkavefenssfrglfqfirfidelidrkkdfgeenvvgpndnvvrmmti
	heskqlefpfviysglekkfnkgdlnapvilnqqyglgmdyfdvnkdnafpslasvayra
	inekeliseemrliyvaltrakeqlilvgrvkdekslikyeqlavsdthiavnerltatn
	pfvliygvlakhqspslpndqrferdidqlnsevkprvsividhyedvsteevvndneir
	tieelkaintgnedvkikihogdlsydypfkvntmboskqsvselkrqleteesntmydrv rqyrigvasyerpkfltqtkkrkaneigtlmhtvmqhlpfreqrltkdelfqyldrlidk
	qlidedakedirideimhfidgplymeiagadnvytelpfvvnqikvdgltsededvsii
	qgmidliyesdgqfyfvdyktdafnrrkgmsdeelgnqlkekyqiqmtyyrntletilkr
445	pvkgylyffxfgtleidd
445.	ctgtaccatcaaatggtgctacaatttctcctgaatctggtacaaatccgataccatcac . ccatcatcttttcagagaaaactttatcaggtacttcagataacggtattatctcaccat
	gtccaggtgcgtaaatttctgtttctacaatatcttccacatgtacaggatcatctgaca
	cttcttcatcaattgttgtttcacttggttttg
446.	lyhqmvlqfilnlvqiryhhpssfqrklyqvlqitvlshhvqvrkflflqylphvqdhlt llhqllfhlvl
	LAMPAGNITYA

447.	cgcatactttggtcatcactatgcgtaatccacaaaatggcaatccctttatctgctagt ttaaatataatttcttcaattttcttttattatgtgtatctaaagcgctagtagcttcg tccaataataaaacttcaggttcatacatgagttgtctagcgatggtaatacgttgttgc tccccccagacatgtgctcaatt
448.	rilwsslcvihkmaiplsaslniissiffllcvskalvassnnktsgsymsclamvircc sppdmcsi
449.	tcacgtactttacgcgctctactcttaatactccaaacaggcatgatgtgtggtttgtta tggtcatcatctgaaatcataataaaattcttttcacctttgtttg
450.	srtlralllilqtgmmcgllwssseiiikffsplfvnpytssyfatslinslilissnsd inssviltistmfpssplftltktlspgskissisyvtkrsisalmils
451.	gcaggatttttgactaaagcagtacttaaatcaacttcatctctgtcatcaaacacttct tctacgacttctttacgtgcaatcactctaaatgaaccttcgtccatatttaattctact cttacatttctggcactatca
452.	agfltkavlkstsslssntssttslraitlnepssifnstltflals
453.	tatttettataagettttaattagaetaatateatgeteattgattaeegaaaaatt tegatttgteeatttttagatataattgageeattaeeaeeaateaaggtateateegea aatteaggaatgaetggaageaagtetetaatgggaegtgetgatgeaaeeattaeattg
454.	yffisflirliscslitetisicpfldiieplppikvssansgmtgskslmgradanitl
455.	ttatettettetaaagetttacetteaaegteaaegtttggeaataetgeaeetaaeeat ttaggaaggtaeeatgaagetttaeeaaagagtttegteaatgetggaattaatgteata egtaegaegaatgegtegaataaeaeaeegaaaeetaatgegataeeeattgaettaatt geaetgteatettggaagaegaatgegatgaataeaetgaaeataataagtgeageaget aegataaeaggteeaetttettgataeetaeaeggattgaa
456.	lssskalpststfgntapnhlgryhealpksfvnaginvirttnasnntpkpnaipidli alsswktnammtlniisaaatitgplsliptrie
457.	tcatcaactgcttgcattaagtctaagattttttgttcgtattcagcatcgccttctaat gcttttaatgcagaaccagcgattacaggtacatcgtcacctgggaagtcatattcgctt aataagtcacgaacttccatttcactaattctaataattcttagtcgtctaccatgtca actttgtttaagaatacaactaatgctggtacaccaacgttacgtgataataagatgtgt tcacgagtttgtggcattggaccgtcagcagcagatacaactaagataccgccgtccatt tga
458.	sstacikskifcsysaspsnafnaepaitgtsspgksyslnksrtsistnsnnsssstms tifknttnagtptlrdnkmcsrvcgigpsaadttkippsi
459.	ttagaaccacctacscgacgagetttaacttetaatactggcatgatattattaattget tettegaacacttetaatgcatcacgaccactacgttgtteaacaagatcaaatgcagaa
460.	lepptrraltsntgmilliassntsnasrplrcstrsnae
.461.	aggaggcgaccgcccagtcaaactgcccgcctgacactgtctcccaccacgataagtgg tgcgggttagaaagccaacacagc
462.	rrrppgsncppdtvshhdkwcglesqhs
463.	tgtgctattatteccectattgaaggacetaaeeetteaeetaaagetaeaattgateet ataaaaceaaaggetttgeettgtttttttettgtaattatttetagetaeaeeaeata ateagtgaagggaatgeageagateetaeteettgtaetaaeetaeeaaaateaaaata aaaaag
464.	gccagtcacttctcgttccatttgattcaatacaaacaaa
465.	tgtcgtattaatactgccttcaccagtattgctagcatttggatcttgagtttgtgcgtt tgctgctaccaggtgctggttgctgctgctggagcatttcggatcgttgtgtgttt tgccggtgttgcctgtttggttgcttggttgg
466.	atccaacgtttcaggaataaatgttttcaaaccactttgaaatggatcgcggtgttgtgc ttgatatactttgtagcgataacgtttacctaccaatcataacgacaatgaaaatcgtc atcgactgtaactacattgttgacataaatatcatcagg
467.	cggtataaaggtaaagcaaaatgcatcagcttgcttagaatgattgtcctttttttgata atagcgttccattgcaatgacggcagaaggatggtttgcaaacaaa
468.	atgcaagagtaccaaaaatcgttaaatacgcttaaaaagcctataaatgttccytatgag caagaaactgaaaaagtaggtggtttatttagcaaagaaatcaagaaactggaaatgtt gtaataagccaaaaagatttcaatgaatttcagaaaacagataactggaaatgtt tcggaagattacgagtatataaagtctggtagagccttagatgataaaagctgagaaata cgagagaaagatgatttattaaagtctggtagagccttagatgataaaggaaata tttaaccaactttacgaaaatgcaattaaagagttgagcaatatagagataaag cttttaaaaatcttactaaaagagttagaacgagtttaggaaatatagagttaaag cttttaaaaatcttactaaaagagttagaacgagtttaggaaatatactttgcggaa agagttaataagttaacagaagatgaaccaaaactaaatggtttagcaggaaacttagat aaaaaatgaatccagaattatattcagaacaggaacagcaacaagaacaagaat caaaaacgagatagaggtatgcactta
469.	atgctaactactttcgctgttgtactcattttcttcttacttccatcttcatttttattg
470.	ttgagcatctgcatcattattateattcatgcgatcatttttgttcacattattaaaaat ggcattcaaaataacaat
471.	ttgcctataccaagtactagaagtgcaccaataattccagcaatcaat
472.	atgettttgagttaetteataataeteateagttttttgtgtateettttgaettttatt tatttettteeaettaeeagtatgaetttettttttaeagttattteggtttgtt

· Lightly deline.

473.	atgacttgtgaaaaactggaaaatttcttgaccagtagcaaagccggcaccaacgacaac accaacaaaggcaaatgccacaataatggactcttt
474.	ttgattgtcattagtaacgttattgccattattttgatttttatctgttttgtctgcact atcatcttgttgatcattttcttcggtttctgtcttttatgcgtagatttattt
475.	atgtgcagaaattgcccagcattcaccagttgtttcattagggatatcatagttaaatgc
476.	gtggtatacaacgcaacgtatatgcatcttgtacacgtatttctgattgtcgcgtcgtta atgttgatccttctaaccaatcacgcatacgcgctgccacat
477.	gtgacaaatatcacactaaacagtgcatttgcagatgctacgataagcgtatttttatac caagtcaggtat
478.	ttgtgcagtagtagcttggttactattcttaagcttttgttctgcatctctcaactgttt aagtttttgatacgcatcttgtttacgttgatttgtacgtttatattgattttcagcttt tttaagttctgtattcga
479.	ttgccttcttgtttatattgttcaacaagtgctttatgcttagcggactgcttctgtact gcgtcacttgctctttttagttgtgcagtagtagcttggttactattcttaagcttttgt tctgcatctctcaactgtttaagtttt
. 480.	calippiegpnyspkatidpikpkalpcfflviflatttiisegnaadptpctnlpkiki kk
481.	ashfsfhligykqiilnifrstvasillffcllfmiyfrtvkfflnfliindfcfymafn rkrhilsflk
482.	crintaftsiasiwilelcvccyrccwlrccwsirwlclicrcciiircclvisltclvc rcclisrlclcsvirislitlsswlciwlccsscwislstlvcwlycwlslvgrcswlcc rislstsicvrlcigiswlcwlilcrlillccrrccrvsryksnsgn
483.	iqrfrnkcfqttlkwiavlcliyfvaitftytiittmkividcnyivdiniir
484.	rykgkakcisllrmivlfliiafhcndgrrmvckqmiciftf
485.	mgeygkslntlkkpinvpyegetekvgglfskeigetgnvvisgkdfnefgkqikaaqdi sedyeyiksgralddkdkeirekddllnkaverienaddnfnglyenakplkenieialk llkillkelervlgrntfaervnkltedepklnglagnldkkmnpelysegeqqqeqqkn qkrdrgmhl
486.	mlttfavvliffllpssfll
487.	lsiciiiihaiifvhiikngiqnnn
488.	lpipstrsapiipainatmtvlnhgnlgllylgvwlwfvve
489.	mllsyfiilisflcilltflyffpltsmtfffysyfrfv
490.	mtceklenfltsskagtndntnkgkchnnglf
491.	livisoviailificfvctiilliiffgfclfmrrfiflflvit
492. 493.	mcrncpaftscfirdiivkcf vvynatymhlvhvflivaslmlilltnhayalph
494.	vtnitlnsafadatisvflyqvry
495.	lcssslvtilkllfcisglfkflirilftlictfilifsffkfcir
496.	lpsclycstsalcladcfctaslalfscavvawllflsfcsaslnclsf
497.	caagtgctgaaaatgcttcagaacatcctcttgctgatgctattgttacttatgctaaag ataaaggtcttaatttacttgataatgacacttttaaatcaattccgggacatggtatta aagctacgattcatcaacaacaaatccttgtgggcaatcgaaaat
498.	aagaggettgttatgcagcaacacetgcaattcaacttgccaaagattatettgctcaac gcctaacgaaaaggttettgtcattgctagtgacacagetcgttatggtattcattctg gtggtgagcctactcaaggtgccggtgcagttgcaa
499.	ctgcgcctacgccagtttcagctattatgcacgctggtattgttaatgctggtggcgtta ttcttacacgcttttctccggtatttaatgacgaaa
500.	cgtttacgatatacttcatacatcattaaacttgcagccacagacgcgttcaagctattg acatgtccaaccattggaatcttaata
501.	tcaagcgtltttgctatacgacttactatcacttlttctcgattttcaaatgttggatgc aaaaacatatcaagggagccataataatgaagaaagaataatagaatggattgtagcc ataatcgttgcaattgttatcgtcacacttgtgcaaaagtttttatttgcttcttataca gtcaaaggagcatctaatgtcatttatcac
502.	agatetgtaeeacatattgtegtettaaetatgegaataatagegteagtaetgetegta atagttggettetettateegtaagttgtgea
503.	actgccantantatcatcagcttcatanttacgcttaccaacatttaccanaaccanaactg atgggatatttecttacaactantcganttgaggantaagttcatcaggaggtgctgggcg atttgtttatagccatcatacatttcattt
504.	ttgaataccatttgtaggaattcctttagaattgtacataaattgattg
505.	atttttatatttagattteagtataatgateatattgtaagtaetattgt atttttatattacatgegggtgtagtacaacatcagettggaaggetgaggttttgeca ttaagggttegattecateaccegetecattt
506.	ctaagggtttgatttttattattattt ctaaagaattattgaggattgtatttattgctggtttgacagttttcttctctggtcct ggccaaacttattcaaacgcagcatttattgatgaatatattcaaacatttggatgga
507.	aggaattecaateaaatgtaceaaacatttacageggatattgtaettatatttatgatt attgtaettggaggaettgtagttecaagtteeaatgeeaattttageaggtattatggtt atggtttetgagaeaatetaetgtttgeaeetgat
508.	aatcaacgactcgaggaaacaatttcctctccccatcacagctcagcctta

LIMEN CONTROL OF CALL OF MALLINETTE CONTROL AND INTEREST

509.	atgaaacaatttttaacatcactcaacytaaatttatcgaatggttgattatcttatc
510	atgacaaàtcaaaaaaactgtgggtctagtcgtcqctccaggtgttactgaacgccttgcag gaaaatctcatacaagaaatgcctaaaatgttatctacacattatgatcatcagcaagaa tggatttttgatttagttacggatccycttactggttttgctgaatctgtagatgaaatt tttgggaaagtagccgattatcacgataaggagacaatgggattatgtgatagcaattaca gatttaccgatgtttgcggacaagcaagtgatggcattatgatattaaataggaaaatg gcagctatattctcatatccggcatttggctggcgtccagttaaaaaaaggttcaagcat gcgatttataatattattcaagaaattcagtaagtgaactagaagtcgtaatatgat aataataagcaaatagaaaattcagtaagtgaactgaac
511.	atgaaattetgeceteattgtggaaateegataaaaaggaacagteattttgtaataaa tgtggaaaacatttaaagacategacacaagaaaaaggaaaateaaattgaacatatg cgtgaacagcaategtatatteteegtgaggaaagacaacatcatgatteaacatttat aaagaacaaaaacatactggttggetaattgtattatcaattatatttgtettgttgata gcagegetattgtatggtgegtactagettacaateattatattagtgatgagaaagt caccaaacaacagagteteagacaatcaaatgaaagtgatcaaaatagggaccaatecact ggtecaaggcattgatgttttagtgatgatttgatcaaggttatatgaagtegacatecact acaagtggatatagaggtgtttaaatggaatgacatgagattatgaagttgaagatagat
512.	atgttattgtttatcatagaaatcataatcatgattctagcgatattattaggattaaga actgctggtgcactgggattgggatcttttgctatagtagcagctattatatgatattt ggattccagttactccaggttcagcaccagtgacggcaggttaatcatgatattt ggattaccagttactccaggttcagcaccagtgacggcaggttaatcatattatactatt ggtatagcaggtggtacgttacaagccactggtggtattgactatttagtatacattgca tcacgtgtgattgaacgcttccaaaatcaattatttatagcgccaatgattgctttt gtctttgttttggaattggacgtactcaacagcgcattaactgcttcagtactatcatacag aaaactgcacaaaaagcacgaattcagcctaaacgcgcattaactgcttcggtacttaca gccaatttagcttacttgttagtggccggaaggttttgctacaggttatattattttcgta ttagcagggtatgaaatacgatgggcaagtatttaagtattgtttacctacagctta attagcagggtatgaaatacgatgggcaagtatttaagtattgtttacctacagctta attagtatgttaatgcttagtacattttgtacatttgtaggacgaaanagaacacgtggt gatgagtcagaacgtttagttacagatgccagaagtcgaaatcaaaaatgacttttcatta aaagtaaaaaataggtgttatctcattactattatgtgcatgggatgttaaacgtttggc atatttcctaatcccatgccgcaattcaatggaatgg

.

513.	atgggaagttttttaatcggatgactcgaaagagaatcctactatttatcaaaataaa gatggcatcttaagcgcacgttacgtgtacgtgactttcttgcactagtgtgttggtaca attgtcctacactatacttactttacatggtgtgttgcggactt gctgtggcattatcattcttattacgttgcacgttgtgcaggtcttgagcagact gctgtggcattatcattcttattagctgcattgtgaggtcttgtagccttactat gcagaaatggcatctacaatgccttttgctggatcagcttattgtgagtattattgtactt ttttgtgaattattcggatgggtgccggttggggcgttttagcagaatacttattgct gttgcttccgttgctcaggctttctgctaacttaagaggtcttattgcaccattaggc atttctttacctaaatcattatcaatcattggaagtaagggtgtcattgatac attgctgtgagtgattatttaaacgcattactattacacgcggaatgaacgaagcc gctcgtatggaaaatgtattgdtatattaaagggtttagccatcatttttcagaacataaggtt gttgggctaactgcgattaatttcagtaaccattattccagaacataaggtt gttgggctaactgcgactttggaggttggcaaggtattatgcggaggttcaatgatttc gttgggctaactgcggattattcagtgacatattatccagaacgatagatttc ttagcttatattggttttggcaggttgcacgattattgcggaggttcaatgatttc ttagcttatattggttttggcatgttcactattgtgcgtagtagaaggtattattcaacaa aagacaatgcctagaggaattttaggtcactcatagtagcaattgtattgtgcc gtagcactgttcttgtggaaggttcaccactactctcaatacgctgataattgcagaacca gtaggttgggcattacgagaaagtggtcatggtatgattattgctgcaattgtacagcaatt tctgtcatcggtatgttcactgcattaatcggtagtattattgcaggttcaacgcatt tacttactggacgagatgtttactcccttcttgttaagtcaattgaatcaacaacat ttacttaacggcacttgtcaactactaactactagatagtagtatattgcagtacaacacat ttacttaacggcacttgtcaactactacaacaatgattgtagtgaagaagatttaccaacaacat ttacttaacggacactgtcaactactacaacaatgattgtagtgtacatggagtttacctaagtttgtg tcactaggaattacctatttgccgcaattacatggttattcattgatgcattcaggattt tagggattaagttttgaagcaasttgtatacactgatatggtttatttattagtaggtagtattt taggggattaagttttgaagctaagttgtatacactgatatggttattattgaggagaagctatcaatgt tcattatttaattta	
514.	atgacanagaanacagtttatcgcctagtgagtggttgcttaaacaatctaaaagacat anaaggaanaatcaatttacacggcanttgacttttagtagcgttagttctactcata tttgctgttanatcaatacangtagaacctgtananaagtgatacgagagacaaagatagc attcgtatcacctatttaggtaacgtcactttaaataacatattcgacaaactaact	
515.	atgattgaacatttaggaattaatacaccttattttgggatattagtatcattaatacca tttgtcataggacttattttataaaaaaacgaatggatttettttactagcaccttta ttcgtaaggacttattttatataaaaaacgaatggattactttactagcaccttta ttcgtaagtatggttgcaggtattgcttttttgaaattgacaggaattagttatgagaat tataaaatcggtggcgacattattaatttcttcctagaaccagctacaatatgctttgcg attcctttatatcgcaagcgcgaagtattaaaaaaatattggttacaaatatttggtgt atagctgttggtacaattattgccttgttattaatttatcttgttgcaataacattccaa tttggcaatcaaattattgccttgttattaatttatcttgttgcaacgacagcaattccaa tttggcaatcaaattattgctgtagctcaagcagctgcaacgacagcaattcatta cctgtatctgacggtatcggtggtcaaagaattaacctcactcgcagttatttaaat gcagttgtcatttctgctttaggtgctaaaatagttaaattattaaaatattaaccct attgccagaggacttgcactagggacaagtggacacactttaggtgtcgcggcagctaaa gaattgggtgagacgaagaatcaatgggaagtattgcagttgtcatcgttggcgttatt gttgtagcagtagttcctatacttgctccaatcttatta	
516.	atgaaaagaacagataaatatagagattcatacaaatatgatgaccaatatcaaaatcat cgtaaacgttcagaagaagatatgtatcgacaacatcaagagtcccaacagagagcaaat tcaaatcgtgcaacacaaagtgaaaatgatagagagtatgaaaatcatccgtgaacgtcat tcaaatggaagaagactatcgacgtgagcagcaattggaagaagaaaatgaaaatcaagc aaaactaaaaaatggctgattgcaatcatagttattttactcattattgtagctatctt atcacgcgtgcaattatcaatcataataatgataagatagacctaacgtttca caaaactataaaaggaagttgaaaatcaaacgacgacattaatcgacagttgatca gccaaagcgatataaaanataaaaaggacacccaatccaaaattgataaactacaaaat caaattgatcaattaaaacaaatgagaaactaatgcgattctaaatcaaaaat tatcaaaaccaaatcgacaaactgaaaatgcaaatagcgctcaacttaatacgaaaat caaagtaaagt	
517.	atgaacatgaaaaagggtgtttctcagcttacgttacagacattgagtttggtcgaggc tttatggcatggagtattatttctccattaatgccatttattt	

518.	atgaaaaataaaaaggattaggcataggtettateaeaattatgattategtttgtatt gtaetagtaateatgatgttegtgggtggtaagaaagaateataetaeggtattatgaaa
i	aptococcactattcataaaataataataataataataaaaatcaaaaaa
	Anarthmorenagetoreagtotateagttaaaaaaagaagattttgtgatgctctttaad
1	datdaaaaactdgaaaaattactaaagttaagaaagttaatcacgatgacgtacccat
	ggtttaatgtcaaaaatccatgatatgggtaatatgaaacacggaatg
519.	atggctatgtcattactcgtgagtcttgtggtttatatgatgacactcacatctgatata
	ttagaagatattetateatttaaattagaagtgataatgeaattteegtatatattaage tetattteaetaateattttgtttataetttteattttaaaagatatggaaaaaatatgg
	tactggctcatttcaatagttatgattgctgtgataagtatgtctggacacgtgtggtca
1	caacaagtgccattatggtgaattatcataagaacaattcatcttatagggctaacgtta
l .	ragtraggttcactcattatctcatttqttatqctattaaaqtgaaaattaatcagttg
	acceptotagegetatocttttaaaagttaatatcattgctgtgattatgctcgttttt
1	acammattttaatmortattoatoaaacoaatactttaacactttggaataatgtgagc
i	gettggtetatttatettgteataaaaategeaggaattattgetatgatgetattaggt
1	ttctatcaaacgatgcgtgctttgagacaacgacaacaggtccatcgttttgcactgatg actgaattgttaattggtatgatattaattttgcaggtatca
520.	atgaatagttutteggettecaatgggctatgatggtctttgtatttttcgtt
520.	atcacaatggcattgtccgtgatactcagagattttcaagcgactatcggagtgaaacgt
	rregrettragtattagatttagctcctttcatagctgcaattgtgtgcatattagta
1	+++approaceaeaeaeaeaettaceaggattgaaattttctatcagtttaaaagggatt
	gagcgtctacttttagcactcattctaccacttatcattttaatgattggcttgtttagc
I	tttaatacttatgctgatagtttcatcctattacaaacttcagatttatcagtatcatta
İ	ttaactatattaattggtcatattttaatggcttttgtagtggagtttggtttccgttct tacttacaaaatattcttgaaacaagaatgaacacattttttgcgagtattgtcgttggt
i	cttatttattcagtatttacagctaacacgacatatggtgtagaatacgccggataccat
1	rrcrtararacatrcatottttcaatoattattootgaattaattagagctactaatggt
1	cotacaatttatattocaactgcttttcacgcatccatgacttttgctctcgtctttta
1 .	tttagtgaagaaacaggcgaccttttctcaatgaaagtcatcgcactttctacaacaatt
1	argantatttcatttattattagtctagtcattcgtgctattqtttataaacgacg
1	anacaaagtttagacgaagttgatcctaataattattatctcatattcaagatgaagaa
-	ccaagtcaagaagacgcctcttcaacttcaaatcatgatgtatcatctaaagatgaaaca aagcaacaagatattgataatgacaaacatcaatcaaagaaacctaataagagtgacgat
i	gcacttactacttctaattataaagaagacgcctcttcagttaataaagaaacggataca
1	actcacaatgataacattaaagatcattcaacttataccgaagatagacactcatctgtt
1	gtcaacgatgttaaagatgaaattcacgaagttgaagatcataaagccgacacagataaa
	teacat
521.	atggaaataatgagttgcaaggggattgaatgcacgtcagatgcagatgattgctctt
	ggtggaacaattggtgttggtcttttatgggagcaacaagcacaattaagtggacaggt
	ccatcagttattcttgcatatttaattgctggtatttttttt
1	tatattcatccagcagctggctacatgactgcttggagcaatgtatttcaatgggttgtc
	gtcggcatgagtgaagtgattgcagtaggagaatatatgaactactggttcccaagcctt
	cetaattggataceaggagtgatageagttetetttttgatggetgetaacetagttea
1	gtaaaagcgtttggaggtttgaatttggtttgccttaattaa
	ttaatgattattgcaggattaggattaattttatttggtataggcaatggagggaatcca
	atagggatttctaacttatggtcacatggtggatttatgccaaatggattcattggattt ttctttgctttatctattgtgattggatcataccaaggtgttgaattgattg
1	gcaggtgaaaccaaaaatcctcaaacaatattgtaaaggcagtcaacggagtgatatgg
	agaattttaattttctatattggtgcaatttttgtcattgtatcagtatatccttggaac \
	caattaggtagtattggtagtccttttgttgcaacgtttgctaaagtgggcattacgttt
	gctgctggtttaataaactttgtagtcttaacagcagcattgtctggttgtaattcaggt
1	attittägtgcaagtcgaatgatttatactttggcaaaaaaaggacaaatgcctaaagta tttactaaagtaatgaaaaatggcgtacctttctacactgtatttgcagtatctatggga
1	atattaattggtgctttattaaatgttatacttccattaatta
1	atctttgtatatgtatatagtgcctctattttaccgggaatgataccttggtttatgatt
	rtatttagtcatctaggatttagaaggttacatcctgaaaaggttcacaatcatcctttt
1	manatgccgggagggcaattgccanttatttaactatcatgtttttactcctagtatta
1	gtoggtatgttacttaacaaagaaactgtagtatoggttgttattggtatogtgttctta
<u> </u>	acagctgtgacactttattatcttattagatatcacaaaaaggaacgacaaata
522.	gtgaaaagacttaagaattttattctcggcttactcattgtggctatagttggcttccta
	ttatttatgtatatagatgatagtegeatteaaagttateaagactaettettacaattt aattggtteeaaccaetattgattgggettgeaggattaettatattaateggaettata
1	ttagtacttagtatttttaaacctacgcatcgcaaacctggactttataaaaactttgat
1	i matogacatatttacotatcacotaaagctgttgaaaaaacaatttacgatacaatcgct
I	i aaatatgatcaagttagacaaccaaatgttgtaagtaagctttatagcaaaaagaataaa
1	tcatttattgacatcaaagcagatttcttcgtaccaaaccatgttcaagttaagagtta
I	acagagagtatccgtgctgatatcaaaagtaAtgttgaacactttactgaaattcctgtt
1	agahaattagaagttaacgtacgtgatcagaaascatctggtccacgtgtattg

523.	ttgcaagattttgataacttaattctggttgtttaaaacatttgttcaagtcgggaat gacttaatttggtctcaatatcttattggattattattaacagcaggtttttctttaca attagttctaaatttattattactcagtagtacagaagatgtttagagcattaactgaa aagccagaaactttaagtagtgggagaagggtattcaccatttcaagcttttgcgatt agtgctgggtcaagagtattctggatgtgggatttgccagttgcaactgctattgttctt ggtgggccaggtcttctggatgtgggattattgcttttattggtacagtagtgca tttatggaagcaagcttgctcaagttataaggactatacaaagaaggtggattctgg ggcggaccagctattacataacaaagggctaaaccaaaaatggcttggaattgtattt gctgttttaattacagttacatttgctttgatttga
524.	ttgaaaaagaaattttagagtggattgtbgccatagccgttgccattgcacttattgc ataatcactaaattttgcgaaaatcatattctattaaaggtgattcaatggatcctaca ttaaaagatgggagcgtgtagtggtaaatattattggctataaattaggtggcgttgaa aaaggaaatgtcattgtatttcatgctaataaaaaagatgattatgttaaaaggagttatt ggaactccaggagatagtgttgaattataaaaatgatacactctatgttaatggtaaaaag caatcaggaaccatacttgaactataatgaaaaagtaagcaaactgagtaatacacaggt agtttcaaaacaaaa
525.	atgttcaataaggtttggtttagaacaggaatattttttattatgtgttcatcatc aaactatttatggaagtgcatgaagtatttgtccaatagctactatcattggtcagtc ttccttccattttaataggagtgcatttgtctcttttacatatgtttaccttttcaataa ttagaaaagtgggctttccacgttgggctagtataacaacaatattcataggttaata gctatcatcgtattgtggtatcattatagcacctatcattatttccaatattaataac ttaattaaacaacaccatcattacaaaaagaagccgaacaattaatt
526.	gat atgaatacaatcgtaaaacatacagtaggtttattgcttctatcgtactaacgctttta gcagtttttgtaactctatacactaatatgacattccatgctaaggtaactatcatcttt ggtttttgctttcattcaaggtgccttcaattattaatgttcatgcatttaactgaaggt aaagatggacgtttacaatcgttcaaagttatctttgcaattatcattactttagtaact gttatcggaacatactgggtaatgcaaggtggacactcttctactta
527.	atgtetttettaggaaacacaccgaaattatatttagttatateactggtategttea etttttacaggteteattattttatatettacettaateaacaattaaaggtgac aaaaaggttgatacgattgcataacgtatgggaatteetaaatgcetttttgeegag attataaaagtgatgagataaatttattggtggettteeaattacaagtgceatagaaate ategtatttggatteetagtgetgttaggteataggtaattatatagacetttataaatac gatattggatteetagtgatgeetttttggeattatgtaetttaatataetata ttgetaatgacacaagtgtatggetttttgetategteettattateettaataett ttgetaatgacacaagtgtatggettttttgetategtetttattateettaataett ttgetaatggacacaagtgtatggettttttgetategtetttattateettataeatta ttgetaatggacacaagtgtatggettttttgetategtetttattateetataagta catattggtacatagttataaggaggtaggttaetetaataccaagacaategaagaaccattat atgtggattattgtaacttatggaatgga

528.	atgttaggagagcaatatacacaaattaagcgtccagcaaatcggctaactgaaaaata ttaggttggttttagtgggtattcttactcatattaactattgtttcaatgtttattgcg ctcgtatcttttagtaatgatacgtcaattgccaatttagaaaacaccttaatatatag gactcgtacacacaattttagccaattagtataatgatcaactcaattggtttattgg ttacaaaatggagtttgggcaattattgtttattttat
529	abggaggaataaaantcaacctaataatgagaatatgtcgaataagacgataataca atccatttgaatgatagtcaaagtaatgaagacttagagctttttagacggaataataca gctcgccaacgcagaagacgtcgcatagataaccaaagtaaagaaaaagatgctacgtct accaattcaagttagaaactaaaccaatggataaatttattgataatcacaagtcgcat aatcaagataaagaaataaaatggatttaattggagataatgttaatgaagatgac aatcaagataaagaagaggaatttctaactgatcgtttcaacaagcagaaacg cgtcaaagtaatgaagacgaagaggaatttctaactgatcatcagagcgaaaacaaccg cgtcaaagtaatgaagacgaagaggaatttctaactgatcatcagagcgaaaaacaact aaagactctcgtcattctaaaaaacataaattactaagtaaatttacttctaaaaaagaa aaggaaacatttacatcgttcaatagtaatgagagggaaattcaaattaaccgttagt ttagaagaaaaagagccataagacgtaaaaagagaaggtaactcaaattaaccactaagtaaa atacaaatgtaaatattaaaggtaataacaacgtaagtacgagtaaaataaagaaag
531.	atgaagtgtttgttcanaatgctatcaataataataataattaagttaag
·	agaacaatcattactgitgcaattcaqtatcqtattagcaagcattacctattatgda aatctacaaatgattgtaccagcaacatcaaattcaaataacgaaactaaagaaactaca agaaataatgtaaatgataaagaacgagcaaatcaaaagcagaactaaagaaactacaa actaattatgactccaccaaagaaaatactaaagaacctggaaaagaaatgaatctgca acacgattggagaactctgcgcttgaaaaggcaaagtcatattatgatgatttccacatg tctaaactaggaatttatgatattttacactattatctgaatatgagaaaatgaatctgaatagacacatgaacaagaagcaaaatcacatgaatattatgacgaaaagcaaatatgcacatgaacacacac

532.	atgagtcataagatattagtatcagacccaatttctgaggatggtttacaaagtattta aaacatccagaatttgacgtagatatacaaaccagatttatctgaaaatgattagtaaat atgatttcaacttatgatgetcttatcgtacgaagtcaaacccaagtaccagagcgaatt attaatgctgcaacaaatttgaaggtcattgcaagagctggtgtaggtggataatat aataatgctgcaacaaatttgaaggtcattgcaagagctggtgtaggtggataatat aattatgcagcagcgactttaaaaggtattttagtaattaat	
533.	ttgaagcagaattattagcactaagttaacaatt  ttgaagcggaattttattaataattaatcatattattaattgctattatgttaagtctg  ttattaaaaaattattaataatttaatcatattattaattgctattatgttaagtctg  ttattaaaaaattacattgattttgccatttatgtttggaccaatattagggggtta  ttatgtgtaaaagtattaaaattaaaaatagaatgccattttggttgagtcaaattggt  ttaatactacttggagttcaaattggctctaccttcacctacataatttattaagcttgata  agtaaaaattggctaactatgtttttgtcactatcctacataatttattagcttgata  attgcattctttttaagaaaattgcacaagtaaatttagaaaactgcaatttaagtgtt  ataccaggtgggctaagccaaatgattagtaggagaagaaaataagaaagcaaatata  ttagttgtgagtttaacacagacatcacgtgtaatatttgttgttattttagtaccactt  atttcgtatttttttcaggataatacggagaaataatcatcttattccaatggaggaacc  acactttctcagactttaaatatggcaaataacattatctattccaatggagggaatc  atctatataggaatgtcaaaaattaacttccccactaaacaattatggagggaacc  atctatataggaatgtcaaaaattaactttccccactaagacattaggtgggaacc  atctatatatggaatatgcaatagcattaggatttcaagatcattggttgtta  gccacagcgcaacttatttatatggataggattaggattacagattgccaacttaatgg  gatttaaagggaggaattgcaatagcaatagccttcaaaatataatgccaatatgatttt  ttaggagcagcaccaggaggtatgagcaaaatagtttaggtcatggctatggctatggct  gatgtagcggtagatttcaagctatcacattttaaaatatttttatatttgtcatt  gcgccactaattggttatttatatagataaattaaat	
534.	gtgaagaanacgatagaatatactcatactcctatagtctaatttcaaga atggtatgacttaagattgaattgtaanaatgtaattaattagttaatttagatttgaaaga atggtattgaagattgtaaaatgttaatttaggtctagatttgaaaga ggttttgaagtccttcaagatgtagatcctttaaatagaggataaaattggtaataaaatgggatacaatctaagaa ccgaanaatacanatcgaagatcaaaatcgagttacaattagagattcaagaa ccgaanaatacanatcgagatcaaatcgaattagttaaaattagagatgtgaa caagcacaagcggtaaattattacgacactaaacaaggttacaattaagagattcaagaatcaagaattaataaacaaggaatttaaaattaagagattttaaagaaag	

535.	atgggggaaattecaaacaagatttcaatcaaaaaggacaaaattttaattcacaaaa aaacatagacgattattatatgttcagtttttttaatggctacatcagctattggtca gcatttctgactcaaactgcagtgtttactgcacaattttatgctacatttggtca atattaatttctattattatagatataggcgctcaaataaat	
536.	gtictaataataattitaaagattaagatgattetgaaagaatgteaatgteaatetattaateagae gaacatcaaacagaattaaaagaagatgataaaacaaatgaaaataaaaaagaagetgae ctcaaaacagttaatcaataatcaaataacaaatteeteegagaaatgeecaaga cgaaaaagaegeagagagaagaaactaatcaagaaacaacaagaegaaaacatcaa aaaaatagtgacgetaaaactaacagaaggtteattagatgacegttatgacgaagaacatcaa ttacagcaacaacatggaaaatgcaagcagcaacaaaatacaagagatgaaaaatacaagat aatagaatgaaagatggaaaagatgcagctattgtaaatggaacatctgagtcaccagaa cataaatcaaaatcaaaaatagaacaggeectaaagetcaacaacaaaagggtaaa cataaatcaaaatcaacaaaatagaacaggeectaaaggtcaacaacacaaaagggtat ggaatagctggtgcagctggtgttgctggtgcagcagaaacatccaaagtgtcataaaaagagataaaaagagtataaaaaagagtatcaaaagaggtatagaaaaagagtacagcagcagcagcagcagcagcagcagcagcagcagcag	Type
538	gcraataataacteaaattatacaaaccaaaatcaacaagataatgcaaaccaaaatagc aataatcaacaggcaactcaaggtcaacaatcacatacagtatacggtcaagaaaactta tatcgtatcg	
537	atggctaaaggggaccaatatcaagctcatactgaaaaatatcatgataaaagcttaaa aaagttataaacctgtgtggattatcattagtttattatttaattaa	
538.	atgitaggatticathaaccattigcitagtiatcaattittaaatcgigcattaatcaca tctattitagitgggatigtatgiggaacgatgggtagcattatigtittacgiggtcit tctitaatgggtgatgccatgagtcatgcigtittaccaggigttgcittactitctit tttaatattccaatgittatcggggcactigtaacgggaatgcitgcaagittgttatt ggtittattacticaacagtaaaacaaaaccagatgcigcaataggaataagittcact gcattcctagcatctggcgtcataattattagtitaatcaatagitacaacagatttatat cacattitattiggcaatttattagcaattacacatcaatcattiggacaacaatgitcaaca tttgatgcaactttaatgacggggctgaacacaacattaatcacatactitgc atgatattactcgcactigtaactgitgcgagcatacaaacaatgitgcaattatcctgta gttgttattactcaccccagcittciacagcttittaatcagttaatcactattagc atgatggtaattgcaagcataatcagcgtgataagtcgattatacggtcatattagc atgatggtaattgcaagcataatcagcgggataagtcgattatacggtctatatttagc atgatggtaattgcaagcataatcagcgggataagtcgattatcggtctatatttagc atgatggtaattacaattacagagggacaactattgtaacctgtaccttatggattaatt gtaacgctatcaattactagaattaaaaaaaaaa	

539.	ttggcaagctattatacaaactaggaaaatttatacgccataatgataaatgatgatgtt ataggatggcttyttatactacggcgttagttatcacgccataatgataaaatcagt tttgacagtgacatcactatgaacggcctaagtagtagacacaaacgataaaatcagt aaagaatttcatcaggacagtgagaaagcctgatgaaaatagtcttccatttcaataag aatgatggactacatataaagatacgaagaagatattgaagatgctttagacaatatc agacaaaatgatgattatataccaaaatatctctaatccatatgacagtggacaagttaat gatgaaggcgatactgctatacgctaagttagttattccaaaactggattaaa gatgatgatatatatcaaagatggcgcatagaattccgaacgtggacaccataatgtg caaattganaaaactcaaggtggcgctatgaattccgaactgggcgacaccataatgtg caaattganaaaactcaaggtggcgctatgaattccgaactgggtgacaacgataatg gtcggtatcatcgtagcattcgtaatcttacttatacctttggtcaactactgcaatt gtcggtatcaactgagaattcgcgtttaggttcaagttcagctgatata gtcgtggtattgactactcaactttacttattctattc
540	ttcaaagcattaatgttatacgctcgtgaaaacaacaaaggtgtttacgatagata
540.	atgaataaaaagtagaacatatcggtaaccaatatacgtcacaagaaaataagaaaaa caacgacaaaaatgaaaatgggttgtacgtagacgtattgctttattcggaggtatt cttttagcgattatcctcattctacttgtattgcttgtcattcaaagacataataacgat caagatgcagttgaaaggaaag
541.	atgaagatacgtttaacatttattatcttagcaatactatccaccatcggcttagtactt gttttagcaaaatatccaacaggcccaaccacaatcaactataacgaaccttatacagta ctcatagccattacgacaatagttataatggctttaccagcactcatattaggtatattt aatcatcttgcatgtagaatcatatcggcgatattacaaataagtgcactgatgatgtgg gggtttttagtaatcattagcttaattatgggacaaattgtcattatggcttatggctcc ttaacgataacttgcattacttgttagttcattgtcacactttcagtgcacccatctact tcagataaaataaa
542.	atgaataagaaactattgtggagcatcattggtattgtaattattgtcgtattatatcatt gctgctttttatattaaaacaagttaatggttaggtattaagtaatgtatgt

Commence of the Commence of th

543	atggctgaaactactaaaatatttgaatcacatttggtcaaacaggctctaaaagacagt gtattgaagctctatcctgtttatatgattaaaaatccgattatgtttgtt
	attgtattattgattccgattgcgatgdaaggcgtgaaatttaaaggtgcctcaacgcaa accatattgatgaaaaatatgttagtttacggcttaggcggtatgatcgtgccatttatc ggcattaagctcattgatctcatcatccaactctttgtc
544	atgattgtgttacgtcgtctattcaagatagaggtgccatattgctatagctattatt acaatctacgtagtgctttggagttttagctcctttaattacattctatgaaccgaatcac attgatacagcaaataatttgctggatatagttgttctcactggttgggaacagaccat ttaggtcgagatgtattacacggataatatacgccataagacctagtttgttatatgta tttgtcgcattgattatttccgttgtgataggaagcgatacttgggtttatttcaggttat ttcccaggttatatcgatggatgatagtaggcgatacttgggtttatttccaggttat ttcccaggttatatcgatggattgattaggtgttttggatgggatgtagttagt
545.	atgaaaggtgccatgtettggccttttttaagattatatattttaacattgatgttttt agtgcgaatgccatactcaatgttttcatacctctaaggaggacatggacttgggggcgacg aatactgtaattggaattgtaatggaggctatatgtcaatggcgacg aatactgtaattggaattgtaatggaggctatatgtcatatgcgccc tgggctggtcaaattattgcacgtattggtcgattaatgcgtattgatgtcattg attaatgctatggcactggtattattggtctgataggacttgaaggttatttgattgca cgtatcatgcaaggtgtgtgtacggcattcttctcaatgtctttacaattgggtattata gatgctttacctgagaaatatcgttcagaggtgtattctcatttcaatgggtattata attccaatttattaggaccattaattgcagtaggatttgcacgtggaaaatatgtcc atatttgctattgttatgatttttatgcagtagaacgaagtcttgccttttaatgca attttgcaatacaaaaagaggtatcaccaaaagacgaagtcttgccttttaatgca attattgctatatgtccaattttttaaaaataaagcactcttctgcagtggtatgattatg atcttgtcatcatcgtgtttggtggatgagatattttatacaagtgtagattatg gaaggttccggaatgcaggtattttcccacaattcaagcattacagtaggtgatagattatg attatttacgtagtggtggtggtgtttatggtttatggacacaataagtg attgcttaacgttactgatggttgctcaattgatggtttatggacacaataagtg attgcttaacgttactgatggtgcatcattgatggtttatggaccacataagtg agtattttgtatatataagtgcaattttatcgagaataacacaagcgctcgtttatcct acattgacaacqtatttaggttgttgtcatacacaggagtggtcaatatggag ttgttataggaagatttaaatgggattttcacaaaggagtggctaatatggggccaata tcagaacggtaggatttaaaatgggatttattttaccaaaggagtgctcaataggggccaata tcagaacgtagagatttaaaatgggattattttaccaaaggagtctcaaatgggccaata atgacaccaagtagagagatttaaaatggagttatattttacaaaaggcctca

546.	gtgggaagtactgttaaatatcgtaagtttattctacctattgtcgttggtttaattatc tgggcattgacgcctattaaaccagatgccttaaatgatcaagcttggtttatgttgct atttttgtgtcaaccatcattgcttgtattacccaacctatgactatagtgcagtatca atcattggtttacaatcatgcttgtattacccaacctatgactatagtgcagtatca ggcttcggtaatagtagtatttggcttggaattgttgtattcaatagacgcttcaa ggcttcggtaatagtagtattgcttgctgcaattgcttttcatttcaagaggattt gtaaaaacagggctaggtcgacgtattgctctcaattcgttaaattatttggaaagaaa
	agtgcaacagcacatgtcagcgccatgtacgccgcgttactcggtgttgcagtcgcttcg ggtgcaccgccattattcagtgcattaatgttagggttctttggtaacttactggcatca acaacacactatagtaggaccagcgcccatattatacgcagctggctagttacacaa aagcgctggtggactatgaatattgtacttggtatagtctatttatt
547.	atganagataataaaatgttgttcattattttatgataggacatttacagtaggaatg gctgaatatgtagtgacaggattacttacacaaatcgctgacgatatgnaggtttctatt tcgagtgcaggtttattattattgtttatgctattagtttgcattgatagggccttta atgcgaatcataacattgaaagttcacgccaccgtctgttaccgattttagtagggccttta atgcgaatcataacattgaaagttcacgccaccgtctgttaccgattttagtagggccttta ttataataagtaatttagtgggaatgttagcaccgaattttaatgtattgttattatca agactcatgtctgcggcaatgcatgcacccattcttcggtgttgtatgagtgttgctgcg acagtcgcacctcctgctaaaaaaacacaggccattgtttaggtgcaggtttaact attgctgtaatgttaggtgtaccattcggatcatttttaggtggcatgtttacaattggaga gttgtttttgggatttatggttggcagaagcaatattttaggtggcattgcaaattggaga gttgtttttgggatttatagttggtggcaaacaattattactagttaggaatgattaaattt gttccaaatgtttctttaagtgcagaagcaaatattagcaaagaattaccatggttttaag aatccacacattttaattgtgattgcaattattgtttgtt
548.	gylkmlgnilllmllllmlkikvliylimtllngfrdmvlklrfinnkslwaien
549.	krlvmqqhlqfnlpkiillnaltkrflsllvtqlvmvfilvvsllkvpvqlq
550.	lrlrqfqllctlvllmlvalflhaflrylmtk . rlrytsyliklaatdafklltcptigili
551. 552.	ssvfairltitfsrfsnvgckkhikgaiimkkeiiewivaiivaivivtlvqkflfasyt vkgasnviyh
553.	rsvphivvltmriiasvllvivgfslsvsca
554.	tammiisfiitltniyktklmgyffniielrnkfirrcwailfiaiihfisecflphipt ncyvsrfdfldsaknmsyktlnticrnsfrivhkliv ffcrltqlnwlkylsvrmlymyfmifsimnhivstic
555. 556.	ifistcgcsttsawkaevlplrvrfpspapf
557.	lmilrivfiagltvffsgpgqtysnaafideyiqtfgwsrtev
558.	rnsngmygtftadivlifmiivlgglvvqvpmpilagimvmvsetiyclhl
559.	ngrleetissphhssal
560.	mkqflnitqrkfiewliilsifivsipnkwtlmisialslllkrgalgovqliilymlr sqiytpydtqemahyivsmkyiliyvigvfflfkyvkhwirnemilrfikstmilmilyi imslvvsndplesilkllnffiplilivmyvslikkknlimvinqfitlviaftflfiv iapksylideeslrsvfkdahsfavilemglulymvtiikqqdydvfnllllnigmiely lemarhifisvilclmlllplshikkrikhpiigamilmaiaiinqpyiyhlfiklilkg knsqevfmpsdmnikaidyaltehpflgsgfgipmikasseiqyfnvatsniifgmiift giigltlctiymlhmvllvtfpmsitillflitifvnmdyiilfdsvglgilcyifwgiy lkegmygynnggw
561.	mtnqktvglvvapgvterlaenliqempkmlsthydhqqewifdlvtdpltgfaesvdei fgkvadyhdkrqwdyviaitdlpmfadkqvmaldinmengaaifsypafgwrpvkkrfkh aiyniiqelneaeqesrnydnnkqiensvkkqfplskidketiymketdsyhlrylsssr symfrlvsgmtfannplnmmaslsnivaiafttgafglvfttmwqmaynfsmwrlfgis iiaiigmliwimmshdlwepvnksnhkhitwlynlttimtlifaiiiyyiilyllfliae ivllpsgflgqqyglkgpagidlylsipwfaasistvagaigagllndelikestygyrq rvryeeqrr
562.	mkfcphcgnpikkeqsfcnkcgkhlktstqrksenqiehmreqqsyisreerqhhdstfy keqkhtgwlivlsiifvlliaallygayyaynhyisdeqshqttesqqanesdqnrdqst gpsidvfsddfdqgymksastsgyrgvyngmtreevedkfgtsngsveslkwsyetygdl avayddnevvsvgvapnhisedqflsmynepddrnssqliydsnkdndfsvlanvkngdv tvlenvnqi
563.	mllfiieiiimilaillglrtagalgcgifaivaqlimifgfqlppgsapvtavliilsi giaggtlqatggidylvyiasrvierfpksiifiapmivfvfvfgigtanialslepiia ktaqkariqpkraltasvltanlallcspaasatayiisvlagyeismgkylsivlptal ismimlstfctfvgrkehvrdeserlvqmpeveikndfslkvkigvisfllcymgiltfg ifpnlmpqfnvngdvvkvemteivqffmylsatinlllikintsdilssnitgsamgalf avlgpgwlgatifnaphnlkilkndigsiisevpwlviilvsvvamivisqtatasimvp ivmslgippiyfvamvqtlnvnfvipaqptllfaveldetgrtrptsfmipgffvitvsv itafviktilgv

were the second of the second

564.	mgsffnrmtrkenptiyqnkdghlkrtlrvrdflalgvgtivstsiftlpgvvaaehagp avalsfllaaivaglvaftyaemastmpfagsaysvinvlfgelfgwvagwallaeyfia vafvasgfsanlrgliaplgislpkslsnpfgsnggviddiaavviiltalllsrymmea armenvlvilkvlaiilfvivgltainfsnyipfipehkvtetgdfggwgglyagvsmif laylgfdsiaansaeainpqktmprgilgsllvaivlfvavalvlvgmfhysqvadnaep vgwalresghgiiaaivqaisvlgmftaligmmlagsrllyafgrdgllpswlsqlnhkd lpnralviltiigvvigsmfpfaflaqlisagtlvafmfvalamyxlrkregkdlpkpef klplypilpaitfilvllvfwglsfeaklytliwfivgiiiyliygirhskkndeeayqv pre
565.	mtkkrispsewilkqskrhkrkntlytaivilvalvilifavksiqvepvksdtrdkds iritylgnvtlnkhirqtnlndvfkgiqdtldhsdfstgslivndfsrnqkdninknien inflrkhnvksvnlinesmdniqatammrkidsqagynfltgngsnpinsktvqqdlkgk klanvsftdlesnytnslknttsisldpaifyplikklkenndyvvvnvdwgipnernvt trqkeyahalanagadviighntviqkvenykrtpifyslgnttsdinflsknqkgmivqq dwkgshnqfhitpiqskdgkiskdnmnkmdhirfknnikdksidlksdqnggytfey
566.	miehlgintpyfgilvslipfviatyfykktngffllaplfvsmvagiaflkltgisyen ykiggdiinfflepaticfaiplyrkrevlkkywlqlfgglavgtiiallliylvaitfq fgnqiiasmlpqaattaialpvsdgiggvkeltslavilnavvisalgakivklfkisnp iarglalgtsghtlgvaaakelgeteesmgsiavvivgvivvavvpilapill
567.	mkrtdkyrdsykyddqyqnhrkrseedmyrqhqesqqransnratqsendreyenhpery yngrdyrreqqleeenekssktkkuliaiivilliivaifitraiinhnndkvsndpnvs qnykkevenqnddinrqvdsaksdiknkkdtqsqidklqqqidqlkqneetnadskftkf yqnqidklknannaqlnnenqskvnmaledintkfdsikaklenilngsnsgn
568.	mknkkglgiglitimiivcivlvimmfvyykkesyyyimkdsttidkmintknekieknv elpkdanvsvkkedfvmlfkdektykitkvkkvnhddvphglmskihdmynmkhym
569.	mamsllvslvvymmtltsdiledilsfklevimqfpyilssisliilfilfilkdmekiw ywlisivmiavismsghvwsqqyplwsiiirrihligltlwlgslvylicyaikvkinql tsvrrmllkvniiavimlvftgilmaidetntltlwnvsawsiylvikiagiiammllg fyqtmralrqrqqvhrfalmtelligmililqvs
570.	mknsrfsgfqwammvfvffvitmalsvilrdfqatigvkrfvfsikdlapfiaaivcilv fkhrkeqlaglkfsislkvierlllaiilpliilmiglfsfntyadsfiilqtsdlsval ltilighilmafvvefgfrsylqmiletrmmtffasivvgliysvftanttygveyagyh flytfmfsmiigeliratngrtfyiatafhasmtfalvflfseetgdlfsmkvialstti vgvsfiiisliiraivykttkqsldevdynnylshiqdeepsqedasstsnhdvsskdet. kqqdidndkhqskkpnksddalttsnykedassynketdtthndnikdhstytedrhssv vndvkdeihevedhkadtdksh
571.	mennelgrglnargmgmialggtigvglfmgatstikwtgpsvilayllagififlimra mgemiyinpttgsfatfasdylhpaagymtawsnvfgwvvymseviavgeymnywfpsl pnwipyviavlflmaanlvsvkafgefefwfalikvvtivlmiiaglglilfglgnggmp igisnlwshggfmpngfigfffalsivigsyggveligisagetknpqtnivkavngviw rilifylgaifvivsvypwnglgsigspfvatfakvgliffaaglinfvvltaalsgcnsg ifsasrmiytlakkgqmpkvftkvmkngvpfytvfavsmgiligallnvilpllidgads ifvyvysasilpgmipwmilfshlfrrlhpekvhmhpfkmpggaianyltimflllvl ygmllnketvvsvvigivfltavtlyyliryhkkergi
572.	lqdfdnlipgwfktfvqvgmdliwsqyligllltagffftisskfiqlrmlpemfralte kpetlssgekgispfqafaisagsrvytgmiagvataivlggpgavfwmwliafigaasa fmeatlaqvykvhdkeggfrggpayyitkgliqkwlgivfavlitvtfafvfntvqanti aeslntqynispvitgivlavitgiifggvrsiatlsslivpimaivyigmvliillln idqivmmigtiiksafgvqqvtggavgaailqqikrglfsneagmgsapnaaatsavphp vkqyligslyvffdtmlvctataimillysglqfgdsapqgvavtqsalnehlgsagqif ltvavtlfafssvvgnyyygqsnieflsnnkmilfifrcfvvllvfvgavaktetvwsta dlfmglmaivniisiiglsniafavmkdyqrqrkegkrpvfkpenleinlfgietwgqha kmpkk
573.	lkkeilewivaiavaialiaiitkfygksysikgdsmåptlkdgervyvniigyklggve kgnvivfhankkddyvkrvigtpgdsveykndtlyvngkkqsepylnynekrkqteyitg sfktknlpnanpqsnvipkgkylvlgdnrevskdsrsfglidkdqivgkvslrywpfsef ksnfnpmtkn
574.	mfnkvwfrtgiffimlfiliklfmevhevfæpiatiigsvflpflisgflfyiclpfqmi lekwgfprwasitrifigliailaivvsfiæpiiisnimnlikqtpslqkeaeqlinfsl rymdklpddvthrinkavksmgdgatsilsnsvsyitsfistvfllimvpffllymlkdh ekfipaigkffkgerkvfvvdllkdlnftlksyiggqvtvsiilgiilyigytliglpyt pllvlfagvanlipflgpwlsfapaailgiidgpstfiwvcvvtliaqqlegnvitpnvm gkslsihpltiivvilaagdlggftliivavplyaviktlvsnifkyrqrivdkansnvkd
575.	mntivkhtvgfiasivltllavfvtlytnmtfhakvtiifgfafiqaalqllmfmhlteg kdgrlqsfkvifaiiitlvtvigtywvmqgghsshl
576	mlgeqytqikrpanritekilgwfswvflliltivsmfialvsfsndtsianlentlnnn elvqqilanndisttqfviwlqngvwadivyfivcllisflalismmirilsgllfliaa ivtiplvllivtliipliffiiammmfarrdrietvpsyneydqpydergfyepesrn ehgynddvyepmhtkkedrntrrqfnrnaqqqdsyngitdnqpdedtssdqlysdeyvdn edkysqfpkraveseyasqqtedeptvmsrqakynkkskntdfedaqqehmegnqfddvg vvepqidpkelkaqrkrekaeirakkkekrkaynkrmkerrknqpsavnqrrmnyeerrq minneqedtdnnlnqqedskken
577.	meenlngnnenmenkddhihlndsgsmedlelfrrnknargrrrrridngskekdats tqsqletkpmlkfidnhkshmqdkeiksdliednvndeddnqkynndklndrsvqgtset rqsnedeeefltdngsekqtkdsrhskkhkllskftskkeketftsfnsnekvtqlkpls leekrairrkkqkriqytiitlliliivlillymftplskisnvnikgnnnvstskikke lnvtsrsrmytfsknkairnlkamplikevdihkqlpntltvnvteyqivglekhkdkyv piiedgkelteykdevshdgpiidgfkgdkktriikalsemspkvrnliaevsyaptknk qsrikiftkdnmqvigdittiadhmqyppmsqslsrddsgelktngyidlsvgasfipy ggsstyngsteqnvtkstqeendakeelgnvlnkinkgskenn

	1
578.	mkclfkmlsiiiimlstftlfispstyanedenwtkiknrgelrvglsadyaplefekti
•	hgkteyagvdielakkiakdnhlklkivnmqfdsllgalktgkidliisgmtttperkke
1	vdftkpymitnnvmmikkddakryqnikdfegkkiaaqkgtdqekiaqteiedskissln
1 .	rlpeailslksgkvagvvvekpvgeaylkgnseltfskikfneekkqtciavpknspvll
1	dkingtidnykeknlidgymtkaaedmyddgnfiskygsffikgikntilislygyvlgs
	ilgsfiallkiskirplqwiasiyieflrgtpmlvqvfivffgttaalgldisalicgti alvinssayiaeiiraginavdkgqteaarslglnyrqtmqsvvmpqaikkilpalgnef
1	vtlikessivstigvseimfnaqvvqgisfdpftpllvaallyflltfaltrvmnflegr
	wasd
579.	mshkilvsdpisedglqsilkhpefdvdiqtdlsendlvnmistydalivrsqtqvteri
1 3.5.	inaatnlkviaragvgvominieaatlkgilvinapdgmtisatehsvamllamarnipg
	ahqslrnkewnrkafrqvelygktlgvigagriglgvakraqsfgmkilafdpyltedka
	ksldiqiatvdelaeksdfvtvhtpltpktrgivgssffnkakqnlqlinvarggildet
ì	aliealdnnlidraaidvfehepptdspliqhdkiivtphlgastveaqekvavsvseei
	ieiltkgnvehavnapkmdlskvdkttgsfiglsttigefaiqlldgapseikvkyagdl
1	aqndtslitrtiitnilkedlgnevniinalailnqqgvtyniekqkkhsgfssyielel yndqdkikigatvfagfgprivrindysldfkpnqyqlvtchkdkpgivgqtgnllgshg
	iniasmtlgrndaggdalmilsidqqaseevikilnetsgfnkiistklti
580.	lkrnfinnliilliaimlslllkmlhvilpfmfgpilaallcvkvlklkirwpfwlsqig
1	lillgyqigstftqqvikdiskmyltivfvtillillaliiafffkkiaqvnletailsv
	ipgalsgmlvmaeenkkanilvvsltqtsrvifvvilvplisyffqdnhhemhttmevp
1 .	tlsqtlniwqiiilfsmvgiiyigmskinfptkqllaplivlliwnmtthltfsldhwll
	ataqliymiriglqianlmsdlkgriaiaiafqnimlivttfimiigihlitnesinelf
	lgaapggmsqlvlvamatgadvamissyhifriffilfviapligyfinvklnnk
581.	vkktsriiafilliallftgmgmtyknvvknvnlgldlqggfevlfqvdplnkgdkidkk alqatsqtlenrvnvlgvsepkiqiedpnrirvqlagikdqaqarkllstqanltirdae
	dhvlmsgsdikqgsakqefkqetnqptvtfkvkskdkfkkvtekiskkxdnvmvvvldfe
İ	kgdsykkeakkqegkkpkfisaasvdqpinsssveisggfngkkgveeakqiaellnag
	slpvdlkeiysnsvgaqfgqdaldktmfasivgialiylfmlgfyrlpglvaiialttyi
1	yltlvafnfisgvltlpglaalvlgvgmavdaniimyerikdelrigrtlkqayskanks
	sfltifdsnlttviaaavlfffgessykgfatmlllgilmifvtavflsrgllsllyssn
	ffkkqywlfgykkkdrhdinegkdyhdlktsyerlnfyklakplislsiliviigliiis
į	ifklnlgidfssgtradiqsknaitqaqvektvksvglepdqiqingsgnknatvqfkkd   lsreednklsakvksefgdnpqintvspligqelaknavtalilasigiiiyvslrfewr
	mglssvlallhdvfiiiaifslfrlevdltfiaavltivgysindtivtfdrvrenlhkv
	kvithtdqiddivnrsirqtmtrsintvltvvvvvvaililgaptifnfslalligllsg
<u> </u>	vfssifiavplwgmlkkrqfkktknnklvvhkekksndekilv
582.	mgentkqdfnqkgqnfkftkkhrrllygsvflmatsaigpafltqtavftaqfyasfafa
1	ilisiiidigaqiniwrilvvtglrgqeisnkvlpglgtiisiliafqglafnigniaga
}	glglnamfgldvkwgaaitaifailifvsrsgqkimdvismilgivmilvvayvmvvsnp pygdalvhtfapehpfklilpiitlvggtvggyitfagahrildsgikgksylpfvnrsa
ì	vagilttgvmrtllflavlgvvvtgvtlssemppasvfqhalgpigknifgvvifaaams
i	svigsaytsatflktlhksllnkmllvitfivistfvflfigkpvsllilagaingwil
L	pitlgailiasrkksivgnyqhptwmlvfgiiavivtimtgifslqdlaslwkg
583.	vsnnnfkddfekurgsinpdehqtelkeddktnenkkeadsgnslsnnsnggfppmagr
	rkrrretatngskqqddkhqknsdakttegslddrydeaqlqqddksqqqnktekqsqd
	nrmkdgkdaaivngtsespehkskstqnrpgpkaqqqkrksestqskpstnkdkkaatga giagaagvagaaetskrhhnkkdkqdskhsnhendeksvknddqkqskkgkkaavyagaa
1 .	agvgaagvahhnnqnkhhneeknsnqnnqyndqsegkkkggfmkillpliaaililgaia
	ifggmalnnhndsksddgkiangskkdsdkkdgagsednkdkksdsnkdkksdsdknadd
	dsdnsssnpnatetnnndnvannsnytnomogdnanomsnnqqatqqqshtvyqqenl
	yriaiqyygegtqanvdkikranglssnnihmgqtlvipq
584.	makgdqyqahtekyhdkkskksykpvwiiisfiilitilllptpaglpvmakaalailaf
1	avymwyteavtypysatlilglmill]glspygdlseklgnpkegdiilkgsdigtnna
1	lshafsgfstsavalvaaalflavamqetnlhkrlallvlsivgnktrnivigailvsiv   laffvpsataragavvpillgmiaafnvskdsrlaslliitavqavsiwnigiktaaaqn
	ivainfinqnlghdvswgewflyaapwsiimsialyfimikfmppehdaieggkelikke
Ī	lnklgpvshrewrlivisvlllffwstekvlhpidsasitlvalgiilmpkigvitwkgv
I	ekkipwgtiivfgvgislgnvllktgaaqwlsdqtfglmglkhlpiiatialitlfnili
ŀ	hlgfasatslasalipvfisltstlnlgdhaigfvliggfvlsfgfllpvsapqnmlayg
585.	tgtftvkdflktgipltivgyilvivfsltyskwlglv
285.	mldfinhllsyqflnralitsilvgivcgtmgsiivlrglslmgdamshavlpgvalsf1   fnipmfigalvtgmlaslfigfitsnsktkpdaaigisftaflasgviiislinsttdly
I	hilfgnllaithqsfwttivitvlvilliiifyrplmistfdatfsrmsglnttlihyfv
1.	mlllalvtvasiqtvgiilvvallitpastafliskqlyammviasiisvissiiglyfs
	yiynipsgativictfmiyivtlsitriknkqkrsalt
586.	lakllyklgkfiaknkwlsvigwlvilgwlitplminspkfdsditmmglksldtndkis
1	kefhqdsekasmkivfhsnkndglnnkdtkkdiedaldnironddyignisnpydsgqvn degdtaianvsyvvpqtglkdsskhiidkelkdvtdnhnvqiektqggamnsepggtsei
1	degatalanvsyvvpqtglkdsskdltdkelkdvtdnimvqlektddgsmisepyglsel   vgiivafvillitfgsliaagmpiisaiiglgssvgiialltyifdipnftltlavmigl
· [	avgidyslfilfrfkelkkkgvdtveaiatavgtagsavifagltvmiavcglslvgidf
1	lavmgfasaisvlfavlaaltllpalisifhksikikdkptkskdpkdhswakfivgkpv
1 .	iavivsliililaaipvsgmrlgipddslkptdsseykayklisdnfgegyngqivmlvn
j	tkdggskstierdlnnmrsdledidnvdtvskaqltdnnnyalftiipekgpnsqsteul vydlrdyhsqaqekydygteisgqsvinidmseklnnaipvfagvivvlaffllmivfrs
1	ivplkavlgfilslmatlgfttlviqhqfmgslfgientgpllaflpvitigllfglai
1	dyelflmtrvheeysktgdndhsirvgikesgpvivaaalimfsvfiafvfqddsaiksm
1 .	gialgfgvlfdafvvrmtlipaltklfgkaswylpkwlgavlpnvdvegkaleednhhdt
1	ssekghyndkuseysrqdkdnyvyondkrnynrnyndedynrsyhl nnhhdqhhroddyd
1	ngrddidyeslytgdgdhthhdernyndrhygdnydroddyrhnnhdhgndnhdyhdsnf dkttnlykeltdsnidgdvlfkalmlyarennkgvydrynrssghrhddelrd
587.	
387.	mnkkvehigmqytsqenkkkqrqkmkmrvvrrrialfggillaiilillvllviqrhnnd qdaverkeketefqkqqdeeialkeklnnlndkdyiekiarddyylsnkgevifrlpddk
	ksagsktsnekyn
588.	mkirltfiilailstiglvlvlakyptgohtinynepytvliaittivimalpalilgif
	nhlacriisailqisalmmwgflviislimgqivimlmasltilallvssivtlsvhpst
1	sdkin

			``		
589.	mnkkllwsiigiviivvliiaafilkqvngsgskdsnaydtytvrketpislegkaspes vktynnnqsvgnflsvsvqdgqtvkqgeriinydtngakrqqllnkvnqaqsqvnddydk vnqspnnhqlqvkltqdqsalneaqqslsqydrqlndsmnasfdgkinikndadygegq ilqlissmpqlnatitefdinkikegdevnvtvnstgktgkgkilkidelptsydtsdds tassaqagaqdseegtemttsnptinqptggksgetskykviigdldipvrsgfsmdak iplktkklpnnvltkdnnvfvvdkmkvhkreikiernngeiivkkglksgdkvlkspkg nlndgekvevss			· '\	/
590.	maettkifeshlvkgalkdsvlklyvymiknpinfvvevgmllalgltiypdlfhqesv srlyvfsifillltlvfanfsealaegrgkaqanalrqtqtemkarrikqdgsyemida sdlkkghivrvatgeqipndgkvikglatvdesaitgesapvikesggdfdnviggtsva sdwleveitsepghsfldkmiglvegatrkktpneialftllmtltiiflvviltmypla kfinfalsiamlialavclipttiggllsaigiagmdrvtqfnilaksgrsvetcgdvnv liidktgitygnrmadafipvksssferlvkaayessiaddtpegrsivklaykqhidl pqevgeyipftaetrmsgvkfttrevykgapnsmvkrvkeagghipvdldalvkgvakkg gtplvvledneilgviylkdvikdglverfrelremgietvmctgdneltaatiakeagv drfvaectpedkinvireeqakghivamtgdgtndapalaeanvglammsgtmsakeaan				
	lidldsmptklmevvligkqllmtrgslttfsiandiakyfailpamfmaampamnhlni mhlhspesavlsalifnaliivllipiamkgvkfkgastqtilmknmlvyglggmivpfi giklidliiqlfv				
591.	mivlrrlfqdrgaifaiaiitiyvvlgvlaplitfyepnhidtankfagiswshwlgtdh lgrdvltriiyairpsllyvfvallisvvigailgfisgyfpgyidaiimricdvmlaff syvvtlalitlfgmgveniiiafiltrwawfcrvirtsvmqyieadhvkfakvigmndlt iirkhilpltftdiaiiasssmcsmilqmsgfsflglgvkaptaewgmmlnearkvmfth pgmmmttqvaiviivmafnflsdalqmaidprmsakekrlalkkgvkardta	√ <sub>24</sub> 1			
592.	mkgamswpflrlyiltlmffsanailnvfiplrghdlgatntvigivmgaymltamlcrp wagqilarigpikvlriillinamalvlyyfiglegyilarimqyvctaffsmslqlgii dalpekyrsegvslyslfstipnllgpliavgiwhvenmsifaivmlfiavtttlfgyrt tfantqkevspkdevlpfnamtvyvqffknkalfcsgmimilssivfgamstfiplytvr egfanagifltiqaitvviarfylrkyvpsdglwhrfmmivltllmvasvivafgphiv sifvyjsaifigitqalvyptlttylsfvlpkigrnmllglfiacadlgislggvlmgpi sdtvgfkwmyilcallvtiamtlskirqrqsvskas		· · · · ·		
593.	vgstvkyrkfilpivvgliiwaltpikpdalndgawfmfalfvstiiacitqmtigavs ilgftimilvglvdtktavqgfgnssiwliamaffisryfvktglgrrialqfvklfgkk tlglayelvgvdlilapatpsitaraggimfpiikslsesfgsspxdgserkmgaflift efqmlitsamfltamagnpiaqslaektahvqitvmnwfvaaiipglislivvpfliyk lypptvketpnakkwateqleemghmsiaeklmwyfiialalwvlgsfinvdatltafi alallltgvlawsdilnetgawntlvwfsvlvlmaeqlnklgfipwlskliaqglngfs wpivlvllifyfyshylfasatahvsamyaallgvavasgapplfsalmlgffgnllas tthyssgpapilyaagyvtqkrwwtmnivlgivyfiwigvgslwmkligmm				
594.	mkdnkmlfiifmigtftvgmaeyvvtglltqiaddmkvsissagllisvyaisvaligpl mriitlkvhahrllpilvaifiisnlvgmlapnfnvlllsrlmsaamhapffgvcmsvaa tvappakktqaialvqagltiavmlgypfgsflggfamvrvvfgfmivlaiitmlgmikf vpnvslsaeaniskeltvfknphiliviaiivfgysgvfttytfmepmirdfspfkivgl tvclfmfglggvignlitgnvpedkltknlyltfillfvtiilfvtviqnsilaliicfl fgfgtfgttpllnskiilsgkeapllastlaasifnvamflgaiigsillsiglpyiqit lisgglivlgmllnlvnqlyekkhitfneys				
595.	MANKVALMSFGRIGRIAFRRIQEVEGIEVVAVNDITDDEMIAHILKYDTMQGRFTGEVEV VDGSFRVNSKBVKSFSEPDASKIPNKDLNIDVVLECTGFYTDKDKAQAHIRAGAKKVLIS APATGDLKTIVPNTHHQBLDGSETVVSGASCTTNSLAPVAKVLNDDFGINEGIAFTTIHAY TEDQNTQDAPHRKGDKRRARAABNIIPNSTGAAKAIGKVIPRIDGKLDGGAQRVPVATG SLITELTVVLEKQDVTVEQVNEAMKNASNESFGYTEDEIVSSDVVGYTYGSLFDATQTRVM SVGDRQLVKVAAWYDNEMSYTAQLVRTLAYLAELSK				
596.	vkrlknfilgllivaivgfllfmyiddsriqsyqdyflqfmwfqplliglagllillgli lvlsifkpthrkpglyknfddghiyvsrkavektiydtiakydqvrqpnvvsklymklnk sfidikadffypnhvqyksltesiradiksnvahffeipyrklevnvrdqktsgprvl				
597.	msflrkhteilfsyiigivslftgliifinlpllkqfkgdkvdthvhnvweflnaffae ilkvmskfiggfpitsalviivfgilvmllghtlfrtikydydisifflvigimyfiitl llmtqygffaivfilpftvhigylyykdelnqdnrknhymmlivtygmsylitqislyg ridaneiesidilsvntfflimwllgqmaiwnflflrrslpltkeelgeeepelsrthkg nvsnqtkvhlkqlqmlktteyarktrsvdldkirakrdyfkqkinsivdiqeddinmmk kpkwvkpmyvqlfcgviilffaflefnnrnalfltgewelsqtqyvvewvtlllllfiii iylattltyylrdkyyylqlfmgsilffkfltefinimvhglllsifitpillmliami vayslqlrek				
598.	mqqettswykqewfivlsllfifplglflmwkfskwpsiartiitvaisvivlasityyg nlqmivpatsnsmetkettennvndkdernhktaveetktnydstkentkepgkenesa trlensalekaksyyddflmsklgiydiltseygekfdkedagyaidhleadyeknalek aksyakdmhmsndsiydllvsnygekfteseakyaiehldn	<u>.</u>			